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Abstract	
	Osteoarthritis	(OA)	is	a	disabling	disease	of	the	synovial	joints.	Structurally,	OA	involves	the	 degenerative	 breakdown	 of	 articular	 cartilage,	 inflammation	 of	 the	 synovium	 and	sclerosis	 of	 the	 subchondral	 bone,	 which	 ultimately	 results	 in	 a	 loss	 of	 function	 and	integrity	of	 the	synovial	 joints.	Clinically,	 it	 is	 the	chronic	pain	associated	with	OA	that	causes	 patients	 to	 seek	 medical	 attention.	 Traditional	 analgesics	 used	 to	 relieve	 the	chronic	pain	associated	with	OA	aim	 to	alleviate	peripheral	nociception	at	 the	 level	of	the	 diseased	 joint.	 However,	 OA	 patients	 often	 develop	 referred	 pain	 and	 suffer	 with	chronic	pain	even	after	total	joint	replacement	surgery,	which	indicates	that	the	chronic	pain	 associated	 with	 OA	 is	 not	 always	 driven	 by	 purely	 peripheral	 mechanisms.	Therefore,	 a	 better	 understanding	 of	 the	 central	 mechanisms	 involved	 in	 the	development	 of	 OA	 associated	 chronic	 pain	 may	 aid	 the	 development	 of	 effective	analgesics	that	tackle	the	centrally	driven	element.			Diffuse	Noxious	Inhibitory	Controls	(DNIC)	describes	the	phenomenon	where	one	pain	inhibits	another;	this	system	utilizes	endogenous	descending	inhibitory	controls,	which	mediate	an	inhibitory	effect	at	the	level	of	the	spinal	cord.	In	order	to	characterize	this	system	in	rats,	in	vivo	electrophysiological	recordings	were	made	from	single	unit	dorsal	horn	convergent	neurons.	The	dorsal	horn	neurons	were	activated	by	mechanical	 and	thermal	 stimulation	 of	 the	 hind	 paw	 and	 DNIC	was	 induced	 by	 a	 concurrent	 noxious	conditioning	pinch.	This	thesis	aimed	to	investigate	the	pharmacology	of	DNIC.			OA	 of	 the	 knee	 was	 modeled	 in	 this	 thesis	 with	 a	 2mg	 monoiodoacetate	 (MIA)	intrarticular	injection	in	the	rat.	This	thesis	investigated	central	neuronal	plasticity	with	spinal	 electrophysiology,	 assessed	 the	 functionality	 of	 descending	 controls	 through	measuring	 DNIC	 responses,	 and	 characterized	 the	 joint	 histopathology	 and	 pain-like	behaviour	associated	with	this	model.			Studies	 presented	 in	 this	 thesis	 confirmed	 that	 DNIC	 are	mediated	 via	 noradrenergic	inhibitory	 descending	 controls,	 but	 that	 serotonergic	 descending	 controls	 can	 also	influence	 the	 expression	 of	 DNIC.	 Early	 phase	 MIA	 animals	 (2-6	 days	 post	 injection)	displayed	 significant	 mechanical	 hypersensitivity,	 yet	 showed	 little	 articular	 cartilage	degradation	and	had	a	functional	DNIC	system.	DNIC	expression	was	abolished	in	early	phase	 animals	 through	 blocking	 the	 actions	 of	 spinal	 α2-adrenoceptors	 with	 the	antagonist	 atipamezole,	 while	 blocking	 the	 actions	 of	 spinal	 5-HT7	 receptors	 reduced	DNIC	 expression.	 Late	 phase	 MIA	 animals	 (14-20	 days	 post	 injection)	 demonstrated	significant	 articular	 cartilage	 degradation,	 mechanical	 hypersensitivity,	 and	 an	abolished	 DNIC	 system.	 DNIC	 expression	 was	 restored	 in	 late	 phase	 MIA	 animals	 by	enhancing	 noradrenergic	 modulation	 with	 the	 NRI	 and	 μ-opioid	 receptor	 agonist	tapentadol,	 and	by	 activating	 spinal	 5-HT7	 receptors	with	 the	 selective	5-HT7	receptor	agonist	AS-19.	In	addition,	pregabalin	significantly	reduced	spinal	neuronal	responses	in	late	phase	MIA	animals	yet	had	no	effect	 in	early	phase	animals.	Overall,	 these	results	suggest	there	is	a	decreased	noradrenergic	inhibitory	descending	drive	acting	at	spinal	α2-adrenoceptors,	and	modulation	of	serotonergic	descending	controls	acting	at	spinal	5-HT7	receptors	in	late	phase	MIA	animals.			The	studies	presented	 in	 this	 thesis	demonstrate	 the	applications	of	assessing	DNIC	 in	this	experimental	model	of	OA,	 that	 the	DNIC	system	becomes	abolished	as	 the	model	progresses,	 and	 that	 DNIC	 can	 be	 restored	 through	 pharmacologically	 manipulating	monoaminergic	descending	controls.	Overall,	this	may	represent	a	strategy	for	relieving	centrally	driven	OA	associated	chronic	pain.			
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1.	Introduction		
1.1	The	nociceptive	system	
	
1.1.1	What	is	pain?	
	The	International	Association	for	the	Study	of	Pain	describes	pain	as	“an	unpleasant	sensory	and	emotional	experience	associated	with	actual	or	potential	tissue	damage,	or	described	in	terms	of	such	damage”	(Merksey	and	Bogduk	1994).	Pain	is	a	warning	mechanism	that	exists	to	prevent	tissue	damage,	however	the	experience	of	pain	can	often	outlast	its	protective	purpose	and	remain	present	for	weeks,	months	and	even	years.	Nociception	is	the	process	in	which	the	sensory	nervous	system	transmits	information	and	responds	to	potentially	harmful	stimuli,	while	pain	is	a	highly	subjective	experience	influenced	by	memories,	emotional,	genetic	and	cognitive	factors	and	the	resultant	perceived	pain	is	not	always	be	equal	to	the	stimulus	(Tracey	and	Mantyh	2007).		Conceptually,	pain	can	be	classified	according	to	its	persistency.	Acute	pain	is	commonly	associated	with	ongoing	tissue	damage	and	but	is	time	limited,	in	contrast	chronic	pain	persists	for	longer	periods	of	time	exceeding	3	months	outlasting	its	biological	efficacy	(Merskey	and	Bogduk	1994).	If	the	ongoing	tissue	damage	does	not	recover	acute	pain	can	become	chronic	and	outlast	the	usual	time	of	healing,	therefore	it	is	important	to	treat	acute	pain	before	it	can	progress	to	this	more	severe,	chronic	pain	state	(Lynch	2011).	Both	acute	and	chronic	pain	are	an	enormous	social	and	economic	burden	severely	reducing	a	patients	quality	of	life,	and	the	primary	management	of	chronic	pain	accounts	for	4.6	million	general	practitioner	(GP)	appointments	a	year	in	the	UK	costing	the	NHS	69	million	pounds	(Phillips	2009).	There	is	an	unmet	need	for	treatment	and	management	of	chronic	pain,	thus	understanding	the	biological	mechanisms	underlying	pain	processing	and	its	circuitry	is	crucial	for	the	development	of	therapeutic	targets.			The	basics	of	pain	circuitry	have	been	established.	The	pain	signal	is	initiated	in	the	peripheral	afferent	fibres,	which	carry	nociceptive	stimuli	as	electrophysiological	activity	to	superficial	spinal	dorsal	horn	neurones.	Within	the	dorsal	horn,	nociceptive	information	is	then	modulated	and	transmitted	along	ascending	pathways	to	higher	centres	in	the	brain	via	projection	neurones	(Porecca	2002).	The	main	termination	sites	for	the	ascending	projections	are	the	brainstem	and	thalamus,	which	contain	higher	
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order	neurones	that	project	the	signal	to	various	cortical	regions,	which	subsequently	modulate	the	different	aspects	of	the	pain	experience	(Fields	2004).	These	supraspinal	sites	integrate	a	response	and	activate	the	relay	of	descending	pathways	to	modulate	the	excitability	of	deeper	dorsal	horn	neurones	and	ultimately	determine	the	perception	of	pain	(Bridgestock	and	Rae	2013).		Pain	can	be	classified	into	broad	categories	based	on	the	underlying	mechanism	(Figure	1.1).	Firstly,	there	is	nociceptive	acute	pain;	this	is	an	early	warning	physiological	protective	system	essential	for	sustaining	bodily	integrity.	This	is	the	type	of	pain	felt	when	stubbing	ones	toe	or	touching	something	too	hot,	cold	or	sharp.	The	withdrawal	reflex	activated	by	this	high	threshold	pain	causes	immediate	attention	and	withdrawal	from	the	intense	noxious	stimuli	(Woolf	2010).	Neuropathic	pain	is	a	type	of	chronic	pain	caused	by	a	lesion	or	disease	state	affecting	the	somatosensory	system	(Treede	et	al	2008)(Backonja	2003).	Post	herpetic	neuralgia	(PHN),	diabetic	neuropathy	and	human	immunodeficiency	virus	(HIV)	related	neuropathies	are	all	examples	of	damage	to	the	periphery,	subsequently	transmission	of	signals	from	the	afferent	to	the	nervous	system	is	partially	or	completely	lost	(Jenson	and	Baron	2003).	Nonetheless,	neuropathic	pain	can	also	be	caused	by	lesion	to	the	CNS,	which	occurs	in	multiple	sclerosis,	stroke	and	spinal	cord	injury.	A	second	mechanism	underlying	the	development	of	chronic	pain	is	inflammation,	whereby	damaged	tissues	release	chemical	mediators	that	can	activate	and	sensitise	the	pain	signaling	system.	Many	conditions	cause	this	sort	of	pain	including	osteoarthritis	(OA),	rheumatoid	arthritis	(RA)	and	post-operative	pain.	Neuropathic	and	inflammatory	pain	can	also	occur	at	the	same	time,	a	good	example	is	the	pain	related	to	cancer;	as	the	tumour	expands	it	causes	tissue	damage	and	the	release	of	inflammatory	mediators	as	well	as	causing	nerve	damage	through	compression	and	invasion.	Recently,	evidence	has	suggested	it	also	has	unique	features	and	so	should	be	considered	a	separate	pain	state	(Falk	and	Dickenson	2014).	Finally,	in	generalized	or	dysfunctional	pain	there	is	no	obvious	damage	or	inflammation	to	the	nervous	system	yet	patients	feel	substantial	pain.	Conditions	evoking	dysfunctional	pain	include	fibromyalgia,	irritable	bowel	syndrome	(IBS),	tension	headaches	and	interstitial	cystitis	(Woolf	2010).			
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Figure	1.1.	Pain	mechanisms.	Acute	pain	is	a	first	response	to	noxious	stimuli	that	can	be	of	chemical,	mechanical	or	thermal	origin.	This	triggers	a	reflex	response	and	withdrawal	from	the	stimulus	but	with	no	lasting	damage	to	the	nociceptive	system.	Inflammatory	pain	involves	inflammatory	mediators	released	in	response	to	tissue	damage	sensitizing	the	nociceptive	system.	Lesions	to	peripheral	or	central	neurons	can	cause	neuropathic	pain.	Figure	taken	from	(Falk	and	Dickenson	2014).	
	
1.1.2 The	primary	afferent	fibres	
	The	nociceptive	system	begins	with	the	nociceptor:	a	primary	sensory	neuron	that	becomes	activated	in	response	to	stimuli	capable	of	causing	tissue	damage	(Sherrington	1906).	Nociceptors	are	polymodal	sensory	neurons	that	can	respond	to	multiple	stimulus	modalities	of	mechanical,	thermal	and	chemical	origin.	Nociceptors	selectively	detect	and	respond	to	potentially	harmful	stimuli	as	they	are	only	activated	once	the	intensity	reaches	the	noxious	range	due	to	their	biophysical	properties	(Basbaum	et	al	2009).	The	sensory	nerve	ending	of	nociceptors	are	dispersed	throughout	the	body	
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innervating	skin,	muscle,	joints	and	internal	organs	(Julius	and	Basbaum	2001).	The	nociceptors	have	a	peripheral	axonal	branch	innervating	their	target	organ	in	the	periphery,	while	the	central	axonal	branch	innervates	the	spinal	cord	(Basbaum	et	al	2009).		The	dorsal	root	ganglia	(DRG)	are	located	peripherally	alongside	the	spinal	cord,	they	contain	the	cell	bodies	of	nociceptors	dispersed	through	the	body	and	directly	synapse	onto	spinal	neurons	(Lopes	et	al	2017).	The	trigeminal	ganglion	are	localized	at	the	base	of	the	skill	and	contain	the	cell	bodies	for	nociceptors	located	in	the	face,	which	then	project	to	the	brainstem	or	upper	regions	of	the	spinal	cord	(Lopes	et	al	2017).			The	nociceptors	can	be	grouped	into	three	populations	based	on	their	anatomical	and	functional	properties	as	shown	in	Table	1.1.	The	Aδ	fibres	are	a	type	of	thinly	myelinated	primary	afferent	fibre	found	in	the	periphery.	The	Aδ	afferent	fibres	can	be	further	subdivided	into	two	main	classes.	Firstly,	the	Type	I	Aδ	fibres	are	also	known	as	the	high-threshold	mechanical	receptors.	They	respond	to	mechanical	stimuli	but	have	a	high	threshold	for	thermal	stimulation	of	>50°C.	However,	these	fibres	can	become	sensitised	to	both	tissue	injury	and	continued	thermal	stimulation,	such	that	if	an	intense	heat	stimulus	is	maintained	the	Type	I	Aδ	afferents	will	begin	to	respond	to	lower	temperatures	(Basbaum	et	al	2009).	The	Type	II	Aδ	fibres	have	a	lower	thermal	threshold	but	a	much	higher	mechanical	threshold.	The	Aδ	fibres	are	thought	to	mediate	the	first	response	to	noxious	stimuli,	mediating	an	acute	and	sharp	pain.	In	summary,	type	II	Aδ	fibres	are	responsible	for	the	first	response	to	acute	heat	and	the	type	I	Aδ	fibres	trigger	a	rapid	response	to	intense	mechanical	stimulation.			The	C	fibres	are	a	further	subtype	of	peripheral	nociceptor,	which	are	unmyelinated,	have	a	small	diameter	and	a	slow	conduction	velocity	of	<1.4m/s	(Harper	and	Lawson	1985).	There	are	also	two	major	classes	of	C	fibres,	which	are	distinguished	by	their	biochemical	and	anatomical	differences	(Snider	and	McMahon	1998).	Firstly	is	the	peptidergic	population,	they	contain	the	neurotransmitter	substance	P	and	express	the	tyrosine	kinase	A	(TrkA)	receptor,	which	nerve	growth	factor	(NGF)	binds	to	with	high	affinity	(Julius	and	Basbaum	2001.	The	second	non-peptidergic	population	can	be	labeled	with	the	α-D-galactosyl	binding	lectin	IB4	and	express	the	ATP-gated	ion	channel	P2X3,	indicating	that	these	nociceptors	use	ATP	as	a	neurotransmitter	for	transmitting	the	pain	signal	(Burnstock	2000).	C	fibres	are	responsible	for	a	dull	and	diffuse	pain	response,	which	follows	the	rapid,	sharp	pain	mediated	by	Aδ	fibres.			
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There	is	an	additional	type	of	peripheral	afferent,	the	Aβ	fibre,	which	has	a	larger	diameter,	is	highly	myelinated	and	a	fast	conduction	velocity	of	>14m/s	(Harper	and	Lawson	1985).	The	Aβ	fibres	have	a	low	threshold	for	activation	and	so	respond	to	light	brush	and	innocuous	mechanical	stimulation.	Under	normal	conditions	the	Aβ	fibres	are	not	involved	in	the	pain	sensation	but	are	believed	to	be	recruited	in	sensitising	pathological	conditions	(Woolf	and	Doubell	1994)(Julius	and	Basbaum	2001).				Furthermore,	there	are	also	silent	nociceptors	which	are	heat	responsive	but	mechanical	insensitive	(Basbaum	et	al	2009).	However,	they	can	become	sensitive	to	mechanical	stimulation	in	a	state	of	tissue	injury	(Julius	and	Basbaum	2001).	These	silent	afferent	fibres	are	more	responsive	to	chemical	stimuli	than	the	polymodal	C	fibres	and	so	when	chemical	mediators	are	released	due	to	an	inflammatory	state,	their	properties	can	become	altered	and	they	can	be	activated	by	mechanical	stimulation	too	(Schmidt	et	al	1995).			
				
1.1.3 Detection	of	noxious	stimuli	and	transduction	of	the	pain	signal	
	The	ability	to	react	and	respond	to	potentially	injurious	external	stimuli	is	a	process	crucial	to	survival.	The	pain	experience	begins	in	the	periphery	as	the	nociceptors	detect	potentially	harmful	stimuli.		The	primary	afferent	fibres	found	in	the	periphery	are	
Fibre	
Type	
Diameter	 Myelination	 Conduction	
velocity	
(m/s)	
Stimuli	 Sensation	in	
normal	state	
Sensation	in	
injured	state	
Aβ	 Large	 Myelinated	 >14	 Light	touch	and	brush	 Innocuous	 Pain	(allodynia)	
Aδ	Type	I	 Medium	 Partly	Myelinated	 2.2-8	 Noxious	mechanical	 Nociceptive	 Exaggerated	pain	(hyperalgesia)	
Aδ	Type	II	 Medium	 Partly	Myelinated	 2.2-8	 Noxious	thermal	 Nociceptive	 Exaggerated	pain	(hyperalgesia)	
C	 Small	 Unmyelinated	 <1.4	 Noxious	mechanical,	thermal	and	chemical	
Nociceptive	 Exaggerated	pain	(hyperalgesia)	
Table	1.1.		Populations	of	nociceptors	based	on	their	conduction	velocity,	morphology	and	response	
characteristics.	
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capable	of	responding	to	various	stimulus	modalities	dependent	on	the	types	of	receptors	they	possess,	which	are	found	on	unencaspsulated	nerve	endings.	Receptors	in	the	periphery	respond	to	noxious	stimuli	to	create	a	generator	potential,	if	the	generator	potential	is	of	sufficient	magnitude	it	can	be	amplified	to	an	action	potential	through	the	opening	of	sodium,	calcium	and	potassium	channels.	As	such,	activation	of	receptors	results	in	either	an	influx	or	efflux	of	cations	across	the	plasma	membrane	and	subsequent	depolarization	or	hyperpolarization	of	the	afferent	respectively.	Once	the	generator	potential	is	converted	to	electrophysiological	activity,	it	can	be	transduced	to	the	spinal	cord	and	higher	centres	(Bridgestock	and	Rae	2013).	The	receptors	and	channels	that	mediate	membrane	depolarization	of	the	nociceptor	and	the	subsequent	transduction	of	the	pain	signal	will	be	discussed	in	greater	detail	in	this	section.			
1.1.3.1	TRP	Channels	
	Heat	sensitive	ion	channels	found	on	primary	afferent	nerve	endings	mediate	the	detection	of	thermal	stimuli	(Tominaga	and	Caterina	2004).	Cesare	and	McNaughton	provided	the	first	evidence	of	this	by	demonstrating	that	application	of	pulses	of	noxious	heat	to	a	subpopulation	of	nociceptors	isolated	from	the	DRG	rapidly	activated	inward	currents	(Cesare	and	McNaughton	1996).	The	authors	proposed	that	the	equilibrium	between	the	ion	channels	closed	and	open	states	is	dependent	on	a	large	entropy	difference.	They	suggested	that	elevations	in	temperature	must	change	the	heat	sensitive	ion	channels	from	an	ordered	(closed)	to	a	more	disordered	(open)	state	(Cesare	er	al	1999).	Due	to	the	transient	opening	and	closing	states	the	channels	were	considered	Transient	Receptor	Potential	(TRP)	channels.		The	TRP	channels	are	vital	components	of	our	sensory	systems	being	expressed	almost	ubiquitously	on	peripheral	nociceptors	and	responding	to	temperature,	touch,	pain,	osmolarity	and	other	stimuli	(Clapham	2003).	The	TRP	channels	are	a	large	family	of	voltage-gated	ion	channels;	to	date	28	mammalian	isoforms	have	been	identified	that	can	be	subdivided	into	7	families	(O’Neill	et	al	2014).	Six	transmembrane	domain	(TMD)	polypeptide	subunits	make	up	the	TRP	channels,	these	subunits	assemble	as	tetramers	and	form	pores	in	the	cell	membrane	(O’Neill	et	al	2014).	Voltage-gated	channels	function	by	using	a	charged	gating	unit	in	the	membrane	field	that	can	be	displaced	in	response	to	changes	in	membrane	potential,	this	induces	a	conformational	changed	that	gates	the	channel	opened	or	closed	(Cesare	et	al	1999).	The	opening	of	the	TRP	ion	channel	results	in	the	entry	of	cations	(Na+	and	Ca2+)	into	the	neuron,	while	the	TRP	
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channels	are	unselective	they	have	been	shown	to	have	a	higher	affinity	for	Ca2+	(Cesare	et	al	1999,	O’Neill	et	al	2014).			Humans	are	capable	of	sensing	a	wide	range	of	external	temperatures	spanning	cold	to	heat,	but	when	temperatures	begin	to	exceed	43°C	or	drop	below	15°C	not	only	a	thermal	sensation	is	evoked	but	also	one	of	pain	(Tominaga	and	Caterina	2004).	The	thermo-TRP	channels	are	activated	over	a	distinct	range	of	both	noxious	and	innocuous	temperatures.	The	thermo-TRP	channels	include	TRPV1-4,	TRPM2,	TRPM4,	TRPM5.	TRPM8	and	TRPA1	are	included	in	the	thermo-TRP	channel	category	as	they	are	proposed	to	be	responsible	for	the	transduction	of	cold	stimulation	in	primary	afferents	(Kobayashi	et	al	2005a).		The	thermo-TRP	channel	with	the	highest	threshold	for	activation	is	the	TRPV2	channel	with	an	activation	threshold	of	52°C	(Caterina	et	al	1999).			The	activation	of	the	TRPV1	receptor	is	proposed	to	lead	the	perception	of	heat	pain	as	it	is	the	first	receptor	to	detect	noxious	heat	with	an	activation	threshold	of	>43°C	(Dhaka	et	al	2006).	This	suggests	that	the	TRPV1	channel	is	capable	of	exciting	Aδ	and	C	afferents	to	send	pain	signals	to	the	dorsal	horn	of	the	spinal	cord.	TRPV1	can	be	activated	by	noxious	heat,	protons	(pH	<	5.2),	endogenous	lipids,	inflammatory	mediators	and	capsaicin	–	the	pungent	ingredient	in	hot	chilli	peppers	(O’Neill	et	al	2014).	Upon	detection	of	noxious	heat	or	capsaicin,	the	opening	of	the	outwardly	rectifying,	non-selective	cation	channel	TRPV1	evokes	membrane	currents.	However,	despite	the	channel	being	non-selective,	it	has	been	shown	to	have	a	high	preference	for	Ca2+	(Caterina	et	al	1997).	To	confirm	the	involvement	of	the	TRPV1	channel	in	thermal	nociceptive	function,	a	TRPV1	knockout	mouse	was	generated	(Caterina	et	al	2000).	These	mice	displayed	deficient	behavioural	responses	to	capsaicin,	heat	and	protons.	However,	the	knockout	mice	showed	normal	responses	to	noxious	mechanical	stimulation,	suggesting	that	nociceptors	require	alternative	molecular	mechanisms	to	respond	to	noxious	mechanical	stimulation.			The	speed	required	for	the	detection	of	harmful	mechanical	stimuli	is	vital	for	protection	from	environmental	dangers	suggesting	that,	like	our	responses	to	thermal	stimuli,	ion	channels	are	opened	in	response	to	mechanical	forces	(Brierly	et	al	2011).	The	TRPA1	channel	has	been	proposed	as	the	candidate	receptor	responsible	for	our	response	to	noxious	mechanical	stimulation	(Vilceanu	and	Stucky	2010).	The	TRPA1	receptor	is	expressed	in	a	subset	of	small	diameter	neurons,	predominantly	
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unmyelinated	C	fibres	that	co-express	the	TRPV1	channel.	TRPA1	can	also	be	found	in	larger	diameter	neurones	but	its	functional	expression	is	more	abundant	in	small	fibres	(Kerstein	et	al	2009).	To	investigate	whether	the	TRRPA1	channel	played	any	role	in	mechanical	responses,	Kwan	and	collaborators	generated	a	mouse	model	in	which	essential	exons	required	for	the	proper	function	of	the	TRPA1	gene	were	deleted	(Kwan	et	al	2006).	The	authors	demonstrated	that	TRPA1	knockout	animals	displayed	deficient	behavioural	responses	to	punctate	mechanical	stimuli,	cold	stimulation	(0°C),	and	mustard	oil	(Kwan	et	al	2006).	Following	this	study,	to	directly	determine	the	contribution	of	TRPA1	to	mechanically	evoked	responses	at	the	level	of	the	nociceptor,	Kerstein	et	al	used	an	ex-
vivo	skin	preparation	with	pharmacological	blockade	of	the	TRPA1	receptor.	They	found	a	markedly	reduced	number	of	action	potentials	were	fired	in	C	fibres	in	response	to	mechanical	stimulation	when	the	TRPA1	channel	was	blocked	(Kerstein	et	al	2009).			The	use	of	whole	cell	patch	clamping	has	further	confirmed	the	TRPA1	receptors	role	in	mechanical	sensation.	Neurons	cultured	from	mice	with	TRPA1	deletion	and	pharmacological	blockage	of	TRPA1	with	an	antagonist	were	shown	to	reduce	mechanically	activated	intermediate	adapting	current	in	small	diameter	DRG	neurons	(Brierly	et	al	2011).	Similarly,	overexpressing	the	TRPA1	channel	in	neurons	through	transfection	of	a	plasmid	increased	the	current	amplitude	to	mechanical	stimulation	(Brierly	et	al	2011).	The	specific	responses	to	mechanical	stimulation	of	nociceptors,	depending	on	the	expression	levels	of	TRPA1,	was	investigated	further	by	Vilcenau	and	Stucky	when	they	found	that	significantly	more	IB4	negative	neurons	(non-peptidergic)	responded	to	mechanical	stimulation	than	IB4	positive	(peptidergic)	(Vilcenau	and	Stucky	2010).	They	found	that	slowly	adapting	currents	in	response	to	mechanical	stimulation	were	completely	abolished	in	IB4	negative	neurons	in	TRPA1	knockout	mice,	and	in	wild-type	mice	in	the	presence	of	a	TRPA1	antagonist.	Interestingly	the	authors	also	found	that	slowly	and	intermediate	adapting	currents	are	non-cation	specific	while	rapidly	adapting	currents	are	carried	solely	by	Na+	ions.	This	suggests	that	mechanical	responses	utilize	Ca2+	and	Na+	signaling.	Taken	together,	all	of	the	studies	discussed	above	demonstrate	the	importance	of	the	TRPA1	channel	in	the	transduction	of	nociceptive	information	in	response	to	mechanical	stimulation.			
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1.1.3.2 Voltage	gated	sodium	channels	
	Upon	detection	of	noxious	stimuli,	the	receptors	on	the	free	nerve	endings	of	nociceptors	become	activated	leading	to	membrane	depolarization;	it	is	this	encoding	of	action	potentials	that	sends	the	pain	signal.	The	generation	and	propagation	of	action	potentials	is	dependent	upon	voltage-gated	sodium	channels.	There	are	four	voltage-gated	sodium	channel	subtypes	which	are	particularly	interesting	to	the	pain	pathway	due	to	their	expression	on	nociceptors,	the	channels	sensitive	to	the	neurotoxin	tetrodotoxin	(TTX-S),	Nav1.3	and	Nav1.7	and	the	tetrodotoxin-resistant	(TTX-R)	channels	Nav1.8	and	Nav1.9	(Wood	and	Momin	2008).			The	Nav1.3	channel	subtype	is	highly	expressed	during	development	but	there	is	little	expression	in	the	adult	sensory	neurons,	however	it	can	be	upregulated	along	the	pain	pathways	in	response	to	injury	(Waxman	et	al	1994).	Waxman	and	collaborates	demonstrated	that	mRNA	levels	of	Nav1.3	were	highly	expressed	in	sensory	neurons	following	both	axotomy	and	inflammation.	The	Nav1.3	channel	has	a	rapid	recovery	from	inactivation	so	this	re-expression	could	suggest	a	role	for	this	channel	in	high	frequency	firing	and	bursts	of	action	potentials	in	chronic	pain	states	(Wood	and	Momin	2008).			The	Nav1.7	channel	produces	a	fast	activating	and	inactivating,	slow-repriming	current	suggesting	this	channel	is	responsible	for	amplifying	the	small	subthreshold	depolarizations	known	as	generator	potentials	(Dib-Hajj	et	al	2010).	This	proposes	that	this	channel	acts	as	the	threshold	channel	for	firing	action	potentials	and	regulates	the	excitability	of	nociceptors	(Dib-Hajj	et	al	2013).	A	mutation	in	the	SC9NA	gene	which	encodes	the	Nav1.7	channel.	results	in	a	phenotype	of	a	complete	inability	to	perceive	any	form	of	pain	(Cox	et	al	2006).	Therefore,	the	Nav1.7	channel	appears	to	be	an	essential	requirement	for	nociception.			The	pain	signal	then	recruits	the	Nav1.8	channel	that	is	present	along	peripheral	axons	and	free	nerve	terminals	in	the	skin.	The	Nav1.8	channel	contributes	most	of	the	sodium	current	underlying	the	action	potential	and	accounts	for	most	of	the	current	in	latter	action	potential	spikes	(Dib-Hajj	et	al	2010).			Finally,	the	Nav1.9	channel	is	expressed	in	small	diameter,	non-peptidergic	DRG	neurons.	In	humans,	the	Nav1.9	channel	activates	at	approximately	-80mV,	very	close	to	
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the	resting	membrane	potential	and	its	very	slow	inactivation	leads	to	a	persistent	current.	This	Nav1.9	channel	is	not	thought	to	contribute	to	the	action	potential	upstroke	but	to	enhance	and	prolong	the	response	to	subthreshold	depolarizations	(Dib-Hajj	et	al	2010).			
1.1.3.3	Voltage	gated	calcium	channels			Similarly	to	sodium	ions,	the	rapid	entry	of	calcium	into	a	cell	causes	changes	in	membrane	potential,	and	contributes	to	repetitive	firing	and	electrical	excitability	of	nociceptors	(Snutch	2006).	Voltage	gated	calcium	channels	(VGCC)	can	open	following	membrane	depolarization	and	are	responsible	for	the	entry	of	calcium	into	the	neuron	along	its	electrochemical	gradient	(Simms	and	Zamponi	2014).	Following	the	activation	of	nociceptors	and	the	resulting	action	potential	mediated	by	sodium	channels,	the	electrical	signal	is	also	translated	into	a	chemical	one	mediated	by	neurotransmitters.	Calcium	entry	into	presynaptic	nerve	terminals	is	the	initial	trigger	for	the	release	of	neurotransmitters	into	the	synapse;	this	depends	on	calcium	dependent	fusion	of	synaptic	vesicles	(Snutch	2005).	The	N-type	voltage	gated	calcium	channels	(VGCC)	are	highly	expressed	in	C	and	Aδ	primary	afferents,	with	the	Cav2.2	channel	being	the	most	abundant	VGCC	in	nociceptors	(Woolf	and	Ma	2007).	It	has	been	demonstrated	that	high	voltage	activated	calcium	currents	contribute	much	less	than	sodium	to	the	inward	charge	during	the	upstroke	of	the	nociceptor	action	potential	(Blair	and	Bean	2002).	Indeed,	high	threshold	calcium	channels	typically	activate	at	membrane	potentials	of	approximately	-30mV.	However,	the	action	potentials	had	a	prominent	shoulder	during	the	falling	phase,	which	is	characteristic	of	nociceptors,	and	they	found	the	high	voltage	activated	calcium	currents	contributed	significantly	to	this	part	of	the	action	potential	(Blair	and	Bean	2002).			The	electrical	activity	of	a	neuron	is	dependent	upon	the	state	of	voltage-gated	channels	on	their	membrane.	The	opening	of	voltage-gated	sodium	and	calcium	channels	and	the	subsequent	entry	of	cations	into	the	neuron	propagate	an	action	potential.	This	can	trigger	membrane	depolarization	and	the	opening	of	voltage-gated	continues	along	the	length	of	the	neuron	allowing	the	pain	signal	to	be	transduced	as	electrical	activity.		
1.1.4 Peripheral	sensitization	
	The	properties	of	primary	afferent	nociceptors	can	be	altered	upon	injury	or	inflammation,	this	can	result	in	increased	spontaneous	firing,	changes	in	their	
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conduction	properties,	and	increased	neurotransmitter	release.	The	increased	excitability	of	primary	afferents	is	thought	to	contribute	to	persistent	and	chronic	pain	states	and	is	known	as	peripheral	sensitization.		
1.1.4.1 Inflammatory	mediators	sensitising	primary	afferents		
	Peripheral	sensitisation	occurs	most	often	when	tissue	damage	causes	inflammatory	associated	changes	in	the	environment	of	the	nociceptor.	In	addition	to	the	TRP,	voltage	gated	sodium	and	calcium	channels	mentioned	above,	the	primary	afferents	express	a	myriad	of	other	receptors.	This	includes	voltage-gated	and	voltage-insensitive	potassium	(K+)	channels,	tyrosine	kinase	receptors	activated	by	growth	factors,	G-protein	coupled	receptors	(GPCRs),	and	ASIC	channels	activated	by	protons.	The	inflammatory	mediators	released	due	to	tissue	injury	can	activate	and	sensitise	the	array	of	receptors	found	on	primary	afferent	nerve	endings.			Upon	tissue	injury,	there	is	a	surge	of	inflammatory	mediators	released	by	blood	vessels,	resident	mast	cells,	recruited	immune	cells,	epithelial	cells,	Schwann	cells	and	fibroblasts	surrounding	the	nociceptor	(Basbaum	et	al	2009).	The	sensitising	substances	released	by	these	sources	in	response	to	inflammation	are	often	referred	to	as	the	‘inflammatory	soup’.	This	‘inflammatory	soup’	contains	a	wide	array	of	components	including	neurotransmitters,	peptides	such	as	substance	P,	calcitonin	gene-related	peptide	(CGRP)	and	bradykinin,	prostaglandins,	neutrophins,	cytokines	and	chemokines	(Basbaum	et	al	2009)(Gold	and	Gebhart	2010).	The	multiple	components	of	the	‘inflammatory	soup’	released	due	to	tissue	injury	and	the	myriad	of	receptors	they	can	potentially	sensitise	are	shown	in	Figure	1.2.	Upon	release,	these	inflammatory	agents	can	either	directly	activate	receptors	to	modulate	their	responses,	or	function	by	binding	to	their	own	receptors	on	primary	afferents	which	subsequently	alters	other	receptor	properties	via	activation	of	downstream	intracellular	signaling	pathways	(Basbaum	et	al	2009).			Preventing	the	sensitization	of	primary	afferents	caused	by	this	‘inflammatory	soup’	became	an	attractive	target	for	analgesics.	A	good	example	of	this	is	the	
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non-steroidal	anti-inflammatory	drugs	(NSAIDs),	which	function	by	preventing	the	synthesis	of	these	inflammatory	mediators.	An	example	of	this	is	ibuprofen	and	aspirin	that	work	by	inhibiting	cyclooxygenases	(Cox-1	and	Cox-2),	which	are	required	for	the	synthesis	of	prostaglandins	(Basbaum	et	al	2009).			
	
Figure	1.2.	The	release	of	inflammatory	mediators	in	response	to	tissue	injury	and	the	
potential	receptors	they	sensitize.	Upon	tissue	injury,	both	neuronal	and	non-neuronal	cell	types	that	either	reside	within	or	infiltrate	the	nociceptor	environment	release	a	wide	array	of	inflammatory	components.	These	sensitising	components	can	activate	the	myriad	of	receptors	expressed	on	primary	afferent	nerve	endings.	(IL-1β	–Interleukin	1β,	NGF	–	nerve	growth	factor,	LIF	–	leukemia	inhibitory	factor,	IL-6	–	Interleukin-6,	TNF-α	–	tumour	necrosis	factor	α,	PGE2	–	Prostaglandin	E2,	ATP	–	Adenosine	triphosphate,	CGRP	–	calcitonin	gene	related	peptide,	RTK	–	tyrosine	kinase	receptor,	K2P	–	Two	pore	potassium	channel,	GPCR	–	G-protein	coupled	receptor,	TRP	–	Transient	receptor	potential	channel,	ASIC	–	acid-sensing	ion	channel,	P2X	–	ATP	gated	ion	channel.	Figure	taken	from	(Basbaum	et	al	2009).		Firstly,	components	of	the	inflammatory	soup	can	directly	modulate	receptor	responses	by	functioning	as	direct	positive	allosteric	modulators	of	ion	channels.	Cytokines	are	one	of	the	components	released	due	to	tissue	damage,	the	main	ones	being	interleukin-1β	(IL-1β),	interleukin-6	(IL-6),	and	tumour	necrosis	factor	α	(TNFα)	(Zhang	and	An	2007).	Whilst	these	cytokines	have	a	direct	action	on	nociceptors	they	are	also	responsible	for	further	potentiating	the	inflammatory	response	by	causing	an	increased	production	of	further	inflammatory	mediators	(Zhang	and	An	2007).	As	many	channels	found	in	the	primary	afferent	nerve	ending	are	voltage	dependent,	the	resting	membrane	potential	is	a	very	important	factor	influencing	transduction	of	the	pain	signal.	Under	normal	
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conditions	there	is	little	spontaneous	activity	in	nociceptors	due	to	a	large	K+	conductance,	which	works	to	oppose	the	high	membrane	permeability	to	depolarizing	Na+	and	Ca2+	(Gold	and	Gebhart	2010).	Therefore,	a	direct	modulation	of	inflammatory	mediators	on	potassium	channels	may	influence	the	resting	membrane	potential	and	alter	the	level	of	stimulation	required	for	spike	initiation.			Metabotropic	receptors	such	as	GPCRs	signal	through	second	messenger	pathways,	therefore	activation	of	these	receptors	initiates	a	cascade	of	intracellular	signaling	events,	and	the	intracellular	substances	that	become	activated	can	subsequently	modulate	the	activity	of	other	receptors	within	the	plasma	membrane.	Prostaglandin	E2	(PGE2)	binds	to	GCRPs	to	increase	the	levels	of	cyclic	AMP	(cAMP)	within	nociceptors	to	subsequently	activate	protein	kinases	.	Protein	kinase	A	(PKA)	has	been	shown	to	phosphorylate	TTX-R	Na+	channels	which	shifts	their	voltage	dependence	in	the	hyperpolarizing	direction,	reducing	the	stimulation	needed	for	initiation	of	an	action	potential	(Julius	and	Basbaum	2001).	Bradykinin	can	activate	GPCRs	and	results	in	activation	of	phospholipase	C	(PLC),	this	intracellular	increase	in	PLC	can	modulate	TRPA1	receptors	and	evoke	mechanical	hypersensitivity	(Kwan	et	al	2006).			One	receptor	particularly	susceptible	to	modulation	via	second	messenger	intracellular	cascades	is	the	TRPV1	channel	as	shown	in	Figure	1.3.	The	TRPV1	channel	is	associated	with	a	number	of	intracellular	proteins;	one	example	is	phosphatidyl	inositol	4,5	biphosphate	(PIP2),	which	is	attached	to	TRPV1	through	its	C	terminal	domain	and	inhibits	channel	gating	(Prescott	and	Julius	2003).	The	activation	of	intracellular	PLC	through	GPCRs	can	cause	cleavage	of	PIP2	from	the	plasma	membrane	and	activates	the	TRPV1	receptor	(O’Neill	et	al	2014).	A	further	downstream	consequence	of	the	activation	of	intracellular	PLC	is	an	increase	in	intracellular	calcium	through	a	diglyceride	(DAG)	and	Inositol	1,4,5-triphosphate	(IP3)	mediated	pathway,	causing	further	activation	of	protein	kinases	(Basbaum	et	al	2009,	Gold	and	Gebhart	2010).		The	activation	of	GPCRs	can	also	cause	activation	of	adenylate	cyclases	and	subsequent	activation	of	PKA	and	PKCε	through	a	cAMP-activated	guanine	exchange	factor	(EPAC)	dependent	pathway	(Gold	and	Gebhart	2010).	In	addition,	activation	of	Ca2+-calmodulin-dependent	protein	kinase	II	(CaMKII)	can	be	caused	by	an	increase	in	intracellular	Ca2+.	TRPV1	can	become	sensitized	by	phosphorylation	via	both	of	these	protein	kinases	(Gold	and	Gebhart	2010).	Finally,	activated	second	messenger	cascades	can	cause	TRPV1	to	be	translocated	to	the	plasma	membrane,	further	increasing	nociceptor	excitability.		
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Figure	1.3.	Sensitisation	the	TRPV1	channel	due	to	the	activation	of	GPCRs	and	the	
subsequent	activation	of	intracellular	second	messenger	cascades.	The	activation	of	GPCRs	by	inflammatory	mediators	activates	intracellular	second	messenger	cascades	resulting	in	activation	of	phospholipase	C	(PLC),	protein	kinases	and	an	increase	in	intracellular	Ca2+.	All	of	these	intracellular	factors	can	sensitise	the	TRPV1	channel.	CaMKII	-	Ca2+-calmodulin-dependent	protein	kinase	II,	PKC	–	protein	kinase	C,	CaM	–	Calmodulin,	PLC	–	phospholipase	C,	DAG	–	diglyceride,	IP3	–	Inositol	1,4,5-triphosphate,	AC	–	adenylate	cyclase,	cAMP	–	cyclic	AMP,	PKA	–	protein	kinase	A,	EPAC	–	cAMP	activated	guanine	exchange	factor,	PKCε	–	protein	kinase	C	ε.	Figure	adapted	from	(Gold	and	Gebhart	2010).		As	there	are	multiple	sources	of	inflammatory	mediators,	a	vast	array	of	receptors	they	can	act	upon,	and	a	positive	feedback	response	to	activation	of	receptors	on	primary	afferents,	it	is	unsurprising	that	tissue	injury	has	a	rapid	and	intense	impact	upon	nociceptor	sensitization	and	the	resultant	pain	signal.	Overall,	the	increased	excitability	of	primary	afferents	fibres	results	in	an	increased	sensitivity	and	response	to	mechanical	and	thermal	stimuli.		
1.1.4.2	Primary	hyperalgesia	and	allodynia	Tissue	damage	and	the	subsequent	inflammatory	response	cause	excessive	activation	of	nociceptors	and	an	increased	sensitivity	to	pain.	There	are	two	main	clinical	symptoms	of	chronic	or	persistent	pain,	which	are	allodynia	and	hyperalgesia.	Firstly,	allodynia	is	characterized	by	a	painful	response	to	innuocuous	stimuli,	specifically	a	stimulus	that	would	not	usually	be	encoded	by	nociceptors.	Therefore,	the	Aβ	primary	afferents	that	usually	encode	innocuous	light	touch	and	brush	are	thought	to	be	responsible	for	
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allodynia	(Woolf	and	Doubell	1994).	In	contrast,	hyperalgesia	is	an	increased	response	to	noxious	stimuli	(Jensen	and	Finnerup	2014).	In	persistent	pain	states,	the	curve	that	describes	the	relationship	between	stimulus	strength	and	the	pain	response	is	shifted	leftwards,	as	shown	in	Figure	1.4,	as	patients	become	more	sensitive	to	mechanical	and	thermal	stimuli	(Jensen	and	Finnerup	2014).	The	consequence	of	this	leftward	shift	is	that	patients	show	allodynia	and	hyperalgesia	as	shown	in	Figure	1.4.	Mechanical	and	thermal	hyperalgesia	can	be	demonstrated	in	a	rat	model	of	acute	inflammation	induced	in	the	rat	paw	with	an	injection	of	complete	Freunds	adjuvant	(CFA)	(Andrew	and	Greenspan	1999).	Single	fibre	recordings	taken	from	the	sciatic	nerve	in	these	animals	showed	a	sensitised	response	to	suprathreshold	mechanical	and	thermal	stimuli	for	both	A	and	C	fibres,	but	mechanical	sensitization	was	greater	in	A	fibres.	The	authors	concluded	that	the	primary	hyperalgesia	caused	by	peripheral	inflammation	was	due	to	the	sensitised	state	of	the	nociceptors	(Andrew	and	Greenspan	1999).			
	
Figure	1.4.	Stimulus	strength	and	the	resulting	pain	response	in	both	the	normal	and	
sensitised	state.	The	Purple	curve	shows	the	stimulus-pain	relationship	expected	in	a	normal	subject.	The	blue	curve	shows	the	left-ward	shift	you	would	expect	to	the	stimulus-pain	relationship	in	a	patient	sensitised	to	pain.	The	bottom	of	the	curves	shows	allodynia,	where	low	strength	stimulation	that	would	usually	be	innocuous	causes	a	larger	pain	response.	The	difference	in	the	tops	of	the	curves	indicates	hyperalgesia,	where	noxious	stimulation	causes	a	greater	pain	intensity.		
1.1.4.3 Nerve	Growth	Factor	
	Of	particular	interest	in	inflammatory	conditions	such	as	osteoarthritis,	is	the	contribution	of	the	neurotrophin	NGF	to	peripheral	sensitization.	NGF	is	a	vital	component	of	the	‘inflammatory	soup’	produced	in	response	to	tissue	damage	and	can	act	as	a	sensitizing	agent	at	peptidergic	C	fibres	(McMahon	1996).	NGF	can	bind	to	two	receptors;	the	TrkA	receptor	selectively	binds	NGF	with	high	affinity	while	the	p75	
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receptor	will	bind	any	neutrophin	but	has	a	low	affinity	for	NGF	(Chao	2003).	Upon	the	binding	of	growth	factors	to	TrkA,	receptor	dimerization	is	induced	and	the	receptor	becomes	activated	(Lemmon	and	Schlessinger	2010).			NGF	has	been	shown	to	contribute	to	hypersensitivity	of	nociceptors	especially	through	sensitization	of	TRPV1.	The	TrkA	receptor	is	frequently	co-expressed	on	nociceptors	with	the	TRPV1	channel.	It	has	been	shown	that	NGF	rapidly	potentiates	the	responses	of	nociceptors	to	capsaicin;	specifically	NGF	enhanced	the	rise	of	intracellular	Ca2+	observed	in	primary	afferents	following	application	of	capsaicin	(Bonnington	and	McNaughton	2003).	Furthermore,	the	authors	found	a	specific	inhibitor	of	phosphoinositide	(PI3K)	totally	abolished	this	effect.	The	authors	suggest	that	through	binding	TrkA,	NGF	causes	activation	of	intracellular	PI3K,	which	activates	CaMKII,	this	subsequently	activates	PKC	and	hence	can	phosphorylate	the	TRPV1	receptor	(Bonnington	and	McNaughton	2003).	They	propose	this	pathway	is	a	crucial	initial	step	in	sensitization	of	TRPV1	in	response	to	NGF.	In	addition	to	this	second	messenger	cascade,	NGF	binding	TrkA	receptors	can	stimulate	intracellular	PLC	signaling	(Chuang	et	al	2001).	Further	co-immunoprecipitation	studies	showed	that	TRPV1	forms	a	complex	in	the	plasma	membrane	with	TrkA	and	PLC.	Once	activated,	PLC	can	mediate	the	hydrolysis	of	PIP2	from	TRPV1	to	sensitize	the	receptor	(Chao	et	al	2003).	Overall,	the	binding	of	NGF	to	TrkA	receptors	on	the	nociceptor	membrane	can	exacerbate	peripheral	sensitisation.			Additionally,	increased	levels	of	NGF	induce	nociceptor	sensitization	as	it	is	retrogradely	transported	to	the	nucleus	where	it	can	influence	gene	expression.	Specifically,	NGF	promotes	and	increases	expression	of	the	pronociceptive	proteins	substance	P	and	the	Nav1.8	channel.	This	change	in	gene	expression	and	subsequent	increase	in	Nav1.8	levels	can	lower	the	level	of	stimulation	needed	for	an	action	potential	to	fire	and	hence	enhances	the	excitability	of	the	nociceptor	(Basbaum	et	al	2009).			Increased	levels	of	NGF	at	the	site	of	inflammation	is	linked	to	an	increased	level	of	pain,	making	NGF	particularly	interesting	with	regard	to	osteoarthritis,	an	inflammatory	condition	of	the	joints.	Several	NGF	neutralizing	antibodies	have	been	produced	and	are	being	tested	for	their	effectiveness	at	reducing	peripheral	sensitisation.	Tanezumab	is	a	humanized	IgG2	monoclonal	antibody	that	functions	by	blocking	the	interaction	of	NGF	with	both	the	TrkA	and	p75	receptor.	In	clinical	trials	Tanezumab	reduced	joint	pain	in	patients	with	moderate	to	severe	osteoarthritis	of	the	knee	joint	(Lane	et	al	2010).		
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1.1.5 The	dorsal	horn	
	The	dorsal	horn	contains	the	first	synapse	of	ascending	pathways	that	subsequently	transmit	the	pain	signal	to	higher	centres,	making	it	the	first	relay	site	where	nociceptive	information	converges	and	is	transmitted	from	the	periphery	to	the	brain	(D’Mello	and	Dickenson	2008).	The	cell	bodies	in	the	DRG	split	into	two	main	branches,	the	peripheral	branch	innervates	external	tissue	such	as	skin	and	detects	noxious	stimuli,	while	the	central	branch	of	axons	travels	through	a	dorsal	root	to	enter	the	dorsal	horn	of	the	spinal	cord.	Here	the	peripheral	afferents	form	synapses	with	second	order	neurons	as	shown	in	Figure	1.5	(Bridgestock	and	Rae	2013).	Within	the	spinal	cord,	the	pain	signal	can	be	modulated	by	a	vast	array	of	neuron	types,	such	as	interneurons	or	descending	projections,	found	throughout	the	dorsal	horn.	Additionally,	the	primary	afferents	can	form	synapses	with	second	order	neurons	that	transmit	the	nociceptive	information	to	the	ventral	horn	to	mediate	a	nocifensive	reflex	(Todd	2010).		
	
Figure	1.5.	The	dorsal	horn.	Primary	afferent	nociceptors	converge	onto	the	dorsal	horn	of	the	spinal	cord	via	dorsal	root	ganglia.	Upon	termination	in	the	spinal	cord,	the	primary	afferent	fibres	form	synapses	with	second	order	neurons	that	transmit	the	signal	to	higher	centers	in	the	brain.	Figure	taken	from	(Bridgestock	and	Rae	2013).	The	dorsal	horn	is	divided	into	ten	lamina	starting	with	the	most	superficial	layer,	lamina	I,	and	moving	ventrally	through	to	lamina	X	(Figure	1.7).	A	brief	summary	of	the	lamina	arrangements	is	shown	in	Table	1.2.	The	functional	class	and	sensory	modality	of	the	primary	afferents	determines	where	they	terminate	within	the	dorsal	horn.	The	lumbar	region	of	the	spinal	cord	in	which	the	peripheral	nociceptors	terminate	depends	on	the	region	of	the	body	they	innervate.	Aβ	fibres	enter	the	dorsal	horn	through	the	dorsal	root,	where	the	main	axon	can	branch	into	collateral	fibres	which	then	terminate	throughout	lamina	II	to	lamina	V	(Todd	2010).	Aδ	primary	afferents	terminate	mainly	in	the	superficial	lamina	I	and	II	but	some	axonal	branches	pass	ventrally	to	terminate	in	lamina	IV	and	V	of	the	deep	dorsal	horn	(Light	and	Perl	1979).	Mainly,	C	fibres	terminate	in	the	superficial	dorsal	horn	in	lamina	I	and	II	(Todd	2010).		
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	The	exact	sites	at	which	peripheral	afferent	fibres	terminate	within	the	dorsal	horn	depend	upon	their	biochemical	properties.	Specifically,	the	non-peptidergic	C	fibres	project	to	the	dorsal	part	of	lamina	IIi.	Meanwhile	the	peptidergic	fibres	arborize	mostly	in	lamina	I	and	IIo,	however	they	have	some	further	terminations	in	the	deeper	dorsal	horn,	starting	at	lamina	IIi	and	scattered	through	to	lamina	V.	The	main	termination	sites	of	the	primary	afferents	are	shown	in	Figure	1.6.		The	primary	afferents	form	synapses	with	two	major	types	of	second-order	neurons	in	the	dorsal	horn,	these	neurons	are	the	nociceptive	specific	(NS)	neurons	and	the	wide	dynamic	range	(WDR)	neurons,	which	are	responsible	for	transmitting	the	pain	signal	to	higher	brain	centres	(Figure	1.6).	The	NS	neurons	specifically	detect	noxious	stimuli	and	are	mainly	located	in	lamina	I	(D’Mello	and	Dickenson	2008).	The	WDR	neurons	can	detect	a	range	of	stimulations,	from	innocuous	stimulation	such	as	light	touch	or	brush	to	stimulations	in	the	noxious	range.	The	WDR	neurons	are	located	in	lamina	V	and	receive	convergent	input	from	Aβ,	Aδ	and	C	fibres	(D’Mello	and	Dickenson	2008).		
		
Figure	1.6.	The	location	of	nociceptive	specific	and	wide	dynamic	range	neurons	and	the	
termination	zones	of	primary	afferents	in	the	dorsal	horn	of	the	spinal	cord.	The	Aβ 	fibres	have	termination	zones	extending	from	lamina	II	to	lamina	V.	The	Aδ	primary	afferents	terminated	mainly	in	the	superficial	lamina	I	and	II.	The	peptidergic	and	non-peptidergic	C	fibres	have	distinct	termination	patterns	with	the	peptidergic	fibres	terminating	more	superficially	in	the	dorsal	horn	than	the	non-peptidergic	C	fibres.	Figure	taken	from	(Todd	2010	and	D’Mello	and	Dickenson	2008).	Another	major	component	of	the	dorsal	horn	are	the	interneurons,	which	have	axons	that	remain	in	the	spinal	cord	and	arborize	locally	to	mediate	the	actions	of	surrounding	neurons.	These	are	particularly	abundant	in	the	superficial	lamina	with	interneurons	making	up	almost	all	of	the	neurons	in	lamina	II	and	most	of	the	neurons	in	lamina	I	and	
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III	(Todd	2010).	The	interneurons	that	are	involved	in	local	circuits	have	axons	that	terminate	in	the	same	segment	close	to	their	cell	body.	Some	interneurons	also	contain	axons	that	extend	into	other	lamina,	some	of	the	lamina	II	interneurons	have	axons	terminating	in	lamina	I	or	passing	ventrally	through	to	lamina	III-IV	(Todd	2010).			The	interneurons	can	be	characterized	into	excitatory	or	inhibitory	interneurons.	The	excitatory	interneurons	use	glutamate	as	their	neurotransmitter,	whereas	inhibitory	interneurons	use	the	neurotransmitters	GABA	and	glycine	(Todd	and	Spike	1993).	It	has	been	shown	using	immunocytochemistry	that	GABAergic	inhibitory	interneurons	are	dispersed	in	large	numbers	throughout	the	dorsal	horn,	whilst	the	termination	sites	of	gylcinergic	interneurons	are	more	common	in	the	deep	lamina	II-IV.	Furthermore,	immunostaining	studies	have	shown	that	GABA	and	glycine	can	be	co-released	from	these	neurons	(Todd	and	Sullivan	1990,	Todd	and	Spike	1993).	Through	the	release	of	these	neurotransmitters,	the	interneurons	can	target	other	nearby	neurons	within	the	dorsal	horn	to	modulate	their	activity.		Similarly	to	interneurons,	projection	neurons	can	also	be	found	in	the	dorsal	horn	concentrated	in	large	numbers	in	lamina	I,	with	a	few	scattered	through	lamina	III-VI	(Todd	2010).	With	the	use	of	tract	tracing	and	immunocytochemical	techniques,	it	was	demonstrated	that	lamina	I	and	III	projection	neurons	are	densely	innervated	by	pepetidergic	primary	afferent	C	fibres	containing	substance	P,	indicating	they	receive	nociceptive	signals	from	nociceptors	(Todd	et	al	2002).	Neurokinin-1	(NK1)	receptors	are	found	on	80%	of	lamina	I	projection	neurons.	The	release	of	substance	P	into	the	dorsal	horn	following	noxious	stimulation	can	then	activate	and	internalize	NK-1	receptors	located	on	the	projection	neurons	(Mantyh	et	al	1997,	Nichols	et	al	1999,	Suzuki	et	al	2002)	The	projection	neurons	have	axons	that	project	to	the	brain,	making	them	responsible	for	the	transmission	of	the	pain	signal	from	the	dorsal	horn	to	the	brain.	Many	of	these	axons	cross	the	midline	and	transmit	the	pain	signal	rostrally	through	the	contralateral	white	matter	where	they	subsequently	terminate	in	various	brain	regions.	The	brain	regions	in	which	the	lamina	I	projection	neurons	terminate	include	the	caudal	ventrolateral	medulla	(CVLM),	the	nucleus	of	the	solitary	tract	(NTS),	the	lateral	parabrachial	area	(LPb),	the	periaqueductal	grey	(PAG)	and	nuclei	in	the	thalamus	(Todd	2010).	Therefore	the	projection	neurons	represent	the	relay	point	responsible	for	the	transmission	of	the	nociceptive	signal	from	peripheral	afferent	neurons	to	brain	neurons	where	the	information	is	processed.			
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Table	1.2.	The	distribution	of	neurons	in	the	dorsal	horn.	
Lamina	 Neuronal	distribution	I	 Contains	the	highest	density	of	projection	neurons	in	the	dorsal	horn.	However,	projection	neurons	make	up	only	5%	of	the	total	neurons	in	lamina	I.	The	remaining	neurons	are	interneurons.	II	 Contains	virtually	all	unmyelinated	interneurons.	III	 Mostly	contains	small	myelinated	interneurons	but	also	includes	a	scattering	of	large	projection	neurons.		IV-VI	 Contains	heterogenous	neurons	of	various	sizes	some	of	which	are	projection	neurons.			
1.1.5.1 Transmission	of	the	pain	signal	
	The	depolarization	of	peripheral	sensory	fibres	leads	to	activation	of	VGCCs,	specifically	the	Cav2.2	channel.	The	subsequent	influx	of	Ca2+	initiates	the	release	of	neurotransmitters	from	presynaptic	terminals	into	the	spinal	cord.	All	primary	afferent	fibres	release	glutamate	as	the	main	excitatory	neurotransmitter	but	the	peptidergic	C	fibres	also	release	substance	P,	CGRP,	somatostatin,	brain-derived	neurotrophic	factor	(BDNF)	and	galanin	(Dickenson	1995).	There	are	three	ionotropic	glutamate	receptors	present	in	the	dorsal	horn:	the	α-amino-3-hydroxy-5-methylisoxazole-4-proprionic	acid	(AMPA)	receptor,	the	N-methyl	D-aspartate	(NMDA)	receptor,	and	the	kainite	receptor.	The	AMPA	receptor	mediates	fast	glutamatergic	neurotransmission;	hence	they	are	responsible	for	the	acute	response	to	the	nociceptive	signal	(Hartmann	et	al	2004,	Keinanen	et	al	1990).	The	NMDA	receptor	has	a	high	Ca2+	permeability	and	is	responsible	for	mediating	the	slower	component	of	excitatory	post-synaptic	potentials	(Monyer	et	al	1992)(Bleakman	et	al	2006).	The	activation	of	these	post-synaptic	receptors	on	second	order	neurons	in	the	dorsal	horn	evokes	an	influx	of	Ca2+	and	allows	the	transmission	of	the	nociceptive	signal	to	multiple	brain	regions.		
	
1.1.5.2	The	NMDA	receptor	and	wind-up	
	The	lamina	V	WDR	neurons	display	a	unique	characteristic	known	as	wind-up.	Wind-up	occurs	when	there	is	rapid	and	repeated	noxious	stimulation	acting	on	C	fibres,	which	results	in	an	enhanced	output	of	spinal	cord	neurons	(Dickenson	and	Sullivan	1987).	The	NMDA	receptor	has	voltage-dependent	sensitivity	to	magnesium,	under	normal	conditions	this	channel	is	closed	due	to	a	Mg2+	plug.	However	upon	peptidergic	C	fibres	co-releasing	neuropeptides,	such	as	substance	P	and	CGRP,	along	with	glutamate,	a	slow	membrane	depolarization	is	maintained	and	results	in	removal	of	the	Mg2+	plug	(D’Mello	and	Dickenson	2008).	Upon	removal	of	the	Mg2+	block	the	NMDA	channel	is	opened	and	
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in	this	configuration	is	highly	permeable	to	Ca2+,	meaning	Ca2+	floods	into	the	neuron	where	it	can	activate	effectors	and	subsequently	alter	downstream	signaling.	This	causes	an	increased	excitability	of	the	neuron	whereby	more	action	potentials	are	fired	in	response	to	subsequent	noxious	stimulation.	Wind-up	reflects	a	form	of	activity	dependent	plasticity	occurring	in	the	spinal	cord	and	the	NMDA	receptor	has	been	shown	to	be	sensitised	and	upregulated	in	both	inflammatory	and	neuropathic	pain	states	(Bleakman	et	al	2006,	Brown	and	Krupp	2006).	
	
1.1.6	Central	Sensitisation		The	sensory	processing	of	noxious	stimuli	can	be	amplified	in	chronic	pain	states	through	peripheral	sensitisation,	as	discussed	in	section	1.1.4,	and	also	through	neuronal	plasticity	in	the	spinal	cord.	Neuronal	plasticity	refers	to	the	ability	of	neurons	to	adjust	their	activities	and	connections	in	response	to	increased	stimulation.	Ongoing	stimulation	of	the	primary	afferent	C	and	Aδ	fibres	can	result	in	the	sensitisation	of	dorsal	horn	neurons.	Neurons	are	capable	of	changing	their	function,	chemical	profile	and	structure	in	response	to	an	intense	and	continuous	barrage	of	noxious	stimulation.	This	plasticity	results	in	an	increase	in	the	efficacy	and	strength	of	synapses	they	form	within	the	dorsal	horn.	Wind-up	demonstrates	a	form	of	plasticity	in	the	spinal	cord,	but	it	is	a	short-lived	phenomenon	that	disappears	upon	removal	of	the	stimulation,	when	the	normal	resting	membrane	potential	is	restored	(Herrero	et	al	2000).	Conversely	central	sensitisation	causes	profound	changes	in	sensory	processing,	which	outlasts	the	period	of	peripheral	stimulation	(Woolf	2011,	Woolf	and	Salter	2000).			There	are	different	forms	of	plasticity	within	the	dorsal	horn	that	can	contribute	to	the	overall	manifestation	of	central	sensitisation.	When	the	neuronal	changes	are	limited	to	the	activated	synapse	they	are	referred	to	as	homosynaptic,	when	the	modulation	of	responses	spreads	to	adjacent	synapses	it	is	heterosynpatic	(Woolf	and	Salter	2000).	Long	term	potentiation	(LTP)	is	a	homosynaptic	potentiation	which	occurs	due	to	brief	high	frequency	peripheral	inputs.	The	excitability	of	synapses	can	be	modulated	by	pre-	and	post-synaptic	transcriptional	changes,	this	process	takes	the	longest	to	manifest	and	can	last	for	days	(McMahon	et	al	2013,	Section	1	Chapter	5).	Finally	there	can	be	a	depression	of	inhibition,	mediated	by	both	inhibitory	interneurons	and	descending	controls,	in	the	dorsal	horn	(Rahman	et	al	2008,	Todd	2010).			
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Similarly	to	wind-up,	activity	dependent	central	sensitization	begins	with	intense	stimulation	of	small	unmyelinated	nociceptors.	The	peptidergic	C	fibres	synthesize	substance	P,	BDNF	and	CGRP,	which	can	be	released	upon	nociceptor	activation	and	ultimately	result	in	the	release	of	the	Mg2+	plug	from	post-synaptic	NMDA	receptors.	Activation	of	the	NMDA	channel	results	in	a	dramatic	enhancement	in	the	influx	of	Ca2+	into	the	neuron	(Dickenson	and	Sullivan	1987).	In	addition,	substance	P,	BDNF	and	GCRP	are	released	from	pre-synaptic	terminals,	and	can	bind	to	post-synaptic	NK-1,	Tyrosine	kinase	B	(TrkB)	and	CGRP	receptors	respectively	(Latremoliere	and	Woolf	2009).	The	binding	of	these	neuropeptides	to	their	post-synaptic	receptors	and	an	increase	in	intracellular	Ca2+	above	a	sufficient	threshold	can	set	off	a	cascade	of	intracellular	signaling	pathways,	and	this	leads	to	subsequent	modifications	of	other	post-synaptic	receptors.	Activation	of	intracellular	signaling	cascades	subsequently	activates	the	downstream	protein	kinases	PKA,	PKC,	CamKII	and	the	nonreceptor	tyrosine	kinase	Src,	which	can	all	go	on	to	phosphorylate	tyrosine	and	serine	residues	on	other	intracellular	proteins	(Ji	and	Woolf	2001).	PKA	and	PKC	phosphorylate	several	serine	residues	on	the	C	terminus	of	AMPA	and	NMDA	receptors,	this	post-translational	modification	changes	channel	activity	and	increases	trafficking	of	these	receptors	to	the	membrane.	PKC	mediated	phosphorylation	of	AMPA	receptors	and	their	subsequent	insertion	into	the	plasma	membrane	activates	‘silent’	glutamatergic	synpases	between	primary	afferents	and	second	order	dorsal	horn	neurons	(Li	et	al	1999).	Secondly,	CaMKII	can	phosphorylate	the	Ser831	residue	on	GluR1	subunits	of	AMPA	receptors,	which	causes	the	channel	to	open	in	a	high	conductance	state	(Latremoliere	and	Woolf	2009).	Furthermore,	the	conductance	properties	of	NMDA	receptors	can	be	modified	by	phosphorylation	of	tyrosine	residues,	mediated	by	Src	(Yu	et	al	1997,	Woolf	and	Salter	2000).	Most	of	these	activated	signaling	pathways	converge	to	activate	the	intracellular	protein	ERK.	ERK	phosphorylates	the	Ser616	residue	on	the	voltage-gated	potassium	channel	Kv4.2,	which	decreases	K+	currents	and	subsequently	increases	membrane	excitability	(Latremoliere	and	Woolf	2009).	Overall,	the	phosphorylation	of	membrane	receptors	and	intracellular	proteins	play	a	major	role	in	the	increased	neuronal	activity	observed	in	central	sensitisation.		The	activation	of	intracellular	signaling	cascades	due	to	activity	dependent	central	sensitisation	can	also	mediate	transcriptional	changes.	Another	function	of	activated	ERK	in	central	sensitisation	involves	its	entry	into	the	nucleus	along	with	other	activated	transcription	factors	to	drive	the	expression	of	genes	through	binding	to	their	promoter	regions.	Specifically,	when	ERK	enters	the	nucleus	it	phosphorylates	the	
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Ser133	residue	on	the	cAMP	response	element-binding	protein	(CREB)	(Latremoliere	and	Woolf	2009).	An	increased	expression	of	the	early	response	genes	c-Fos	and	Cox-2,	and	the	late	response	genes	NK1	and	TrkB	have	been	shown	in	dorsal	horn	neurons	in	response	to	noxious	stimulation	and	inflammation	(Woolf	and	Salter	2000,	Hunt	et	al	1987).	The	intracellular	mechanisms	mediating	activity	dependent	central	sensitisation	are	shown	in	Figure	1.7.			Long	term	potentiation	(LTP)	involves	long-term	enhancement	and	structural	changes	at	the	level	of	the	synapse	(Soderling	and	Derkach	2000).	This	phenomenon	has	been	mostly	studied	in	CA1	hippocampal	synapses	where	it	has	been	shown	that	enhancement	of	NMDA	receptor	function	mediated	by	Src	phosphorylating	tyrosine	residues	raises	intracellular	Ca2+	and	subsequently	activates	CaMKII	and	PKC	(Bliss	and	Collingridge	1993).	These	kinases	can	increase	trafficking	of	AMPA	receptors	to	the	cell	surface	and	enhance	the	conductance	of	this	channel	(McMahon	et	al	2013,	Section	1	Chapter	5).	The	expression	of	CaMKII	is	relatively	low	in	the	dorsal	horn,	therefore	the	serine/threonine	kinase	PKC	is	believed	to	play	the	principle	role	in	increasing	the	excitability	of	the	AMPA	receptor	for	LTP	in	the	spinal	cord	(Woolf	and	Salter	2000,	Soderling	and	Derkach	2000).			The	final	mechanism	believed	to	play	a	role	in	central	sensitisation	is	disinhibition,	where	spinal	inhibitory	interneurons	are	suppressed	allowing	excitatory	transmission	to	be	sustained	(Todd	2010).	This	phenomenon	has	been	confirmed	using	nerve	injury	models	in	the	rat.	Firstly,	GABAergic	density	has	been	demonstrated	to	be	significantly	reduced	in	lamina	I-III	of	the	dorsal	horn	following	injury	of	the	sciatic	nerve	(Ibuki	et	al	1997).	Yet,	some	GABAergic	immunoreactivity	returned	several	weeks	after	injury,	suggesting	there	was	a	downregulation	of	this	neurotransmitter	rather	than	a	loss	of	immunoreactivity	due	to	neuronal	death	(Ibuki	et	al	1997).	Furthermore,	GABA	receptor	mediated	inhibitory	post-synaptic	currents	were	found	to	be	decreased	in	two	models	of	peripheral	nerve	injury,	both	chronic	constriction	and	spared	nerve	injury	(Moore	et	al	2002).	However,	peripheral	nerve	injury	does	cause	cell	death	in	the	dorsal	horn	as	an	increase	in	the	number	of	apoptotic	cells	has	been	shown	in	the	ipsilateral	dorsal	horn	following	chronic	constriction	injury	(Whiteside	and	Munglani	2001).	Taken	together,	the	cell	death	of	inhibitory	interneurons,	or	a	reduction	in	GABAergic	inhibitory	currents	could	be	contributing	to	the	maintenance	of	central	sensitisation	(Woolf	2000).		
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The	main	symptoms	of	central	sensitisation	are	secondary	hyperalgesia	and	allodynia.	Secondary	hyperalgesia	occurs	due	to	the	increased	synaptic	efficacy	in	the	dorsal	horn,	which	means	that	there	is	an	increase	in	the	number	of	action	potentials	fired	in	response	to	noxious	stimulation,	and	subsequently	a	heightened	response.	While	this	increased	response	is	found	in	central	terminal	synapses	for	nociceptors	that	are	activated	by	the	initiating	stimulus,	low	threshold	Aβ	fibres	that	would	not	respond	in	a	normal	setting	also	begin	to	activate	second	order	dorsal	horn	neurons	(McMahon	et	al	2013,	Section	1	Chapter	5).	As	such,	the	NS	neurons	found	in	superficial	lamina	begin	to	function	as	WDR	neurons	responding	to	both	noxious	and	innocuous	simulation	(Latremoliere	and	Woolf	2009).	In	response	to	injury,	the	central	axons	of	myelinated	Aβ	fibres	can	sprout	from	their	normal	termination	site	in	the	deeper	lamina	of	the	dorsal	horn	into	the	superficial	lamina	and	enter	termination	sites	normally	restricted	to	C	and	Aδ	fibres	(Baba	et	al	1999).	The	NS	neurons	now	have	a	reduced	activation	threshold;	meaning	innocuous	stimuli	in	the	periphery	can	now	elicit	a	noxious	response,	this	is	known	as	secondary	allodynia.	Furthermore,	Aβ	fibres	have	been	shown	to	start	expressing	and	releasing	substance	P	following	nerve	injury	(Malcangio	et	al	2000).	This	allows	Aβ	fibres	to	contribute	to	central	sensitisation	further	by	increasing	the	activation	of	sensitising	intracellular	signaling	cascades	(Malcangio	2000).	In	an	inflammatory	arthritis	model	displaying	secondary	hyperalgesia,	stimulation	of	A	nociceptors	results	in	c-Fos	like	immunoreactivity	in	lamina	I	and	IV-V	of	the	dorsal	horn,	suggesting	sensitisation	of	dorsal	horn	neurons	in	these	lamina	contribute	to	secondary	sensitivity	(Hsieh	et	al	2015).	Additionallt,	the	ablation	of	NK1	receptor-expressing	projection	cells	in	the	superficial	lamina	of	the	dorsal	horn	with	a	substance	P	saporin	conjugate	prevents	the	development	of	hyperalgesia	in	models	of	inflammatory	and	neuropathic	pain	(Mantyh	et	al	1997,	Nichols	et	al	1999).	Overall,	an	expansion	of	the	receptive	fields	of	dorsal	horn	neurons	occurs	due	to	the	recruitment	of	subthreshold	synaptic	input	meaning	that	areas	adjacent	to	the	site	of	injury	become	sensitised	(Latremoliere	and	Woolf	2010).			
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Figure	1.7.	The	intracellular	pathways	responsible	for	activity	dependent	central	
sensitisation.	The	influx	of	calcium	through	NMDA	receptors	and	activation	of	TrkB,	CGRP	and	NK1	receptors	cause	activation	of	intracellular	protein	kinases.	(A)PKC,	PKA	and	CaMKII	phosphorylation	of	post-synaptic	receptors	alters	their	threshold	and	activation	kinetics	to	produce	an	increased	synaptic	efficacy.	(B).This	phosphorylation	can	also	result	in	increased	trafficking	of	these	receptors	to	the	plasma	membrane.	(C)	Transcirptional	changes	can	be	mediated	by	CREB,	driving	the	expression	of	pain	responsive	genes:	c-Fos,	neurokinin	1	(NK1),	tyrosine	kinase	B	(TrkB)	and	cyclooxygenase-2	(Cox-2).	mGluR	–	metabotropic	glutamate	receptor,	B2	–	β2	adrenoceptor,	AMPAR	-	α-amino-3-hydroxy-5-methylisoxazole-4-proprionic	acid	Receptor,	NMDAR	-	N-methyl	D-aspartate	Receptor,	NK1R	–	Neurokinin-1	receptor,	TrkB	–	Tyrosine	kinase	B	receptor,	CGRPR	–	calcitonin	gene-related	peptide	receptor,	VDGC	–	voltage-dependent	gated	channel,	ER	–	endoplasmic	reticulum,	PKA	–	protein	kinase	A,	CaMKII	-	Ca2+-calmodulin-dependent	protein	kinase	II,	PKC	–	protein	kinase	,	CREB	–	cAMP	response	binding	element	protein.	Figure	taken	from	(Woolf	and	Salter	2000).		The	overall	and	combined	effect	of	central	sensitisation	mechanisms	is	an	amplified	response	to	subsequent	noxious	and	innocuous	stimulation	(McMahon	et	al	2013,	Section	1	Chapter	5).	Peripheral	sensitisation	and	central	sensitisation	often	exist	together	in	chronic	pain	states.	For	instance,	the	barrage	of	peripheral	nociceptive	information	due	to	peripheral	sensitisation	can	lead	to	the	development	of	central	sensitisation.	Therefore,	it	can	be	difficult	to	dissect	the	specific	peripheral	and	central	contributions	resulting	in	an	increased	pain	perception.		
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1.1.6.1	Glia	in	the	spinal	cord	
	Within	the	central	nervous	system,	glial	cells	outnumber	neurons	ten	to	one	(McMahon	et	al	2013,	Section	1	Chapter	5).	Glial	cells	are	not	directly	involved	in	synaptic	signaling	of	electrical	activity	but	provide	functional	support	to	the	neurons	by	maintaining	their	synaptic	connections	and	signaling	ability,	glia	are	abundant	in	the	spinal	cord	and	are	believed	to	play	a	crucial	role	in	central	sensitisation	(Purves	et	al	2001).	The	neurons	can	influence	the	functional	properties	of	glial	cells,	and	vice	versa,	neurons	can	initiate	signals	to	alter	the	function	of	glial	cells,	this	causes	the	glial	cells	to	release	factors	that	regulate	neuronal	function	(McMahon	and	Malcangio	2009).	There	are	three	types	of	glial	cells	found	in	the	central	nervous	system:	the	oligodendrocytes,	astrocytes	and	microglia.	In	the	central	nervous	system,	oligodendrocytes	are	involved	in	providing	support	and	insulation	to	the	neurons	through	myelinating	axons	(Purves	et	al	2001).		Astrocytes	are	the	most	abundant	glial	cell	type	in	the	central	nervous	system	making	up	around	40-50%	of	the	glial	cells.	Astrocytes	are	derived	from	the	neuroectoderm	and	can	become	activated	in	response	to	tissue	damage	(Milligan	and	Watkins	2009).	In	inflammatory	pain	models,	both	astrocytes	and	microglia	are	activated	in	the	spinal	cord	(Bradesi	2010).	The	astrocytes	have	an	intimate	relationship	with	neurons	as	they	enwrap	synapses	to	provide	anatomical	support.	Furthermore,	astrocytes	also	regulate	the	extracellular	ions	in	the	synapse	through	the	use	of	voltage	gates	channels	on	their	cell	surface.	There	are	two	mechanisms	by	which	astrocytes	can	regulate	extracellular	ions.	Firstly,	astrocytes	express	a	Na+/K+	ATPase	channel,	which	is	responsible	for	the	removal	of	K+	from	the	synapse.	Secondly,	astrocytes	can	remove	glutamate	from	the	synaptic	cleft	via	high	affinity	glutamate	transporters	expressed	on	their	cell	surface.	Through	these	mechanisms	astrocytes	help	to	maintain	a	normal	synaptic	excitability	but	following	nerve	injury	the	expression	of	these	channels	can	be	differentially	regulated,	the	subsequent	deficient	removal	of	glutamate	and	K+	from	the	synapse	could	contribute	to	the	enhancement	of	neuronal	excitability	(Xin	et	al	2009).				Microglia	are	a	population	of	macrophages	with	a	mesodermal	origin,	being	derived	from	myeloid	precursor	cells.	In	the	normal	setting,	microglia	are	dormant	but	upon	injury	or	tissue	damage	they	can	detect	various	stimuli	or	factors	that	may	be	released	into	the	spinal	cord	that	may	threaten	the	physiological	homeostasis	(McMahon	and	Malcangio	2009).	Upon	detecting	tissue	damage	associated	stimuli	microgliosis	can	occur,	whereby	the	local	density	of	microglia	increases	by	local	proliferation	and	
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through	migration	of	these	cells	from	other	sites	within	the	central	nervous	system	(Calvo	and	Bennett	2010).	Upon	detection	of	potentially	harmful	stimuli	and	activation	of	the	microglia,	they	change	their	morphology	from	a	resting	ramified	shape	into	an	active	amoeboid	one.	Activation	of	microglia	can	also	occur	due	to	damage	outside	of	the	central	nervous	system;	when	peripheral	afferents	become	damaged	microgliosis	occurs	in	the	dorsal	horn	where	the	injured	sensory	afferents	terminate.	Activated	microglia	can	exacerbate	the	pain	state	further	through	the	production	of	pro-inflammatory	cytokines,	chemokines	and	extracellular	proteases	(Schomberg	and	Olsen	2012).			The	activated	microglia	express	ATP-gated	P2X	receptor	ion	channels	on	their	cell	surfaces,	which	are	permeable	to	Ca2+.	ATP	can	be	released	by	activated	primary	afferents,	glial	cells,	and	central	neurons	(McMahon	and	Malcangio	2009).	When	ATP	stimulates	these	receptors,	a	Ca2+	influx	occurs	in	microglia	and	subsequently	activates	downstream	signaling	proteins.	One	such	pathway	that	becomes	activated	is	the	p38	mitogen-activated	protein	kinase	(p38	MAPK),	which	can	subsequently	cause	release	of	the	cysteine	protease	Cathepsin	S	(CatS)	from	microglia	(Clark	and	Malcangio	2012).	The	release	of	CatS	can	liberate	the	transmembrane	chemokine	Fractalkine	(FKN)	from	neurons,	which	can	then	feed	back	to	microglia	to	promote	activation	of	the	p38	MAPK	pathway	and	enhance	the	release	of	inflammatory	mediators	further	(Clark	and	Malcangio	2012).	This	creates	a	positive	feedback	loop	between	the	neurons	and	microglia	that	ultimately	causes	an	increase	in	the	activation	of	neurons	signaling	to	higher	centres	in	the	brain.	Therefore,	pharmacologically	interrupting	the	cathepsin/fractalkine	signaling	could	prevent	hypersensitivity	developing	in	chronic	pain	states.	Previous	studies	have	confirmed	this,	firstly	a	pharmacological	inhibitor	of	p38	MAPK	has	been	shown	to	reverse	mechanical	allodynia	(Tsuda	et	al	2003).	Secondly,	the	expression	of	the	P2X4	receptor	has	been	found	to	be	increased	in	the	ipsilateral	dorsal	horn	in	response	to	nerve	injury.	The	pharmocological	blockade	of	this	receptor	with	an	intrathecal	antagonsist	or	intraspinal	administration	of	P2X4R	antisense	oligodeoxynucleotides	prevented	allodynia	in	a	spinal	nerve	ligation	model	(Tsuda	et	al	2003).	Overall,	the	ATP-mediated	communication	between	neurons	and	microglia	in	the	spinal	cord	may	be	a	major	mechanism	responsible	for	exacerbation	and	development	of	central	sensitisation.		Additionally,	the	activation	of	glia	can	induce	the	expression	of	pro-inflammatory	cytokines	in	the	spinal	cord.	A	spinal	injection	of	the	pro-inflammatory	cytokines	IL-1β,	TNFα	and	IL-6	increase	CREB	phosphorylation	in	superficial	dorsal	horn	neurons	and	
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induce	hyperalgesia	(Kawasaki	et	al	2008).	Furthermore,	TNFα	and	IL-1β	enhance	AMPA	and	NMDA	induced	currents,	while	IL-1β	and	IL-6	suppress	GABA	and	glycine	induced	currents.	Therefore,	pro-inflammatory	cytokines	can	induce	synaptic	and	contribute	to	central	sensitisation	by	increasing	excitatory	and/or	decreasing	inhibitory	synaptic	transmission	(Kawasaki	et	al	2008).			
1.1.7	Ascending	projections,	the	brain	and	descending	controls	
	Once	the	nociceptive	information	in	the	periphery	has	converged	onto	neurons	in	the	dorsal	horn,	projection	neurons	can	form	ascending	tracts	that	transmit	the	nociceptive	signal	to	specific	brain	regions.	Upon	reaching	higher	centers	in	the	brain,	the	nociceptive	information	can	be	consciously	perceived	as	a	pain	signal.	Multiple	brain	regions	are	responsible	for	the	processing	of	the	pain	signal	and	may	subsequently	project	from	the	site	from	which	descending	fibres	are	projected	back	to	the	dorsal	horn	of	the	spinal	cord.	These	descending	fibres	can	have	either	inhibitory	or	facilitatory	actions,	which	modulate	pain	processing	by	determining	the	overall	excitability	of	dorsal	horn	neurons.	Therefore,	the	descending	controls	are	largely	responsible	for	determining	pain	perception	as	a	result	of	peripheral	nociceptive	drive.			
1.1.7.1 The	spinothalamic	tract	
	A	main	ascending	pathway	involved	in	transmitting	nociceptive	activity	from	the	dorsal	horn	of	the	spinal	cord	to	the	brain	in	humans	is	the	spinothalamic	(STT)	tract.	This	pathway	initiates	in	the	spinal	grey	matter,	from	where	it	can	convey	pain-related	information	directly	to	the	thalamus.	This	pathway	is	associated	with	the	sensation	of	pain,	itch	and	temperature	and	can	originate	from	lamina	I	or	IV-V	cells	within	the	dorsal	horn	(McMahon	et	al	2013,	Section	1	Chapter	11).	The	thalamus	is	a	supraspinal	structure	responsible	for	the	processing	and	integration	of	nociceptive	signals	before	transferring	this	information	on	to	other	brain	structures.	It	is	the	role	of	the	thalamic	relay	nuclei	to	filter	and	process	sensory	information	before	it	is	sent	to	the	cerebral	cortex	(Kuner	2010).	It	can	encode	information	regarding	the	type,	temporal	pattern,	intensity	and	localization	of	the	pain	signal,	whilst	interlinking	with	cortical	and	limbic	structures	involved	in	both	the	sensory-discriminative	and	emotional	components	of	the	pain	sensation	(Milligan	1998).				
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1.1.7.2 The	spino-bulbo-spinal	loop	
	There	are	also	indirect	ascending	pathways	that	send	messages	to	the	forebrain	through	the	contact	of	homeostatic	sites	within	the	brainstem,	these	are	the	spinobulbar	projections.	It	was	shown	using	retrograde	labeling	that	spinobulbar	cells	initiating	these	tracts	are	found	specifically	in	lamina	I,	V	and	VII	in	primates	(Wiberg	et	al	1987).	Two	major	areas	of	the	brainstem	where	these	spinobulbar	projections	terminate	are	the	parabrachial	nucleus	and	the	periaqueductal	grey	(PAG).	The	PAG	receives	direct	spinal	nocicieptive	input	and	is	connected	with	other	levels	of	the	central	nervous	system	including	the	forebrain	structures	involved	in	the	transmission	of	pain	.	This	makes	it	ideally	located	for	integration	of	brain	areas	involved	in	the	emotional-affective	components	of	pain	(Cerminara	et	al	2009).	Therefore,	the	PAG	is	thought	to	be	a	critical	site	for	managing	different	types	of	stress	and	threat	(Vaccarino	et	al	1997).	Similar	to	the	spinobulbar	projections	are	the	spinomedullar	projections,	which	contact	homeostatic	sites	in	the	medulla	of	the	brain	but	also	have	further	links	to	forebrain	areas	(McMahon	et	al	2013,	Section	1	Chapter	11).			Importantly,	this	system	is	a	loop	and	therefore	it	also	forms	projections	from	the	brain	back	to	the	spinal	cord	where	dorsal	horn	excitability	is	modulated.	The	PAG	is	an		important	site	for	the	initiation	of	descending	pathways,	which	project	to	the	dorsal	horn	via	the	rotralventomedial	medulla	(RVM)	The	Rostroventromedial	Medulla	(RVM)	is	a	heterogenous	area	within	the	brainstem	that	consists	of	several	nuclei	including	the	5HT	rich	Nucleus	Raphe	Magnus	(NRM).	It	receives	direct	sensory	input	whilst	also	relaying	descending	modulatory	projections	to	both	superficial	and	deeper	dorsal	horn	neurones	of	the	spinal	cord	(Milligan	2002,	Suzuki	et	al	2004,	Bee	and	Dickenson	2007,	Heinricher	et	al	2009).	The	RVM	is	the	final	relay	for	midbrain	modulatory	influences	and	can	facilitate	or	inhibit	incoming	inputs	to	the	deep	dorsal	horn.	(Fields	et	al	1991).		The	PAG-RVM	system	can	inhibit	spinal	nociceptive	transmission,	preferentially	inhibiting	C-fibre	mediated	nociceptive	signals	(Heinricher	et	al	2009).	Peripheral	tissue	damage	can	have	long-lasting	effects	on	the	excitability	of	cells	found	in	the	RVM	(Gebhart	2004).				The	RVM	is	capable	of	bimodal	modulation	through	recruitment	of	different	cell	types,	which	can	be	characterized	by	their	responses	to	noxious	stimuli.	OFF-cells	are	inhibitory	and	under	normal	conditions	they	are	constantly	firing.	However,	in	response	
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to	a	noxious	stimulus	OFF	cells	will	pause	in	activity	immediately	before	a	reflex	(De	Felice	et	al	2011).	GABAergic	axons	arising	in	the	RVM	arborize	throughout	the	dorsal	horn	and	can	form	synapses	with	lamina	II	interneurons,	indicating	a	mechanism	for	the	RVM	mediated	inhibition	in	the	dorsal	horn.	On	the	contrary,	ON-cells	will	accelerate	in	firing	in	response	to	a	noxious	stimulus	before	a	nociceptive	reflex	(Porecca	2002).	It	is	these	cells	that	are	responsible	for	the	descending	facilitation	from	the	RVM	and	are	inhibited	by	analgesic	opioids.			
1.1.7.3 The	cortical	processing	of	pain	
	There	are	two	different	types	of	neuroanatomical	ascending	pathway;	monosynaptic	pathways	project	directly	to	higher	cerebral	structures	while	polysynaptic	pathways	use	a	relay	station	with	other	neurones	to	transmit	the	information	(Milligan	1998).	The	ascending	pathways	that	carry	nociceptive	information	are	complex	and	stimulate	many	areas	within	the	brain.	The	areas	of	the	brain	consistently	activated	by	nociceptive	input	are	known	as	the	“pain	matrix”	as	shown	in	Figure	1.8.	Through	the	use	of	imagining	techniques	in	humans	it	has	been	possible	to	detect	these	regions.	The	identified	areas	of	the	brain	are	the	anterior	cingulate	cortex	(ACC),	the	primary	and	secondary	somatosensory	cortices,	the	prefrontal	cortices	and	the	thalamus	(Tracey	and	Manyth	2007)(Talbot	et	al	1991).	Additionally,	the	hypothalamus	and	amygdala	are	activated	in	the	pain	process	through	projections	from	the	parabrachial	nucleus,	and	these	are	known	as	the	spinohypothalamic	and	spinoamygdalar	tracts.	The	involvement	of	these	brain	areas	in	nociceptive	transmission	would	explain	why	pain	is	accompanied	by	motivational-affective	symptoms	like	anxiety	and	suffering	(Benzon	et	al	2013)(Rainville	2002).	Overall,	the	pain	matrix	has	two	components;	the	sensory-discriminative	component	determines	the	location	and	intensity	of	the	incoming	pain	signal	while	the	affective-cognitive	component	defines	the	emotional	aspect	of	the	pain	experience	(Tracey	and	Mantyh	2007).			
1.1.7.4 Descending	pathways		
	Cortical	centres	can	influence	spinal	function	through	monoaminergic	descending	pathways	(Bannister	et	al	2009).	The	serotonergic	(5-HT)	descending	pathway	originates	mainly	in	the	nucleus	raphe	magnus	of	the	RVM	while	the	noradrenergic	(NA)	descending	system	arises	from	the	locus	coeruleus	(LC)	and	other	pontine	regions	of	the	brainstem.	The	axons	originating	from	these	brainstem	areas	terminate	diffusely	throughout	the	dorsal	horn.	While	some	of	these	axons	form	synapse	in	the	dorsal	horn,	
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much	of	the	action	of	5-HT	and	NA	is	mediated	through	volume	transmission	(Todd	2010).			Once	the	monoamines	are	released	into	the	dorsal	horn,	they	can	have	inhibitory	or	faclitatory	actions	depending	on	the	receptor	they	activate.	Noradrenaline	has	inhibitory	actions	in	the	spinal	cord	through	activation	of	α2-adrenergic	receptors.	The	α2-adrenergic	receptors	are	found	on	both	the	central	terminals	of	primary	afferent	fibres	where	NA	elicits	pre-synaptic	inhibition,	and	on	spinal	pain-relay	neurons	where	NA	mediates	post-synaptic	inhibition.	Noradrenaline	can	also	mediate	inhibitory	actions	in	the	spinal	cord	through	its	binding	to	α1-adrenergic	receptors	on	inhibitory	interneurons	(Petrovaara	2013).			The	actions	of	5-HT	are	more	complex	and	have	been	shown	to	mediate	both	pro-nociceptive	and	anti-nociceptive	actions	at	the	level	of	the	spinal	cord.	5-HT	can	mediate	facilitatory	actions	in	the	dorsal	horn,	particularly	in	chronic	pain	states,	as	the	depletion	of	spinal	5-HT	attenuates	hypersentivity	in	neuropathic	pain	(Rahman	2006).	Both	5-HT2	and	5-HT3	receptors	are	shown	to	play	pro-nociceptive	roles	in	the	dorsal	horn,	implicating	them	in	the	facilitation	carried	out	by	5-HT	(Rahman	et	al	2011,	Suzuki	et	al	2002).	However,	the	spinal	application	of	5-HT	has	an	overall	antinociceptive	role	indicating	that	activation	of	other	5-HT	receptors	in	the	spinal	cord	mediate	inhibition	(Milligan	1995).	Recently,	the	5-HT7	receptor	has	attracted	attention	as	a	promising	candidate	for	carrying	out	the	antinociceptive	actions	of	5-HT.	Indeed,	the	analgesic	action	of	morphine	microinjected	into	the	RVM	is	prevented	with	the	spinal	application	of	a	5-HT7	receptor	antagonist	(Dogurl	et	al	2009).	This	suggests	that	inhibitory	descending	pathways	arising	in	the	RVM	act	in	the	spinal	cord	through	activation	of	the	5-HT7	receptor.			A	balance	exists	between	the	descending	inhibitory	and	facilitatory	pathways.	However,	the	plasticity	that	exists	within	these	NA	and	5-HT	pathways	suggests	they	can	be	altered	in	chronic	pain	states.	Specifically,	an	increased	5-HT	facilitatory	drive	and	a	downregulation	of	the	NA	descending	pathway	may	contribute	to	the	maintenance	of	hypersensitivity	in	chronic	pain	(Porecca	et	al	2002,	Leiphart	et	al	2003).			
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Figure	1.8.	The	brain	regions	involved	in	the	processing	of	the	pain	signal.	Peripheral	afferent	fibres	carry	nociceptive	information	to	the	dorsal	horn	of	the	spinal	cord.	Projection	neurons	then	carry	the	nociceptive	signal	from	the	dorsal	horn	to	higher	brain	centres	along	ascending	pathways.	The	highlighted	areas	show	the	brainstem,	midbrain	and	forebrain	areas	activated	during	the	pain	experience.	Descending	controls	can	then	modulate	the	pain	signal	at	the	level	of	the	spinal	cord	by	exhibiting	a	facilitatory	or	inhibitory	drive.				
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1.2 Diffuse	Noxious	Inhibitory	Controls	
	
1.2.1 What	are	diffuse	noxious	inhibitory	controls?	
	Diffuse	noxious	inhibitory	controls	(DNIC)	describe	the	phenomenon	whereby	one	pain	inhibits	another.	This	unique	form	of	endogenous	inhibitory	control	can	be	seen	in	spinal	and	trigeminal	convergent	WDR	neurons	(Le	Bars	1979a,	Le	Bars	et	al	1981,	Cadden	et	al	1993).	All	activities	of	WDR	neurons,	both	noxious	and	innocuous,	can	be	strongly	inhibited	by	a	second	concomitant	noxious	conditioning	stimulus	outside	of	their	receptive	field	(Bannister	and	Dickenson	2017).	The	WDR	neurons	are	important	for	the	transmission	of	nociceptive	signals	through	the	dorsal	horn.	The	inhibition	of	the	transmission	of	these	signals,	mediated	by	a	nociceptive	stimulation	that	is	outside	of	their	own	receptive	field,	demonstrates	that	this	inhibitory	modulation	is	not	somatotopically	organized	but	rather	applies	to	the	whole	body	(Le	Bars	and	Willer	2008).	An	intense	noxious	conditioning	stimulus	can	cause	long-lasting	post-stimulus	effects,	where	persistent	inhibition	of	convergent	neurons	can	be	seen	for	several	minutes	following	removal	of	the	conditioning	stimulus	(Le	Bars	and	Willer	2008).	This	phenomenon	is	often	referred	to	as	counter	irritation	or	counter	stimulation.			DNIC	is	mediated	by	a	final	post-synaptic	mechanism	that	acts	on	the	cell	bodies	of	convergent	neurons	in	the	spinal	cord	(Villanueva	et	al	1984).	To	confirm	this	extracellular	recordings	were	taken	from	convergent	neurons	in	the	dorsal	horn	that	were	excited	by	electrophoretic	application	of	glutamate,	and	this	was	then	repeated	in	the	presence	of	a	noxious	conditioning	stimulus	(Villanueva	et	al	1984).	The	doses	of	glutamate	used	were	much	greater	than	the	threshold	for	firing	and	when	applied	alone	induced	an	intense	discharge	and	excessive	depolarization	of	the	convergent	neurons.	Following	application	of	a	concomitant	noxious	conditioning	stimulus,	the	glutamate-evoked	activity	in	convergent	neurons	was	significantly	depressed.	This	demonstrates	that	despite	the	presence	of	glutamate	in	the	spinal	cord,	as	would	be	the	case	with	activation	of	peripheral	afferent	fibres	terminating	centrally	in	the	dorsal	horn,	the	activation	of	second	order	neurons	is	prevented.	This	suggests	that	the	conditioning	noxious	stimulus	triggers	inhibitory	post-synaptic	potentials	and	hyperpolarization	of	the	membrane	of	spinal	convergent	neurons	(Villaneuva	et	al	1984a,	Villaneuva	et	al	1984b).			
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	To	elicit	DNIC	the	conditioning	stimulus	must	be	noxious,	suggesting	that	DNIC	is	specifically	triggered	by	the	activation	of	peripheral	Aδ	and	C	nociceptors.	The	fibre	types	required	for	DNIC	expression	were	investigated	in	rats	using	recordings	from	trigeminal	WDR	neurons	that	were	excited	by	microelectrophoretic	application	of	glutamate	(Bouhassira	et	al	1987).	The	percutaneous	application	of	single	square-wave	electrical	stimulus	to	the	tail	induced	a	biphasic	depression	of	trigemincal	WDR	neuron	activity.	The	early	and	late	components	of	this	inhibition	occurred	with	shorter	latencies	when	the	base	of	the	tail	was	electrically	stimulated,	compared	to	the	tip.	The	differences	in	the	latencies	were	used	to	calculate	the	conduction	velocities	of	the	peripheral	fibres	triggering	the	biphasic	inhibition.	The	mean	conduction	velocities	were	found	to	be	7.3ms-1	and	0.7ms-1,	which	fall	into	the	Aδ	and	C	fibre	ranges	respectively	(Bouhassira	et	al	1987).	This	suggests	that	DNIC	is	made	up	of	two	inhibitory	components,	one	is	mediated	by	the	activation	of	Aδ	fibres	and	the	other	component	is	mediated	by	the	activation	of	C	fibres.			The	induction	of	inhibitory	post-synpatic	potentials	in	convergent	spinal	neurons	requires	the	activation	of	supraspinal	structures	and	functional	descending	controls.	DNIC	cannot	be	observed	in	convergent	neurons	in	anesthetized	animals	with	spinal	cord	transection	(Le	Bars	et	al	1979b,	Dickenson	and	Le	Bars	1983).	This	confirms	that	the	endogenous	inhibitory	controls	utilized	by	DNIC	are	not	confined	to	the	spinal	cord	and	require	supraspinal	structures.	It	has	been	proposed	that	the	conditioning	noxious	stimulus	activates	supraspinal	structures,	and	this	subsequently	initiates	descending	inhibitory	controls	that	act	upon	neurons	in	the	dorsal	horn	to	mediate	the	inhibitory	response.			
1.2.2 What	is	Conditioned	Pain	Modulation?	
	The	phenomenon	of	one	pain	inhibiting	another	pain	can	also	be	observed	in	humans,	where	the	mechanism	is	known	as	Conditioned	Pain	Modulation	(CPM)(Nir	and	Yarnitsky	2015,	Yarnitsky	2010).	CPM	can	be	observed	in	the	clinic	when	a	distant	painful	conditioning	stimulus	is	used	to	affect	a	test	stimulus.	Similarly	to	DNIC,	the	second	conditioning	noxious	stimulus	must	be	noxious.	CPM	can	be	initiated	by	noxiously	stimulating	multiple	areas	of	the	body,	but	this	noxious	stimulus	must	be	outside	of	the	excitatory	receptive	field	of	the	original	stimulation.	This	whole	body	effect	suggests	that	like	DNIC,	CPM	is	mediated	by	a	final	post-synaptic	mechanism	in	the	spinal	cord.		
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	Similarly	to	DNIC,	CPM	requires	supraspinal	structures	and	intact	descending	pathways	as	demonstrated	by	its	absence	in	tetraplegic	patients	(Roby-Brami	et	al	1987).	This	was	confirmed	in	a	study	where	the	nociceptive	spinal	flexion	reflex	RIII	was	evoked	in	the	right	leg	by	electrical	stimulation	of	the	sural	nerve,	and	a	noxious	conditioning	stimulus	was	applied	by	electrical	stimulation	on	the	left	hand.	Responses	in	normal	human	subjects	were	compared	to	tetraplegic	patients	with	lesions	in	the	C5-C7	levels	of	the	spinal	cord	due	to	traumatic	injury.	In	normal	subjects,	strong	depression	of	the	spinal	flexion	reflex	and	the	associated	pain	were	seen	in	the	presence	of	the	conditioning	stimulus.	However,	in	tetraplegic	patients	the	noxious	conditioning	stimulus	did	not	produce	any	depression	of	the	spinal	flexion	reflex	(Roby-Brami	et	al	1987).	The	conditioning	stimulus	used	was	electrical	stimulation	applied	to	the	digital	branches	of	the	ulnar	nerve,	which	was	below	the	level	of	spinal	transection	for	all	patients.	This	suggests	that	the	inhibitory	effects	on	the	RIII	reflex	mediated	by	a	conditioning	nociceptive	stimulus	are	sustained	by	a	loop	that	requires	the	activation	of	supraspinal	structures.			The	similarities	observed	in	the	function	of	DNIC	and	CPM	offers	opportunities	for	forward	translation	from	preclinical	studies	to	the	clinic	(Bannister	and	Dickenson	2016).			
1.2.3	DNIC	in	chronic	pain	
	The	transition	from	an	acute	to	chronic	pain	state	often	involves	an	altered	function	of	endogenous	pain	modulation	(Porecca	2002,	Rahman	2006,	Bannister	et	al	2015).	Analysing	the	underlying	mechanisms	of	DNIC	or	CPM	provides	a	method	for	investigating	the	descending	modulation	of	pain	(van	Wijk	and	Veldhuizen	2010).	In	a	wide	and	varied	array	of	chronic	pain	conditions,	there	is	a	less	efficient	or	abolished	DNIC.	The	facilitation	and	inhibition	of	nociception	occurs	simultaneously,	mediated	through	descending	controls	originating	in	the	brainstem.	The	noxious	conditioning	stimulus	induces	DNIC	via	activation	of	the	descending	systems.	Therefore,	DNIC	studies	measure	the	net	output.	As	such,	a	lack	of	DNIC	could	be	due	to	a	combination	of	enhanced	facilitatory	influences	and	a	masked	inhibitory	controls	(Arendt-Nielsen	et	al	2008).			Compromised	DNIC	has	been	shown	in	both	human	studies	and	animal	models	of	osteoarthritis.	This	was	demonstrated	in	a	rat	model	by	comparing	acute	and	chronic	
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monoarthritis	induced	by	injection	of	CFA	into	the	ankle	joint.	Behaviourally,	both	groups	displayed	an	increased	sensitivity	to	mechanical	stimuli	applied	to	the	ankle.	Electrophysiological	recordings	taken	from	trigeminal	convergent	neurons	in	the	animals	with	acute	monoarthitis	displayed	a	large	inhibition	upon	application	of	a	concomitant	mechanical	or	thermal	noxious	conditioning	stimulation	at	the	injured	joint.	In	contrast,	this	large	inhibitory	response	was	lost	from	trigeminal	convergent	neurons	in	animals	with	chronic	monoarthritis,	the	authors	suggested	that	the	inputs	activated	by	the	conditioning	noxious	stimulus	on	the	injured	joint	could	no	longer	recruit	a	DNIC	response	(Danziger	1999).	Similar	results	have	been	found	in	a	human	study,	where	pain	pressure	thresholds	(PPTs)	were	measured	around	the	knee	joint	in	patients	with	both	severe	and	moderate	osteoarthritis	of	the	knee.	The	PPTs	were	then	reassessed	in	the	presence	of	cuff	pressure	stimulation	on	the	arm	as	the	noxious	conditioning	stimulus.	The	CPM	responses	were	compared	to	healthy	age-matched	controls.	In	patients	with	both	severe	and	moderate	osteoarthritis	of	the	knee,	there	was	no	increase	in	PPT	indicating	a	lack	of	CPM	(Arendt-Nielsen	et	al	2010).			A	dysfunctional	CPM	is	also	demonstrated	in	humans	with	experimentally	induced	muscle	pain.	Firstly,	PPTs	around	the	knee	joint	were	measured	in	healthy	human	subjects.	A	cold	pressor	was	then	applied	as	a	noxious	conditioning	stimulus,	and	this	produced	an	increase	in	PPTs	demonstrating	CPM.	However,	when	the	subjects	were	injected	with	hypertonic	saline	to	evoke	muscle	pain	the	increases	in	PPT	due	to	the	cold	pressor	conditioning	stimulus	were	much	smaller.	This	suggests	that	patients	with	chronic	musculoskeletal	pain	may	have	impaired	CPM	(Arendt-Nielsen	et	al	2008).		Fibromyalgia	patients	present	with	chronic	persistent	pain,	yet	no	damage	or	inflammation	in	the	nervous	system	can	be	detected.	A	CPM	paradigm	in	the	clinic	was	used	to	analyse	the	function	of	descending	modulation	in	fibromyalgia	patients	(Lautenbacher	and	Rollman	1997).	Electrical	pain	thresholds	were	determined	and	used	as	the	test	stimulus,	while	a	tonic	thermal	stimulation	was	used	as	the	conditioning	stimulus.	The	concurrent	tonic	thermal	stimuli	significantly	increased	the	electrical	pain	threshold	in	pain-free	control	subjects	but	not	in	fibromyalgia	patients	(Lautenbacher	and	Rollman	1997).	Interestingly,	it	was	also	found	that	fibromyalgia	patients	with	depressive	symptoms	had	increased	clinical	pain	and	a	more	pronounced	deficit	in	CPM	than	fibromyalgia	patients	lacking	these	symptoms	(de	Souza	et	al	2009).	Depression	is	often	associated	with	chronic	pain	and	both	have	been	reported	to	involve	
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dysnfunctional	descending	controls,	indicating	that	fibromyalgia	pain	could	arise	from	an	imbalance	in	descending	inhibitory	and	facilitatory	pathways.			A	further	chronic	pain	state	with	abnormal	endogenous	inhibitory	mechanisms	is	irritable	bowel	syndrome	(IBS).	In	both	IBS	patients	and	normal	subjects,	rectal	pain	was	scored	during	rectal	balloon	distention	alone	or	in	the	presence	of	noxious	heterotopic	stimulation	of	the	foot	in	ice	water.	In	the	healthy	controls,	the	conditioning	stimulation	decreased	rectal	pain	but	this	was	not	the	case	in	IBS	patients	(Wilder-Smith	et	al	2004).		Furthermore,	through	assessing	the	functionality	of	a	patients	CPM	expression	before	surgery,	it	can	be	predicted	how	likely	the	patient	is	to	develop	post-operative	chronic	pain.	DNIC	assessment	was	conducted	in	62	patients	before	and	after	thoracotomy.	The	efficiency	of	pre-operative	CPM	was	negatively	correlated	with	chronic	post-operative	pain,	indicating	that	a	weak	CPM	before	surgery	may	predict	a	patient’s	susceptibility	to	developing	chronic	pain.	This	suggests	that	the	endogenous	inhibitory	system	activated	by	CPM	is	required	for	coping	with	noxious	events.	Assessing	this	in	patients	could	allow	individually	tailored	pain	prevention	and	post-operative	management	(Yarnitsky	et	al	2008).		Interestingly,	the	abolished	DNIC/CPM	system	often	found	in	chronic	pain	states	can	be	restored	upon	patient	recovery	or	through	pharmacological	manipulation.	In	cluster	headache	patients	a	cold	pressor	was	used	as	a	conditioning	noxious	stimulus	to	inhibit	a	nociceptive	withdrawal	reflex.	When	the	patients	were	undergoing	the	active	phase	of	the	headache,	the	cold	pressor	could	induce	no	inhibitory	effect	on	pain	responses	indicating	a	dysfunctional	CPM.	Yet,	during	the	remission	phase	the	cold	pressor	produced	a	clear	inhibition,	indicating	that	CPM	was	quickly	restored	(Perrotta	et	al	2013).	Secondly,	in	patients	with	painful	osteoarthritis	of	the	hip,	PPTs	were	not	influenced	by	a	heterotopic	noxious	conditioning	stimulation.	Following	hip	replacement	surgery,	the	patients	who	were	pain	free	were	re-assessed,	their	PPTs	were	now	significantly	modulated	by	the	heterotopic	noxious	conditioning	stimulation	(Kosek	and	Orderberg	2000).	This	suggests	that	the	chronic	nociceptive	pain	maintained	the	dysfunctional	CPM	as	observed	pre-surgery.	Upon	relief	of	the	chronic	persistent	pain,	the	CPM	system	could	reset	itself	to	a	functional	state.	Finally,	it	has	recently	been	shown	that	DNIC	is	abolished	in	a	spinal	nerve	ligation	model	of	neuropathy	in	the	rat	(Bannister	et	al	2015).	However,	the	authors	showed	they	could	pharmacologically	
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restore	the	expression	of	DNIC	by	manipulating	the	descending	monoaminergic	system	(Bannister	et	al	2015).	Taken	together,	these	finding	suggest	that	the	loss	of	DNIC/CPM	in	chronic	pain	states	is	due	to	a	plasticity	in	descending	controls	rather	than	a	complete	abolishment	of	this	system.			
1.2.4 Role	of	monoamines	in	DNIC	
	DNIC	expression	requires	activity	of	supraspinal	structures,	functional	descending	controls,	and	is	lost	in	multiple	chronic	pain	conditions.	As	noradrenergic	and	serotonergic	descending	controls	arise	in	the	brainstem	and	are	also	modulated	in	chronic	pain	states,	the	monoamines	seemed	likely	candidates	for	neurotransmitters	involved	in	the	final	postsynaptic	mechanism	mediating	DNIC	in	convergent	neurons.			Serotonin	transporter	gene	polymorphisms	affect	the	magnitude	of	CPM	in	healthy	subjects	(Lindstedt	et	al	2011).	The	serotonin	transporter	(5-HTT)	is	an	important	component	for	5-HT	signaling	as	it	ceases	the	actions	of	extracellular	5-HT	through	sodium-dependent	intracellular	reuptake	(Le	Bars	2002).	Low	expression	of	the	5-HTT	gene	has	been	associated	with	an	increased	risk	of	developing	chronic	pain,	and	polymorphisms	of	the	5-HTT	gene	have	been	implicated	in	the	development	of	fibromyalgia	(Offenbaecher	et	al	1999).	Lindstedt	et	al	carried	out	a	study	in	which	healthy	subjects	were	grouped	according	to	their	5-HTT	genotype.	Pateints	were	spilit	into	either	high	or	low	expressing	groups.	Individual	noxious	heat	and	pain	pressure	thresholds	(PPTs)	were	assessed	and	used	as	subjective	test	stimuli.	A	submaximal-effort	tourniquet	test	was	used	as	the	noxious	conditioning	stimulus	to	evoke	CPM.	The	authors	found	that	the	low	5-HTT	expressing	patient	group	exhibited	a	significantly	lower	degree	of	CPM-mediated	inhibition	for	both	pressure	and	heat	pain	(Lindstedt	et	al	2011).	This	indicates	that	the	level	of	5-HTT	expression	is	an	important	contributing	component	in	determining	the	efficiency	of	an	individuals	CPM.			Another	human	study	that	investigated	the	efficacy	of	duloxetine	in	patients	with	neuropathic	pain	strongly	supports	the	concept	that	noradrenaline	and	serotonin	mediate	CPM	(Yarnitsky	et	al	2012).	Duloxetine	is	a	serotonin	noradrenaline	reuptake	inhibitor	(SNRI).	Pain	modulation	assessment	was	carried	out	before	duloxetine	treatment	to	measure	individual	baseline	CPM	efficacy.	The	authors	found	that	baseline	CPM	was	correlated	with	the	efficacy	of	duloxetine,	such	that	duloxetine	was	most	effective	in	patients	with	a	less	efficient	CPM	(Yarnitsky	et	al	2012).	This	suggests	t
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patients	with	a	malfunctioning	pain	modulation	will	benefit	from	drugs	that	restore	the	functionality	of	descending	inhibitory	pain	control.	Meanwhile,	patients	with	a	functional	CPM	may	not	benefit	from	such	drugs	as	they	already	have	a	functional	descending	inhibition.	Determining	the	type	of	drug	to	administer	to	patients	by	evaluating	the	functionality	of	their	CPM	promotes	the	development	of	personalized	medicine.			It	has	been	demonstrated	in	naïve	rats	that	activation	of	the	DNIC	system	requires	the	action	of	noradrenaline	(NA)	acting	at	α2-adrenoceptors	in	the	spinal	cord	(Bannister	et	al	2015).	When	the	α2-adrenoceptor	antagonists	yohimbine	and	atipamezole	were	administered	in	naïve	animals	DNIC	expression	was	completely	abolished.	This	demonstrates	that	a	NA	mediated	mechanism	acting	via	α2-adrenoceptors	in	the	spinal	cord,	is	crucial	for	the	activation	of	DNIC.	During	the	transition	to	a	chronic	pain	state	the	descending	monoaminergic	pathways	undergo	dynamic	changes,	which	can	lead	to	an	increased	descending	facilitatory	drive	and	this	is	mediated	by	5-HT,	as	well	as	a	downregulation	of	the	descending	noradrenergic	system	(Suzuki	et	al	2004,	Rahman	et	al	2008).	In	a	spinal	nerve	ligation	model	of	neuropathy	in	the	rat,	where	the	descending	systems	are	known	to	be	dysregulated,	DNIC	was	abolished	(Bannister	et	al	2015).	DNIC	could	be	restored	in	these	animals	when	the	levels	of	NA	were	augmented	with	the	noradrenaline	reuptake	inhibitors	(NRIs)	Reboxetine	and	Tapentadol.	DNIC	could	also	be	restored	by	blocking	5-HT	mediated	descending	facilitations	acting	at	spinal	5-HT3	receptor	with	the	5-HT3	receptor	antagonist	ondansetron	(Bannister	et	al	2015).	This	suggests	after	nerve	injury	a	shift	in	the	balance	of	descending	inhibitory	and	facilitatory	pathways	occurs,	and	that	a	balance	of	these	opposing	systems	is	required	for	the	maintenance	of	DNIC.	The	result	is	a	dominant	5-HT	facilitatory	descending	drive	acting	at	5-HT3	receptors,	which	now	outweighs	the	noradrenergic	inhibitory	pathway	activated	by	the	conditioning	stimulus.			The	involvement	of	noradrenaline	and	serotonin	in	DNIC	will	be	discussed	in	greater	detail	in	Chapters	4	and	6.		
1.2.5 Supraspinal	pathways	sub-serving	DNIC	
	DNIC	is	known	to	be	mediated	by	a	final	post-synaptic	mechanism	that	relies	on	supraspinal	structures	and	functional	descending	controls.	However,	the	exact	brain	regions	required	for	DNIC	to	be	expressed	have	not	been	conclusively	determined.	As	
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DNIC	is	decreased	or	abolished	in	chronic	pain	conditions,	defining	the	supraspinal	networks	responsible	for	mediating	DNIC	may	allow	us	to	better	understand	the	neural	mechanisms	responsible	for	the	maintenance	of	persistent	pain.			The	involvement	of	serotonin	and	opioids	in	the	DNIC	system	highlighted	a	potential	role	for	brainstem	structures	that	utilize	these	systems,	such	as	the	RVM.	It	was	an	early	animal	study	that	first	suggested	DNIC	relies	partially	on	a	descending	serotonergic	pathway	(Dickenson	et	al	1981).	The	authors	found	that	animals	depleted	of	serotonin	due	to	pre-treatment	with	p-chlorophenylalanine	(pCPA)	had	a	strongly	reduced	DNIC	response.	The	DNIC	system	is	also	thought	to	rely	partially	on	endogenous	opiates	since	a	systemic	injection	of	naloxone	reduced	the	neuronal	inhibition	observed	alongside	application	of	a	noxious	conditioning	noxious	stimulus	(Le	Bars	et	al	1981).	These	findings	led	to	the	hypothesis	that	the	dorsolateral	funiculus	pathway	would	be	involved	in	the	induction	of	DNIC	as	this	comprises	the	PAG	and	RVM	descending	inhibitory	projections	onto	the	dorsal	horn	(Basbaum	and	Fields	1979).	However,	in	animals	with	lesions	of	the	PAG	or	RVM,	convergent	neurons	display	the	same	level	of	inhibition	evoked	by	a	conditioning	noxious	stimulus	as	compared	to	sham	groups	(Bouhassira	et	al	1990,	Bouhassira	et	al	1993).	Furthermore	in	human	CPM	studies,	no	signal	intensity	changes	could	be	observed	with	fMRI	in	the	PAG	or	medullary	raphe	when	a	noxious	conditioning	stimulus	was	applied	(Youssef	et	al	2015).	However,	microinjection	of	morphine	into	the	caudal	PAG	depressed	the	DNIC	response	(Dickenson	and	Le	Bars	1987)	and	inactivation	of	the	RVM	with	lidocaine	restored	DNIC	in	chronic	morphine	treated	animals	(Okada-Ogawa	et	al	2009).	This	suggests	that	the	PAG	and	RVM	may	be	able	to	indirectly	modulate	DNIC	expression.			In	humans	CPM	was	investigated	in	patients	with	unilateral	thalamic	vascular	lesions	and	also	in	patients	with	Wallenberg’s	syndrome,	in	which	unilateral	lesions	of	the	retro-olivary	portion	of	the	medulla	have	occurred	due	to	stroke	(De	Broucker	et	al	1990).	In	the	patients	with	thalamic	lesions,	the	RIII	reflex	was	significantly	inhibited	by	a	nociceptive	electrical	conditioning	stimulus	applied	to	the	hand.	The	nociceptive	conditioning	stimulus	had	long-lasting	inhibitory	effects	that	were	comparable	to	that	seen	in	healthy	subjects	(De	Broucker	et	al	1990).	The	authors	concluded	that	lemniscal	and	spinothalamic	pathways	were	not	required	to	trigger	a	DNIC	response.	In	contrast,	the	patients	with	Wallenberg’s	syndrome	displayed	no	inhibition	of	the	RIII	reflex	with	a	conditioning	noxious	stimulus	(De	Broucker	et	al	1990).	This	suggested	that	the	
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brainstem	and	spinoreticular	tract	are	vital	components	of	the	supraspinal	loop	that	activates	the	DNIC	response.			The	spinorecticular	tract	contains	branches	that	terminate	in	the	most	caudal	part	of	the	medulla,	which	suggests	this	component	of	the	supra-spinal	loop	sub-serves	DNIC	(Bouhassira	et	al	1992a).	Furthermore,	a	particular	nucleus	within	this	area,	the	subnucleus	reticularis	dorsalis	(SRD),	contains	neurons	that	encode	nociceptive	information	and	respond	specifically	to	activation	of	peripheral	Aδ	and	C	fibres	from	any	part	of	the	body,	indicating	that	these	neurons	have	a	whole-body	receptive	field	(Villanueva	et	al	1988).	This	theory	was	confirmed	in	rodents	with	unilateral	quinolinic	acid	induced	lesions	of	the	SRD.	In	the	SRD	lesioned	animals,	neuronal	inhibitions	produced	by	heterotopic	noxious	conditioning	stimuli	were	significantly	reduced	in	spinal	convergent	neurons,	suggesting	that	the	SRD	is	a	crucial	supraspinal	site	in	the	neuronal	circuitry	mediating	DNIC	(Bouhassira	et	al	1992a).	Despite	the	significantly	reduced	magnitude,	DNIC	mediated	inhibition	of	spinal	convergent	neurons	still	remained	in	animals	with	SRD	lesions.	Additionally,	low	doses	of	systemic	morphine	have	been	shown	to	significantly	depress	the	DNIC	response,	yet	this	has	no	effect	on	SRD	neurons	(Le	Bars	and	Villanueva	1988,	Bing	et	al	1989).	This	suggests	that	while	the	SRD	is	a	vital	brainstem	structure	in	the	expression	of	DNIC,	other	supraspinal	structures	may	be	involved	in	this	endogenous	inhibitory	system.			Interestingly,	it	may	be	a	reduction	of	activity	within	the	SRD	that	is	responsible	for	mediating	a	DNIC	response.	This	was	suggested	following	a	human	study	that	used	fMRI	to	analyse	brain	structures	involved	in	CPM	analgesia	in	healthy	subjects	(Youssef	et	al	2015).	Even	in	healthy	individuals,	only	half	of	the	subjects	displayed	a	functional	CPM	indicating	the	variability	of	CPMs	expression	from	one	individual	to	the	next.	The	authors	reported	that	subjects	with	a	functional	CPM	showed	a	reduction	in	signal	intensity	in	the	SRD	when	a	test	stimulus	was	applied	in	the	presence	of	a	noxious	conditioning	stimulus	(Youssef	et	al	2015).	Meanwhile,	the	changes	in	signal	intensity	in	the	SRD	were	not	observed	in	subjects	with	no	CPM	response.	The	SRD	is	proposed	to	play	a	facilitatory	role	in	pain	processing;	the	activation	of	this	nucleus	through	injection	of	glutamate	causes	a	long-lasting	enhancement	of	WDR	neuronal	responses	to	electrical	stimulation	of	the	sciatic	nerve	(Dugast	et	al	2003).	The	lack	of	CPM	response	observed	in	half	the	subjects	could	be	caused	by	ongoing	activity	in	the	SRD.	This	suggests	that	the	noxious	conditioning	stimulus	mediates	CPM	through	reducing	neuronal	activity	within	
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the	SRD	and	subsequently	prevents	the	SRDs	from	having	a	facilitatory	influence	on	convergent	neurons	in	the	dorsal	horn.			The	Parabrachial	nucleus	(PbN)	is	found	in	the	brainstem	and	can	influence	the	descending	modulation	of	pain	(Bernard	et	al	1996,	Suzuki	et	al	2002).	Interestingly,	in	the	fMRI	study	discussed	above	the	authors	found	a	significantly	reduced	signal	intensity	in	the	Pb	nucleus	in	subjects	that	displayed	a	functional	CPM	response	upon	application	of	a	concomitant	noxious	conditioning	stimulus	(Youseff	et	al	2015).	This	contrasts	with	previous	findings	that	show	an	ibotenic	acid	lesion	of	the	PbN	in	the	rat	had	no	effect	on	the	magnitude	of	inhibition	seen	in	convergent	trigeminal	neurons	upon	application	of	a	heterotopic	noxious	stimulus,	which	lead	to	the	conclusion	that	this	brain	region	was	not	critical	for	the	DNIC	response	(Bouhassira	et	al	1990).	These	conflicting	results	suggest	that	the	PbN	is	not	directly	involved	in	the	supraspinal	pathway	sub-serving	DNIC	but	is	capable	of	modulating	the	DNIC	response.			Higher	brain	structures	in	the	cortex	have	also	been	demonstrated	to	modulate	CPM	expression	(Youssef	et	al	2016).	A	further	fMRI	study	found	that	subjects	with	no	CPM	response	had	signal	intensity	increases	in	the	dorsolateral	prefrontal	cortex	(dlPFC),	the	cingulate	cortex	(CC),	and	the	amygdala	upon	application	of	a	noxious	conditioning	stimulus.	However,	in	individuals	with	a	functional	CPM,	the	signal	intensity	in	these	higher	brain	structures	remained	stable	(Youssef	et	al	2016).	Furthermore,	in	the	subjects	with	a	lack	of	CPM,	the	strength	of	functional	connectivity	between	the	SRD	and	dlPFC	and	CC	increased	upon	application	of	the	noxious	conditioning	stimulus	(Youssef	et	al	2016).	This	suggests	the	dlPFC	and	CC	can	have	a	direct	influence	on	the	SRD.	Therefore	a	lack	of	CPM	may	arise	due	to	increased	cortical	control	from	the	dlPFC	and	CC	acting	upon	the	SRD,	which	prevents	its	reduced	activation	and	allows	the	SRD	to	continue	sending	facilitaory	influences	to	convergent	spinal	neurons.				As	DNIC	is	mediated	predominantly	by	a	noradrenergic	mechanism,	the	locus	coeruleus	(LC)	is	a	further	brainstem	structure	which	seemed	likely	to	be	involved	in	the	DNIC	circuitry.	The	inhibitory	effect	on	spinal	convergent	neurons	induced	by	a	concomintant	noxious	conditioning	stimulus	relies	on	a	noradrenergic	descending	system	and	the	LC	contains	noradrenergic	projections	that	terminate	in	the	dorsal	horn	of	the	spinal	cord	(Bannister	et	al	2015,	Kwiat	and	Basbaum	1992).	This	was	investigated	in	rats	with	ipsilateral,	contralateral	and	bilateral	lesions	of	the	LC	(Bouhassira	et	al	1992b).	The	authors	found	no	significant	difference	in	the	magnitude	of	inhibition	seen	in	spinal	
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convergent	neurons	in	these	animals,	compared	to	controls	animals,	when	a	heterotopic	noxious	conditioning	stimulus	was	applied.	This	suggests	the	LC	is	not	directly	involved	in	the	supraspinal	loop	that	mediates	DNIC.	However,	as	the	action	of	noradrenaline	is	crucial	for	a	DNIC	response,	as	shown	by	the	complete	abolishment	of	DNIC	in	naïve	animals	with	α2-adrenoceptor	antagonists,	it	has	been	proposed	there	may	be	a	projection	from	the	SRD	to	the	LC	(Bannister	et	al	2015,	Bannister	et	al	2017).	If	this	is	the	case,	reduced	activity	in	the	SRD	triggered	by	a	conditioning	noxious	stimulus	may	allow	a	noradrenergic	pathway	arising	in	the	LC	to	become	active.	Therefore,	DNIC	may	be	triggered	by	a	reduced	facilitatory	drive	from	the	SRD	and	an	increased	inhibitory	drive	from	the	LC,	which	mediates	the	final	inhibitory	post-synaptic	mechanism	acting	on	convergent	spinal	neurons.		The	SRD	is	a	crucial	brainstem	nucleus	required	for	the	expression	of	DNIC	(Bouhassira	et	al	1992a).	Upon	application	of	a	heterotopic	noxious	conditioning	stimulation	a	reduced	activity	in	the	region	of	the	SRD	reduces	the	facilitatory	influences	that	arise	in	this	brainstem	region	acting	on	convergent	neurons	in	the	dorsal	horn	(Youssef	et	al	2015).	A	reduction	in	the	activity	of	the	SRD	may	also	allow	the	activation	of	a	noradrenergic	inhibitory	descending	system	that	arises	from	the	LC	(Bannister	et	al	2017).	The	activity	of	the	SRD	can	be	modulated	by	higher	brain	structures	such	as	the	dlPFC,	CC	and	amygdala.	Increased	activity	in	these	brain	regions	can	act	directly	on	the	SRD	to	prevent	the	reduction	in	its	activity	and	this	causes	a	reduction	in	the	magnitude	of	inhibition	seen	with	DNIC	(Youssef	et	al	2016).	Despite	lesion	experiments	showing	the	PAG	and	RVM	are	not	involved	directly	in	the	surpapinal	loop	that	sub-serves	DNIC	(Bouhassira	et	al	1990,1993),	they	are	likely	involved	in	the	activation	of	monoaminergic	descending	controls	that	mediate	DNIC	in	the	spinal	cord.	Ultimately,	a	series	of	complex	interconnections	between	midbrain	and	brainstem	structures	that	comprise	the	dorsolateral	funiculus	pathway	likely	play	an	indirect	role	on	the	SRD	and	impact	upon	the	release	of	serotonin	and	noradrenalin	in	the	dorsal	horn	to	mediate	DNIC.	The	supraspinal	structures	that	are	thought	to	play	a	role	in	DNIC	are	shown	in	Figure	1.9.										
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Figure	1.9.	The	supraspinal	structures	involved	in	the	expression	of	DNIC.	When	Aδ	and	C	fibres	in	the	periphery	are	activated	by	noxious	stimuli	they	project	the	signal	onto	second	order	nociceptive	specific	(NS)	and	wide-dynamic	range	(WDR)	neurons	in	the	dorsal	horn	of	the	spinal	cord.	Ascending	projections	then	transmit	the	nociceptive	signal	to	the	parabrachial	nucleus	(PbN)	which	can	then	send	further	projections	to	structures	in	the	limbic	system	such	as	the	amygdala.	Descending	modulatory	pathways	can	be	triggered	which	arise	in	the	Periaqueductal	grey	(PAG),	rostraventral	medial	medulla	(RVM),	and	Locus	coeruleus	(LC).	This	can	inhibit	or	facilitate	the	responses	of	WDR	neurons	through	the	release	of	noradrenaline	and/or	serotonin.	Upon	application	of	a	conditioning	noxious	stimulus,	DNIC/CPM	is	mediated	by	the	subnucleus	reticularis	dorsalis	(SRD)	in	the	caudal	brainstem.	The	full	block	arrows	show	
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the	brain	structures	known	to	interact	with	the	SRD.	The	dorsolateral	prefrontal	cortex	(dlPFC)	and	cingulate	cortex	(CC)	have	been	shown	to	have	direct	connections	with	the	SRD	and	can	modulate	the	expression	of	DNIC/CPM.	The	dashed	arrows	show	the	brain	structures	that	potentially	interact	with	the	SRD	and	play	a	role	in	the	modulation	of	DNIC/CPM.	The	reduced	activity	in	the	SRD	induced	by	a	conditioning	noxious	stimulus	may	act	upon	the	LC	to	initiate	noradrenergic	descending	inhibition.	The	RVM	and	PAG	are	not	directly	involved	in	the	supraspinal	loop	subserving	DNIC	but	may	modulate	DNIC	expression	through	the	activation	of	monoaminergic	descending	pathways	that	terminate	in	the	dorsal	horn.		
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1.3 Osteoarthritis	
	
1.3.1 What	is	Osteoarthritis?	
	Osteoarthritis	(OA)	is	a	painful	and	disabling	disease	caused	by	a	loss	of	function	and	integrity	of	the	synovial	joints.	This	disease	affects	a	number	of	joints	including	the	hands,	feet,	shoulders	and	spine	but	is	most	common	in	weight	bearing	joints	such	as	the	hips	or	knees.	This	thesis	will	focus	on	OA	of	the	knee.			Structurally,	OA	can	be	characterized	by	the	degenerative	breakdown	of	articular	cartilage,	sclerosis	of	the	subchondral	bone,	bony	outgrowths	known	as	osteophytes,	and	a	thickened	or	inflamed	synovium	(McMahon	et	al	2013:	Section	4,	Chapter	43,	Wieland	et	al	2005).	Clinical	symptoms	of	OA	include	joint	stiffness	and	instability,	functional	impairment,	movement-evoked	pain,	and	episodic	inflammation.	Importantly,	pain	is	the	major	clinical	symptom	of	OA,	and	the	reason	patients	report	the	disease	(Peat	et	al	2001).	Despite	a	clear	clinical	need	for	better	OA	pain	management,	current	analgesics	remain	relatively	ineffective.			OA	can	be	triggered	by	a	combination	of	mechanical,	developmental,	metabolic,	and	genetic	factors	that	result	in	multiple	pathophysiological	mechanisms,	but	it	remains	difficult	to	pinpoint	the	exact	causes	for	initiation	and	maintenance	of	the	disease	(Moskowitz	2007).			
1.3.2 The	subchondral	joints	
	The	joint	can	be	described	simply	as	the	point	at	which	two	or	more	bones	meet,	they	act	to	provide	structural	support	and	movement	of	the	skeleton.	Joints	can	be	subcategorized	into	three	categories	based	on	their	function	and	composition;	these	are	fibrous,	cartilaginous	and	subchondral	joints.	The	synovial	joints	allow	the	most	movement,	and	are	the	most	common	site	of	OA.			All	subchondral	joints	are	contained	within	a	synovial	capsule,	which	contains	multiple	strictures	that	aim	to	lubricate	the	joint	and	allow	smooth	movement.	In	the	healthy	subchondral	joint,	the	articulating	bone	endings	are	not	in	direct	contact	due	to	a	dense	layer	of	articular	cartilage	covering	the	end	of	each	bone.	The	cartilage	is	a	firm	visco-elastic	tissue	that	acts	as	a	cushion	between	the	bones	to	prevent	mechanical	damage	(Wieland	et	al	2005).	The	synovium	is	the	inner	membrane	of	the	synovial	capsule,	it	is	a	
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highly	innervated	tissue	and	secretes	synovial	fluid	to	provide	nutrients	and	lubrication	to	the	joint.	Finally	muscles,	tendons	and	ligaments	surround	the	synovial	joint	to	provide	further	structural	stability.			Although	the	degradation	of	articular	cartilage	is	a	central	feature	of	OA,	it	is	becoming	increasingly	clear	that	OA	is	a	disease	of	the	whole	joint	(Loeser	2006,	Dieppe	2011).	The	articular	structures	affected	in	OA	of	the	knee	are	shown	in	Figure	1.10.			
	
1.3.2.1 The	Cartilage	
	The	cartilage	found	in	synovial	joints	is	hyaline	cartilage,	this	is	a	resilient	tissue	that	reduces	friction	between	bones	and	withstands	high	compressive	loads	to	provide	protection	from	mechanical	forces.	This	is	provided	by	the	physico-chemical	properties	of	the	macromolecules	that	make	up	hyaline	cartilage.	Cartilage	is	composed	of	the	highly	differentiated	mesenchymal	cells	known	as	chondrocytes.	The	chondrocytes	are	responsible	for	secreting	and	maintaining	the	extracellular	matrix	(ECM)	components	of	the	cartilage,	while	also	controlling	the	movement	of	water	and	ions	across	the	membrane	(Muir	1995).	The	ECM	components	making	up	cartilage	are	collagen,	proteoglycans,	hyaluronic	acid	(HA),	and	a	mixture	of	elastic	fibres	(Kiani	et	al	2002).	Type	II	Collagen	is	the	principle	molecular	component	of	articular	cartilage	in	mammals,	it	is	composed	of	three	identical	α	chains	that	form	a	triple	helix.	The	collagen	molecules	self-associate	to	form	a	fibrilar	network,	stabilized	by	intermolecular	crosslinks,	and	this	provides	tensile	strength	to	the	ECM	(Troeberg	and	Nagase	2012,	Dejica	et	al	2008).	The	thin	layer	of	calcified	cartilage	that	provides	the	interface	with	articular	cartilage	and	the	bone	also	contains	collagen	X	(Eyre	2002).		Aggrecan	is	the	major	proteoglycan	found	in	the	articular	cartilage,	it	is	formed	of	numerous	monomers	non-covalently	bound	to	HA	(Kiani	et	al	2002,	Roughley	and	Mort	2014).	Aggrecan	is	responsible	for	drawing	water	into	the	matrix	and	allows	the	cartilage	to	resist	compression	(Troeberg	and	Nagase	2012).	A	dense	network	of	collagen	and	aggrecan	fibres	is	essential	for	the	biochemical	properties	that	maintain	the	mechanical	protection	provided	by	cartilage	(Wieland	et	al	2005).	The	articular	cartilage	contains	no	nerves	or	blood	vessels.			In	osteoarthritis	the	anabolic/catabolic	mechanisms	that	maintain	the	homeostasis	within	articular	cartilage	is	disrupted,	which	can	lead	to	striking	alterations	in	the	physical	structure	of	articular	cartilage	(Dejica	et	al	2008).	This	is	mediated	by	the	chondrocytes;	a	number	of	genetic,	biochemical,	or	mechanical	stress	factors	can	cause	a	
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disruption	in	chondrocyte-matrix	associations	and	an	alteration	of	the	chondrocytes	metabolic	responses.	The	early	morphological	changes	associated	with	early	OA	are	cartilage	surface	fibrillation	and	cleft	formation.	As	the	disease	progresses	there	is	an	increased	synthesis	of	catabolic	cytokines	in	the	chondrocytes	of	catabolic	cytokines	and	ECM,	leading	to	a	loss	of	cartilage	volume(Goldring	2000,	Dieppe	and	Lohmander	2005).				One	of	the	early	events	in	the	development	of	OA	is	the	degradation	of	aggrecan.	Metalloproteinases	(MMPs),	which	are	capable	of	degrading	proteoglycans,	including	aggrecans,	and	have	been	isolated	from	human	articular	cartilage	(Gunja-Smith	et	al	1989).	However,	this	remains	controversial	as	it	was	shown	that	the	aggrecan	fragments	present	in	the	synovial	fluid	of	OA	patients	had	not	been	cleaved	at	an	MMP	sensitive	site	suggesting	the	MMPs	were	not	responsible	for	the	degradation	of	aggrecan	(Sandy	et	al	1992).	The	ADAMTS	(A	distintegrin	and	metalloproteinase	with	thrombospondin	motifs)	are	zinc-dependent	metalloproteinases	and	the	major	enzymes	responsible	for	the	pathological	cleavage	of	aggrecan	in	OA	(Sandy	and	Verscharen	2001).	This	has	been	particularly	demonstrated	with	ADAMTS5,	as	knockout	mice	develop	less	severe	cartilage	damage	in	a	destabilized	medial	meniscus	model	and	an	antigen-induced	model	of	OA	(Glasson	et	al	2005,	Stanton	et	al	2005).	Interestingly,	ADAMTS4-/-		knockout	mice	did	not	exhibit	this	protection	against	aggrecan	degradation	(Glasson	et	al	2004),	but	suppression	of	ADAMTS4	attenuated	the	degradation	of	aggrecan	in	human	cartilage	explants	(Song	et	al	2007).	Song	et	al	also	found	a	reduction	in	aggrecan	degradation	in	human	OA	cartilage	following	siRNA	mediated	knockdown	of	the	ADAMST4	gene	(Song	et	al	2007).	In	both	ADAMTS1-/-	knockout	mice	and	in	human	OA	cartilage	lacking	expression	of	the	ADAMTS1	gene	there	is	no	inhibition	of	aggrecan	loss,	suggesting	this	enzyme	may	not	play	a	role	in	cartilage	degradation	(Little	et	al	2005,	Song	et	al	2007).	Both	ADAMTS4	and	ADAMTS5	appear	to	play	a	role	in	the	structural	damage	of	cartilage	observed	in	human	OA,	making	them	attractive	targets	for	therapy.			Aggrecan	plays	a	protective	role	to	prevent	degradation	of	the	type	II	collagen	fibrils	in	cartilage,	such	that	degradation	of	collagen	only	occurs	once	aggrecan	is	lost	from	the	cartilage	(Pratta	et	al	2003,	Karsdal	et	al	2008).	Collagen	is	a	stable	molecule,	yet	it	can	be	degraded	by	MMPs	and	Cathepsin	K	(CatK)	(Troeberg	and	Nagase	2012).	Particularly,	there	is	an	increased	expression	of	MMP-13	in	human	OA	cartilage	(Kevorkian	et	al	2004).	Furthermore,	the	conditional	overexpression	of	constitutively	active	human	MMP-13	in	murine	cartilage	resulted	in	spontaneous	degradation	of	articular	cartilage	(Neuhold	et	al	2001),	while	MMP-13	knockout	mice	with	surgically	induced	OA	showed	
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an	inhibited	erosion	of	cartilage	even	once	aggrecan	was	depleted	(Little	et	al	2009).	MMP-1	can	also	efficiently	cleave	type	II	collagen	and	is	thought	to	play	a	role	in	the	degradation	of	human	cartilage.	This	presents	the	MMPs	as	potential	therapeutic	targets,	but	their	translation	potential	was	hampered	as	high	homology	inhibitors	tend	to	lack	specificity	and	cause	toxic	and	musculo-skeletal	side	effects	(Troeberg	and	Nagase	2012).	However,	a	MMP-13	specific	inhibitor	has	been	generated	and	this	shown	to	effectively	prevent	cartilage	damage	in	a	surgical	rat	model	of	OA	without	producing	any	musculoskeletal	side	effects	(Johnson	et	al	2007).	Cathepsin	K	(CatK)	is	a	cysteine	protease	expressed	by	chondrocytes	in	the	articular	cartilage	(Connor	et	al	2009).	In	cartilage	explants	taken	from	patients	with	OA,	CatK	mRNA	levels	and	the	number	of	CatK-containing	chondrocytes	were	found	to	be	increased	relative	to	the	severity	of	OA	(Konttinen	et	al	2002).	In	addition,	CatK	inhibitors	were	found	to	reduce	collagen	breakdown	in	cartilage	explants	from	OA	patients	(Dejica	et	al	2008).	Increased	levels	of	MMPs	and	CatK	may	act	together	to	mediate	the	pathological	degradation	of	collagen	within	the	articular	cartilage	as	seen	in	advanced	OA,	and	inhibiting	the	activity	of	these	proteinases	may	provide	an	effective	way	of	preventing	such	damage.			Tissue	inhibitors	of	metalloproteinases	(TIMPs)	are	endogenous	inhibitors	that	can	inhibit	the	activity	of	MMPs	and	some	members	of	the	ADAMTS	family.	TIMP-3	is	thought	to	be	a	key	player	in	the	inhibition	of	cartilage	degradation	as	it	can	inhibit	both	MMPs	and	ADAMTS	(Kashiwagi	et	al	2001).	TIMP3	knockout	mice	develop	increased	cartilage	degradation	(Sahebjam	et	al	2007),	while	an	injection	of	TIMP-3	in	a	rat	meniscal	tear	model	of	OA	blocked	the	degradation	of	cartilage	(Black	et	al	2006).	Furthermore	reduced	levels	of	TIMP-3	protein	were	found	in	human	OA	cartilage	compared	to	normal	cartilage,	suggesting	a	lack	of	this	enzyme	may	contribute	to	the	development	of	OA	(Morris	et	al	2010).			Excessive	mechanical	loading	can	drastically	alter	the	homeostasis	of	cartilage.		Joint	injury	caused	by	extreme	force	or	overuse	can	initiate	a	cascade	of	responses	that	result	in	the	breakdown	of	cartilage	and	the	subsequent	pain	and	compromised	joint	function	seen	in	OA.	In	mechanically	injured	cartilage	co-cultured	with	joint	capsule	tissue,	there	was	increased	expression	of	MMP1,	MMP3,	MMP13,	and	ADAMTS5	genes	in	the	chondrocytes	(Lee	et	al	2009).	The	alteration	of	the	genetic	expression	of	chondrocytes	and	the	subsequent	upregulation	of	proteinases	indicates	how	important	a	factor	mechanical	loading	can	be	for	initiating	cartilage	damage.			
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Once	mature	cartilage	has	been	formed	after	development,	it	can	become	damaged	due	to	instance	mechanical	forces	or	in	response	to	inflammation.	This	can	occur	due	to	dysregulated	expression	of	aggrecanases,	collagenases,	and	their	respective	inhibitors.	Aggrecan	degradation	resulting	in	cartilage	damage	is	fully	reversible	due	to	chondroyctes	capacity	to	repair	this	structure	(Karsdal	et	al	2008,	Roughley	and	Mort	2014).	However	once	the	collagen	becomes	damaged	or	undergoes	degradation,	it	seems	the	chondrocytes	have	little	capacity	for	repairing	cartilage	architecture	(Eyre	2002,	Karsdal	et	al	2008).			
1.3.2.2 The	synovium	
	The	synovial	membrane	lies	between	the	joint	capsule	and	the	joint	cavity.	The	synovium	is	highly	vascularized,	and	through	the	secretion	of	synovial	fluid	it	supplies	the	avascular	articular	cartilage	with	nutrients	and	oxygen	whist	also	providing	lubrication.	As	the	synovium	and	articular	cartilage	are	in	close	proximity	and	solutes	can	flow	freely	between	the	two,	the	damaged	cartilage	has	an	effect	on	the	synovial	membrane.	In	many	OA	cases	the	synovial	membrane	is	inflamed	and	enlarged	(Revell	et	al	1988,	Krasnokutsky	et	al	2008).			The	histological	changes	observed	in	the	synovial	membrane	of	OA	patients	include	hyperplasia,	a	thickening	of	the	lining	layer	of	cells,	increased	vascularity	and	an	infiltration	of	lymphocytes	(Samuels	et	al	2008,	Wenham	and	Conaghan	2010).	The	synovial	enlargement	and	inflammation	observed	in	OA	is	confined	to	areas	adjacent	to	the	pathologically	damaged	cartilage,	this	is	in	contrast	to	rheumatoid	arthritis	(RA)	where	there	is	a	much	larger	extent	of	synovial	inflammation	(Krasnokutsky	et	al	2008,	Sweeney	and	Firestein	2004,	Wenham	and	Conaghan	2010).			While	the	synovium	has	the	physiological	responsibility	of	nourishing	the	chondrocytes	via	the	synovial	fluid,	synovial	cells	also	phagocytose	the	metabolites	and	products	of	matrix	degradation	produced	during	injury	(Sellam	and	Berenbaum	2010).	The	cartilage	breakdown	products	in	the	synovial	fluid	can	provoke	the	metabolically	active	synoviocytes	to	release	collegenases	and	other	hydrolytic	enzymes	which	can	exacerbate	the	destruction	of	articular	cartilage	further	(Krasnokutsky	et	al	2008).	Indeed,	knee	synovial	fluid	from	OA	patients	showed	a	persistent	increase	in	the	levels	of	MMP-1	and	MMP-3,	while	synovial	specimens	taken	from	patients	with	rapidly	destructive	hip	OA	show	high	levels	of	MMP-1,	MMP-3	and	MMP-9	(Tchetverikov	et	al	
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2005,	Masuhara	et	al	2002).	While	this	confirms	the	synovium	is	capable	of	producing	MMPs	that	degrade	cartilage,	cartilage	itself	produces	most	of	these	destructive	enzymes	which	work	in	a	paracrine	and	autocrine	fashion	(Samuels	et	al	2008).	The	production	of	proteolytic	enzymes	by	the	synovium	amplifies	the	cartilage	degradation,	causing	more	cartilage	breakdown	products	to	be	deposited	in	the	synovial	fluid,	which	then	further	potentiates	synovial	inflammation	(Sellam	and	Berenbaum	2010).	When	cartilage	degradation	begins	in	OA,	a	viscious	positive-feedback	loop	can	persist	between	the	synovium	and	articular	cartilage,	which	initiates	and	maintains	and	perpetuates	the	pathogenesis	of	the	disease.			The	inflammatory	component	associated	with	OA	is	discussed	further	in	Section	1.3.3.		
1.3.2.3 The	bone	
	The	femur,	tibia	and	patellar	are	the	bones	that	meet	to	form	the	synovial	knee	joint.	Bone	is	a	dynamically	mineralized	tissue,	in	response	to	mechanical	demand	it	can	adapt	its	functional	state	and	begin	a	remodeling	process	(Goldring	2009).	The	joint	contains	three	types	of	mineralized	tissue	with	different	mechanical	and	physiological	properties,	the	calcified	cartilage,	the	subchondral	plate,	and	the	subchondral	trabecular	bone.	Directly	between	the	articular	cartilage	and	before	the	subchondral	bone	is	a	layer	of	calcified	cartilage,	a	histological	tidemark	indicates	the	interface	between	articular	and	calcified	cartilage.	Following	the	calcified	cartilage	is	the	subchondral	bone	plate,	this	section	of	the	bone	is	not	very	porous	or	vascular	but	is	capable	of	remodeling	by	changing	its	density.	Directly	beneath	the	subchondral	bone	plate	is	the	subchondral	trabecular	bone	(Burr	2004).	The	advancement	of	imagining	techniques	such	as	magnetic	resonance	imaging	(MRI)	have	allowed	a	more	accurate	determination	of	the	changes	that	occur	in	the	bones	of	OA.	The	most	prominent	abnormalities	detected	are	bone	marrow	necrosis,	fibrosis,	osteophyte	formation,	an	abnormally	remodeled	trabeculae	and	sclerosis	of	the	subarticular	bone	(Wieland	2005,	Conaghan	et	al	2006).			The	subchondral	bone	and	articular	cartilage	are	intimately	connected,	together	they	adapt	to	mechanical	stress	(Buckland-Wright	2004).	One	of	the	processes	that	mediate	this	is	remodeling	of	the	bone,	which	involves	reshaping	by	either	the	deposition	of	new	bone	by	osteoblasts	or	the	resorption	of	bone	by	osteoclasts	at	a	given	site.	In	the	normal	bone	there	is	a	balance	in	the	remodeling	process	but	this	can	become	dysregulated	in	disease	(Bettica	et	al	2002,	Burr	2004).	In	the	early	stages	of	OA	there	is	an	increase	in	both	bone	formation	and	resorption	at	the	bone-cartilage	interface,	
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especially	in	areas	of	bone	adjacent	to	damaged	cartilage	(Wieland	2005).	Osteoarthritis	can	cause	an	increased	rate	of	bone	turnover	resulting	in	architectural	changes	of	the	subchondral	cancellous	bone,	particularly	an	increased	bone	density	and	volume	(Burr	2004).	In	patients	with	hip	OA,	their	trabecular	bone	volume	was	found	to	be	increased	by	20%	(Fazzalari	and	Parkinson	1997).	Fractal	signature	analysis	(FSA)	has	allowed	quantification	of	the	changes	in	cancellous	bone	organization,	it	indicated	one	of	the	earliest	changes	detected	in	patients	with	knee	OA	is	a	thickening	of	the	horizontal	trabecular.	As	the	disease	progresses	this	is	followed	by	thickening	of	the	vertical	structures	also	(Lynch	et	al	1991,	Bukland-Wight	et	al	1996).	The	accelerated	remodeling	causes	thickening	of	the	subchondral	bone	and	calcified	cartilage	layer	such	that	fibrous	calcified	tissue	often	advances	into	the	non-calcified	articular	cartilage	layer,	which	is	often	seen	histologically	as	the	duplication	of	the	tidemark	(Wieland	2005,	Brandt	et	al	2006).	This	causes	thinning	of	the	hyaline	articular	cartilage	layer	as	it	becomes	replaced	by	bone,	this	thinner	structure	is	more	susceptible	to	damage	and	loss	and	so	exacerbates	the	progressive	degradation	of	the	joint	(Brandt	et	al	2006).	The	increased	subchondral	bone	density,	as	a	result	of	increased	bone	turn	over,	has	been	found	to	have	a	reduced	mineral	content	making	it	mechanically	weaker	(Li	and	Aspden	1997).	The	complete	loss	of	articular	cartilage	and	the	weakening	of	the	subchondral	bone	can	cause	the	femoral	and	tibial	articular	surfaces	to	become	flattened.	In	advanced	stages	of	OA,	the	articular	surfaces	can	become	further	deformed	and	distorted	which	leaded	to	an	altered	alignment	of	the	joint	(Buckland-Wight	2004,	Brandt	et	al	2006).	Subchondral	sclerosis	occurs	initially	due	to	an	increased	thickness	of	subarticular	cancellous	bone,	which	contributes	further	to	the	loss	of	articular	cartilage.	This	can	cause	distortion	of	the	articular	surfaces,	and	ultimately	results	in	an	increased	mechanical	load	upon	the	joint	(Buckland-Wight	2004).			One	of	the	first	definite	symptoms	of	OA	that	can	be	seen	by	radiography	is	the	presence	of	osteophytes	(Neogi	et	al	2012).	Osteophytes	are	bony	projections	that	form	at	the	joint	margins,	and	are	associated	with	joint	space	narrowing,	sclerosis	of	the	subchondral	bone	and	pain	(Conaghan	et	al	2006).	Osteophytes	are	thought	to	be	a	consequence	of	localized	mechanical	stress	that	results	in	a	proliferative	response,	they	start	as	cartilage	outgrowths	that	become	ossified	(Felson	and	Neogi	2004).	Osteophytes	may	cause	further	malalignment	of	the	joint	while	also	playing	a	role	in	the	pain	associated	with	OA	by	putting	mechanical	pressure	on	innervated	neighbouring	joint	tissues	(Wieland	2005).				
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As	the	cartilage	is	not	innervated	the	pain	associated	with	OA	must	arise	from	another	structure	within	the	joint,	the	bone	is	highly	innervated	and	may	be	one	of	the	sources	of	osteoarthritic	pain.	One	feature	of	OA	that	has	been	particularly	associated	with	pain	is	bone	marrow	lesions	(BMLs)	(Felson	et	al	2001).	BMLs	have	been	shown	to	be	associated	with	the	fluctuations	of	pain	seen	with	knee	OA,	and	pain	resolution	occurred	more	frequently	if	the	BMLs	became	smaller	(Zhang	et	al	2011).	Furthermore,	BMLs	have	been	shown	to	be	associated	with	the	progression	of	disease.	MRI	performed	on	knees	with	OA	over	a	30	month	period	indicated	that	enlarging	BMLs	were	strongly	associated	with	an	increased	loss	of	articular	cartilage	(Hunter	et	al	2006).	A	second	study	found	the	development	of	BMLs	in	the	knees	of	middle-aged	adults	over	two	years	was	associated	with	progressive	cartilage	pathology,	while	subjects	that	displayed	resolution	of	BMLs	had	reduced	progression	of	cartilage	pathology	(Davies-Tuck	et	al	2010).	This	suggests	that	BMLs	may	exacerbate	the	degradation	of	cartilage.	Furthermore,	MRI	performed	on	knees	prior	to	joint	replacement	surgery	indicated	that	in	sclerotic	BMLs	there	is	an	increased	bone	volume	and	trabecular	thickness,	while	the	mineral	density	of	lesions	was	reduced	(Hunter	et	al	2009).	This	suggests	BMLs	present	a	further	mechanically	compromised	region	of	OA	knees	that	could	be	susceptible	to	further	damage.			Overall,	the	altered	properties	of	the	bone	observed	in	OA	suggest	this	tissue	may	now	be	less	capable	of	absorbing	force	transmitted	through	the	joint.	The	mechanically	weakened	subchondral	plate	and	trabecular	bone	result	in	more	pressure	and	subsequent	deformation	of	the	articular	surfaces.	As	the	disease	advances	this	can	result	in	sub-articular	osteoporosis	and	reduced	bone	mineral	density.				
1.3.2.4 The	ligaments,	meniscus	and	muscle	
	The	knee	joint	is	a	mechanical	structure	that	relies	on	multiple	tissues	to	maintain	its	structural	and	functional	integrity.	Tissues	crucial	for	knee	structure	are	the	ligaments,	surrounding	periarticular	muscle,	tendons,	and	meniscus.	The	disability	and	pain	associated	with	OA	can	be	associated	with	problems	in	these	tissues	(Dieppe	2011).	It	remains	questionable	if	abnormalities	in	these	tissue	structures	cause	the	progression	of	OA	or	arise	as	a	consequence	of	the	disease.			The	medial	and	lateral	collateral	ligaments	stabilize	a	joint	against	valgus	and	varus	stress,	therefore	it	has	been	suggested	that	ligament	damage	and	the	resultant	
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instability	of	the	joint	could	lead	to	the	progression	of	OA	(Brandt	2006).	Indeed,	Sharma	et	al	found	that	varus	knee	malalignment	which	resulted	in	an	increased	medial	load	in	the	knee,	which	subsequently	increased	the	risk	of	medial	OA	progression,	while	valgus	knee	malalignment	resulted	in	an	increased	lateral	load	and	increased	risk	of	lateral	OA	progression	(Sharma	et	al	2001).	Similarly,	it	has	been	shown	that	patients	with	hypermobility	syndrome	caused	by	ligamentous	laxity	are	more	likely	of	developing	OA	(Bird	et	al	1978).	Additionally,	MRI	studies	have	shown	that	anterior	cruciate	ligament	(ACL)	rupture	was	found	in	23%	of	OA	patients	in	a	cohort	study	while	this	was	only	present	in	3%	of	patients	without	knee	OA	(Hill	et	al	2005).			The	meniscus	provides	cushioning	support	between	the	femur	and	tibia,	and	abnormalities	in	this	structure	are	often	found	in	knee	OA	(Conaghan	et	al	2006).	Gale	et	al	found	with	MRI	that	increasing	meniscal	sublaxation	correlated	with	the	severity	of	joint	space	narrowing	in	patients	with	symptomatic	knee	OA	(Gale	et	al	1999).	Meniscal	damage	and	extrusion	is	a	further	factor	that	can	contribute	to	knee	malalignment,	and	potentially	lead	to	the	development	of	OA	(Hunter	et	al	2005).	Furthermore,	the	ligaments	and	meniscus	tissues	contain	type	I	collagen	so	also	may	be	in	danger	of	cleavage	by	enzymes	released	during	cartilage	degradation.			The	quadriceps	muscle	provides	anteroposterior	stability	to	the	knee,	weakness	of	this	muscle	is	common	in	patients	with	knee	OA,	and	this	could	be	both	an	initiating	risk	factor	or	a	result	of	the	disease.	If	the	quadriceps	muscle	is	weak	it	may	increase	the	impact	of	weight	loading	on	the	knee	joint,	which	could	cause	injury	and	the	development	of	OA.	However,	the	weakening	of	the	quadriceps	muscle	could	be	a	consequence	of	the	pain	that	arises	when	loading	an	injured	OA	joint,	which	leads	to	patients	minimizing	the	load	they	place	on	this	joint	and	could	lead	to	atrophy	of	the	muscle	due	to	lack	of	use	(Brandt	et	al	2006).			Malalignment	of	the	joint	can	be	caused	by	ligament	damage,	meniscal	degeneration	or	position,	and	muscle	weakness,	in	addition	to	bone	damage	and	the	development	of	osteophytes.	Previously,	these	factors	were	thought	to	be	the	result	of	joint	damage	but	are	now	also	considered	a	potential	cause	of	OA	(Dieppe	and	Lohmander	2005).			
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Figure	1.10.	The	articular	structures	involved	in	osteoarthritis	of	the	knee.	The	image	on	the	left	(a)	shows	the	healthy	subchondral	joint,	with	a	normal	smooth	layer	of	cartilage	covering	the	end	of	each	bone,	a	normal	synovium	and	undamaged	bone,	meniscus,	muscle	and	ligaments.	The	image	on	the	right	in	(b)	shows	the	abnormalities	that	can	occur	in	the	synovial	joint	during	the	progression	of	knee	osteoarthritis.	The	cartilage	becomes	degraded	and	fragmented	and	the	synovium	becomes	enlarged	and	inflamed.	There	is	also	scelorsis	of	the	subchondral	bone	and	the	formation	of	osteophytes	at	the	joint	margin.	The	ligaments,	tendons	and	meniscus	can	become	damaged	or	ruptured,	while	the	surrounding	muscle	can	become	weakened.	Figure	taken	from	Wieland	et	al	2005.		
	
	
1.3.3 The	inflammatory	component	of	Osteoarthritis	
	OA	has	been	classified	as	a	non-inflammatory	arthritis	as	synovial	fluid	from	OA	patients	has	a	leukocyte	count	below	the	threshold	that	defines	an	inflammatory	condition	(Dougados	1996).	However,	the	clinical	presentation	of	joint	swelling	seen	in	OA	is	thought	to	arise	from	inflammation	and	thickening	of	the	synovium,	and	an	inflamed	synovium	is	linked	with	the	progression	of	cartilage	damage	(Sellam	and	Berenbaum	2010,	Pozgan	et	al	2010).	This	indicates	that	inflammation	of	the	synovial	membrane	
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impacts	disease	pathogenesis	(Sellam	and	Berenbaum	2010).	The	release	of	proinflammatory	cytokines	also	occurs	in	the	cartilage	and	subchondral	bone	during	the	progression	of	OA,	indicating	inflammation	plays	a	role	across	the	whole	joint.	This	is	shown	in	Figure	1.11.		The	synovial	membrane	of	OA	patients	displays	an	infiltration	of	inflammatory	cells	composed	mainly	of	activated	T-cells,	B-cells	and	macrophages	(Sellam	and	Berenbaum	2010).	The	inflammatory	component	of	OA	pathophysiology	is	thought	to	play	a	large	role	in	early	development	of	the	disease	as	synovial	tissue	from	patients	with	early	OA	contain	more	CD4+	lymphocytes	and	CD68+	macrophages	than	patients	with	advanced	OA	(Benito	et	al	2005).		This	inflammatory	response	within	the	synovial	membrane	can	cause	an	overproduction	of	cytokines	and	growth	factors.	The	proinflammatory	cytokines	produced	can	then	diffuse	through	the	synovial	fluid	and	influence	the	metabolic	state	of	chondryocytes,	contributing	to	and	amplifying	the	damage	of	the	cartilage	matrix	(Hedborn	and	Hausleman	2002,	Sellem	and	Berenbaum	2010).			The	proinflammatory	cytokines	that	appear	to	be	the	most	directly	involved	in	the	pathology	of	OA	are	IL-1β	and	TNFα	(Westacott	and	Sharif	1996).	The	levels	of	IL-1β	and	TNFα	are	elevated	in	synovial	fluid,	the	synovial	membrane,	subchondral	bone	and	cartilage	in	OA	patients	(Kapoor	et	al	2011).	Chondrocytes,	mononuclear	cells	and	osteoblasts	can	produce	these	proinflammatory	cytokines,	but	they	appear	to	be	produced	mainly	in	the	synovium	by	CD14+	synovial	macrophages	(Bondeson	et	al	2006).	IL-1	activates	cells	through	binding	to	the	cell	surface	IL-1	receptor	type	I	(IL-1R1),	the	expression	of	which	is	increased	in	human	OA	chondrocytes	and	synovial	fibroblasts	(Sadouk	et	al	1995).	The	TNF	Receptor	1	(TNFR1)/p55	receptor	appears	to	be	the	dominant	cell	surface	receptor	that	mediates	TNFα	signaling,	and	human	OA	synovial	fibroblasts	express	higher	levels	of	this	receptor	than	non-OA	synovial	fibroblasts	(Alaaeddine	et	al	1997).	The	high	expression	of	these	receptors	on	synovial	fibroblasts	means	IL-1β	and	TNFα	can	further	stimulate	their	own	production	in	an	autocrine	fashion	(Sellam	and	Berenbaum	2010).			The	increased	level	of	IL-1β	and	TNFα	in	osteoarthritic	joint	tissues	further	accelerates	cartilage	destruction	through	stimulating	the	expression	of	MMPs	and	ADAMTS	in	chondrocytes	(Kapoor	et	al	2011,	Troeberg	and	Nagase	2012).	The	stimulation	of	human	articular	chondrocytes	with	IL-1	results	in	an	increase	in	the	expression	of	several	MMPs	(Borden	et	al	1996).	Additionally,	the	blockade	of	IL-1β	and	TNFα	in	
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human	OA	articular	culture	resulted	in	a	down-regulation	of	MMP-1,	MMP-3	and	MMP-13	expression	(Kobayashi	et	al	2005b).	Once	IL-1β	and	TNFα	have	bound	their	specific	cell	surface	receptors,	their	proinflammatory	actions	are	mediated	through	the	activation	of	MAPK	intracellular	signaling	pathways,	and	the	nuclear	factor	κB	(NFκB)	signaling	pathway	which	subsequently	mediates	the	expression	of	several	inflammatory	genes	(Kapoor	et	al	2011).	This	causes	an	upregulated	expression	of	the	genes	encoding	inducible	nitrous	oxide	synthase	(iNOS)	and	cyclooxygenase-2	(Cox-2),	these	are	enzymes	critical	for	the	synthesis	of	nitrous	oxide	(NO)	and	Prostaglandin	E2	(PGE2)	respectively	(Hedborn	and	Hausleman	2002).	Increased	levels	of	NO	and	PGE2	further	enhance	the	activation	and	production	of	MMPs	(Kapoor	et	al	2011).	Furthermore,	it	has	been	shown	in	human	OA	synovium	that	upregulation	of	AMAMTS4	was	dependent	on	IL-1β	and	TNFα	(Bondeson	et	al	2006).	The	increased	secretion	of	the	proinflammatory	cytokines	IL-1β	and	TNFα	results	in	the	cleavage	of	collagen	and	aggrecan	in	the	cartilage	ECM.			In	addition	to	upregulating	the	enzymes	responsible	for	cartilage	destruction,	IL-1β	and	TNFα	play	a	role	in	preventing	the	synthesis	of	the	cartilage	ECM	components.	IL-1	has	been	shown	to	suppress	the	synthesis	of	type	II	collagen	in	cultured	human	chondrocytes,	and	TNFα	has	been	found	to	inhibit	the	synthesis	of	proteoglycan	in	human	cartilage	explants	(Goldring	et	al	1994,	Saklatvala	1986).	During	OA	inflammatory	cytokines	are	secreted	in	the	joint,	this	amplifies	the	degradation	of	articular	cartilage	by	increasing	the	expression	of	destructive	enzymes	and	preventing	the	synthesis	of	ECM	components.			The	increased	levels	IL-1β	and	TNFα	also	promote	the	production	of	other	cytokines	and	chemokines	through	stimulating	chondrocytes	and	synovial	cells,	amplifying	the	inflammatory	response	(Sellam	and	Berenbaum	2010).	Interleukin-17	(IL-17)	is	a	proinflammatory	cytokine	that	can	act	alone	or	in	concert	with	TNFα	to	induce	the	release	of	chemokines	from	chondrocytes	and	synovial	fibroblasts,	exacerbating	inflammation	in	the	joint	(Honorati	et	al	2006).	IL-1β	and	TNFα	can	induce	de	novo	synthesis	of	Interleukin-6	(IL6)	in	human	articular	chondrocytes	(Guerne	et	al	1990).		IL6	expression	has	been	shown	to	upragulate	the	expression	of	MMP-1	and	MMP-13,	and	consequently	promotes	collagen	release	in	human	and	bovine	cartilage	explants	(Rowan	et	al	2001).	IL6	is	a	particularly	important	cytokine	in	bone	physiology	as	it	can	trigger	osteoclast	activity	and	bone	resportion,	suggesting	it	may	be	involved	in	the	altered	metabolism	of	subchondral	bone	observed	in	OA	(Kwan	et	al	2004).	Increased	
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levels	of	further	inflammatory	mediators	such	as	Interleukin-8	(IL8),	Interleukin-10	(IL-10),	granulocyte-macrophage	stimulating	factor	(GM-CSF),	and	Reactive	oxygen	species	(ROS)	are	also	found	in	OA	joints	(Kapoor	et	al	2011,	Sellam	and	Barenbaum	2010).			As	the	role	of	the	synovium	is	to	provide	cartilage	with	nutrients	and	oxygen	this	tissue	needs	to	be	highly	vascularized.	During	the	progression	of	OA,	angiogenesis	occurs	in	the	inflamed	areas	of	the	synovium	adjacent	to	cartilage	damage.	Indeed	synovial	tissue	from	patients	with	OA	show	increased	levels	of	vascular	endothelial	growth	factor	(VEGF)	and	blood	vessel	formation	(Sellam	and	Berenbaum	2010,	Shibakawa	et	al	2003).	The	angiogenic	growth	factor	VEGF	is	generated	by	the	inflamed	synovium,	VEGF	immunoreactivity	in	synovial	tissue	from	OA	patients	was	localized	with	macrophages,	and	increased	with	histological	inflammation	and	angiogenesis	(Haywood	et	al	2003).	IL-1β,	TNFα	and	IL-17	have	been	shown	to	increase	the	secretion	of	VEGF	from	synovial	fibroblasts	indicating	that	the	inflammatory	response	in	early	OA	contributes	to	the	development	of	angiogenesis	(Honorati	et	al	2006).	The	development	of	new	blood	vessels	allows	additional	transport	of	inflammatory	cells	to	sites	of	damage	in	the	joint.	The	processes	of	inflammation	and	angiogenesis	are	closely	integrated,	with	inflammation	producing	growth	factors	that	stimulate	angiogenesis	and	angiogenesis	facilitating	inflammation	to	produce	a	viscous	positive	feedback	loop	accelerating	the	progression	of	OA	(Bonnet	and	Walsh	2005).			The	initial	inflammatory	response	that	occurs	in	the	early	stages	of	OA	can	trigger	events	that	exacerbate	the	symptoms	of	the	disease.	The	proinflammatory	cytokines	secreted	within	the	joint	consequently	cause	further	degradation	of	the	cartilage	ECM,	angiogenesis	within	the	joint,	and	alterations	in	subchondral	bone	metabolism.			
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Figure	1.11	The	involvement	of	inflammation	during	Osteoarthritis	of	the	joint.	Inflammatory	cells	can	infiltrate	the	synovium	and	release	pro-inflammatory	cytokines	such	IL-1β,	TNFα,	IL-17	and	IL-6.	The	pro-inflammatory	cytokines	can	act	on	chondrocytes,	synovial	fibroblasts,	and	osteoclasts	and	osteoblasts	in	the	subchondral	bone.	The	cytokine	decrease	the	levels	of	collage	type	II	and	aggrecan	in	the	cartilage	through	promoting	the	upregulation	of	MMP	and	ADAMTS-4	enzymes	and	also	preventing	the	synthesis	of	these	macromolecules.	(taken	from	Kapoor	et	al	2011).			
1.3.4	Innervation	of	the	joint		
	Despite	cartilage	degradation	being	the	central	feature	of	OA,	the	articular	cartilage	contains	no	neurons	meaning	any	pain	associated	with	OA	must	be	derived	in	other	joint	tissues.	In	contrast	to	the	cartilage,	all	other	joint	tissues	are	densely	innervated	by	small	diameter	nociceptive	neurons	(Wieland	et	al	2005).	The	clinical	finding	that	OA	pain	is	associated	with	bone	marrow	lesions	suggests	that	the	subchondral	bone	may	be	particularly	sensitive	to	nociceptive	stimuli.	Retrograde	labeling	has	show	that	the	majority	of	afferent	neurons	innervating	the	subchondral	bone	were	peptidergic	neurons	expressing	CGRP	and	the	receptor	for	NGF	TrkA,	both	of	which	are	important	inflammatory	mediators	(Aso	et	al	2014).	Interestingly,	retrograde	nerve	tracing	has	demonstrated	a	complete	absence	of	the	non-peptidergic	IB4-binding	neurons	in	the	rat	knee	joint,	suggesting	that	it	is	unlikely	this	population	of	neurons	contribute	to	inflammatory	pain	in	OA	(Ivanavicus	et	al	2004).	High	threshold	nociceptive	afferents	also	terminate	in	the	synovium,	this	joint	tissue	contains	a	vast	supply	of	thinly	myelinated	and	unmyelinated	afferent	fibres	(Mapp	1995,	Grubb	2004).	The	cell	bodies	
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of	the	joint	afferents	are	located	in	lumbar	DRGs	and	L3,	L4	and	L5	levels	of	the	spinal	cord	(Edoff	et	al	2000,	Ivanavicus	et	al	2004).	The	central	axons	branching	from	the	DRG	terminate	in	two	main	projection	fields	in	the	spinal	cord;	superficially	in	LI	of	the	dorsal	horn,	and	in	LV-VII	of	the	deep	dorsal	horn	(Craig	et	al	1988).	This	allows	nociceptive	information	about	forces	exerted	on	articular	structures	and	potential	damage	to	be	conveyed	to	the	central	nervous	system	(Grubb	2004).			As	the	majority	of	sensory	afferents	within	the	joint	are	peptidergic	they	can	release	the	neuropeptides	CGRP	and	substance	P	into	the	joint	upon	activation,	producing	local	inflammation	(Saito	and	Koshino	2000,	Wieland	et	al	2005).	This	paired	with	the	inflammatory	mediators	released	during	the	development	of	joint	inflammation	observed	in	OA	can	result	in	hyperexcitability	of	joint	afferents	and	leads	to	peripheral	sensitization	(Schaible	2004).	In	cases	of	persistent	inflammation,	the	hyperexcitability	of	joint	afferents	is	maintained	resulting	in	an	amplification	of	nociceptive	information	being	transmitted	from	the	joint	to	the	spinal	cord.	This	can	lead	to	central	sensitization,	where	neuroplastic	changes	in	the	spinal	cord	enhance	the	pain	sensation	(Wieland	et	al	2005,	Schaible	2004).			
1.3.5	Diagnosis	
	The	causes	of	OA	are	the	microscopic	chemically	mediated	changes	and	the	macroscopic	structural	changes	within	the	joint.	However,	clinically	it	is	the	symptoms	associated	with	OA	that	cause	individuals	to	seek	medical	attention.	Joint	pain	and	tenderness,	a	limitation	or	stiffness	of	joint	movement,	inflammation	and	effusion	are	the	main	features	presented	with	symptomatic	OA.	Therefore	a	swollen,	tender,	or	deformed	joint	tends	to	be	the	first	clinical	sign	indicating	OA.			Originally	OA	was	confirmed	by	taking	an	X-ray	of	the	painful	joint,	this	could	be	used	to	identify	joint	space	narrowing	caused	by	cartilage	destruction	(Dieppe	2011).	X-rays	can	also	be	used	to	detect	subchondral	bone	sclerosis	and	osteophyte	formation	at	the	joint	margins	(McMahon	et	al	2013,	Section	4	Chapter	43).	Recently	newer	imaging	techniques,	such	as	ultrasound	and	MRI,	allow	visualization	of	subchondral	bone	marrow	lesions,	synovial	inflammation,	joint	effusions	and	other	joint	abnormalities	that	cannot	be	seen	with	radiography	but	contribute	to	the	pathogenesis	of	OA	(Kornaat	et	al	2006).	The	detection	of	joint	abnormalities	within	the	joint	using	MRI	is	shown	in	Figure	1.12.	Despite	the	development	of	more	advanced	imaging	techniques	there	is	a	
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still	a	lack	of	correlation	between	the	intensity	of	pain	and	the	level	of	damage	observed	within	the	join	(Finan	et	al	2013).			
	
Figure	1.12.	Magnetic	Resonance	Imaging	(MRI)	of	the	knee	joint	and	the	clinical	features	
observed	in	osteoarthritis.	The	arrows	indicate	the	particular	features	indicative	of	OA	in	each	panel.	Panel	(A)	shows	reactive	synovitis,	(B)	shows	the	formation	of	subchondral	cysts,	(C)	shows	bone	marrow	edema,	(D)	shows	partial	cartilage	wear,	and	(E)	and	(F)	show	complete	cartilage	loss,	subchondral	bone	sclerosis	and	osteophyte	formation	at	the	joint	margin.	(Taken	from	Loser	et	al	2012).			
1.3.6	Epidemiology	of	Osteoarthritis	
	Of	all	of	these	clinical	features	associated	with	OA,	pain	and	disability	are	the	major	problems	reported	by	patients.	The	quality	and	intensity	of	pain	are	variable	between	patients	depending	upon	the	severity	and	progression	of	the	disease.	In	the	early	stages	of	disease	pain	is	episodic	or	elicited	by	movement	and	weight	bearing	but	is	relieved	at	rest	(Schaible	et	al	2009).	However,	in	advanced	cases	of	OA	the	pain	can	be	constant,	in	many	cases	resting	pain	is	observed	through	the	night	(Schaible	2012).	Overall,	the	pain	and	limited	movement	within	the	joint	can	have	a	large	impact	upon	an	individual’s	quality	of	life.	
	
1.3.6.1	Incidence	and	Prevalence		
	OA	is	the	most	common	form	of	arthritis	with	a	much	higher	prevalence	than	rheumatoid	arthritis	(RA)	and	one	of	the	most	common	forms	of	musculoskeletal	disease	in	the	world	(Wieland	et	al	2005).	As	OA	is	a	disease	strongly	associated	with	
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aging,	longer	life	expectancy	means	the	incidence	is	rising	and	will	continue	to	do	so	(Pereira	et	al	2011).	The	World	Health	Organization	(WHO)	state	that	10%	of	men	and	18%	of	women	over	the	age	of	60	will	have	some	clinical	presentation	of	OA	(Woolf	and	Pfleger	2003).	In	the	UK,	8.75	million	people	in	the	UK	seek	treatment	for	OA	every	year	(Conaghan	et	al	2015).	Table	1.3	shows	the	number	of	diagnosed	prevalent	cases	in	different	areas	of	the	world,	this	indicates	the	increasing	number	of	cases	every	five	years.	It	should	be	noted	that	a	large	proportion	of	patients	have	radiological	evidence	of	OA	but	report	no	pain	or	symptoms,	meaning	there	may	be	additional	cases	of	OA	that	may	cause	future	problems	but	have	not	been	reported	(Srikanth	et	al	2005).			
Table	1.3.	Osteoarthritis	Epidemiology,	the	number	in	millions	of	diagnosed	total	
prevalent	cases.	This	table	is	taken	from	Wieland	et	al	2005.		
Geographical	Area	 2002	 2007	 2012	United	States	 13.2	 14.4	 15.5	Europe	 14.5	 15.2	 15.8	Japan	 6.6	 6.9	 7.2		
1.3.6.2	Economic	burden	of	Osteoarthritis	
	In	a	UK	wide	survey	of	subjects	with	self-reported	OA,	52%	of	participants	reported	that	OA	had	a	large	impact	on	their	lives	(Conaghan	et	al	2015).	Most	OA	patients	have	impaired	movement	to	some	degree,	with	knee	OA	being	the	major	cause	of	impaired	mobility	(Woolf	and	Pfleger	2003).	This	can	compromise	an	individual’s	ability	to	perform	their	job,	indeed	15%	of	the	UK	survey	participants	had	taken	retirement	an	average	of	7.8	years	early	(Conaghan	et	al	2015).	The	absence	from	work	caused	by	OA	costs	the	UK	economy	upwards	of	£18	billion	a	year	(Conaghan	et	al	2015).	In	addition	to	trouble	at	work,	25%	of	patients	with	OA	are	not	able	to	perform	activities	associated	with	daily	life,	which	can	cause	a	burden	on	family	members	and	even	lead	to	patients	to	develop	depression	(Wieland	et	al	2005).	Furthermore	these	patients	will	receive	a	disability	living	allowance,	further	contributing	to	the	economical	burden	in	the	UK.			OA,	along	with	the	other	musculoskeletal	diseases,	cost	the	National	Health	Service	(NHS)	one	tenth	of	its	annual	budget	(Conaghan	et	al	2015).	OA	of	the	knee	and	hip	contribute	the	highest	burden	to	immobility	and	often	result	in	total	joint	replacement	(Cross	et	al	2014).		In	Europe,	a	joint	is	replaced	every	1.5	minute	due	to	OA	(Wieland	et	al	2015).	A	patient	undergoing	total	knee	replacement	will	cost	the	NHS	£7458,	including	the	5	years	of	care	they	will	receive	following	surgery	(Dakin	et	al	2012).			
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OA	presents	an	enormous	burden	upon	the	individual	affected,	their	family,	the	NHS	and	the	economy.	The	costs	associated	with	OA	are	expected	to	increase	due	to	the	aging	population.			
1.3.6.3	Risk	factors	associated	with	Osteoarthritis	
	There	are	a	multitude	of	genetic,	environmental,	and	metabolic	triggers	that	can	increase	the	risk	of	developing	OA.	Trauma	or	physically	demanding	activities	can	cause	intense	mechanical	forces	to	be	inflicted	on	the	joint,	which	may	cause	injury	to	joint	tissues	and	initiate	the	development	of	OA	(Woolf	and	Pfleger	2003).	Systemic	risk	factors	can	increase	the	susceptibility	of	joints	to	injury	or	impair	the	repair	process	and	so	prevent	the	recovery	of	damaged	joints	(Litwick	et	al	2013).	The	risk	factors	identified	likely	promote	the	onset	of	disease	and	seem	to	contribute	to	the	development	of	OA	rather	than	disease	progression	(Litwick	et	al	2013).	Osteoarthritis	usually	progresses	slowly	over	a	number	of	years,	the	associated	risk	factors	may	hasten	this	progression	but	this	is	yet	to	be	proven	(Litwick	et	al	2013).	The	specific	risk	factors	associated	with	the	development	of	OA	are	age,	obesity,	gender,	ethnicity,	smoking,	bone	density,	muscle	function	and	knee	injury.	These	risk	factors	are	summarized	in	Table	1.4.		
Table	1.4.	The	risk	factors	associated	with	the	development	of	OA.		
Risk	Factor	 Association	with	Osteoarthritis	
Age	 Aging	is	the	major	risk	factor	associated	with	the	development	of	OA,	affecting	80%	of	the	population	over	the	age	of	75	years	old	(Arden	and	Nevitt	2006).	This	is	likely	due	to	progressive	cartilage	thinning	over	time,	weakened	surrounding	muscles	and	the	joint	generally	being	less	capable	of	coping	with	mechanical	forces	(Zhang	and	Jordan	2010).		
Obesity	 Obesity	is	especially	linked	to	the	development	of	OA	in	knees	and	hips	mainly	due	to	the	increased	strain	put	upon	these	joints.	However	obesity	can	be	caused	by	metabolic	dysfunction	such	as	leptin	resistance,	as	leptin	regulates	bone	mass	and	mineralization	a	resistance	to	this	hormone	may	cause	an	enhanced	subchondral	bone	mass	and	contribute	to	the	development	of	OA	(Wieland	et	al	2005,	Ducy	et	al	2000).		
Gender	 The	incidence	of	knee,	hip,	and	hand	OA	is	higher	in	women	than	men	and	this	incidence	increases	dramatically	following	the	menopause,	suggesting	hormones	may	play	a	role	in	the	development	of	OA	but	this	is	yet	to	be	proven	(Srikanth	et	al	2005).		
Ethnicity	 The	prevalence	and	joints	affected	by	OA	vary	among	ethnic	groups	(Litwick	et	al	2013).		
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Smoking	 There	is	a	negative	association	between	smoking	and	OA	suggesting	smoking	may	play	a	protective	role	(Woolf	and	Pfleger	2003)	but	it	is	thought	this	may	to	smoking	reducing	an	individuals	body	mass	index	(Blagojevic	et	al	2010).		
Bone	density	 An	altered	metabolism	of	the	subchondral	bone	contributes	to	the	pathophysiology	of	OA.	An	increased	bone	mineral	density	seems	to	predispose	women	to	developing	knee	OA	(Hart	et	al	2002).	Meanwhile,	the	reduced	bone	mineral	density	that	occurs	in	osteoporosis	seems	to	protect	against	osteoarthritis	(Litwick	et	al	2013).		
Trauma	 Physically	demanding	activities	or	occupations	that	may	result	in	joint	injury	are	central	risk	factors	for	the	development	of	OA.	Indeed,	50%	of	patients	diagnosed	with	anterior	cruciate	ligament	or	meniscal	tears	developed	OA	later	in	life	(Lohmander	et	al	2005).		
	
1.3.7 Current	Osteoarthritis	treatments	
	The	main	reason	that	patients	visit	their	General	Practitioner	(GP)	for	OA	is	due	to	the	associated	pain.	A	UK	report	produced	in	2012	showed	that	71%	of	patients	living	with	OA	are	in	constant	pain,	and	1	in	8	of	these	patients	said	their	pain	was	unbearable	(Smith	2012).	Therefore	the	primary	concern	for	GPs	is	alleviating	this	pain,	however	2	in	5	patients	in	the	UK	said	their	treatment	was	ineffective	(Smith	2012).	There	are	a	number	of	pharmacological	interventions	available	to	provide	pain	relief.	However	in	advanced	OA	cases,	if	these	pharmacological	interventions	prove	ineffective	and	joint	damage	causes	complete	immobility	the	final	option	is	surgical	intervention	and	total	joint	replacement,	which	will	require	further	substantial	pain	management.			
1.3.7.1 Pharmacology	
	
Paracetamol	Paracetamol	is	the	first-line	oral	analgesic	recommended	for	treating	the	pain	associated	with	knee	OA	(Wieland	et	al	2005).	Up	to	4g	a	day	is	though	to	provide	relatively	effective	pain	relief	and	have	limited	side	effects	(Zhang	et	al	2004).	In	two	placebo	controlled	trials,	one	showed	paracetamol	to	be	more	effective	at	alleviating	pain	than	placebo,	but	the	other	showed	that	paracetamol	was	no	better	at	treating	pain	than	placebo	(Zhang	et	al	2004).	This	suggests	that	despite	its	safety	and	low	risk	of	side	effects,	it	may	prove	ineffective	in	many	patients.			
NSAIDs	For	patients	who	do	not	respond	to	paracetamol	the	next	line	of	treatment	to	be	considered	are	non-steroidal	anti-inflammatory	drugs	(NSAIDs).	NSAIDs	function	by	
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targeting	the	cyclooxygenase	isoforms	Cox-1	and	Cox-2,	which	are	key	enzymes	in	the	synthesis	of	prostaglandins.	The	synthesis	of	prostaglandins	at	sites	of	inflammation	is	thought	to	contribute	to	peripheral	sensitisation	(See	section	1.1.4).	Prostaglandins	can	bind	to	cell	surface	receptors	on	primary	afferents	to	initiate	intracellular	signaling	cascades;	the	subsequent	activation	of	intracellular	PKA	mediates	phosphorylation	of	sodium	channels	in	nociceptor	terminals	(Wieland	et	al	2005).	The	phosphorylation	of	sodium	channels	lowers	their	activation	threshold	and	causes	increased	excitability	of	peripheral	nociceptors.	Therefore	through	preventing	the	synthesis	of	prostaglandins,	NSAIDs	target	peripheral	sensitization	that	arises	due	to	the	inflammatory	component	of	OA.	Topical	NSAIDs	have	been	shown	to	be	effective	at	reducing	knee	OA	pain	for	a	short	period	of	time,	but	their	effectiveness	was	reduced	over	time	with	continual	application	(Lin	et	al	2004).			The	Cox-1	isoform	is	constitutively	expressed	in	many	cell	types,	while	the	expression	of	the	Cox-2	isoform	is	induced	by	pro-inflammatory	cytokines	and	growth	factors	meaning	it	is	often	present	at	sites	of	inflammation	(Wieland	et	al	2005).	Despite	the	pain	sensitizing	effects	of	prostaglandin	during	inflammation,	prostaglandins	can	have	important	protective	effects.	Protective	prostaglandins	are	synthesized	by	Cox-1	to	preserve	the	integrity	of	the	stomach	lining	and	are	also	required	for	normal	renal	function	(Vane	et	al	1998).	Therefore,	oral	NSAIDs	can	have	gastrointestinal	side	effects	including	ulcerations	and	perforations	(Russell	et	al	2001).	However,	drugs	designed	to	specifically	target	the	Cox-2	isoform	can	reduce	inflammation	without	removing	the	protective	prostaglandins	from	the	stomach	(Flower	2003).	Cox-2	specific	inhibitors	are	as	effective	as	traditional	NSAIDs	but	cause	fewer	gastrointenstinal	complications	(Laine	et	al	2008).			
Opioids	If	both	paracetamol	and	NSAIDs	prove	ineffective	at	relieving	OA	pain	opioid	analgesics,	such	as	Tramadol,	can	be	the	next	alternative.	Opioids	have	been	shown	to	be	effective	at	relieving	pain	and	restoring	physical	function	in	OA,	but	they	also	come	with	adverse	side	effects	such	as	dizziness	and	drowsiness	(Avouac	et	al	2007).		These	side	effects	can	be	particularly	dangerous	in	the	elderly.	Due	to	the	adverse	side	effects	and	the	development	of	tolerance	that	can	lead	to	potential	abuse,	opioids	are	not	considered	to	be	particularly	safe	and	should	only	be	considered	for	short-term	pain	relief.			
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Corticosteroids	For	patients	suffering	with	episodic	inflammation	within	the	damaged	joint	intra-articular	injections	of	corticosteroids	may	provide	anti-inflammatory	action.	Intra-articular	corticosteroids	have	been	shown	to	reduce	joint	pain	and	disability	while	relieving	inflammation	for	up	to	1	week,	and	this	is	accompanied	with	very	few	side	effects	(Bellamy	et	al	2006,	Hepper	et	al	2009).	However	this	only	provides	short-term	relief,	so	should	only	be	used	occasionally	to	supplement	paracetamol/NSAIDs.			
Hyaluronan		Hyaluronan	is	synthesized	by	synoviocytes,	fibroblasts	and	chondrocytes,	and	plays	an	important	physiological	role	in	the	joint	aiding	lubrications	and	inhibiting	the	synthesis	of	prostaglandins	(Brandt	et	al	2000).	In	OA	the	concentration	of	hyaluronan	in	the	synovial	fluid	is	reduced,	which	may	contribute	to	the	compromised	function	of	the	joint	(Brandt	et	al	200).	Intra-articular	injections	of	hyaluronic	acid	are	designed	to	compensate	for	this	deficiency.	However	when	intra-articular	hyaluronic	acid	injections	were	compared	to	placebo	injections,	they	were	found	to	only	have	a	small	effect	in	treating	knee	OA	(Lo	et	al	2003).		
	
Glucosamine	and	chondroitin	sulphate	Both	glucosamine	and	chondroitin	sulphate	are	compenents	of	the	cartilage	ECM,	they	are	marketed	as	nutritional	supplements	that	may	have	structural-modifying	effects	in	OA	(Reginster	et	al	2003).	Although	both	have	been	reported	to	potentially	prevent	joint	space	narrowing	over	time,	they	are	relatively	ineffective	at	relieving	the	symptoms	of	OA	(Richette	and	Bardin	2004,	Reichenbach	et	al	2007).			
1.3.7.2 Surgical	intervention	
	When	pharmacological	interventions	have	failed	to	provide	any	pain	relief	or	improvement	in	function,	the	final	stage	treatment	for	OA	is	a	total	joint	replacement.	During	this	surgical	procedure	the	ends	of	the	articular	structures	are	removed	and	replaced	with	synthetic	materials	such	as	metal,	plastic	or	ceramic.	This	is	a	relatively	cost-effective	procedure	in	terms	of	the	number	of	quality-adjusted	life	years	that	can	be	gained	(Dakin	et	al	2012,	Rasanen	et	al	2007).	Total	joint	replacement	has	been	shown	to	dramatically	improve	joint	function	and	relive	joint	pain	with	the	greatest	improvements	seen	3-6	months	following	surgery	(Ethgen	et	al	2004).	Recovery	
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following	the	surgery	usually	takes	6-10	weeks	and	the	prosthetic	joints	usually	remain	functional	for	approximately	10	years.			Despite	this	surgical	intervention	being	designed	primarily	to	alleviate	the	chronic	pain	that	can	accompany	OA,	the	surgery	can	leave	patients	with	post-operative	pain.	Wylde	et	al	found	that	in	patients	who	had	undergone	total	knee	replacement	or	total	hip	replacement	between	2004-2006,	44%	and	27%	suffered	from	some	form	of	post-operative	pain	respectively	(Wylde	et	al	2011).		It	has	been	found	that	females,	younger	patients	needing	total	joint	replacement,	patients	with	a	high	BMI,	and	patients	with	a	higher	pre-operative	pain	score	are	most	likely	to	develop	post-operative	pain	(Singh	et	al	2006,	Liu	et	al	2012).	Additionally,	as	OA	patients	are	often	elderly	or	obese	this	can	complicate	the	surgery,	result	in	inferior	improvements,	or	increase	the	likelihood	of	mortality	following	surgery	although	the	risk	is	small	(Amin	et	al	2006).		
	
1.3.8 Evidence	of	central	sensitization	in	Osteoarthritis	
	The	treatment	options	for	OA	discussed	above	all	aim	at	tackling	the	pain	at	the	peripheral	source,	however	there	are	features	of	the	pain	associated	with	OA	that	cannot	be	explained	by	a	purely	peripheral	mechanism.	Patients	often	develop	referred	pain	in	an	area	distant	to	the	damaged	joint,	and	even	though	total	joint	replacement	relieves	the	pain	caused	by	OA	in	the	majority	of	patients	a	subset	of	patients	are	left	with	pain	following	joint	replacement	(Wylde	et	al	2011).	Additionally,	multiple	animals	models	of	OA	have	highlighted	altered	central	nociceptive	processing	(Orderberg	2004).	This	suggests	patients	may	develop	central	sensitisation	as	OA	progresses.			As	discussed	previously,	the	inflammatory	mediators	released	in	the	joint	during	OA	can	cause	sensitization	of	nociceptors	innervating	articular	structures	(See	section	1.1.4,	section	1.3.3,	and	section	1.3.4).	The	subsequent	hyperexcitability	of	joint	primary	afferents	can	result	in	an	increase	in	the	intensity	and	number	of	pain	signals	being	sent	to	the	dorsal	horn.	The	neuroplasticity	that	exists	in	the	central	nervous	system	may	result	in	second	order	neurons	in	the	spinal	cord	becoming	hyperexcitable	or	for	an	increased	activation	of	supraspinal	structures,	which	may	result	in	an	amplified	pain	response	(Pinto	et	al	2007,	Gwilym	et	al	2009).	Together	these	mechanisms	could	be	attributed	to	a	long-term	centrally	dysfunctional	amplification	of	the	pain	response.				The	plasticity	that	exists	within	the	somatosensory	system	upon	the	development	of	chronic	pain	begins	in	the	dorsal	horn	(DH).	The	expression	of	c-fos	within	the	spinal	
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cord	was	found	to	be	higher	in	a	chronic	articular	inflammatory	rat	model	compared	to	an	acute	articular	inflammatory	model,	which	suggests	spinal	cord	neurons	were	abnormally	active	during	the	induction	of	chronic	inflammatory	pain	(Pinto	et	al	2007).	Patients	with	chronic	knee	OA	have	extended	areas	of	referred	and	radiating	pain	in	response	to	hypertonic	saline	compared	to	control	subjects	(Bajaj	et	al	2001).	The	appearance	of	referred	pain	is	delayed	compared	to	local	muscle	pain,	indicating	the	mechanism	behind	this	phenomenon	is	time-dependent	(Graven-Nielsen	2006).	The	persistent	noxious	input	from	the	osteoarthritic	joint	may	allow	latent	synaptic	connections	to	become	operational,	and	afferent	terminal	connections	spread	over	several	segments	of	the	spinal	cord	to	become	activated,	allowing	convergence	of	input	and	development	and	expansion	of	the	receptive	field.	The	release	of	sensitizing	neuropeptides,	such	as	substance	P,	around	second	order	neurons	in	the	dorsal	horn	may	contribute	to	the	expansion	of	the	receptive	field.	Indeed	animal	studies	have	shown	peripheral	tissue	damage	and	inflammation	to	alter	the	neurochemical	state	of	excitatory	amino	acids	at	the	spinal	level	to	induce	activation	of	the	NMDA	receptor	(Dickenson	et	al	1997).	Amplification	of	pain	signals	within	the	DH,	and	the	unmasking	of	new	receptive	fields	due	to	central	sensitisation	may	be	mediating	the	referred	pain	that	develops	in	OA	and	explain	why	the	pain	perceived	does	not	always	match	the	peripheral	stimulus	(Graven-Nielsen	2006).		The	increased	excitability	within	the	spinal	cord	may	be	accompanied	by	supraspinal	changes	that	contribute	to	central	sensitisation.	The	use	of	fMRI	has	indicated	increased	activation	of	brainstem	areas	upon	application	of	noxious	stimulation,	but	this	can	only	be	observed	in	states	of	central	sensitisation	(Lee	et	al	2008).	This	technique	has	also	shown	increased	activity	within	the	PAG	when	referred	pain	areas	were	stimulated	in	patients	with	hip	OA,	indicating	brain	biomarkers	for	central	sensitisation	in	patients	with	chronic	OA	(Gwilym	et	al	2009).	The	brainstem	is	also	the	area	in	which	descending	systems	arise	that	can	modulate	the	excitability	of	spinal	neurons.	A	further	clinical	feature	observed	in	OA	patients	is	secondary	hyperalgesia	where	sites	away	from	the	joint	become	sensitive	to	noxious	and	innocuous	stimuli.	In	a	rat	model	of	OA,	the	descending	serotonergic	faciliatory	system	was	shown	to	play	a	role	in	mediating	the	responses	of	spinal	neurons	to	innocuous	stimuli	in	the	area	of	secondary	hyperalgesia	(Rahman	et	al	2009).	This	indicated	that	adaptive	changes	in	the	brainstem	and	subsequent	alterations	in	the	descending	modulatory	pathways,	may	mediate	the	amplified	responses	of	spinal	neurons	to	noxious	and	innocuous	inputs.			
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Alterations	with	the	central	nervous	system	that	may	contribute	to	the	development	of	chronic	pain	in	OA	are	discussed	in	greater	detail	in	chapters	5	and	6.			The	development	of	chronic	pain	as	a	result	of	OA	may	be	attributed	to	both	peripheral	mechanisms	due	to	the	release	of	inflammatory	mediators	within	the	joint,	and	subsequent	centrally	mediated	mechanisms.	Both	mechanisms	should	be	considered	when	deciding	on	the	appropriate	analgesics	used	to	target	pain	in	OA	patients.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 89	
1.4	Thesis	Aims	and	Hypothesis	
	The	specific	pathways	and	mechanisms	subserving	diffuse	noxious	inhibitory	controls	(DNIC)	remain	unclear,	understanding	these	mechanisms	may	allow	us	to	better	understand	the	central	changes	that	occur	during	the	development	of	chronic	pain.	Many	patients	with	osteoarthritis	develop	clinical	features	to	their	pain	that	suggest	complex	changes	in	the	central	nervous	system	are	involved,	and	the	analgesics	currently	available	to	osteoarthritis	patients	remain	relatively	ineffective.	Investigating	DNIC	in	a	rat	model	of	osteoarthritis	may	indicate	the	central	changes	involved	in	the	development	of	chronic	pain.	Through	better	understanding	of	the	mechanisms	involved	in	the	development	of	chronic	pain	during	the	progression	of	OA,	we	may	be	able	to	target	and	manipulate	these	mechanisms	to	provide	better	analgesia	to	OA	patients.			The	experiments	in	this	thesis	aimed	to:		
• Develop	a	model	for	assessing	DNIC	at	the	spinal	level,	using	recordings	from	convergent	wide	dynamic	range	neurons	in	the	deep	dorsal	horn.		
• 	Further	unravel	the	roles	of	noradrenaline	and	serotonin	in	mediating	DNIC.		
• Investigate	potential	changes	in	DNIC	in	a	rat	model	of	osteoarthritis.		
• Understand	the	processes	that	may	be	leading	to	a	loss	of	DNIC	during	the	development	of	chronic	pain	in	OA.			
• Pharmacologically	manipulate	DNIC	in	a	rat	model	of	osteoarthritis;	investigating	potential	therapeutics	for	OA	patients	who	suffer	from	chronic	pain	due	to	altered	central	processing	of	nociception.			
Hypothesis:	
	
• A	conditioning	noxious	pinch	will	produce	WDR	neuronal	inhibition	in	response	to	a	multiple	stimulus	modalities,	including	mechanical,	thermal	and	electrical.	
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• The	noradrenergic	descending	pathway	acting	at	α2-adrenoceptors	in	the	dorsal	horn	results	plays	an	anti-nociceptive	role	and	enhances	the	magnitude	of	neuronal	inhibition	induced	by	DNIC,	while	the	release	of	serotonin	from	descending	pathways	in	the	dorsal	horn	plays	an	pro-nociceptive	role	and	inhibits	the	neuronal	inhibition	induced	by	DNIC.	
	
• As	alterations	in	the	descending	noradrenergic	and	serotonergic	systems	have	previously	been	demonstrated	in	the	MIA	model,	the	neuronal	inhibition	induced	by	DNIC	will	be	lost.	
	
• There	is	a	neuropathic	component	to	the	2mg	MIA	model	of	OA.																														
	 91	
2.	Materials	and	Methods	
	
2.1	In	vivo	electrophysiology	
	
2.1.1	Animals	
	All	animal	experiments	were	approved	by	the	United	Kingdom	Home	Office	and	were	carried	out	in	accordance	with	guidelines	set	by	personal	and	project	licenses	and	thus	complied	with	the	UK	Animals	(Scientific	Procedures)	Act	1986.	Every	care	was	taken	to	reduce	the	suffering	of	animals	and	the	number	of	animals	used	in	accordance	with	the	guidelines	provided	by	the	International	Association	for	the	Study	of	Pain	(IASP)	for	the	care	and	use	of	laboratory	animals.			Male	Sprague	Dawley	rats	were	housed	in	the	UCL	Central	Biological	Unit.	Food	and	water	were	provided	ab	libitum	in	cages	that	were	under	a	12	hour	light/dark	cycle.	The	weight	of	rats	used	for	electrophysiology	experiments	were	between	220-290g.			
2.1.2	Preparation	
	The	protocol	used	has	been	previously	described	(Urch	and	Dickenson	2003).	Rats	were	anesthetised	in	an	induction	box	with	4%	isofluorane	carried	in	66%	nitrous	oxide	and	33%	oxygen.	Once	the	rats	were	fully	unconscious	and	a-reflexive,	they	were	removed	from	the	box	and	placed	on	a	nose	cone	to	continue	anaesthetic	delivery.	Isofluorane	anesthetic	was	dropped	to	3%	while	a	tracheotomy	was	performed.	The	trachea	was	exposed	through	dissection	and	a	cannula	inserted,	which	was	secured	with	silk	thread.	The	anesthetic	was	then	dropped	to	2.5%	and	was	delivered	via	this	cannula	for	the	rest	of	the	experiment.			The	rats	were	secured	into	a	stereotaxic	frame	including	ear	bars	and	a	laminectomy	was	performed.	Within	the	stereotaxic	frame	the	rat	was	placed	onto	a	homeothermic	heat	mat	and	a	rectal	temperature	probe	was	inserted	in	order	to	maintain	the	animals	core	temperature	at	37°C.			For	the	laminectomy	an	incision	was	made	into	the	skin	along	the	length	of	the	back.	The	bottom	of	the	ribs	were	located	and	incisions	were	made	either	side	of	the	vertebral	column	such	that	the	spinal	cord	could	be	clamped	securely.	Rangeurs	were	used	to	remove	muscle	and	vertebrae	and	expose	L4-L5	segments	of	the	spinal	cord.	The	dura	was	removed.	A	well	of	muscle	bone	and	connective	tissue	were	left	surrounding	the	
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spinal	cord	such	that	50μL	drug	aliquots	could	be	applied	spinally.	Below	the	laminectomy,	two	more	incisions	were	made	either	side	of	the	spinal	column	to	place	the	second	clamp	towards	the	bottom	of	the	cord.	Crucially,	the	cord	was	straight	and	held	tightly	and	securely	such	that	no	movement	was	evoked	by	respiration.	Following	the	laminectomy	the	isofluorane	was	lowered	to	1.5%	and	maintained	at	this	level	for	the	duration	of	the	experiment.		
	
2.1.3	Single	unit	recording	
	Spinal	neuronal	recordings	were	made	from	wide	dynamic	range	(WDR)	neurons	located	in	the	deep	dorsal	horn.	A	headstage	containing	a	parylene-coated	tungsten	electrode	(125µM	diameter)	was	lowered	into	the	spinal	cord	to	a	depth	of	approximately	500µM-1000µM	in	correspondence	with	the	expected	depth	of	lamina	V	using	a	micromanipulator.	Within	the	headstage	were	two	further	connections	used	to	ground	the	system.	Firstly,	a	grounding	lead	was	attached	to	the	stereotaxic	frame	and	collected	background	electrical	activity.	The	second	grounding	lead	was	fixed	to	the	animal	to	collate	electrical	information	not	connected	to	spinal	cord	activity	such	as	heart	beat.	This	information	was	fed	into	a	NeuroLog	AC	recording	system	(NeuroLog	system,	Digitimer,	UK)	set	at	the	A-B	setting	such	that	the	input	from	the	grounding	cables	was	subtracted	from	that	of	the	electrode.	The	incoming	signal	was	band-passed	filtered	with	the	low/high	frequency	cut	off	set	at	1.5-2KHz,	as	this	frequency	band	allowed	for	clear	differentiation	of	action	potentials.			To	identify	an	individual	WDR	neuron	the	electrode	was	slowly	lowered	through	the	dorsal	horn	while	the	receptive	field	was	stimulated	through	light	tapping.	Once	an	area	of	evoked	potential	was	discovered	the	electrode	was	adjusting	slightly	to	ensure	a	single	unit	had	been	isolated.	A	single	unit	is	represented	on	the	osciliscope	as	one	consistent	amplitude	of	action	potential	firing	with	no	interference	from	adjacent	cells.	Once	a	single	cell	was	identified,	its	responses	to	different	stimuli	were	quantified.	Neurons	were	confirmed	as	WDR	if	they	responded	to	both	innocuous	(8g)	and	noxious	(60g)	mechanical	stimulation,	thermal	stimulation	of	48°C	and	exhibited	wind-up.	Data	was	captured	using	Spike	2	software	coupled	to	a	CED	1401	interface	(Figure	2.1).	Action	potentials	fired	were	displayed	in	a	histogram	format.			Responses	were	recorded	to	natural	mechanical	and	thermal	stimuli.	For	mechanical	stimulation	von	Frey	hairs	(Touch-Test,	North	Coast	Medical,	USA)	of	increasing	bending	force	(8g,	26g	and	60g)	were	applied	to	the	receptive	field	(the	hind	paw).	For	
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thermal	stimulation	a	water	jet	(42°C,	45°C,	48°C	and	50°C)	was	applied	to	the	receptive	field.	Natural	stimuli	were	applied	for	a	period	of	5	seconds	per	stimulus	and	there	was	a	60	second	separation	between	the	application	of	each	stimulus.	All	WDR	neurons	met	the	inclusion	criteria	of	<10%	variation	in	action	potential	firing	for	all	evoked	neuronal	responses	An	example	trace	of	one	WDR	neuron	firing	in	response	to	natural	stimulation	is	shown	in	Figure	2.2.			
	
Figure	2.1	Schematic	of	electrophysiological	and	Neurolog	recording	system.	A	laminectomy	was	performed	to	expose	L4-L5	segments	of	the	spinal	cord.	The	receptive	field	of	
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the	hind	paw	is	stimulated	with	natural	or	electrical	stimulation.	Recordings	were	made	from	WDR	neurons	in	the	deep	dorsal	horn	of	the	spinal	cord	with	a	tungsten	electrode.	The	input	from	the	recording	electrode	enters	the	recording	system	via	a	headstage.	Background	electrical	activity	is	subtracted	and	the	signal	is	amplified,	filtered	and	fed	into	a	speaker	and	oscilloscope	so	the	cell	can	be	heard	and	visualized	to	ensure	a	single	unit	has	been	isolated.	Action	potentials	with	amplitude	above	a	determined	threshold	were	recorded	and	output	to	the	CED	1401	interface,	which	were	quantified	via	the	computer.	Electrical	stimulations	were	delivered	to	the	receptive	field	via	two	stimulating	electrodes.	Electrical	inputs	were	captured	and	converted	into	a	post-stimulus	time	histogram	to	provide	information	on	the	fibre	types.				
	
Figure	2.2	Responses	of	a	WDR	neuron	to	natural	stimulation.	A	representative	histogram	trace	from	a	single	WDR	neuron	to	show	the	coded	range	of	responses	to	a	range	of	natural	stimulation.		Single	electrical	pulses	were	delivered	in	increasing	mA	increments	to	determine	the	minimum	stimulating	threshold	for	C	fibres.	A	train	of	16	pulses	were	delivered	to	the	receptive	field	(2ms	wide	pulse	at	0.5Hz)	at	3	times	the	C	fibre	threshold.	A	post-stimulus	time	histogram	(PSTH)	was	constructed	to	quantify	and	separate	responses	evoked	by	peripheral	afferent	fibres	based	on	their	latency	(Figure	2.3).	This	was	0-20ms	for	Aβ	fibres,	20-90ms	for	Aδ	fibres,	and	90-300ms	for	C	fibres.	Any	activity	that	occured	after	C	fibre	latency	(anything	from	300ms	to	800ms)	was	calculated	as	the	post	discharge	(PD).			
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Figure	2.3	Response	of	a	WDR	neuron	to	electrical	stimulation.	An	example	post-stimulus	time	histogram	(PSTH)	from	a	single	WDR	neuron	responding	to	electrical	stimulation.	The	PSTH	separated	fibre	types	based	on	the	latency	of	the	evoked	potential.	Aβ	fibres	are	classed	as	having	a	latency	of	0-20ms,	Aδ	fibres	between	20-90ms,	and	C	fibres	between	90-300ms.	Evoked	activity	measured	post	300ms	is	measured	as	post-discharge.			A	predicted	no	wind-up	response	is	calculated	by	multiplying	the	number	of	action	potentials	fired	by	the	first	electrical	stimulation	by	16.	This	hypothetical	value	is	termed	Input	and	is	what	we	would	expect	if	a	cell	had	no	change	in	the	evoked	response	with	subsequent	stimulations	over	the	16	pulse	period	(Figure	2.4).	Wind-up	was	calculated	by	taking	the	input	value	from	the	actual	accumulative	count	of	action	potentials	fired	from	the	16	stimulations:		Wind-up	=	total	number	of	action	potentials	fired	after	16	stimuli	–	Input			A	rest	period	of	10	minutes	was	allowed	between	each	round	of	electrical	stimulation	to	prevent	sensitisation	of	the	receptive	field	and	to	ensure	that	the	neuronal	responses	had	returned	to	baseline.			
	
Figure	2.4	An	example	of	wind-up	in	a	single	WDR	neuron.	The	number	of	action	potentials	fired	by	a	single	WDR	neuron	in	response	to	16	consecutive	electrical	pulses	delivered	at	3	times	
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the	C	fibre	threshold	were	quantified.	The	theoretical	input	(purple)	is	what	we	would	expect	if	a	neuron	exhibited	no	change	in	evoked	response	with	subsequent	electrical	stimulations.	The	actual	number	of	action	potentials	fired	(pink)	shows	that	with	each	subsequent	electrical	stimulation	an	increasing	number	of	action	potentials	are	fired.		
		To	validate	that	setting	the	threshold	was	a	sufficient	method	for	ensuring	recordings	were	taken	from	a	single	unit,	an	experiment	was	performed	on	the	Spike2	software	usually	used	for	brain	recordings.	This	programme	allowed	recordings	of	multiple	neurons	and	separated	them	based	on	their	waveform.	It	was	considered	that	during	intense	noxious	stimulation	other	neurons	might	begin	firing	such	as	nociceptive	specific	(NS)	and	this	might	count	towards	the	action	potential	count	histogram.	This	programme	characterizes	specific	waveforms	and	expresses	them	as	separate	colours.	When	the	isolated	WDR	neuron	was	mechanically	stimulated	with	von	Frey	hairs	of	increasing	intensity,	only	one	type	of	neuron	was	detected	on	the	Spike2	software	(Figure	2.5).	This	suggested	that	monitoring	the	threshold	carefully	throughout	the	experiment	was	a	sufficient	method	for	ensuring	action	potentials	fired	were	resulting	from	a	single	unit.			At	the	end	of	each	study,	the	isofluorane	was	set	to	5%	to	overanaesthetise	the	rat	and	a	cervical	dislocation	was	performed	to	confirm	death.			
2.1.4	Pharmacology	Detailed	protocols	for	pharmacology	experiments	including	doses	and	time	points	are	given	in	individual	chapter	methods.		
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Figure	2.5	Recordings	taken	from	a	WDR	neuron	using	Spike2.	The	top	panel	represents	neuronal	populations	based	on	their	waveform,	it	expresses	each	neuronal	population	as	a	different	colour.	The	middle	panel	shows	the	number	of	action	potentials	fired	over	a	determined	threshold	and	expressed	as	a	histogram.	The	bottom	panel	is	a	representation	of	the	oscilloscope.	Each	time	the	receptive	field	is	stimulated,	the	oscilloscope	displays	a	change	in	voltage	due	to	neuronal	action	potentials.	As	the	recordings	are	extracellular,	the	change	in	voltage	displayed	is	relative	to	that	outside	the	neuron.		
	
2.2	DNIC	experiment	design	
	
2.2.1	Mechanical	stimulation	
	Firstly,	the	pre-conditioned	mechanically	evoked	neuronal	firing	rates	were	quantified	in	response	to	8g,	26g	and	60g	von	Frey	filament	stimulation	applied	to	the	hind	paw.	This	was	repeated	3	times	to	obtain	a	stable	average	pre-conditioned	response	value.	For	the	DNIC	response,	the	von	Frey	filaments	were	applied	to	the	receptive	field	in	the	presence	of	a	concomitant	noxious	ear	pinch	(15.75	x	2.3	mm	Bulldog	Serrefine,	Interfocis,	Linton,	UK).	The	DNIC	response	was	characterized	as	the	number	of	action	potentials	fired	when	the	receptive	field	was	stimulated	alone	and	compared	to	the	number	of	action	potentials	fired	in	the	presence	of	a	concurrent	noxious	conditioning	
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pinch.	This	counted	as	one	DNIC	trial,	which	was	repeated	such	that	the	baseline	responses	were	calculated	as	the	mean	of	the	two	trials.	In	MIA	animals,	DNIC	was	also	induced	with	a	noxious	knee	pinch,	where	a	clamp	was	placed	around	the	knee	and	the	two	prongs	pushed	together	to	a	set	distance	of	0.75cm.				
2.2.2	Thermal	stimulation	
	The	number	of	action	potentials	fired	when	a	water	jet	(42°C,	45°C,	48°C	and	50°C)	was	applied	to	the	hind	paw	was	quantified.	This	was	repeated	twice	to	obtain	an	average	stable	pre-conditioned	response.	DNIC	was	then	induced	by	stimulating	the	hind	paw	with	a	water	jet	of	a	specific	temperature	in	the	presence	of	a	concomitant	noxious	ear	pinch.	This	DNIC	trial	was	repeated	and	the	mean	values	from	the	two	trials	were	used	as	pre-conditioned	and	DNIC	responses.		
2.2.3	Electrical	stimulation	
	A	train	of	16	pulses	were	delivered	to	the	receptive	field	(2ms	wide	pulse	at	0.5Hz)	at	3	times	the	C	fibre	threshold.	This	was	repeated	3	times	with	a	10-minute	break	between	each	train	of	16-pulse	stimulations.	The	same	16	pulses	of	electrical	stimulation	were	then	applied	to	the	hind	paw	in	the	presence	of	a	concomitant	noxious	ear	pinch.	This	was	counted	as	one	DNIC	trial	and	repeated	to	obtain	the	average	pre-conditioned	and	DNIC	responses.		
2.3	Experimental	Pain	Models	
	
2.3.1	Spinal	Nerve	Ligation		
	The	L5/L6	spinal	nerve	ligation	(SNL)	model	has	been	previously	described	by	(Kim	and	Chung	1992).	Male	Sprague-Dawley	rats	weighing	approximately	120g	were	anesthetised	in	3%	isofluorane	delivered	in	66%	nitrous	oxide	and	33%	oxygen	for	induction	and	the	isofluorane	was	maintained	at	2%	for	the	remainder	of	the	surgery.	Under	aseptic	conditions,	a	small	left	hand	incision	was	made	at	approximately	L4-S2.	The	left	tail	muscle	and	fat	were	removed	to	expose	the	L5	and	L6	spinal	nerves.	The	L5	and	L6	spinal	nerves	were	then	isolated	with	a	fine	glass	hook	and	then	tightly	tied	with	non-absorbable	6-0	braided	silk	thread.	The	surrounding	skin	and	muscle	were	closed	with	absorbable	3-0	sutures.			For	all	SNL	animals	used	in	Chapter	4,	the	surgery	was	performed	by	Dr	Leonor	
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Gonçalves.	For	this	study,	half	of	the	WDR	neuronal	recordings	were	contributed	by	Dr	Kirsty	Bannister	as	part	of	a	collaborative	project.				
2.3.2	Monoiodoacetate	induced	arthritis	
	The	Monoiodoacetate	(MIA)	model	of	osteoarthritis	was	originally	described	by	Kalbhen	and	colleagues	(Kalbhen	et	al	1987).	Male	Sprague-Dawley	rats	weighing	190-210g	(Early	phase)	or	120-140g	(Late	phase)	were	anaesthetized	with	3.5%	isofluorane	delivered	in	66%	nitrous	oxide	and	33%	oxygen	until	the	animals	were	fully	unconscious	and	a-reflexive.	Animals	were	then	placed	on	a	heated	mat,	and	the	isofluorane	anaesthetic	was	delivered	at	2%	via	a	nose	cone	for	the	remainder	of	the	surgery.	The	ventral	surface	of	the	hind	limb	was	clipped	of	hair	around	the	knee	area	and	cleaned	with	clorhexidine.	The	joint	was	flexed	in	the	left	knee	and	arthritis	was	induced	by	an	intrarticular	injection	of	2mg	MIA	in	25µL	of	0.9%	saline.	The	MIA	was	administered	with	a	27g	needle	through	the	infrapatellar	ligament,	the	needle	was	held	in	place	for	30	seconds	and	withdrawn	slowly	to	avoid	any	leakage	of	the	MIA.	For	Sham	animals,	25µL	of	0.9%	saline	was	injected.	Rats	were	placed	in	an	incubator	to	recover,	and	subsequently	in	clean	cages	and	monitored	for	the	next	72	hours.	The	day	of	injection	was	considered	day	0.	Early	phase	and	Early	phase	Sham	animals	were	used	for	electrophysiology	2-6	days	post	injection,	while	Late	phase	and	Late	phase	Sham	animals	were	used	14-20	days	post	injection.			
2.4	Behavioural	Testing	
	For	all	behavioural	testing	the	experimenter	was	blinded	as	to	which	were	MIA	injected	animals	and	saline	injected	sham	controls.		
	
2.4.1	Acclimatization	
	Before	any	behavioural	testing	animals	were	allowed	to	acclimatize	to	the	equipment	used.	This	was	carried	out	on	two	consecutive	days	before	baseline	responses	were	recorded.	Equipment	used	for	paw	withdrawal	threshold	testing	includes	a	rack	of	Perspex	boxes	open	at	the	top	and	bottom	and	placed	on	a	wire	mesh	rack.	Rats	were	placed	in	individual	boxes	and	given	20	minutes	to	acclimatize	to	their	surroundings.	For	weight	bearing	an	incapacitance	tester	(Linton	Instrumentation,	Norfolk,	UK)	was	used	as	described	by	(Bove	et	al	2003)	where	the	animals	are	placed	in	a	clear	angled	Perspex	chamber.	In	the	chamber	the	animals	placed	each	hind	paw	on	separate	force	
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platforms,	with	their	tail	placed	out	of	hole	in	the	back,	and	their	front	hind	paws	on	the	Perspex	surface	as	depicted	in	Figure	2.5.	During	the	acclimatization	days	the	rats	were	trained	to	stand	with	equal	weight	on	each	platform.	During	acclimatization	and	behavioural	testing	the	room	was	booked	to	prevent	interruption	so	that	a	quiet	and	undisrupted	environment	was	provided.		
2.4.2	Mechanical	Hypersensitivity	
	Rats	were	placed	in	individual	Perspex	boxes	within	the	rack	and	allowed	to	acclimatize	for	10	minutes	before	testing.	Mechanical	hypersensitivity	was	tested	at	the	site	of	the	hind	paw	in	order	to	assess	the	presence	of	secondary	hyperalgesia	as	a	result	of	the	MIA	injection.			For	the	first	method	used	to	test	mechanical	hypersensitivity,	von	Frey	hairs	of	increasing	intensity	were	applied	to	the	plantar	surface	of	the	hind	paw	(1g,	2g,	4g,	6g,	8g,	10g,	15g	and	26g).	If	the	animal	removed	its	paw	from	the	von	Frey	hair	stimulation	all	5	times	the	testing	stopped	and	this	was	noted	as	the	animals	paw	withdrawal	threshold	(PWT).	From	this	point	von	Frey	hairs	of	higher	bending	force	were	not	used	on	this	animal.	This	was	performed	on	both	ipsilateral	and	contralateral	hind	paws	with	ipsilateral	testing	performed	first	on	all	rats	followed	by	testing	on	the	contralateral	paw.			The	second	method	used	to	test	mechanical	hypersensitivity,	the	up-down	method,	has	been	previously	described	by	(Chaplan	et	al	1994).	Von	Frey	filaments	were	applied	to	the	plantar	hind	paw	for	5	seconds	and	any	withdrawal	from	this,	including	flinching	or	shaking,	counted	as	a	positive	response.	The	von	Frey	hairs	used	in	this	test	were	1.4g,	2g,	4g,	6g,	8g,	10g	and	15g.	To	begin	with	the	6g	stimulation	was	tested	and	subsequently	the	weight	of	the	next	von	Frey	filament	used	would	be	greater	or	less	depending	on	a	negative	or	positive	response	respectively.	Following	a	positive	response,	4	more	von	Frey	filaments	were	tested,	either	increasing	or	decreasing	in	weight	depending	on	responses.	50%	paw	withdrawal	thresholds	(PWT)	were	then	calculated	with	the	following	formula:	PWT	=	(10^(x		+	kδ)/10,000),	where	x	represents	the	log	of	the	last	von	Frey	tested,	δ	represents	the	mean	difference	between	the	von	Frey	filaments	in	log	units	(0.17)	and	k,	a	value	dependent	on	the	series	of	responses	(Dixon	et	al	1965).	This	was	performed	on	both	ipsilateral	and	contralateral	hind	paws.	Ipsilateral	testing	occurred	first,	with	a	full	test	carried	out	on	one	animal	to	determine	PWT,	this	was	then	continued	on	the	rest	of	the	rats	before	returning	to	the	first	rat	to	
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repeat	the	tests	on	the	contralateral	hind	paw.			Baseline	PWT	was	carried	out	twice	on	two	consecutive	days	and	the	average	taken.	For	early	phase	animals	tests	were	then	carried	out	on	day	2	and	day	4	post	injection.	For	late	phase	animals	tests	were	carried	out	on	day	2,	day	4,	day	7	and	day	14	post	injection.		
2.4.3	Weight	bearing	assessment	
	Animals	were	placed	in	the	angled	Perspex	chamber	on	the	incapacitance	tester	and	were	given	5	minutes	to	acclimatize.	Once	animals	were	stood	in	the	correct	position	with	one	hind	paw	in	contact	with	each	force	platform,	the	force	exerted	by	each	hind	paw	was	measured	over	a	5	second	period.	This	was	repeated	3	times	with	each	animal.	From	these	3	recordings,	the	average	weight	placed	on	the	ipsilateral	limb	was	quantified	and	expressed	as	a	percentage	of	both	hind	paws.	Weight	bearing	assessment	was	only	performed	in	animals	that	remained	calm;	if	an	animal	seemed	stressed	in	the	equipment,	assessed	through	vocalization,	it	was	returned	to	the	cage	and	tested	again	after	recovery.			Baseline	weight	bearing	was	obtained	from	the	average	of	two	trials	performed	on	consecutive	days.	For	early	phase	animals	further	tests	were	carried	out	on	day	2	and	day	4	post	injection.	For	late	phase	animals	further	tests	were	carried	out	on	day	2,	day	4,	day	7	and	day	14	post	injection.		
	
Figure	2.6	Weight	bearing	assessment	using	a	incapacitance	tester.	The	animal	was	placed	in	a	Perspex	box	with	the	front	paws	leaning	on	the	angled	surface	while	each	hind	paw	was	
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placed	on	a	separate	panel	on	the	incapacitance	tester.	Once	the	rat	was	in	the	correct	position,	the	panels	measured	how	much	weight	the	rat	was	placing	on	each	hind	paw	in	grams.	Image	gifted	by	Dr	Louisa	Townson.	
	
	
2.5	Knee	Histology	
	
2.5.1	Dissection,	fixation	and	decalcification	
	At	the	end	of	electrophysiology	experiments,	the	isofluorane	was	increased	to	5%	to	over-anaesthetise	the	animal	and	a	cervical	dislocation	confirmed	death.	Following	this	the	knee	joint	was	roughly	dissected	with	the	tibia	and	femur	and	any	excess	muscle	or	tissue	surrounding	the	joint	was	removed.	It	was	not	necessary	to	perfuse	the	animal	before	hand	as	the	cartilage	contains	no	blood	vessels	so	perfusion	would	not	have	help	preserve	this	particular	tissue.	Following	dissection	the	entire	knee	joint	was	placed	into	4%	paraformaldehyde	(PFA)	for	24-48	hours	for	fixation.			Following	fixation	the	knees	were	rinsed	in	water	for	30	minutes	on	a	shaker.	The	knee	joints	were	then	dehydrated	with	steps	of	increasing	concentrations	of	ethanol.	Firstly,	in	30%	ethanol	for	30	minutes,	then	in	50%	ethanol	for	30	mins	and	finally	placed	in	70%	ethanol.	For	all	of	these	steps	the	knees	were	placed	on	a	shaker.	At	this	point	the	knees	were	stored	until	they	were	ready	to	be	processed.			Before	decalcification	the	knees	were	rehydrated;	they	were	placed	in	50%	ethanol	for	30	minutes,	followed	by	30%	ethanol	for	30	minutes,	and	finally	were	placed	into	water.	The	knees	were	then	placed	in	Immunocal®	(Quarttet,	Berlin,	Germany)	for	decalcification	for	approximately	one	week.	To	check	the	progress	of	decalcification	the	joints	were	checked	using	a	microCT	(SkyScan	1172)	on	day	3	and	day	7	(Figure	2.6).	This	was	used	to	confirm	the	joint	was	completely	decalcified	as	any	calcium	remains	would	cause	the	knee	to	be	too	brittle	to	section.		
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Figure	2.7	microCT	images	of	the	joint	decalcifying	over	time.	The	day	before	decalcification	begins	(Day	0)	the	knee	joint	was	scanned,	and	had	obvious	structure	with	clean	edges.	3	days	into	the	decalcification	process	the	knee	was	scanned	again,	at	this	point	the	joint	had	lost	a	lot	of	structural	integrity.	After	7	days	of	decalcification	in	immunocal	the	joint	had	lost	its	structural	integrity	and	had	no	calcium	remaining	on	the	bone.		
	
2.5.2	Processing,	embedding	and	cutting	
	Following	decalcification	the	knees	were	removed	from	Immunocal®	and	rinsed	in	water	before	being	dehydrated	in	increasing	concentrations	of	ethanol.	The	decalcified	knees	were	placed	in	30%	ethanol	for	30	minutes,	then	50%	ethanol	for	30	minutes	and	were	finally	placed	in	70%	ethanol.	The	knees	were	then	placed	in	individual	cassettes	for	overnight	processing.				The	processing	protocol	involved	a	series	of	ethanol	and	wax	washes	in	a	Tissue-Tek®	VIPTM	(Vaccum	Infiltration	Processor,	Sakura,	USA).	Firstly,	the	knee	joints	were	washed	in	70%	Industrial	Methylated	Spirits	(IMS)	for	one	hour.	This	was	followed	by	a	90%	IMS	wash	for	one	hour,	followed	by	4	100%	IMS	washes	each	at	90	minutes.	Next,	there	were	two	xylene	washes	for	90	minutes,	followed	by	two	more	xylene	washes	at	105	minutes	each.	The	final	step	was	a	wax	wash	for	1	hour	followed	by	two	wax	and	vacuum	steps	each	for	1	hour.			Upon	the	final	stage	of	overnight	processing	in	the	Tissue-Tek®	VIPTM,	the	knees	were	
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placed	in	liquid	wax	ready	for	embedding.	The	knees	were	placed	into	individual	plastic	moulds	and	submerged	fully	in	paraffin	wax.	The	orientation	of	the	knee	was	important	for	sectioning;	the	patella	was	faced	down	with	the	tibia	perpendicular	to	the	front	of	the	mould	and	the	femur	facing	upwards	out	of	the	mould.	This	allowed	for	all	condyles	of	the	joint	to	be	cut	evenly	(Figure	2.7).			The	joint	was	then	cut	in	the	paraffin	wax	block	into	10µM	sections	using	a	microtome	(Microm	HM	360).	Four	consecutive	knee	slices	were	placed	on	a	superforst	plus	slide	(ThermoFisher),	approximately	80	slides	were	produced	per	knee	with	the	first	slide	representing	the	dorsal	part	of	the	knee	and	the	last	slide	the	ventral	part	of	the	knee.	The	slides	were	then	left	to	dry	in	a	37°C	oven	overnight.			
	
Figure	2.8	Orientation	of	the	knee	joint	for	sectioning.	The	knee	joint	was	placed	correctly	in	the	mould	ready	for	sectioning,	such	that	all	4	condiles	would	be	respresented	in	each	knee	section	imaged.			
2.5.3	Staining	with	Toluidine	blue	
	Every	fourth	slide	was	stained	to	give	an	accurate	representation	of	cartilage	damage	throughout	the	entire	knee,	I.e.	slide	1,	5,	9,	13	etc	was	stained	with	toluidine	blue.	To	begin	with	the	slides	underwent	2	washes	with	NeoClear,	each	for	10	minutes.	The	slides	were	then	hydrated,	starting	with	2	100%	ethanol	washes	at	1	minute	each.	The	slides	were	then	placed	in	90%	ethanol,	followed	by	70%	ethanol,	followed	by	50%	ethanol,	followed	by	distilled	water,	for	1	minute	at	each	concentration.	The	slides	were	then	washed	in	acetate	buffer	for	1	minute	before	being	placed	in	1%	toluidine	blue	
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solution	for	2	minutes.	The	slides	were	rinsed	twice	in	distilled	water	until	the	water	ran	off	clear.	The	slides	were	then	placed	into	2	acetone	washes,	both	for	2	minutes	each.	The	slides	were	then	placed	in	xylene	for	5	minutes	and	the	placed	into	a	second	wash	of	fresh	xylene	for	2	minutes.	There	was	a	final	fresh	xylene	wash	before	a	cover	slip	(22mm	x	70mm,	0.17mm	thickness.	Thermo	Scientific)	was	mounted	onto	each	slide	with	DPX.			
2.5.4	Grading	Lesions	
	Every	fourth	slide	(1,5,9	etc.)	was	stained	with	toluidine	blue	to	visualize	cartilage	and	bone	so	that	cartilage	damage	can	be	scored.	Scoring	was	blinded	and	carried	out	by	two	individuals	using	a	Zeiss	light	microscope	with	each	condyle	being	scored	separately.	Knee	scores	were	then	calculated	using	two	different	methods.	Firstly,	the	average	maximum	score	was	used	where	the	highest	scoring	condyle	was	taken	from	each	slide	and	averaged	for	all	slides	to	represent	damage	throughout	the	knee.	Secondly,	the	maximum	score	was	used	where	the	highest	score	through	the	entire	knee	was	taken	alone	to	represent	the	area	of	the	most	damage.	The	scoring	system	has	been	previously	described	(Glasson	et	al	2010);	the	scores	are	given	as	shown	in	Table	2.1	and	Figure	2.8.	The	knee	histology	images	presented	in	this	thesis	were	produced	using	a	Zeiss	Axioskop	microscope.			
Table	2.1.	Scoring	system	
Grade	 Osteoarthritic	damage	0	 No	damage	0.5	 Some	loss	of	toluidine	blue	staining	1	 Small	superficial	lesions	of	the	articular	cartilage	2	 Small	lesions	immediately	below	the	superficial	layer	of	articular	cartilage	3	 Large	lesions	or	erosion	of	the	articular	cartilage	covering	up	to	20%	of	the	condyle	4	 Loss	of	articular	cartilage	tissue	from	20%	to	50%	of	the	condyle	surface	5	 Loss	of	articular	cartilage	tissue	from	50%	to	80%	of	the	condyle	surface	6	 Loss	of	articular	cartilage	tissue	from	more	than	80%	of	the	condyle	surface					
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Figure	2.9.	Sections	of	knee	joints	stained	with	toluidine	blue	showing	the	grades	of	
articular	cartilage	lesions.	The	red	circles	show	the	area	of	damage	and	scores	are	determined	based	on	the	criteria	set	in	Table	2.1.		
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2.6	Immunohistochemistry	
	
2.6.1	Fast	Blue	retrograde	neuronal	tracer	injection	
	Male	Sprague-Dawley	rats	were	anaesthetized	with	ketamine	[0.6ml	sterile	saline,	0.1ml	medetomidine	hydrochloride	(1mg/ml),	0.24ml	ketamine	(0.3mg/ml)],	with	250μL	injected	interperitoneally	per	100g	of	rat.	The	animals	were	checked	to	be	fully	unconscious	and	areflexive.	The	ventral	surface	of	the	hind	limb	was	clipped	of	hair	around	the	knee	area	and	cleaned	with	clorhexidine.	The	joint	was	flexed	in	the	left	knee	and	an	intra-articular	injection	of	25µL	of	Fast	Blue	(2%	w/v	in	dH2O)(Polysciences	Europe	GmbH)	was	adminstred	with	a	27g	Hamilton	needle	through	the	infrapatellar	ligament.	The	needle	was	held	in	place	for	30	seconds	and	withdrawn	slowly,	and	the	animals	remained	unconscious	for	2	hours	to	avoid	movement	and	leakage	of	the	Fast	Blue.	The	animals	were	bought	back	to	consciousness	with	the	reversing	agent	atipamezole	(5mg/ml),	where	25µL	was	injected	subcutaneously	per	100g	of	animal.			
2.6.2	Perfusion,	dissection,	embedding	and	slicing	
	Animals	were	terminally	over-anaesthetised	with	an	overdose	of	isoflourane	and	transcardially	perfused,	first	with	chilled	0.1%	phosphate	buffer	to	remove	excess	blood	followed	by	4%	PFA	for	tissue	fixation.	The	lumbar	spinal	cord	was	dissected	out	with	the	L3,	L4	and	L5	ipsilateral	and	contralateral	DRGs.	The	tissue	was	placed	in	4%	PFA	overnight	for	post-fixation.	The	tissue	was	then	placed	in	30%	sucrose	overnight	before	being	mounted	in	OCT,	frozen	in	liquid	nitrogen	and	stored	at	-80°C.			DRGs	were	cut	on	a	cryostat	into	10µM	sections	and	placed	on	SuperFrost	Plus	slides	(ThermoFisher).	Spinal	cords	were	cut	on	a	cryostat	into	20µM	sections	and	placed	on	SuperFrost	Plus	slides	(ThermoFisher).		
2.6.3	Antibody	incubation	and	visualization	
	Slides	were	incubated	with	blocking	buffer	(10%	donkey	serum	and	0.02%	Triton-X-100	in	PBS),	for	approximately	6	hours	(over	the	day)	at	room	temperature.	Primary	antibodies	(βIII-tubulin	-	Invitrogen,	mouse	monoclonal,	1:1000,	ATF-3	-	Santa	Cruz,	rabbit	polyclonal,	1:500)	were	incubated	overnight	at	room	temperature.	Primary	antibodies	were	removed	by	washing	with	PBS,	3	times	(2	minutes	each	wash).	Secondary	antibodies	conjugated	with	either	Alexa-488	(anti-mouse)	(Invitrogen),	or	Alexa-564	(anti-rabbit)(Invitrogen,	1:1000)	were	diluted	in	the	blocking	buffer	
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(1:1000),	and	slides	were	incubated	for	2	hours	at	room	temperature.	Slides	were	washed	3	times	in	PBS	(2	minutes	each	wash)	and	mounted	in	Fluoromount-G	(ThermoFisher).				Immunofluorescence	was	visualized	using	a	Zeiss	Imager	Z.1	microscope.		
	For	Fast	Blue	retrograde	neuronal	tracer	studies	DRGs	were	taken	for	each	lumbar	section	from	3	animals	and	4	random	slices	of	each	DRG	were	chosen	for	images	of	complete	DRG	sections	using	mosaic-photomicrographs.	The	total	numbers	of	βIII-tubulin	nucleated	neurons	were	counted	in	each	DRG	and	their	diameters	measured	using	ImageJ.	This	was	compared	to	the	number	of	Fast	Blue	positive	stained	neurons	so	that	the	size	distribution	of	the	Fast	Blue	positive	neurons	and	total	population	could	be	determined.		
	
2.7	Quantitative	Polymerase	Chain	Reaction	(qPCR)	
	
2.7.1	Perfusion	and	dissection	
	Animals	were	terminally	over-anaesthetised	with	an	overdose	of	Isofluorane	and	transcardially	perfused	with	chilled	0.1%	phosphate	buffer	to	remove	excess	blood.	The	lumbar	spinal	cord	was	dissected	and	was	sliced	carefully	down	the	central	vessel	to	retrieve	the	ipsilateral	side	of	the	spinal	cord	and	this	was	cut	in	half	again	to	leave	the	ipsilateral	dorsal	horn.	The	L3,	L4	and	L5	DRGs	were	also	dissected	on	both	the	ipsilateral	and	contralateral	side.	The	tissue	was	then	placed	in	RNAse	free	tubes	and	snap	frozen	using	liquid	nitrogen	and	stored	at	-80°C	until	RNA	was	extracted.			
2.7.2	RNA	extraction	
	Firstly	the	tissue	is	homogenized	in	Qiazol,	chloroform	is	then	added,	the	solution	placed	in	Phase	Lock	Gel-Heavy	(PLG)	tubes	and	span	in	the	centrifuge	for	15	minutes	at	12,000rpm	at	4°C.	The	resulting	aqueous	phase	from	the	centrifuge	is	poured	onto	RNAeasy	spin	columns	(Qiagen	RNAse	microkit	–	Qiagen	Germany)	and	processed	according	to	the	manufacturers	instruction.	In	brief;	1.5	times	the	volume	of	ethanol	was	added	to	the	spin	column	and	span	again	at	11,000	rpm	for	1	minute.	After	each	spin	the	flow	through	is	discarded.	RW1	buffer	was	added	and	span	at	13,000	rpm	for	15	seconds,	DNAse	was	then	added	and	left	to	incubate	at	room	temperature	before	spinning	at	13,000	rpm	for	15	seconds.	The	RW1	buffer	step	from	above	was	repeated	
	 109	
and	then	this	step	was	repeated	with	RPE	buffer.	Finally,	30µL	RNAse	free	water	was	added	onto	the	collection	tube	and	the	sample	span	at	11,000	rpm	for	1	minute.	The	resulting	RNA	was	immediately	placed	on	ice	and	the	concentrations	determined	using	a	Nanodrop	Spectrophometer	ND-100	(Labtech	International,	UK).			
2.7.3	cDNA	synthesis	
	First	strand	cDNA	synthesis	was	performed	with	Superscript	III	Reverse	Transcriptase	(Invitrogen,	Canada)	according	to	manufacturers	instruction.	In	brief,	RNA	was	diluted	to	500ng	with	RNAse	free	water	made	up	to	12µL.	To	this	solution,	a	1µL	aliquot	of	deoxynucleotide-triphosphate	(dNTPs)	was	added	containing	equal	amounts	of	adenine,	guanine,	thymine	and	cytosine	(Promega,	USA).	Finally,	a	1µL	aliquot	of	random	primers	(50µM)	was	added	(Promega,	USA).	This	solution	was	then	placed	in	a	thermocycler	(GeneAmp®	PCR	System	9700,	Applied	Biosciences)	and	heated	to	65°C	for	5	minutes	before	being	placed	back	on	ice.	Secondly,	a	mastermix	containing	first	strand	buffer,	dithiothreitol	(DTT)	and	superscript	III	reverse	transciptase	was	added	to	the	RNA	mixture	(all	Invitrogen,	Canada).	The	entire	sample	is	then	placed	back	in	the	thermocycler	using	the	following	programme:	25°C	for	5min,	50°C	for	60min	and	70°C	for	15min.	The	cDNA	was	then	stored	at	4°C	until	qPCR	was	performed.			
2.7.4	Primer	validation	
	New	primers	were	designed	using	primer-blast	following	pre-established	criteria	in	our	lab:	product	size	between	70-150	base	pairs,	spanning	exon-exon	juntions,	and	minimal	or	no	self-complimentary.	Primers	designed	this	way	were	IL-1β	(InterLeukin-1β),	HTR7	(5-HT7-receptor),	HTR3a	(5-HT3A-receptor),	HTR3b	(5-HT3B-receptor),	ADRA2	(α2-adrenoceptor).	In	addition,	ATF-3	(Activiating	transcription	factor	3),	TNFα	(tumour	necrosis	factor	α),	IL-6	(interleukin-6),	GFAP	(glial	fibrillary	acid	protein),	Cacna2d1	(the	α2δ1	subunit	of	vaoltage	gated	calcium	channels),	AIF1	(Ionized	calcium	binding	adaptor	molecule	1),	and	GAPDH	(Glyceraldehyde	3-phosphate	dehydrogenase),	which	were	also	used	in	this	study,	had	all	been	previously	validated	in	the	lab.	The	primer	sequences	used	are	shown	in	Table2.2.			
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Table	2.2	Primer	sequences	
Gene	 Forward	sequence	(5’-3’)	 Reverse	sequence	(5’-3’)	 Source	IL-1β	 AGGAGAGACAAGCAACGACA	 TTTGGGATCCACACTCTCCAG	 Invitrogen	HTR7	 ACCTGAGGACCACCTATCGT	 GGTCAGAGTTTTGTCTTACAGCA	 Invitrogen	HTR3a	 GGCTGCTAGATCACCTCCTG	 AACCTGGTTCTTCTCATCCACG	 Invitrogen	HTR3b	 GTGGCTGTCGTAGGTATTCTAGG	 CTGGTCTGACCTCCTTGTGG	 Invitrogen	ADRA2	 ACACGGACCTGCTTTGACAT	 TATGCTGTTAGGCACAGGGG	 Invitrogen	Ntrk1	 TGTCAAGGCACTGAAGGAGAC	 TGCAGACTCCAAAGAAGCGT	 Invitrogen	AIF1	 TCCCCACCTAAGGCCACCAGC	 CGTCTCCTCGGACCACTGGA	 Sigma	ATF-3	 GGTCGCACTGACTTCTGAGG	 CTCTGGCCGCTCTCTGGA	 Sigma	TNFα	 CGTCGTAGCAAACCACCAAGC	 ATGGCGGAGAGGAGGCTGACT	 Sigma	IL-6	 TCTCTCCGCAAGAGACTTCC	 CCGGACTTGTGAAGTAGGGA	 Sigma	GFAP	 CAACCTCCAGATCCGAGAA	 TCTTGAGGTGGCCTTCTGAC	 Sigma	Cacna2d1	 CATTGTTGGGCTCCACAGTAT	 GACCTTGTCACACTGGCAAA	 Sigma	GAPDH	 CTGCACCACCAACTGCTTAG	 TGATGGCATGGACTGTGG	 Sigma		For	primer	validation	both	rat	spinal	cord	cDNA	alone	and	a	pool	of	rat	cDNA	containing	heart,	lung,	spinal	cord,	muscle	and	liver	were	used.	A	1:3	serial	dilution	of	the	cDNA	was	made	with	5	concetrations;	12ng,	4ng,	1.33ng,	0.44ng	and	0.15ng.	RNAse	free	water	was	also	used	as	a	negative	control.	The	exact	protocol	for	qPCR	is	below.	For	each	primer	the	serial	dilution	was	used	to	create	a	standard	curve,	so	the	efficacy	of	the	primer	could	be	determined,	as	well	as	its	melting	curve.	Furthermore,	to	confirm	only	one	PCR	product	was	being	amplified,	the	products	from	the	4nd	cDNA	dilution	were	ran	on	electrophoresis	2%	agarose	gel	(w/v	TBE	buffer,	(PanReac	AppliChem)	containing	Ethidium	Bromie	(Promega	USA).	To	make	the	2%	gel	4g	agarose	(Sigma)	was	diluted	in	200ml	10x	TB	buffer	(PanReac	AppliChem).	Ethidium	Bromide	(14µL)	was	also	added	to	the	gel	mixture,	ethidium	bromide	binds	to	the	DNA	and	allows	us	to	visualize	it	using	UV	light.	The	set	gel	was	placed	in	the	electrophoresis	unit	and	the	unit	was	filled	with	10x	TB	buffer	until	the	gel	was	covered.	After	the	qPCR	reaction,	2µL	loading	buffer	(Promega,	USA)	was	added	to	each	sample	so	that	they	could	be	loaded	into	wells	within	the	gel.	A	100	bp	DNA	ladder	(Promega,	USA)	was	loaded	into	the	first	well	to	verify	the	size	of	our	PCR	products.	The	gel	was	run	at	100V	for	1	hour	so	that	the	DNA	products	move	towards	the	positive	electrode	at	the	bottom	of	the	gel.	The	gel	was	imaged	with	UV	light	using	GeneSnap	(SynGene).	The	bands	created	by	the	PCR	products	were	used	to	determine	their	molecular	size	and	this	is	compared	to	the	expected	product	size	from	the	primers.		
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2.7.5	Quantitative	Polymerase	Chain	Reactions	
	For	the	qPCR,	an	8µL	aliquot	of	master	mix	containing	5µL	LightCycler®	480	SYBR	Green	I	Master	(Roche),	2µL	RNAse	free	water,	and	1µL	(10µM)	of	the	primers	forward	and	reverse	was	prepared	for	each	reaction.	For	each	reaction	,	2µL	of	5ng/µL	of	cDNA	was	used.	For	all	experiments,	two	technical	replicates	(duplicates)	of	each	reaction	were	performed.	A	LightCycler®	384	well	plate	was	placed	in	the	LightCycler®	480	instrument	(Roche),	using	a	pre-optimised	LightCycler®	480	SYBR	Green	I	Master	programe	(for	details,	see	Table2.3).				
Table	2.3	LightCycler®	480	SYBR	Green	I	Master	Programme	
Step	 Target	
Temp	(°C)	
Hold	
(hh:mm:ss)	
Ramp	rate	
(°C/s)	
Cycles	 Analysis	
Pre-Incubation	 95	 00:05:00	 4.8	 1	 None	
Amplification	 95	 00:00:10	 4.8	 45	 Quantification	72	 00:00:30	 4.8	
Melting	Curve	 95	 00:00:05	 4.8	 1	 Melting	Curves	65	 00:01:00	 2.5	97	 -	 -	
Cooling	 40	 00:00:10	 2.0	 1	 None		
	
2.7.6	Analysis	
	Using	the	analysis	tab	on	the	LightCycler®	480	programme,	it	was	determined	at	which	cycle	the	cDNA	begins	to	be	amplified	into	double	stranded	DNA	products.	When	unbound,	the	SYBR	Green	dye	exhibits	very	little	fluorescence,	however	during	the	PCR,	when	double	stranded	DNA	was	produced	the	dye	becomes	intercalated	into	the	DNA	helix.	The	fluorescence	of	the	SYBR	green	dye	is	greatly	enhanced	upon	DNA	binding.	Therefore,	an	increase	in	the	SYBR	Green	fluorescence	is	proportional	to	the	amount	of	double-stranded	DNA	that	has	been	produced;	this	is	expressed	as	the	Cp	value	(Figure	2.9).	For	all	genes,	expression	was	normalized	to	the	expression	of	the	housekeeper	gene	glyceraldehyde-3-phosphate	dehydrogenase	(GAPDH)	and	this	was	expressed	as	the	ΛCT	value.	Graphically,	mRNA	expression	has	been	shown	in	two	ways.	Firstly,	mRNA	expression	was	expressed	as	the	log	of	the	ΛCT	value.	Secondly,	the	mRNA	expression	has	been	normalized	relative	to	the	Sham	mRNA	expression	for	comparison.			
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Figure	2.10	Analysis	of	qPCR	results.	The	LightCycler®	480	programme	uses	45	cycles	of	amplification.	It	determines	at	which	cycle	the	cDNA	begins	to	be	amplified	into	double	stranded	DNA	products	resulting	in	an	increase	in	SYBR	Green	fluorescence	and	this	is	expressed	as	the	Cp	value.		
2.8	Statistical	Analysis	
	All	analysis	was	carried	out	with	GraphPad	Prism	6.0	for	Mac	OS	X	and	SPSS	Statistics	version	22.	Asterisks	denote	statistically	significant	differences	(*P<0.05,	**P<0.01,	***P<0.001).		
	
2.8.1	Electrophysiology	
	Electrophysiological	data	is	displayed	as	the	number	of	action	potentials	fired	±	the	standard	error	of	the	mean	(SEM).				The	DNIC	response	was	characterized	as	the	number	of	action	potentials	fired	when	the	receptive	field	was	stimulated	alone	and	compared	to	the	number	of	action	potentials	fired	with	a	concurrent	noxious	conditioning	pinch.	Statistical	differences	in	neuronal	firing	following	application	of	the	noxious	ear	pinch	were	determined	using	a	two-way	repeated-measures	analysis	of	variance	(ANOVA)	with	a	Bonferroni	post-hoc	test.		The	drug	time	points	plotted	were	the	ones	that	produced	the	maximum	change	from	the	averaged	pre-drug	baseline	values	per	animal.	Statistical	differences	in	the	number	of	action	potentials	fired	before	and	after	drug	administration	were	determined	using	a	
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two-way	repeated-measures	ANOVA	with	a	Bonferroni	post-hoc	test.	The	DNIC	percentages	are	determined	as	the	inhibition	of	neuronal	firing	with	concurrent	application	of	the	noxious	ear	pinch.	The	level	of	inhibition	on	neuronal	firing	and	statistical	differences	between	percentages	following	drug	treatment	in	naïve	animals	were	determined	using	a	Kruskal-Wallis	independent	samples	one-way	ANOVA.		Statistical	differences	in	mechanically	evoked	WDR	neuronal	responses	between	early	and	late	phase	MIA	and	Sham	groups	were	tested	using	a	one-way	repeated-measures	ANOVA	with	a	Bonferroni	correction.			
2.8.2	Behavioural	assessment	of	pain	Data	showing	mechanical	hypersensitivity	of	the	hind	paw,	representing	secondary	hyperalgesia,	is	presented	as	either	the	number	of	paw	withdrawals	(out	of	5),	the	paw	withdrawal	threshold	determined	by	the	animal	withdrawing	5	times	to	that	von	Frey	hair,	or	as	the	50%	paw	withdrawal	threshold	(PWT)	derived	from	the	up-down	method	as	defined	by	Chaplan	and	colleagues	(Chaplan	et	al	1994).	For	weight	bearing,	data	is	presented	as	the	percentage	of	weight	placed	on	the	ipsilateral	hind	paw.	All	data	is	presented	as	the	mean	±	standard	error	of	the	mean	(SEM).	A	Kurskall-wallis	independent	samples	one-way	ANOVA	was	used	to	test	for	differences	in	the	number	of	withdrawals	and	paw	withdrawal	thresholds.	A	Freidmans	two-way	ANOVA	by	ranks	was	used	to	test	for	differences	in	the	percentage	weight	distributed	between	ipsilateral	and	contralateral	hind	paws,	while	a	Kruskall-wallis	independent	samples	one-way	ANOVA	was	used	to	test	differences	in	the	percentage	of	weight	placed	on	the	injected	knee	between	MIA	and	Sham	animals.			
2.8.3	Knee	histology	Knee	histology	scores	were	either	presented	as	the	maximum	score	where	the	highest	score	was	taken	through	the	entire	knee	or	the	average	maximum	score	where	the	maximum	score	was	taken	from	each	slide	and	averaged	through	the	knee.	All	the	data	was	presented	as	the	mean	score	±	SEM.	A	Friedmans	two-way	ANOVA	by	ranks	test	was	used	to	determine	statistical	differences	in	knee	histology	scores	between	the	four	knee	condyles.	A	Kruskall-wallis	independent	samples	one-way	ANOVA	was	used	to	test	statistical	differences	in	knee	histology	scores	between	MIA	animals	and	sham	controls.			
	
	
	 114	
2.8.4	Correlation	between	pain	behaviour	and	knee	histology	score	Data	was	presented	comparing	either	maximum	knee	histology	score	or	average	maximum	knee	histology	score	versus	50%	PWT	or	the	percentage	of	weight	placed	on	the	ipsilateral	paw.	Linear	regression	analysis	was	used	to	test	for	correlations	between	knee	histology	scores	and	pain-like	behaviour	in	late	phase	MIA	animals;	when	using	this	test	R2	represents	the	strength	of	the	relationship	between	knee	histology	score	and	pain-like	behaviour	and	an	F	test	of	overall	significance	determined	if	this	relationship	was	significant.		
2.8.5	Immunohistochemistry	Data	was	presented	as	the	percentage	of	Fast	Blue	positive	cell	bodies	in	the	DRGs	±	SEM.	A	Freidmans	two-way	ANOVA	with	ranks	test	was	used	to	test	for	statistical	differences	between	the	number	of	Fast	Blue	positive	cell	bodies	between	DRGs.		
	
2.8.6	qPCR	All	data	represented	mRNA	expression	levels	relative	to	the	housekeeping	gene	GAPDH,	and	the	data	was	presented	as	either	2-ΔCT	values	or	values	relative	to	the	sham	control	group.	A	one-way	repeated-measures	ANOVA	with	Bonferroni	correction	was	used	to	test	for	differences	in	the	mRNA	expression	between	groups	when	data	was	expressed	as	2-ΔCT	values.	A	Kruskall-wallis	independent	samples	one-way	ANOVA	was	used	to	test	for	differences	in	mRNA	expression	between	groups	when	the	values	were	normalized	to	sham	controls.				
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3.	A	model	for	investigating	Diffuse	Noxious	
Inhibitory	Controls	
	
3.1	Introduction			
3.1.1	Assessing	Diffuse	Noxious	Inhibitory	Controls	and	Conditioned	Pain	
Modulation	DNIC	and	CPM	responses	are	mediated	by	final	post-synaptic	mechanisms	acting	on	spinal	convergent	neurons	(Villaneuva	et	al	1984a,	Villaneuva	et	al	1984b).	Consequently,	there	are	three	potential	areas	of	study	to	investigate	the	function	of	these	endogenous	inhibitory	controls	further.	Firstly,	these	controls	of	spinal	neuronal	activity	and	their	pharmacology	can	be	studied	in	animals	using	electrophysiology.	Secondly,	spinally	mediated	reflexes	can	be	studied	in	both	animals	and	humans.	Thirdly,	the	perceived	pain	sensations	to	a	testing	stimulus	in	the	presence	of	a	noxious	conditioning	stimulus	can	be	studied	in	humans.	The	combination	of	these	methods	has	provided	a	lot	of	information	on	this	endogenous	descending	inhibitory	system	(Yarnkitsky	2015).				
3.1.2	Diffuse	Noxious	Inhibitory	Controls	can	be	observed	in	convergent	
neurons	The	dorsal	horn	is	an	important	site	involved	in	processing	sensory	information	and	contains	a	diverse	range	of	neurons	(Todd	2010).	Dorsal	horn	neurons	can	respond	to	a	diverse	range	of	stimuli	depending	upon	the	synapses	they	form	with	primary	afferents.	As	previously	discussed,	WDR	neurons	are	localized	to	the	deep	dorsal	horn	and	receive	input	from	Aβ,	Aδ	and	C	fibres	meaning	they	respond	to	both	innocuous	and	noxious	peripheral	stimulation.	DNIC	responses	are	observed	in	WDR	neurons	when	a	concurrent	noxious	stimulus	is	applied	distant	to	the	control	stimulus,	which	activates	top-down	endogenous	controls	and	results	in	powerful	inhibition	of	all	activities	in	WDR	neurons	(Le	Bars	et	al	1979a).	The	Nociceptive	Specific	(NS)	neurons	are	found	predominantly	in	the	superficial	lamina	of	the	dorsal	horn,	where	they	form	synapses	with	Aδ	and	C	afferents	and	so	are	specifically	activated	by	noxious	stimuli	in	the	periphery	(D’Mello	and	Dickenson	2008).	Despite	their	role	in	the	transmission	of	nociceptive	information,	NS	neurons	do	not	appear	to	be	modulated	by	DNIC	(Le	Bars	et	al	1979b).	The	dorsal	horn	also	contains	proprioceptive	neurons	that	respond	to	innocuous	stimulation,	they	synapse	only	with	Aβ	primary	afferents	and	therefore	
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respond	to	touch,	light	pressure,	and	some	joint	movement.	The	proprioceptive	neurons	cannot	be	activated	by	peripheral	noxious	stimulation	within	their	receptive	field,	and	their	activity	in	response	to	innocuous	stimulation	appears	to	be	unaffected	by	conditioning	noxious	stimulation	outside	of	their	receptive	field	(Le	Bars	et	al	1979b).	This	suggests	that	DNIC	specifically	influences	the	activity	of	convergent	neurons.	Therefore,	to	assess	the	endogenous	inhibitory	actions	of	DNIC	at	the	level	of	the	spinal	cord	recordings	must	be	taken	from	convergent	neurons.			So	long	as	the	heterotopic	noxious	conditioning	stimulus	is	noxious,	a	range	of	modalities	can	be	used	to	activate	a	DNIC	response.	The	activation	of	DNIC	has	been	demonstrated	with	natural	mechanical	and	thermal	stimuli,	through	electrical	stimulation	of	the	periphery,	and	by	more	prolonged	noxious	stimulations	such	as	chemical	or	visceral	pain	models	(Bannister	and	Dickenson	2017).	Electrophysiological	recordings	in	the	rat	have	demonstrated	that	the	activity	of	convergent	spinal	neurons	can	be	inhibited	upon	application	of	a	concurrent	noxious	stimulation	outside	of	the	receptive	field	of	the	test	stimulus,	which	includes	immersion	of	the	tail	or	the	muzzle	into	a	water	bath	heated	within	the	noxious	range,	and	a	noxious	mechanical	pinch	to	the	tail,	ear	or	muzzle	(Le	Bars	et	al	1981,	Dickenson	et	al	1981,	Villanueva	et	al	1986).	The	actions	of	thermal	conditioning	stimulation	have	also	been	demonstrated	in	humans,	where	the	thresholds	required	for	activation	of	the	nociceptive	flexion	spinal	reflex	mediated	by	electrical	stimulation	of	the	sural	nerve	were	increased	upon	application	of	a	concurrent	heterotopic	noxious	thermal	stimuli	(Willer	et	al	1989).	In	rats,	the	neuronal	activity	of	spinal	convergent	neurons	evoked	by	electrical	stimulation	of	C-fibres	in	the	receptive	field	is	inhibited	by	noxious	conditioning	stimuli	(Villanueva	et	al	1986).	Inflammatory	pain	models	such	as	peripheral	capsaicin	injection,	or	intraperitoneal	administration	of	acetic	acid	or	bradykinin	to	induce	visceral	pain	have	also	been	used	as	the	noxious	conditioning	stimulus	to	elicit	a	DNIC	response	(Calvino	et	al	1984,	Dickenson	et	al	1981,	Wiiting	et	al	1998,	Itomi	et	al	2016).	However	this	intense	inflammation	may	lead	to	peripheral	sensitization	and	may	even	mediate	central	neuronal	changes.	The	model	used	to	induce	DNIC	in	this	thesis	needed	to	utilize	a	noxious	conditioning	stimulus	that	was	short-lived	and	allowed	for	quick	recovery	without	any	risk	of	long-term	neuronal	changes.			
3.1.3	Conditioned	Pain	modulation	paradigms		There	are	multiple	CPM	paradigms	that	have	been	used	in	the	clinic	to	measure	the	efficiency	of	the	endogenous	inhibitory	system.	CPM	in	human	subjects	allow	for	
	 117	
assessment	of	changes	in	the	perceived	pain	response	upon	application	of	a	distant	noxious	stimulation,	which	when	coupled	with	fMRI	has	allowed	for	brain	areas	that	may	be	involved	in	the	CPM	process	to	be	identified	(Youseff	et	al	2015,	Youseff	et	al	2016).	Similarly	to	DNIC,	a	large	range	of	innocuous	and	noxious	stimulus	modalities	can	be	used	as	the	test	stimulus,	but	the	conditioning	stimulus	must	be	noxious	and	at	a	distant	body	region.	CPM	paradigms	often	involve	applying	a	test	stimulus	to	the	leg	while	simultaneously	applying	a	conditioning	stimulus	to	the	opposite	arm,	or	vice	versa,	and	analyzing	any	changes	to	perceived	pain	thresholds.	However,	as	there	is	no	standardized	protocol	specifying	the	stimulus	modality	or	duration	of	conditioning	stimulus	it	can	be	difficult	to	compare	findings	from	CPM	studies	(Pud	et	al	2009,	Lewis	et	al	2012).	Lewis	et	al	found	CPM	responses	to	cold	pressor	and	ischemic	tests	were	reliable	and	consistent	when	repeated	in	the	same	session	but	the	responses	were	more	variable	over	multiple	sessions	(Lewis	et	al	2012).	One	problem	with	assessing	perceived	pain	responses	rather	than	directly	assessing	DNIC	at	the	neuronal	level	is	that	the	perceived	pain	is	a	complex	response	that	can	be	influenced	by	a	subject’s	mood,	expectation,	and	their	hormone	and	stress	levels	(Vincent	and	Tracey	2008,	Lumley	et	al	2011).		Furthermore,	animal	studies	have	shown	that	the	inhibitory	response	of	neurons	can	continue	once	the	conditioning	stimulus	is	removed,	meaning	a	further	discrepancy	between	CPM	paradigms	is	when	the	inhibitory	response	is	tested	(Dickenson	et	al	1981,	Villanueva	et	al	1986).	As	the	duration	of	post-stimulus	inhibition	has	not	been	conclusively	determined,	it	is	difficult	to	know	if	the	CPM	response	finishes	upon	removal	of	the	conditioning	stimulus	or	once	pain	thresholds	have	returned	to	baseline	(Lewis	et	al	2012).	A	standardized	test	for	measuring	pressure	pain	thresholds	and	a	reliable	paradigm	for	inducing	inhibition	with	a	conditioning	noxious	stimuli	would	allow	for	a	more	consistent	comparison	between	CPM	studies.				
3.1.4	Chapter	3	aims	For	this	thesis,	an	anesthetized	rat	model	was	used	to	directly	assess	the	inhibitory	responses	of	convergent	WDR	neurons	in	the	dorsal	horn	upon	application	of	a	noxious	conditioning	stimulus	at	a	site	distant	to	the	receptive	field.								
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3.2	Methods	
	
3.2.1	Noxious	conditioning	stimulus	placement	
	Pre-conditioned	mechanically	evoked	WDR	neuronal	responses	to	8g,	26g,	and	60g	stimulations	on	the	hind	paw	receptive	field	were	measured.	A	concurrent	conditioning	stimulus	was	then	applied	outside	of	the	receptive	field	whilst	stimulating	the	receptive	field	with	the	same	von	Frey	hairs.	The	noxious	conditioning	stimuli	was	applied	to	the	ipsilateral	ear	in	most	studies,	but	was	also	applied	to	the	contralateral	ear,	the	contralateral	paw	and	the	tip	of	the	tail.	All	conditioning	stimulations	were	induced	with	a	bulldog	serrefine	clip	(Interfocis,	Linton,	UK)	and	lasted	for	5	seconds.	Pre-conditioned	and	DNIC	responses	were	averaged	from	two	trials	and	DNIC	was	quantified	as	an	inhibitory	effect	on	neuronal	firing	during	the	concurrent	noxious	pinch.			
3.2.2	The	duration	of	DNIC	induced	neuronal	inhibition	
	Two	methods	were	used	to	assess	how	long	the	inhibitory	effect	on	neuronal	firing	lasted	once	the	concurrent	conditioning	stimulus	had	been	removed.			Firstly,	pre-conditioned	mechanically	evoked	WDR	neuronal	responses	to	8g,	26g,	and	60g	stimulations	on	the	hind	paw	receptive	field	were	measured.	The	receptive	field	was	then	stimulated	with	a	concurrent	noxious	ear	pinch	for	5	seconds	to	obtain	a	DNIC	response.	The	bulldog	serrefine	clip	was	then	removed	from	the	ear,	and	the	receptive	field	was	mechanically	stimulated	immediately	after	removal	of	the	ear	pinch	and	10	seconds	after	removal	of	the	ear	pinch.	DNIC	was	quantified	as	an	inhibitory	effect	on	neuronal	firing	compared	to	pre-conditioned	neuronal	responses.	However,	this	only	allowed	a	5-10	second	break	between	subsequent	stimulations	of	the	receptive	field.	Therefore,	in	a	separate	experiment	I	mechanically	stimulated	the	receptor	field,	removed	the	von	Frey	hair	and	applied	the	same	stimulation	5	seconds	later.	This	was	repeated	with	8g,	26g	and	60g	von	Frey	hairs	3	times	and	a	mean	average	was	taken	for	number	of	action	potentials	fired	to	the	first	and	second	stimulus,	to	explore	if	this	was	an	adequate	time-frame	for	the	WDR	neuronal	responses	to	return	to	baseline.			Due	to	the	limitations	described	above	a	second	method	for	measuring	the	duration	of	the	DNIC	response	was	used.	Again,	pre-conditioned	mechanically	evoked	WDR	neuronal	responses	to	8g,	26g,	and	60g	stimulations	on	the	hind	paw	receptive	field	were	measured.	The	receptive	field	was	then	stimulated	with	the	same	von	Frey	hairs	
	 119	
but	with	a	concurrent	noxious	ear	pinch	for	5	seconds	to	obtain	a	DNIC	response.	In	this	instance	the	bulldog	serrefine	clip	was	then	applied	to	the	ear	for	5	further	minutes.	The	noxious	ear	pinch	was	then	removed	and	the	receptive	field	was	mechanically	stimulated	1	minute,	5	minutes	and	10	minutes	after.	DNIC	was	quantified	as	an	inhibitory	effect	on	neuronal	firing	compared	to	pre-conditioned	neuronal	responses.		
	
3.2.3	Statistical	Analysis	
	For	a	description	of	the	statistical	tests	used	for	analysis	please	refer	to	section	2.8.																			
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3.3	Results	
	
3.3.1	Diffuse	Noxious	Inhibitory	Controls	upon	natural	stimulation	of	the	
receptive	field	as	the	test	stimulus	
	Electrophysiological	recordings	were	taken	from	WDR	neurons	located	in	the	dorsal	horn	at	the	depth	expected	(700-1000μM)	for	lamina	IV-V	of	the	dorsal	horn,	and	received	input	from	the	hind	paw.	For	mechanical	stimulation,	vonFrey	hairs	of	increasing	bending	force,	8g,	26g,	and	60g	were	applied	to	the	receptive	field	3	times	to	obtain	a	stable	baseline	response	(<10%	variation	in	action	potential	firing	for	all	mechanically	evoked	neuronal	responses).	DNIC	was	characterized	by	mechanically	stimulating	the	hind	paw	receptive	field	in	the	presence	of	a	concurrent	noxious	ear	pinch	(Figure	3.1).	For	thermal	stimulation,	water	jets	heated	to	42°C,	45°C,	48°C,	and	50°C	were	applied	to	the	receptive	field	twice	to	obtain	a	baseline	response	and	DNIC	was	then	induced	during	application	of	the	thermal	stimuli	by	a	concurrent	noxious	ear	pinch	(Figure	3.1).	Both	mechanical	and	thermal	DNIC	trials	were	repeated	twice	and	baseline	and	DNIC	responses	were	averaged.	The	neuronal	responses	of	WDR	neurons	were	significantly	inhibited	to	both	mechanical	and	thermal	stimuli	upon	application	of	the	noxious	ear	pinch	as	shown	in	Figure	3.1.	The	concurrent	noxious	ear	pinch	consistently	inhibited	the	WDR	neuronal	firing	rate	in	response	to	both	innocuous	and	noxious	stimulation.	Specifically,	the	levels	of	neuronal	inhibition	induced	by	a	concurrent	noxious	ear	pinch	were	29%,	30%	and	30%	in	response	to	8g,	26g	and	60g	stimulations	respectively.	The	levels	of	neuronal	inhibition	induced	by	a	concurrent	noxious	ear	pinch	were	21%,	29%,	30%	and	20%	in	response	to	42°C,	45°C,	48°C,	and	50°C	stimulations	respectively.			
3.3.2	Diffuse	Noxious	Inhibitory	Controls	upon	electrical	stimulation	of	the	
receptive	field	as	the	test	stimulus	
	WDR	neuronal	responses	to	electrical	stimulation	of	the	hind	paw	receptive	field	were	taken.	Specifically,	the	receptive	field	was	stimulated	with	a	train	of	16	electrical	pulses	at	3	times	the	C-fibre	threshold,	and	a	post-stimulus	time	histogram	(PSTH)	was	constructed	to	separate	the	responses	evoked	by	peripheral	afferent	fibres	based	on	their	latency.	The	number	of	action	potentials	fired	by	Aβ,	Aδ,	and	C	fibres,	as	well	as	the	number	of	action	potentials	fired	due	to	post	discharge,	in	response	to	the	16	electrical	pulses	was	quantified.			
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A	predicted	no	wind-up	response	was	calculated	and	the	hypothetical	value	was	termed	“input”,	which	is	what	would	be	expected	if	the	WDR	neuron	had	no	change	in	the	evoked	response	with	subsequent	stimulations	over	the	16	pulse	period.	This	allowed	for	a	calculation	of	“wind-up”	by	taking	the	input	value	from	the	actual	accumulative	count	of	action	potentials	fired	from	the	16	stimulations.		The	electrical	stimulation	of	the	receptive	field	was	repeated	3	times,	with	a	10	minute	rest	period	between	each	stimulation	to	allow	for	the	neuronal	response	to	return	to	baseline,	and	the	results	were	averaged	to	obtain	a	pre-conditioned	neuronal	response.	The	electrical	stimulation	of	the	receptive	field	was	then	repeated	but	in	the	presence	of	a	concurrent	noxious	ear	pinch.	Overall	this	counts	as	one	DNIC	trial,	which	is	repeated	twice	and	an	average	of	the	results	were	taken	to	obtain	pre-conditioned	and	DNIC	response	values.			Interestingly,	the	noxious	ear	pinch	appeared	to	exhibit	no	inhibitory	effect	on	the	electrically	induced	activity	of	the	WDR	neuron	(Figure	3.2).	There	was	no	significant	difference	in	the	number	of	action	potentials	fired	by	the	WDR	neurons	evoked	by	Aβ,	Aδ,	and	C	fibres	with	a	concurrent	noxious	conditioning	ear	pinch.	There	was	also	no	significant	difference	in	the	number	of	action	potentials	fired	due	to	post-discharge	of	the	neuron	with	the	concurrent	conditioning	noxious	ear	pinch.	Furthermore,	the	concurrent	noxious	ear	pinch	appeared	to	have	no	significant	effect	on	the	“wind-up”	of	the	WDR	neuron,	as	the	number	of	action	potentials	fired	increased	by	similar	proportions	with	each	subsequent	electrical	pulse	in	both	the	pre-conditioned	and	DNIC	set-up.			
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Figure	3.1.	Mechanical	and	thermal	stimulation	of	WDR	neurons	and	the	DNIC	response.	Electrophysiological	recordings	were	taken	from	WDR	neurons	in	the	deep	dorsal	horn.	A)	The	receptive	field	was	mechanically	stimulated	with	vonFrey	hairs	of	increasing	bending	force	(n=25).	B)	The	receptive	field	was	thermally	stimulated	by	applying	water	jets	of	increasing	temperatures	(n=20).	The	mechanical	and	thermal	stimulations	were	repeated	to	obtain	baseline	responses	and	DNIC	was	then	induced	with	a	concurrent	noxious	ear	pinch.	C)	A	raw	trace	from	a	single	WDR	neuron	showing	3	stable	baseline	responses	to	von	Frey	hairs	of	increasing	bending	force	and	one	DNIC	response	in	the	presence	of	a	noxious	conditioning	ear	pinch.	D)	A	raw	trace	from	a	single	WDR	neuron	stimulated	twice	to	obtain	stable	thermal	responses	to	water	jets	of	increasing	temperature	followed	by	a	DNIC	response	induced	with	a	concurrent	noxious	ear	pinch.	Two-way	ANOVA	with	Bonferroni	post-hoc	test	(***P<0.001).		
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Figure	3.2.	Electrical	stimulation	of	WDR	neurons	and	the	DNIC	response.	Electrophysiological	recordings	were	taken	from	WDR	neurons	in	the	deep	dorsal	horn	and	the	number	of	action	potentials	fired	in	response	to	stimulation	of	the	receptive	field	with	a	train	of	16	electrical	pulses	at	3	times	the	C-fibre	threshold	was	quantified.	The	responses	evoked	by	Aβ,	Aδ,	and	C	peripheral	afferent	fibres	were	quantified	based	on	the	latency	of	the	responses.	There	was	no	significant	difference	in	the	number	of	action	potentials	fired	by	the	WDR	neurons	due	to	activation	of	peripheral	Aβ,	Aδ,	or	C	fibres	with	a	concurrent	noxious	ear	pinch.	There	was	no	significant	difference	in	the	“input”	or	“wind-up”	responses	of	the	WDR	neurons	in	the	presence	of	the	noxious	conditioning	ear	pinch.	Two-way	ANOVA	with	Bonferroni	post-hoc	test	(n=6).	
	
3.3.3	Placement	of	the	conditioning	noxious	stimulus	
	It	was	evaluated	how	consistent	the	inhibitory	response	were	when	the	concurrent	conditioning	noxious	stimulus	was	applied	to	other	areas	of	the	body.	The	pre-conditioned	mechanically	evoked	WDR	neuronal	responses	were	measured	in	response	to	8g,	26g	and	60g	von	Frey	hairs.	Whilst	mechanically	stimulating	the	receptive	field	a	concurrent	noxious	pinch	was	applied	at	sites	outside	of	the	receptive	field,	this	included	the	ipsilateral	ear,	the	contralateral	ear,	the	contralateral	hind	paw,	and	the	tail.	When	the	receptive	field	was	mechanically	stimulated	with	8g	and	26g	von	Frey	hairs,	there	was	a	reduction	in	the	number	of	action	potentials	fired	upon	application	of	conditioning	noxious	pinch	to	all	areas,	however	this	was	only	significant	for	the	8g	
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stimulation	of	the	receptive	field	with	noxious	pinch	of	the	contralateral	paw	(Figure	3.3).	For	mechanical	stimulation	of	the	receptive	field	with	the	60g	von	Frey	hair,	the	noxious	conditioning	pinch	applied	to	all	areas	resulted	in	a	significant	inhibition	of	neuronal	firing	(Figure	3.3).	This	indicates	that	the	noxious	conditioning	stimulus	can	be	applied	anywhere	distant	to	the	receptive	field	to	produce	an	neuronal	inhibition.		
	
Figure	3.3	Placement	of	the	noxious	conditioning	stimulus.	Pre-conditioned	neuronal	responses	to	mechanical	stimulation	with	8g,	26g,	and	60g	von	Frey	hairs	were	measured	from	3	stable	baseline	responses.	The	receptive	field	was	then	mechanically	stimulated	with	the	von	Frey	hairs	but	in	the	presence	of	a	noxious	pinch	applied	to	the	ipsilateral	ear,	contralateral	ear,	contralateral	hind	paw,	and	tail	(n=6).	The	noxious	pinch	reduced	the	number	of	action	potentials	fired	by	WDR	neurons	in	response	to	8g	and	26g	stimulation	at	all	locations	but	this	was	only	significant	for	the	8g	stimulation	with	the	noxious	pinch	applied	to	the	contralateral	paw.	For	the	most	noxious	mechanical	stimulation	of	60g,	the	number	of	action	potentials	fired	by	WDR	neurons	was	significantly	inhibited	by	the	noxious	conditioning	pinch	applied	at	all	body	areas.	Two-way	ANOVA	with	Bonferroni	post-hoc	test	(*P<0.05,	**P<0.01).		
3.3.4	The	duration	of	the	neuronal	inhibition	following	removal	of	the	
noxious	conditioning	stimulus.		
	Previous	electrophysiological	studies	in	the	rat	have	demonstrated	that	a	concurrent	noxious	conditioning	stimulus	causes	strong	post-stimulus	inhibitory	effects,	yet	the	duration	of	these	effects	have	not	been	quantified	(Dickenson	et	al	1981,	Villanueva	et	al	1986).	Therefore,	the	duration	of	the	DNIC	induced	WDR	neuronal	inhibition	was	evaluated	once	the	noxious	conditioning	ear	pinch	had	been	removed.		
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Firstly,	the	ear	pinch	was	applied	for	5	seconds	and	the	DNIC	was	quantified	as	an	inhibitory	effect	on	neuronal	firing	compared	to	pre-conditioned	mechanically	evoked	neuronal	responses.	The	concurrent	noxious	ear	pinch	was	then	removed	and	the	receptive	field	mechanically	stimulated	with	von	Frey	hairs	immediately	following	removal	of	the	noxious	conditioning	ear	pinch	and	10	seconds	after	removal.	The	number	of	action	potentials	fired	by	the	WDR	neuron	following	removal	of	the	noxious	conditioning	ear	pinch	were	counted	and	compared	to	pre-conditioned	baselines.	Similarly	to	the	results	observed	in	section	3.3.1,	there	was	a	significant	inhibition	of	neuronal	firing	upon	simultaneous	mechanical	stimulation	of	the	receptive	field	in	the	presence	of	the	conditioning	noxious	ear	pinch	(Figure	3.4A).	The	neuronal	response	was	still	inhibited	immediately	after	removal	of	the	noxious	conditioning	ear	pinch	but	this	was	not	significant	for	any	mechanical	weights	tested	(Figure	3.4A).	When	the	receptive	field	was	mechanically	stimulated	with	von	Frey	hairs	10	seconds	after	the	removal	of	the	noxious	conditioning	stimulus,	the	neuronal	responses	had	returned	to	pre-conditioned	baseline	levels	(Figure	3.4A).	However,	this	only	allowed	a	few	seconds	between	subsequent	mechanical	stimulations	of	the	receptive	field,	so	the	effects	of	subsequent	stimulations	on	neuronal	responses	were	determined.	The	subsequent	mechanical	stimulation	of	the	receptive	field	resulted	in	a	higher	number	of	action	potentials	fired	by	the	WDR	neuron	than	the	original	mechanical	stimulation	for	all	weights	tested,	and	this	was	a	significant	increase	for	8g	and	26g	(Figure	3.4B).	This	may	suggest	that	the	inhibitory	response	induced	by	the	noxious	conditioning	stimulus	is	still	ongoing	but	the	effect	is	being	masked	by	the	sensitisation	of	the	WDR	neuron	due	to	subsequent	stimulations	of	the	receptive	field.			Secondly,	the	noxious	ear	pinch	was	applied	for	5	minutes	and	DNIC	was	quantified	as	the	inhibitory	effect	on	neuronal	firing	compared	to	pre-conditioned	neuronal	responses.	There	was	a	significant	neuronal	inhibition	induced	with	the	concurrent	noxious	conditioning	ear	pinch.	The	noxious	conditioning	ear	pinch	was	then	removed	and	the	receptive	field	was	mechanically	stimulated	with	von	Frey	hairs	of	increasing	bending	force	at	1,	5	and	10	minutes	following	removal.	Neuronal	inhibition	was	observed	1	minute	and	5	minutes	following	removal	of	the	noxious	conditioning	ear	pinch,	but	this	was	only	significant	for	the	most	noxious	mechanical	stimulation	of	60g	(Figure	3.4C).	The	neuronal	responses	had	returned	to	pre-conditioned	levels	10	minutes	after	removal	of	the	conditioning	noxious	ear	pinch	(Figure	3.4D).	This	suggests	the	DNIC	response	has	powerful	post-stimulus	inhibitory	effects	that	may	be	dependent	on	the	intensity	and	duration	of	the	noxious	conditioning	stimulus.		
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Figure	3.4.	The	duration	of	post-stimulus	neuronal	inhibition	induced	with	DNIC.	The	duration	of	neuronal	inhibition	after	removal	of	the	conditioning	noxious	ear	pinch	was	evaluated.	A)	The	pre-conditioned	neuronal	responses	to	mechanical	stimulation	of	the	receptive	field	with	von	Frey	hairs	of	increasing	bending	force	were	determined.	Significant	neuronal	inhibition	was	induced	by	a	concurrent	noxious	ear	pinch.	The	neuronal	responses	were	inhibited	immediately	after	the	removal	of	the	noxious	conditioning	ear	pinch	but	had	returned	to	pre-conditioned	baseline	levels	10	seconds	following	removal	of	the	noxious	conditioning	ear	pinch	(n=5).	B)	The	subsequent	mechanical	stimulation	of	the	receptive	field	with	von	Frey	hairs	directly	after	removal	of	the	original	mechanical	stimulation	caused	WDR	neurons	to	produce	an	increased	number	of	action	potentials	(n=5).	C)	The	noxious	conditioning	ear	pinch	was	applied	for	5	minutes.	WDR	neuronal	firing	was	significantly	reduced	with	a	noxious	conditioning	ear	pinch.	The	neuronal	responses	were	also	inhibited	1	minute	and	5	minutes	after	removal	of	the	noxious	conditioning	ear	pinch	but	this	was	only	significant	when	the	receptive	field	was	stimulated	with	60g.	At	10	minutes	following	removal	of	the	conditioning	noxious	ear	pinch	the	neuronal	responses	returned	to	pre-conditioned	levels	(n=6).	D)	This	graph	shows	DNIC	quantified	as	a	percentage	of	the	pre-conditioned	values.	With	the	concurrent	noxious	ear	pinch	and	1	minute	following	removal	of	the	conditioning	noxious	ear	pinch	the	neuronal	responses	
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are	approximately	60%	of	the	pre-conditioned	baseline	values.	At	5	minutes	following	removal	of	the	noxious	conditioning	ear	pinch	the	neuronal	responses	were	approximately	75%	of	the	pre-conditioned	values	for	all	weights	tested.	At	10	minutes	following	removal	of	the	conditioning	noxious	ear	pinch	the	neuronal	responses	returned	to	pre-conditioned	levels	(n=6).	Two-way	ANOVA	with	Bonferroni	correction	(*P<0.05,	**P<0.01).																																		
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3.4	Discussion		
	DNIC	represents	the	phenomenon	whereby	one	pain	inhibits	another	pain	and	relies	on	an	endogenous	inhibitory	system.	The	model	investigated	in	this	chapter	explores	an	electrophysiological	method	for	exploring	this	phenomenon	further.	The	model	measures	DNIC	at	the	level	of	WDR	convergent	neurons	located	in	the	deep	dorsal	horn,	and	is	quantified	as	an	inhibitory	effect	on	evoked	neuronal	firing.	The	noxious	conditioning	stimulus	used	in	this	model	is	a	noxious	mechanical	pinch	but	different	stimulus	modalities	were	explored	for	use	as	the	test	stimulus.	The	noxious	mechanical	pinch	used	for	the	conditioning	stimulus	resulted	in	an	inhibition	of	neuronal	firing	when	applied	to	multiple	body	regions	so	long	as	it	was	distant	from	the	test	stimulus.	Furthermore,	the	duration	of	the	inhibitory	response	induced	by	the	conditioning	noxious	pinch	was	explored	at	the	neuronal	level.	This	study	reinforces	the	relevance	and	usefulness	of	studying	WDR	convergent	neurons	to	analyse	the	DNIC	phenomenon.			
3.4.1	The	use	of	different	test	stimulus	modalities	in	the	DNIC	protocol	
	This	study	used	recordings	from	WDR	neurons	in	the	deep	dorsal	horn	receiving	Aβ,	Aδ	and	C	fibre	input	from	the	hind	paw.	The	first	test	stimulus	tested	was	mechanical,	where	neuronal	responses	were	evoked	by	applying	von	Frey	hairs	of	increasing	bending	force	to	the	receptive	field	on	the	hind	paw.	The	weights	used	in	the	study	were	8g,	which	is	considered	innocuous,	26g	which	is	a	noxious	stimulation	and	would	result	in	a	withdrawal	response	behaviourally,	and	60g	which	is	a	supra	threshold	stimulation	at	the	highest	end	of	the	noxious	range.	The	application	of	von	Frey	hairs	heavier	than	60g	was	not	used	as	this	may	begin	to	cause	tissue	damage.	The	noxious	conditioning	ear	pinch	resulted	in	an	inhibition	of	neuronal	firing	in	response	to	all	mechanical	stimulations,	indicating	that	DNIC	is	capable	of	inhibiting	responses	to	both	innocuous	and	noxious	stimuli.			The	DNIC	response	was	then	explored	with	a	thermal	test	stimulus	and	a	concurrent	noxious	conditioning	ear	pinch.	Thermal	stimulation	of	the	WDR	neuron	was	induced	by	applying	water	jets	(42°C,	45°C	,	48°C	,	and	50°C)	to	the	receptive	field	of	the	hind	paw.		The	thermo-TRP	channels	in	the	periphery	are	responsible	for	transducing	thermal	stimuli	and	can	be	activated	over	a	range	of	both	innocuous	and	noxious	stimuli	(Tominaga	and	Caterina	2004).	The	TRPV1	channel	is	the	first	receptor	to	detect	noxious	heat	and	has	an	activation	threshold	of	>43°C,	therefore	the	42°C	may	be	considered	an	innocuous	thermal	stimulation	(Dhaka	et	al	2006).	The	45°C	thermal	
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stimulation	is	at	the	lower	end	of	the	noxious	range	while	the	48°C	and	50°C	stimulations	are	noxious.	None	of	the	stimulations	will	activate	the	TRPV2	channels	that	do	not	become	activated	until	temperatures	of	52°C	(Caterina	et	al	1999).	Applying	the	noxious	conditioning	ear	pinch	resulted	in	an	inhibition	of	neuronal	firing	in	response	to	all	thermal	test	stimulations,	again	suggesting	that	the	concurrent	noxious	conditioning	stimulation	results	in	inhibition	of	both	innocuous	and	noxious	test	stimulations.			Finally	the	DNIC	response	was	assessed	when	the	receptive	field	was	electrically	stimulated	with	a	train	of	16	electrical	pulses	at	3	times	the	C-fibre	threshold,	with	a	concurrent	noxious	conditioning	ear	pinch.	The	WDR	neurons	form	synapses	with	Aβ,	Aδ	and	C	fibres	that	arise	in	the	periphery	and	terminate	in	the	dorsal	horn,	and	the	number	of	action	potentials	fired	by	the	WDR	neuron	due	to	activation	of	these	peripheral	afferent	fibres	can	be	quantified	by	separating	the	responses	based	on	their	latency	(Urch	and	Dickenson	2003,	D’Mello	and	Dickenson	2008).	Interestingly,	the	application	of	the	conditioning	noxious	ear	pinch	had	no	inhibitory	effect	on	the	number	of	action	potentials	evoked	by	Aβ,	Aδ	or	C	fibres,	or	on	the	post-discharge	of	the	neuron.	Wind-up	refers	to	the	enhanced	output	of	spinal	cord	neurons	in	response	to	rapid	and	repeated	noxious	stimuli,	this	can	be	observed	when	electrically	stimulating	the	cell	at	3	times	the	C	fibre	threshold	as	an	increase	in	the	number	of	action	potentials	fired	in	response	to	each	subsequent	electrical	pulse	in	the	train	of	16.	The	noxious	conditioning	ear	pinch	did	not	inhibit	the	wind-up	response	of	WDR	neurons.			These	results	conflict	with	previous	findings	that	A	and	C	fibre	activities	of	both	trigeminal	and	dorsal	horn	convergent	neurons	evoked	electrically	are	strongly	inhibited	by	DNIC	(Dickenson	et	al	1980,	Bouhassira	et	al	1993).	However,	Bouhassira	et	al	electrically	stimulated	the	receptive	field	at	the	lower	intensity	of	2	times	the	C-fibre	threshold	rather	than	3	times	as	was	used	in	this	study	(Bouhassira	et	al	1993).	Additionally	a	thermal	noxious	conditioning	stimulus	was	used	in	both	studies,	induced	by	immersion	of	either	the	tail	or	muzzle	in	50°C	heated	water.	A	further	method	used	by	Dickenson	et	al	1980	for	inducing	a	noxious	conditioning	stimulus	was	the	intraperitoneal	administration	of	bradykinin,	causing	visceral	inflammation	(Dickenson	et	al	1980).	The	50°C	thermal	stimulation	used	is	at	the	higher	end	of	the	noxious	range,	while	interperitoneal	bradykinin	would	cause	extreme	visceral	tissue	damage,	thus	eliciting	a	more	intense	noxious	conditioning	stimulation	than	the	use	of	noxious	ear	pinch.	Dickenson	et	al	did	also	show	a	DNIC	induced	neuronal	inhibition	elicited	by	applying	a	noxious	pinch	as	the	conditioning	stimulus	but	they	do	not	explain	how	this	
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was	applied.	Therefore,	this	was	potentially	of	greater	strength	than	the	noxious	ear	pinch	used	in	this	study	(Dickenson	et	al	1980).	Therefore,	the	level	of	neuronal	inhibition	may	be	dependent	upon	the	intensity	of	the	conditioning	stimulus.		The	DNIC	system	functions	through	the	conditioning	noxious	stimulus	activating	descending	inhibitory	controls,	which	reduces	excessive	pain	through	a	negative	feedback	loop	and	allows	the	body	to	focus	on	the	most	dangerous	stimuli	(Le	Bars	et	al	1979a).	Three	times	the	C	fibre	threshold	has	been	used	in	these	experiments	to	ensure	the	WDR	neurons	exhibit	a	wind-up	response.	A	noxious	ear	pinch	was	used	as	the	condition	stimulus	to	elicit	a	short	lived	noxious	stimulation	that	would	not	result	in	further	problems	such	as	tissue	damage,	but	also	for	consistency	as	a	noxious	ear	pinch	has	been	previously	show	to	produce	a	sufficient	inhibitory	response	on	neuronal	firing	(Bannister	et	al	2015).		It	has	been	reported	that	the	magnitude	of	the	DNIC	response	depends	upon	the	intensity	and	stimulus	modality	used	as	the	noxious	conditioning	stimulus	(Fujii	et	al	2006).	In	this	instance	the	noxious	intensity	of	the	electrical	stimulation	may	be	much	greater	than	the	conditioning	ear	pinch,	this	may	cause	the	test	stimulus	to	out-weight	the	conditioning	stimulus	meaning	although	the	conditioning	stimulus	is	noxious,	it	is	not	of	adequate	intensity	to	elicit	an	inhibitory	effect	on	electrically	evoked	neuronal	firing.			
3.4.2	Placement	of	the	conditioning	noxious	stimulus	
	This	study	demonstrated	that	mechanically	evoked	WDR	neuronal	activity	can	be	significantly	inhibited	upon	the	application	of	a	concurrent	noxious	conditioning	pinch	applied	to	widespread	areas	of	the	body.	This	indicates	that	descending	inhibitory	controls	can	be	activated	when	the	noxious	conditioning	stimulus	is	applied	both	ipsilaterally	and	contralaterally	to	the	test	stimulus.	There	are	many	methods	used	for	evoking	CPM	in	healthy	subjects	that	have	involved	applying	various	stimulus	modalities	to	various	body	regions,	although	the	most	common	CPM	paradigm	uses	a	thermal	or	cold	conditioning	stimulus	applied	to	the	limbs	or	upper	extremities	(Pud	et	al	2009).	The	study	confirms	the	validity	of	these	studies	for	assessing	CPM	in	humans	as	it	demonstrates	that	a	DNIC	effect	can	be	evoked	by	a	noxious	conditioning	stimulus	at	multiple	body	regions	distant	to	the	test	stimulus.			
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3.4.3	The	duration	of	neuronal	inhibition		
	This	study	demonstrated	that	the	application	of	a	noxious	conditioning	ear	pinch	had	strong	inhibitory	post-stimulus	effects	on	mechanically	evoked	WDR	neuronal	firing.	The	duration	of	the	inhibitory	effects	following	removal	of	the	noxious	conditioning	stimulus	appeared	to	be	related	to	the	duration	the	noxious	conditioning	stimulus	was	applied	for.	However,	the	duration	of	post-stimulus	inhibitory	effects	may	also	be	influenced	by	other	factors	such	as	the	intensity,	placement	or	stimulus	modality	used	for	the	noxious	conditioning	stimulus	as	the	duration	of	inhibitory	effects	observed	varied	greatly	between	studies	(Lewis	et	al	2012).	The	findings	in	this	study	are	consistent	with	other	electrophysiological	studies	that	quantify	the	DNIC	effects	as	a	reduction	in	convergent	neuron	firing,	where	powerful	inhibitory	were	also	observed	after	removal	of	the	noxious	conditioning	stimulus	(Dickenson	et	al	1981,	Cadden	1993).			The	use	of	fMRI	in	CPM	paradigms	has	allowed	for	the	identification	of	activated	brain	areas	during	the	CPM	process	(Youseff	et	al	2015,	Youseff	et	al	2016).	However,	as	a	subject	is	required	to	stay	still	in	the	fMRI	machine	to	obtain	good	images,	one	of	the	problems	with	this	set-up	is	applying	two	separate	stimulations	to	the	body	while	the	subject	stays	still	and	inside	the	machine.	Therefore,	the	finding	that	the	noxious	conditioning	stimulus	has	powerful	inhibitory	effects	even	once	it	has	been	removed	may	have	important	clinical	consequences.	Potentially,	the	test	and	conditioning	stimulations	could	be	applied	before	the	subject	enters	the	fMRI	machine,	if	the	noxious	conditioning	stimulus	is	of	the	optimum	intensity	and	quality	the	ongoing	inhibitory	effects	may	allow	for	activated	brain	areas	to	be	identified	shortly	after	the	stimulus	has	been	removed.			
3.4.4	Concluding	remarks		This	chapter	confirms	that	DNIC	can	be	assessed	using	electrophysiological	recordings	from	convergent	WDR	neurons	in	the	deep	dorsal	horn.	In	this	DNIC	set-up	the	mechanically	and	thermally	evoked	WDR	neuronal	responses	were	strongly	and	consistently	inhibited	by	the	application	of	a	concurrent	noxious	conditioning	pinch.	The	noxious	conditioning	ear	pinch	did	not	result	in	an	inhibition	of	WDR	neuronal	firing	when	the	receptive	field	was	electrically	stimulated,	therefore	electrical	stimulations	is	not	used	beyond	this	point.	Pud	et	al	reviewed	the	commonly	used	experimental	methods	for	evoking	a	CPM	response	in	healthy	subjects	and	found	the	average	magnitude	of	the	inhibitory	effect	on	pain	thresholds	to	be	29%	across	the	studies	(Pud	
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et	al	2009).	Interestingly,	the	noxious	conditioning	ear	pinch	consistently	results	in	an	approximately	30%	reduction	in	mechanically	and	thermally	evoked	WDR	neuronal	firing	rates.	The	comparable	inhibitory	magnitude	coupled	with	the	similar	function	and	pharmacology	observed	between	DNIC	and	CPM	suggests	that	this	model	may	provide	a	useful	tool	for	forward	translation	studies	with	great	clinical	relevance.			This	model	can	be	used	as	a	tool	to	better	understand	the	mechanisms,	neurotransmitters	and	pathways	involved	in	the	DNIC	phenomenon.	A	further	clinical	application	of	this	model	is	to	evaluate	DNIC	responses	in	animal	models	of	chronic	pain	to	assess	any	central	changes	that	may	occur.	Specifically	in	this	thesis,	the	DNIC	protocol	is	used	to	analyse	any	changes	in	descending	inhibitions	during	the	progression	of	an	animal	model	of	osteoarthritis.					
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4.	The	roles	of	Noradrenaline	and	Serotonin	
in	Diffuse	Noxious	Inhibitory	Controls	
	
4.1	Introduction		
	
4.1.1	Descending	Controls		
	Descending	controls	originating	in	the	midbrain	and	brainstem	can	exert	top-down	modulation	of	pain	processing	at	the	level	of	the	spinal	cord	(Lumb	2014).	Descending	controls	mediate	nociceptive	transmission	predominantly	through	the	release	of	monoamines.	There	is	a	serotonergic	system	originating	mainly	in	the	rostral	ventromedial	medulla	(RVM)	and	a	noradrenergic	pathway	originating	from	pontine	regions	of	the	brainstem	(Bannister	and	Dickenson	2016b).	Serotonergic	and	Noradrenergic	axons	terminate	diffusely	throughout	the	dorsal	horn	and	release	noradrenaline	(NA)	and	5-hydroxytryptamine	(5-HT)	as	neurotransmitters,	this	can	mediate	both	excitatory	and	inhibitory	effects	depending	upon	which	receptor	they	activate	(Todd	2010,	Bannister	and	Dickenson	2016b).	While	some	serotonergic	and	noradrenergic	axons	form	synapses	with	other	neurons	within	the	dorsal	horn	the	majority	of	their	action	occurs	through	volume	transmission,	whereby	the	monoaminergic	neurotransmitters	are	released	directly	into	the	non-synaptic	extracellular	dorsal	horn	space	and	can	activate	nearby	receptors	(Todd	2010).	The	bi-directional	role	of	the	monoamines	on	pain	processing	means	they	can	both	facilitate	or	inhibit	the	pain	response.			It	has	previously	been	demonstrated	that	diffuse	noxious	inhibitory	controls	(DNIC)	depend	upon	a	balance	between	the	opposing	receptor-mediated	actions	of	NA	and	5-HT	(Bannister	et	al	2015).	Additionally,	both	noradrenergic	and	serotonergic	systems	can	become	altered	in	chronic	pain	states	while	DNIC-effects	are	often	lost.	Taken	together	these	findings	indicate	that	dysregulated	monoaminergic	descending	controls	may	play	a	major	role	in	the	absence	of	DNIC	in	chronic	pain	states.			
4.1.2	The	noradrenergic	descending	system		Noradrenaline	(NA)	is	a	catecholamine	produced	and	released	by	both	peripheral	and	central	nerve	terminals,	the	subsequent	physiological	effects	of	NA	depend	upon	the	
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activation	of	noradrenergic	receptor	subtypes	(Summers	and	McMartin	1993).	There	are	two	major	classes	of	noradrenergic	receptor:	the	α-adrenoceptors	and	β-adrenoceptors,	which	can	be	further	classified	into	α1,	α2,	β1,	and	β2	subtypes	(Molinoff	1984).	The	α1-adrenoceptors	are	localized	centrally	in	the	CA3	regions	and	denate	gyrus	of	the	hippocampus,	and	can	also	be	found	peripherally	in	smooth	muscle	(Hoyer	et	al	1990,	Summers	and	McMartin	1993).	The	α2-adrenoceptor	subtype	has	been	identified	in	multiple	brain	areas,	specifically	the	hypothalamus,	cerebral	cortex	and	brainstem	(Boyajian	and	Leslie	1987).	In	addition	the	α2-adrenoceptor	subtype	is	located	centrally	within	the	spinal	cord,	high	densities	of	α2	binding	sites	have	been	shown	in	both	rat	and	human	spinal	cords,	and	α2-adrenoceptor	mRNA	was	identified	in	cell	bodies	at	all	lamina	levels	of	the	dorsal	horn	(Unnerstall	et	al	1984,	Smith	et	al	1995).	The	α2-adrenoceptor	can	be	divided	further	into	three	pharmacological	subtypes:	α2A,	α2B,	α2C.	While	the	α2A	and	α2C	subtypes	are	found	mainly	in	the	central	nervous	system,	the	α2B	subtype	is	found	on	vascular	smooth	muscle	and	associated	with	vasopressor	effects	(Giovannitti	et	al	2015).	The	β-adrenoceptors	are	highly	expressed	throughout	the	brain,	with	the	β1-adrenoceptors	found	in	the	cortex,	hippocampus,	and	ventral	gelatinosa,	while	the	β2-adrenoceptors	have	been	identified	in	the	cerebellum,	thalamic	nuclei,	cerebral	cortex	and	olfactory	tubercle	(Summers	and	McMartin	1993).	The	β-adrenoceptors	are	also	thought	to	play	vital	physiological	roles	in	the	kidney,	blood	vessels,	uterus	and	heart	(Summers	and	Mcmartin	1993).	As	expression	of	the	α2-adrenoceptor	subtype	has	been	identified	at	high	levels	in	the	spinal	cord,	and	DNIC	is	mediated	by	a	final	post-synaptic	mechanism	at	the	level	of	the	spinal	cord,	this	thesis	shall	focus	specifically	on	the	α2-adrenoceptor.			The	noradrenergic	cell	groups	are	dispersed	through	the	brainstem	and	are	classified	as	A1-A7,	with	the	A5-A7	cell	groups	forming	descending	noradrenergic	projections	to	the	spinal	cord	(Kwiat	and	Basbaum	1992,	Pertovaara	2006).	The	A6	cell	group	is	also	know	as	the	locus	coeruleus	(LC),	this	brainstem	area	has	prominent	expression	of	α2-adrenoceptors	and	was	found	to	have	the	highest	expression	levels	of	α2A-adrenoceptor	mRNA	in	the	brain,	therefore	the	LC	is	thought	to	be	the	main	source	of	central	noradrenaline	(Unnerstall	et	al	1984,	Scheinin	et	al	1994).	However,	the	noradrenergic	descending	system	also	originates	in	the	catecholaminergic	A5	and	A7	cell	groups	located	in	the	ventral	and	dorsolateral	pons	respectively	(Petrovaara	2006).	The	A5	and	A7	cell	groups	also	form	projections	that	innervate	the	PAG,	which	subsequently	projects	to	higher	cortical	structures,	indicating	that	these	noradrenergic	cell	groups	modulate	nociception	through	both	ascending	and	descending	systems	(Petrovaara	
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2006).	Once	the	NA	neurotransmitter	is	released	from	the	brainstem	it	can	travel	along	descending	axons	to	carry	out	its	effect	at	the	level	of	the	spinal	cord.		Therefore	the	influences	from	higher	cortical	structures	impact	upon	the	noradrenergic	cell	groups,	and	ultimately	influence	the	pain	response	at	the	level	of	the	spinal	cord	through	noradrenergic	neurotransmission.		
	The	catecholamine	receptors	that	mediate	the	actions	of	noradrenaline	generally	utilize	a	guanine	nucleotide	regulatory	binding	protein	(G-protein),	which	initiate	a	cascade	of	downstream	cellular	signaling	events	upon	activation	(Pertovaara	2013).	The	α2-adrenoceptor	subclass	is	coupled	specifically	to	a	Gi	protein,	which	inhibits	the	actions	of	andenylate	cyclase	upon	activation,	this	in	turn	reduces	the	intracellular	levels	of	cAMP,	and	the	final	overall	physiological	response	is	hyperpolarization	of	the	neuron	(Giovannitti	et	al	2015).	In	addition	the	activation	of	α2-adrenoceptors	has	been	demonstrated	to	directly	modify	the	activity	of	ion	channels,	in	particular	Ca2+	and	K+	channels	and	Na+/H+	antiports	(Pertovaara	2013).		In	nociception,	noradrenaline	is	known	to	have	an	antinociceptive	effect	through	its	interaction	with	α2-adrenoceptors	in	the	spinal	cord	(Cervero	and	Jenson	2006).	The	spinal	administration	of	noradrenaline	has	been	shown	to	suppress	the	noxious	evoked	activity	of	dorsal	horn	WDR	neurons	in	cats,	and	while	this	suppressive	effect	can	be	replicated	by	α2-adrenoceptor	agonists,	the	spinal	application	of	α2-adrenoceptor	antagonists	has	been	demonstrated	to	attenuate	this	inhibition	in	both	the	cat	and	rat	(Collins	et	al	1984,	Pertovaara	et	al	1991,	Fleetwood-Walker	et	al	1985).	Taken	together,	these	results	suggest	that	the	antinociceptive	action	of	noradrenaline	is	mediated	in	the	dorsal	horn	through	activation	of	the	α2-adrenoceptor.			Noradrenaline	is	thought	to	suppress	the	evoked	activity	of	spinal	dorsal	horn	neurones	through	several	mechanisms.	Firstly,	presynaptic	inhibition	is	thought	to	occur	through	action	of	noradrenaline	on	central	terminals	of	substance	P	containing	nociceptive	primary	afferent	fibres,	whereby	noradrenaline	acts	to	reduce	noxious	stimuli-induced	excitatory	postsynaptic	potentials	and	inhibits	the	release	of	excitatory	neurotransmitters	such	as	glutamate	and	substance	P,	this	subsequently	prevents	the	transmission	of	nociceptive	inputs	to	the	dorsal	horn	(Stone	et	al	1998).	There	is	also	thought	to	be	a	postsynaptic	element	to	noradrenaline’s	actions,	which	is	mediated	by	the	activation	of	Gi	and	second	messenger	cascades.	As	discussed	above	the	inhibition	of	cAMP	results	in	hyperpolarization	of	the	neuron,	this	occurs	due	to	an	efflux	of	K+	
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through	calcium-activated	potassium	channels,	which	subsequently	prevents	the	influx	of	Ca2+	and	suppresses	neuronal	firing	(Giovannitti	et	al	2015).	The	hyperpolarization	of	substantia	gelantinosa	neurons,	found	in	lamina	II	of	the	dorsal	horn	has	been	demonstrated	upon	perfusion	of	NA	onto	the	spinal	cord	surface	with	in	vivo	whole-cell	patch	clamping	(Sonohanata	et	al	2004).	The	hyperpolarization	of	dorsal	horn	neurons	and	the	prevention	of	action	potential	firing	inhibits	the	release	of	noradrenaline	from	these	neurons	into	the	dorsal	horn,	this	subsequently	prevents	the	activation	of	noradrenergic	ascending	projects,	thus	creating	a	negative	feedback	loop	between	the	spinal	cord	and	the	brain	(Giovannitti	et	al	2015).	This	negative	feedback	loop	has	been	demonstrated	to	involve	neurones	of	the	spinothalamic	tract,	further	confirming	that	noradrenaline	is	capable	of	modulating	both	ascending	and	descending	pain	signals	(Westlund	et	a	1990).	Finally	α2c-adrenoceptors	are	located	on	axon	terminals	of	spinal	excitatory	interneurons,	indicating	that	noradrenaline	may	activate	and	hyperpolarize	these	neurons	to	further	inhibit	the	pain	response	at	the	level	of	the	spinal	cord	(Olave	and	Maxwell	2004).	The	multiple	mechanisms	of	action	indicate	the	importance	of	noradrenaline	in	central	pain	modulation.			The	noradrenergic	system	forms	a	prominent	descending	inhibitory	pathway	originating	in	the	brainstem	that	often	becomes	altered	in	chronic	pain	states	(Bannister	et	al	2009).	The	abundance	of	noradrenaline	in	the	central	nervous	system	and	its	multiple	modes	of	action	indicate	an	important	system	that	could	potentially	be	pharmacologically	manipulated	to	provide	efficient	therapy	of	chronic	pain.			
4.1.3	The	serotonergic	descending	system		As	the	actions	of	monoamines	released	from	descending	projections	are	mediated	through	volume	transmission,	the	distribution	of	receptor	subtypes	within	the	dorsal	horn	largely	determine	their	physiological	action	(Todd	2010).	There	are	a	myriad	of	receptors	within	the	dorsal	horn	that	5-HT	can	act	upon,	meaning	the	roles	of	5-HT	in	nociception	are	much	more	complex	and	difficult	to	determine	(Bannister	and	Dickenson	2016b).		The	descending	serotonergic	pathway	arises	in	the	RVM,	which	is	a	key	brainstem	structure	responsible	for	relaying	processed	pain	information	from	higher	cortical	structures	to	the	spinal	dorsal	horn	(Cai	et	al	2014,	Bannister	and	Dickenson	2016b).	The	serotonergic	neurones	are	located	mainly	in	the	nucleus	raphe	magnus	(NRM)	of	
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the	RVM	and	become	activated	in	response	to	noxious	stimulation,	this	evokes	the	release	of	5-HT	in	the	spinal	cord	(Dogrul	et	al	2009).	The	descending	serotonergic	system	exerts	a	bi-directional	role	on	pain	processing	as	both	inhibitory	and	facilitatory	actions	have	been	demonstrated	upon	5-HT	release	in	the	dorsal	horn,	this	is	thought	to	depend	upon	the	receptor	subtype	activated	and	the	physiological	pain	state	of	the	subject	(Porecca	et	al	2002,	Gebhart	2004,	Vanegas	and	Schaible	2004).			
4.1.3.1	The	5-HT	receptors		There	are	seven	families	of	5-HT	receptors	that	together	comprise	at	least	fourteen	pharmacologically	and	structurally	distinct	receptors	subtypes	that	vary	in	their	localization,	coupling	and	ligand	binding	properties	(Hoyer	et	al	1994,	Barnes	and	Sharp	1999).	The	majority	of	the	5-HT	receptor	subtypes	are	G-protein	coupled	receptors	(GPCRs),	with	the	exception	of	the	5-HT3	subtype	which	is	a	cation	selective	ion	channel	(Barnes	and	Sharp	1999).			
5-HT1	receptor	The	5-HT1	family	is	made	up	of	five	subtypes:	the	5-HT1A,	5-HT1B,	5-HT1D,	5-HT1E,	and	5-HT1F	receptors	(Barnes	and	Sharp	1999).		All	5-HT1	receptor	subtypes	are	reported	to	be	coupled	negatively	to	adenylate	cyclase	via	Gi	proteins,	and	can	mediate	the	hyperpolarization	of	the	neurons	through	the	opening	of	K+	channels,	indicating	they	are	likely	to	be	involved	in	antinociception	(Barnes	and	Sharp	1999).	Particularly,	the	5-HT1A	receptor	subtype	is	found	in	high	densities	in	superficial	lamina	of	the	dorsal	horn	and	its	agonists	have	been	shown	to	block	formalin-induced	nociceptive	responses,	indicating	that	5-HT	can	suppress	nociception	at	the	level	of	the	spinal	cord	through	activation	of	the	5-HT1A	receptor	(Oyama	et	al	1996).			
5-HT2	receptor	There	are	three	5-HT2	receptor	subtypes,	the	5-HT2A,	5-HT2B,	and	5-HT2C	receptors,	all	with	similar	signaling	properties	(Barnes	and	Sharp	1999,	Rahman	et	al	2011).	All	three	receptor	subtypes	are	coupled	positively	to	PLC	via	Gq	proteins,	their	activation	lead	to	increased	accumulation	of	intracellular	IP3	and	Ca2+,	these	intracellular	signaling	events	regulate	neuronal	excitability	(Barnes	and	Sharp	1999,	Billups	et	al	2006).	The	roles	played	by	this	receptor	family	in	nociception	are	controversial	with	studies	showing	both	antinociceptive	and	pronociceptive	actions	(Bardin	et	al	2000,	Kjorsvik	et	al	2001,	Rahman	et	al	2011).	The	intrathecal	administration	of	5-HT2A/C	receptor	agonists	
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immediately	before	the	formalin	test	increased	both	early	and	late	phase	pain	behaviours	in	the	rat,	indicating	a	pronociceptive	role	for	this	receptor	(Kjorsvik	et	al	2001).	In	agreement,	rat	electrophysiological	studies	showed	that	a	spinally	administered	5-HT2A	receptor	antagonist	dose	dependently	inhibited	the	evoked	responses	of	WDR	neurons	to	noxious	mechanical	and	thermal	stimuli,	suggesting	in	normal	conditions	5-HT2	receptors	facilitate	spinal	nociceptive	transmission	(Rahman	et	al	2011).	However,	the	intrathecal	pretreatment	with	both	5-HT2C	and	5-HT2A	receptor	antagonists	reversed	the	antinociception	produced	by	intrathecal	5-HT	alone	in	rats,	indicating	that	increased	levels	of	5-HT	were	mediating	antinociception	through	activation	of	these	spinal	5-HT2	receptors	(Bardin	et	al	2000).	These	conflicting	findings	mean	a	facilitatory	or	inhibitory	role	for	this	receptor	in	nociception	has	not	been	conclusively	determined.			
5-HT3	receptor	Unlike	the	controversial	roles	in	nociception	of	other	5-HT	receptors,	the	5-HT3	receptor	has	been	clearly	demonstrated	to	play	a	role	in	pronociception	at	the	level	of	the	spinal	cord,	particularly	in	chronic	pain	states	(Green	et	al	2000,	Suzuki	et	al	2002,	Dogrul	et	al	2009,	Kim	et	al	2015).	In	contrast	to	other	5-HT	GPCRs,	the	5-HT3	receptor	is	a	ligand	gated	ion	channel	that	mediates	a	rapidly	activating	and	desensitizing	inward	current	carried	predominantly	by	Na+	and	K+	ions,	but	the	channel	is	also	permeable	to	Ca2+	(Barnes	and	Sharp	1999,	Thompson	and	Lummis	2006).			One	study	confirming	the	involvement	of	the	5-HT3	receptor	in	pronociception	chemically	interrupted	the	spino-bulbo-spinal	loop,	investigated	the	consequences	and	used	pharmacology	to	unravel	the	receptors	involved	in	facilitating	the	pain	response	at	the	level	of	the	spinal	cord	(Suzuki	et	al	2002).	The	NK-1	receptor	expressing	projection	neurons	are	found	in	superficial	lamina	of	the	dorsal	horn	and	form	part	of	an	ascending	pathways	to	the	brainstem,	which	subsequently	drives	descending	serotonergic	inputs	to	the	dorsal	horn	(Suzuki	et	al	2002).	Suzuki	and	colleagues	used	a	substance	P-saporin	(SP-SAP)	conjugate	to	selectively	ablate	lamina	I/III	NK-1	expressing	neurones	within	the	spinal	cord	(Suzuki	et	al	2002).	This	treatment	was	found	to	reduce	the	excitability	of	WDR	neurones	and	inhibit	both	mechanical	and	thermal	evoked	responses,	while	also	attenuating	the	second	phase	of	the	formalin	response	(Suzuki	et	al	2002).	Interestingly,	the	authors	found	spinal	administration	of	a	5-HT3	receptor	antagonist	ondansetron	exactly	mimicked	this	response	in	naïve	and	SAP	injected	animals,	yet	had	no	effect	in	the	SP-SAP	animals.	The	similar	results	observed	with	both	SP-SAP	treatment	and	
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pharmacological	blockade	of	5-HT3	receptors	in	the	dorsal	horn	suggest	both	cause	a	reduction	in	descending	excitatory	pathways.	The	authors	proposed	that	facilitatory	descending	projections	arising	in	the	RVM	act	on	deep	dorsal	horn	WDR	neurones	through	5-HT3	receptors	to	create	a	pronociceptive	drive	(Suzuki	et	al	2002).			Furthermore,	adaptive	changes	in	the	excitatory	serotonergic	drive	mediating	facilitation	of	the	pain	response	through	interactions	with	the	5-HT3	receptors	in	the	dorsal	horn	have	been	previously	demonstrated	in	rat	models	of	both	osteoarthritis	and	SNL	induced	neuropathy	(Bee	and	Dickenson	2008,	Rahman	et	al	2009).	This	indicates	that	the	activation	of	facilitatory	descending	controls	and	the	subsequent	release	of	serotonin	within	the	dorsal	horn	may	mediate	an	increase	in	the	pain	response	at	the	level	of	the	spinal	cord	through	activating	5-HT3	receptors,	and	that	this	may	become	over	functional	in	states	of	chronic	pain.			
5-HT4	and	5-HT6	receptors	The	5-HT4	and	5-HT6	receptor	families	are	both	positively	coupled	to	adenylate	cyclase	via	Gs	proteins.	The	activation	of	5-HT4	and	5-HT6	receptors	leads	to	increased	intracellular	levels	of	cAMP	and	subsequent	activation	of	protein	kinases,	which	can	mediate	phosphorylation	of	other	channels	or	receptors	expressed	on	the	plasma	membrane	(Barnes	and	Sharp	1999,	De	Maeyer	et	al	2008).	Specifically	the	activation	of	intracellular	protein	kinases	can	mediate	the	phosphorylation	of	K+	channels	and	lead	to	their	closure,	which	may	suggest	the	activation	of	the	5-HT4	and	5-HT6	receptors	is	likely	to	result	in	depolarization	and	an	increase	in	neuronal	excitability		(Barnes	and	Sharp	1999).	Both	receptor	subtypes	are	expressed	in	the	lumbar	spinal	cord	and	so	are	likely	to	become	activated	upon	the	release	of	5-HT	from	descending	pathways	(Pineda-Farias	et	al	2017).	The	antinociception	induced	by	intrathecal	administration	of	5-HT	in	the	rat	could	not	be	alleviated	by	intrathecal	administration	of	a	5-HT4	receptor	antagonist,	indicating	that	this	receptor	was	not	involved	in	the	antinociceptive	actions	of	5-HT	at	the	level	of	the	spinal	cord	(Bardin	et	al	2000).	Furthermore,	selective	5-HT4	and	5-HT6		receptor	antagonists	have	been	found	to	reduce	allodynia	in	spinal	nerve	ligated	rats,	indicating	a	role	for	these	receptors	in	facilitating	the	pain	response	(Pineda-Farias	et	al	2017).	This	suggests	that	spinal	5-HT4	and	5-HT6	receptors	have	a	pronociceptive	role	and	their	activation	may	contribute	to	the	maintenance	of	persistent	pain.			
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5-HT5	receptor	There	are	two	subtypes	of	the	5-HT5	receptor	family,	the	5-HT5A	and	5-HT5B	receptors	(Nelson	2004).	While	both	receptor	subtypes	have	been	found	to	be	expressed	in	the	rat	and	mouse,	the	5-HT5B	receptor	is	not	expressed	in	humans	due	to	stop	codons	interrupting	the	gene	(Nelson	2004).	The	5-HT5	receptor	is	coupled	to	Gi/o	proteins,	therefore	its	activation	inhibits	intracellular	adenylate	cyclase	and	mediates	neuronal	hyperpolarization	(Nelson	2004).	The	use	of	specific	antibody	staining	has	shown	particularly	dense	labeling	for	5-HT5	receptors	in	superficial	layers	of	the	dorsal	horn	suggesting	this	receptor	may	play	a	role	in	modulating	nociception	(Doly	et	al	2004).	In	rats	with	spinal	nerve	ligation,	the	intrathecal	administration	of	5-HT	reversed	the	tactile	allodynia	caused	by	neuropathy,	but	an	intrathecal	5-HT5A	receptor	antagonist	reduced	this	antiallodynic	effect	(Avila-Rojas	et	al	2015).	This	indicates	an	antinociceptive	role	for	this	receptor	and	that	its	activation	may	inhibit	pain	processing	at	the	level	of	the	spinal	cord.			
5-HT7	receptor	Finally,	the	5-HT7	receptor	is	a	seven-transmembrane-domain	GPCR	positively	coupled	to	adenylate	cyclase	(Hedlund	and	Sutcliffe	2004).	As	the	5-HT7	receptor	is	linked	to	adenylate	cyclase	through	a	Gs	protein,	its	activation	results	in	increased	intracellular	levels	of	cAMP,	this	can	initiate	further	downstream	signaling	events	such	as	the	activation	of	protein	kinase	A,	and	can	also	lead	to	the	modulation	of	ion	channels	and	receptors	located	in	the	plasma	membrane	(Barnes	and	Sharp	1999,	Cooper	2000).	While	there	are	four	splice	variants	of	the	5-HT7	receptor,	only	the	5-HT7a,	5-HT7b,	and	5-HT7c	variants	appear	to	be	expressed	in	rat	and	human	tissue	(Barnes	and	Sharp	1999).		The	5-HT7		receptor	is	expressed	by	umyleinated	and	thinly	myelinated	primary	afferent	fibres	and	pepetidergic	neurons	in	the	superficial	lamina	of	the	dorsal	horn,	making	them	likely	candidates	for	mediating	serotonins	actions	in	pain	control	(Doly	et	al	2005).			The	5-HT7	receptor	has	been	demonstrated	to	play	an	antinociceptive	role	at	the	level	of	the	spinal	cord	(Dogrul	et	al	2009,	Brenchat	et	al	2010,	Viguier	et	al	2012).	Firstly,	a	spinally	administered	5-HT7	receptor	antagonist	SB-269970	reversed	the	antinocicepive	actions	of	a	morphine	microinjection	into	the	RVM	in	uninjured	rats	(Dogrul	et	al	2009).	The	authors	proposed	that	opioidergic	descending	inhibitory	projections	arising	in	the	RVM	release	5-HT	into	the	dorsal	horn,	which	can	subsequently	activate	5-HT7	receptors	and	suppress	nociceptive	transmission	(Dogrul	et	al	2009).	Additionally,	systemic	
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administration	of	the	selective	5-HT7	receptor	agonist	AS-19	reduced	the	nerve-injury	evoked	mechanical	and	thermal	hypersensitivity	in	mice,	and	this	could	be	revered	by	the	co-administration	of	the	5-HT7	receptor	antagonist	SB-258719	(Brenchat	et	al	2009).	Similarly,	in	rats	with	unilateral	constriction	injury	to	the	sciatic	nerve,	subcutaneous	administration	of	5-HT7	receptor	agonists	markedly	reduced	mechanical	and	thermal	hyperalgesia	(Viguier	et	al	2012).	These	studies	indicate	that	activation	of	the	5-HT7	receptor	mediates	inhibition	of	nociception	at	the	level	of	the	spinal	cord	in	both	naïve	and	neuropathic	animals.		
	While	the	5-HT7	receptor	shares	molecular	biology	and	activation	properties	with	the	5-HT4	and	5-HT6	receptor,	the	5-HT7	receptor	contrasts	in	that	it	mediates	inhibitory	actions	in	pain	control	at	the	level	of	the	spinal	cord.	The	different	nociceptive	actions	could	be	attributed	to	distinctive	neuronal	localizations	of	these	receptors.	The	5-HT7	receptor	has	been	found	to	be	co-localized	with	GABAergic	cells	in	the	dorsal	horn,	indicating	the	5-HT7	receptor	is	located	on	and	plays	a	role	in	modulating	the	activity	of	inhibitory	interneurons	(Brenchat	et	al	2009).	In	agreement,	an	intrathecal	injection	of	bicuculine,	a	competitive	antagonist	of	GABA	receptors,	significantly	reduced	the	anti-hyperalgesic	effects	of	5-HT7	receptor	activation	with	systemic	administration	of	selective	agonists	in	nerve	injured	rats	(Viguier	et	al	2012).	The	activation	of	descending	inhibitory	projections	arising	in	the	RVM	and	the	subsequent	release	of	5-HT	in	the	dorsal	horn	may	activate	5-HT7	receptors	to	mediate	excitation	of	GABAergic	interneurons,	which	ultimately	causes	an	inhibition	of	the	pain	response.	This	thesis	will	focus	on	the	role	played	by	the	5-HT7	receptor	in	modulating	the	pain	response	at	the	level	of	the	spinal	cord,	and	particularly	its	role	in	mediating	DNIC.		
4.1.3.2	The	modulation	of	the	serotonergic	system			In	addition	to	the	myriad	of	receptors	that	5-HT	can	act	upon	in	the	dorsal	horn,	the	serotonergic	descending	system	becomes	yet	more	complex	due	to	the	variation	in	its	signaling	observed	in	different	physiological	states.	Following	the	depletion	of	5-HT	in	the	lumbar	cord	with	5,7-dihydroxytryptamine	(5,7-DHT),	the	intrathecal	administration	of	5-HT	was	found	to	have	a	bi-directional	effect	on	the	second	phase	of	the	formalin	response	(Oyama	et	al	1996).	The	authors	found	that	a	low	dose	of	5-HT	inhibited	aversive	responses	and	that	this	could	be	blocked	by	intrathecal	administration	of	a	5-HT1A	receptor	antagonist.	Whereas,	a	high	dose	of	5-HT	facilitated	the	aversive	behaviours	observed	in	the	formalin	test	and	this	could	be	blocked	by	
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intrathecal	administration	of	a	5-HT3	receptor	antagonist.	The	authors	concluded	that	the	5-HT	receptor	subtypes	possessed	different	affinities	for	5-HT	and	their	activation	was	dependent	upon	the	levels	of	5-HT	present	in	the	dorsal	horn	(Oyama	et	al	1996).	Similarly,	the	depletion	of	5-HT	in	the	RVM	using	a	short-hairpin-RNA-interference	to	block	the	actions	of	the	rate-limiting	enzyme	for	the	synthesis	of	5-HT,	tryptophan	hydroxylase	2	(Tph-2),	attenuated	formalin-induced	nocifensive	behaviours	during	the	second	phase	but	had	no	effect	in	the	first	phase	(Wei	et	al	2010).	The	authors	suggest	that	release	of	5-HT	from	descending	projections	arising	in	the	RVM	may	not	be	involved	in	the	initiation	of	acute	pain	but	does	play	a	role	in	the	development	and	maintenance	of	persistent	pain	(Wei	et	al	2010).	The	bi-directional	role	of	the	RVM	mediating	both	descending	inhibitory	and	excitatory	influences	at	the	level	of	the	dorsal	horn	may	shift	towards	facilitation	following	tissue	or	nerve	injury	and	this	may	be	mediated	by	an	alteration	in	the	5-HT	receptors	activated.			
4.1.4	The	use	of	noradrenaline	and	serotonin	re-uptake	inhibitors	for	the	
treatment	of	chronic	pain		The	main	clinical	symptoms	associated	with	chronic	pain	are	allodynia	and	hyperalgesia,	whereby	innocuous	stimuli	produce	a	painful	response	and	responses	to	noxious	stimuli	become	increased	(Jensen	and	Finnerup	2014)	(See	Section	1.1.4.2).	Chronic	pain	conditions,	especially	neuropathic	pain,	are	becoming	increasingly	difficult	to	treat	in	the	long-term	with	conventional	analgesics	such	as	opioids	and	NSAIDs,	due	to	their	limited	effectiveness,	adverse	side	effects,	and	patients	developing	tolerance	(Foley	2003,	Bomholt	et	al	2005,	Ong	et	al	2007).	A	further	potential	option	for	analgesia	is	the	use	of	drugs	traditionally	designed	as	antidepressants	that	function	by	modulating	the	levels	of	extracellular	noradrenaline	and	serotonin	(Bomholt	et	al	2005,	Sindrup	et	al	2005).	Tricyclic	antidepressants	inhibit	the	presynaptic	reuptake	of	the	monoamines	NA	and	5-HT	but	are	also	thought	to	work	through	other	mechanisms	involving	the	blockade	of	ion	channels	and	NMDA	receptors	(Sindrup	et	al	2005).	Similarly,	selective	serotonin	reuptake	inhibitors	(SSRIs)	and	selective	noradrenaline	reuptake	inhibitors	(NRIs)	function	by	specifically	inhibiting	the	presynaptic	reuptake	of	either	serotonin	or	noradrenaline,	while	serotonin	noradrenaline	re-uptake	inhibitors	(SNRIs)	combine	this	effect	and	prevent	the	reuptake	of	both	monoamines	from	the	synaptic	space.	Therefore,	these	drugs	function	by	increasing	the	availability	of	NA	and	5-HT	at	the	synapse,	which	may	act	on	α2-adrenoceptors	and/or	5-HT	receptors	in	the	dorsal	horn	to	mediate	inhibitory	control	of	the	pain	response	(Singh	et	al	2001).	
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Tricyclic	antidepressants,	SNRIs,	and	SSRIs	have	proved	effective	at	relieving	pain	in	patients	with	peripheral	neuropathy	(Sindrup	et	al	2005).			Along	with	the	clinical	symptoms	of	allodynia	and	hyperalgesia,	chronic	pain	is	often		coupled	with	dysfunctional	CPM	or	DNIC,	which	has	been	demonstrated	in	both	human	subjects	and	animal	models	respectively	(Ardent-Nielsen	et	al	2008,	Bannister	et	al	2015)	(See	Section	1.2.3).	Duloxetine	is	a	selective	SNRI,	and	the	efficacy	of	this	drug	in	patients	with	painful	diabetic	neuropathy	was	found	to	be	correlated	with	baseline	CPM,	such	that	patients	with	an	ineffective	CPM	system	pre-treatment	would	benefit	the	most	from	duloxetine	treatment	(Yarnitsky	et	al	2012).	Additionally,	Bannister	et	al	have	demonstrated	that	both	spinal	and	systemic	administration	of	the	NRIs,	Reboxetine	and	Tapentadol	respectively,	restored	DNIC	in	a	spinal	nerve	ligation	rat	model	of	neuropathy	(Bannister	et	al	2015).	These	findings	indicated	that	increased	synaptic	availability	of	5-HT	and	NA	may	be	sufficient	to	restore	this	endogenous	inhibitory	system,	and	may	be	one	mechanism	by	which	these	drugs	produce	analgesia	in	patients.			
4.1.5	Chapter	4	aims	
	In	this	chapter	a	tricyclic	antidepressant,	an	NRI,	and	SSRIs	are	used	to	increase	the	systemic	and	spinal	synaptic	availability	of	noradrenaline	and	serotonin,	and	the	subsequent	effect	on	DNIC	is	investigated	in	both	naïve	and	neuropathic	animals.	In	the	case	of	spinally	administered	SSRIs,	when	the	synaptic	content	of	5-HT	is	dramatically	increased,	the	5-HT	receptors	activated	were	investigated.														
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4.2	Methods		
	
4.2.1	Pharmacology	
	One	pharmacological	study	was	carried	out	per	animal,	using	one	WDR	neuron.	In	SNL	animals	the	WDR	neuron	was	located	in	the	ipsilateral	dorsal	horn	relative	to	the	nerve	injury.		
	
Naïve	animals:		
• Reboxetine	(Tocris,	Bristol,	UK)	is	a	noradrenaline	reuptake	inhibitor	(NRI).	Reboxetine	was	dissolved	in	vehicle	(97%	normal	saline,	2%	cremaphor,	1%	DMSO)	and	100μg/50μL	was	applied	topically	to	the	spinal	cord.	Neuronal	responses	were	tested	20,	40	and	60	minutes	after	application.		
• Fluoxetine	(Sigma,	Welwyn	Garden	City,	UK)	is	a	selective	serotonin	reuptake	inhibitor	(SSRI).	Fluoxetine	was	dissolved	in	normal	saline	and	applied	both	spinally	(100μg/50μL)	and	systemically	(20mg/kg).	For	the	systemic	dose	fluoxetine	was	dissolved	in	normal	saline	and	administered	via	a	subcutaneous	injection.	The	dose	used	was	20mg/kg,	for	this	a	20mg/ml	solution	was	made	up	and	the	amount	injected	was	dependent	on	the	weight	of	the	animal.	For	example	a	250g	rat	would	receive	250μL	of	this	solution.	In	both	cases	neuronal	responses	were	tested	20,	40	and	60	minutes	after	administration.			
• Amitriptyline	(Tocris)	is	a	tricyclic	antidepressant	that	predominantly	inhibits	the	reuptake	of	serotonin	and	noradrenaline.	This	was	dissolved	in	normal	saline	and	delivered	via	a	subcutaneous	injection	at	a	dose	of	5mg/kg.	Neuronal	Responses	to	the	drug	were	followed	over	an	hour	with	tests	carried	out	at	10,	30	and	50	minutes.			
SNL	animals:		
• Fluoxetine	was	dissolved	in	normal	saline	and	applied	spinally	(100μg/50μL).	A	20mg/kg	systemic	dose	of	fluoxetine	was	also	used.	For	this	fluoxetine	was	dissolved	in	normal	saline	and	administered	via	a	subcutaneous	injection.			
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• Citalopram	(Tocris)	is	also	a	selective	serotonin	reuptake	inhibitor	(SSRI).	Citalopram	was	dissolved	in	normal	saline	and	applied	spinally	(100μg/50μL).	A	systemic	dose	of	citalopram	was	investigated,	for	this	citalopram	was	dissolved	in	normal	saline	and	administered	via	a	subcutaneous	injection	with	a	dose	of	10mg/kg.		
• SB-269970	(Tocris)	is	a	selective	5-HT7	receptor	antagonist.	This	was	dissolved	in	saline	and	applied	spinally	(100μg/50μL)	in	combination	with	fluoxetine	or	citalopram	delivered	at	the	same	concentration.			
• Atipamezole	(Sigma)	is	an	α2-adrenoceptor	antagonist.	Atipamezole	was	dissolved	in	vehicle	(97%	normal	saline,	2%	cremaphor,	1%	DMSO)	and	a	concentration	of	(100μg/50μL)	was	applied	topically	to	the	spinal	cord	in	combination	with	fluoxetine	or	citalopram	at	the	same	concentration.			For	all	experiments	in	SNLs,	the	neuronal	response	to	drug	was	followed	for	one	hour	with	tests	carried	out	at	the	time	points	20	and	40	minutes.			For	all	drug	time	points	one	DNIC	trial	was	carried	out	involving	3	baseline	pre-conditioned	responses	and	one	DNIC	response	in	the	presence	of	noxious	ear	pinch.			
4.2.2	Statistical	Analysis	For	a	description	of	the	statistical	tests	used	for	analysis	please	see	section	2.8.		
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4.3	Results		
	
4.3.1	Spinal	reboxetine	in	naïve	animals	Throughout	this	chapter,	DNIC	was	induced	by	a	concurrent	noxious	ear	pinch	ipsilateral	to	the	WDR	neuron	being	recorded.	The	magnitude	of	inhibition	produced	by	DNIC	was	investigated	in	naïve	rats	following	the	spinal	application	of	the	NRI	reboxetine.	For	mechanical	stimulation	of	8g,	26g,	and	60g	the	pre-treatment	inhibition	produced	with	DNIC	were	26%,	36%,	and	35%	respectively.	Following	spinal	administration	of	reboxetine,	the	inhibition	of	neuronal	firing	with	DNIC	was	41%,	50%,	and	42%	for	mechanical	stimulations	of	8g,	26g,	and	60g	respectively	(Figure	4.1a).	Additionally,	the	spinal	application	of	reboxetine	significantly	reduced	the	pre-conditioned	mechanically	evoked	neuronal	responses	to	26g	and	60g	(Figure	4.1b).	For	thermal	stimulation	of	42°C,	45°C,	48°C,	and	50°C	the	pre-treatment	inhibition	of	neuronal	firing	produced	with	DNIC	were	33%,	30%,	26%,	and	17%	respectively.	Following	spinal	administration	of	reboxetine,	the	magnitude	of	inhibition	produced	by	DNIC	was	27%,	34%,	36%,	and	27%	for	42°C,	45°C,	48°C,	and	50°C	respectively	(Figure	4.1c).	The	spinal	application	of	reboxetine	does	not	increase	the	magnitude	of	inhibition	produced	by	DNIC	to	the	thermal	stimulations	of	42°C	and	45°C,	but	does	increase	the	degree	of	inhibition	produced	by	DNIC	for	the	thermal	stimulations	higher	in	the	noxious	range.	In	addition,	the	spinal	application	of	reboxetine	significantly	reduced	the	pre-conditioned	thermal	evoked	neuronal	responses	to	45°C	and	48°C	(Figure	4.1d).	Overall	for	all	mechanically	evoked	responses	and	for	the	thermally	evoked	responses	in	the	higher	noxious	range,	the	spinal	application	of	reboxetine	increases	the	magnitude	of	inhibition	induced	by	DNIC	by	approximately	10%.			
4.3.2	Systemic	amitriptyline	in	naïve	animals	The	level	of	inhibition	produced	by	DNIC	was	investigated	in	naïve	rats	following	a	subcutaneous	injection	of	the	tricyclic	antidepressant	amitriptyline.	For	pre-treatment	mechanical	stimulation,	the	inhibition	of	neuronal	firing	in	response	to	8g,	26g,	and	60g	was	27%,	25%,	and	26%	respectively.	Following	systemic	administration	of	amitriptyline	the	magnitude	of	inhibition	induced	with	DNIC	was	42%,	34%,	and	33%	to	8g,	26g,	and	60g	respectively	(Figure	4.2a).	The	systemic	amitriptyline	did	not	significantly	affect	the	pre-conditioned	mechanically	evoked	responses	(Figure	4.2b).	For	thermally	evoked	neuronal	responses,	the	inhibition	induced	by	DNIC	before	amitriptyline	treatment	was	8%,	19%,	28%,	and	20%,	in	response	to	42°C,	45°C,	48°C,	
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and	50°C	respectively.	Following	subcutaneous	injection	of	amitriptyline	the	magnitude	of	inhibition	induced	by	DNIC	was	10%,	19%,	22%,	and	15%	in	response	to	42°C,	45°C,	48°C,	and	50°C	respectively	(Figure	3.2c).	While	amitriptyline	treatment	reduced	the	pre-conditioned	neuronal	responses	evoked	by	the	more	noxious	thermal	stimulations	of	48°C	and	50°C	this	effect	was	not	significant	(Figure	4.2d).	Therefore,	amitriptyline	treatment	increased	the	magnitude	of	inhibition	produced	by	DNIC	for	mechanical	stimulation	but	did	not	inhibit	the	pre-conditioned	mechanically	evoked	neuronal	responses.	Additionally,	amitriptyline	treatment	did	not	increase	the	magnitude	of	inhibition	induced	by	DNIC	in	response	to	thermal	stimulation	or	inhibit	the	pre-conditioned	thermally	evoked	neuronal	responses.			
	
Figure	4.1.	Spinal	application	of	the	NRI,	reboxetine,	in	naïve	animals.	A)	The	mechanically	evoked	neuronal	responses	and	the	degree	of	inhibition	induced	by	DNIC	before	and	after	spinal	application	of	reboxetine	(100μg/50μL)	(n=8).	B)	The	baseline	pre-conditioned	mechanically	evoked	neuronal	responses	were	significantly	inhibited	for	26g	and	60g	following	spinal	administration	of	reboxetine.	C)	The	thermally	evoked	neuronal	responses	and	the	magnitude	of	inhibition	induced	by	DNIC	before	and	after	spinal	application	of	reboxetine	(100μg/50μL)	(n=8).	D)	The	baseline	pre-conditioned	thermally	evoked	neuronal	responses	were	significantly	
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inhibited	for	45°C	and	48°C.	E)	A	raw	trace	from	one	example	WDR	neuron,	displaying	one	example	pre-conditioned	baseline	response	to	vonFrey	hairs	of	increasing	bending	force,	followed	by	a	pre-treatment	DNIC	response,	the	raw	trace	shows	a	concurrent	reduction	in	neuronal	firing	upon	application	of	the	noxious	conditioning	ear	pinch.	Following	spinal	administration	of	reboxetine,	one	example	pre-conditioned	mechanically	evoked	response	is	shown	to	vonFrey	hairs	of	increasing	bending	force,	followed	by	a	DNIC	response	induced	by	concurrent	application	of	a	noxious	conditioning	ear	pinch.	This	raw	trace	displays	how	the	mechanically	evoked	neuronal	firing	is	inhibited	to	a	greater	magnitude	following	spinal	application	of	reboxetine.	Two-way	ANOVA	with	Bonferroni	post-hoc	test	(*P<0.05,	**P<0.01,	***P<0.001).		
4.3.3	Spinal	and	Systemic	fluoxetine	in	naïve	animals	The	magnitude	of	inhibition	on	mechanical	and	thermal	evoked	neuronal	responses	induced	by	DNIC	was	investigated	in	naïve	rats	following	both	spinal	and	systemic	administration	of	the	SSRI	Fluoxetine.	For	mechanically	evoked	responses	before	spinal	Fluoxetine	treatment	the	magnitude	of	inhibition	induced	by	DNIC	was	33%,	23%,	and	30%	for	8g,	26g	and	60g	respectively.	Following	spinal	application	of	Fluoxetine	the	degree	of	inhibition	induced	by	DNIC	was	31%,	36%,	and	24%	to	8g,	26g,	and	60g	respectively	(Figure	4.3a).	The	spinal	application	of	Fluoxetine	significantly	inhibited	the	pre-conditioned	mechanically	evoked	neuronal	firing	in	response	to	26g	and	60g	(Figure	4.3b).	For	mechanically	evoked	responses	before	systemic	Fluoxetine	treatment	the	magnitude	of	inhibition	induced	by	DNIC	was	44%,	34%,	and	31%	for	8g,	26g,	and	60g	respectively.	Following	subcutaneous	injection	of	Fluoxetine	the	magnitude	of	inhibition	induced	by	DNIC	was	54%,	34%,	and	27%	to	8g,	26g,	and	60g	respectively	(Figure	4.3c).	The	subcutaneous	injection	of	Fluoxetine	did	not	significantly	affect	the	pre-conditioned	mechanically	evoked	neuronal	responses	(Figure	4.3d).	For	mechanically	evoked	neuronal	responses,	neither	the	spinal	or	systemic	administration	of	Fluoxetine	consistently	affected	the	degree	of	inhibition	induced	by	DNIC.	Additionally,	the	spinal	application	of	Fluoxetine	significantly	reduced	the	mechanically	evoked	pre-conditioned	neuronal	responses	while	the	systemic	application	of	Fluoxetine	have	this	effect.	For	thermally	induced	neuronal	responses	before	spinal	Fluoxetine	treatment	the	degree	of	inhibition	induced	by	DNIC	was	11%,	32%,	26%,	and	21%	in	response	to	42°C,	45°C,	48°C,	and	50°C	respectively.	Following	the	spinal	administration	of	Fluoxetine,	the	degree	of	inhibition	induced	by	DNIC	was	20%,	24%,	25%,	and	17%	in	response	to	42°C,	45°C,	48°C,	and	50°C	respectively	(Figure	4.3e).	The	spinal	application	of	Fluoxetine	significantly	inhibited	the	thermally	evoked	pre-conditioned	neuronal	responses	to	48°C	and	50°C	(Figure	4.3f).	For	thermally	evoked	neuronal	responses	the	spinal	application	of	Fluoxetine	did	not	increase	the	magnitude	
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of	inhibition	induced	by	DNIC,	but	did	significantly	inhibit	the	pre-conditioned	neuronal	responses	to	thermal	stimulations	in	the	higher	noxious	range.		
	
Figure	4.2.	Systemic	amitriptyline	in	naïve	animals.	A)	The	mechanically	evoked	neuronal	responses	and	the	degree	of	inhibition	induced	by	DNIC	before	and	after	a	subcutaneous	injection	of	amitriptyline	(n=6)	(5mg/kg).	B)	The	pre-conditioned	mechanically	evoked	neuronal	responses	to	vonFrey	hairs	of	increasing	bending	force	and	the	pre-conditioned	mechanically	evoked	neuronal	responses	following	Amitriptyline	treatment.	C)	The	thermally	evoked	neuronal	responses	and	the	magnitude	of	inhibition	induced	by	DNIC	before	and	after	systemic	Amitriptyline	(5mg/kg)	(n=6).	D)	The	pre-conditioned	thermally	evoked	neuronal	responses	to	water	jets	of	increasing	temperature	and	the	pre-conditioned	thermal	evoked	responses	following	subcutaneous	injection	of	amitriptyline.	Two-way	ANOVA	with	Bonferonni	post-hoc	test	(*P<0.05,	**P<0.01,	***P<0.001).		
	
4.3.4	The	magnitude	of	neuronal	inhibition	induced	by	DNIC	following	
reboxetine,	amitriptyline	and	fluoxetine	treatment.		
	While	the	NRI	reboxetine	consistently	increased	the	magnitude	of	inhibition	induced	by	DNIC	to	both	noxious	mechanical	and	thermal	stimulations,	the	percentage	of	inhibition	on	neuronal	firing	was	not	significantly	different	before	drug	treatment	and	following	spinal	application	of	reboxetine.	The	tricyclic	antidepressant	amitriptyline	and	the	SSRI	fluoxetine	did	not	appear	to	affect	the	degree	of	inhibition	induced	by	DNIC	to	either	mechanical	and	thermal	stimulations	in	naïve	animals	as	shown	in	Figure	4.4.			So	far,	the	inhibition	induced	by	DNIC	was	tested	in	both	mechanical	and	thermal	evoked	neuronal	responses.	At	each	time	point	3	baseline	responses	were	tested	to	obtain	an	average	and	one	DNIC	response	was	obtained,	this	meant	the	mechanical	and	
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thermal	pharmacology	experiments	could	not	be	combined	due	to	limited	time	for	each	drug	time	point.	Due	to	the	nature	of	electrophysiological	recordings	and	to	avoid	accumulative	doses,	one	animal	was	used	per	experiment.	Therefore	in	keeping	with	the	3Rs	of	replacement,	reduction	and	refinement	(NC3Rs)	the	inhibition	induced	by	DNIC	was	tested	in	mechanical	evoked	neuronal	responses	from	this	point	on.		
	
Figure	4.3	Spinal	and	systemic	administration	of	fluoxetine	in	naïve	animals.	A)	The	mechanical	evoked	neuronal	responses	and	the	degree	of	inhibition	induced	by	DNIC	before	and	after	spinal	application	of	fluoxetine	(100μg/50μL)	(n=6).	B)	The	pre-conditioned	mechanical	evoked	neuronal	responses	were	significantly	reduced	at	26g	and	60g	following	spinal	application	of	fluoxetine.	C)	The	mechanical	evoked	neuronal	responses	and	the	magnitude	of	inhibition	induced	by	DNIC	before	and	after	a	subcutaneous	injection	of	Fluoxetine	(20mg/kg)	(n=5).	D)	The	pre-conditioned	mechanical	evoked	neuronal	responses	were	unaffected	by	the	subcutaneous	injection	of	fluoxetine.	E)	The	thermal	evoked	neuronal	responses	and	the	degree	of	inhibition	induced	by	DNIC	before	and	following	spinal	application	of	fluoxetine	(100μg/50μL)	(n=6).	F)	The	pre-conditioned	thermal	evoked	neuronal	responses	were	significantly	inhibited	at	48°C	and	50°C.	Two-way	ANOVA	with	Bonferroni	correction	(*P<0.05,	**P<0.01,	***P<0.001).			
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Figure	4.4.	The	magnitude	of	inhibition	on	neuronal	firing	induced	by	DNIC	following	
reboxetine,	amitriptyline,	and	fluoxetine	treatment.	The	degree	of	inhibition	induced	by	a	concurrent	noxious	ear	pinch	in	Naïve	animals	before	any	pharmacological	treatment	is	compared	to	the	degree	of	inhibition	induced	by	DNIC	following	spinal	and	systemic	treatment	with	an	NRI,	tricyclic	antidepressant,	and	SSRI.	A)	The	degree	of	inhibition	induced	by	DNIC	on	mechanically	evoked	neuronal	responses.	This	indicated	that	following	treatment	with	systemic	amitriptyline,	systemic	fluoxetine	and	spinal	fluoxetine	the	degree	of	inhibition	induced	by	DNIC	remains	similar	to	the	levels	observed	pre-drug.	However,	the	spinal	application	of	reboxetine	increases	the	magnitude	of	inhibition	induced	by	DNIC	to	mechanically	evoked	responses,	however	this	is	not	significant.	B)	The	degree	of	inhibition	induced	by	DNIC	on	thermally	evoked	neuronal	responses.	Following	treatment	with	systemic	amitriptyline	and	spinal	fluoxetine	the	
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degree	of	inhibition	induced	by	DNIC	remains	similar	to	the	levels	observed	pre-drug.	Meanwhile,	the	spinal	application	of	reboxetine	increases	the	degree	of	inhibition	induced	by	DNIC	to	thermal	evoked	neuronal	responses,	yet	this	effect	is	not	significant.	Kruskall-Wallis	Independent	Samples	One	Way	Anova.		
	
4.3.5	DNIC	expression	in	SNL	animals	
	The	magnitude	of	neuronal	inhibition	induced	by	DNIC	was	then	assessed	in	a	Spinal	Nerve	Ligation	(SNL)	rat	model	of	neuropathy.	The	work	presented	in	the	rest	of	this	chapter	was	a	collaborative	study	with	Dr	Kirsty	Bannister	(Bannister	et	al	2017).	The	lab	has	previously	examined	the	magnitude	of	DNIC	in	Naïve	and	Sham	operated	animals	and	found	there	to	be	no	difference	in	the	level	of	neuronal	inhibition	upon	induction	of	DNIC	(Bannister	et	al	2015).			The	magnitude	of	inhibition	induced	by	DNIC	on	mechanical	evoked	neuronal	responses	was	assessed	in	nerve	ligated	rats	at	least	14	days	after	surgery,	the	DNIC	was	induced	by	a	concurrent	noxious	conditioning	ear	pinch	ipsilateral	to	the	side	of	injury.	Interestingly	and	unlike	naïve	animals,	where	DNIC	produced	a	consistent	inhibition	of	neuronal	firing	of	approximately	30%,	no	inhibition	on	neuronal	firing	was	observed	in	SNL	animals	with	the	noxious	conditioning	ear	pinch.	The	difference	in	DNIC	responses	between	naïve	and	SNL	animals	is	shown	in	Figure	4.5.			
4.3.6	Fluoxetine	in	SNL	animals		The	degree	of	inhibition	induced	by	DNIC	on	mechanically	evoked	neuronal	firing	was	assessed	in	SNL	rats	following	spinal	and	systemic	administration	of	the	SSRI	fluoxetine.	When	the	spinal	content	of	5-HT	was	increased	following	the	spinal	application	of	fluoxetine,	mechanically	evoked	neuronal	responses	to	8g,	26g,	and	60g	were	significantly	inhibited	in	the	presence	of	a	concurrent	noxious	conditioning	ear	pinch	by	42%,	39%,	and	34%	respectively	(Figure	4.6a).	Additionally,	the	spinal	administration	of	fluoxetine	significantly	inhibited	the	pre-conditioned	neuronal	responses	to	both	innocuous	and	noxious	mechanical	stimulation	(Figure	4.6b).	However	following	the	subcutaneous	injection	of	fluoxetine,	there	was	no	significant	reduction	in	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	conditioning	ear	pinch	(Figure	4.6c).	The	systemic	administration	of	fluoxetine	had	no	significant	affect	on	the	pre-conditioned	mechanically	evoked	neuronal	firing	(Figure	4.6d).	This	indicates	that	
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increased	synaptic	levels	of	5-HT	must	occur	specifically	in	the	spinal	cord	to	restore	the	DNIC	system.			
	
Figure	4.5	The	inhibition	on	neuronal	firing	induced	by	DNIC	in	naïve	and	SNL	rats.	A)	In	naïve	animals	a	concurrent	noxious	conditioning	ear	pinch	produces	a	significant	reduction	in	mechanically	evoked	neuronal	firing	(n=25).	B)	In	SNL	animals	the	concurrent	noxious	conditioning	ear	pinch	does	not	produce	any	inhibition	on	mechanically	evoked	neuronal	firing	(n=39).	C)	A	raw	trace	of	one	example	WDR	neuron	from	a	Naïve	animal;	this	shows	three	pre-conditioned	neuronal	responses	to	mechanical	stimulation	of	vonFrey	hairs	of	increasing	bending	force,	upon	application	of	a	concurrent	noxious	conditioning	ear	pinch	the	mechanically	evoked	neuronal	firing	was	inhibited.	D)	A	raw	trace	of	one	example	WDR	neuron	from	a	neuropathic	animal;	this	demonstrates	that	the	mechanically	evoked	neuronal	firing	is	similar	for	both	pre-conditioned	responses	and	in	the	presence	of	a	concurrent	noxious	conditioning	ear	pinch.	Two-way	ANOVA	with	Bonferroni	post-hoc	test	(***P<0.001).		
		
4.3.7	Citalopram	in	SNL	animals	Citalopram	is	also	an	SSRI,	which	was	spinally	and	systemically	administered	to	neuropathic	rats	to	further	assess	the	effect	of	increased	synaptic	content	of	5-HT	on	the	degree	of	inhibition	induced	by	DNIC.	While	both	fluoxetine	and	citalopram	have	been	demonstrated	using	microdialysis	to	increase	extracellular	concentration	of	5-HT	2-4	
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fold,	Fluoxetine	was	found	to	also	increase	the	concentrations	of	NA	and	dopamine	in	the	prefrontal	cortex	(Bymaster	et	al	2002).	Citalopram	was	found	to	only	cause	an	increase	in	the	extracellular	concentration	of	5-HT	and	so	has	been	suggested	to	be	a	more	selective	SSRI	(Bymaster	et	al	2002).	Therefore,	the	spinal	and	systemic	administration	of	citalopram	was	investigated	to	ensure	the	restoration	of	DNIC	was	occurring	due	to	increased	5-HT	spinal	synaptic	content	rather	than	through	a	NA	mediated	mechanism.			When	the	spinal	content	of	5-HT	was	increased	following	spinal	application	of	citalopram,	mechanically	evoked	neuronal	responses	to	8g,	26g,	and	60g	were	inhibited	with	a	concurrent	noxious	conditioning	ear	pinch	by	22%,	46%,	and	38%	respectively.	For	the	noxious	mechanical	stimulations	of	26g	and	60g	the	DNIC	induced	a	significant	reduction	in	neuronal	firing	(Figure	4.7a).	The	spinal	application	of	citalopram	did	not	significantly	inhibit	the	pre-conditioned	mechanically	evoked	neuronal	firing	(Figure	4.7b).	Similarly	to	fluoxetine,	the	systemic	administration	of	citalopram	did	not	restore	any	degree	of	inhibition	of	neuronal	firing	with	a	concurrent	noxious	conditioning	ear	pinch	(Figure	4.7c).	The	systemic	administration	of	citalopram	also	had	no	effect	on	the	pre-conditioned	mechanically	evoked	neuronal	firing	(Figure	4.7d).			
	 155	
	
Figure	4.6	The	spinal	and	systemic	administration	of	fluoxetine	in	SNL	rats.	A)	The	mechanically	evoked	WDR	neuronal	responses	and	the	degree	of	inhibition	induced	by	DNIC	following	spinal	application	of	fluoxetine	(100μg/50μL)	(n=6).	This	indicates	that	increasing	the	spinal	synaptic	content	of	5-HT	restores	the	DNIC	system	in	SNL	animals.	B)	The	pre-conditioned	mechanically	evoked	neuronal	responses	were	significantly	inhibited	following	the	spinal	application	of	fluoxetine	(100μg/50μL)	(n=6).	C)	The	pre-conditioned	mechanically	evoked	neuronal	responses	and	the	neuronal	responses	with	a	concurrent	noxious	conditioning	ear	pinch,	subcutaneous	injection	of	fluoxetine	(20mg/kg)	did	not	restore	the	DNIC	system	in	SNL	animals	(n=5).	D)	The	pre-conditioned	mechanically	evoked	neuronal	responses	were	not	significantly	affected	by	a	systemic	injection	of	fluoxetine	(20mg/kg)	(n=5).	Two-way	ANOVA	with	Bonferroni	post-hoc	test	(*P<0.05,	**P<0.01).		
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Figure	4.7.	The	spinal	and	systemic	administration	of	citalopram	in	SNL	animals.	A)	The	mechanically	evoked	neuronal	responses	and	the	magnitude	of	inhibition	induced	by	DNIC	before	and	after	spinal	application	of	citalopram	(100μg/50μL)	(n=6).	The	spinal	application	of	citalopram	results	in	a	significant	reduction	in	mechanically	evoked	neuronal	firing	with	the	concurrent	noxious	conditioning	ear	pinch.	B)	The	spinal	citalopram	does	not	significantly	inhibit	the	pre-conditioned	mechanically	evoked	neuronal	responses.	C)	A	subcutaneous	injection	of	citalopram	(10mg/kg)	does	not	produce	a	significant	reduction	of	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	conditioning	ear	pinch	(n=5).	D)	Systemic	Citalopram	does	not	affect	the	pre-conditioned	mechanically	evoked	neuronal	responses.	E)	A	raw	trace	of	one	example	WDR	neuron	from	an	SNL	rat	following	spinal	application	of	citalopram.	One	example	pre-conditioned	response	is	shown	and	the	DNIC	response	shows	there	is	a	reduction	in	mechanically	evoked	neuronal	firing	in	the	presence	of	the	concurrent	noxious	conditioning	ear	pinch.	F)	A	raw	trace	from	one	example	WDR	neurons	from	an	SNL	rat	following	subcutaneous	injection	of	citalopram.	This	trace	shows	that	there	is	no	reduction	in	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	conditioning	ear	pinch.	Two-Way	ANOVA	with	Bonferroni	post-hoc	test	(*P<0.05).		
	 157	
	
4.3.8	Co-administration	of	spinal	selective	serotonin	reuptake	inhibitors	
and	a	5-HT7	receptor	antagonist	
	The	increased	spinal	synaptic	content	of	5-HT	restored	DNIC	in	SNL	animals,	therefore	the	inhibitory	effect	must	be	caused	by	5-HT	receptor	mediated	actions.	As	the	5-HT7	receptor	has	recently	been	reported	to	play	an	antinociceptive	role	at	the	level	of	the	spinal	cord,	a	selective	5-HT7	receptor	antagonist	SB-267790	was	co-administered	to	the	spinal	cord	along	with	Fluoxetine	or	Citalopram.	Interestingly,	when	SB-267790	was	applied	to	the	spinal	cord	with	Fluoxetine	or	Citalopram	the	inhibitory	effect	was	blocked.	There	was	no	longer	a	reduction	of	mechanically	evoked	neuronal	firing	in	the	presence	of	a	concurrent	noxious	conditioning	ear	pinch,	indicating	a	complete	block	on	the	restoration	of	DNIC.	This	indicates	that	increased	5-HT	content	in	the	spinal	cord	can	activate	5-HT7	receptors	to	mediate	an	inhibition	of	the	pain	response.			
4.3.9	Co-administration	of	spinal	selective	serotonin	reuptake	inhibitors	
and	an	α2-adrenergic	receptor	antagonist	
	DNIC	has	been	shown	to	rely	on	a	NA	mechanism	acting	through	α2-adrenergic	receptors	in	the	spinal	cord	(Bannister	et	al	2015).	Therefore	the	degree	of	inhibition	on	neuronal	firing	following	spinal	application	of	Fluoxetine	and	Citalopram	was	analysed	when	these	SSRIs	were	co-administered	spinally	with	an	α2-adrenergic	receptor	antagonist	Atipamezole.	Remarkably	Atipamezole	blocked	the	reduction	in	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	conditioning	ear	pinch	as	shown	in	Figure	4.9.	This	indicates	that	even	with	increased	extracellular	levels	of	5-HT	in	the	spinal	cord,	NA	actions	through	the	α2-adrenergic	receptors	are	required	for	DNIC	to	function.		
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Figure	4.8.	The	co-administration	of	fluoxetine	or	citalopram	with	the	5-HT7	antagonist	
SB-267790	in	SNL	rats.	A)	The	mechanically	evoked	neuronal	responses	and	the	degree	of	inhibition	induced	by	a	concurrent	noxious	conditioning	ear	pinch	in	SNL	animals	before	and	after	the	spinal	co-administration	of	fluoxetine	(100μg/50μL)	and	SB-267790	(100μg/50μL)	(n=5).	The	5-HT7	antagonist	blocked	the	inhibitory	actions	and	restoration	of	DNIC	observed	with	fluoxetine	alone.	B)	The	spinal	co-administration	had	no	affect	on	the	pre-conditioned	mechanically	evoked	neuronal	responses.	C)	The	mechanically	evoked	neuronal	responses	and	the	degree	of	inhibition	induced	by	a	concurrent	noxious	conditioning	ear	pinch	in	SNL	rats	before	and	after	spinal	application	of	citalopram	(100μg/50μL)	and	SB-267790	(100μg/50μL).	There	is	no	reduction	in	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	ear	pinch	following	citalopram	and	SB-267790	indicated	SB-267790	blocks	the	inhibitory	actions	of	citalopram	applied	alone.	D)	The	pre-conditioned	mechanically	evoked	neuronal	responses	were	unaffected	by	the	spinal	co-administration	of	citalopram	and	SB-267790.	Two-way	ANOVA	with	Bonferonni	post-hoc	test.			
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Figure	4.9	The	co-administration	of	fluoxetine	or	citalopram	with	the	α2-adrenergic	
receptor	atipamezole.	A)	The	mechanically	evoked	WDR	neuronal	responses	and	the	degree	of	inhibition	induced	by	a	concurrent	noxious	conditioning	ear	pinch	in	SNL	rats	before	and	after	the	spinal	co-administration	of	fluoxetine	(100μg/50μL)	and	atipamezole	(100μg/50μL)	(n=6).	Atipamezole	blocks	the	inhibitory	action	of	fluoxetine	as	there	is	no	reduction	of	neuronal	firing	induced	by	DNIC	as	is	seen	when	fluoxetine	is	administered	alone.	B)	The	pre-conditioned	mechanically	evoked	neuronal	responses	were	not	significantly	affected	by	the	co-administration	of	fluoxetine	and	atipamezole.	C)	The	mechanically	evoked	WDR	neuronal	responses	and	the	magnitude	of	inhibition	induced	by	a	concurrent	noxious	conditioning	ear	pinch	in	SNL	animals	before	and	after	the	spinal	co-administration	of	citalopram	(100μg/50μL)	and	atipamezole	(100μg/50μL)	(n=6).	The	spinal	co-administration	of	citalopram	and	atipamezole	did	not	produce	a	reduction	in	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	conditioning	ear	pinch.	D)	The	pre-conditioned	mechanically	evoked	neuronal	responses	were	reduced	following	spinal	co-administration	of	Citalopram	and	Atipamezole	but	this	was	not	significant.	E)	A	raw	trace	from	one	WDR	neuron	in	an	SNL	rat	showing	baseline	responses	before	drug	treatment.	This	shows	three	pre-conditioned	mechanically	evoked	neuronal	responses	and	mechanically	evoked	neuronal	responses	in	the	presence	of	a	concurrent	noxious	
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conditioning	ear	pinch.	F)	A	raw	trace	from	the	WDR	neuron	in	an	SNL	rat	following	spinal	co-administration	of	Citalopram	and	Atipamezole.	The	trace	shows	three	pre-conditioned	mechanically	evoked	neuronal	responses	and	the	mechanical	evoked	responses	in	the	presence	of	a	noxious	conditioning	ear	pinch.	The	spinal	co-administration	of	Citalopram	and	Atipamezole	does	not	reduce	the	mechanically	evoked	neuronal	responses	in	the	presence	of	a	noxious	conditioning	ear	pinch.	Two-way	ANOVA	with	Bonferroni	post-hoc	test.																														
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4.4	Discussion		4.4.1	The	balance	in	descending	noradrenergic	and	serotonergic	controls	
in	naïve	animals	This	study	provides	further	evidence	that	a	concurrent	noxious	conditioning	stimulus	reliably	and	consistently	inhibits	the	evoked	activity	of	convergent	WDR	neurons	in	naïve	rats.	The	DNIC	system	has	previously	been	reported	to	rely	on	NA	mechanisms	acting	through	α2-adrenergic	receptors	as	blockade	of	this	receptor	abolished	DNIC	in	naïve	animals	(Bannister	et	al	2015).	Descending	modulatory	systems	arising	in	the	brainstem	can	exert	bi-directional	controls	on	pain	perception	at	the	level	of	the	spinal	cord	through	the	release	of	monoamines	(Bannister	and	Dickenson	2016b).	Under	normal	conditions	the	concurrent	noxious	conditioning	stimulus	is	thought	to	activate	descending	inhibitory	pathways	to	prompt	NA	release	in	the	dorsal	horn,	which	can	activate	α2-adrenergic	receptors	to	mediate	inhibition	of	the	pain	response.	This	study	explored	the	roles	played	by	both	NA	and	5-HT	in	mediating	DNIC	further	by	increasing	the	synaptic	availability	of	NA	and	5-HT	using	an	NRI,	SSRI,	and	tricyclic	antidepressant,	and	investigating	the	subsequent	effects	on	the	magnitude	of	inhibition	induced	by	DNIC.			
4.4.1.1	Reboxetine	in	Naïve	animals		This	study	demonstrates	that	spinal	application	of	the	NRI	reboxetine	increases	the	degree	of	inhibition	induced	by	DNIC	in	naïve	animals.	This	demonstrates	that	increasing	the	synaptic	content	of	NA	amplifies	the	endogenous	inhibitory	system	utilized	by	DNIC	in	Naïve	animals.	This	suggests	that	in	naïve	animals	the	application	of	the	noxious	conditioning	ear	pinch	activates	a	descending	noradrenergic	inhibitory	system,	which	dominates	over	the	descending	facilitatory	system	to	trigger	DNIC	and	cause	a	reduction	in	WDR	neuronal	firing.			The	importance	of	the	NA	system	in	mediating	DNIC	has	previously	been	described	in	both	animal	models	and	human	subjects	with	chronic	pain.	The	spinal	application	of	reboxetine	has	also	been	demonstrated	to	restore	DNIC	in	a	spinal	nerve	ligation	rat	model	of	neuropathy	(Bannister	et	al	2015).	Furthermore	in	patients	with	diabetic	polyneuropathy	and	a	dysfunctional	CPM	system,	tapentadol	(a	μ-opioid	receptor	agonist	and	NRI)	treatment	activated	the	CPM	system	(Niester	et	al	2014).	Interestingly,	intrathecal	reboxetine	was	found	to	partially	reverse	mechanical	allodynia	in	rats	with	
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tibial	nerve	transection,	which	was	blocked	by	intrathecal	administration	of	the	α2-adrenoceptor	antagonist	yohimbine.	However,	the	α1-adrenoceptor	antagonist	prazosin	and	the	β-adrenoceptor	antagonist	propranolol	had	no	effect	on	the	antinociceptive	actions	of	reboxetine	(Hughes	et	al	2015).	These	findings	indicate	that	the	endogenous	inhibitory	system	utilized	by	DNIC	can	be	restored	through	pharmacologically	modulating	noradrenergic	descending	inhibitory	controls	by	increasing	the	synaptic	levels	of	NA,	which	can	ultimately	activate	inhibitory	α2-adrenoceptors.	Restoring	DNIC	by	enhancing	the	noradrenergic	inhibitory	systems	indicates	that	the	loss	of	DNIC	in	chronic	pain	states	is	likely	due	to	reduced	activity	of	the	noradrenergic	descending	inhibitory	controls	arising	in	the	brainstem.		The	importance	of	a	functional	endogenous	inhibitory	system	utilized	by	DNIC	and	the	noradrenergic	inhibitory	descending	controls	that	sub-serve	this	system	have	been	further	demonstrated	in	the	clinic.	Firstly	a	correlation	has	been	demonstrated	between	pain-free	patients	with	an	inefficient	CPM	and	the	development	of	chronic	pain	following	thoracotomy	surgery	(Yarnitsky	et	al	2008).	This	indicates	that	patients	with	an	inefficient	endogenous	analgesic	system	are	more	likely	to	develop	chronic	pain	in	the	future	(Yarnitsky	et	al	2008).	Secondly	in	patients	with	painful	diabetic	neuropathy,	the	efficiency	of	the	SNRI	duloxetine	was	found	to	be	correlated	with	CPM	efficiency,	such	that	patients	with	an	inefficient	CPM	would	benefit	most	from	the	drug	(Yarnitsky	et	al	2012).	This	demonstrates	that	increasing	the	synaptic	availability	of	NA	in	patients	with	inefficient	CPM	may	be	sufficient	to	restore	the	endogenous	inhibitory	system	mediated	by	DNIC,	and	reduce	their	likelihood	of	developing	chronic	pain	in	the	future.		Overall,	the	ability	of	increased	extracellular	levels	of	NA	to	amplify	the	inhibition	induced	by	DNIC	in	naïve	animals	confirms	the	importance	of	NA	actions	at	spinal	α2-adrenoceptors	in	mediating	DNIC.	Furthermore,	while	reboxetine	increased	the	degree	of	inhibition	induced	by	DNIC,	amitriptyline	and	fluoxetine	treatment	that	act	to	increase	the	synaptic	availability	of	both	NA	and	5-HT	or	specifically	5-HT,	do	not	produce	this	effect.	This	indicates	that	NA	may	be	the	monoamine	that	holds	the	greatest	potential	for	mediating	the	inhibition	induced	by	DNIC.		
	
4.4.1.2	Amitriptyline	in	Naïve	animals		The	effect	of	the	tricyclic	antidepressant,	amitriptyline,	on	WDR	neuronal	firing	and	magnitude	of	inhibition	induced	in	DNIC	was	then	investigated	in	naïve	animals.	
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Amitriptyline	is	primarily	a	serotonin-noradrenaline	reuptake-inhibitor	(SNRI)	but	has	a	less	specific	mode	of	action	than	reboxetine	and	fluoxetine,	it	also	blocks	histamine	H1,	muscarinic,	and	NMDA	receptors	giving	it	a	sedative	and	hypotensive	effect	too	(Bomholtet	al	2005,	Sindrup	et	al	2005).	Tricyclic	antidepressants	are	the	most	widely	used	antidepressant	drugs	in	the	treatment	of	neuropathic	pain,	they	were	found	to	be	more	effective	than	SNRIs	and	SSRIs	at	relieving	peripheral	neuropathic	pain	in	terms	of	numbers	needed	to	treat	(Sindrup	et	al	2005).	Interestingly	in	this	study,	the	subcutaneous	injection	of	Amitriptyline	had	little	effect	on	pre-conditioned	mechanical	and	thermal	evoked	neuronal	responses	and	on	the	degree	of	inhibition	induced	by	DNIC.		As	amitriptyline	functions	primarily	as	a	serotonin	and	noradrenaline	reuptake	inhibitor,	the	effect	on	the	degree	of	inhibition	induced	by	DNIC	was	tested	with	the	increased	synaptic	availability	of	5-HT	and	NA.	The	subcutaneous	injection	of	amitriptyline	had	little	effect	on	the	magnitude	of	inhibition	induced	by	DNIC,	with	the	inhibition	on	mechanical	and	thermal	evoked	neuronal	firing	upon	application	of	the	noxious	ear	pinch	at	similar	levels	before	and	after	drug	administration.	Although	amitriptyline	has	been	demonstrated	to	be	an	effective	analgesic	in	both	neuropathic	and	inflammatory	pain	states,	the	exact	analgesic	mechanisms	have	not	been	conclusively	determined	(Acton	et	al	1992,	Sawynok	et	al	1999,	Sindrup	et	al	2005)	Amitriptyline	has	been	shown	to	have	an	effective	analgesic	effect	in	patients	with	tension-type	headache	(Ashina	et	al	2004).	To	better	understand	the	analgesic	mechanisms	in	tension-type	headache	the	authors	compared	Amitriptyline’s	analgesic	effect	and	efficiency	to	prevent	5-HT	presynaptic	reuptake	to	the	SSRI	Citalopram	by	measuring	platelet	5-HT	levels	in	blood	samples	from	treated	patients	(Ashina	et	al	2004).	The	authors	found	that	while	amitriptyline	was	much	more	effective	in	relieving	the	pain	associated	with	the	headaches,	citalopram	was	much	more	effective	in	inhibiting	the	reuptake	of	5-HT,	indicating	amitriptyline’s	analgesic	effects	are	likely	due	to	other	mechanisms	of	action	(Ashina	et	al	2004).	Amitriptyline	being	relatively	ineffective	at	preventing	the	presynaptic	reuptake	of	5-HT	and	NA	may	explain	why	it	is	does	not	enhance	the	magnitude	of	inhibition	induced	by	DNIC	in	this	study.			The	subcutaneous	injection	of	amitriptyline	also	had	little	effect	on	the	pre-conditioned	mechanically	and	thermally	evoked	WDR	neuronal	responses,	amitriptyline	did	reduce	neuronal	firing	in	response	to	the	more	noxious	thermal	stimulations	of	48°C	and	50°C	but	this	effect	was	not	significant.	Similarly,	previous	findings	have	reported	that	
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amitriptyline	is	more	effective	at	relieving	thermally	evoked	pain	than	mechanically	evoked	pain.	In	a	rat	ligation	model	of	neuropathy,	amitriptyline	reversed	thermal	hyperalgesia	yet	had	no	effect	in	alleviating	mechanical	allodynia	(Esser	and	Sawynok	1999).	Similarly,	in	rats	with	chronic	constriction	injury	amitriptyline	was	demonstrated	to	fully	reverse	thermal	hypersensitivity	yet	could	only	slightly	reduced	mechanical	hyperalgesia	and	could	not	attenuate	mechanical	allodynia	(Bomholt	et	al	2005).	However,	the	authors	also	found	that	amitriptyline	was	ineffective	at	modulating	the	nocicieptive	response	latencies	in	naïve	rats	during	the	hot	plate	test	and	was	also	ineffective	at	relieving	the	aversive	behavior	observed	with	the	formalin	test	(Bomholt	et	al	2005).	These	findings	suggest	that	the	analgesic	properties	of	amitriptyline	are	inconsistent	and	may	depend	upon	the	chronic	pain	model,	but	our	electrophysiological	results	suggest	that	amitriptyline	has	a	limited	effect	on	neuronal	responses	in	naïve	animals.			Finally,	amitriptyline	was	delivered	by	a	subcutaneous	injection	rather	than	the	spinal	administration	used	for	reboxetine	and	fluoxetine,	this	may	account	for	the	ineffectiveness	of	amitriptyline	on	neuronal	firing.	This	route	was	chosen	due	to	previous	experiments	in	the	lab	that	found	spinal	administration	of	amitriptyline	caused	neuronal	damage	and	prevented	electrophysiological	recordings.	However	in	a	spinal	nerve	ligation	rat	model	of	neuropathy,	amitriptyline	was	found	to	have	an	antihyperalgesic	effect	when	administered	through	intrathecal,	intraperitoneal,	and	subcutaneous	injection	(Esser	and	Sawynok	1999).	A	subcutaneous	injection	also	most	accurately	represents	the	systemic	administration	of	amitryptiline	as	would	be	the	case	in	the	clinic.			Overall	while	Amitriptyline	has	been	demonstrated	to	have	analgesic	properties	in	models	of	chronic	pain,	it	may	not	be	the	best	pharmacological	tool	for	investigating	the	function	of	NA	and	5-HT	in	mediating	DNIC.			
4.4.1.3	Fluoxetine	in	Naïve	animals		The	effect	of	a	spinal	application	of	the	SSRI	fluoxetine	on	mechanically	and	thermally	evoked	WDR	neuronal	firing	and	the	degree	of	inhibition	induced	by	DNIC	was	investigated.	Interestingly	the	spinal	application	of	fluoxetine	significantly	inhibited	the	pre-conditioned	noxious	mechanical	and	thermal	evoked	neuronal	firing,	suggesting	when	the	5-HT	content	in	the	cord	is	increased	an	overriding	inhibitory	pathway	
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dominates.	However,	the	spinal	application	of	fluoxetine	had	little	effect	on	the	magnitude	of	inhibition	induced	by	DNIC,	indicating	that	increased	extracellular	5-HT	cannot	enhance	the	degree	of	inhibition	on	WDR	neuronal	firing	upon	concurrent	application	of	the	noxious	conditioning	ear	pinch.		This	study	suggests	that	when	the	SSRI	fluoxetine	increases	the	spinal	synaptic	levels	of	5-HT,	5-HT	mediates	an	inhibitory	action.	The	role	played	by	5-HT	in	nociception	is	complex	due	to	myriad	of	5-HT	receptors	and	alterations	in	the	serotonergic	system	in	chronic	pain	states,	therefore	studies	have	shown	conflicting	findings	as	to	whether	the	serotonergic	descending	faciliatory	or	inhibitory	pathways	originating	in	the	RVM	predominate.	Recently,	Cai	et	al	demonstrated	that	optogenetic	stimulation	of	5-HT	neurons	in	the	RVM	decreased	both	mechanical	and	thermal	pain	thresholds,	suggesting	5-HT	exerts	a	pre-dominant	facilitatory	effect	under	normal	conditions	(Cai	et	al	2014).	A	contrasting	study	investigated	spinally	projecting	serotonergic	neurons	arising	in	the	RVM,	they	found	these	neurons	expressed	the	Neurotensin	Receptor	Subtype	1	(NRT1),	and	found	an	agonist	for	this	receptor	produced	dose-dependent	antinociception	in	the	tail-flick	test	(Buhler	et	al	2005).	The	authors	suggested	that	NRT1-expressing	serotonergic	neurons	arising	in	the	RVM	that	project	to	the	spinal	cord	mediate	antinocieption	through	the	release	of	5-HT	in	the	dorsal	horn	(Buhler	et	al	2005).	In	addition,	intrathecal	administration	of	the	selective	5-HT	enhancer	Tianeptine	was	demonstrated	to	dose-dependently	attenuate	mechanical	allodynia	in	a	spinal	nerve	ligation	rat	model	of	neuropathy	(Lin	et	al	2015).	Therefore,	the	facilitatory	or	inhibitory	actions	mediated	by	5-HT	may	be	determined	by	the	receptor	activated,	the	pain	state,	and	5-HT	levels	present.			Unlike	the	inhibitory	actions	mediated	by	spinal	application	of	fluoxetine,	a	subcutaneous	injection	of	fluoxetine	had	little	effect	on	mechanically	evoked	WDR	neuronal	responses	or	the	degree	of	inhibition	induced	by	DNIC.	This	indicates	that	increased	synaptic	levels	of	5-HT	need	to	occur	specifically	in	the	spinal	cord	to	have	an	inhibitory	effect.	Although	fluoxetine	crosses	the	blood-brain-barrier	(Warren	2012),	the	systemic	administration	of	fluoxetine	may	not	be	sufficient	to	raise	5-HT	synaptic	levels	enough	in	the	spinal	cord	to	mediate	inhibitory	actions.	In	addition,	studies	have	demonstrated	that	peripheral	and	central	5-HT	receptors	play	opposing	roles	in	nociception.	In	both	inflammatory	and	neuropathic	conditions,	a	peripherally	applied	5-HT7	receptor	agonist	produced	pronociceptive	effects	while	the	central	application	of	the	5-HT7	receptor	agonist	produced	antinociceptive	effects	(Brenchat	et	al	2012).	
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These	findings	may	suggest	that	the	subcutaneous	injection	of	fluoxetine	produces	opposing	centrally	and	peripherally	mediated	effects,	which	may	balance	out	and	prevent	the	increased	5-HT	synaptic	content	from	mediating	an	inhibition	on	neuronal	firing.			
4.4.2	The	actions	of	serotonin	in	SNL	animals		This	study	confirmed	that	DNIC	is	abolished	in	an	SNL	rat	model	of	neuropathy,	which	is	in	agreement	with	previous	findings	(Bannister	et	al	2015).	Previous	studies	have	demonstrated	that	DNIC	can	be	restored	in	SNL	animals	with	the	NRIs,	Reboxetine	and	Tapentadol,	and	also	by	blocking	the	actions	of	5-HT3	receptor	with	the	antagonist	Ondansetron	(Bannister	et	al	2015).	These	findings	suggest	that	following	neuropathy	neurobiological	mechanisms	cause	an	inactivation	of	DNIC,	whereby	the	noradrenergic	descending	inhibitory	system	becomes	quiescent	and	the	serotonergic	facilitatory	descending	inhibitory	system	acting	through	5-HT3	receptors	becomes	upregulated.	The	balance	that	exists	between	descending	facilitation	and	inhibition	is	abolished	such	that	the	activation	of	inhibitory	controls	upon	application	of	the	noxious	conditioning	stimulus	is	no	longer	sufficient	to	override	facilitation.	This	study	investigated	the	role	of	5-HT	at	the	level	of	the	spinal	cord	further	in	SNL	animals.	
	
4.4.2.1	Selective	Serotonin	Re-uptake	inhibitors	in	SNL	animals			The	spinal	application	of	the	SSRIs	Fluoxetine	and	Citalopram	restored	DNIC	in	SNL	animals,	the	mechanically	evoked	neuronal	firing	was	now	significantly	inhibited	upon	application	of	a	concurrent	conditioning	noxious	ear	pinch.	This	suggests	that	when	the	synaptic	levels	of	5-HT	are	increased	in	the	spinal	cord,	5-HT	can	predominantly	mediate	inhibitory	actions.	This	was	interesting	as	the	serotonergic	facilitatory	system	acting	at	the	5-HT3	receptor	is	known	to	be	enhanced	following	neuropathy,	however	it	appears	when	the	extracellular	5-HT	levels	are	increased	further	in	the	dorsal	horn	5-HT	can	predominantly	mediate	inhibitory	actions	(Suzuki	et	al	2002,	Dogrul	et	al	2009).	Previous	studies	have	demonstrated	that	descending	serotonergic	pathways	are	required	for	the	full	inhibitory	effects	of	DNIC	(Dickenson	et	al	1981,	Lindstedt	et	al	2011).	Dickenson	et	al	found	that	depletion	of	5-HT	in	the	spinal	cord	strongly	reduced	the	magnitude	of	inhibition	induced	by	DNIC	(Dickenson	et	al	1981).	In	addition,	patients	with	low	expression	of	the	5-HT	transporter	have	a	less	efficient	CPM	(Linstedt	
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et	al	2011).	Overall	the	pronociceptive	or	antinociceptive	direction	of	5-HT	in	the	spinal	cord	appears	to	depend	upon	the	5-HT	levels	and	subsequent	receptor	activated.			Interestingly,	the	subcutaneous	injection	of	the	SSRIs	Fluoxetine	and	Citalopram	did	not	restore	the	neuronal	inhibition	induced	by	DNIC	in	SNL	animals.	This	is	similar	to	the	findings	in	Naïve	animals	where	spinal,	but	not	systemic,	Fluoxetine	inhibited	mechanically	evoked	neuronal	firing.	This	suggests	that	for	the	increased	synaptic	availability	of	5-HT	to	mediate	an	inhibitory	action	and	predominate	over	the	5-HT3	receptor	mediated	facilitation,	the	increased	levels	of	5-HT	must	exist	specifically	in	the	spinal	cord.	Both	Fluoxetine	and	Citalopram	cross	the	blood	brain	barrier	but	they	may	not	increase	levels	of	5-HT	in	the	spinal	cord	a	sufficient	amount	to	mediate	inhibition	(Warren	2012,	Paulzen	et	al	2016).	Furthermore,	there	may	be	opposing	nociceptive	actions	mediated	by	activation	of	peripheral	and	central	5-HT	receptors	(Brenchat	et	al	2012).			
4.4.2.2	The	inhibitory	actions	of	Selective	Serotonin	reuptake	inhibitors	in	
the	spinal	cord	are	mediated	by	the	5-HT7	receptor	Remarkably,	the	5-HT7	receptor	antagonist	SB-267790	completely	blocked	the	inhibitory	actions	mediated	by	spinally	administered	Fluoxetine	and	Citalopram.	This	would	suggest	that	when	the	spinal	synaptic	levels	of	5-HT	are	increased	further,	5-HT	can	now	mediate	a	5-HT7	receptor	mediated	inhibition,	that	can	overcome	the	5-HT3	receptor	mediated	facilitation.	This	is	in	agreement	with	previous	findings	that	suggest	an	antinociceptive	role	for	the	5-HT7	receptor	at	the	level	of	the	spinal	cord	(Dogrul	et	al	2006,	Dogrul	et	al	2009).	Both	a	subcutaneous	injection	and	RVM	microinjection	of	morphine	produce	antinociception,	in	both	cases	the	antinociceptive	effects	were	blocked	with	spinal	application	of	the	5-HT7	receptor	antagonist	SB-267790	(Dogrul	and	Seyrek	2006,	Dogrul	et	al	2009).	This	suggests	that	in	addition	to	morphine’s	activation	of	opioid	receptors	in	the	brain	and	spinal	cord,	it	activates	serotonergic	neurons	in	the	RVM	to	release	5-HT	in	the	spinal	cord	and	mediate	antinociception	through	5-HT7	receptors.	As	DNIC	has	also	been	shown	to	rely	partly	on	opiods,	it	may	be	that	combinations	of	these	systems	arising	in	the	RVM	are	required	for	the	expression	of	DNIC	(Le	Bars	et	al	1981).	Additionally,	a	5-HT7	receptor	agonist	was	found	to	induce	c-Fos	expression	in	the	nucleus	tractus	solitaris	and	Parabrachial	area	in	the	brainstem,	suggesting	supraspinal	mechanisms	might	also	be	involved	in	5-HT7	receptor	mediated	antinociception	(Viguier	et	al	2012).	This	further	indicates	that	the	5-HT7	receptor	is	likely	to	be	involved	in	the	spinal	inhibition	induced	by	a	noxious	conditioning	stimulus	
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as	DNIC	is	not	present	in	animals	with	spinal	cord	transection	(Le	Bars	et	al	1979b,	Dickenson	and	Le	Bars	1983).			In	addition,	the	5-HT7	receptors	in	the	dorsal	horn	have	found	to	be	localized	to	opiodergic	and	GABAergic	interneurons	suggesting	activation	of	5-HT7	may	mediate	inhibition	at	the	level	of	the	spinal	cord	through	the	activation	of	inhibitory	interneurons	(Brenchat	et	al	2010,	Viguier	et	al	2012).	Interestingly	in	mice	with	partial	sciatic	nerve	ligation	there	was	an	increase	in	5-HT7	receptor	density	in	the	ipsilateral	dorsal	horn,	suggesting	there	may	be	a	neuropathy	induced	up-regulation	of	the	5-HT7	receptor	(Brenchat	et	al	2010).	Therefore,	an	increase	in	the	synaptic	level	of	5-HT	and	increase	in	the	5-HT7	receptors	available	for	activation	may	be	responsible	for	mediating	inhibition	at	the	level	of	the	spinal	cord.			
4.4.2.3	The	actions	of	spinal	noradrenaline	at	α2-adrenergic	receptors	in	SNL	
animals	Curiously,	the	spinal	application	of	an	α2-adrenergic	receptor	antagonist	Atipamezole	also	blocked	the	inhibitory	actions	of	spinal	application	of	Fluoxetine	and	Citalopram	in	SNL	animals.	As	has	been	previously	demonstrated	in	both	naïve	and	neuropathic	animals,	the	NA	mediated	actions	through	the	α2-adrenergic	receptor	are	vital	for	the	expression	of	DNIC	(Bannister	et	al	2015).	The	noradrenergic	descending	controls	that	mediate	inhibition	at	the	level	of	the	spinal	cord	through	activation	of	α2-adrenergic	receptors	has	been	found	to	be	downregulated	following	neuropathy	(Rahman	et	al	2008).	However	these	findings	would	suggest	that	there	is	still	a	background	inhibitory	noradrenergic	tone,	albeit	at	much	lower	levels	than	in	the	naïve	state.	Therefore,	it	may	be	that	this	inhibitory	noradrenergic	system	must	be	present	even	at	low	levels	for	DNIC	to	be	induced.		
	
4.4.3	Concluding	remarks		This	study	demonstrates	that	DNIC	is	a	complex	endogenous	inhibitory	system	that	relies	on	both	noradrenergic	and	serotonergic	descending	inhibitory	systems	to	mediate	a	reduction	in	convergent	neuronal	firing.	However,	the	experiments	in	naïve	animals	demonstrate	that	NA	may	be	the	more	important	neurotransmitter	for	the	expression	of	DNIC	as	increasing	the	synaptic	availability	of	NA	with	Reboxteine	enhances	the	degree	of	inhibition	induced	by	DNIC,	whereas	increasing	the	synaptic	availability	of	5-HT	with	Fluoxetine	does	not	have	this	effect.	However	when	DNIC	is	lost	in	a	model	of	
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neuropathy,	increasing	the	synaptic	levels	of	5-HT	in	the	spinal	cord	with	Fluoxetine	and	Citalopram	restored	this	endogenous	inhibitory	system.	This	study	proposes	a	pharmacological	mechanism	for	this	inhibition	as	the	5-HT7	antagonist	SB-267790	completely	blocks	the	inhibition	on	mechanically	evoked	neuronal	firing	upon	application	on	the	noxious	conditioning	ear	pinch.	Serotonergic	facilitatory	descending	controls	mediating	pronociception	at	the	level	of	the	spinal	cord	through	activation	of	5-HT3	receptors	are	thought	the	be	enhanced	following	neuropathy	(Green	et	al	2000,	Suzuki	et	al	2002).	However	this	study	demonstrates	that	when	the	spinal	5-HT	content	is	raised	further,	5-HT	can	now	switch	to	mediate	an	antinociceptive	role	through	the	activation	of	5-HT7	receptors	located	on	inhibitory	interneurons.	Furthermore,	even	low	levels	of	noradrenergic	neurotransmission	acting	at	α2-adrenergic	receptors	in	the	dorsal	horn	must	occur	to	produce	an	inhibition	of	neuronal	firing,	as	abolishment	of	this	system	with	Atipamezole	completely	blocks	the	inhibitory	actions	and	restoration	of	DNIC,	even	with	raised	synaptic	levels	of	5-HT	following	spinal	administration	of	Fluoxetine	and	Citalopram.	This	proposes	that	while	a	low-level	tonic	noradrenergic	inhibitory	descending	system	must	be	present	for	DNIC	to	induce	an	inhibition	on	WDR	neuronal	firing,	the	conditioning	noxious	stimulation	can	evoke	further	noradrenergic	and	serotonergic	descending	inhibitory	controls.			
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5.	Investigating	the	expression	of	Diffuse	
Noxious	Inhibitory	Controls	in	a	
monoiodoacetate	model	of	Osteoarthritis.	
	
5.1	Introduction	
	
5.1.1	Modeling	Osteoarthritis	
	Animal	models	of	OA	provide	powerful	tools	to	investigate	the	mechanisms	behind	how	OA	arises	and	progresses.	Understanding	the	structural	pathology	that	occurs	in	the	knee	and	the	mechanisms	involved	in	the	development	of	chronic	pain	using	animals	that	accurately	model	OA	can	help	with	the	pre-clinical	development	of	new	therapies	(Little	and	Zaki	2012).	Multiple	animal	models	of	OA	have	been	designed	that	show	varied	histological,	behavioural	and	biochemical	changes.	The	OA-like	structural	joint	damage	and	associated	pain	can	be	initiated	by	different	methods,	but	mostly	OA	is	surgically,	chemically,	and	genetically	induced	(Bendele	2001).			The	surgically	induced	OA	models	work	on	the	principal	of	joint	instability	and	involve	transection	of	the	medial	meniscus,	medial	collateral	ligament,	or	anterior	cruciate	ligament	(Pond	and	Nuki	1973,	Janusz	et	al	2002,	Hayami	et	al	2006).	Most	surgical	models	focus	on	the	knee	joints,	where	a	loss	of	cartilage	is	often	observed	in	the	unstable	knees	(Brandt	et	al	1991).	These	surgically	induced	models	have	been	demonstrated	to	mimic	both	nociceptive	and	neuropathic	OA-like	pain,	and	behaviourally	animals	display	changes	in	weight	bearing	and	develop	tactile	allodynia	(Bove	et	al	2006).	The	surgically	induced	models	also	show	a	similar	histopathological	progression	to	human	OA,	with	an	initial	cartilage	surface,	proteoglycan	and	chondrocyte	loss,	followed	by	vascular	invasion	and	osteophyte	formation	(Junusz	et	al	2002,	Hayami	et	al	2006).	In	the	anterior	cruciate	ligament	transection	(ACLT)	model	the	ligament	is	destroyed	and	produces	a	more	severe	disease,	with	extensive	subchondral	bone	erosion	and	so	may	not	be	the	most	accurate	means	for	modeling	a	slowly	progressing	OA	phenotype	(Glasson	et	al	2007,	Lorenz	and	Grassel	2014).			The	use	of	transgenic	and	knockout	mice	to	model	OA	have	provided	information	on	the	molecular	mechanisms	that	may	induce	cartilage	degradation	and	the	potential	genetic	defects	that	may	predispose	individuals	to	develop	OA	(Goldring	1998).	Transgenic	mice	models	often	involve	genetic	modifications	affecting	cartilage	matrix	components.	
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Transgenic	mice	with	deletions	in	the	type	II	procollagen	gene	develop	erosions	of	the	articular	cartilage	followed	by	bony	sclerosis,	degeneration	of	the	meniscus	and	exposure	of	the	subchondral	bone,	which	is	similar	to	the	phenotype	observed	in	human	OA	suggesting	this	model	may	be	a	useful	tool	for	understanding	the	mechanisms	involved	in	initiation	of	disease	(Helminen	et	al	1993,	Saamanen	et	al	2000).	Similarly,	transgenic	mice	over-expressing	the	matrix	metalloproteinase	MMP-13	display	joint	pathology	similar	to	that	in	OA,	including	damage	to	the	articular	cartilage	and	proteoglycan	loss	(Neuhold	et	al	2001).	However,	mutating	genes	required	for	the	expression	of	crucial	ECM	components	can	cause	other	symptoms	in	the	mice	not	related	to	OA	such	as	a	generally	disturbed	growth	(Helminen	et	al	1993).			There	are	also	naturally	occurring	animal	models	of	OA	where	disease	pathogenesis	develops	in	joints	over	time;	this	has	been	demonstrated	in	aging	guinea	pigs,	mice	and	non-human	primates	(Nordling	et	al	1992,	Carlson	et	al	1996,	Jimenez	et	al	1997).	Histological	changes	similar	to	human	OA	can	be	observed	in	the	joints	of	these	animals	as	they	age	and	these	changes	become	more	severe	as	the	animals	age	(Carlson	et	al	1996,	Jimenez	et	al	1997).	While	naturally	occurring	OA	animal	models	may	most	accurately	represent	the	slowly	progressing	OA	that	is	seen	in	humans,	studying	the	development	of	pathogenesis	and	effectiveness	of	therapeutics	takes	a	long	time	(Bendele	2001).			Finally,	OA	can	be	induced	in	animal	models	through	injecting	enzymes	or	chemicals	into	the	articular	space.	Collagenase	is	an	enzyme	that	functions	to	cleave	collagen,	when	collagenase	was	injected	into	the	knee	of	mice	it	was	found	to	cause	instability	of	the	joint	and	subsequent	OA-like	histological	changes	such	as	cartilage	lesions	and	osteophyte	formation	(van	der	Kraan	et	al	1990).	Additionally	OA	can	be	induced	by	chemically	damaging	the	joint;	an	intrarticular	injection	of	monoiodoacetate	causes	pain-like	behavior	and	destruction	of	articular	cartilage	similar	to	that	observed	in	human	OA	(Kalbhen	1987).	The	animal	model	used	to	represent	knee	OA	in	this	thesis	is	the	monoiodoacetate	(MIA)model.			
5.1.2	The	Monoiodoacetate	(MIA)	model			Monoiodine	acetate	was	first	used	by	Kalbhen	and	Blum	in	hens	to	reduce	the	anabolic	reactions	that	occur	in	articular	cartilage,	an	intrarticular	injection	was	found	to	cause	degeneration	of	joint	cartilage,	and	this	finding	was	extended	to	rats	in	1987	(Kalbhen	
	 172	
and	Blum	1977,	Kalbhen	1987).	Monoiodoacetate	(MIA)	is	a	potent	inhibitor	of	the	activity	of	glyceraldehyde-3-phosphate	dehydrogenase	(GAPDH),	which	is	required	for	glycolysis	(Dunham	et	al	1992,	Clements	et	al	2009).		Glycolysis	is	the	first	key	stage	of	respiration,	and	the	process	used	in	anaerobic	conditions	for	the	cell	to	create	energy.	This	process	allows	cells	to	break	down	glucose	and	produce	ATP	(Engelking	2015).	Therefore,	MIA	prevents	chondrocytes	in	the	articular	cartilage	from	producing	ATP	and	leads	to	their	eventual	cell	death	(Guzman	et	al	2003).	Following	the	loss	of	chondrocytes,	cartilage	erosion	and	a	loss	of	proteoglycan	develop,	and	over	time	this	can	result	in	exposure	of	the	subchondral	bone	(Guzman	et	al	2003).			There	are	many	advantages	to	the	MIA	model,	including	the	lack	of	invasiveness	and	the	simplicity	of	induction,	its	rapid	onset,	the	pain-like	behaviour	that	develops,	and	the	histological	changes	that	occur	in	the	articular	cartilage,	which	are	similar	to	clinical	features	observed	in	human	OA.	The	MIA	model	is	particularly	relevant	for	studying	the	pain	associated	with	OA	as	animals	display	significant	pain	behaviour;	the	animals	develop	sensitivity	at	both	the	knee	joint	and	ipsilateral	hind	paw	as	they	avoid	putting	weight	on	the	injured	limb	and	show	a	decreased	paw	withdrawal	threshold	(Fernihough	et	al	2004,	Ferland	et	al	2011,	Ogbonna	et	al	2013).	Additionally,	micro-CT	and	histology	images	have	confirmed	that	MIA	injected	animals	show	similar	knee	pathology	to	that	observed	in	OA	patients,	with	cartilage	fibrillation,	loss	of	proteoglycan,	osteophyte	formation	and	subchondral	bone	sclerosis	(Guzman	et	al	2003,	Mohan	et	al	2011).	A	further	advantage	of	this	model	is	that	the	dose	of	MIA	injected	into	the	intrarticular	space	can	be	altered	to	modify	the	progression,	severity	of	the	structural	joint	damage	and	the	associated	pain	(Guingamp	et	al	1997,	Schulert	and	McDougall	2009,	Thakur	et	al	2012).	Overall,	the	MIA	model	represents	the	joint	pathology	and	associated	pain	observed	in	human	OA,	and	this	is	the	most	common	method	used	to	model	the	disease	(Little	and	Zaki	2012).			
5.1.2.1	Knee	pathology	in	the	MIA	model	
	The	injection	of	MIA	into	the	articular	space	has	been	shown	to	cause	an	initial	inflammatory	response,	which	is	followed	by	structural	changes	to	the	joint	at	later	time	points	(Clements	et	al	2009).	Various	histological	changes	can	be	observed	in	the	knee	joint	in	both	the	early	inflammatory	phase	and	the	later	chronic	phase,	the	pathological	changes	and	joint	structures	affected	are	dependent	upon	the	dose	of	MIA	used	and	the	chosen	time	point.		
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The	changes	within	the	joint	following	MIA	injection	occur	rapidly.	The	degradation	process	begins	with	an	inhibition	of	glycolysis	and	chondrocyte	degeneration,	and	as	such	proteoglycan	loss	can	be	observed	just	1	day	following	MIA	injection	(Guzman	et	al	2003).	There	is	also	a	significant	increase	in	the	levels	of	monocytes,	neutrophils	and	basophils	1	day	after	the	MIA	injection,	indicating	a	large	inflammatory	infiltrate	(Guzman	et	al	2003,	Clements	et	al	2009).	The	increased	level	of	white	blood	cells	peaks	around	day	3	and	then	begins	to	decline	over	time	(Clements	et	al	2009).		In	addition	to	the	inflammatory	changes	that	occur	in	the	early	stages,	necrosis	of	the	synovial	membrane	and	oedema	of	the	infrapatellar	fat	pad	can	be	observed	3	days	post-MIA	injection	(Guzman	et	al	2003,	Clements	et	al	2009).			At	5	days	post	MIA	injection	histological	changes	in	the	articular	cartilage	can	be	observed,	this	includes	a	collapsed	or	eroded	cartilaginous	matrix	with	extensive	proteoglycan	loss	(Dunham	et	al	1992.	Guzman	et	al	2003,	Mohan	et	al	2011).	Although	the	inflammatory	response	in	the	synovium	is	still	present,	this	has	begun	to	subside	(Guzman	et	al	2003).	The	subchondral	bone	begins	to	show	signs	of	damage	at	7	days	following	a	medium	to	high	dose	MIA	injection,	which	comprises	bone	necrosis	and	an	increased	number	of	osteoclasts	adjacent	to	the	damaged	cartilage	(Guzman	et	al	2003,	Clements	et	al	2009).	Overall	by	day	7-post	MIA	injection	the	significant	loss	of	articular	cartilage	and	damage	to	the	subchondral	bone	begin	to	reflect	the	pathology	observed	in	human	OA.			At	2-weeks	post	MIA	injection	the	cartilage	damage	becomes	more	severe	and	extensive,	while	the	proteoglycan	content	remains	greatly	reduced	(Guingamp	et	al	1997,	Clements	et	al	2009).	Additionally	more	extensive	damage	can	be	observed	in	the	underlying	subchondral	bone,	with	bone	sclerosis	and	areas	of	bone	marrow	lesions	adjacent	to	the	damaged	cartilage	(Guingamp	et	al	1997,	Guzman	et	al	2003).	Micro-CT	imaging	has	identified	that	injected	joints	show	a	significantly	lower	bone	volume	fraction	at	2	weeks	post	injection,	even	with	a	low	dose	of	MIA	(0.2mg)	(Mohan	et	al	2011).	If	the	model	is	continued	further	a	complete	loss	of	cartilage	from	the	bone	surface	is	observed,	coupled	with	extensive	subchondral	bone	remodeling	that	includes	bone	sclerosis	and	even	bone	fragmentation	in	extreme	cases	as	shown	in	Figure	5.1	(Guingamp	et	al	1997,	Guzman	et	al	2003,	Mohan	et	al	2011).	The	joint	pathology	induced	by	an	MIA	injection	worsens	over	time,	with	increasing	severity	in	cartilage	degradation	and	subchondral	bone	damage.		
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Figure	5.1.	Femoro-tibial	joint	28	days	post	1mg	MIA	injection.	The	arrow	indicates	an	extensive	area	of	cartilage	loss,	while	the	subchondral	bone	adjacent	to	this	cartilage	damage	has	begun	to	collapse	and	fragment	and	be	replaced	by	fibrous	tissue.	(Taken	from	Guzman	et	al	2003).		
5.1.2.2	Pain-like	behaviour	in	the	MIA	model		As	the	focus	of	this	thesis	is	the	pain	associated	with	OA	it	is	important	to	use	an	animal	model	that	consistently	develops	OA-like	pain.	Following	MIA	injection	animals	adjust	their	gait	and	shift	their	weight	to	the	uninjured	limb,	this	is	similar	to	patients	who	avoid	using	the	injured	limb	to	minimise	the	associated	pain	(Bove	et	al	2003,	Zeni	and	Higginson	2011).	The	MIA	injection	has	been	demonstrated	to	cause	a	biphasic	shift	in	weight	bearing;	with	the	animals	avoiding	placing	weight	on	the	injured	joint	on	day	3	in	line	with	the	peak	of	inflammation,	the	joint	pain	recovers	slightly	by	day	7	with	animals	applying	more	weight	to	the	injured	limb,	and	weight	bearing	then	declines	again	on	day	14	when	structural	damage	has	developed	in	the	knee	(Bove	et	al	2003,	Thakur	et	al	2012,	Kelly	et	al	2013).	The	alteration	in	weight	bearing	has	been	shown	to	remain	constant	when	the	duration	of	MIA	model	is	extended	to	6	weeks	(Bove	et	al	2003,	Kelly	
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et	al	2013,	Ogbonna	et	al	2015).	Additionally,	the	MIA	injection	has	been	shown	to	increase	movement	evoked	nociception,	as	MIA	animals	have	higher	knee	bend	scores	than	controls	(Ferreira-Gomes	et	al	2008).	Furthermore,	CatWalk	analysis	has	demonstrated	that	MIA	injected	animals	load	less	weight	on	their	injured	limb	when	walking	and	also	show	significant	differences	in	their	dynamic	gait	between	hind	limbs	indicating	the	animals	walk	with	a	well-defined	limp	as	they	are	unwilling	to	place	weight	on	the	injured	limb	(Ferland	et	al	2011,	Ferreira-Gomes	et	al	2008).	These	finding	indicate	that	the	MIA	model	accurately	mimics	the	clinical	joint	pain	experienced	by	patients,	as	3D	walking	analysis	has	demonstrated	that	patients	with	knee	OA	reduce	knee	joint	contribution	when	walking	(Zeni	and	Higginson	2011).			In	addition	to	sensitivity	within	the	joint	the	animals	also	develop	secondary	mechanical	hyperalgesia	and	tactile	allodynia	on	the	ipsilateral	hind	paw.	The	MIA	injection	induces	mechanical	hypersensitivity,	as	demonstrated	by	a	reduction	in	paw	withdrawal	threshold	to	mechanical	stimulation,	which	occurs	around	3	days	post	MIA-injection	depending	upon	the	dose,	the	paw	withdrawal	threshold	then	declines	further	at	approximately	14	days	and	this	is	sustained	for	4	weeks	(Ogbonna	et	al	2013,	Pitcher	et	al	2016).	This	secondary	hypersensitivity	may	represent	the	referred	pain	that	develops	in	many	OA	patients,	indicating	the	MIA	model	may	prove	a	useful	model	for	analyzing	the	involvement	of	central	changes	and	testing	the	effectiveness	of	analgesics	(Kean	et	al	2004,	Graven-Nielsen	2006,	Gwilym	et	al	2009).			
5.1.2.3	Electrophysiology	in	the	MIA	model	
	One	mechanism	involved	in	the	development	of	joint	pain	is	peripheral	sensitisation	where	there	is	increased	activity	of	primary	afferent	fibres	(See	Section	1.1.4).	Electrophysiological	recordings	have	indicated	that	knee	joint	afferents	become	sensitised	following	MIA	injection	(Schuelert	and	McDougall	2006,	Schuelert	and	McDougall	2009,	Schuelert	and	McDougall	2012,	Kelly	et	al	2012).	Schuelert	and	McDougall	have	demonstrated	that	MIA	induces	a	dose-dependent	increase	in	both	spontaneous	joint	afferent	firing	frequency	and	evoked	joint	afferent	activity	in	response	to	normal	and	noxious	hyper-rotation	of	the	knee	joint	(Schuelert	and	McDougall	2006,	Schuelert	and	McDougall	2009,	Schuelert	and	McDougall	2012).	Furthermore,	the	authors	found	that	the	enhanced	activity	of	knee	joint	afferents	could	be	significantly	reduced	by	NSAIDs,	a	neuropeptide	antagonist,	and	a	Nav1.8	channel	blocker,	indicating	this	may	be	a	model	for	analyzing	the	effectiveness	of	analgesics	
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(Schuelert	and	McDougall	2006,	Schuelert	and	McDougall	2009,	Schuelert	and	McDougall	2012).	Furthermore,	it	was	demonstrated	that	A	fibres	specifically	exhibit	an	increased	spontaneous	firing	rate	while	C	fibres	show	an	increased	evoked	firing	frequency	to	mechanical	stimulation	(Kelly	et	al	2012).	This	may	indicate	that	peripheral	A	fibre	joint	afferents	are	responsible	for	spontaneous	pain	at	rest	while	C	fibres	contribute	to	the	increased	pain	response	upon	movement,	both	of	which	are	clinical	features	reported	by	OA	patients	(Kelly	et	al	2012).	These	two	distinct	physiological	mechanisms	may	combine	to	produce	a	barrage	of	peripheral	input	resulting	in	spontaneous	and	evoked	joint	pain	and	potentially	leading	to	the	development	of	central	sensitization	(Woolf	2011).			Electrophysiological	recordings	taken	from	spinal	neurons	in	the	dorsal	horn,	which	are	responsible	for	transmitting	the	nociceptive	signal	from	the	periphery	to	the	brain,	have	also	demonstrated	enhanced	firing	rates	in	MIA	animals	indicative	of	central	sensitization	(Rahman	et	al	2009,	Harvey	and	Dickenson	2009,	Sagar	et	al	2010,	Burnham	and	Dickenson	2013).	While	most	of	these	studies	found	that	WDR	neurons	had	an	increased	firing	rate	in	response	to	mechanical	stimulations	in	the	noxious	range,	Sagar	et	al	found	an	increased	WDR	neuronal	response	to	innocuous	mechanical	stimulation	only	(Rahman	et	al	2009,	Harvey	and	Dickenson	2009,	Sagar	et	al	2010,	Burnham	and	Dickenson	2013).	Additionally,	enhanced	WDR	neuronal	responses	have	been	demonstrated	in	response	to	thermal	stimulations	in	the	noxious	range	(Rahman	et	al	2009,	Burnham	and	Dickenson	2013).	This	conflicts	with	an	MIA	study	in	mice	by	Harvey	and	Dickenson	where	thermally	evoked	WDR	neuronal	responses	were	not	significantly	different	from	shams	and	no	thermal	hypersensitivity	was	detected	behaviourally	(Harvey	and	Dickenson	2013).	Furthermore,	two	thesis’s	produced	by	the	lab	reported	no	alteration	in	either	the	mechanically	or	thermally	evoked	responses	of	WDR	neurons	located	in	the	deep	dorsal	horn	between	MIA	and	Sham	groups	(Thakur	2012,	Patel	2012).	Finally,	it	has	been	reported	that	WDR	neurons	receiving	input	from	both	the	knee	and	hind	paw	in	MIA	animals	have	an	enhanced	spontaneous	firing	rate	compared	to	Shams	(McGaraughty	et	al	2010,	Chu	et	al	2011).	The	lack	of	thermal	hypersensitivity	in	this	model	is	in	agreement	with	clinical	findings,	a	study	using	quantitative	sensory	testing	(QST)	in	patients	with	chronic	knee	OA	showed	that	only	7%	of	patients	displayed	thermal	hyperalgesia	while	37%	of	patients	displayed	mechanical	hyperalgesia,	the	authors	subsequently	used	mechanical	hyperalegsia	as	a	marker	to	define	central	sensitization	in	patients	yet	did	not	use	thermal	hyperalgesia	(Hochman	et	al	2013).	While	the	contrasting	electrophysiological	observations	in	MIA	
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animals	are	difficult	to	explain	and	may	come	down	to	inter-experimenter	differences,	they	do	represent	the	variability	in	clinical	pain	symptoms	found	in	OA	patients	(Gwilym	et	al	2009).			A	further	clinical	feature	of	central	sensitisation	in	OA	patients	is	the	development	of	referred	pain	distant	to	the	site	of	joint	damage	(Bajaj	et	al	2001,	Gwilym	et	al	2009).	WDR	spinal	neurons	in	animal	models	of	both	chronic	neuropathy	and	inflammation	have	demonstrated	significantly	expanded	receptive	fields	from	the	hind	paw	(Neugebauer	et	al	1993,	Chu	et	al	2004).	In	MIA	animals,	WDR	neurons	receiving	input	from	the	knee	showed	an	expansion	in	the	peripheral	receptive	field	of	the	knee	following	an	intra-articular	injection	of	NGF,	a	neurotrophin	implicated	in	the	inflammatory	component	and	development	of	chronic	pain	in	OA	(Sagar	et	al	2015).	The	expansion	of	the	receptive	field	means	second	order	neurons	in	the	spinal	cord	now	receive	input	from	a	wider	array	of	afferent	fibres	and	will	subsequently	produce	an	increased	response	to	peripheral	stimulation,	this	indicates	the	involvement	of	central	plasticity	contributing	to	hypersensitivity	(Graven-Neilsen	2006).			Taken	together	these	electrophysiological	findings	indicate	that	the	initial	peripheral	damage	and	enhanced	activity	of	afferent	fibres	produces	a	barrage	of	nociceptive	signaling	to	second	order	spinal	neurons,	which	may	drive	the	increased	activity	of	central	neurons	and	the	development	of	central	sensitisation.	Therefore,	the	spontaneous	and	movement-evoked	chronic	pain	profile	observed	in	MIA	animals	may	be	due	to	a	combination	of	both	peripheral	and	central	hypersensitivity.			
5.1.2.4	Descending	controls	in	the	MIA	model			Many	patients	are	left	with	persistent	pain	even	following	total	joint	replacement	surgery,	indicating	that	pain	remains	even	when	the	peripheral	nociceptive	input	is	removed	(Wylde	et	al	2011).	An	alteration	in	descending	controls	and	supraspinal	systems,	together	with	central	sensitisation	and	the	development	of	referred	pain	may	be	responsible	for	this	persistent	pain.	Indeed,	a	clinical	study	using	fMRI	identified	an	abnormal	descending	system	from	the	PAG	to	the	spinal	cord	in	patients	with	hip	OA	and	referred	pain	(Gwilym	et	al	2009).	An	adaptive	descending	system	has	also	been	identified	in	the	MIA	model	(Rahman	et	al	2009,	Li	et	al	2011,	Burnham	and	Dickenson	2013).	Firstly,	Rahman	and	colleagues	found	that	a	5-HT3	receptor	antagonist	inhibited	evoked	responses	to	innocuous	stimuli	yet	did	not	produce	this	effect	in	Sham	controls,	
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indicating	an	alteration	in	the	faciliatorty	serotonergic	system	acting	at	5-HT3	receptors	in	the	spinal	cord	was	modulating	low	threshold	neuronal	responses	(Rahman	et	al	2009).	Meanwhile,	Li	and	colleagues	found	a	5-HT2A/C	receptor	antagonist	blocked	the	analgesic	effect	of	electroacupuncture	in	MIA	animals,	and	suggested	that	electroacupunture	mediated	its	inhibitory	effect	by	activating	serotonergic	neurons	in	the	NRM,	which	projected	to	the	spinal	cord	and	activated	5-HT2	receptors	(Li	et	al	2011).	These	contrasting	serotonergic	findings	further	suggest	that	the	adaptive	serotonergic	system	can	switch	from	an	antinocicieptove	to	pronociceptive	role	depending	upon	which	receptors	are	activated	in	the	spinal	cord.	Furthermore,	a	reduced	inhibitory	noradrenergic	descending	system	has	been	demonstrated	in	MIA	animals	(Burnham	and	Dickenson	2013).	As	a	subset	of	OA	patients	have	displayed	reduced	descending	inhibition	and	an	alteration	in	descending	systems	from	the	brainstem,	similar	alterations	in	the	MIA	model	suggest	this	may	prove	a	useful	tool	for	assessing	the	effectiveness	of	therapeutics	that	act	to	modulate	the	endogenous	descending	system	(Gwilym	et	al	2009,	Ardendt-Nielson	et	al	2010).			
5.1.3	Chapter	aims	
	This	chapter	will	use	both	behavioural	and	histological	techniques	to	validate	the	2mg	MIA	model	in	the	rat.	Furthermore,	the	alteration	in	descending	facilitatory	and	inhibitory	systems	shall	be	investigated	through	assessing	DNIC	in	the	MIA	model.	As	variations	in	the	activity	of	inhibitory	and	faciliatory	pathways	have	been	demonstrated	over	the	course	of	the	MIA	model,	DNIC	shall	be	investigated	in	both	the	early	inflammatory	phase	and	late	chronic	phase	of	the	model	(Burnham	and	Dickenson	2013).												
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5.2	Methods	
	
5.2.1	Electrophysiology		Electrophysiological	recordings	were	taken	as	previously	described	(See	Section	2.1);	in	early	phase	animals	this	was	2-6	days	post	MIA	injection,	and	for	late	phase	animals	this	was	14-20	days	post	MIA	injection.	Extracellular	recordings	were	taken	from	WDR	neurons	both	ipsilateral	and	contralateral	to	MIA	injection.		
	
	
5.2.1.1	Characterisation	of	DNIC	expression	in	WDR	neurons	in	early	and	late	
Phase	MIA	animals	
	In	MIA	injected	and	saline	injected	Sham	animals,	WDR	neurons	were	found	in	both	the	ipsilateral	and	contralateral	deep	dorsal	horn	relative	to	injection,	and	the	DNIC	response	was	characterized.	The	receptive	field	was	mechanically	stimulated	with	von	Frey	hairs	of	increasing	intensity:	8g,	26g	and	60g,	this	was	repeated	3	times	to	obtain	an	average	pre-conditioned	response.	DNIC	was	then	induced	with	a	concurrent	noxious	ear	pinch	as	the	receptive	field	was	mechanically	stimulated	with	the	von	Frey	hairs	of	increasing	intensity.	For	this	study	DNIC	was	also	induced	with	a	concurrent	noxious	knee	pinch.	For	the	noxious	knee	pinch	a	metal	clamp	was	used	that	was	wrapped	around	the	knee	and	the	two	sides	were	pushed	together,	the	clamp	was	set	to	always	pinch	at	0.75cm.	Both	the	MIA	injected	knee	and	the	contralateral	uninjured	knee	received	a	concurrent	noxious	pinch.	Therefore,	one	DNIC	trial	consists	of	3	pre-conditioned	mechanically	evoked	responses,	1	mechanically	evoked	response	with	concurrent	noxious	ear	pinch,	1	mechanically	evoked	response	with	concurrent	ipsilateral	noxious	knee	pinch	and	1	mechanically	evoked	response	with	a	concurrent	contralateral	noxious	knee	pinch.	Each	characterization	consisted	of	2	DNIC	trials	and	the	mean	of	these	two	trials	was	taken	for	the	pre-conditioned	and	DNIC	responses.			
5.2.2	Behavioural	assessment		Both	paw	withdrawal	thresholds	and	weight	bearing	between	the	animals	hind	paws	were	assessed	as	described	in	Section	2.4.		
5.2.3	Knee	Histology	Knee	histology	was	carried	out	in	early	phase	MIA	animals	and	saline	injected	sham	controls,	where	the	knee	was	taken	on	day	4	post-injection.	Knee	histology	was	carried	
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out	in	late	phase	MIA	animals	and	saline	injected	sham	controls,	where	the	knee	was	taken	on	day	14	post-injection.	The	tissue	was	processed	as	discussed	in	Section	2.5.		
5.2.4	Quantitative	Polymerase	Chain	Reaction	The	ipsilateral	lumbar	dorsal	horn	and	ipsilateral	L3-L5	DRGs	were	taken	from	MIA	and	sham	animals.	For	early	phase	MIA	and	sham	animals	the	tissue	was	taken	4	days	post-injection.	For	late	phase	MIA	and	sham	animals	the	tissue	was	taken	14	days	post-injection.	The	tissue	was	processed	as	discussed	in	Section	2.7.		
5.2.3	Statistical	analysis	For	a	description	of	the	statistical	tests	used	for	analysis	please	refer	to	section	2.8.			
							
	
	
	
	
	
	
	
	
	
	
	
	 181	
5.3	Results	
	
5.3.1	Pain-like	behaviour	in	the	MIA	model		Pain-like	behaviour	was	assessed	by	testing	for	puncate	mechanical	hypersensitivity	and	incapacitance	in	MIA-injected	rats	and	compared	to	Sham	controls.	Both	groups	of	MIA	injected	animals,	the	early	inflammatory	phase	and	late	chronic	phase,	developed	mechanical	hypersensitivity	on	the	ipsilateral	hind	paw	and	avoided	putting	weight	on	the	injured	limb.			Early	phase	MIA-injected	animals	demonstrated	a	significant	reduction	of	weight	borne	on	the	MIA	injected	limb,	such	that	on	day	2	they	only	placed	28.17%	±	2.7%	and	on	day	4	they	only	placed	35.35%	±	2.14%	of	their	distributed	weight	between	the	two	hind	limbs	on	the	injured	paw	(Figure	5.2A).	On	day	2	the	early	phase	MIA-injected	animals	placed	significantly	less	weight	on	the	injured	limb	compared	to	saline-injected	sham	controls	at	the	same	time	point.	Although	the	weight	placed	on	the	hind	paw	by	early	phase	MIA-injected	animals	was	reduced	at	day	4	compared	to	saline-injected	shams	this	did	not	reach	significance	(Figure	5.2C).	Late	phase	MIA-injected	animals	also	demonstrated	a	significant	reduction	in	the	weight	placed	on	the	MIA	injected	limb.	MIA-injected	animals	in	the	late	phase	group	placed	24.54%	±	2.72%,	32.34%	±	2.28%,	33.5%	±	1.85%,	32.34%	±	2.31%	of	their	weight	on	the	injured	limb	on	day	2,	4,	7	and	14	respectively	(Figure	5.2D).	At	all	time	points,	other	than	on	day	4,	the	MIA-injected	animals	in	the	late	phase	group	placed	a	significantly	reduced	amount	of	weight	on	the	injured	limb	compared	to	saline-injected	sham	controls	at	the	same	time	points	(Figure	5.2F).			To	begin	with,	testing	how	often	the	rat	withdrew	its	paw	to	a	specific	von	Frey	hair	out	of	5	trials	was	the	method	used	for	assessing	punctate	mechanical	hypersensitivity,	and	the	paw	withdrawal	threshold	was	determined	as	the	point	at	which	the	animal	withdrew	5	times.	This	test	revealed	that	early	phase	MIA	animals	had	a	significantly	reduced	paw	withdrawal	threshold	on	the	ipsilateral	paw	at	day	2	compared	to	saline-injected	sham	controls	(Figure	5.3A).	While	the	early	phase	MIA	animals	withdrew	more	frequently	to	2g,	8g,	and	15g	von	Frey	hairs	compared	to	saline-injected	sham	controls,	this	was	only	significant	for	2g	on	day	2	and	15g	on	day	2	and	4	(Figure	5.3C	and	5.3G).	The	up-down	method	was	also	used	to	assess	any	changes	in	the	paw	withdrawal	thresholds,	this	test	revealed	that	early	phase	MIA	animals	had	a	significantly	reduced	
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paw	withdrawal	threshold	on	the	ipsilateral	paw	at	day	2	compared	to	saline-injected	sham	controls.	Both	tests	indicate	that	early	phase	MIA	animals	develop	mechanical	hypersensitivity	at	day	2	but	recover	slightly	around	day	4.	No	mechanical	hypersensitivity	was	observed	in	the	contralateral	hind	paw	in	early	phase	MIA	or	Sham	animals	with	either	behavioural	method	used	(Figure	5.3).			
	
Figure	5.2.	Weight	bearing	in	early	phase	and	late	phase	MIA-injected	animals	compared	
to	saline-injected	sham	controls.	A)	Early	phase	MIA-injected	animals	placed	significantly	less	weight	on	the	injured	joint	(n=15).	B)	Saline-injected	sham	controls	consistently	placed	similar	
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amounts	of	weight	on	both	hind	paws	(n=12).	C)	Early	phase	MIA	injected	animals	placed	less	weight	on	the	ipsilateral	paw	compared	to	saline-injected	sham	controls	and	this	was	significant	at	day	2.	D)	MIA-injected	animals	in	the	late	phase	groups	placed	significantly	less	weight	on	the	injured	joint	at	every	time	point	other	than	day	4	(n=14).	E)	Saline-injected	sham	controls	consistently	placed	similar	amounts	of	weight	on	both	hind	paws	at	the	same	times	points	tested	for	late	phase	animals	(n=14).	E)	MIA-injected	animals	in	the	late	phase	group	placed	significantly	less	weight	on	the	ipsilateral	hind	paw	compared	to	saline-injected	sham	controls	at	all	time	points	tested.	A	Friedmans	two-way	ANOVA	by	ranks	test	was	used	to	assess	significant	differences	in	weights	placed	between	hind	paws.	A	Kruskal-Wallis	independent	samples	one-way	Anova	was	used	to	assess	significant	differences	in	weight	placed	on	the	ipsilatral	paw	between	MIA-injected	animals	and	saline-injected	sham	controls.	*P<0.05,	**P<0.01.				Behavioural	tests	were	also	used	to	assess	the	development	of	mechanical	hypersensitivity	in	late	phase	MIA	animals	and	saline-injected	sham	controls.	The	paw	withdrawal	threshold	determined	by	the	animal	withdrawing	5	times	demonstrated	that	MIA	injected	animals	have	a	significantly	reduced	paw	withdrawal	threshold	at	days	2,	4	and	14	(Figure	5.4A).	The	MIA	injected	animals	in	the	late	phase	group	withdrew	more	frequently	to	the	2g	vonFrey	hair	compared	to	saline-injected	controls	and	this	was	significant	on	day	2	and	14	(Figure	5.4C),	significantly	more	frequently	to	the	8g	vonFrey	hair	compared	to	saline-injected	controls	on	day	2,	4	and	14	(Figure	5.4E),	and	significantly	more	frequently	to	the	15g	vonFrey	hair	compared	to	saline-injected	controls	on	day	4,	7	and	14	(Figure	5.4G).	The	up-down	method	also	indicated	that	MIA	injected	animals	develop	mechanical	hypersensitivity	as	they	had	a	significantly	reduced	paw	withdrawal	threshold	compared	to	saline-injected	sham	controls	at	all	time	points	tested	(Figure	5.4I).	Taken	together	these	results	indicated	that	the	MIA	animals	in	the	late	phase	group	developed	bi-phasic	mechanical	hypersensitivity	on	the	paw	ipsilateral	to	injection.	The	data	demonstrate	that	mechanical	hypersensitivity	becomes	apparent	by	day	2,	appears	to	recover	slightly	around	day	4	and	7	as	paw	withdrawal	threshold	increases	and	paw	withdrawal	frequency	decreases	although	for	some	tests	and	von	Frey	hairs	tested	there	is	still	a	statistically	significant	difference	between	MIA	injected	animals	and	saline-injected	controls	at	these	time	points,	and	then	all	tests	indicate	mechanical	hypersensitivity	returns	again	at	day	14.	Similarly	to	early	phase	animals	there	is	no	mechanical	hypersensitivity	observed	on	the	contralateral	paw	with	any	of	the	behavioural	methods	tested	(Figure	5.4).		
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Figure	5.3.	Mechanical	hypersensitivity	in	early	phase	MIA	animals.	A)	The	paw	withdrawal	threshold	was	determined	by	the	animal	withdrawal	withdrawing	5	times	to	that	von	Frey	hair.	This	method	indicates	that	early	phase	MIA	animals	have	a	significantly	reduced	withdrawal	threshold	on	the	ipsilateral	paw	to	injection	on	day	2	(EP	n=16,	EPS	n=12).	B)	The	MIA-injected	animals	and	saline-injected	sham	controls	displayed	no	significant	changes	in	their	withdrawal	threshold	on	the	contralateral	hind	paw.	C)	The	MIA-injected	animals	withdraw	their	paw	more	frequently	to	a	2g	von	Frey	hair,	this	is	significant	at	day	2.	D)	There	is	no	significant	difference	in	the	number	of	withdrawals	on	the	contralateral	hind	paw	between	MIA-injected	and	saline	injected	animals.	E)	The	MIA	injected	animals	withdraw	more	frequently	to	an	8g	von	Frey	hair	yet	this	is	not	significant.	F)	There	is	no	significant	difference	in	the	number	of	withdrawals	on	the	contralateral	hind	paw	between	MIA	injected	animals	and	saline	injected	sham	controls.	G)	There	is	a	significant	increase	in	the	number	of	withdrawals	to	a	15g	von	Frey	hair	in	the	MIA	injected	animals	on	day	2	and	day	4	compared	to	saline	injected	sham	controls.	H)	There	is	no	significant	difference	in	the	number	of	withdrawals	with	the	hind	paw	contralateral	to	injection	between	MIA	injected	animals	and	saline	injected	sham	controls.	I)	The	up-down	method	for	assessing	mechanical	hypersensitivity	demonstrates	that	early	phase	MIA	injected	animals	have	a	significantly	reduced	paw	withdrawal	threshold	on	day	2	compared	to	saline	injected	sham	controls	(EP	n=10,	EPS	n=10).	J)	The	up-down	method	also	shows	that	no	mechanical	hypersensitivity	develops	in	the	contralateral	paw	to	injection	as	there	is	no	significant	difference	in	the	paw	withdrawal	threshold	between	MIA	injected	animals	and	saline	injected	sham	controls.	Kruskall-wallis	independent	samples	one-way	ANOVA.	*P<0.05,	**P<0.01,	***P<0.001.			
5.3.2	Histology	in	the	MIA	model	
	Knee	histology	was	performed	to	assess	any	damage	to	the	cartilage	in	the	knee	caused	by	the	MIA	injection.	The	maximum	knee	histology	score	represents	the	point	of	greatest	damage	while	the	maximum	per	slide	average	score	represents	the	cartilage	damage	throughout	the	knee.	Both	of	these	scoring	methods	demonstrate	that	that	cartilage	in	the	MIA	injected	animals	in	the	late	phase	group	was	significantly	damaged	compared	to	saline-injected	controls	(Figure	5.5A,	5.5B	and	5.5D).	Remarkably	MIA	injected	animals	in	the	early	phase	group	displayed	very	little	cartilage	damage,	in	fact	there	was	no	significant	difference	in	knee	scores	between	early	phase	MIA	animals	and	early	phase	sham	animals	with	either	scoring	method	(Figure	5.5A,	5.5B	and	5.5C).	There	was	little	to	no	damage	in	the	cartilage	of	early	phase	and	late	phase	saline-injected	sham	controls	(Figure	5.5E	and	Figure	5.5F).	There	was	no	significant	difference	in	the	level	of	cartilage	damage	between	the	four	knee	condyles	in	either	early	phase	or	late	phase	MIA	injected	animals,	suggesting	the	MIA	is	evenly	dispersed	through	the	intrarticular	space	(Figure	5.5G	and	5.5H).	These	results	indicate	that	the	early	phase	MIA	injected	animals	may	not	accurately	represent	the	knee	pathology	of	osteoarthritis,	while	the	late	phase	MIA	injected	animals	display	a	significant	destruction	of	cartilage	similar	to	that	observed	in	patients.				
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Figure	5.4.	Mechanical	hypersensitivity	in	late	phase	MIA	animals.	A)	The	paw	withdrawal	threshold	was	determined	by	the	animals	withdrawing	5	times	to	a	specific	vonFrey	hair.	This	behaviour	method	demonstrates	that	MIA	injected	animals	develop	a	significantly	reduced	paw	withdrawal	threshold	at	the	ipsilateral	hind	paw	to	injection	on	day	2	and	day	14	post-injection	compared	to	saline	injected	sham	controls	(LP	n=20,	LPS	n=15).	B)	There	was	no	change	in	paw	withdrawal	threshold	on	the	contralateral	hind	paw	between	MIA	injected	animals	and	saline	injected	sham	controls.	C)	The	MIA	injected	animals	withdrew	their	ipsilateral	hind	paw	to	the	2g	von	Frey	hair	significantly	more	times	at	day	2	and	day	14.	D)	There	is	no	change	in	the	number	of	withdrawals	to	2g	on	the	contralateral	hind	paw.	E)	The	MIA	injected	animals	withdraw	the	ipsilateral	hind	paw	to	an	8g	von	Frey	hair	more	frequently	on	day	2,	4	and	14	compared	to	saline	injected	sham	controls.	F)	There	was	no	change	in	the	number	of	withdrawals	to	an	8g	von	Frey	hair	on	the	contralateral	hind	paw	to	injection	in	either	MIA	injected	animals	or	saline	injected	sham	controls.	G)	The	MIA	injected	animals	withdrew	their	ipsilateral	hind	paw	significantly	more	frequently	to	a	15g	von	Frey	hair	at	all	time	points	compared	to	saline	injected	controls.	H)	There	is	no	change	in	the	number	of	withdrawals	to	a	15g	von	Frey	hair	on	the	contralateral	hind	paw	to	injection	in	either	MIA	injected	animals	or	saline	injected	sham	controls.	I)	The	up-down	method	to	assess	mechanical	hypersensitivity	demonstrates	that	MIA	injected	animals	develop	a	significantly	reduced	paw	withdrawal	threshold	at	all	time	points	tested	following	injection	compared	to	saline	injected	sham	controls	(LP	n=10,	LPS	n=13).	J)	The	up-down	method	demonstrated	there	was	no	significant	difference	in	the	paw	withdrawal	threshold	of	the	contralateral	hind	paw	to	injection	following	MIA	or	saline	injection.	Kruskal-wallis	independent	samples	one-way	ANOVA.	*P<0.05,	**P<0.01,	***P<0.001.		
	
5.3.3	Correlation	between	cartilage	damage	and	pain-like	behaviour	in	late	
phase	MIA	animals	
	The	MIA	model	has	faced	criticism	that	while	it	represents	the	symptoms	associated	with	the	development	of	OA,	especially	pain,	it	may	not	accurately	model	the	structural	changes	that	occur	within	the	human	joint	(Little	and	Zaki	2012).	It	has	also	been	suggested	that	aspects	of	the	pain	phenotype	may	be	attributed	to	the	neurotoxicity	of	the	MIA	destroying	other	tissues	surrounding	the	joint	(Thakur	et	al	2012,	Malfait	et	al	2013).	The	results	from	early	phase	MIA	animals	agree	with	this	concept	as	rats	development	significant	pain-like	behaviour	despite	the	absence	of	any	joint	pathology	(Figure	5.5).	However,	significant	cartilage	destruction	was	observed	in	late	phase	MIA	animals,	and	a	correlation	between	the	level	of	cartilage	damage	and	the	pain-like	behaviour	on	day	14	was	assessed.	A	negative	correlation	exists	between	knee	scores	and	weight	bearing	such	that	the	less	weight	placed	on	the	ipsilateral	paw	the	higher	knee	histology	score	was	observed	(Figure	5.6A	and	B).	The	correlation	was	only	significant	for	weight	bearing	v	maximum	average	knee	histology	score	suggesting	the	more	cartilage	damage	that	occurred	throughout	the	entire	joint	the	more	animals	avoided	placing	weight	on	that	limb	(Figure	5.6B).	There	was	also	a	negative	correlation	between	knee	histology	scores	and	paw	withdrawal	thresholds	such	that	animals	with	lower	paw	withdrawal	thresholds	had	higher	knee	scores,	suggesting	increased	mechanical	hypersensitivity	developed	on	the	ipsilateral	hind	paw	on	day	14	when	there	was	extensive	cartilage	damage	(Figure	5.6C	and	D).		
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Figure	5.5.	Knee	histology	in	MIA	animals.	A)	For	maximum	knee	histology	score	the	maximum	score	from	each	knee	was	selected.	MIA	injected	animals	in	the	early	phase	group	do	not	demonstrate	damaged	cartilage	compared	to	saline	injected	sham	controls,	while	MIA	
	 189	
injected	animals	in	the	late	phase	group	had	significantly	degraded	cartilage	compared	to	saline-injected	sham	controls.	B)	For	the	max	per	slide	average	score	the	highest	score	on	every	fourth	slide	was	taken	and	averaged	to	obtain	the	level	of	cartilage	damage	throughout	the	knee.	This	scoring	system	demonstrated	no	significant	cartilage	damage	between	early	phase	MIA	injected	animals	and	saline	injected	sham	controls.	Meanwhile,	the	MIA	injected	animals	in	the	late	phase	group	had	significantly	damaged	cartilage	throughout	the	knee	compared	to	the	saline	injected	controls.	C)	An	example	image	taken	from	knee	histology	from	an	early	phase	MIA	injected	animal,	this	demonstrates	that	little	cartilage	damage	can	be	observed.	D)	Knee	histology	from	a	late	phase	MIA	injected	animal,	this	demonstrates	extensive	cartilage	damage	on	two	condyles	such	that	most	of	the	cartilage	has	been	degraded	and	subchondral	bone	is	almost	exposed.	E)	Knee	histology	from	a	saline	injected	sham	control	taken	at	the	same	time	point	as	early	phase	animals,	this	demonstrates	that	no	cartilage	damage	can	be	observed.	F)	Knee	histology	from	a	saline	injected	sham	control	taken	at	the	same	time	point	as	late	phase	animals,	this	demonstrates	a	lack	of	cartilage	damage	in	these	animals.	G)	The	average	histology	scores	on	each	condyle	in	early	phase	MIA	injected	animals	show	no	significant	difference	in	the	damage	of	any	condyles.	H)	The	average	histology	scores	per	condyle	from	late	phase	MIA	injected	animals	show	there	is	no	significant	damage	between	the	level	of	cartilage	damage	on	each	condyle.	A	Kruskall-wallis	independent	samples	one-way	ANOVA	was	used	to	test	significance	differences	in	knee	scores	between	groups.	A	Friedmans	two-way	ANOVA	by	ranks	was	used	to	test	for	significant	differences	in	knee	scores	between	condyles.	**P<0.01.	(EP	n=6,	EPS	n=6,	LP	n=9,	LPS	n=5).			
	
Figure	5.6	Correlation	between	cartilage	damage	and	pain-like	behaviour	in	late	phase	
MIA	animals.	A)	Late	phase	MIA	animals	with	higher	maximum	knee	histology	schools	put	less	weight	on	the	ipsilateral	hind	limb,	but	this	correlation	does	not	reach	significance	(n=9)	B)	There	is	a	significant	negative	correlation	between	the	average	knee	histology	score	and	weight	placed	on	the	ipsilateral	hind	paw	in	late	phase	MIA	injected	animals	(n=9).	C)	Late	phase	MIA	animals	with	higher	maximum	knee	histology	score	have	reduced	paw	withdrawal	thresholds	but	this	correlation	is	not	significant	(n=9).	D)	Late	phase	MIA	injected	animals	with	higher	
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average	knee	scores	have	lower	paw	withdrawal	thresholds	but	this	correlation	is	not	significant	(n=9).	Linear	regression	analysis	was	performed	to	assess	correlation,	R2	value	represent	strength	of	relationship	and	P	value	calculated	from	an	F-test	of	overall	significance.	A:	p=0.1219,	B:	p=0.0253,	C:	p=0.1086,	D:	p=0.1420.		
	
5.3.4	Electrophysiology	in	the	MIA	model		
	Electrophysiological	recordings	were	than	taken	from	WDR	neurons	located	in	the	deep	dorsal	horn	receiving	input	from	the	hind	paw	ipsilateral	to	the	MIA	injection.	The	hind	paw	was	stimulated	mechanically	with	both	innocuous	and	noxious	von	Frey	hairs	of	increasing	bending	force.	The	mechanically	evoked	firing	rates	were	not	significantly	enhanced	in	MIA	injected	animals	in	either	the	early	or	late	phase	groups	compared	to	saline	injected	sham	controls	(Figure	5.7).			
	
Figure	5.7.	The	mechanically	evoked	neuronal	responses	in	early	and	late	phase	MIA	
animals	compared	to	saline	injected	sham	controls.	There	is	no	significant	difference	between	the	mechanically	evoked	WDR	neuronal	responses	between	MIA	and	Sham	animals	in	response	to	8g	(A),	26g	(B),	and	60g	(C)	von	Frey	hair	stimulation	of	the	hind	paw.	(Early	phase	MIA	n=19,	Early	phase	sham	n=16,	Late	phase	MIA	n=41,	Late	phase	sham	n=27).	One-way	ANOVA	with	Bonferroni	post-hoc	test.		
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5.3.5	Expression	of	Diffuse	Noxious	Inhibitory	Controls	in	the	MIA	model	
	Throughout	this	chapter	DNIC	was	induced	by	a	concurrent	noxious	ear	pinch	ipsilateral	to	the	WDR	neuron	being	recorded	and	by	a	concurrent	noxious	knee	pinch.	The	concurrent	noxious	ear	pinch	produced	a	significant	inhibition	of	neuronal	firing	in	early	phase	MIA	injected	animals	and	saline	injected	sham	controls.	The	level	of	neuronal	inhibition	produced	with	noxious	ear	pinch	in	early	phase	MIA	animals	was	44%,	31%,	and	33%	for	8g,	26g,	and	60g	respectively	(Figure	5.8A),	while	the	level	of	neuronal	inhibition	produced	by	noxious	ear	pinch	in	early	phase	sham	animals	was	48%,	31%,	and	30%	for	8g,	26g,	and	60g	respectively	(Figure	5.8D).	A	concurrent	noxious	pinch	placed	on	the	injected	knee	produced	a	significant	reduction	of	neuronal	firing	in	early	phase	MIA	and	saline	injected	controls.	The	level	of	neuronal	inhibition	produced	by	the	concurrent	noxious	knee	pinch	in	early	phase	MIA	animals	was	54%,	34%,	and	41%,	for	8g,	26g,	and	60g	respectively	(Figure	5.8A),	while	the	level	of	neuronal	inhibition	produced	by	a	concurrent	noxious	knee	pinch	in	early	phase	sham	animals	was	51%,	39%,	and	38%	for	8g,	26g,	and	60g	respectively	(Figure	5.8D).	There	was	a	significant	difference	between	pre-conditioned	neuronal	firing	rates	and	neuronal	firing	rates	with	concurrent	noxious	ear	and	knee	pinch	in	both	early	phase	MIA	and	sham	animals	at	all	von	Frey	weights	tested.	Furthermore,	the	level	of	inhibition	produced	by	the	concurrent	noxious	ear	pinch	and	concurrent	noxious	knee	pinch	were	comparable	between	early	phase	MIA	and	sham	animals.			Electrophysiological	recordings	were	also	taken	from	WDR	neurons	in	the	contralateral	dorsal	horn	to	injection	and	the	expression	of	DNIC	was	investigated	with	a	concurrent	noxious	ear	pinch	and	a	concurrent	noxious	knee	pinch	placed	on	both	the	injected	and	uninjured	knee.	While	all	of	these	methods	produced	an	inhibition	on	neuronal	firing	in	both	early	phase	MIA	and	sham	animals,	this	was	only	significant	with	a	concurrent	noxious	ear	pinch	with	the	mechanical	stimulation	of	26g	and	60g	in	early	phase	MIA	animals	(Figure	5.8B),	and	with	a	concurrent	noxious	knee	pinch	on	the	uninjured	knee	with	the	mechanical	stimulation	of	60g	in	sham	animals	(Figure	5.8E).	With	a	concurrent	noxious	ear	pinch	the	level	of	inhibition	on	neuronal	firing	in	early	phase	MIA	animals	was	61%,	33%,	and	33%	for	8g,	26g,	and	60g	respectively,	while	in	early	phase	sham	animals	the	concurrent	noxious	ear	pinch	produced	a	54%,	34%,	and	40%	reduction	in	neuronal	firing	for	8g,	26g	and	60g	respectively	(Figure	5.8B	and	5.8E).	In	early	phase	MIA	injected	animals	the	concurrent	noxious	knee	pinch	placed	on	the	uninjured	knee	produced	a	54%,	40%,	and	35%	reduction	on	neuronal	firing	for	8g,	26g	
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and	60g	respectively,	while	this	produced	a	42%,	38%,	and	41%	reduction	of	neuronal	firing	for	8g,	26g	and	60g	respectively	in	sham	animals	(Figure	5.8B	and	5.8E).	In	early	phase	MIA	animals	the	concurrent	noxious	knee	pinch	placed	on	the	injected	knee	produced	a	reduction	in	neuronal	firing	rate	of	55%,	39%,	and	30%	for	8g,	26g	and	60g	respectively,	with	in	early	phase	sham	animals	the	concurrent	noxious	injected	knee	pinch	produced	a	52%,	53%,	and	38%	reduction	in	neuronal	firing	for	8g,	26g,	and	60g	respectively.	Overall,	the	levels	of	inhibition	on	mechanically	evoked	neuronal	firing	of	WDR	neurons	in	the	contralateral	dorsal	horn	were	comparable	between	early	phase	MIA	and	sham	animals	for	all	methods	used	to	induce	DNIC.	These	findings	indicate	that	the	endogenous	inhibitory	system	functions	as	normal	in	the	early	phase	MIA	animals.		Electrophysiological	recordings	were	also	taken	from	WDR	ipsilateral	to	injection	in	late	phase	MIA	and	sham	animals	(at	least	14	days	post-injection).	DNIC	was	abolished	in	late	phase	MIA	animals;	there	was	no	reduction	in	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	ear	pinch	(Figure	5.9A).	Yet	remarkably,	when	the	concurrent	noxious	pinch	was	placed	on	the	MIA	injected	knee	there	was	a	significant	reduction	in	mechanically	evoked	neuronal	firing	(Figure	5.9A).	The	level	of	inhibition	on	neuronal	firing	produced	by	the	noxious	knee	pinch	was	10%,	18%	and	17%	for	8g,	26g	and	60g	mechanically	evoked	responses	respectively.	In	late	phase	saline	injected	sham	controls	both	concurrent	noxious	ear	and	injected	knee	pinch	produced	a	significant	reduction	in	mechanically	evoked	neuronal	firing	(Figure	5.9D).	In	late	phase	sham	animals	the	level	of	inhibition	on	neuronal	firing	with	concurrent	noxious	ear	pinch	was	45%,	38%,	and	34%	for	8g,	26g,	and	60g	respectively,	while	concurrent	noxious	knee	pinch	produced	a	51%,	39%,	and	37%	reduction	on	neuronal	firing	for	8g,	26g,	and	60g	respectively	(Figure	5.9D).	Therefore,	although	the	concurrent	noxious	MIA	knee	pinch	produces	an	inhibitory	effect	on	neuronal	firing	in	late	phase	MIA	animals	it	is	at	much	lower	levels	compared	to	saline	injected	sham	controls.		Taken	together	these	results	indicate	an	alteration	in	the	endogenous	inhibitory	system	that	is	utilized	by	DNIC	in	late	phase	MIA	animals.			
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Figure	5.8.	The	expression	of	DNIC	in	early	phase	MIA	injected	animals	and	saline	injected	
sham	controls.	A)	Electrophysiological	recordings	were	taken	from	WDR	neurons	ipsilateral	to	injection	in	early	phase	MIA	animals.	Both	concurrent	noxious	ear	and	knee	pinch	produced	a	significant	reduction	in	mechanically	evoked	neuronal	firing	(n=16).	B)	Electrophysiological	recordings	were	also	taken	from	WDR	neurons	contralateral	to	injection.	In	early	phase	MIA	animals,	concurrent	noxious	ear	and	injured	and	uninjured	knee	pinch	reduced	mechanically	evoked	neuronal	firing	but	this	was	only	significant	with	noxious	ear	pinch	at	26g	and	60g	(n=5)	C)	A	raw	trace	from	one	example	ipsilateral	WDR	neuron	in	an	early	phase	MIA	animal,	demonstrating	three	pre-conditioned	baselines	and	a	reduction	in	mechanically	evoked	neuronal	firing	with	concurrent	noxious	ear	pinch	and	injected	knee	pinch.	D)	In	early	phase	sham	animals	a	concurrent	noxious	ear	and	knee	pinch	produced	a	significant	reduction	in	mechanically	
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evoked	neuronal	firing	(n=16).	E)	Electrophysiological	recordings	were	taken	from	contralateral	WDR	neurons	in	saline	injected	sham	controls.	A	concurrent	noxious	ear,	uninjured	knee,	and	injected	knee	pinch	reduces	mechanically	evoked	neuronal	firing	but	this	was	only	significant	for	uninjured	knee	pinch	at	60g.	(n=2).	F)	A	raw	trace	from	one	example	ipsilateral	WDR	neuron	from	an	early	phase	saline	injected	sham	control,	this	demonstrates	3	pre-conditioned	baseline	controls	and	a	reduction	in	mechanically	evoked	neuronal	firing	with	concurrent	noxious	ear	and	injected	knee	pinch.	Two-way	ANOVA	with	Bonferroni	correction.	*P<0.05,	**P<0.01,	***P<0.001.			
	Electrophysiological	recordings	were	also	taken	from	WDR	neurons	contralateral	to	injection	in	late	phase	MIA	and	sham	animals.	DNIC	was	also	abolished	in	WDR	neurons	found	in	the	contralateral	dorsal	horn	to	MIA	injection;	there	was	no	reduction	in	neuronal	firing	with	concurrent	noxious	ear	pinch	and	when	the	concurrent	noxious	ear	pinch	was	placed	on	the	uninjured	knee	(Figure	5.9B).	However,	when	the	concurrent	noxious	knee	pinch	was	placed	on	the	MIA	injected	knee	(now	contralateral	to	the	WDR	neuron	being	recorded)	there	is	a	small	reduction	on	neuronal	firing	(Figure	5.9B).	The	concurrent	noxious	MIA	injected	knee	pinch	produced	an	18%,	14%,	and	9%	reduction	in	neuronal	firing	to	8g,	26g,	and	60g	respectively	in	contralateral	WDR	neurons.	Meanwhile,	in	contralateral	WDR	neurons	in	late	phase	saline	injected	sham	controls	the	concurrent	noxious	knee	pinch	placed	on	the	injected	knee	produced	a	46%,	39%,	and	30%	reduction	in	mechanically	evoked	neuronal	firing	for	8g,	26g,	and	60g	respectively	(Figure	5.9E).	A	concurrent	noxious	ear	pinch	and	concurrent	noxious	pinch	placed	on	the	uninjured	knee	also	produced	a	reduction	in	contralateral	WDR	neuronal	firing	in	late	phase	sham	controls	(Figure	5.9E).	The	reductions	in	mechanically	evoked	neuronal	firing	rates	in	contralateral	WDR	neurons	observed	in	late	phase	MIA	animals	with	a	concurrent	injured	knee	pinch	were	to	a	lesser	extent	than	that	observed	in	early	phase	MIA	animals	and	sham	controls	and	were	not	significantly	different	to	pre-conditioned	baseline	responses.	The	loss	of	DNIC	in	WDR	neurons	both	ipsilateral	and	contralateral	to	MIA	injection	suggests	that	the	alteration	that	occurs	in	the	endogenous	inhibitory	system	is	a	global	phenomenon.											
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Figure	5.9.	The	expression	of	DNIC	in	late	phase	MIA	animals	and	saline	injected	sham	
controls.	A)	Electrophysiological	recordings	of	WDR	neurons	ipsilateral	to	MIA	injection	in	late	phase	MIA	injected	animals.	There	was	no	reduction	in	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	ear	pinch,	however	there	was	a	significant	reduction	when	the	MIA	injured	knee	was	noxiously	pinched	(n=42).	B)	There	was	also	no	reduction	in	mechanically	evoked	neuronal	firing	in	WDR	neurons	contralateral	to	MIA	injection	with	a	concurrent	noxious	ear	or	uninjured	knee	pinch.	Yet	there	was	a	reduction	in	neuronal	firing	when	the	MIA	injected	knee	was	noxiously	pinched	but	this	effect	was	not	significant	(n=7).	C)	A	raw	trace	from	one	example	ipsilateral	WDR	neuron	from	a	late	phase	MIA	animals,	demonstrated	three	pre-conditioned	baseline	responses,	no	reduction	in	mechanically	evoked	neuronal	firing	with	concurrent	
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noxious	ear	pinch,	but	a	reduction	in	mechanically	evoked	neuronal	firing	with	concurrent	noxious	MIA	knee	pinch.	D)	In	saline	injected	sham	controls	at	the	same	time	point	as	late	phase	MIA	injected	animals,	there	was	a	significant	reduction	in	mechanically	evoked	WDR	neuronal	firing	with	concurrent	noxious	ear	and	ipsilateral	knee	pinch	(n=27).	E)	Electrophysiological	recordings	were	also	taken	from	WDR	neurons	contralateral	to	injection	in	sham	controls.	There	was	a	reduction	in	mechanically	evoked	neuronal	firing	with	concurrent	noxious	ear	pinch	and	with	a	noxious	knee	pinch	on	both	knees	(n=7).	F)	A	raw	trace	from	example	WDR	neuron	in	a	saline	injected	sham	control,	demonstrated	three	pre-conditioned	baseline	responses,	and	a	reduction	in	mechanically	evoked	neuronal	firing	with	concurrent	noxious	ear	and	ipsilateral	knee	pinch.	Two-way	ANOVA	with	Bonferroni	post-hoc	test.	*P<0.05,	**P<0.01,	***P<0.001.			The	concurrent	noxious	knee	pinches	produced	varied	DNIC	responses	between	ipsilateral	and	contralateral	WDR	neurons.	For	WDR	neurons	ipsilateral	to	MIA	injection,	a	concurrent	noxious	pinch	placed	on	the	MIA	injected	knee	(ipsilateral	to	the	cell	being	recorded)	induced	a	significant	reduction	in	mechanically	evoked	neuronal	firing	(Figure	5.9A).	Meanwhile,	in	WDR	neurons	contralateral	to	MIA	injection	a	concurrent	noxious	pinch	places	on	the	uninjured	knee	(ipsilateral	to	the	cell	being	recorded)	did	not	induce	a	reduction	in	mechanically	evoked	neuronal	firing	(Figure	5.9B).	Yet	remarkably	when	the	noxious	knee	pinch	was	placed	on	the	MIA	injected	knee	(contralateral	to	the	cell	being	recorded)	it	did	produce	a	reduction	in	mechanically	evoked	neuronal	firing	in	the	contralateral	WDR	neurons,	although	this	effect	was	small	and	not	significant	(Figure	5.9B).	To	investigate	this	further,	the	concurrent	noxious	knee	pinch	was	also	placed	on	the	uninjured	knee	(contralateral	to	the	cell	being	recorded)	to	assess	the	DNIC	effect	in	WDR	neurons	ipsilateral	to	injection.	The	concurrent	noxious	knee	pinch	placed	on	the	uninjured	knee	produced	a	significant	reduction	in	mechanically	evoked	neuronal	firing	in	early	phase	MIA	animals	and	both	sham	groups	(Figure	5.10).	The	reduction	in	mechanically	evoked	neuronal	firing	was	around	the	levels	usually	observed;	in	early	phase	MIA	animals	the	contralateral	knee	pinch	produced	a	53%,	38%	and	42%	reduction	in	neuronal	firing	rates	to	8g,	26g,	and	60g	respectively,	in	early	phase	sham	animals	the	contralateral	knee	pinch	produced	a	46%,	45%,	and	38%	reduction	in	neuronal	firing	rates	to	8g,	26g,	and	60g	respectively,	and	in	late	phase	sham	animals	the	contralateral	late	phase	sham	animals	the	contralateral	knee	pinch	produced	a	47%,	38%,	and	37%	reduction	in	neuronal	firing	rates	to	8g,	26g,	and	60g	respectively	(Figure	5.10A,	5.10C	and	5.10G).	Remarkably,	the	contralateral	noxious	knee	pinch	also	produced	significant	reductions	in	mechanically	evoked	neuronal	firing	in	late	phase	MIA	animals,	however	the	inhibitory	effects	were	at	much	lower	levels.	In	late	phase	MIA	animals	the	contralateral	noxious	knee	pinch	produced	only	a	12%,	6%,	and	7%	reduction	in	neuronal	firing	rates	to	8g,	26g,	and	60g	respectively	(Figure	5.10E	and	5.10F).	This	indicates	that	although	the	contralateral	
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knee	pinch	produces	a	reduction	in	neuronal	firing	rates	in	late	phase	MIA	animals,	the	inhibitory	effect	is	much	less	powerful	than	that	observed	in	other	animals	groups.		
	
Figure	5.10.	The	DNIC	expression	in	early	and	late	phase	MIA	and	sham	animals	in	
response	to	a	concurrent	noxious	pinch	on	the	contralateral	uninjured	knee.	A	and	B)	In	early	phase	MIA	animals	the	concurrent	noxious	contralateral	knee	pinch	produced	a	significant	
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reduction	in	mechanically	evoked	WDR	neuronal	firing	(n=9).	C	and	D)	In	early	phase	saline	injected	sham	controls	the	concurrent	noxious	contralateral	knee	pinch	produced	a	significant	reduction	in	mechanically	evoked	neuronal	firing	(n=11).	E	and	F)	In	late	phase	MIA	injected	animals	the	concurrent	noxious	contralateral	knee	pinch	produces	a	much	smaller	reduction	in	mechanically	evoked	neuronal	firing	rates	compared	to	other	groups,	yet	this	effect	is	still	significant	(n=23).	G	and	H)	In	late	phase	saline	injected	sham	controls	the	concurrent	noxious	contralateral	knee	pinch	produced	a	significant	reduction	in	mechanically	evoked	WDR	neuronal	firing	rates	(n=19).	Two-way	ANOVA	with	Bonferroni	post-hoc	test.	*P<0.05,	***P<0.001.				In	early	phase	MIA	injected	animals,	early	phase	saline	injected	sham	controls,	and	late	phase	saline	injected	sham	controls	the	concurrent	noxious	ear	pinch	consistently	produced	a	30-40%	reduction	in	mechanically	evoked	neuronal	firing	(Figure	5.11A,	5.11C,	and	5.11E).	However,	the	concurrent	noxious	ear	pinch	consistently	produced	no	inhibitory	effect	on	mechanically	evoked	neuronal	firing	in	late	phase	MIA	injected	animals	(Figure	5.11A,	5.11C,	and	5.11E).	Therefore	there	was	significant	difference	between	the	percentage	neuronal	inhibition	produced	by	noxious	ear	pinch	in	late	phase	MIA	animals	compared	to	early	phase	MIA,	early	phase	sham,	and	late	phase	sham	animals.			A	concurrent	noxious	ipsilateral	knee	pinch	also	produced	a	consistent	reduction	in	WDR	neuronal	firing	at	similar	levels	to	that	achieved	with	ear	pinch,	approximately	30-40%,	in	early	phase	MIA,	early	phase	sham,	and	late	phase	sham	animals	(Figure	5.11B,	5.11D,	and	5.11F).	The	level	of	inhibition	on	neuronal	firing	produced	by	the	concurrent	noxious	ipsilateral	knee	pinch	was	much	more	varied	in	late	phase	MIA	animals	(Figure	5.11B,	5.11D,	and	5.11F).	The	concurrent	noxious	knee	pinch	produced	a	reduction	in	mechanically	evoked	WDR	neuronal	firing	in	some	late	phase	MIA	animals,	but	this	was	incapable	of	producing	a	DNIC	response	in	other	animals	within	the	late	phase	MIA	group.	Despite	the	varied	responses	observed	in	late	phase	MIA	animals	with	concurrent	noxious	knee	pinch,	the	level	of	neuronal	inhibition	produced	was	to	a	lesser	extent	in	this	group	compared	to	early	phase	MIA,	early	phase	sham,	and	late	phase	sham	animals,	such	that	there	was	a	significant	difference	between	the	percentage	neuronal	inhibition	produced	by	noxious	ipsilateral	knee	pinch	in	late	phase	MIA	animals	compared	to	all	other	groups.			The	similar	neuronal	inhibition	observed	in	early	phase	MIA	animals	and	sham	controls	with	both	noxious	ear	and	knee	pinch	suggests	early	phase	MIA	animals	have	a	normally	functioning	DNIC	pathway.	Meanwhile,	the	significant	differences	in	neuronal	inhibition	produced	by	noxious	ear	and	knee	pinch	between	late	phase	MIA	animals	and	sham	
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controls	suggests	late	phase	MIA	animals	have	an	abolished	DNIC	system,	potentially	due	to	an	alteration	in	the	descending	controls	arising	in	the	brainstem.			
	
Figure	5.11.	The	percentage	neuronal	inhibition	produced	by	concurrent	noxious	ear	and	
knee	pinch	in	early	and	late	phase	MIA	and	sham	animals.	A)	A	concurrent	noxious	ear	pinch	produced	a	consistent	inhibition	of	the	8g	mechanically	evoked	neuronal	response	in	early	phase	MIA,	early	phase	sham	and	late	phase	sham	animals,	this	was	significantly	different	to	late	phase	MIA	animals	where	the	concurrent	noxious	ear	pinch	did	not	produce	an	inhibitory	effect	on	neuronal	firing	rates.	B).	A	conditioning	noxious	knee	pinch	produced	a	consistent	inhibitory	
	 200	
effect	on	the	8g	mechanically	evoked	neuronal	firing	rate	in	early	phase	MIA,	early	phase	sham	and	late	phase	sham	animals,	while	the	neuronal	inhibition	was	much	more	varied	in	late	phase	MIA	animals	and	significantly	lower	than	other	groups.	C)	A	concurrent	noxious	ear	pinch	produced	a	consistent	inhibition	of	neuronal	firing	in	response	to	a	26g	stimulation	in	early	phase	MIA,	early	phase	sham	and	late	phase	sham	animals,	this	was	significantly	different	to	late	phase	MIA	animals	where	the	concurrent	noxious	ear	pinch	did	not	produce	an	inhibitory	effect	on	neuronal	firing	rates.	D)	A	conditioning	noxious	knee	pinch	produced	a	consistent	inhibition	of	26g	mechanically	evoked	neuronal	firing	rates	in	early	phase	MIA,	early	phase	sham	and	late	phase	sham	animals,	while	the	neuronal	inhibition	in	late	phase	MIA	animals	was	much	more	varied	and	at	a	significantly	lower	level	compared	to	other	groups.	E)	A	conditioning	noxious	ear	pinch	consistently	inhibited	60g	mechanically	evoked	neuronal	firing	in	early	phase	MIA,	early	phase	sham	and	late	phase	sham	animals,	this	was	significantly	different	to	late	phase	MIA	animals	where	the	concurrent	noxious	ear	pinch	did	not	produce	an	inhibitory	effect	on	60g	mechanically	evoked	neuronal	firing	rates.	F)	A	concurrent	noxious	knee	pinch	produced	a	consistent	inhibition	of	60g	evoked	neuronal	firing	rates	in	early	phase	MIA,	early	phase	sham	and	late	phase	sham	animals,	while	the	inhibitory	effect	produced	by	noxious	knee	pinch	in	late	phase	MIA	animals	was	more	varied	and	at	a	significantly	lower	extent.	(Early	phase	MIA	n=19,	early	phase	Sham	n=13,	late	phase	MIA	n=40,	late	phase	Sham	n=25).	Kruskall-Wallis	independent	samples	one-way	ANOVA.	*P<0.05,	**P<0.01,	***P<0.001.			
5.3.6	Microgliosis	and	astrogliosis	in	the	dorsal	horn	of	MIA	animals	
	The	activation	of	spinal	glial	cells	is	thought	to	contribute	to	the	development	of	central	sensitisation;	both	inflammatory	and	neuropathic	chronic	pain	states	are	associated	with	the	activation	of	neuroimmune	cells	(See	Section	1.1.6.1)(Calvo	and	Bennet	2012,	Carniglia	et	al	2017).	The	MIA	model	of	OA	has	previously	been	demonstrated	to	result	in	an	increased	number	of	activated	microglia	in	the	spinal	cord	at	7,	14	and	28	days	post	injection	(Sagar	et	al	2011,	Thakur	et	al	2012).	Therefore,	the	contribution	of	spinal	glial	cells	to	the	development	of	central	sensitisation	was	assessed	in	both	early	and	late	phase	MIA	animals.	Specifically,	the	numbers	of	microglia	and	astrocytes	in	the	spinal	cord	were	investigated.	The	mRNA	expression	of	the	microglia	marker	Ionized	calcium	binding	adaptor	molecule	1	(Iba1)	and	astrocyte	marker	glial	fibrillary	acid	protein	(GFAP)	in	the	lumbar	dorsal	horn	were	assessed	with	quantitative-PCR	in	early	and	late	phase	MIA	injected	animals	and	saline	injected	sham	controls.	There	was	an	increased	level	of	Iba1	mRNA	expression	in	both	MIA	groups	compared	to	their	respective	sham	controls	especially	in	late	phase	animals,	indicating	microgliosis	in	the	spinal	cord	of	MIA	animals,	although	the	effect	was	not	significant	(Figure	5.12A	and	5.12B).	No	difference	in	the	levels	of	GFAP	mRNA	expression	was	seen	between	MIA	groups	and	their	respective	sham	controls,	suggesting	there	is	no	increase	in	the	number	of	astrocytes	in	the	dorsal	horn	following	MIA	injection	at	these	time	points	(Figure	5.12A	and	5.12C).	The	rise	in	the	levels	of	microglia	in	the	dorsal	horn	of	MIA	animals,	particularly	in	late	phase	animals	suggests	the	potential	proliferation	of	microglia,	which	may	be	contributing	to	central	changes	within	the	spinal	cord	and	the	associated	pain-like	behaviour	in	MIA	animals.		
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Figure	5.12.	The	mRNA	expression	of	the	microglia	marker	Iba1	and	the	astrocyte	marker	
GFAP	in	the	dorsal	horn	of	MIA	animals	and	sham	controls.	A)	The	mRNA	expression	of	Iba1	and	GFAP	in	the	dorsal	horn	relative	to	the	housekeeping	gene	GAPDH	and	normalized	to	sham	control	values.	This	demonstrates	an	increase	in	the	levels	of	Iba1	expression	in	MIA	animals	compared	to	their	sham	control	groups,	but	no	difference	in	the	levels	of	GFAP	expression	(EP	n=4,	EPS	n=3,	LP	n=4,	LPS	n=4).	B)	The	mRNA	expression	of	Iba1	in	the	dorsal	horn	relative	to	the	housekeeping	gene	GAPDH,	this	indicates	that	late	phase	MIA	animals	had	consistently	higher	levels	of	Iba1	mRNA	while	the	Iba1	expression	in	early	phase	MIA	animals	was	more	varied.	C)	The	mRNA	expression	of	GFAP	in	the	dorsal	horn	relative	to	the	housekeeping	gene	GAPDH,	this	demonstrates	no	difference	in	the	mRNA	expression	of	GFAP	between	MIA	groups	and	their	respective	sham	control	group.	A	Kruskall-wallis	independent	samples	one-way	ANOVA	was	used	to	test	for	statistical	differences	between	MIA	and	sham	groups	when	the	mRNA	expression	was	normalized	to	sham.	A	One-way	ANOVA	with	Bonferroni	correction	was	used	to	test	for	statistical	differences	in	mRNA	expression	represented	as	2-ΛCT	values	between	MIA	and	Sham	groups.	
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5.3.7	The	expression	of	pro-inflammatory	cytokines	in	the	MIA	model	
	Activated	spinal	glia	release	proinflammatory	cytokines	into	the	central	nervous	system	and	enhanced	levels	of	key	proinflammatory	cytokines,	including	IL-1β,	TNFα,	and	IL6,	have	previously	been	demonstrated	in	the	spinal	cord	following	peripheral	injury	(Zhang	and	An	2007,	Lopes-Castejon	and	Brough	2011).	Additionally,	the	levels	of	proinflammatory	cytokines	are	elevated	in	the	synovium,	chondrocytes,	and	subchondral	bone	in	OA	patients,	and	form	part	of	an	inflammatory	soup	that	contributes	to	peripheral	sensitisation	(See	section	1.1.4.1	and	1.3.3).	Therefore,	the	mRNA	expression	levels	of	the	proinflammatory	cytokines,	IL-1β,	TNFα,	and	IL6,	were	investigated	both	centrally	in	the	dorsal	horn	and	peripherally	in	DRGs	in	MIA	animals	and	sham	controls.			The	mRNA	expression	of	IL-6	and	TNFα	in	the	dorsal	horn	remained	relatively	constant	in	both	MIA	and	sham	controls	groups	(Figure	5.13A,	5.13C	and	5.13D).	However,	the	mRNA	expression	of	IL-1β	was	increased	in	late	phase	MIA	animals	compared	to	their	sham	control	group,	although	this	was	not	significant	(Figure	5.13A	and	5.13B).	There	was	also	a	rise	in	the	mRNA	expression	of	the	microglia	marker	Iba1	in	the	late	phase	dorsal	horn,	as	IL-1β	expression	is	enhanced	following	the	activation	of	microglia	these	two	findings	are	potentially	linked	(Zhang	and	An	2007).			Meanwhile,	in	the	DRGs	the	mRNA	expression	of	IL-1β	and	IL-6	remained	similar	between	both	MIA	groups	and	their	respective	sham	control	groups	(Figure	5.13E,	5.13F	and	5.13G).	When	the	mRNA	expression	was	normalized	to	the	levels	observed	in	sham,	the	mRNA	expression	of	TNFα	appeared	to	be	increased	in	the	DRGs	of	late	phase	MIA	animals,	but	this	difference	was	not	significant	(Figure	5.13E).	However,	when	the	mRNA	expression	was	expressed	as	the	2-ΔCT	values	it	is	clear	that	only	one	data	point	in	the	late	phase	MIA	group	is	skewing	the	data	such	that	the	levels	appear	to	be	increased,	as	the	remaining	late	phase	MIA	expression	levels	remain	similar	to	the	respective	late	phase	sham	group	(Figure	5.13H).			Overall,	these	findings	indicate	there	may	be	a	slight	increase	in	the	release	of	the	pro-inflammatory	cytokine	IL-1β	in	the	dorsal	horn	of	late	phase	MIA	animals,	potentially	due	to	the	activation	of	microglia,	but	there	is	no	increase	in	the	levels	of	IL-6	and	TNFα	in	the	dorsal	horn	of	MIA	animals.	Furthermore,	there	does	not	appear	to	be	an	increase	
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in	the	levels	of	the	pro-inflammatory	cytokines	IL-1β,	TNFα,	and	IL6,	in	the	periphery	at	the	level	of	the	DRG	in	either	early	or	late	phase	MIA	animals.			
	
Figure	5.13.	The	mRNA	expression	of	the	pro-inflammtory	cytokines	IL-1β,	IL6,	and	TNFα,	
in	the	dorsal	horn	and	DRGs	of	early	and	late	phase	MIA	animals	and	sham	controls.	A)	The	mRNA	expression	of	the	proinflammatory	cytokines	IL-1β,	IL6,	and	TNFα	in	the	dorsal	horn	of	early	and	late	phase	MIA	animals	relative	to	the	housekeeping	gene	GAPDH	and	normalized	to	their	respective	Sham	group.	This	demonstrates	an	increase	in	the	mRNA	levels	of	IL-1β	in	the	
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dorsal	horn	of	late	phase	MIA	animals	(EP	n=4,	EPS	n=3,	LP	n=4,	LPS	n=4).	B)	The	mRNA	expression	of	IL-1β	in	the	dorsal	horn	of	early	and	late	phase	animals	relative	to	the	housekeeping	gene	GAPDH.	This	indicates	that	early	phase	MIA	and	early	phase	Sham	animals	have	similar	levels	of	IL-1β	mRNA	expression,	while	late	phase	MIA	animals	appear	to	have	slightly	increased	levels	of	IL-1β	mRNA	expression	compared	to	the	late	phase	Sham	group	but	this	difference	is	not	significant.	C)	The	mRNA	expression	of	IL-6	in	the	dorsal	horn	of	early	and	late	phase	MIA	animals	relative	to	housekeeping	gene	GAPDH,	indicates	similar	IL-6	mRNA	expression	levels	between	both	MIA	groups	and	their	relative	sham	controls.	D)	The	mRNA	expression	of	TNFα	in	the	dorsal	horn	of	early	and	late	phase	animals	relative	to	housekeeping	gene	GAPDH,	this	indicates	similar	TNFα	mRNA	expression	levels	between	both	MIA	groups	and	their	respective	sham	controls.	E)	The	mRNA	expression	of	the	proinflammatory	cytokines	IL-1β,	IL6,	and	TNFα	in	the	DRGs	of	early	and	late	phase	MIA	animals	relative	to	the	housekeeping	gene	GAPDH	and	normalized	to	their	respective	sham	group.	This	demonstrates	an	increased	expression	level	of	TNFα	in	the	DRGs	of	late	phase	MIA	animals	yet	this	different	is	not	significant.	The	levels	of	IL-1β	and	IL6	remain	similar	between	groups.	(EP	n=4,	EPS	n=4,	LP	n=4,	LPS	n=4).	F)	The	mRNA	expression	of	IL-1β	in	the	DRGs	of	early	and	late	phase	animals	relative	to	the	housekeeping	gene	GAPDH	indicates	similar	expression	levels	between	groups.	G)	The	mRNA	expression	of	IL-6	in	the	DRGs	of	early	and	late	phase	MIA	animals	relative	to	the	housekeeping	gene	GAPDH,	indicates	similar	levels	of	expression	between	groups.	H)	The	mRNA	expression	of		TNFα	in	the	DRGs	of	early	and	late	phase	MIA	animals	relative	to	the	housekeeping	gene	GAPDH	indicates	overall	similar	levels	of	expression	between	groups.	A	Kruskall-wallis	independent	samples	one-way	ANOVA	was	used	to	test	statistical	differences	when	the	expression	levels	were	normalized	to	the	relative	sham	group.	A	One-way	ANOVA	with	Bonferroni	correction	was	used	to	test	statistical	differences	between	mRNA	expressions	expressed	as	2-ΔCT	values	between	MIA	and	Sham	groups.																														
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5.4	Discussion		
	This	study	examined	several	pathological	features	associated	with	the	MIA	model	of	OA	at	both	early	(2-6	days	post	injection)	and	late	(at	least	14	days	post	injection)	time	points.	Firstly,	the	development	of	pain	like	behaviour	and	the	degree	of	cartilage	joint	damage	were	assessed.	Secondly,	the	expression	of	DNIC	was	investigated	using	electrophysiological	recordings	from	WDR	neurons	in	the	deep	dorsal	horn	to	assess	any	changes	in	the	descending	inhibitory	system.	Finally,	the	involvement	of	spinal	glia	cells	and	pro-inflammatory	cytokines	and	their	contribution	to	peripheral	and	central	sensitization	were	evaluated.			This	study	indicated	that	both	early	and	late	phase	MIA	animals	develop	significant	mechanical	hypersensitivity	on	the	hind	paw	and	place	significantly	less	weight	on	the	injured	limb.	Despite	the	development	of	pain-like	behaviour,	early	phase	animals	demonstrate	very	little	cartilage	loss	within	the	joint.	Meanwhile,	knee	histology	in	animals	from	the	late	phase	group	demonstrated	severe	cartilage	loss.	The	early	phase	MIA	animals	displayed	a	normally	functioning	DNIC	system,	as	both	concurrent	noxious	ear	and	knee	pinch	produced	a	significant	reduction	in	mechanically	evoked	neuronal	firing	at	levels	similar	to	that	observed	in	sham	controls.	However,	the	concurrent	noxious	ear	pinch	produced	no	inhibition	on	neuronal	firing	in	late	phase	animals	suggesting	an	alteration	in	the	descending	inhibitory	system.	Interestingly,	DNIC	could	be	induced	in	some	late	phase	MIA	animals	by	a	concurrent	noxious	pinch	placed	on	the	MIA	injured	knee,	which	may	demonstrate	that	pinching	the	injured	knee	produces	a	noxious	stimulation	of	adequate	strength	to	trigger	descending	inhibition.	Furthermore,	a	rise	in	the	levels	of	microglia	and	the	pro-inflammatory	cytokine	IL-1β	were	identified	in	the	ipsilateral	dorsal	horn	of	late	phase	MIA	animals,	which	may	contribute	to	the	development	of	central	sensitisation.			
5.4.1	The	clinical	relevance	of	the	MIA	model	Although	animals	models	cannot	mimic	the	exact	aetiology	of	OA,	a	clinically	relevant	model	should	develop	similar	pathological	features	and	symptoms,	to	better	our	understanding	of	the	mechanisms	involved	in	the	development	of	disease.	As	pain	is	the	major	cause	for	patients	reporting	OA	in	the	clinic,	and	this	thesis	focuses	on	the	development	of	chronic	pain,	it	was	important	to	use	an	OA	model	that	develops	a	significant	pain	phenotype.	As	the	MIA	model	has	previously	been	reported	to	develop	
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both	histopathological	joint	damage	and	ongoing	pain	in	the	joint	and	at	distant	sites,	this	model	was	selected	for	the	study.		
5.4.1.1.	The	importance	of	MIA	dose		A	range	of	MIA	doses,	from	0.1mg	to	4.8mg,	have	been	demonstrated	to	dose	and	time	dependently	initiate	structural	joint	pathology	and	pain	like	behaviour	(Guingamp	et	al	1997,	Bove	et	al	2003,	Pomonis	et	al	2005,	Ogbanna	et	al	2013).	Low	doses	of	MIA	have	been	demonstrated	to	cause	low	level	destruction	of	the	articular	cartilage,	while	high	doses	produce	more	structural	damage	to	the	joint	such	as	subchondral	bone	damage	(Udo	et	al	2016).	The	most	commonly	used	MIA	doses	for	studying	the	pain	associated	with	OA	are	1mg	and	2mg	(Thakur	et	al	2012).	Both	1mg	and	2mg	doses	of	MIA	have	been	demonstrated	to	result	in	a	significant	behavioural	profile	indicating	joint	pain	and	mechanical	hypersensitivity	of	the	paw	(Thakur	et	al	2012,	Mapp	et	al	2013).	Additionally,	both	1mg	and	2mg	MIA	doses	cause	structural	pathology	in	the	knee	characteristic	of	clinical	OA,	including	chondrocyte	degeneration,	a	loss	of	proteoglycans,	and	destruction	of	articular	cartilage	(Thakur	et	al	2012,	Mapp	et	al	2013).	In	fact	it	has	been	reported	there	is	no	difference	in	the	severity	of	histopathology	between	the	two	doses	(Thakur	et	al	2012).	However,	a	previous	thesis	produced	by	the	lab	reported	a	lack	of	involvement	from	descending	serotonergic	and	noradrenergic	pathways	influencing	spinal	cord	excitability	in	the	1mg	MIA	model	(Townson	2017).	This	contrasts	to	electrophysiological	studies	in	the	2mg	MIA	model	where	an	increased	serotonergic	facilitatory	drive	and	decreased	noradrenergic	inhibitory	drive	have	been	reported	to	influence	WDR	neurons	(Rahman	et	al	2009,	Burnham	and	Dickenson	2013).	As	discussed	in	Chapter	4,	the	descending	noradrenergic	and	serotonergic	pathways	are	believed	to	be	crucial	for	the	expression	of	DNIC.	As	this	thesis	aimed	to	investigate	how	adaptions	due	to	plasticity	in	the	central	nervous	system	may	be	contributing	to	alterations	in	DNIC	and	the	pain	associated	with	OA,	the	2mg	MIA	model	was	chosen.			
5.4.1.2	Structural	pathology	in	the	knee	and	the	associated	pain	behaviour	
	The	MIA	model	has	faced	criticism	that	while	it	displays	symptoms	of	joint	pain	and	pain	distant	to	the	joint,	which	may	represent	referred	pain	observed	in	patients,	the	initiating	events	and	joint	pathology	following	MIA	injection	are	not	representative	of	human	OA	(Little	and	Zaki	2012).	The	behaviour	and	histology	scores	in	early	phase	
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animals	reported	in	this	study	agree	with	this	criticism,	as	significant	pain-like	behaviour	develops	in	the	absence	of	joint	damage.	As	discussed	in	Section	5.1.2.1	the	MIA	injection	causes	an	initial	inflammatory	infiltrate	of	monocytes,	neutrophils	and	basophils	in	the	joint,	which	peaks	around	day	3	and	begins	to	decline	at	approximately	day	7	(Guzman	et	al	2003,	Clements	et	al	2009).	Interestingly,	this	study	demonstrated	bi-phasic	pain	like	behaviour	in	the	MIA	model,	as	the	animals	reluctance	to	place	weight	on	the	injured	limb	and	mechanical	hypersensitivity	appears	to	recover	between	days	4-7,	which	is	in	agreement	with	previous	findings	(Bove	et	al	2003,	Thakur	et	al	2012,	Kelly	et	al	2013).	Together	these	findings	indicate	that	the	initial	pain	behaviour	may	be	due	to	the	general	toxicity	of	the	MIA	injection	and	the	subsequent	inflammatory	response.	However,	it	should	be	considered	that	that	only	cartilage	damage	was	scored	with	histology	and	since	cartilage	is	both	anueral	and	avascular,	damage	to	cartilage	cannot	be	the	direct	cause	of	pain	(Hunter	et	al	2009b).	Indeed,	there	is	discordance	in	patients	between	the	OA	associated	knee	pain	and	the	radiographic	knee	damage	observed	(Hannan	et	al	2000).	Therefore,	the	pain	behaviour	observed	in	early	phase	animals	may	be	a	result	of	damage	to	other	joint	structures,	such	as	the	synovium.	Overall	the	pain-like	behaviour	observed	in	the	early	phase	MIA	model	may	not	be	a	result	of	joint	pathology	that	is	typical	to	human	OA,	and	therefore	may	not	be	entirely	representative	of	the	mechanisms	driving	OA	associated	pain.			The	histopathological	joint	damage	that	has	common	features	with	human	OA,	such	as	cartilage	destruction	and	subchondral	bone	damage,	has	been	demonstrated	to	progress	in	a	time-dependent	manner	following	MIA	injection	(Udo	et	al	2016).	In	agreement,	this	study	demonstrated	that	severe	joint	damage,	including	complete	loss	of	articular	cartilage	and	exposure	of	subchondral	bone,	occurs	in	late	phase	MIA	animals.	Therefore,	it	may	be	concluded	that	pain	behaviour	recovers	around	days	4-7	as	the	inflammatory	infiltrate	within	the	joint	declines,	and	that	pain	behaviour	returns	around	day	14	due	to	structural	damage	within	the	knee.	Indeed,	a	significant	negative	correlation	was	reported	between	knee	histology	score	and	the	percentage	weight	placed	on	the	ipsilateral	limb.	The	relationship	between	an	increase	of	cartilage	damage	and	the	reluctance	of	the	late	phase	MIA	animals	to	place	weight	on	the	injured	joint	indicates	that	the	pain	behaviour	observed	is	due	to	histopathology	in	the	knee.	Overall,	this	study	suggests	that	the	development	of	pain	in	late	phase	MIA	animals	is	due	to	pathological	events	within	the	joint	that	are	similar	to	clinical	features	observed	in	human	OA.			
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5.4.1.3	Time	dependency	of	the	MIA	model		While	the	extent	of	MIA-induced	joint	pathology	has	been	demonstrated	to	depend	upon	MIA	dose,	it	also	depends	on	the	time	post	injection	(Guzman	et	al	2003,	Udo	et	al	2016).	While	inflammatory	changes	in	the	synovium	and	infrapatellar	fat	pad	have	been	demonstrated	to	occur	rapidly	(less	than	7	days	post	injection),	structural	joint	changes	have	been	demonstrated	to	occur	at	later	time	points	(Dunham	et	al	1992,	Clements	et	al	2009).		When	1mg	MIA-induced	histopathological	features	were	monitored	for	an	extended	period	of	time,	it	was	demonstrated	that	subchondral	bone	marrow	lesions	began	to	form	around	day	14,	followed	by	a	complete	loss	of	articular	cartilage	and	subsequent	fragmentation	of	subchondral	bone	at	day	28-30,	and	significant	bone	remodeling	at	day	56	(Guingamp	et	al	1997,	Guzman	et	al	2003).	Similarly,	imaging	studies	in	OA	patients	have	identified	bone	marrow	lesions,	subchondral	bone	fibrosis	and	extensive	bone	remodeling	as	common	clinical	features	(Wieland	2005,	Conaghan	et	al	2006).	Therefore,	the	histology	results	in	this	study	and	previous	studies	suggest	that	at	later	time	points	post	MIA	injection,	the	more	accurately	the	model	may	represent	structural	joint	changes	and	associated	joint	pain	that	occur	in	human	OA.			
5.4.2	Diffuse	Noxious	Inhibitory	Controls	in	the	MIA	model		This	study	reported	that	early	phase	MIA	animals	have	a	normally	functioning	DNIC	as	both	concurrent	noxious	ear	and	knee	pinch	produced	a	significant	reduction	in	mechanically	evoked	neuronal	firing	at	similar	levels	to	that	observed	in	saline	injected	sham	controls.	This	thesis	and	previous	studies	have	demonstrated	that	DNIC	expression	is	reliant	upon	a	functioning	noradrenergic	descending	inhibitory	system	(Bannister	et	al	2015,	Bannister	et	al	2017).	A	previous	2mg	MIA	study	reported	that	early	phase	MIA	animals	had	a	functioning	noradrenergic	system,	as	the	spinally	applied	α2-adrenergic	receptor	antagonist	atipamezole	fully	reversed	the	inhibitory	effects	produced	by	the	SNRI	Milnacipran	(Burnham	and	Dickenson	2013).	Furthermore,	NSAIDs	have	been	demonstrated	to	be	effective	in	early	phase	MIA	animals,	while	late	phase	MIA	animals	do	not	respond	indicating	the	development	of	central	sensitisation	(Fernihough	et	al	2004).	Together	these	findings	suggest	that	the	pain	behaviour	demonstrated	in	early	phase	animals	may	be	a	result	of	peripheral	sensitisation,	and	the	fully	functioning	DNIC	system	may	indicate	a	lack	of	central	changes.			On	the	other	hand,	this	study	demonstrated	there	was	a	loss	of	DNIC	in	late	phase	MIA	animals,	as	the	concurrent	noxious	ear	pinch	no	longer	produced	a	reduction	in	
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mechanically	evoked	neuronal	firing.	It	has	previously	been	reported	that	there	is	a	reduction	in	descending	noradrenergic	inhibitory	controls	in	late	phase	MIA	animals,	as	atipamezole	could	not	longer	fully	reverse	the	inhibitory	effects	of	the	SNRI	milnacipran	(Burnham	and	Dickenson	2013).	Additionally,	an	enhanced	descending	serotonergic	facilitatory	drive	acting	at	5-HT3	receptors	in	the	spinal	cord	has	been	demonstrated	in	late	phase	2mg	MIA	animals	(Rahman	et	al	2009).	Interestingly,	in	a	previous	study	where	DNIC	was	lost	in	SNL	animals,	the	spinal	application	of	the	5-HT3	receptor	antagonist	ondansetron	restored	DNIC,	indicating	that	an	increased	serotonergic	facilitatory	drive	may	be	contributing	to	the	loss	of	DNIC	(Bannister	et	al	2015).	Furthermore,	NSAIDs	have	been	demonstrated	to	be	ineffective	at	relieving	hyperalgesia	and	allodynia	in	late	phase	MIA	animals,	potentially	indicating	central	changes	(Fernihough	et	al	2004).	Therefore,	the	loss	of	DNIC	in	late	phase	MIA	animals	observed	in	this	study	may	be	a	result	of	an	imbalance	in	descending	controls,	specifically	a	reduced	descending	inhibitory	noradrenergic	and	enhanced	descending	facilitatory	serotonergic	system.			Remarkably,	in	some	late	phase	MIA	animals	a	reduction	in	neuronal	firing	was	observed	when	the	concurrent	noxious	pinch	was	placed	on	the	injured	knee.	Firstly,	this	indicates	that	the	DNIC	system	is	not	completely	abolished	and	proposes	that	activation	of	the	reduced	descending	noradrenergic	system	by	the	conditioning	stimulus	is	no	longer	sufficient	to	override	the	enhanced	descending	serotonergic	faciltatory	drive	acting	at	the	spinal	cord.	Overall,	the	imbalance	in	descending	inhibitory	and	serotonergic	controls	is	masking	the	expression	of	DNIC,	this	agrees	with	previous	studies	demonstrating	DNIC	can	be	revealed	pharmacologically	(Bannister	et	al	2015,	Bannister	et	al	2017).	Previous	studies	using	electrophysiological	recordings	from	joint	afferents	have	demonstrated	MIA	produces	a	graded	sensitisation	and	increased	firing	rate	(Schuelert	and	McDougall	2009,	Schuelert	and	McDougall	2012).	Furthermore,	a	Nav1.8	channel	blocker	reduced	the	firing	rate	of	joint	afferents	in	response	to	noxious	rotation	of	the	joint	but	had	no	effect	during	non-noxious	rotation	(Schuelert	and	McDougall	2012).	This	may	indicate	that	upon	noxious	conditioning	stimulation	of	the	MIA	injured	knee	there	is	likely	an	increased	firing	rate	of	joint	afferents	and	an	increased	transduction	of	nocicieptive	signal	via	sodium	channels	to	the	dorsal	horn.	Therefore,	the	concurrent	MIA	injured	knee	pinch	may	now	produce	a	sufficient	nociceptive	signal	to	activate	descending	inhibitory	controls	and	produce	a	small	level	of	neuronal	inhibition.		
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Surprisingly,	the	concurrent	contralateral	uninjured	knee	pinch	also	appeared	to	produce	a	significant	reduction	in	neuronal	firing	in	late	phase	animals,	but	this	was	at	much	lower	levels	than	that	observed	in	early	phase	animals	and	sham	controls.	As	discussed	in	Section	2.1.3,	a	10%	variation	in	neuronal	firing	is	expected.	Therefore,	the	marginal	reduction	in	number	of	action	potentials	may	be	due	simply	to	variations	in	neuronal	firing,	which	may	be	significant	due	to	large	n	numbers.	Due	to	the	low	levels	of	neuronal	inhibition	observed	with	concurrent	contralateral	knee	pinch	in	late	phase	MIA	animals	of	12%,	6%,	and	7%	for	8g,	26g	and	60g	respectively,	I	would	be	reluctant	to	characterize	this	as	a	DNIC	response.			
5.4.3.	The	involvement	of	spinal	glia	in	the	MIA	model	As	discussed	in	Section	1.1.6.1,	the	glial	cells	form	a	huge	part	of	the	central	nervous	system,	can	become	activated	in	response	to	peripheral	tissue	damage,	and	release	factors	that	interact	with	neurons	to	regulate	their	function	(McMahon	and	Malcangio	2009,	Clark	and	Malcangio	2012).	In	particular,	immunohistochemistry	studies	have	demonstrated	the	proliferation	and	activation	of	microglia	in	the	L3,	L4	and	L5	levels	of	the	ipsilateral	spinal	cord	following	MIA	injection	(Sagar	et	al	2011,	Thakur	et	al	2012,	Ogbonna	et	al	2013).	This	study	found	that	there	was	a	rise	in	the	mRNA	expression	of	Iba1,	a	microglia	specific	calcium	binding	protein,	in	late	phase	MIA	animals	compared	to	late	phase	sham	controls	but	this	effect	did	not	reach	significance.	While	measuring	mRNA	levels	of	Iba1	provides	information	on	the	proliferation	of	microglia,	it	cannot	identify	their	activation.	Indeed,	a	previous	study	demonstrated	that	the	increase	in	Iba-1	expressing	microglia	in	the	ipsilateral	dorsal	horn	following	MIA	injection	did	not	reach	significance	at	day	7	but	did	at	day	28	(Ogbonna	et	al	2013).		Therefore,	at	our	time	point	of	day	14	there	may	be	considerable	activation	of	microglia	as	previously	described	but	a	less	substantial	proliferation	(Sagar	et	al	2011,	Thakur	et	al	2012,	Ogbonna	et	al	2013).			One	mechanism	in	which	activated	microglia	can	modulate	the	function	of	spinal	neurons	is	through	the	release	of	pro-inflammatory	cytokines,	particularly	IL-1β,	IL-6	and	TNFα	(Schomberg	and	Olsen	2012,	Calvo	and	Bennett	2012).	This	study	found	a	rise	in	IL-1β	mRNA	expression	in	the	spinal	cord	of	late	phase	MIA	animals	compared	to	late	phase	sham	controls,	but	this	effect	did	not	reach	significance.	It	should	be	noted	that	this	study	used	the	entire	lumbar	dorsal	horn	for	qPCR,	while	microgliosis	has	previously	been	described	specifically	in	L3,	L4	and	L5	lumbar	levels,	therefore	the	increased	levels	of	microglia	and	subsequent	release	of	pro-inflammatory	cytokines	in	
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late	phase	MIA	animals	may	be	diluted	in	these	results.	IL-1β	has	been	shown	to	enhance	AMPA	and	NMDA	induced	currents	and	suppress	GABA	and	glycine	induced	currents	in	the	dorsal	horn	(Kawaski	et	al	2008).	Overall,	this	rise	in	mRNA	expression	could	indicate	that	the	peripheral	tissue	damage	caused	by	the	MIA	injection	in	late	phase	animals	is	resulting	in	microgliosis	in	the	ipsilateral	dorsal	horn	and	the	subsequent	release	of	the	pro-inflammatory	cytokine	IL-1β.	Microgliosis	and	the	release	of	IL-1β	may	contribute	to	an	increased	excitatory	and	decreased	inhibitory	synaptic	transmission	at	second	order	neurons	in	the	dorsal	horn,	contributing	to	the	development	of	central	sensitisation	(Kawaski	et	al	2008).			Astrocytes	are	the	most	abundant	glial	cell	in	the	central	nervous	system,	and	they	regulate	the	synaptic	levels	of	K+	and	glutamate	(Milligan	and	Watkins	2009,	Bradesi	2010).	This	study	found	no	difference	in	the	mRNA	expression	levels	of	GFAP	between	either	early	or	late	phase	MIA	animals	and	their	respective	sham	control	group.	This	is	in	agreement	with	previous	studies	that	identified	no	increased	in	spinal	GFAP	immunofluorescence	at	days	7	and	14	post	MIA	injection	(Sagar	et	al	2011,	Thakur	et	al	2012,	Ogbonna	et	al	2013).	However,	there	are	conflicting	findings	for	GFAP	immunofluorescence	at	later	time	points,	with	one	study	identifying	a	significant	increase	and	another	finding	no	alteration	in	GFAP	intensity	at	28	days	post	MIA	injection	(Sagar	et	al	2011,	Ogbonna	et	al	2013).	GFAP	is	not	be	an	absolute	biomarker	of	astrocytes	as	it	may	not	detect	non-reactive	astrocytes,	but	it	is	a	reliable	and	sensitive	biomarker	for	reactive	astrocytes	(Sofroniew	and	Vinters	2010).	Therefore,	the	results	from	this	study	and	previous	findings	suggest	astrogliosis	is	not	contributing	to	the	development	of	central	sensitisation	in	MIA	animals	at	these	time	points.			
5.4.4	Peripheral	pro-inflammatory	cytokines	in	the	MIA	model		As	discussed	in	Section	1.3.3,	there	are	increased	levels	of	pro-inflammatory	cytokines,	particularly	IL-1β	and	TNFα	in	several	OA	joint	structures,	which	mediate	the	progression	of	cartilage	damage	and	joint	destruction	(Kapoor	et	al	2011).	IL-1β	and	TNFα	can	perpetuate	the	OA	disease	state	in	the	joint	as	they	result	in	an	inhibition	of	anabolic	activities	in	the	chondrocytes,	and	subsequently	prevent	the	synthesis	of	ECM	components	(Goldring	1994,	Kapoor	et	al	2011).	The	mRNA	levels	of	the	proinflammatory	cytokines,	IL-1β,	TNFα,	and	Il-6	were	assessed	at	the	level	of	the	DRG	to	investigate	any	inflammatory	response	in	peripheral	neurons.	This	study	identified	no	alteration	in	the	mRNA	levels	of	any	of	these	pro-inflammatory	cytokines	at	the	level	of	the	DRG	in	either	early	or	late	phase	MIA	animals.	This	may	indicate	that	any	
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neuronal	sensitisation	at	the	level	of	the	DRG	in	MIA	animals	is	not	due	to	an	inflammatory	infiltrate,	but	it	could	also	be	that	the	pro-inflammatory	cytokines	are	being	produced	and	secreted	at	the	level	of	the	joint,	and	as	such	the	measurement	of	mRNA	levels	at	the	DRG	would	not	detect	this.	It	has	previously	been	demonstrated	that	there	are	elevated	levels	of	the	pro-inflammatory	cytokines	TNFα	and	IL-6	in	knee	soft	tissue	structures	following	MIA	injection	(Orita	et	al	2011).	Therefore,	analysing	the	expression	of	pro-inflammatory	cytokines	in	the	joint	may	have	been	a	better	approach	to	better	understand	the	local	inflammation	that	occurs	in	the	MIA	model.			
5.4.5	Concluding	remarks	This	study	indicates	that	while	both	early	and	late	phase	MIA	animals	develop	significant	pain	behaviour,	late	phase	MIA	animals	also	have	severe	cartilage	damage	and	so	may	be	the	more	accurate	representation	of	clinical	OA.	The	synaptic	plasticity	that	exists	in	the	dorsal	horn	means	that	after	14	days	of	receiving	a	barrage	of	nociceptive	information	from	the	MIA	injured	knee	it	is	likely	central	sensitisation	develops,	and	this	potentially	occurs	through	microgliosis	and	the	subsequent	release	of	pro-inflammatory	cytokines,	which	modulate	excitatory	and	inhibitory	currents.	The	loss	of	DNIC	in	late	phase	MIA	animals	indicates	an	imbalance	in	descending	facilitatory	and	inhibitory	controls	from	the	brainstem.	However,	a	concurrent	noxious	pinch	on	the	MIA	injured	knee	produces	a	reduction	in	neuronal	firing,	potentially	suggesting	that	noxiously	stimulating	the	sensitised	joint	afferents	and	increasing	the	transduction	of	the	nociceptive	signal	to	the	dorsal	horn	is	sufficient	to	produce	inhibitory	control.	Overall,	early	phase	animals	may	respond	to	analgesics	that	act	peripherally,	such	as	NSAIDs	or	Nav1.8	channel	blockers.	Whereas,	therapeutics	that	target	the	central	nervous	system	or	act	to	restore	the	balance	in	descending	systems	from	the	brainstem	may	be	the	most	effective	option	for	relieving	pain	in	late	phase	MIA	animals	and	also	in	a	subset	of	OA	patients.							
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6.	Pharmacologically	restoring	Diffuse	
Noxious	Inhibitory	Controls	and	
investigating	a	neuropathic	component	in	
the	monoiodoacetate	model	of	
Osteoarthritis.		
	
6.1	Introduction	
	As	discussed	in	Section	1.3.5	there	are	several	analgesics	used	in	the	clinic	to	treat	the	pain	associated	with	OA,	with	most	of	these	treatment	options	aiming	to	relieve	inflammation	or	replace	lost	ECM	components	in	the	joint	(Wieland	et	al	2005).	Yet,	many	OA	patients	develop	referred	pain	and	a	subset	suffers	with	chronic	pain	even	following	total	knee	replacement	surgery,	which	suggests	discordance	between	nociceptor	activation	and	the	resulting	pain	experience	(Malfait	and	Schnitzer	2014).	Together	these	features	indicate	that	the	pain	associated	with	OA	cannot	always	be	considered	purely	peripheral,	but	there	are	fewer	treatment	options	available	which	target	the	central	nervous	system	to	tackle	centrally	driven	chronic	pain	(Gwylim	et	al	2009,	Wylde	et	al	2011).	Additionally,	a	subset	of	OA	patients	report	neuropathic	features	to	their	pain	and	so	may	benefit	from	analgesics	tailored	to	treat	the	neuropathic	component	(Thakur	et	al	2014).	Overall,	the	advancement	in	the	understanding	of	the	peripheral	and	central	molecular	mechanisms	that	cause	the	pain	associated	with	OA	and	the	shift	towards	personalized	medicine	in	the	clinic,	means	patients	are	now	being	more	thoroughly	diagnosed	to	understand	their	individual	pain	phenotype	in	order	to	prescribe	the	most	effective	analgesic.			
6.1.1	Spinal	and	supraspinal	plasticity	in	Osteoarthritis	patients	
	As	discussed	in	Section	1.3.6	and	Chapter	5,	the	continuous	barrage	of	nociceptive	information	from	the	joint	and	the	high	level	of	plasticity	that	exists	in	the	CNS,	often	results	in	hypersensitivity	of	second	order	neurons	in	the	dorsal	horn	and	the	subsequent	development	of	central	sensitisation.	The	exact	molecular	mechanisms	behind	the	development	of	central	sensitisation	are	discussed	in	Section	1.1.6,	but	overall	a	facilitation	in	synaptic	neurotransmission,	an	increase	in	membrane	excitability	of	second	order	neurons,	and	a	lack	of	inhibitory	control	from	interneurons	are	the	main	drivers	(Malfait	and	Schnitzer	2014).	Additionally,	peripheral	tissue	
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damage	can	activate	spinal	glia	cells,	which	subsequently	modulate	neuronal	function	(McMahon	and	Malcangio	2009).	The	result	is	a	reduction	of	activation	threshold,	increased	spontaneous	activity,	and	an	expansion	of	the	receptive	field	in	dorsal	horn	neurons,	which	is	presented	in	the	clinic	as	allodynia,	hyperalgesia	and	referred	pain	at	sites	distant	to	initial	joint	damage	(Malfait	and	Schnitzer	2014).	The	development	of	central	sensitisation	may	explain	the	discordance	between	radiological	joint	damage	and	the	pain	experienced	by	OA	patients	(Hannan	et	al	2000).			In	addition,	spinal	cord	neurons	receiving	input	from	the	joint	are	under	the	influence	of	descending	controls	arising	in	the	brainstem,	therefore	impairment	of	descending	controls	may	also	contribute	to	an	exaggerated	pain	response	in	OA	patients.	Indeed,	a	study	investigating	sensitization	in	patients	with	painful	knee	OA	demonstrated	reduced	pressure	pain	thresholds	and	facilitated	temporal	summation	to	repeated	pressure	pain	stimulation	at	the	both	the	knee	and	sites	distant	to	the	joint,	which	reflects	altered	spinal	processing	of	afferent	input	(Arendt-Nielsen	et	al	2010).	In	addition,	these	patients	had	a	reduced	CPM	response,	indicated	the	importance	of	central	sensitisation	and	the	impairment	of	descending	inhibition	in	contributing	to	the	OA	associated	chronic	pain	(Arendt-Nielsen	et	al	2010).	Similarly,	a	study	in	patients	with	painful	hip	OA	reported	that	pressure	pain	thresholds	could	not	be	modulated	by	heterotopic	noxious	conditioning	stimulation,	whereas	this	produced	an	increased	threshold	in	controls,	indicating	a	dysfunction	DNIC	system	(Kosek	and	Orderberg	2000).	However,	when	these	patients	were	re-assessed	in	a	pain	free	state	6-14	months	after	total	joint	replacement	surgery,	pressure	pain	thresholds	could	be	modulated	by	heterotopic	noxious	conditioning	stimulation,	indicating	the	return	of	a	functional	DNIC	system	(Kosek	and	Orderberg	2000).	This	finding	agrees	with	previous	studies	that	report	the	DNIC	system	is	not	completely	abolished	in	chronic	pain	states,	rather	the	enhanced	descending	faciliatory	system	overrides	the	reduced	descending	inhibitory	system	activated	by	the	conditioning	stimulus	(Bannister	et	al	2015,	Bannister	et	al	2017).	It	has	previously	been	demonstrated	that	DNIC	can	be	restored	pharmacologically,	but	this	study	highlights	that	simply	treating	the	peripheral	nociceptive	drive	could	also	restore	DNIC.	However,	this	finding	contradicts	with	the	observation	that	a	subset	of	patients	remain	with	chronic	pain	following	total	joint	replacement	surgery	(Kosek	and	Orderberg	2000,	Wylde	et	al	2011).	Overall,	these	findings	highlight	the	importance	of	considering	spinal	hypersensitivity	and	dysfunctional	descending	controls	when	tackling	the	clinical	manifestations	associated	with	chronic	OA	pain.		
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The	chronic	pain	associated	with	OA	may	also	be	influenced	by	modulation	at	the	supraspinal	level;	morphological	alterations	and	increased	levels	of	activity	have	been	reported	in	brain	regions	in	OA	patients	with	signs	of	central	sensitisation	(Gwilym	et	al	2009,	Rodriguez-Raecke	et	al	2009,	Parks	et	al	2012).	Firstly,	Gwilym	and	colleagues	carried	out	an	fRMI	study	in	patients	with	chronic	hip	OA;	they	identified	increased	activity	in	the	PAG	midbrain	area	when	stimulating	areas	of	referred	pain,	indicating	PAG	activity	may	be	influencing	the	development	of	central	sensitisation	(Gwilym	et	al	2009).	Additionally,	Rogriguez-Raecke	and	colleagues	monitored	whole	brain	structures	in	patients	with	chronic	hip	OA	and	found	a	decrease	in	grey	matter	in	the	anterior	cingulate	cortex	(ACC),	dorsolateral	prefrontal	cortex	(dlPFC),	amygdala	and	brainstem	compared	to	age-matched	controls	(Rodriguez-Raecke	et	al	2009).	Remarkably,	when	this	procedure	was	repeated	in	a	subset	of	these	patients	who	were	pain	free	following	total	joint	replacement	an	increase	in	grey	matter	in	the	ACC,	dlPFC,	amygdala	and	grey	matter	was	observed,	indicating	the	grey	matter	abnormalities	were	reversible	consequences	of	the	nociceptive	drive	from	the	injured	hip	(Rodriguez-Raecke	et	al	2009).	Finally,	a	further	fMRI	study	in	patients	with	painful	knee	OA	found	a	dissociation	between	stimulus	evoked	and	spontaneous	pain	related	brain	area	activity,	with	the	latter	associated	with	the	activation	of	prefrontal-limbic	regions	(Parks	et	al	2012).	Interestingly,	the	brain	areas	highlighted	that	display	morphological	or	activity-related	changes,	have	all	been	reported	to	play	a	role	in	the	DNIC	response	(See	Section	1.2.4),	further	indicating	the	important	role	played	by	this	system	towards	the	development	of	chronic	OA	pain.			While	the	DNIC	system	represents	one	descending	pathway	controlled	by	the	SRD,	a	further	descending	system	in	the	dorsolateral	funiculus	(DLF)	exists,	which	is	controlled	from	other	brainstem	regions	such	as	the	RVM	(Bannister	and	Dickenson	2016a).	As	discussed	in	Section	1.1.5.5,	the	RVM	sends	modulatory	projections	directly	to	the	spinal	cord,	and	can	exert	bi-directional	control	of	the	pain	response	through	the	activation	of	pronociceptive	ON-cells	or	antinociceptive	OFF-cells	(Heinricher	et	al	1994).	As	the	RVM	receives	direct	inputs	from	the	PAG,	PbN,	and	LC,	and	is	considered	the	final	relay	for	descending	modulation	to	the	spinal	cord,	this	descending	pathway	may	also	be	contributing	to	the	development	of	central	sensitisation	(Ossipov	et	al	2010,	Ossipov	et	al	2014).	In	addition	to	the	interaction	between	the	RVM	and	the	noradrenergic	nucleus,	the	LC,	the	activation	of	RVM	descending	projections	results	in	the	release	of	serotonin	in	the	spinal	cord	(Ossipov	et	al	2014).	As	DNIC	has	been	demonstrated	to	rely	upon	noradrenergic	and	serotonergic	neurotransmission,	this	may	suggest	a	complex	
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interplay	between	the	two	descending	systems	is	required	for	the	final	DNIC	response	(Bannister	and	Dickenson	2016a).	Furthermore,	an	fMRI	study	in	human	subjects	demonstrated	that	increased	pain	perception	due	to	central	sensitisation	is	associated	with	activation	of	this	brainstem	region	(Lee	et	al	2008).	Overall,	neuronal	plasticity	in	supraspinal	brain	structures	and	alterations	in	both	ascending	and	descending	systems	should	be	considered	when	tackling	the	development	and	maintenance	of	central	sensitisation	in	OA	patients.			Experimentally	probing	the	DNIC	response	in	animals	models	holds	great	clinical	relevance,	and	allows	us	to	assess	the	functionality	of	descending	controls	in	chronic	pain	states	(Edwards	et	2003).	The	lack	of	DNIC	observed	in	the	late	phase	MIA	model	(See	Chapter	5),	indicates	that	neuronal	plasticity	within	the	spinal	cord,	supraspinal	brain	structures,	and	descending	controls	may	be	modulating	the	pain	response	in	this	model.	Therefore,	through	pharmacologically	manipulating	descending	controls	and	probing	the	DNIC	response	in	the	MIA	model,	we	can	better	understand	the	mechanisms	behind	its	loss	and	better	explore	therapies	that	restore	this	system.			
6.1.2	Tapentadol:	manipulating	the	descending	noradrenergic	and	
opioidergic	systems	to	achieve	analgesia	
	Tapentadol	Hydrochloride	((-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol	hydrochloride)	is	a	centrally	acting	novel	analgesic	that	combines	two	modes	of	action	in	one	molecule	(Wade	and	Spruill	2009,	Tzschentke	et	al	2009).	Tapentadol	is	a	μ-opioid	receptor	(MOR)	agonist	and	hence	activates	descending	opiodergic	controls,	while	also	functioning	as	a	NRI,	which	functions	to	increase	the	synaptic	availability	of	noradrenaline	and	subsequently	produces	analgesia	through	the	activation	of	α2-adrenoceptors	(Schroder	et	al	2011,	Tzschentke	et	al	2012).	Both	the	opioid	antagonist	naloxone	and	the	α2-adrenoceptor	antagonist	atipamezole	partially	block	tapentadols	analgesic	effect,	and	whole-cell	patch	clamping	has	demonstrated	that	tapentadol	has	similar	potency	for	MOR	activation	and	noradrenaline	transporter	inhibition,	indicating	the	importance	of	the	two	distinct	modes	of	actions	in	mediating	analgesia	(Schroder	et	al	2011,	Sadeghi	et	al	2015).	Tapentadol	has	44-fold	lower	affinity	for	the	MOR	than	morphine	and	yet	its	analgesic	potency	is	only	2-3	fold	lower	(Tzschentke	et	al	2007,	Tzschentke	et	al	2012).	In	addition,	tapentadols	NRI	activity	is	moderate,	as	it	has	weaker	binding	affinity	for	the	NA	transporter	than	other	NRIs	inclusing	duloxetine	and	nisoxetine	(Tzschentke	et	al	2007).	The	potent	analgesic	potential	of	tapentadol,	despite	
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its	moderate	affinities	for	the	MOR	and	NA	transporter,	suggests	a	synergistic	interaction	between	these	two	distinguished	mechanisms	(Schroder	et	al	2011).	Overall,	tapentadol	has	the	potential	to	be	a	powerful	analgesic	molecule,	which	also	avoids	the	adverse	side	effects	associated	with	opioid	analgesia	(Tzschentke	et	al	2014).			
6.1.2.1	The	efficacy	of	Tapentadol	in	patients	Tapentadol	has	proved	an	effective	analgesic	in	patients	with	several	chronic	pain	states	in	both	Phase	II	and	Phase	III	clinical	trials	(Wade	and	Spruill	2009).	Phase	II	clinical	trials	have	investigated	patients	with	moderate	to	severe	chronic	pain	following	bunionectomy	or	dental	surgical	extraction,	and	its	efficacy	and	tolerability	compared	to	morphine,	ibuprofen	and	placebo	(Lange	et	al	2006,	Stegmann	et	al	2006).	Both	studies	indicated	that	tapentadol	provided	rapid-onset	analgesia	and	produced	a	lower	incidence	of	adverse	side	effects,	such	as	nausea,	vomiting	and	dizziness,	than	morphine	(Lange	et	al	2006,	Stegmann	et	al	2006).	Furthermore,	Phase	III	clinical	trials	investigated	the	efficacy	and	tolerability	of	tapentadol	in	comparison	to	an	active	control,	the	opioid	oxycodone,	in	patients	with	low	back	pain	and	chronic	pain	associated	with	OA	of	the	hip	or	knee	(Hale	et	al	2009,	Hatrick	et	al	2009).	While	both	trials	indicated	that	tapentadol	provided	pain	relief	at	a	similar	level	to	oxycodone,	they	found	that	tapentadol	was	associated	with	an	improved	gastrointestinal	tolerability	as	fewer	patients	suffered	from	adverse	effects	(Hale	et	al	2009,	Hatrick	et	al	2009).	Overall,	these	clinical	findings	suggest	tapentadol	has	the	potential	to	be	an	effective	and	well-tolerated	analgesic	for	use	in	patients	with	OA	associated	chronic	pain	(Wade	and	Spruill	2009).			
6.1.2.2	The	efficacy	of	Tapentadol	in	animal	models	The	analgesic	efficacy	of	tapentadol	has	also	been	explored	in	animal	models	of	nociceptive,	inflammatory	and	neuropathic	pain	(Schroder	et	al	2010,	Bee	et	al	2011,	Schiene	et	al	2011).	Firstly,	tapentadol	proved	to	have	effective	antinociceptive	and	antihyperalgesic	properties	in	CFA,	formalin,	and	carrageenan-induced	models	of	acute	inflammation,	and	in	a	CFA-induced	arthritis	model	of	chronic	inflammatory	pain	(Schiene	et	al	2011).		Interestingly,	the	antinociceptive	effects	of	tapentadol	in	naïve	rats	were	demonstrated	to	be	mediated	predominantly	through	its	action	at	the	MOR,	while	the	antihypersensitive	effects	of	tapentadol	in	a	rat	SNL	model	were	demonstrated	to	rely	mainly	upon	the	inhibitory	actions	at	the	noradrenaline	transporter,	indicating	the	precise	molecular	mechanisms	through	which	tapentadol	functions	depends	upon	the	particular	pain	state	(Schroder	et	al	2010).	Similarly,	Bee	and	colleagues	investigated	
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the	efficacy	of	tapentadol,	in	combination	with	the	α2-adrenoceptor	antagonist	atipamezole	and	the	opioid	receptor	antagonist	naloxone,	in	SNL	and	sham	rats	(Bee	et	al	2011).	The	authors	demonstrated	both	atipamezole	and	naloxone	produced	near	complete	reversal	of	tapentadol	induced	inhibitory	actions	in	SNL	animals,	yet	in	sham	controls	tapentadol	induced	inhibitory	actions	functioned	predominantly	through	a	opioid	inhibitory	mechanisms	(Bee	et	al	2011).	Therefore,	the	authors	proposed	a	shift	in	tapentadols	analgesic	properties	from	a	predominant	opiodergic	mechanism	to	a	predominant	noradrenergic	mechanism	in	neuropathic	pain	states	(Bee	et	al	2011).	Furthermore,	the	action	of	the	serotonin	receptor	antagonist	ritanserin	was	explored	in	combination	with	tapentadol	in	both	inflammatory	and	neuropathic	animal	models	(Schroder	et	al	2010,	Schiene	et	al	2011).	Ritanserin	proved	ineffective	at	blocking	the	analgesic	actions	of	tapentadol	in	both	a	neuropathic	rat	model	and	a	CFA-induced	arthritis	model	of	chronic	inflammations,	indicating	tapentadol’s	inhibitory	actions	do	not	rely	on	the	serotonin	reuptake	inhibition	(Schroder	et	al	2010,	Schiene	et	al	2011).	Overall,	these	findings	incidate	that	both	MOR	agonism	and	NRI	mechansims	are	crucial	for	the	analgesic	actions	of	tapentadol,	with	the	predominant	mechanism	depending	upon	the	pain	state.	Previous	reports	have	suggested	that	the	DNIC	system	is	partly	opioid,	while	this	thesis	and	previous	work	have	demonstrated	functional	descending	noradrenergic	controls	are	crucial	for	DNIC	(Le	Bars	et	al	1981,	Bannister	et	al	2015,	Bannister	et	al	2017).	Therefore,	the	effect	of	tapentadol	on	restoring	the	expression	of	DNIC	is	investigated	in	the	late	phase	MIA	model	in	this	study.			
6.1.3	A	neuropathic	component	to	Osteoarthritis		IASP	define	neuropathic	pain	as	“pain	caused	by	a	lesion	or	disease	of	the	somatosensory	system”,	which	can	be	further	subdivided	into	central	and	peripheral	neuropathy.	Therefore,	to	assess	if	a	patient	is	suffering	with	neuropathic	pain,	a	number	of	diagnostic	criteria	and	clinical	features	are	examined	to	determine	the	likelihood	of	the	pain	arising	as	a	direct	consequence	of	damage	to	the	somatosensory	system	(Treede	et	al	2008)(Figure	6.1).	Conclusively	diagnosing	chronic	pain	as	a	result	of	neuropathy	remains	complicated	as	the	symptoms	and	signs	of	neuropathy	differ	extensively	between	individuals	(Suzuki	and	Dickenson	2000).	Firstly,	lesions	to	peripheral	nerves	can	cause	a	partial	or	complete	loss	of	afferent	inputs	to	the	central	nervous	system	and	a	subsequent	sensory	deficit,	which	demonstrate	negative	symptoms	such	as	areas	of	numbness	or	a	loss	of	sensitivity	(Suzuki	and	Dickenson	2000,	Jensen	and	Baron	2003).	Paradoxically,	patients	often	develop	peripheral	areas	of	
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hypersensitivity	adjacent	to	the	areas	of	sensory	loss,	which	can	be	identified	with	positive	symptoms	such	as	allodynia	and	hyperalgesia	(Suzuki	and	Dickenson	2000,	Jensen	and	Baron	2003).	Patients	with	neuropathy	can	present	with	just	one	of	these	symptoms,	while	many	patients	present	with	multiple	combinations	of	positive	and	negative	symptoms,	indicating	neuropathic	pain	can	arise	from	multiple	mechanisms	(Suzuki	and	Dickenson	2000).	Through	thoroughly	evaluating	the	pathology	behind	the	development	of	the	chronic	pain,	and	identifying	a	potential	neuropathic	component,	practitioners	would	be	better	placed	to	prescribe	effective	analgesics.			
	
Figure	6.1.	A	flow	chart	of	the	clinical	criteria	used	for	diagnosing	neuropathic	pain.	Diagnosing	neuropathic	pain	is	a	complex	task	due	to	the	multiple	and	varied	symptoms	presented	by	patients,	this	flow-chart	indicates	a	tool	for	diagnosing	the	probability	of	neuropathic	pain.	(Taken	from	Treede	et	al	2008).				
6.1.3.1	Osteoarthritis	patients	presenting	with	neuropathic	features	Several	studies	have	reported	that	subsets	of	OA	patients	develop	neuropathic	features	to	their	pain,	indicating	an	unmet	need	for	therapies	that	aim	to	tackle	the	neuropathic	component	(Thakur	et	al	2014).	Indications	of	OA	patients	experiencing	neuropathic	pain	include	patients	presenting	with	hypersensitivity	in	areas	distant	to	the	injured	joint,	and	patients	describing	pain	as	shooting	or	pins	and	needles	with	a	burning	quality	(Hawker	et	al	2008,	Wylde	et	al	2012).	Patients	with	neuropathic	pain	report	a	
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more	severe	pain	phenotype	and	a	poorer	quality	of	life,	hence	it	is	important	to	provide	the	appropriate	analgesic	(Freynhagen	et	al	2006).			The	pain-DETECT	questionnaire	was	originally	designed	for	patients	with	lower	back	pain,	as	a	screening	tool	to	identify	neuropathic	pain	components	(Freynhagen	et	al	2006).	This	questionnaire	proved	to	be	a	reliable,	sensitive	and	accurate	tool	for	detecting	neuropathy	in	patients	with	lower	back	pain,	and	has	now	been	extended	to	other	chronic	pain	states	(Freynhagen	et	al	2006).	In	a	cohort	of	patients	with	hip	OA,	those	with	higher	pain-DETECT	scores	experienced	lower	pain	thresholds	for	punctate	stimuli	in	areas	of	referred	pain	and	displayed	increased	activity	in	the	PAG	with	fMRI	imaging,	indicating	central	sensitisation	and	supraspinal	involvement	was	correlated	with	patients	with	neuropathic	components	of	pain	(Gwilym	et	al	2009).	Additionally,	a	cohort	of	259	patients	with	chronic	OA	of	the	knee	completed	the	pain-DETECT	questionnaire,	and	this	indicated	that	a	quarter	of	the	patients	in	this	study	had	neuropathic	symptoms	localized	to	the	knee	(Hochman	et	al	2011).	In	a	further	cohort	of	patients	with	chronic	knee	OA,	a	higher	pain-DETECT	score	was	positively	correlated	with	signs	of	central	sensitisation,	assessed	through	quantitative	sensory	testing	(QST)	(Hochman	et	al	2013).	Taken	together,	these	findings	indicate	that	OA	patients	describing	neuropathic	features	are	likely	to	have	developed	central	hypersensitivity,	and	may	benefit	from	a	more	thorough	evaluation	of	their	pathology	and	neuropathy	targeted	analgesics	(Hochman	et	al	2010).			
6.1.3.2	The	innervation	of	the	knee:	an	anatomical	case	for	neuropathy?	The	development	of	neuropathy	in	OA	patients	is	likely	due	to	compression	or	damage	of	peripheral	afferent	fibres	either	innervating	or	surrounding	the	joint	(Suzuki	and	Dickenson	2000,	Thakur	et	al	2014).	As	discussed	in	Section	1.3.4,	the	articular	cartilage	is	not	innervated	so	cartilage	damage	cannot	be	the	direct	source	of	pain,	and	also	cannot	be	the	direct	cause	of	neuropathy.	However,	as	all	other	joint	structures	contain	free	nerve	endings,	the	source	of	neuropathy	may	be	the	result	of	OA	induced	damaged	to	such	structures	(Schaible	et	al	2009).	Indeed,	the	subchondral	bone	is	densely	innervated	with	small	diameter	nociceptors	and	increased	incidence	of	OA	pain	is	associated	with	bone	marrow	lesions	(Wieland	et	al	2005,	Zhang	et	al	2011).	This	may	indicate	that	in	extreme	late-stage	cases	of	OA	with	completely	degraded	articular	cartilage	and	subchondral	bone	remodeling,	extensive	nerve	damage	also	occurs.	However,	MRI	scans	do	not	have	the	strength	to	identify	nerve	lesions	and	confirm	neuropathy.	In	addition,	the	synovium	has	a	vast	supply	of	unmyelinated	C	fibres	and	
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undergoes	a	large	inflammatory	infiltrate	following	the	initiation	of	OA	(Buchanan	and	Kean	2002,	Sellam	and	Berenbaum	2010).	Therefore,	the	synovium	may	be	a	further	source	of	peripheral	nerve	lesions,	potentially	due	to	inflammatory	damage.	Given	that	several	innervated	joint	structures	are	damaged	during	OA,	there	is	a	feasible	anatomical	case	for	the	compression	or	lesion	of	peripheral	nerves	within	the	joint.			The	pain	associated	with	OA	of	the	knee	is	most	common	within	medial	and	lateral	compartments	of	the	joint,	in	muscles	surrounding	the	joint,	and	along	the	upper	tibia	(Kean	et	al	2004).	The	presence	of	referred	pain	in	sites	distant	to	the	injured	knee,	most	often	the	hip	and	lower	back,	is	a	symptom	considered	to	be	associated	with	neuropathy	(Hochman	et	al	2011).	Furthermore,	when	the	pain	experience	was	examined	in	a	cohort	of	patient	with	knee	and	hip	OA,	many	participants	used	pain	descriptors	associated	with	neuropathy,	such	as	burning	or	tingling	(Hawker	et	al	2008).	These	neuropathic	features	may	be	a	result	of	spinal	hyperexcitability,	as	the	accumulation	of	nociceptive	input	from	multiple	joints	or	surrounding	areas	may	contribute	to	the	development	of	central	sensitisation	(Hochman	et	al	2011).	Alternatively,	the	anatomical	distribution	of	referred	pain	in	joints	and	surrounding	structures	observed	in	knee	OA	may	be	reflect	the	convergence	of	spinal	neurons	with	receptive	fields	in	the	joint	and	surrounding	tissues.	Overall,	if	a	patient	has	a	history	of	multiple	joint	pain	or	reports	with	neuropathic	features,	the	pathology	of	knee	pain	should	be	examined	extensively.			
6.1.3.3	A	neuropathic	component	to	the	MIA	model	As	the	extent	of	joint	damage	in	the	MIA	model	is	dependent	upon	dose	and	timing,	there	have	been	reports	that	while	the	2mg	model	causes	joint	degeneration	it	also	evokes	neuropathy	within	and	surrounding	the	joint	(Thakur	et	al	2012).	While	the	expression	of	inflammatory	cytokines	in	joints	tissues	and	DRGs	has	been	reported	to	peak	around	day	7-14	and	then	decline	in	the	MIA	model,	the	nerve	stress	marker,	activating	transcription	factor-3	(ATF-3),	has	been	reported	to	become	expressed	7	days	following	injection	and	increase	over	time	in	the	lumbar	DRGs	indicating	the	development	of	nerve	damage	over	time	(Ivanavicius	et	al	2007,	Orita	et	al	2011,	Thakur	et	al	2012).	Furthermore,	activated	microglia	in	the	ipsilateral	spinal	cord	has	been	reported	following	peripheral	nerve	damage,	and	so	microgliosis	may	also	indicate	the	development	of	neuropathy	in	this	model	(Calvo	and	Bennet	2012,	Thakur	et	al	2012).	This	study	will	investigate	the	development	of	a	neuropathic	component	in	the	2mg	MIA	model	further.		
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6.1.4	Gabapentin	and	pregabalin:	effective	analgesics	for	neuropathic	pain	The	gabapentinoid	drugs,	gabapentin	and	pregabalin,	were	originally	designed	as	analogues	of	GABA,	yet	neither	molecules	demonstrated	affinity	for	GABA	receptors	or	produced	significant	effects	on	GABA	levels	(Jensen	et	al	2002).	However,	gabapentin	and	pregablin	were	found	to	bind	to	the	α2δ	subunits	of	VGCCs,	with	the	highest	affinity	for	the	α2δ1	subunit,	which	are	involved	in	the	activation	kinetics	and	trafficking	of	the	channel	to	the	plasma	membrane	(Davies	et	al	2007).	Both	gabapentin	and	pregablin	have	proved	effective	in	animal	models	of	neuropathy,	and	are	now	considered	key	therapies	for	relieving	pain	in	neuropathic	conditions	(Patel	and	Dickenson	2016).			As	discussed	in	Section	1.1.3.3,	VGCCs	are	crucial	for	the	transmission	of	the	nociceptive	signal	from	the	periphery	to	the	spinal	cord,	and	translate	the	electrical	nociceptive	signal	into	a	chemical	one	through	triggering	the	release	of	neurotransmitters	(Snutch	2005,	Simms	and	Zamponi	2014).	The	α2δ1	subunit	is	responsible	for	enhancing	the	trafficking	of	VGCCs	to	the	neuronal	cell	membrane,	which	subsequently	increases	the	calcium	current	density,	and	as	such	the	α2δ1	subunit	can	accelerate	activation	and	inactivation	of	calcium	currents	(Dolphin	2013,	Patel	and	Dickenson	2016).	The	α2δ1	subunit	is	expressed	in	the	dorsal	horn,	predominantly	presynaptically	in	superficial	lamina,	but	there	is	also	a	moderate	expression	postsynaptically	on	neurons	in	the	deeper	lamina	(Taylor	and	Garrido	2008).	The	α2δ1	subunit	is	also	expressed	in	a	subset	of	unmyleinated	C	fibre	neurons	within	the	DRGs	(Taylor	and	Garrido	2008).	Overall,	the	α2δ1	subunit	regulates	the	trafficking	of	VGCCs	to	plasma	membranes,	thereby	influencing	calcium	influx	and	the	synaptic	release	of	neurotransmitters	(Patel	and	Dickenson	2016).		As	discussed	in	Section	1.1.6,	activity	dependent	central	sensitisation	can	be	mediated	via	activation	of	intracellular	signaling	cascades,	which	can	subsequently	activate	transcriptional	changes	within	neurons	(Woolf	and	Salter	2000).	One	example	of	this	is	the	upregulation	of	the	α2δ1	subunit	following	neuropathy;	increased	levels	of	the	α2δ1	subunit	have	been	demonstrated	in	the	dorsal	horn	and	DRGs	following	nerve	injury	in	rat	SNL	models	(Figure	6.2)	(Luo	et	al	2001,	Newton	et	al	2001,	Bauer	et	al	2009).	Interestingly,	uninjured	transgenic	mice	overexpressing	the	α2δ1	subunit	have	reduced	mechanical	withdrawal	thresholds,	which	are	similar	to	those	observed	in	SNL	mice,	yet	this	behavioural	hypersensitivity	was	significantly	attenuated	by	both	N-	and	L-type	calcium	channel	blockers	(Chang	et	al	2015).	Additionally,	whole-cell	patch	clamping	
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recordings	have	demonstrated	that	spinal	neurons	overexpressing	the	α2δ1	subunit	have	an	increased	frequency	of	miniature	excitatory	post-synaptic	currents	(EPSC),	which	is	mediated	by	AMPA	and	NMDA	receptors	(Nguyen	et	al	2009,	Zhou	and	Lou	2014).				Furthermore,	α2δ1-/-	knock-out	mice	show	a	delay	in	developing	mechanical	hypersensitivity	following	partial	sciatic	nerve	ligation,	yet	a	chronic	pain	state	does	eventually	develop,	suggesting	that	increased	expression	of	the	α2δ1	subunit	is	not	crucial	for	the	initiation	and	maintenance	of	central	sensitisation	(Patel	et	al	2013).	These	findings	indicate	that	elevated	levels	of	the	α2δ1	subunit	mediates	an	enhanced	excitability	of	afferent	fibres	and	increased	release	of	pre-synaptic	glutamate,	which	subsequently	leads	to	reduced	excitation	thresholds	of	post-synaptic	second	order	dorsal	horn	neurons	(Nguyen	et	al	2009,	Patel	and	Dickenson	2016).	Overall,	these	mechanisms	manifest	as	behavioural	hypersensitivity.			
	
Figure	6.2.	A	cross-section	of	the	L5	lumbar	region	of	the	spinal	cord	showing	α2δ1	
immunoreactivity	from	an	SNL	rat	24	days	after	surgery.	The	green	staining	represents	α2δ1	subunit	expression	while	blue	represents	nuclear	counter-staining.	There	is	a	substantial	increase	in	the	level	of	staining	for	α2δ1	subunits	in	the	dorsal	horn	ipsilateral	to	nerve	injury.	The	arrow	indicates	an	increase	in	α2δ1	subunit	expression	in	ipsilateral	motor	neurons.	(Taken	from	Bauer	et	al	2009).		Several	studies	indicate	that	α2δ1	subunit	expression	levels	are	increased	following	neuropathy	and	gabapentinoid	drugs	bind	with	high	affinity	to	the	α2δ1	subunit,	supporting	the	concept	that	the	α2δ1	subunit	is	the	molecular	target	for	mediating	the	
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gabapentinoid	drugs	analgesic	effects	(Gee	et	al	1996,	Fields	et	al	2006,	Bauer	et	al	2009,	Li	et	al	2011).	The	exact	molecular	mechanisms	in	which	targeting	the	α2δ1	subunit	inhibits	the	release	of	neurotransmitters	are	yet	to	be	determined.	The	chronic	application	of	Gabapentin	inhibited	voltage-gated	Ca2+	influx	in	DRG	neurons,	yet	acute	application	did	not	consistently	reduce	calcium	currents	(Sutton	et	al	2002,	Hendrich	et	al	2008).	Additionally,	chronic	systemic	pregabalin	has	been	demonstrated	to	inhibit	the	trafficking	of	the	α2δ1	subunit	to	presynaptic	terminals	in	the	dorsal	horn	in	SNL	rats	(Bauer	et	al	2009).	This	indicates	that	reduced	trafficking	of	the	α2δ1	subunit	and	the	subsequent	reduction	in	density	of	VGCCs,	reduces	calcium	currents	and	therefore	inhibits	the	release	of	neurotransmitters	(Hendrich	et	al	2008).	Given	the	time	frame	required	for	axonal	trafficking	effects,	it	is	unlikely	this	mechanism	is	responsible	for	the	analgesic	effects	of	acute	gabapentinoid	treatment	(Field	et	al	2006,	Patel	et	al	2013).	Therefore,	there	is	likely	distinct	molecular	mechanisms	for	the	analgesic	effects	of	acute	and	chronic	gabapentinoid	treatment.			Despite	the	α2δ1	subunit	being	the	sole	target	for	the	analgesic	actions	of	gabapentinoids,	an	upregulation	of	the	α2δ1	subunit	is	not	always	crucial	for	gabapentinoid	drugs	to	have	effective	analgesic	actions	(Suzuki	et	al	2005).	The	development	of	central	sensitisation	and	the	subsequent	enhanced	activity	of	descending	brainstem	facilitations	acting	on	spinal	5-HT3	receptors	has	been	demonstrated	to	create	the	necessary	conditions	for	gabapentinoid	drugs	to	mediate	analgesia	(Suzuki	et	al	2005).	Interestingly,	when	the	spino-bulbo-spinal	loop	was	disrupted	in	SNL	rats,	through	ablation	of	spinal	NK1	projection	neurons	or	µ-opioid	receptor	expressing	neurons	in	the	RVM	with	the	neurotoxin	saporin,	gabapentinoids	could	no	longer	inhibit	the	excitability	of	WDR	neurons	in	the	dorsal	horn	(Suzuki	et	al	2005,	Bee	and	Dickenson	2008).	Furthermore,	the	intrathecal	administration	of	the	5-HT3	receptor	antagonist	ondansetron	attenuated	tactile	allodynia	and	thermal	hyperalgesia	in	SNL	mice	and	transgenic	mice	overexpressing	the	α2δ1	subunit	(Chang	et	al	2013).	Remarkably,	when	a	5-HT3	receptor	agonist	was	applied	spinally	in	naïve	rats,	pregablin	could	inhibit	spinal	neurons	even	in	the	absence	of	injury	(Suzuki	et	al	2005).	These	findings	indicated	that	the	activation	of	pre-synpatic	5-HT3	receptors	in	the	dorsal	horn,	due	to	central	sensitisation	and	enhanced	descending	facilitations,	creates	adequate	conditions	for	gabapentinoid	drugs	to	inhibit	calcium	currents	and	subsequently	prevent	neurotransmitter	release.	This	may	imply	interactions	occur	between	α2δ1	subunits	and	descending	brainstem	controls	acting	at	spinal	5-HT3	receptors,	and	therefore	gabapentinoids	may	be	effective	in	non-neuropathic	pain	
	 225	
conditions	where	there	is	no	upregulation	of	the	α2δ1	subunits	(Patel	and	Dickenson	2016).			Overall,	the	gabapentinoid	drugs	are	effective	analgesic	molecules	in	neuropathic	conditions,	which	function	by	preventing	the	trafficking	of	α2δ1	subunits	of	VGCCs	to	the	plasma	membrane	of	active	synapses	in	the	dorsal	horn,	inhibiting	voltage	gated	calcium	currents	and	subsequently	preventing	the	release	of	neurotransmitters.	However,	the	gabapentinoids	may	also	prove	effective	in	non-neuropathic	conditions	when	central	sensitisation	has	developed	and	there	is	enhanced	activation	of	spinal	5-HT3	receptors	due	to	an	increased	facilitatory	drive	from	the	brainstem.		
6.1.4.1	The	efficacy	of	gabapentin	and	pregabalin	in	patients	Both	gabapentin	and	pregabalin	have	proved	effective	in	patients	with	peripheral	and	central	neuropathy	(Wiffen	et	al	2005,	Moore	et	al	2014a,	Moore	et	al	2014b).	In	advanced	OA	cases,	when	articular	cartilage	is	extensively	damaged	and	destruction	of	the	subchondral	bone	occurs,	there	may	be	the	induction	of	neuropathic	features	(Thakur	et	al	2014).	Therefore,	gabapentinoid	drugs	may	also	prove	effective	in	a	subset	of	OA	patients.	Indeed,	a	combination	therapy	of	pregabalin	with	the	NSAID	Meloxicam	proved	more	effective	at	relieving	pain	in	a	cohort	of	patients	with	knee	OA	than	pregabalin	and	Meloxicam	treatments	alone	(Ohtori	et	al	2013).	The	authors	concluded	that	both	inflammatory	and	neuropathic	elements	contributed	to	the	pain	associated	with	knee	OA	in	these	patients	(Ohtori	et	al	2013).	This	indicates	further	that	if	neuropathic	components	are	identified	in	patients	with	OA,	they	are	likely	to	benefit	from	gabapentinoid	analgesics.			
6.1.4.2	The	efficacy	of	gabapentin	and	pregabalin	in	animal	models		Both	gabapentin	and	pregabalin	have	been	shown	to	have	analgesic	actions	in	the	MIA	model	of	OA	(Ivanavicius	et	al	2007,	Rahman	et	al	2009,	Vonsy	et	al	2009,	Thakur	et	al	2012).	Chronic	gabapentin	treatment	has	been	demonstrated	to	attenuate	cooling	hypersensitivity,	reduce	ambulatory-evoked	pain	scores,	and	weight-bearing	asymmetry	in	rats	14	days	after	MIA	injection	(Ivanavicius	et	al	2007,	Vonsy	et	al	2009).	Electrophysiological	recordings	of	WDR	neurons	in	the	2mg	MIA	rat	model	have	demonstrated	that	systemic	pregabalin	significantly	reduced	mechanically	and	thermally	evoked	neuronal	responses,	while	acute	pregabalin	treatment	did	not	have	this	effect	in	saline	injected	sham	controls	(Rahman	et	al	2009,	Thakur	et	al	2012).	In	addition,	despite	an	elevated	expression	of	α2δ1	mRNA	in	L3-L6	DRGs	from	MIA	animals,	
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the	inhibitory	actions	of	pregabalin	on	spinal	neurons	was	blocked	by	spinal	pre-administration	of	the	5-HT3	receptor	antagonist	ondansetron.	This	indicates	that	even	with	elevated	levels	of	α2δ1,	an	enhanced	descending	faciliatory	drive	acting	at	spinal	5-HT3	receptors	is	required	for	pregabalins	analgesic	actions	(Rahman	et	al	2009).	As	pregabalin	has	proved	effective	in	the	MIA	model	and	involves	an	enhanced	serotonergic	drive	acting	at	5-HT3	receptors	in	the	spinal	cord,	which	is	linked	to	the	loss	of	DNIC	in	chronic	pain	states,	this	study	will	investigate	the	efficacy	of	pregabalin	and	its	subsequent	effect	on	DNIC	expression	in	the	2mg	MIA	model	(Bannister	et	al	2015).			
6.1.5	Chapter	aims	This	study	aimed	to	further	investigate	the	descending	pathways	involved	in	the	expression	of	DNIC.	Firstly,	through	pharmacologically	manipulating	noradrenaline	levels	and	blocking	the	α2-adrenoceptors.	Secondly,	through	pharmacologically	modulating	the	activity	of	the	5-HT7	receptor	with	a	selective	antagonist	and	agonist	in	the	early	and	late	phase	MIA	animals	respectively.	Further,	any	pharmacological	effects	due	to	upregulation	of	the	noradrenergic	and	serotonergic	receptors	in	the	spinal	cord	or	DRGs	was	explored.	A	neuropathic	component	to	the	2mg	MIA	model	was	investigated	through	assessing	the	innervation	of	the	knee	with	a	neuronal	tracer	and	analyzing	expression	of	the	neuronal	damage	marker	ATF-3	in	lumbar	DRGs.	The	efficacy	of	Pregabalin	was	assessed	and	compared	in	the	early	and	late	phase	MIA	model,	and	its	effect	on	the	expression	of	DNIC	was	investigated.	Finally,	the	inhibitory	effect	on	mechanically	evoked	spinal	neuronal	firing	in	response	to	of	a	combination	therapy	of	Tapentadol	and	Pregabalin	was	assessed.	Overall,	this	study	aimed	to	pharmacologically	restore	DNIC	in	late	phase	MIA	animals	to	better	understand	the	alterations	in	descending	controls	that	may	mediate	its	loss,	and	to	better	understand	the	neuropathic	component	of	the	2mg	MIA	model.								
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6.2	Methods	
	
6.2.1	Electrophysiology	Electrophysiological	recordings	were	taken	as	previously	described	(See	Section	2.1);	in	early	phase	animals	this	was	2-6	days	post	MIA	injection,	and	for	late	phase	animals	this	was	14-20	days	post	MIA	injection.	For	pharmacology	experiments,	extracellular	recordings	were	taken	from	WDR	neurons	in	the	ipsilateral	dorsal	horn	relative	to	MIA	injection.		
	
6.2.2	Pharmacology	
	Early	phase	MIA	animals		
• SB-269970	(Tocris)	is	a	5-HT7	receptor	antagonist.	This	was	dissolved	in	saline	and	applied	topically	(100μg/50μL)	to	the	spinal	cord.			
• Atipamezole	(Sigma)	is	an	α2-adrenoceptor	antagonist.	Atipamezole	was	dissolved	in	vehicle	(97%	normal	saline,	2%	cremaphor,	1%	DMSO)	and	a	concentration	of	(100μg/50μL)	was	applied	topically	to	the	spinal	cord.			
• Pregabalin	(gifted	from	Pfizer)	is	an	analogue	of	Gabapentin.	Pregabalin	was	dissolved	in	normal	saline	to	a	concentration	of	10mg/ml.	This	is	then	injected	subcutaneously	with	the	volume	dependent	on	the	weight	of	the	animal	such	that	the	dose	delivered	was	always	10mg/kg.		Early	phase	Sham	control	animals	received	an	intra-articular	injection	of	25μL	saline,	with	electrophysiology	and	pharmacology	carried	out	2-6	days	post	injection.				Late	Phase		
• AS-19	(Tocris)	is	a	selective	5-HT7	receptor	agonist.	This	was	dissolved	in	vehicle	(97%	normal	saline,	2%	cremaphor,	1%	DMSO)	and	applied	topically	to	the	spinal	cord	(100μg/50μL).		
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• Tapentadol	(gifted	from	Grunenthal)	has	a	dual	mode	of	action;	it	is	a	μ	opiod	receptor	agonist	and	a	noradrenaline	reuptake	inhibitor.	This	was	dissolved	in	normal	saline	and	injected	subcutaneously	at	3	doses;	1mg/kg,	2mg/kg	and	5mg/kg.			
• Pregabalin	(Pfizer)	was	dissolved	in	normal	saline	and	injected	subcutaneously	to	give	a	systemic	dose	of	10mg/kg.			Late	phase	Sham	control	animals	received	an	intra-articular	injection	of	25μL	saline,	with	electrophysiology	and	pharmacology	carried	out	14-20	days	post	injection.			
6.2.3	Immunohistochemistry	The	lumbar	spinal	cord	and	the	L3-L5	DRGs	ipsilateral	to	MIA	injection	were	taken	from	early	and	late	phase	MIA	and	sham	animals.	For	early	phase	animals	tissues	were	removed	on	day	4	post-injection,	for	late	phase	animals	tissues	were	removed	on	day	14	post-injection.	The	tissue	was	processed	as	described	in	Section	2.6.		
6.2.4	qPCR	The	ipsilateral	lumbar	dorsal	horn	and	ipsilateral	L3-L5	DRGs	were	taken	from	MIA	and	sham	animals.	For	early	phase	MIA	and	sham	animals	the	tissue	was	taken	4	days	post-injection.	For	late	phase	MIA	and	sham	animals	the	tissue	was	taken	14	days	post-injection.	The	tissue	was	processed	as	discussed	in	Section	2.7.		
6.2.5	Statistical	analysis	For	a	description	of	the	statistical	tests	used	for	analysis	please	refer	to	section	2.8.												
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6.3	Results	
	
6.3.1	The	role	of	the	5-HT7	receptor	in	the	expression	of	DNIC	in	the	MIA	
model	The	loss	of	DNIC	observed	in	late	phase	MIA	animals	may	develop	due	to	an	imbalance	in	descending	inhibitory	and	facilitatory	descending	controls	arising	in	the	brainstem,	which	is	similar	to	that	observed	in	a	SNL	rat	model	of	neuropathy	(Bannister	et	al	2015).		As	discussed	in	Chapter	4,	increased	levels	of	serotonin	acting	upon	the	5-HT7	receptor	in	the	spinal	cord	is	sufficient	to	restore	DNIC	in	a	SNL	rat	model	of	neuropathy	(Bannister	et	al	2017).	Therefore,	the	role	played	by	the	5-HT7	receptor	in	the	expression	of	DNIC	was	assessed	further	in	early	and	late	phase	MIA	animals.			Firstly,	as	a	functioning	DNIC	system	was	present	in	early	phase	MIA	animals,	the	actions	of	serotonin	acting	at	the	5-HT7	receptor	were	blocked	using	the	selective	5-HT7	receptor	antagonist	SB-2669970.	Following	spinal	administration	of	the	5-HT7	receptor	antagonist,	the	resultant	DNIC	expression	was	assessed	in	order	to	investigate	the	role	played	by	the	5-HT7	receptor	when	the	DNIC	system	is	functional.			In	early	phase	MIA	animals,	the	5-HT7	receptor	antagonist	reduced	the	DNIC	expression	with	a	concurrent	noxious	ear	and	knee	pinch	but	did	not	abolish	it.	Following	spinal	application	of	the	5-HT7	receptor	antagonist,	the	inhibition	of	mechanically	evoked	neuronal	firing	induced	by	DNIC	following	application	of	a	concurrent	noxious	ear	pinch	fell	from	approximately	30%	for	all	mechanical	stimulations	to	15%,	21%	and	19%	for	8g,	26g	and	60g	stimulations	respectively	in	early	phase	MIA	animals	(Figure	6.3A).	Furthermore,	the	neuronal	inhibition	induced	by	DNIC	with	a	concurrent	noxious	knee	pinch	fell	to	35%,	16%,	and	17%	with	8g,	26g,	and	60g	stimulations	respectively	in	early	phase	MIA	animals	(Figure	6.3A).	Therefore,	the	level	of	neuronal	inhibition	was	reduced	by	approximately	10%	when	the	actions	of	serotonin	acting	at	5-HT7	receptors	in	the	spinal	cord	was	blocked,	yet	the	reduction	in	neuronal	firing	induced	by	a	concurrent	noxious	ear	or	knee	pinch	was	still	significant	compared	to	pre-conditioned	responses	(Figure	6.3A).	Similarly,	the	level	of	mechanically	evoked	neuronal	inhibition	was	reduced	but	not	abolished	in	early	phase	saline	injected	sham	control	animals	(Figure	6.3C).	Overall,	the	spinal	application	of	the	5-HT7	receptor	antagonist	had	no	significant	effect	on	pre-conditioned	baseline	mechanically	evoked	neuronal	responses	in	either	early	phase	MIA	or	sham	animals	(Figure	6.3B	and	6.3D).	As	the	5-HT7	receptor	
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reduced	but	did	not	block	the	expression	of	DNIC	in	both	early	phase	MIA	and	sham	animals,	it	indicates	that	while	5-HT7	receptors	in	the	spinal	cord	may	play	an	inhibitory	role	involved	with	the	induction	of	DNIC,	other	receptors	in	the	spinal	cord	must	also	be	responsible	for	full	DNIC	expression.			Secondly,	as	DNIC	is	abolished	in	late	phase	MIA	animals,	it	was	investigated	if	activation	of	spinal	5-HT7	receptors	with	the	selective	agonist	AS-19	was	sufficient	to	restore	DNIC.	The	actions	of	the	spinal	application	of	the	selective	5-HT7	receptor	agonist	AS-19	on	the	expression	of	DNIC	was	also	assessed	in	late	phase	saline	injected	sham	controls	where	the	DNIC	system	was	fully	functional.			In	late	phase	MIA	injected	animals,	the	spinal	application	of	the	5-HT7	agonist	restored	DNIC	such	that	a	significant	reduction	in	mechanically	evoked	neuronal	firing	was	achieved	with	concurrent	noxious	ear	and	knee	pinch	(Figure	6.3E).	Following	the	spinal	application	of	the	5-HT7	receptor	agonist	in	late	phase	MIA	animals,	the	mechanically	evoked	neuronal	responses	to	8g,	26g,	and	60g	stimulations	was	reduced	by	28%,	34%,	and	32%	with	a	concurrent	noxious	ear	pinch,	and	51%,	31%,	and	25%	with	a	concurrent	noxious	knee	pinch	(Figure	6.3E).	Furthermore,	the	spinal	application	of	the	5-HT7	receptor	agonist	in	late	phase	MIA	animals	significantly	reduced	pre-conditioned	mechanically	evoked	neuronal	firing.			In	late	phase	saline	injected	sham	controls,	the	pre-drug	level	of	neuronal	inhibitions	were	48%,	44%,	and	40%	induced	with	a	concurrent	noxious	ear	pinch,	and	54%,	42%,	and	46%	induced	with	a	concurrent	noxious	knee	pinch	in	response	to	8g,	26g	and	60g	mechanical	stimulations	respectively	(Figure	6.3G).	Following	spinal	application	of	the	5-HT7	receptor	agonist,	the	levels	of	neuronal	inhibition	were	37%,	45%,	and	37%	induced	with	a	concurrent	noxious	ear	pinch,	and	58%,	54%,	and	42%	induced	with	a	concurrent	noxious	knee	pinch	in	response	to	8g,	26g	and	60g	mechanical	stimulations	respectively	(Figure	6.3G).	This	indicates	that	the	levels	of	neuronal	inhibition	induced	by	DNIC	did	not	appear	to	alter	consistently	following	the	spinal	activation	of	5-HT7	receptors.	Additionally,	the	spinal	application	of	the	5-HT7	receptor	agonist	did	not	significantly	affect	the	pre-conditioned	mechanically	evoked	neuronal	firing	(Figure	6.3F).	Overall,	these	findings	indicate	that	when	DNIC	is	functional,	as	is	the	case	in	saline	injected	sham	controls,	further	activation	of	spinal	5-HT7	receptors	does	not	result	in	an	increased	level	of	inhibition.			
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As	the	spinal	application	of	the	5-HT7	receptor	agonist	restores	DNIC	in	late	phase	MIA	animals	but	has	limited	effects	in	late	phase	saline	injected	sham	controls,	it	indicates	the	function	of	the	5-HT7	receptor	may	become	altered	in	states	of	chronic	pain.	Furthermore,	alterations	in	the	activation	properties	of	spinal	5-HT7	receptors	may	be	involved	in	the	development	of	an	abolished	DNIC	system	in	the	late	phase	MIA	animals.		
	
Figure	6.3.	The	involvement	of	the	5-HT7	receptor	in	the	expression	of	DNIC	in	early	and	
late	phase	MIA	and	sham	animals.	A)	The	spinal	application	of	the	5-HT7	receptor	antagonist	SB-269970	in	early	phase	MIA	animals	reduced	the	level	of	DNIC	induced	by	concurrent	noxious	
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ear	and	knee	pinch	but	did	not	abolish	it	(n=6).	B)	The	spinal	application	of	the	5-HT7	receptor	antagonist	SB-269970	in	early	phase	MIA	animals	did	not	affect	the	pre-conditioned	mechanically	evoked	neuronal	responses.	C)	The	spinal	application	of	the	5-HT7	receptor	antagonist	SB-269970	in	early	phase	sham	animals	reduced	the	level	of	neuronal	inhibition	induced	by	DNIC	but	did	not	abolish	it	(n=6).	D)	The	spinal	application	of	the	5-HT7	receptor	antagonist	SB-269970	in	early	phase	sham	animals	did	not	affect	the	pre-conditioned	mechanically	evoked	neuronal	responses.	E)	The	spinal	application	of	the	5-HT7	receptor	agonist	AS-19	in	late	phase	MIA	animals	restored	neuronal	inhibition	induced	by	a	concurrent	noxious	ear	or	knee	pinch	(n=6).	F)	The	spinal	application	of	the	5-HT7	receptor	agonist	AS-19	in	late	phase	MIA	animals	significantly	reduced	pre-conditioned	mechanically	evoked	neuronal	responses.	G)	The	spinal	application	of	the	5-HT7	receptor	agonist	AS-19	in	late	phase	sham	animals	had	little	effect	on	the	level	of	mechanically	evoked	neuronal	inhibition	induced	by	a	concurrent	noxious	ear	or	knee	pinch	(n=5).	H)	The	spinal	application	of	the	5-HT7	receptor	agonist	AS-19	in	late	phase	sham	animals	did	not	effect	the	pre-conditioned	mechanically	evoked	neuronal	responses.	Two-way	ANOVA	with	Bonferroni	correction.	(*P<0.05,	**P<0.01,	***P<0.001).			
6.3.2	The	involvement	of	the	descending	noradrenergic	system	in	the	
expression	of	DNIC	in	the	MIA	model		
	It	has	been	demonstrated	in	Chapter	4	and	in	previous	studies	that	the	full	expression	of	DNIC	is	reliant	upon	an	inhibitory	descending	noradrenergic	system	acting	at	α2-adrenergic	receptors	in	the	spinal	cord	(Bannister	et	al	2015,	Bannister	et	al	2017).	Therefore,	the	requirement	of	noradrenaline	acting	at	α2-adrenergic	receptors	in	the	spinal	cord	for	the	expression	of	DNIC	was	assessed	in	early	phase	MIA	and	sham	animals,	where	the	DNIC	system	was	functional.	Specifically,	the	actions	of	noradrenaline	at	α2-adrenergic	receptors	in	the	spinal	cord	were	blocked	with	the	α2-adrenergic	receptor	antagonist	atipamezole	and	the	resultant	DNIC	expression	was	assessed	in	early	phase	MIA	and	sham	animals.			In	early	phase	MIA	animals,	the	spinally	applied	α2-adrenergic	receptor	antagonist	blocked	the	DNIC	effect,	such	that	there	was	no	significant	reduction	of	mechanically	evoked	neuronal	firing	with	either	a	concurrent	noxious	ear	or	knee	pinch	(Figure	6.4A).	The	spinal	application	of	the	α2-adrenergic	receptor	antagonist	also	resulted	in	facilitated	pre-conditioned	responses,	with	a	significantly	increased	number	of	action	potentials	fired	in	response	to	8g,	26g	and	60g	(Figure	6.4B).	Similarly,	the	spinal	application	of	the	α2-adrenergic	receptor	antagonist	blocked	the	DNIC	effect	in	early	phase	sham	animals.	There	was	no	significant	inhibition	of	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	ear	pinch,	and	no	significant	reduction	of	26g	and	60g	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	knee	pinch	(Figure	6.4C).	However,	there	was	still	a	significant	23%	reduction	in	neuronal	firing	with	a	concurrent	noxious	knee	pinch	in	response	to	the	8g	stimulation	(Figure	6.4C).	Interestingly,	the	spinal	application	of	the	α2-adrenergic	receptor	antagonist	had	no	
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significant	effect	on	the	pre-conditioned	mechanically	evoked	neuronal	responses	in	early	phase	saline	injected	sham	controls	(Figure	6.4D).	As	the	spinal	application	of	the	α2-adrenergic	receptor	antagonist	facilitates	neuronal	responses	in	early	phase	MIA	animals	but	not	in	saline	injected	controls,	it	may	indicate	an	enhanced	inhibitory	noradrenergic	descending	system	in	the	early	MIA	state.			
	
Figure	6.4.	The	role	played	by	the	inhibitory	noradrenergic	descending	system	in	the	
expression	of	DNIC	in	the	early	phase	MIA	model.	A)	The	spinal	application	of	the	α2-adrenergic	receptor	antagonist	atipamezole	blocks	the	inhibitory	effect	on	mechanically	evoked	neuronal	firing	induced	by	DNIC	in	early	phase	MIA	animals	(n=5).	B)	The	spinal	application	of	the	α2-adrenergic	receptor	antagonist	atipamezole	facilitates	the	pre-conditioned	mechanically	evoked	neuronal	responses	in	early	phase	MIA	animals	(n=5).	C)	The	spinal	application	of	the	α2-adrenergic	receptor	antagonist	atipamezole	blocks	the	inhibitory	effect	on	neuronal	firing	induced	by	a	concurrent	noxious	ear	pinch	to	all	mechanical	stimulations	and	by	a	concurrent	noxious	knee	pinch	in	response	to	26g	and	60g	mechanical	stimulations	in	early	phase	sham	animals	(n=5).	The	spinal	application	of	the	α2-adrenergic	receptor	antagonist	atipamezole	has	no	effect	on	the	pre-conditioned	mechanically	evoked	neuronal	responses	in	early	phase	saline	injected	sham	controls	(n=5).	Two-way	ANOVA	with	Bonferroni	correction.	(*P<0.05,	**P<0.01,	***P<0.001).			
6.3.2.1	The	actions	of	Tapentadol	in	late	phase	MIA	animals	
	Tapentadol	has	a	dual	mode	of	action,	acting	as	both	a	NRI	and	an	agonist	for	the	MOR.	As	the	DNIC	system	has	been	reported	to	rely	upon	descending	noradrenergic	inhibitory	controls,	but	also	have	a	partly	opioid	component,	the	actions	of	Tapentadol	were	assessed	in	late	phase	MIA	animals	and	saline	injected	sham	controls	(Le	Bars	et	al	1981,	Bannister	et	al	2015,	Bannister	et	al	2017).	Specifically,	it	was	investigated	if	the	
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combination	of	increased	levels	of	synaptic	noradrenaline	and	MOR	agonism	were	sufficient	to	restore	DNIC	in	late	phase	MIA	animals.			All	of	the	doses	of	Tapentadol	tested	(1mg/kg,	2mg/kg	and	5mg/kg)	restored	the	inhibitory	effect	on	mechanically	evoked	neuronal	inhibition	induced	by	either	a	concurrent	noxious	ear	or	knee	pinch	(Figure	6.5).	Following	a	systemic	dose	of	1mg/kg	Tapentadol,	the	level	of	neuronal	inhibition	induced	by	a	concurrent	noxious	ear	pinch	was	6%,	22%	and	27%	and	by	a	concurrent	noxious	knee	pinch	was	31%,	22%	and	28%	with	8g,	26g	and	60g	mechanical	stimulations	respectively	(Figure	6.5A).	Following	a	systemic	dose	of	2mg/kg	Tapentadol,	the	level	of	neuronal	inhibition	induced	by	a	concurrent	noxious	ear	pinch	was	21%,	31%	and	31%	and	by	a	concurrent	noxious	knee	pinch	was	10%,	28%	and	32%	with	8g,	26g	and	60g	mechanical	stimulations	respectively	(Figure	6.5C).	Following	a	systemic	dose	of	5mg/kg	Tapentadol,	the	level	of	neuronal	inhibition	induced	by	a	concurrent	noxious	ear	pinch	was	25%,	33%,	and	31%	and	by	a	concurrent	noxious	knee	pinch	was	16%,	33%	and	32%	with	8g,	26g	and	60g	mechanical	stimulations	respectively	(Figure	6.5E).	Interestingly,	for	1mg/kg	of	Tapentadol	there	was	only	a	significant	reduction	of	neuronal	firing	induced	by	DNIC	in	response	to	the	most	noxious	60g	mechanical	stimulation,	while	for	2mg/kg	and	5mg/kg	Tapentadol	there	was	a	significant	reduction	of	neuronal	firing	induced	by	DNIC	in	response	to	26g	and	60g	mechanical	stimulations	(Figure	6.5A,	6.5C,	and	6.5E).	At	no	Tapentadol	dose	was	the	inhibitory	effect	on	8g	mechanically	evoked	neuronal	firing	significant.	Additionally,	Tapentadol	dose-dependently	reduced	pre-conditioned	mechanically	evoked	neuronal	firing	(Figure	6.5H).	This	indicates	that	systemic	Tapentadol	is	sufficient,	even	at	low	doses,	to	restore	the	endogenous	inhibitory	system	required	for	DNIC	expression.			
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Figure	6.5	The	dose-dependent	effects	of	tapentadol	on	mechanically	evoked	neuronal	
firing	and	DNIC	expression.	A)	A	1mg/kg	tapentadol	dose	restores	the	inhibitory	effect	of	DNIC	induced	by	a	concurrent	noxious	ear	or	knee	pinch,	such	that	there	is	a	significant	reduction	of	mechanically	evoked	neuronal	firing	with	a	60g	stimulation	(n=8).	B)	A	1mg/kg	systemic	tapentadol	dose	significantly	inhibits	pre-conditioned	mechanically	evoked	neuronal	responses	to	a	60g	stimulation.	C)	A	2mg/kg	tapentadol	dose	restores	the	inhibitory	effect	of	DNIC	induced	
	 236	
by	a	concurrent	noxious	ear	or	knee	pinch,	such	that	there	is	a	significant	reduction	in	mechanically	evoked	neuronal	firing	in	response	to	26g	and	60g	stimulations	(n=6).	D)	A	2mg/kg	systemic	tapentadol	dose	significantly	inhibits	pre-conditioned	mechanically	evoked	neuronal	responses.	E)	A	5mg/kg	systemic	tapentadol	dose	restores	the	inhibitory	effect	of	DNIC	induced	by	a	concurrent	noxious	ear	or	knee	pinch,	such	that	there	is	a	significant	reduction	of	mechanically	evoked	neuronal	firing	in	response	to	26g	and	60g	stimulations	(n=7).	F)	A	5mg/kg	systemic	tapentadol	dose	significantly	inhibits	pre-conditioned	mechanically	evoked	neuronal	responses	to	26g	and	60g	stimulations.	G)	Increasing	doses	of	systemic	tapentadol	increasingly	inhibit	pre-conditioned	mechanically	evoked	neuronal	responses	and	increase	the	level	of	neuronal	inhibition	induced	with	DNIC.	H)	tapentadol	dose-dependently	inhibits	pre-conditioned	mechanically	evoked	neuronal	responses.	I)	A	raw	trace	from	one	example	WDR	neuron,	indicating	the	pre-drug	baseline	DNIC	trial	consisting	of	3	baseline	pre-conditioned	responses,	one	DNIC	response	with	a	concurrent	noxious	ear	pinch	and	one	DNIC	response	with	a	concurrent	noxious	knee	pinch.	This	trace	also	indicates	a	DNIC	trial	following	a	1mg/kg	systemic	tapentadol	dose,	a	DNIC	trial	following	a	2mg/kg	systemic	tapentadol	dose,	and	a	DNIC	trial	following	a	5mg/kg	tapentadol	dose.	Two-way	ANOVA	with	Bonferroni	correction.	*P<0.05,	**P<0.01,	***P<0.001.			The	effects	of	Tapentadol	on	mechanically	evoked	neuronal	firing	rates	and	DNIC	expression	were	also	explored	in	saline	injected	sham	control	animals.	While	all	doses	of	systemic	Tapentadol	inhibited	pre-conditioned	mechanically	evoked	neuronal	firing	(Figure	6.6H),	it	had	no	consistent	effect	on	the	level	of	neuronal	inhibition	induced	by	DNIC.	Following	a	systemic	dose	of	1mg/kg	Tapentadol,	the	level	of	neuronal	inhibition	induced	by	a	concurrent	noxious	ear	pinch	changed	from	pre-drug	levels	of	48%,	31%,	and	34%	to	46%,	29%,	and	31%	and	by	a	concurrent	noxious	knee	pinch	from	49%.	38%,	and	46%	to	36%,	34%	and	29%	in	response	to	8g,	26g	and	60g	mechanical	stimulations	respectively	(Figure	6.6A).	The	2mg/kg	dose	of	Tapentadol	resulted	in	the	level	of	neuronal	inhibition	induced	by	a	concurrent	noxious	ear	pinch	changing	from	pre-drug	levels	of	45%,	44%,	and	40%	to	35%,	40%,	and	29%	and	with	a	concurrent	noxious	knee	pinch	from	50%,	42%,	and	43%	to	50%,	36%	and	28%	in	response	to	8g,	26g,	and	60g	mechanical	stimulations	respectively	(Figure	6.6C).	The	5mg/kg	dose	of	Tapentadol	resulted	in	the	level	of	neuronal	inhibition	induced	by	a	concurrent	noxious	ear	pinch	changing	from	pre-drug	levels	of	47%,	35%,	and	28%	to	45%,	38%,	and	32%	and	with	a	concurrent	noxious	knee	pinch	from	57%,	36%	and	37%	to	43%,	25%	and	28%	in	response	to	8g,	26g	and	60g	mechanical	stimulations	respectively	(Figure	6.6E).	This	indicates	that	when	the	endogenous	inhibitory	system	serving	DNIC	is	functional,	as	is	the	case	in	late	phase	saline	injected	sham	controls,	increased	synaptic	levels	of	noradrenaline	and	MOR	agonism	have	a	limited	effect	on	the	level	of	inhibition	induced	by	DNIC.					
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Figure	6.6	The	effects	of	tapentadol	on	mechanically	evoked	neuronal	firing	and	DNIC	
expression	in	late	phase	saline	injected	sham	controls.	A)	There	was	a	significant	reduction	in	mechanically	evoked	neuronal	firing	induced	by	DNIC	with	a	concurrent	noxious	ear	or	knee	pinch	both	before	and	after	a	systemic	dose	of	1mg/kg	tapentadol	(n=6).	B)	A	1mg/kg	systemic	dose	of	tapentadol	does	not	significantly	reduce	pre-conditioned	mechanically	evoked	neuronal	firing.	C)	There	was	a	significant	reduction	in	mechanically	evoked	neuronal	firing	induced	by	DNIC	with	a	concurrent	noxious	ear	or	knee	pinch	in	response	to	26g	and	60g	stimulations	both	before	and	after	a	systemic	dose	of	2mg/kg	tapentadol	(n=6).	D)	A	2mg/kg	systemic	dose	of	tapentadol	significantly	inhibited	26g	and	60g	mechanically	evoked	neuronal	firing.	E)	There	was	a	significant	reduction	in	mechanically	evoked	neuronal	firing	induced	by	DNIC	with	a	concurrent	noxious	ear	or	knee	pinch	before	drug	was	injected,	following	a	5mg/kg	systemic	dose	of	tapentadol	there	was	a	significant	reduction	in	mechanically	evoked	neuronal	firing	induced	by	DNIC	with	a	concurrent	noxious	ear	or	knee	pinch	in	response	to	26g	and	60g	stimulations	(n=6).	F)	A	2mg/kg	systemic	dose	of	tapentadol	significantly	inhibited	mechanically	evoked	neuronal	firing.	G)	Increasing	doses	of	systemic	tapentadol	has	limited	effect	on	the	level	of	neuronal	inhibition	induced	by	DNIC	in	saline	injected	sham	controls.	H)	All	doses	of	tapentadol	(1mg/kg,	2mg/kg,	and	5mg/kg)	reduce	mechanically	evoked	neuronal	firing	but	this	does	not	reach	significance.	Two-way	ANOVA	with	Bonferroni	correction.	*P<0.05,	**P<0.01,	***P<0.001.			
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6.3.3	The	expression	of	noradrenergic	and	serotonergic	receptors	in	the	
spinal	cord		
	As	discussed	in	detail	in	Chapter	4,	the	late	phase	MIA	animals	having	an	abolished	DNIC	system	indicates	an	imbalance	in	descending	inhibitory	and	facilitatory	controls,	specifically	a	reduction	of	descending	noradrenergic	controls	acting	at	α2-adrenergic	receptors	and	enhanced	descending	serotonergic	controls	acting	at	5-HT3	receptors	in	the	spinal	cord.	One	mechanism	through	which	this	imbalance	may	be	mediated	could	be	an	increase	or	decrease	in	the	expression	of	receptors	in	the	dorsal	horn,	such	that	the	release	of	monoaminergic	neurotransmitters	into	the	spinal	cord	will	subsequently	produce	larger	or	smaller	effects.	In	addition,	an	increase	in	5-HT7	receptor	density	has	been	demonstrated	in	the	ipsilateral	dorsal	horn	of	mice	with	partial	sciatic	nerve	ligation,	suggesting	a	compensatory	mechanism	whereby	receptor	expression	is	increased	to	mediate	inhibition	(Brenchat	et	al	2010).	Therefore,	the	mRNA	expressions	of	the	α2-adrenergic,	5-HT3,	and	5-HT7	receptors	in	the	lumbar	dorsal	horn	and	DRGs	were	investigated.			There	was	no	significant	difference	in	the	mRNA	expression	of	α2-adrenergic,	5-HT3,	and	5-HT7	receptors	in	the	ipsilateral	lumbar	dorsal	horn	of	the	spinal	cord	between	early	phase	and	late	phase	MIA	animals	and	their	respective	saline-injected	sham	control	groups	(Figure	6.7A).	Additionally,	there	was	no	significant	difference	in	the	mRNA	expression	of	α2-adrenergic,	5-HT3,	and	5-HT7	receptors	in	the	lumbar	DRGs	L3-L5	between	early	phase	and	late	phase	MIA	animals	and	their	respective	saline-injected	sham	control	groups	(Figure	6.7H).	The	lack	of	changes	in	the	mRNA	expression	of	these	noradrenergic	and	serotonergic	receptor	subtypes	indicates	that	the	imbalance	in	inhibitory	and	faciliatorty	descending	controls	is	not	a	result	of	an	upregulated	or	downregulated	expression	of	receptors	in	the	spinal	cord.	Therefore,	the	reduced	inhibitory	noradrenergic	descending	controls	and	enhanced	facilitatory	serotonergic	descending	controls	likely	occur	through	changes	in	volume	transmission	(Todd	2010).									
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Figure	6.7	The	mRNA	expression	of	monoaminergic	receptors	in	the	ipsilateral	lumbar	
dorsal	horn	and	DRGs.	A)	The	mRNA	expression	of	the	5-HT3,	α2-adrenergic,	and	5-HT7	receptors	in	the	ipsilateral	lumbar	dorsal	horn	relative	to	the	housekeeping	gene	GAPDH	and	normalized	to	the	relative	saline	injected	sham	control	group	(EP	n=4,	EPS	n=3,	LP	n=4,	LPS	n=4).	B)	The	mRNA	expression	of	the	5-HT3	receptor	in	the	ipsilateral	lumbar	dorsal	horn	relative	to	GAPDH	in	early	phase	MIA	animals.	C)	The	mRNA	expression	of	the	α2-adrenergic	receptor	in	the	ipsilateral	lumbar	dorsal	horn	relative	to	GAPDH	in	early	phase	animals.	D)	The	mRNA	expression	of	the	5-HT7	receptor	in	the	ipsilateral	lumbar	dorsal	horn	relative	to	GAPDH	in	early	phase	animals.	E)	The	mRNA	expression	of	the	5-HT3	receptor	in	the	ipsilateral	lumbar	dorsal	horn	relative	to	GAPDH	in	late	phase	animals.	F)	The	mRNA	expression	of	the	α2-adrenergic	receptor	in	the	ipsilateral	lumbar	dorsal	horn	relative	to	GAPDH	in	late	phase	animals.	G)	The	mRNA	expression	of	the	5-HT7	receptor	in	the	ipsilateral	lumbar	dorsal	horn	relative	to	GAPDH	in	late	phase	animals.	H)	The	mRNA	expression	of	the	5-HT3,	α2-adrenergic,	and	5-HT7	receptors	in	the	ipsilateral	lumbar	L3-L5	DRGs	relative	to	the	housekeeping	gene	GAPDH	and	normalized	to	the	relative	saline	injected	sham	control	group	(EP	n=4,	EPS	n=4,	LP	n=4,	LPS	n=4).	I)	The	mRNA	expression	of	the	5-HT3	receptor	in	the	ipsilateral	L3-L5	DRGs	relative	to	GAPDH	in	early	phase	animals.	J)	The	mRNA	expression	of	the	α2-adrenergic	receptor	in	the	ipsilateral	L3-L5	DRGs	relative	to	GAPDH	in	early	phase	animals.	K)	The	mRNA	expression	of	the	5-HT7	receptor	in	the	ipsilateral	L3-L5	DRGs	relative	to	GAPDH	in	early	phase	animals.	L)	The	mRNA	expression	of	the	5-HT3	receptor	in	the	ipsilateral	L3-L5	DRGs	relative	to	GAPDH	in	late	phase	animals.	M)	The	mRNA	expression	of	the	α2-adrenergic	receptor	in	the	ipsilateral	L3-L5	DRGs	relative	to	GAPDH	in	late	phase	animals.	N)	The	mRNA	expression	of	the	5-HT7	receptor	in	the	ipsilateral	L3-L5	DRGs	relative	to	GAPDH	in	late	phase	animals.	For	mRNA	expressions	relative	to	the	saline	injected	sham	controls	groups	(A	and	H),	statistical	significance	was	tested	with	a	Kruskall-Wallis	independent	samples	one-way	ANOVA	was	used.	For	mRNA	expression	expressed	as	ΔCT	values	a	significant	difference	was	tested	between	the	MIA	group	and	saline	injected	sham	controls	with	an	independent	T-test.			
6.3.4	The	innervation	of	the	knee		As	previously	discussed	(Section	1.3.4),	while	the	cartilage	is	not	innervated	all	other	subchondral	joint	structures,	including	the	synovium	and	subchondral	bone	are	(Schaible	et	al	2009).	Therefore	any	damage	to	these	joint	structures	has	the	potential	to	cause	a	component	of	peripheral	neuropathy.	To	investigate	the	innervation	of	the	knee	further,	the	neuronal	tracer	FastBlue	was	injected	into	the	intrarticular	space	and	the	number	and	size	of	peripheral	afferent	fibres	taking	up	the	neuronal	tracer	were	examined.	Furthermore,	this	experiment	assessed	in	which	DRGs	these	peripheral	afferents	were	terminating,	to	improve	the	understanding	of	where	the	joint	damage	induced	barrage	of	nociceptive	information	may	be	projecting	to.	Finally,	the	ventral	horn	was	examined	to	assess	if	any	motor	neurons	surrounding	the	knee	had	taken	up	the	neuronal	tracer	as	a	result	of	injection	leakage.			Peripheral	afferent	fibres	that	took	up	the	Fast	Blue	projected	from	L2	to	S1	DRGs,	with	the	highest	number	of	peripheral	afferents	terminating	in	the	L4	DRG	(Figure	6.8A).	While	the	L2	and	S1	DRGs	did	show	some	positive	Fast	Blue	staining,	only	0.24%	of	neurons	in	the	L2	DRGs	and	0.28%	of	neurons	in	the	S1	DRG	showed	positive	Fast	Blue	
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staining	(Figure	6.8B).	The	L4	and	L5	DRGs	had	a	significantly	higher	percentage	of	neurons	showing	positive	staining	for	Fast	Blue,	with	5.7%	of	neurons	in	the	L4	DRG	taking	up	Fast	Blue	and	3.4%	of	neurons	in	the	L5	DRG	taking	up	Fast	Blue	(Figure	6.8B).	Overall,	this	indicates	that	peripheral	afferent	fibres	innervating	the	knee	project	mainly	to	the	L3,	L4,	L5	and	L6	DRGs.			As	the	L3,	L4,	L5	and	L6	DRGs	had	the	highest	percentage	of	neurons	taking	up	the	Fast	Blue	neuronal	tracer,	the	size	distribution	of	the	total	neurons	per	DRG	were	compared	to	the	size	distribution	of	those	taking	up	Fast	Blue	to	identify	what	type	of	peripheral	fibres	were	innervating	the	knee.	Cumulative	sum	analysis	indicated	that	for	L3,	L4,	L5	and	L6	DRGs	the	size	distribution	for	Fast	Blue	positive	neurons	was	very	similar	to	the	size	distribution	of	the	total	neurons	within	the	DRG	(Figure	6.8C,	6.8D,	6.8E	and	6.8F).	This	indicates	that	both	small	and	large	peripheral	afferent	fibres	were	taking	up	the	Fast	Blue,	this	suggests	that	both	A	and	C	fibres	innervate	the	knee.			Furthermore,	Fast	Blue	staining	was	investigated	in	the	lumbar	ventral	horn	to	investigate	if	any	motor	neurons	surrounding	the	knee	were	taking	up	the	neuronal	tracer	as	this	may	indicate	leakage	of	the	injection	to	outside	the	intrarticular	space.	There	no	were	no	motor	neurons	showing	positive	Fast	Blue	staining	in	any	of	the	ventral	horn	slices	investigated	(Figure	6.9).	The	lack	of	Fast	Blue	staining	observed	in	motor	neurons	indicates	that	the	injection	was	unlikely	to	be	leaking	from	the	intrarticular	space.	Therefore	any	positive	Fast	Blue	staining	observed	in	the	DRGs	was	due	to	peripheral	afferents	directly	innervating	the	knee	taking	up	the	neuronal	tracer.			
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Figure	6.8	Investigation	of	Fast	Blue	staining	in	lumbar	DRGs,	to	assess	which	peripheral	
afferent	fibres	were	taking	up	the	neuronal	tracer.	A)	Green	staining	=	βIII-tubulin,	Blue	staining	=	Fast	Blue	neuronal	tracer,	all	scale	bars	=	100μM.	The	ipsilateral	DRGs	from	T12–S1	were	investigated	in	animals	that	had	received	an	intrarticular	injection	of	Fast	Blue.	Positive	Fast	Blue	staining	was	identified	in	L2-S1	DRGs	with	the	most	neurons	taking	up	Fast	Blue	in	L4	and	L5	DRGs	(animal	n=3,	slice	n=12).	B)	The	percentage	of	total	neurons	in	the	ipsilateral	DRGs	that	showed	positive	staining	for	Fast	Blue,	this	indicates	that	the	L4	and	L5	DRGs	had	a	significantly	higher	proportion	of	neurons	stained	positive	for	the	neuronal	tracer	compared	to	the	other	ipsilateral	DRGs	(n=3).	C)	The	size	distribution	of	neurons	in	the	ipsilateral	L3	DRG	taking	up	the	Fast	Blue	neuronal	tracer	compared	to	the	size	distribution	of	total	neurons	in	the	DRG.	D)	The	size	distribution	of	neurons	in	the	ipsilateral	L4	DRG	taking	up	the	Fast	Blue	neuronal	tracer	compared	to	the	size	distribution	of	total	neurons	in	the	DRG.	E)	The	size	distribution	of	neurons	in	the	ipsilateral	L5	DRG	taking	up	the	Fast	Blue	neuronal	tracer	compared	to	the	size	distribution	of	total	neurons	in	the	DRG.	F)	The	size	distribution	of	neurons	in	the	ipsilateral	L6	DRG	taking	up	the	Fast	Blue	neuronal	tracer	compared	to	the	size	distribution	of	total	neurons	in	the	DRG.	Friedmans	two-way	ANOVA	by	ranks	test	was	used	to	
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test	statistical	differences	in	the	proportion	of	neurons	taking	up	the	Fast	Blue	neuronal	tracer	between	the	ipsilateral	DRGs.	*P<0.05,	**P<0.01,	***P<0.001.					
	
Figure	6.9	Investigation	of	Fast	Blue	neuronal	tracer	staining	in	motor	neurons	in	the	
lumbar	ventral	horn.	The	lumbar	spinal	cords	were	investigated	in	animals	who	had	received	an	intrarticular	injection	of	Fast	Blue	(n=3).	Green	staining	=	βIII-tubulin,	Blue	staining	=	Fast	
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Blue	neuronal	tracer,	all	scale	bars	=	500μM.	A-C)	An	example	lumbar	spinal	cord	slice	from	each	injected	animal,	no	motor	neurons	within	the	ventral	horn	showed	positive	Fast	Blue	staining.	
	
6.3.5	A	neuropathic	component	to	the	MIA	model	
	
6.3.5.1	The	efficacy	of	pregabalin	in	the	MIA	model	As	the	2mg	MIA	model	has	been	reported	to	evoke	a	neuropathic	component	both	within	and	surrounding	the	joint,	and	pregabalin	has	proved	effective	in	both	patients	and	animals	models	with	neuropathic	pain,	the	efficacy	of	pregabalin	was	investigated	in	early	and	late	phase	MIA	animals	(Thakur	et	al	2012).			In	early	phase	MIA	animals,	pregablin		proved	ineffective	at	significantly	inhibiting	pre-conditioned	mechanically	evoked	neuronal	responses	and	had	a	limited	effect	on	the	level	of	inhibition	induced	by	DNIC	(Figure	6.10A	and	6.10B).	Before	a	systemic	dose	of	pregabalin	in	early	phase	MIA	animals,	the	levels	of	mechanically	evoked	neuronal	inhibition	induced	a	concurrent	noxious	ear	pinch	were	47%,	38%,	and	33%	and	with	a	concurrent	noxious	knee	pinch	were	59%,	49%,	and	40%	for	8g,	26g,	and	60g	stimulations	respectively.	Following	a	10mg/kg	systemic	dose	of	pregabalin,	the	levels	of	mechanically	the	levels	of	mechanically	evoked	neuronal	inhibition	induced	a	concurrent	noxious	ear	pinch	were	58%,	33%,	and	37%	and	with	a	concurrent	noxious	knee	pinch	were	45%,	41%	and	39%	for	8g,	26g,	and	60g	stimulations	respectively.	Therefore,	the	levels	of	mechanically	evoked	neuronal	inhibition	induced	by	DNIC	were	of	comparative	levels	both	before	and	after	a	systemic	injection	of	pregabalin.	Similar	findings	were	observed	in	early	phase	saline	injected	sham	controls,	as	pregabalin	had	a	limited	effect	on	the	pre-conditioned	mechanically	evoked	neuronal	firing	or	the	levels	of	inhibition	induced	by	DNIC	(Figure	6.10C	and	6.10D).	Overall,	these	findings	indicated	that	pregabalin	was	ineffective	in	early	phase	MIA	and	sham	animals	at	reducing	mechanically	evoked	neuronal	firing.			In	late	phase	MIA	animals,	pregabalin	significantly	inhibited	mechanically	evoked	neuronal	responses	at	all	mechanical	stimulations	tested	(Figure	6.10F).	However,	pregabalin	proved	ineffective	at	restoring	DNIC	in	late	phase	MIA	animals,	as	there	was	no	significant	reduction	in	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	ear	pinch	(Figure	6.10E).	Additionally,	despite	an	observed	reduction	in	26g	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	knee	pinch,	there	was	
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no	significant	reduction	in	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	knee	pinch	for	any	mechanical	stimulations	tested	(Figure	6.10E).	It	should	also	be	noted	that	a	reduction	in	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	knee	pinch	has	been	observed	in	late	phase	MIA	animals	before	drug	application,	so	a	reduction	in	neuronal	firing	with	a	concurrent	noxious	knee	pinch	but	not	a	concurrent	noxious	ear	pinch	would	not	necessarily	demonstrate	a	restored	DNIC	system.	The	ability	of	pregabalin	to	significantly	reduce	mechanically	evoked	neuronal	firing	may	be	indicative	of	central	sensitization	or	a	neuropathic	component	of	pain	in	late	phase	MIA	animals,	which	are	sufficient	conditions	for	pregabalin	to	become	efficacious.			In	late	phase	saline	injected	sham	controls,	pregabalin	did	not	inhibit	pre-conditioned	mechanically	evoked	neuronal	firing	or	affect	the	level	of	neuronal	inhibition	induced	with	DNIC	(Figure	6.10H	and	6.10I).	The	pre-drug	neuronal	inhibition	levels	in	late	phase	shams	with	a	concurrent	noxious	ear	pinch	were	48%,	38%,	and	34%	and	with	a	concurrent	noxious	knee	pinch	were	53%,	44%	and	42%	for	8g,	26g	and	60g	stimulations	respectively	(Figure	6.10H).	Following	a	10mg/kg	systemic	dose	of	pregabalin,	the	levels	of	neuronal	inhibition	induced	by	a	concurrent	noxious	ear	pinch	were	38%,	37%	and	33%,	and	with	a	concurrent	noxious	knee	pinch	were	52%,	33%,	and	39%	for	8g,	26g	and	60g	stimulations	respectively	(Figure	6.10H).	Therefore,	the	levels	of	neuronal	inhibition	induced	by	DNIC	were	comparable	before	and	after	drug	administration,	indicating	pregabalin	was	having	a	limited	effect	on	the	endogenous	inhibitory	system	in	late	phase	sham	animals.			
6.3.5.2	ATF-3	expression	within	DRG	cells	and	ventral	horn	motor	neurons	
following	MIA	injection	
	ATF-3	is	a	transcription	factor,	whose	expression	is	upregulated	in	a	variety	of	tissues	in	response	to	stressful	stimuli	(Hunt	et	al	2012).	ATF-3	expression	has	been	shown	to	be	induced	in	sensory	and	motor	neurons	in	the	DRGs	and	spinal	cord	in	sciatic	nerve	transection	and	neuronal	crush	animal	models	(Tsujino	et	al	2000,	Kataoka	et	al	2007).	ATF-3	was	found	to	be	expressed	in	DRG	and	spinal	cord	neurons	3	days	following	nerve	crush	or	transection	and	remained	up	to	84	days	post	injury,	with	the	number	of	neurons	expressing	ATF-3	slowing	declining	over	time	(Tsujino	et	al	2000,	Kataoka	et	al	2007).	Therefore,	ATF-3	is	considered	a	sensitive	marker	for	detecting	neuronal	damage	or	injury.		
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Figure	6.10	The	efficacy	of	pregabalin	in	the	MIA	model.	A)	A	10mg/kg	systemic	dose	of	pregabalin	did	not	affect	the	level	of	neuronal	inhibition	induced	by	DNIC	in	early	phase	MIA	animals	(n=5).	B)	pregabalin	did	not	inhibit	the	pre-conditioned	mechanically	evoked	neuronal	responses	in	early	phase	MIA	animals.	C)	Pregabalin	did	not	affect	the	level	of	neuronal	inhibition	induced	by	DNIC	in	early	phase	sham	animals	(n=5).	D)	Pregabalin	did	not	inhibit	the	pre-conditioned	mechanically	evoked	neuronal	responses	in	early	phase	sham	animals.	E)	A	10mg/kg	systemic	dose	of	pregabalin	did	not	restore	DNIC	in	late	phase	MIA	animals	(n=6).	F)	
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Pregabalin	significantly	inhibited	pre-conditioned	mechanically	evoked	neuronal	responses.	G)	An	example	trace	from	one	WDR	neuron	showing	mechanically	evoked	responses.	The	pre-drug	DNIC	trial	indicates	no	neuronal	inhibition	was	induced	with	a	concurrent	noxious	ear	pinch.		The	post	pregabalin	DNIC	trial	shows	lower	pre-conditioned	neuronal	responses	but	no	neuronal	inhibition	was	induced	with	a	concurrent	noxious	ear	pinch.	H)	Pregabalin	did	not	affect	the	level	of	inhibition	induced	by	DNIC	in	late	phase	sham	animals	(n=6).	I)	Pregabalin	did	not	inhibit	the	pre-conditioned	mechanically	evoked	neuronal	responses	in	late	phase	sham	animals.	Two-way	ANOVA	with	Bonferroni	correction.	*P<0.05,	**P<0.01,	***P<0.001.			The	expression	of	ATF-3	was	assessed	in	DRG	cell	bodies	in	early	phase	and	late	phase	animals	following	MIA	injection,	to	investigate	if	the	MIA	injection	was	causing	any	nerve	trauma.	In	contrast	to	previous	studies	using	the	2mg	MIA	model,	no	positive	ATF-3	staining	was	observed	in	L3-L5	DRGs	taken	from	either	early	phase	animals	on	day	4,	or	late	phase	animals	on	day	14	(Thakur	et	al	2012)	(Figure	6.11B	and	6.11D).	Due	to	the	lack	of	staining,	the	ATF-3	antibody	was	tested	using	DRGs	taken	from	an	SNL	rat	model	of	neuropathy.	ATF-3	expression	was	observed	in	the	nucleus	of	lumbar	DRG	cells	taken	from	the	SNL	rat,	indicating	the	antibody	was	functional	and	binding	to	ATF-3	(Figure	6.11A).	Therefore,	the	lack	of	ATF-3	positive	neurons	in	the	lumbar	DRGs	taken	from	early	phase	and	late	phase	MIA	animals	indicates	the	absence	of	nerve	trauma	caused	by	the	MIA	injection.	There	were	also	no	ATF-3	positive	cell	bodies	observed	in	lumbar	DRGs	taken	from	early	and	late	phase	saline	injected	sham	controls	(Figure	6.11C	and	6.11E).			The	expression	of	ATF-3	was	also	assessed	in	motor	neurons	in	the	ventral	horn	of	the	spinal	cord,	to	investigate	if	the	MIA	injection	was	leaking	out	and	damaging	motor	neurons	running	adjacent	to	the	knee	joint.	There	was	no	positive	ATF-3	staining	identified	in	lumbar	spinal	cord	slices	from	either	early	or	late	phase	MIA	animals	(Figure	6.12A	and	6.12C).	This	also	contrasts	with	previous	findings	using	the	2mg	MIA	model,	where	ATF-3	positive	motor	neurons	were	observed	in	the	ventral	horn	(Thakur	et	al	2012).	The	absence	of	ATF-3	staining	in	the	lumbar	spinal	cord	indicates	that	it	is	unlikely	the	MIA	injection	is	leaking	from	the	intrarticular	space	and	damaging	motor	neurons	surrounding	the	knee	joint.	There	were	also	no	ATF-3	positive	neurons	found	in	the	lumbar	spinal	cords	taken	from	early	and	late	phase	saline	injected	sham	controls	(Figure	6.12B	and	6.12D).	The	absence	of	ATF-3	staining	in	both	the	lumbar	DRG	cell	bodies	and	motor	neurons	in	the	ventral	horn	suggests	the	absence	of	a	neuropathic	component	to	the	MIA	model.					
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Figure	6.11	The	expression	of	ATF-3	in	the	cell	bodies	of	lumbar	DRGs.	Green	staining	=	βIII-tubulin,	Red	staining	=	nuclear	ATF-3	staining.	All	scale	bars	=	100μM	A)	Lumbar	DRGs	taken	
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from	rats	following	spinal	nerve	ligation	show	ATF-3	positive	cell	bodies	indicating	nerve	trauma	(n=3).	B)	There	were	no	ATF-3	positive	cell	bodies	in	the	lumbar	DRGs	taken	from	early	phase	MIA	and	sham	animals,	indicating	a	lack	of	nerve	injury	(EP	n=3,	EPS	n=3).	C)	There	were	no	ATF-3	positive	cell	bodies	in	the	lumbar	DRGs	taken	from	late	phase	MIA	and	sham	animals,	indicating	a	lack	of	nerve	injury	(LP	n=5,	LPS	n=4).	
	
Figure	6.12	The	expression	of	ATF-3	in	the	motor	neurons	in	the	lumbar	ventral	horn.	Green	staining	=	βIII-tubulin,	red	staining	=	ATF-3,	all	scale	bars	=	500	μM.	EP)	There	was	no	
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ATF-3	positive	motor	neurons	in	the	lumbar	ventral	horn	taken	from	early	phase	MIA	animals	(n=3).	EPS)	There	was	no	ATF-3	positive	motor	neurons	in	the	lumbar	ventral	horn	from	early	phase	saline	injected	sham	controls	animals	(n=3).	LP)	There	was	no	ATF-3	positive	motor	neurons	in	the	lumbar	ventral	horn	from	late	phase	MIA	animals	(n=5).	LPS)	There	was	no	ATF-3	positive	motor	neurons	in	the	lumbar	ventral	horn	from	late	phase	saline	injected	sham	controls	(n=4).			
6.3.5.3	The	mRNA	expression	of	ATF-3	and	the	α2δ1	subunit	in	lumbar	DRGs	
and	dorsal	horns	from	MIA	animals	
	To	further	explore	if	there	was	a	neuropathic	component	associated	with	the	MIA	model,	the	mRNA	expression	of	the	nerve	injury	marker	ATF-3	and	the	α2δ1	subunit	of	VGCCs,	which	is	upregulated	and	contributes	to	spinal	hyperexcitability	in	states	of	neuropathy,	was	quantified	in	the	ipsilateral	lumbar	DRGs	and	dorsal	horn	following	MIA	injection	(Li	et	al	2006).			An	increased	mRNA	expression	of	ATF-3	was	observed	in	the	ipsilateral	lumbar	dorsal	horn	taken	from	both	early	and	late	phase	MIA	animals	compared	to	their	respective	sham	control	group	(Figure	6.13A).	For	early	phase	MIA	animals,	the	ATF-3	mRNA	expression	in	the	dorsal	horn	was	not	significantly	higher	than	the	early	phase	sham	control	group	when	the	data	was	normalized	to	sham	or	expressed	as	ΔCT	values	(Figure	6.13A	and	6.13B).	In	late	phase	MIA	animals	the	ATF-3	mRNA	expression	in	the	dorsal	horn	was	not	significantly	increased	when	normalized	to	the	late	phase	sham	group.	However,	there	was	a	significantly	increased	ATF-3	mRNA	expression	in	the	ipsilateral	lumbar	dorsal	horn	when	expressed	as	ΔCT	values	and	compared	to	late	phase	saline	injected	sham	controls	(Figure	6.13C).	Initially,	this	result	was	surprising	as	no	positive	ATF-3	staining	had	been	identified	in	the	dorsal	horn	of	spinal	cord	slices	in	the	immunohistochemistry	experiment	(Figure	6.12).	However,	microglia	are	reported	to	have	a	high	mRNA	expression	of	ATF-3,	and	as	microgliosis	has	been	reported	in	late	phase	MIA	animals,	both	in	this	thesis	and	in	previous	studies,	it	is	likely	the	increased	ATF-3	mRNA	expression	levels	reflect	increased	microglia	expression	in	the	dorsal	horn	(See	Section	6.4.3.2)(Thakur	et	al	2012,	Zhang	et	al	2014).			There	was	no	significant	increase	in	the	mRNA	expression	of	ATF-3	in	the	ipsilateral	L3-L5	DRGs	in	either	early	or	late	phase	MIA	animals	compared	to	saline	injected	sham	controls	(Figure	6.13F,	6.13G	and	6.13H).	This	is	in	agreement	with	immunohistochemical	studies,	where	no	ATF-3	positive	cell	bodies	were	identified	in	the	L3-L5	DRGs	in	either	early	or	late	phase	MIA	animals	(Figure	6.11).	Overall,	the	
	 251	
combination	of	these	findings	suggest	the	2mg	MIA	injection	is	not	causing	nerve	damage	to	peripheral	afferents	within	and	surrounding	the	knee	joint.				Interestingly,	there	was	no	increase	in	the	mRNA	expression	of	the	α2δ1	subunit	of	VGCCs	in	the	ipsilateral	dorsal	horn	from	either	early	phase	or	late	phase	MIA	animals	compared	to	their	respective	sham	group	(Figure	6.13A,	6.13D	and	6.13E).	Additionally,	there	was	no	increase	in	the	mRNA	expression	of	the	α2δ1	subunit	of	VGCCs	in	the	ipsilateral	L3-L5	DRGs	from	early	or	late	phase	MIA	animals	compared	to	their	respective	sham	group	(Figure	6.13F,	6.13I	and	6.13J).	As	there	is	no	increased	expression	of	the	α2δ1	subunit	mRNA	in	either	the	lumbar	DRGs	or	dorsal	horn	of	late	phase	MIA	animals,	it	indicates	that	the	efficacy	of	Pregabalin	in	late	phase	MIA	animals	is	not	due	to	an	upregulated	expression	of	the	α2δ1	subunit	and	a	subsequent	increase	in	trafficking	of	VGCCs	to	plasma	membranes	(Bauer	et	al	2009).		
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Figure	6.13	The	mRNA	expression	of	ATF-3	and	the	α2δ1	subunit	in	the	lumbar	dorsal	horn	
and	DRGs	following	MIA	injection.	A)	The	mRNA	expression	of	ATF-3	and	the	α2δ1	subunit	of	VGCCs	relative	to	the	housekeeping	gene	GAPDH	in	the	ipsilateral	dorsal	horn	following	MIA	injection	in	early	and	late	phase	animals	and	normalized	to	their	respective	sham	group	(EP	n=4,	EPS	n=3,	LP	n=4,	LPS	n=4).	B)	The	mRNA	expression	of	ATF-3	relative	to	the	housekeeping	gene	GAPDH	in	the	ipsilateral	lumbar	dorsal	horn	of	early	phase	MIA	and	sham	animals.	C)	The	mRNA	expression	of	ATF-3	relative	to	the	housekeeping	gene	GAPDH	in	the	ipsilateral	lumbar	dorsal	horn	of	late	phase	MIA	and	sham	animals,	this	indicates	a	significantly	higher	ATF-3	mRNA	expression	in	the	dorsal	horn	of	late	phase	MIA	animals	compared	to	saline	injected	sham	controls.	D)	The	mRNA	expression	of	the	α2δ1	subunit	of	VGCCs	relative	to	the	housekeeping	gene	GAPDH	in	the	ipsilateral	lumbar	dorsal	horn	of	early	phase	MIA	and	sham	animals.	E)	The	mRNA	expression	of	the	α2δ1	subunit	of	VGCCs	relative	to	the	housekeeping	gene	GAPDH	in	the	ipsilateral	lumbar	dorsal	horn	of	late	phase	MIA	and	Sham	animals.	F)	The	mRNA	expression	ATF-3	and	the	α2δ1	subunit	of	VGCCs	relative	to	the	housekeeping	gene	GAPDH	in	the	ipsilateral	L3-L5	DRGs	following	MIA	injection	in	early	and	late	phase	animals	normalized	to	their	respective	sham	group	(EP	n=4,	EPS	n=4,	LP	n=4,	LPS	n=4).	G)	The	mRNA	expression	of	ATF-3	relative	to	the	housekeeping	gene	GAPDH	in	the	ipsilateral	L3-L5	DRGs	of	early	phase	MIA	and	sham	animals.	H)	The	mRNA	expression	of	ATF-3	relative	to	the	housekeeping	gene	GAPDH	in	the	ipsilateral	L3-L5	DRGs	of	late	phase	MIA	and	sham	animals.	I)	The	mRNA	expression	of	the	α2δ1	subunit	of	VGCCs	relative	to	the	housekeeping	gene	GAPDH	in	the	ipsilateral	L3-L5	DRGs	of	early	phase	MIA	and	sham	animals.	J)	The	mRNA	expression	of	the	α2δ1	subunit	of	VGCCs	relative	to	the	housekeeping	gene	GAPDH	in	the	ipsilateral	L3-L5	DRGs	of	early	phase	MIA	and	sham	animals.	For	mRNA	expression	values	normalized	to	sham	controls,	statistical	significance	between	MIA	and	sham	groups	was	tested	with	a	Kruskall-wallis	independent	samples	one-way	ANOVA.	For	mRNA	expression	expressed	as	ΔCT	values,	statistical	significance	between	MIA	and	sham	groups	was	tested	with	independent	samples	T-tests.	**P<0.01.			
6.3.6	The	combination	of	tapentadol	and	pregabalin	treatment	in	MIA	
animals	
	Tapentadol	was	demonstrated	to	dose-dependently	inhibit	pre-conditioned	mechanically	evoked	neuronal	responses	and	restore	neuronal	inhibition	induced	by	DNIC	in	late	phase	MIA	animals	(Figure	6.5).	However,	the	lower	doses	of	tapentadol	tested	were	only	effective	at	reducing	pre-conditioned	mechanically	evoked	neuronal	responses	to	the	most	noxious	stimulation	tested	of	60g.	As	a	low	dose	of	tapentadol	did	not	inhibit	pre-conditioned	neuronal	responses	to	innocuous	stimulations,	this	may	indicate	that	low	doses	of	tapentadol	would	be	ineffective	at	relieving	allodynia	(Figure	6.5B).	Meanwhile,	pregabalin	proved	effective	at	inhibiting	pre-conditioned	mechanically	evoked	neuronal	responses	to	all	stimulations	tested	in	late	phase	MIA	animals	but	did	not	restore	neuronal	inhibition	induced	by	DNIC	(6.10).	Therefore,	a	combination	therapy	of	tapentadol	and	pregabalin	was	assessed	in	late	phase	MIA	and	sham	animals	to	investigate	if	this	may	be	an	effective	approach	for	inhibiting	pre-conditioned	neuronal	responses,	whilst	also	restoring	neuronal	inhibition	induced	by	DNIC.			In	late	phase	MIA	animals,	the	combined	tapentadol	and	pregabalin	treatments	restored	neuronal	inhibition	induced	by	DNIC	and	significantly	inhibited	pre-conditioned	
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mechanically	evoked	neuronal	responses	for	all	mechanical	stimulations	tested	(Figure	6.14A-D).	Firstly,	a	combined	systemic	dose	of	1mg/kg	tapentadol	and	10mg/kg	of	pregabalin	restored	neuronal	inhibition	such	that	there	was	a	significant	reduction	in	neuronal	firing	with	a	concurrent	noxious	ear	and	knee	pinch	and	mechanical	stimulations	of	26g	and	60g	(Figure	6.14A).	The	level	of	neuronal	inhibition	following	a	systemic	dose	of	1mg/kg	tapentadol	and	10mg/kg	pregabalin	was	41%,	34%,	and	26%	when	induced	with	a	noxious	ear	pinch	and	52%,	29%	and	33%	when	induced	with	a	noxious	knee	pinch	for	8g,	26g,	and	60g	mechanical	stimulations	respectively,	which	is	approximately	the	level	of	neuronal	inhibition	observed	in	naïve	animals	with	a	conditioning	noxious	stimulus.	Secondly,	a	combined	systemic	dose	of	2mg/kg	tapentadol	and	5mg/kg	of	pregabalin	also	restored	neuronal	inhibition	such	that	there	was	a	significant	reduction	in	neuronal	firing	with	a	concurrent	noxious	ear	and	knee	pinch	for	26g	and	60g	mechanical	stimulations	(Figure	6.14B).	The	level	of	neuronal	inhibition	following	2mg/kg	tapentadol	and	5mg/kg	pregabalin	was	also	of	a	similar	level	to	that	observed	in	naïve	animals	with	a	concurrent	noxious	stimulation.	Finally,	both	dose	combinations	significantly	inhibited	pre-conditioned	evoked	neuronal	firing	for	all	mechanical	stimulations	tested,	indicating	a	combined	dose	is	more	effective	at	inhibiting	neuronal	firing	than	a	dose	of	tapentadol	alone.		In	late	phase	saline	injected	sham	control	animals,	both	dose	combinations	had	a	limited	effect	on	the	levels	of	neuronal	inhibition	induced	by	DNIC	(Figure	6.14E	and	6.14G).	Interestingly,	the	combined	systemic	dose	1mg/kg	tapentadol	and	10mg/kg	pregabalin	did	not	significantly	inhibit	pre-conditioned	mechanically	evoked	neuronal	firing	for	any	mechanical	stimulations	tested	(Figure	6.14F).	This	is	in	agreement	with	previous	experiments	demonstrating	that	a	10mg/kg	dose	of	pregabalin	has	no	inhibitory	effect	on	neuronal	firing	in	saline	injected	sham	controls.	This	may	indicate	that	without	sufficient	conditions	for	pregabalin	to	be	effective,	the	low	dose	of	tapentadol	alone	is	not	enough	to	inhibit	pre-conditioned	neuronal	firing.	However,	the	combined	2mg/kg	tapentadol	and	5mg/kg	pregabalin	dose	does	significantly	inhibit	the	pre-conditioned	neuronal	firing	for	the	60g	mechanical	stimulation	(Figure	6.14H).	This	indicates	that	although	pregabalin	is	not	effective	in	sham	controls,	the	higher	dose	of	tapentadol	is	sufficient	to	inhibit	neuronal	firing	to	the	most	noxious	mechanical	stimulations.			Overall,	there	is	a	lack	of	inhibitory	effect	on	pre-conditioned	mechanically	evoked	neuronal	firing	of	tapentadol	and	pregabalin	combined	therapy	in	sham	control	animals.	However,	the	combined	tapentadol	and	pregabalin	treatment	proved	effective	for	
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inhibiting	pre-conditioned	neuronal	firing	for	all	mechanical	stimulations	tested	in	late	phase	MIA	animals.	This	suggests	that	with	sufficient	conditions,	such	as	central	sensitisation	and	an	imbalance	of	descending	controls,	the	combined	therapy	with	lower	doses	of	tapentadol	and	pregabalin	is	most	effective	at	producing	both	pre-conditioned	neuronal	inhibition	and	restoring	the	DNIC	system.			
	
Figure	6.14	A	combined	tapentadol	and	pregabalin	treatment	in	MIA	animals.	A)	A	systemic	dose	of	1mg/kg	tapentadol	and	10mg/kg	pregabalin	restores	neuronal	inhibition	induced	with	a	
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concurrent	noxious	ear	and	knee	pinch	in	late	phase	MIA	animals	(n=6).	B)	A	systemic	dose	of	1mg/kg	tapentadol	and	10mg/kg	pregabalin	significantly	inhibits	pre-conditioned	mechanically	evoked	neuronal	firing	in	late	phase	MIA	animals.	C)	A	systemic	dose	of	2mg/kg	tapentadol	and	5mg/kg	pregabalin	restores	neuronal	inhibition	induced	with	a	concurrent	noxious	ear	and	knee	pinch	in	late	phase	MIA	animals	(n=6).	D)	A	systemic	dose	of	2mg/kg	tapentadol	and	5mg/kg	pregabalin	significantly	inhibits	pre-conditioned	mechanically	evoked	neuronal	firing	in	late	phase	MIA	animals.	E)	A	systemic	dose	of	1mg/kg	tapentadol	and	10mg/kg	pregabalin	has	a	limited	effect	on	the	level	of	neuronal	inhibition	induced	by	DNIC	in	late	phase	sham	animals	(n=6).	F)	A	systemic	dose	of	1mg/kg	tapentadol	and	10mg/kg	pregabalin	has	no	significant	effect	on	pre-conditioned	mechanically	evoked	neuronal	firing	in	late	phase	sham	animals.	G)	A	systemic	dose	of	2mg/kg	tapentadol	and	5mg/kg	pregabalin	has	a	limited	effect	on	the	level	of	neuronal	inhibition	induced	by	DNIC	in	late	phase	sham	animals	(n=5).	H)	A	systemic	dose	of	2mg/kg	tapentadol	and	5mg/kg	pregabalin	significantly	inhibited	pre-conditioned	neuronal	firing	in	response	to	a	60g	mechanical	stimulation.	Two-way	ANOVA	with	Bonferroni	correction.	*P<0.05,	**P<0.01,	***P<0.001.																																						
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6.4	Discussion		
	This	study	examined	the	pharmacological	manipulation	of	DNIC	in	early	and	late	phase	MIA	animals.	This	study	indicated	that	blocking	the	actions	of	spinal	5-HT7		receptors	in	early	phase	MIA	animals	was	not	sufficient	to	block	DNIC,	yet	when	the	5-HT7	receptor	was	activated	in	late	phase	MIA	animals	DNIC	was	restored	(Figure	6.15).	In	contrast,	blocking	the	inhibitory	actions	of	noradrenaline	at	α2-adrenoceptors	in	the	spinal	cord	completely	blocked	DNIC	in	early	phase	MIA	animals	(Figure	6.15).	These	findings	are	in	agreement	with	those	observed	in	chapter	4,	that	the	inhibitory	actions	of	noradrenaline	are	crucial	for	the	expression	of	DNIC,	while	serotonergic	controls	contribute	to	the	DNIC	system	but	are	not	crucial.	Yet	when	the	DNIC	system	is	lost	due	to	an	imbalance	in	descending	controls,	as	is	the	case	in	late	phase	MIA	animals,	the	activation	of	spinal	5-HT7	receptors	is	enough	to	override	this	imbalance	and	restore	inhibition.	A	systemic	dose	of	Tapentadol	also	restores	DNIC	in	late	phase	MIA	animals,	likely	due	to	its	NRI	actions	meaning	more	synaptic	noradrenaline	is	available	to	carry	out	inhibitory	actions	at	α2-adrenoceptors.			This	study	also	examined	if	there	was	a	neuropathic	component	to	the	MIA	model.		While	Pregabalin	proved	ineffective	in	early	phase	and	sham	animals,	it	was	effective	at	inhibiting	mechanically	evoked	neuronal	responses	in	late	phase	MIA	animals.	However,	Pregabalin	did	not	affect	the	magnitude	of	neuronal	inhibition	induced	by	DNIC	in	either	early	or	late	phase	MIA	animals	(Figure	6.15).	The	sensitivity	to	Pregabalin	may	indicate	a	neuropathic	component	exists	in	late	phase	MIA	animals,	or	that	there	are	sufficient	conditions	such	as	central	sensitisation	or	enhanced	descending	facilitation	so	that	Pregabalin	can	prove	effective.	However,	there	was	a	lack	of	ATF-3	staining	in	the	ipsilateral	lumbar	DRG,	which	had	been	demonstrated	to	contain	the	cell	bodies	of	peripheral	afferents	innervating	the	knee	with	the	use	of	a	neuronal	tracer.	The	absence	of	ATF-3	expression	in	late	phase	animals	suggests	the	MIA	injection	is	not	causing	damage	to	nerves	within	and	surrounding	the	knee	joint.	Furthermore,	there	was	no	upregulated	expression	of	the	α2δ1	subunit	of	VGCCs	in	the	lumbar	DRGs	or	dorsal	horn	indicating	Pregabalin	was	not	functioning	through	this	mechanism.	Overall,	this	study	indicated	that	there	was	sufficient	central	sensitisation	in	late	phase	MIA	animals	for	Pregabalin	to	prove	effective,	but	there	was	not	necessarily	a	neuropathic	component	contributing	to	the	chronic	pain	associated	with	the	late	phase	MIA	model.			
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Figure	6.15	The	magnitude	of	neuronal	inhibition	induced	by	DNIC	in	early	and	late	phase	
MIA	animals	following	drug	application.	In	early	phase	MIA	animals	the	spinal	application	of	atipamezole	abolishes	any	neuronal	inhibition	induced	by	DNIC,	while	the	spinal	application	of	SB-267990	partially	blocks	the	neuronal	inhibition	induced	by	DNIC,	and	systemic	pregabalin	has	no	effect	on	the	magnitude	of	neuronal	inhibition	induced	by	DNIC.	In	late	phase	MIA	animals.	systemic	tapentadol	and	spinal	AS-19	significantly	restore	neuronal	inhibition	induced	by	DNIC,	while	systemic	pregabalin	has	no	effect	on	the	magnitude	of	neuronal	inhibition	induced	by	DNIC.	Kruskall-Wallis	one-way	ANOVA	*P<0.05,	**P<0.01.		
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6.4.1	The	noradrenergic	and	serotonergic	descending	controls	subserving	
DNIC	
6.4.1.1	The	5-HT7	receptor	Firstly,	the	contribution	of	spinal	5-HT7	receptors	in	modulating	the	endogenous	inhibitory	system	utilized	by	DNIC	was	explored	in	early	phase	MIA	animals,	where	a	functional	DNIC	system	existed.	While	the	selective	5-HT7	receptor	antagonist	SB-267790	reduced	the	level	of	neuronal	inhibition	induced	with	a	concurrent	noxious	ear	or	knee	pinch	it	did	not	abolish	the	DNIC	system	in	early	phase	MIA	and	sham	animals.	The	5-HT7	receptor	has	been	demonstrated	to	play	an	inhibitory	role	in	uninjured	animals,	as	blocking	the	actions	of	spinal	5-HT7	receptors	blocked	the	antinociceptive	effects	observed	following	both	a	systemic	or	RVM	microinjection	of	morphine	(Dogrul	and	Seyrek	2006,	Dogrul	et	al	2009).	In	this	case	the	selective	5-HT7	receptor	antagonist	SB-267790	completely	blocked	antinociception,	which	indicates	a	principle	role	for	this	receptor	in	mediating	opioidergic	controls	arising	from	the	RVM,	yet	the	DNIC	system	is	reported	to	rely	only	partly	on	opioids	(Le	Bars	et	al	1981).	Overall,	this	study	indicated	that	while	the	5-HT7	receptor	contributes	to	the	neuronal	inhibition	induced	by	DNIC,	blocking	these	actions	cannot	abolish	the	endogenous	inhibitory	system,	therefore	inhibitory	actions	occurring	through	the	activation	of	other	spinal	receptors	are	still	able	to	mediate	the	inhibitory	DNIC	response.				The	activation	of	5-HT7	receptors	has	been	demonstrated	to	mediate	antinociceptive	actions	in	animal	models	of	nerve	injury	and	inflammation	(Brenchat	et	al	2009,	Brenchat	et	al	2010,	Lin	et	al	2015).	Furthermore,	the	5-HT7	receptor	is	co-localized	with	GABAergic	interneurons	in	the	dorsal	horn,	and	has	been	demonstrated	to	mediate	its	inhibitory	actions	through	a	GABAergic	component	rather	than	an	opiodergic	mechanism	following	nerve	injury	(Viguier	et	al	2012).	Therefore,	the	role	played	by	spinal	5-HT7	receptors	in	modulating	endogenous	inhibition	was	assessed	in	late	phase	MIA	animals,	where	the	DNIC	system	was	abolished.	The	activation	of	spinal	5-HT7	receptors	with	the	selective	agonist	AS-19	restored	neuronal	inhibition	induced	with	a	concurrent	noxious	ear	or	knee	pinch,	indicating	that	activation	of	spinal	5-HT7	receptors	was	sufficient	to	override	the	imbalance	in	inhibitory	and	facilitatory	descending	controls	and	mediate	inhibition.	Interestingly,	the	acute	administration	of	5-HT7	receptor	agonists	was	demonstrated	to	reduce	the	nerve	injury	induced	upregulated	mRNA	expression	of	IL-1β	in	the	lumbar	DRGs	and	spinal	cord,	proposing	this	may	be	a	further	mechanism	in	which	5-HT7	receptors	mediate	hyperalgesic	effects	(Viguier	et	al	2012).	In	agreement,	an	increased	mRNA	expression	of	IL-1β	was	found	in	
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the	lumbar	dorsal	horn	of	late	phase	MIA	animals	(See	section	5.3.5),	and	could	be	related	to	the	inhibitory	actions	observed	following	activation	of	spinal	5-HT7	receptors.	Overall,	this	study	confirmed	an	inhibitory	role	for	spinal	5-HT7	receptors,	particularly	in	states	of	central	sensitisation.			
6.4.1.2	Noradrenalin	acting	at	α2-adrenoceptors	in	the	spinal	cord	
	The	role	played	by	noradrenaline	acting	at	α2-adrenoceptors	in	the	spinal	cord	in	mediating	DNIC	was	assessed	in	early	phase	MIA	animals,	where	a	functional	DNIC	system	remained.	Blocking	the	actions	of	spinal	α2-adrenoceptors	completely	blocked	the	neuronal	inhibition	induced	by	a	concurrent	noxious	ear	and	knee	pinch	in	early	phase	MIA	and	sham	animals.	This	indicates	that	the	inhibitory	actions	of	noradrenaline	acting	at	α2-adrenoceptors	in	the	spinal	cord	are	crucial	for	DNIC	expression.	This	is	in	agreement	with	previous	studies,	which	indicate	that	even	with	enhanced	inhibitory	serotonergic	actions	that	restore	DNIC	in	nerve	injured	animals,	a	tonic	noradrenergic	tone,	even	at	reduced	levels	is	required	for	DNIC	expression	(Bannister	et	al	2017).			Interestingly,	blocking	the	actions	of	noradrenaline	acting	at	α2-adrenoceptors	in	the	spinal	cord	significantly	facilitated	mechanically	evoked	neuronal	responses	in	early	phase	MIA	animals	but	did	not	have	this	effect	in	sham	controls.	This	may	be	due	to	enhanced	noradrenergic	inhibitory	descending	controls,	as	have	been	previously	reported	in	the	early	inflammatory	phase	of	the	MIA	model	(Burnham	and	Dickenson	2013).	Overall,	as	noradrenergic	signaling	through	α2-adrenoceptors	are	crucial	for	mediating	neuronal	inhibition	induced	by	a	noxious	conditioning	stimulation,	variations	in	the	noradrenergic	descending	controls	over	the	course	of	the	MIA	model	appear	to	play	a	principle	role	in	the	subsequent	expression	of	DNIC.			
6.4.1.3	The	mRNA	expression	of	noradrenergic	and	serotonergic	receptors	in	
the	lumbar	DRGs	and	dorsal	horn	
	This	study	indicated	the	important	roles	played	by	α2-adrenoceptors	and	5-HT7	receptors	in	mediating	neuronal	inhibition	induced	by	DNIC.	In	addition,	enhanced	serotonergic	descending	facilitatory	controls	have	been	reported	to	be	involved	with	abolished	DNIC	in	animal	models	of	chronic	pain	(Bannister	et	al	2015).	In	a	chronic	constriction	injury	model	of	neuropathic	pain,	the	mRNA	expression	of	the	α2-
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adrenoceptor	was	found	to	be	reduced	in	the	lumbar	spinal	cord	compared	with	controls	rats	(Leiphart	et	al	2003).	Furthermore,	an	increase	in	the	5-HT7	receptor	density	has	been	reported	in	the	ipsilateral	dorsal	horn	following	partial	sciatic	nerve	ligation,	which	lead	to	the	authors	proposing	a	pain-triggered	regulated	expression	(Brenchat	et	al	2010).	Together,	these	findings	indicate	that	changes	in	the	regulation	of	noradrenergic	and	serotonergic	receptor	expression	may	be	contributing	to	the	development	of	central	sensitisation.	Therefore,	the	mRNA	expression	of	these	receptors	was	assessed	in	the	lumbar	DRGs	and	dorsal	horn	to	investigate	if	an	up	or	down	regulation	of	receptor	expression	was	contributing	to	the	abolished	DNIC	system	in	late	phase	MIA	animals.			In	fact,	this	study	found	that	there	were	no	changes	in	the	mRNA	expression	of	the	α2-adrenoceptors,	5-HT3	receptors	or	5-HT7	receptors	in	the	lumbar	DRGs	or	dorsal	horn.	These	results	indicate	that	the	imbalance	in	inhibitory	and	facilitatory	descending	controls	is	not	necessarily	a	consequence	of	an	altered	receptor	expression	in	the	spinal	cord.	As	the	monoaminergic	descending	controls	modulate	nociceptive	transmission	at	the	level	of	the	spinal	cord	mainly	through	volume	transmission,	the	most	likely	mechanism	for	the	imbalance	in	descending	controls	is	a	decreased	release	of	noradrenaline	and	an	increased	release	of	serotonin	from	the	brainstem	(Todd	2010).	However,	although	this	study	indicates	there	are	no	changes	in	the	mRNA	receptor	expression,	other	post-translational	changes	may	occur	and	influence	the	binding	affinity	or	down-stream	signaling	of	receptors	at	the	level	of	the	spinal	cord.			
6.4.1.4	The	efficacy	of	tapentadol	in	the	late	phase	MIA	model	Tapentadol	has	a	dual	mechanism	of	action,	acting	as	both	an	NRI	and	a	MOR	agonist.	As	both	noradrenergic	and	opiodergic	components	are	believed	to	be	involved	in	the	neuronal	inhibition	induced	by	DNIC,	the	efficacy	of	tapentadol	at	restoring	DNIC	in	late	phase	MIA	animals	was	assessed	(Le	Bars	et	al	1981).	All	doses	of	tapentadol	tested	restored	neuronal	inhibition	induced	by	a	noxious	conditioning	ear	or	knee	pinch,	whereas	tapentadol	had	a	limited	effect	on	the	levels	of	neuronal	inhibition	induced	by	DNIC	in	sham	control	animals.	In	addition,	the	higher	doses	of	tapentadol	significantly	inhibited	pre-conditioned	mechanically	evoked	neuronal	firing	rates	in	both	late	phase	MIA	and	saline	injected	sham	controls	animals.			The	MOR	and	NRI	contributions	to	nociceptive	modulation	of	tapentadol	at	the	level	of	the	spinal	cord	have	previously	been	assessed	in	a	spinal	nerve	ligation	rat	model	of	
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neuropathy	(Tzschentke	et	al	2007,	Schroder	et	al	2010,	Bee	et	al	2011).	These	studies	indicated	that	the	inhibitory	actions	of	tapentadol	were	most	effectively	blocked	by	the	MOR	antagonist	naloxone	in	sham	controls	animals,	while	in	SNL	animals	the	analgesic	efficacy	of	tapentadol	was	strongly	reduced	by	the	α2-adrenoceptor	antagonist	yohimbine	or	atipamezole,	but	only	moderately	reduced	by	naloxone	(Tzschentke	et	al	2007,	Schroder	et	al	2010,	Bee	et	al	2011).	The	authors	proposed	that	tapentadol	utilizes	a	predominant	opioid	mechanism	to	mediate	inhibition	in	control	animals,	which	shifts	to	a	predominant	noradrenergic	inhibitory	mechanism	following	central	sensitisation.	Therefore,	the	efficacy	of	tapentadol	at	inhibiting	pre-conditioned	mechanically	evoked	neuronal	firing	in	sham	animals	is	likely	due	to	a	predominant	opioid	mechanism.	Meanwhile,	the	efficacy	of	tapentadol	at	restoring	neuronal	inhibition	induced	by	DNIC	in	late	phase	MIA	animals,	even	at	low	doses,	is	likely	due	to	its	ability	to	increase	the	synaptic	content	of	noradrenaline,	which	can	subsequently	carry	out	an	inhibitory	role	at	the	level	of	the	spinal	cord	through	activating	α2-adrenoceptors.			Interestingly,	at	all	doses	tested	tapentadol	restored	neuronal	inhibition	induced	by	DNIC	for	just	the	noxious	mechanical	stimulations	of	26g	and	60g,	yet	did	not	restore	neuronal	inhibition	induced	by	DNIC	with	the	innocuous	mechanical	stimulation	of	8g.	This	is	in	agreement	with	previous	findings	that	demonstrated	tapentadol	restored	neuronal	inhibition	only	for	noxious	mechanical	stimulations	following	nerve	injury.	This	led	the	authors	to	theorize	that	the	opioidergic	mechanisms	may	preferentially	act	on	noxious	stimulations,	which	when	combined	with	the	increased	noradrenergic	content	allows	tapentadol	to	restore	DNIC	(Bannister	et	al	2015).			
6.4.2	A	neuropathic	component	to	the	MIA	model	
	
6.4.2.1	The	efficacy	of	pregabalin	in	the	MIA	model	The	gabapentinoid	drugs	are	considered	key	therapies	for	relieving	the	chronic	pain	associated	with	neuropathy.	Previous	studies	have	demonstrated	that	gabapentinoid	drugs	are	more	effective	at	modulating	spinal	nociceptive	transmission	in	animal	models	of	nerve	injury	than	those	with	normal	physiological	conditions	(Bee	and	Dickenson	2008,	Bannister	et	al	2017).	Furthermore,	gabapentinoid	treatments	provide	effective	pain	relief	in	patients	with	neuropathy	(Moore	et	al	2014b).	As	a	neuropathic	component	to	the	2mg	MIA	model	have	previously	been	reported,	the	efficacy	of	pregablin	in	early	and	late	phase	MIA	animals	was	assessed	and	its	subsequent	effect	on	
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the	DNIC	system	was	assessed	(Ivanavicius	et	al	2007,	Orita	et	al	2011,	Thakur	et	al	2012).			Pregabalin	proved	effective	in	late	phase	MIA	animals,	as	it	significantly	inhibited	all	pre-conditioned	mechanically	evoked	neuronal	responses.	However,	pregablin	was	ineffective	in	early	phase	MIA	animals	and	sham	controls.	In	animal	models	of	neuropathy,	there	are	increased	levels	of	the	α2δ1	subunit	of	VGCCs	in	the	ipsilateral	lumbar	DRGs	and	dorsal	horn	(Luo	et	al	2001,	Newton	et	al	2001,	Bauer	et	al	2009).	The	increased	α2δ1	subunit	expression,	results	in	increased	trafficking	of	VGCCs	to	neuronal	plasma	membrane,	which	subsequently	increases	calcium	infux	and	neurotransmitter	release	(Hendrich	et	al	2008,	Bauer	et	al	2009).	As	pregabalin	binds	the	α2δ1	subunit	with	high	affinity,	a	proposed	mechanism	for	the	antinociceptive	function	of	pregabalin	is	thought	to	occur	through	its	binding	to	the	α2δ1	subunit,	which	subsequently	inhibits	the	enhanced	release	of	neurotransmitters,	but	the	exact	mechanism	is	yet	to	be	determined	(Bauer	et	al	2009).			In	this	study,	there	was	no	increase	in	the	mRNA	expression	of	the	α2δ1	subunit	of	VGCCs	in	the	ipsilateral	lumbar	DRGs	or	dorsal	horn	of	late	phase	MIA	animals.	This	result	conflicts	with	a	previous	MIA	study,	which	demonstrated	a	significant	increase	in	the	mRNA	expression	of	the	α2δ1	subunit	in	the	L3	and	L4	DRGs	ipsilateral	to	MIA	injection	(Rahman	et	al	2009).	However,	this	study	also	found	no	significant	increase	in	the	mRNA	expression	of	the	α2δ1	subunit	in	the	L5	and	L6	DRGs	ipsilateral	to	MIA	injection	(Figure	6.16).	Therefore,	as	this	study	investigated	mRNA	expression	pooled	from	L3-L5	DRGs,	it	may	have	missed	a	subtle	increase	in	the	mRNA	expression	of	the	α2δ1	subunit,	especially	if	this	only	occurred	in	one	particular	lumbar	DRG.	However,	as	the	mRNA	expression	levels	of	the	α2δ1	subunit	remained	fairly	constant	between	MIA	and	sham	control	animals	in	this	study,	it	may	indicate	that	the	differences	observed	are	due	to	injection	techniques	and	a	difference	in	the	subsequent	neuropathic	component	of	the	MIA	model.		It	has	been	demonstrated	that	an	increased	expression	of	the	α2δ1	subunit	is	not	necessarily	required	for	pregabalin	to	prove	effective	(Suzuki	et	al	2005,	Bannister	et	al	2011).	In	fact,	the	developments	of	central	sensitisation	and	an	enhanced	serotonergic	facilitatory	descending	system	in	animal	models	of	chronic	pain	have	proved	sufficient	conditions	for	gabapentinoid	drugs	to	have	an	antinociceptive	action	(Suzuki	et	al	2005).	An	abolished	DNIC	system	in	the	late	phase	MIA	animals	strongly	suggests	that	
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an	enhanced	serotonergic	facilitatory	descending	system	acting	at	5-HT3	receptors	in	the	spinal	cord	exists	(Bannister	et	al	2015).	Overall,	the	efficacy	of	pregabalin	but	lack	of	an	upregulated	expression	of	the	α2δ1	subunit,	indicates	sufficient	central	sensitisation	and	enhanced	descending	serotonergic	facilitation	are	sufficient	conditions	for	pregabalin	to	prove	effective	at	inhibiting	neuronal	responses	in	late	phase	MIA	animals.			Despite	pregabalin	proving	effective	at	inhibiting	pre-conditioned	mechanically	evoked	neuronal	responses,	it	did	not	restore	the	DNIC	system	in	late	phase	MIA	animals.	Although	this	study	suggests	that	pregabalin	becomes	effective	in	late	phase	MIA	animals	due	to	an	enhanced	descending	facilitatory	system,	pregabalins	sole	target	remains	the	α2δ1	subunit	(Davies	et	al	2007).	Therefore,	although	there	is	no	upregulation	of	the	α2δ1	subunit,	pregabalin	still	mediates	inhibition	of	nociceptive	transmission	in	the	spinal	cord	through	its	actions	at	this	target.	Overall,	there	is	no	evidence	to	indicate	that	pregabalin	restores	the	balance	in	facilitatory	and	inhibitory	descending	controls,	and	therefore	cannot	reinstate	the	DNIC	system	in	late	phase	MIA	animals.			
	
Figure	6.16	The	mRNA	expression	of	the	α2δ1	subunit	of	VGCCs	in	lumbar	DRGs	following	
MIA	injection.	The	mRNA	expression	of	the	α2δ-1	subunit	of	VGCCs	in	pooled	ipsilateral	L3/L4	DRGs	or	pooled	ipsilateral	L5/L6	DRGs	from	sham	and	MIA	animals	14	days	post-injection.				
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6.4.2.2	The	expression	of	ATF-3	in	the	lumbar	DRGs	and	spinal	cord	of	MIA	
animals	While	the	cartilage	is	not	innervated,	histology	studies	indicated	that	in	areas	of	extreme	cartilage	degradation	there	was	exposure	of	the	subchondral	bone,	which	is	highly	innervated,	indicating	that	this	extent	of	damage	may	lead	to	peripheral	nerve	damage	(See	Section	5.3.2).	Retrograde	labeling	studies	have	demonstrated	that	knee	joint	afferents	are	localized	mainly	to	L4	DRGs,	and	the	majority	of	subchondral	bone	afferents	are	localized	in	the	L3	DRGs	(Aso	et	al	2014).	This	was	similar	to	the	Fast	Blue	experiments	carried	out	in	this	study,	which	indicated	the	majority	of	knee	joint	afferents	were	localized	in	the	L4	and	L5	DRGs.	Therefore,	ATF-3	expression	was	investigated	in	the	L3-L5	DRGs	to	investigate	any	nerve	trauma	in	knee	joint	or	subchondral	bone	afferents.			Remarkably,	there	was	no	increase	in	ATF-3	expression	in	the	ipsilateral	L3-L5	DRGs	in	either	early	or	late	phase	MIA	animals	compared	to	sham	controls.	This	contrasts	with	previous	studies	finding	a	large	ATF-3	expression	in	the	lumbar	DRGs	following	a	1mg	or	2mg	MIA	injection,	although	the	exact	results	vary	between	studies	(Ivanavicius	et	al	2007,	Orita	et	al	2011,	Thakur	et	al	2012).	Firstly,	Ivanavicius	et	al	found	a	significant	increase	in	ATF-3	expression	in	ipsilateral	L4	and	L5	DRGs	8	and	14	days	following	MIA	injection	but	that	this	expression	then	decreased	and	was	not	significantly	higher	than	sham	controls	on	day	21,	28	and	35	(Ivanavicius	et	al	2007)	Secondly,	Orita	et	al	found	that	ATF-3	positive	neurons	were	only	observed	in	the	ipsilateral	L4	DRG	14	days	following	a	2mg	MIA	injection,	but	the	proportion	of	ATF-3	positive	neurons	increased	as	the	model	progressed	(Orita	et	al	2011).	Finally,	Thakur	et	al	found	a	significant	increase	in	ATF-3	positive	neurons	in	ipsilateral	L4	and	L5	DRGs	as	soon	as	3	days	following	MIA	injection	(Thakur	et	al	2012).			Interestingly,	none	of	the	above	studies	indicated	a	significant	increase	in	ATF-3	positive	neurons	in	the	L3	DRGs,	which	indicates	the	reported	neuropathic	component	was	not	a	result	of	damage	to	peripherall	afferents	innervating	the	subchondral	bone.	Firstly,	the	differences	in	the	ATF-3	staining	presented	in	this	thesis	and	previous	findings	are	not	due	to	differences	in	MIA	dose,	as	both	Thakur	et	al	and	Orita	et	al	used	a	2mg	dose	of	MIA,	while	Ivanavicius	et	al	used	a	1mg	dose,	therefore	it	cannot	be	that	higher	MIA	doses	were	causing	nerve	trauma.	Secondly,	MIA	was	diluted	in	the	same	volume	of	saline	(25μl)	for	intrarticular	injection	in	this	study	and	previous	studies,	indicating	that	the	differing	results	are	not	down	to	the	volumes	injected	(Orita	et	al	2011,	Thakur	et	al	
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2012).	Thakur	et	al	reported	that	20%	of	L5	DRG	cells	bodies	showed	positive	staining	for	ATF-3,	whereas	the	neuronal	tracer	experiment	in	this	study	indicated	that	only	4%-6%	of	L4	and	L5	neurons	innervated	the	knee	(Figure	6.17A)(See	Section	6.3.4).	Interestingly,	a	study	investigating	an	MIA	mouse	model	found	a	significant	increase	in	ATF-3	positive	cell	bodies	in	L3-L5	DRGs	7	days	after	MIA	injection,	but	this	was	at	much	lower	levels	as	only	2.1%	of	cell	bodies	displayed	positive	staining	(Figure	6.17B)(Ogbonna	et	al	2013).	The	authors	concluded	there	was	no	evidence	to	suggest	MIA	induced	sensory	neuron	damage	(Ogbonna	et	al	2013).	Overall,	the	lack	of	ATF-3	positive	cell	bodies	in	L3	DRGs,	the	high	numbers	of	ATF-3	positive	neurons	reported,	and	the	presence	of	ATF-3	positive	motor	neurons	in	the	ventral	horn,	suggest	primary	afferent	damage	is	occurring	due	to	damage	outside	of	the	joint	and	could	be	attributed	to	intrarticular	injection	technique.			The	investigation	of	ATF-3	mRNA	expression	in	the	lumbar	DRGs	confirmed	the	immunohistochemical	findings	of	this	study,	as	there	was	no	significant	increase	in	the	mRNA	ATF-3	expression	in	either	early	or	late	phase	MIA	animals	compared	to	sham	controls.			In	addition	to	the	ipsilateral	lumbar	DRGs,	the	expression	of	ATF-3	was	also	assessed	in	the	lumbar	spinal	cord.	Previous	MIA	studies	have	also	found	an	expression	of	ATF-3	in	the	ventral	horn,	indicating	that	ATF-3	expression	observed	in	lumbar	DRGs	may	actually	be	a	result	of	damage	to	motor	neurons	surrounding	the	knee	rather	than	sensory	neurons	innervating	the	knee	(Thakur	et	al	2012).	In	this	study,	no	ATF-3	expression	or	Fast	Blue	staining	was	observed	in	the	ventral	horn,	which	may	indicate	a	more	precise	intrarticular	injection	or	less	leakage	in	this	study.			
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Figure	6.17	The	ATF-3	expression	in	ipsilateral	lumbar	DRGs	following		2mg	MIA	injection	
in	the	rat	and	1mg	MIA	in	the	mouse.	A)	This	figure	indicates	that	in	the	2mg	MIA	rat	model,	ATF-3	positive	neurons	are	observed	in	ipsilateral	L4	and	L5	DRGs	as	early	as	3	days	following	a	2mg	MIA	injection.	By	day	7,	20%	of	L4	and	L5	cells	bodies	show	positive	ATF-3	staining.	By	day	14,	the	number	of	ATF-3	positive	cell	bodies	begins	to	decline	but	there	is	still	significant	expression	in	ipsilateral	L4	DRGs	(Taken	from	Thakur	et	al	2012).	B)	This	figure	indicates	in	the	1mg	MIA	mouse	model,	although	there	is	a	significant	increase	in	ATF-3	positive	cell	bodies	in	L3-L5	DRGs	7	days	following	MIA	injection,	this	is	at	much	lower	percentages	than	that	observed	in	partial	nerve	ligation	(Taken	from	Ogbonna	et	al	2013).				
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		Remarkably,	the	qPCR	experiment	carried	out	in	this	study	indicated	a	significant	increase	in	ATF-3	mRNA	expression	in	the	lumbar	dorsal	horn	of	late	phase	MIA	animals	compared	to	sham	controls.	Initially,	this	result	was	confusing	as	in	the	immunohistochemical	study	no	ATF-3	expression	was	observed	in	the	dorsal	horn.	However,	a	recently	developed	RNA	sequencing	database	indicates	that	microglia	have	a	large	expression	of	ATF-3	mRNA,	although	immunohistochemistry	suggests	the	mRNA	is	not	translated	to	the	ATF-3	protein	(Figure	6.18)(Zhang	et	al	2014).	This	thesis	reported	a	rise	in	Iba-1	mRNA	in	the	dorsal	horn,	while	previous	studies	have	reported	significant	microgliosis	occurs	in	the	lumbar	dorsal	horn	following	MIA	injection	(See	Section	5.3.4)(Thakur	et	al	2012,	Ogbonna	et	al	2013).	Therefore,	the	significant	ATF-3	expression	in	the	dorsal	horn	of	late	phase	MIA	animals	likely	reflects	an	increased	proliferation	of	microglia	in	response	to	the	MIA	injection.			
	
Figure	6.18	The	mRNA	expression	of	ATF-3	in	various	cell	types.	This	indicates	a	large	expression	of	ATF	RNA	(fragments	per	kilobase	million)	in	microglia	cells.	Zhang	et	al	2014.		
	
	
	
	 268	
6.4.3	Concluding	remarks		This	study	confirms	that	DNIC	is	a	noradrenergic	endogenous	inhibitory	system	with	a	serotonergic	component.	This	study	demonstrated	that	enhanced	noradrenergic	modulation	and	activating	spinal	5-HT7	receptors	reinstated	the	DNIC	system	in	late	phase	MIA	animals.	This	indicates	that	the	loss	of	DNIC	in	late	phase	MIA	animals	is	due	to	an	imbalance	in	descending	controls,	specifically	decreased	descending	inhibitory	controls.	The	actions	of	noradrenaline	or	serotonin	at	α2-adrenoceptors	or	5-HT7	receptors	respectively,	was	sufficient	to	restore	the	endogenous	inhibitory	system,	and	therefore	may	hold	promise	as	a	therapeutic	mechanism	to	tackle	centrally	driven	chronic	pain	in	OA	patients.				This	study	also	indicated	that	pregabalin	was	effective	in	late	phase	MIA	animals,	despite	there	being	a	lack	of	neuropathy.	Therefore,	central	sensitisation	and	the	subsequent	imbalance	in	descending	controls	arising	in	the	brainstem,	which	causes	the	abolished	DNIC	system,	appears	to	present	sufficient	conditions	for	pregabalin	to	prove	effective.	Finally,	a	combination	therapy	of	pregabalin	and	tapentadol	proved	effective	at	inhibiting	pre-conditioned	neuronal	responses	whilst	also	restoring	the	DNIC	system.	This	indicates	a	combination	therapy	of	low	doses	of	pregabalin	and	tapentadol	may	be	a	feasible	approach	for	providing	effective	pain	relief,	through	synergy	of	their	respective	mechanisms.																	
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7.	General	Discussion	
	
7.1	Diffuse	Noxious	Inhibitory	Controls	
	Throughout	this	thesis,	DNIC	are	investigated	using	single	unit	in	vivo	recordings	of	convergent	WDR	neurons	in	the	deep	dorsal	horn	of	the	spinal	cord.	This	thesis	demonstrates	that	using	in	vivo	electrophysiological	techniques	allows	consistent	and	reliable	measurement	of	DNIC	responses,	and	offers	the	opportunity	to	assess	the	functionality	of	descending	controls	in	animal	models	of	chronic	pain.	Furthermore,	this	thesis	demonstrates	that	even	when	the	DNIC	system	appears	to	be	abolished	in	animal	models	of	chronic	pain,	this	can	be	restored	pharmacologically	by	modulating	the	noradrenergic	and	serotonergic	descending	systems.	Therefore,	pharmacologically	manipulating	these	systems	in	patients	may	present	a	feasible	therapeutic	approach	for	tackling	centrally	driven	chronic	pain.			
7.1.1	The	importance	of	noradrenergic	and	serotonergic	descending	
controls	for	the	neuronal	inhibition	induced	by	DNIC	
	This	thesis	confirms	that	DNIC	are	mediated	via	inhibitory	noradrenergic	descending	controls	that	become	activated	upon	a	noxious	conditioning	stimulus.	Further,	this	thesis	demonstrates	that	a	spinal	serotonergic	component	can	influence	DNIC	expression,	and	this	component	may	become	more	important	following	the	development	of	central	sensitisation	and	chronic	pain.			Blocking	the	actions	of	noradrenaline	at	spinal	α2-adrenergic	receptors	with	the	antagonist	atipamezole	completely	blocked	the	neuronal	inhibition	induced	by	a	noxious	conditioning	stimulation	in	early	phase	MIA	and	sham	animals	that	otherwise	had	a	normally	functioning	DNIC	system.	This	is	in	agreement	with	a	previous	study	that	demonstrated	that	atipamezole	completely	blocked	the	neuronal	inhibition	induced	by	DNIC	in	naïve	animals	(Bannister	et	al	2015).	Together	these	findings	indicate	that	under	normal	physiological	conditions,	the	noxious	conditioning	stimulus	activates	descending	noradrenergic	controls,	which	carry	out	an	inhibitory	response	through	activating	α2-adrenergic	receptors	in	the	spinal	cord.			
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Studies	in	this	thesis	demonstrated	that	DNIC	expression	is	abolished	in	animal	models	of	chronic	pain,	specifically	in	a	SNL	model	of	neuropathy	and	in	late	phase	MIA	animals.	In	addition,	reduced	descending	noradrenergic	controls	acting	at	the	α2-adrenergic	receptors	in	the	spinal	cord	are	demonstrated	following	neuropathy	and	in	MIA	animal	models	of	chronic	pain	(Rahman	et	al	2008,	Burnham	and	Dickenson	2013).	Taken	together,	this	suggests	a	downregulation	of	descending	noradrenergic	controls	may	be	responsible	for	the	loss	of	DNIC.	Interestingly,	blocking	the	inhibitory	actions	of	noradrenaline	at	spinal	α2-adrenergic	receptors	prevented	the	restoration	of	DNIC	with	the	SSRIs	fluoxetine	and	citalopram	in	an	SNL	rat	model	of	neuropathy	(Bannister	et	al	2017).	This	study	indicated	that	a	tonic	descending	noradrenergic	control	is	always	required	for	DNIC	to	induce	neuronal	inhibition,	even	if	this	is	at	reduced	levels	as	is	the	case	in	animal	models	of	chronic	pain.			This	thesis	also	identified	that	a	spinal	serotonergic	component	can	influence	the	expression	of	DNIC.	In	early	phase	MIA	and	sham	animals	that	had	a	normally	functioning	DNIC	system,	the	spinal	application	of	the	selective	5-HT7	receptor	antagonist	SB-267790	reduced	the	level	of	neuronal	inhibition	induced	by	a	noxious	conditioning	stimulation.	However,	unlike	spinal	application	of	atipamezole	that	completely	abolished	DNIC	expression	in	early	phase	MIA	animals,	the	spinal	application	of	SB-267790	did	not	abolish	DNIC,	indicating	that	activation	of	spinal	5-HT7	receptors	is	not	crucial	for	DNIC	expression.			An	enhanced	descending	serotonergic	facilitatory	system	acting	at	5-HT3	receptors	in	the	spinal	cord	has	been	demonstrated	in	neuropathic	and	MIA	animals	models	of	chronic	pain	(Suzuki	et	al	2004,	Suzuki	et	al	2005,	Rahman	et	al	2009).	In	addition,	when	DNIC	was	abolished	in	a	rat	SNL	model	of	neuropathy,	blocking	the	presumed	facilitatory	actions	of	spinal	5-HT3	receptors	with	the	antagonist	ondansetron	restored	neuronal	inhibition	induced	by	DNIC	(Bannister	et	al	2015).	Overall,	the	pharmacological	studies	modulating	spinal	5-HT3	receptors	and	5-HT7	receptors	indicate	that	descending	serotoninergic	controls	can	mediate	a	dual	mode	of	action	on	DNIC	expression	depending	upon	the	spinal	receptor	activated.	These	results	are	in	agreement	with	a	study	demonstrating	that	descending	inhibitory	and	facilitatory	serotonergic	controls	from	the	RVM	act	ultimately	through	the	activation	of	spinal	5-HT7	and	5-HT3	receptors	respectively	(Dogrul	et	al	2009).			
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This	thesis	confirms	that	spinal	5-HT7	receptors	play	an	inhibitory	role	on	spinal	nociceptive	singalling	and	their	activation	mediates	the	expression	of	DNIC.	Firstly,	the	DNIC	system	was	restored	in	an	SNL	model	of	neuropathy	through	enhancing	the	spinal	synaptic	content	of	5-HT	with	the	spinal	administration	of	the	SSRIs	fluoxetine	and	citalopram,	but	this	effect	was	blocked	with	co-administration	of	a	selective	5-HT7	receptor	antagonist	(Bannister	et	al	2017).	This	study	demonstrated	that	increased	spinal	content	of	5-HT	produced	an	inhibition	of	spinal	neuronal	responses	and	induced	DNIC	expression	through	activating	the	5-HT7	receptor.	Secondly,	in	the	late	phase	MIA	model	the	spinal	application	of	the	selective	5-HT7	receptor	agonist	AS-19	restored	the	expression	of	DNIC	to	similar	levels	observed	in	control	animals,	further	confirming	that	spinal	5-HT7	receptors	can	mediate	DNIC	expression	in	states	of	chronic	pain.			While	the	exact	mechanism	by	which	the	spinal	5-HT7	receptors	mediated	antinociception	were	not	determined,	previous	findings	provide	potential	mechanisms.	Firstly,	spinal	5-HT7		receptors	have	been	demonstrated	to	mediate	morphine	antinociception,	and	are	ultimately	responsible	for	mediating	the	antinociceptive	actions	of	opiodergic	controls	arising	in	the	RVM	(Dogrul	and	Seyrek	2006,	Dogrul	et	al	2009).	As	the	MOR	antagonist	naloxone	has	been	demonstrated	to	partially	attenuate	neuronal	inhibition	induced	by	DNIC,	endogenous	opiates	are	thought	to	contribute	to	the	functional	DNIC	system,	therefore	spinal	5-HT7	receptors	may	contribute	to	the	neuronal	inhibition	induced	by	DNIC	through	opiodergic	mechanisms	(Le	Bars	et	al	1981a,	Kraus	et	al	1981).	Secondly,	spinal	5-HT7	receptors	are	colocalised	with	GABAergic	interneurons	in	the	dorsal	horn,	and	therefore	the	activation	of	5-HT7	receptors	may	mediate	inhibition	through	the	activation	of	inhibitory	interneurons	(Figure	7.1)(Brenchat	et	al	2010).	In	fact,	in	a	sciatic	nerve	constriction	injury	model	of	neuropathy,	an	intrathecal	injection	of	the	GABA	receptor	antagonist	bicuculline	but	not	the	MOR	antagonist	naloxone	blocked	the	antihyperalgesic	effects	mediated	by	5-HT7	receptor	activation	(Viguier	et	al	2012).	In	agreement,	central	sensitisation	is	associated	with	disinhibtion,	whereby	spinal	inhibitory	interneurons	are	suppressed	allowing	excitatory	transmission	to	be	sustained,	therefore	activating	spinal	5-HT7	receptors	and	subsequently	activating	inhibitory	interneurons	may	counteract	this	phenomenon	(Todd	2010).	Thirdly,	in	the	sciatic	nerve	constriction	injury	model	of	neuropathy	a	decrease	in	neuropathy-induced	over	expression	of	IL-1β	in	the	ipsilateral	lumbar	DRGs	and	dorsal	horn	was	associated	with	the	activation	of	spinal	5-HT7	receptors	(Viguier	et	al	2012).	As	the	overexpression	of	cytokines	due	to	injury	may	be	associated	with	the	activation	of	spinal	glia,	this	may	suggest	that	the	activation	of	spinal	5-HT7	receptors	
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influences	inflammatory	responses,	the	activation	of	spinal	glia	and	the	subsequent	neuronal	modulation.	Overall,	these	findings	could	indicate	that	the	antinociceptove	actions	of	spinal	5-HT7	receptors	shifts	from	an	opiodergic	mechanism	in	the	naïve	state	to	a	GABAergic	mechanism	in	states	of	chronic	pain.		
	
Figure	7.1.	The	expression	of	5-HT7	and	GABAergic	receptors	in	the	dorsal	horn.	D)	The	expression	of	the	5-HT7	receptor	in	the	dorsal	horn.	E)	The	expression	of	GABA	in	the	dorsal	horn.	F)	double	5-HT7/GABA	immuno-staining	in	the	dorsal	horn	indicates	that	receptors	are	co-localised.	Scale	bar	=	50μM.	(Taken	from	Brenchat	et	al	2010).			
7.1.2	The	applicability	of	testing	CPM	in	the	clinic	
	One	important	goal	when	studying	chronic	pain	in	animal	models	is	to	translate	findings	in	the	clinic	in	order	that	we	may	increase	our	understanding	of	mechanisms	involved	in	particular	pain	pathways	and	thus	recognize	novel	potential	therapeutics.	DNIC	has	a	human	counterpart,	known	as	CPM,	hence	DNIC	studies	obtained	in	the	lab	may	hold	great	clinical	relevance	if	they	can	be	translated	to	patients.	Measuring	CPM	responses	provides	a	useful	tool	for	assessing	the	functionality	of	patients	descending	controls	and	endogenous	inhibitory	systems,	and	can	subsequently	provide	valuable	insights	on	treatment	options	for	particular	chronic	pain	states	(Edwards	et	al	2003).			Testing	the	efficacy	of	a	patients	CPM	system	can	provide	insights	into	their	physiology	and	likelihood	of	benefiting	from	a	particular	treatment.	In	a	cohort	of	patients	with	painful	diabetic	neuropathy,	baseline	CPM	was	correlated	with	duloxetine	efficacy,	such	that	duloxetine	was	most	effective	in	patients	with	a	less	efficient	CPM	(Yarnitsky	et	al	2012).	In	addition,	a	study	investigating	the	development	of	post-operative	chronic	pain	found	that	patients	with	a	less	efficient	CPM	before	surgery	were	more	susceptible	to	developing	chronic	pain	after	surgery	(Yarnitsky	et	al	2008)	Taken	together,	these	studies	indicate	that	carrying	out	extensive	diagnosis	to	begin	with	and	testing	the	functionality	of	a	patients	CPM	system	could	improve	future	therapeutics	in	the	long-term,	through	predicting	how	likely	a	patient	is	to	develop	chronic	pain	and	which	analgesics	a	patient	may	respond	best	to.			
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Importantly,	the	findings	presented	in	this	thesis	and	previous	DNIC	and	CPM	studies	suggest	that	DNIC	and	CPM	share	a	similar	pharmacology.	Firstly,	the	study	demonstrating	that	patients	with	a	weak	CPM	benefit	from	the	SNRI	duloxetine	suggests	that	similarly	to	DNIC,	noradrenergic	and	serotonergic	signaling	pathways	subserve	CPM	(Yarnitsky	et	al	2012).	In	addition,	the	magnitude	of	CPM	in	healthy	subjects	has	been	demonstrated	to	be	associated	with	serotonin	transporter	gene	polymorphisms,	indicating	that	similarly	to	DNIC	in	animals,	CPM	can	be	influenced	by	the	serotonergic	modulatory	system	(Lidstedt	et	al	2011).	Therefore,	as	the	CPM	system	in	humans	also	relies	on	monoaminergic	signaling,	through	pharmacologically	modulating	these	systems	the	endogenous	inhibitory	system	that	CPM	utilizes	can	be	restored	to	provide	effective	pain	relief.			Interestingly,	drugs	traditionally	designed	as	antidepressants	that	function	by	modulating	the	levels	of	extracellular	noradrenaline	and	serotonin	are	often	effective	at	providing	pain	relief	in	patients	with	neuropathy	and	other	chronic	pain	states	(Bomholt	et	al	2005,	Sindrup	et	al	2005).		This	thesis	has	provided	further	indication	that	DNIC	and	CPM	are	influenced	by	noradrenergic	descending	inhibitory	systems,	and	can	be	modulated	by	a	spinal	serotonergic	component.	Due	to	the	importance	of	the	inhibitory	descending	noradrenergic	system	in	mediating	DNIC	expression,	this	is	a	good	first	analgesic	target	to	be	considered	in	patients	with	a	dysfunctional	CPM	system,	such	as	NRIs	that	prevent	the	re-uptake	of	pre-synaptic	noradrenaline	such	that	increased	levels	remain	in	the	synaptic	space	to	carry	out	inhibitory	actions	through	activating	spinal	α2-adrenergic	receptors	(Bannister	and	Dickenson	2017).	The	finding	in	this	thesis	that	Tapentadol,	which	functions	partly	as	an	NRI,	restores	DNIC	in	late	phase	MIA	animals	supports	this	approach.	As	serotonergic	signaling	can	mediate	both	inhibitory	or	facilitatory	influences	depending	upon	which	receptors	become	activated	in	the	spinal	cord,	the	consequences	of	increasing	the	synaptic	availability	of	serotonin	with	SSRIs	are	more	complicated.	Interestingly,	studies	presented	in	this	thesis	demonstrate	that	the	spinally	applied	SSRIs,	fluoxetine	and	citalopram,	produced	antinociception	in	a	model	of	neuropathy,	while	systemic	SSRIs	had	no	effect	(Bannister	et	al	2017).	Therefore,	SSRIs	could	provide	a	second-line	therapy	for	restoring	endogenous	inhibition	in	patients,	but	a	more	accurate	therapeutic	approach	may	be	to	specifically	target	the	inhibitory	serotonergic	receptors,	such	as	the	5-HT7	receptor.			Table	7.1	summarizes	the	key	findings	on	the	pharmacological	basis	of	DNIC	as	covered	by	the	studies	in	this	thesis.	Overall,	the	similarities	in	the	DNIC	and	CPM	systems	
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indicate	that	DNIC	studies	provide	promising	potential	for	forward	translation	from	preclinical	studies	to	patients.	
	
Chronic	
pain	model	
Functional	
DNIC	
expression	
Spinal	receptors	
α2-adrenergic	receptors	 5-HT7	receptors	
Spinal	
Nerve	
Ligation	
x	 A	descending	noradrerngic	tone	is	always	required	for	the	expression	of	DNIC,	even	when	spinal	5-HT	content	is	enhanced	with	SSRIs	in	SNL	animals.		
SSRIs	restore	DNIC	in	SNL	animals,	yet	this	effect	is	blocked	by	the		5-HT7	receptor	antagonist	SB-267790.	
Early	Phase	
MIA	
✓	 An	α2-adrenergic	receptor	antagonist	completely	blocks	DNIC	expression	in	early	phase	MIA	animals.	
A	5-HT7	receptor	antagonist	SB-267790	reduces	DNIC	expression	but	does	not	block	it	in	early	phase	MIA	animals.	
Late	Phase	
MIA	
x	 The	NRI	Tapentadol	restores	DNIC	expression	in	late	phase	MIA	animals.		 A	5-HT7	receptor	agonist	AS-19	restores	DNIC	in	late	phase	MIA	animals.		
Previous	
studies	
N/A	 1. The	α2-adrenergic	receptor	antagonists	atipamezole	and	yohimbine	block	DNIC	expression	in	naïve	animals.	2. The	NRIs	Reboxetine	and	Tapentadol	restored	DNIC	expression	in	an	SNL	model	of	neuropathy.	3. Descending	inhibitory	noradrenergic	controls	are	downregulated	in	animal	models	of	neuropathic	and	MIA	induced	chronic	pain.	
1. Spinal	5-HT7	receptors	play	an	antinocicptive	role	in	neuropathic	and	inflammatory	animal	models.	2. Spinal	5-HT7	receptors	are	colocalised	with	GABAergic	cells	–may	mediate	neuronal	inhibition	through	activation	of	inhibitory	interneurons.		3. Increased	density	of	5-HT7	receptors	following	neuropathy	–	potential	for	modulation	of	this	system	in	chronic	pain.		
References	 N/A	 1. Bannister	et	al	2015	2. Bannister	et	al	2015	3. Rahman	et	al	2008,	Burnham	and	Dickenson	2013.	
1. Brenchat	et	al	2009,	Brenchat	et	al	2010	2. Viguier	et	al	2012	3. Brenchat	et	al	2010	
Table	7.1	The	pharmacological	basis	of	DNIC	
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7.2	The	monoiodoacetate	model	of	Osteoarthritis:	
translational	relevance	to	the	clinic		A	further	objective	of	this	thesis	was	to	better	understand	the	chronic	pain	associated	with	OA,	using	a	2mg	MIA	rat	model.	Chronic	pain	associated	with	OA	is	a	heterogeneous	condition,	with	patients	presenting	with	several	and	varied	symptoms,	which	become	increasingly	complicated	and	difficult	to	interpret	due	to	the	discordance	between	radiological	joint	damage	and	the	associated	pain	phenotype	(Hannan	et	al	2000,	Malfait	and	Schnitzer	2014).	Studies	in	this	thesis	investigated	the	MIA	induced	joint	damage	and	the	associated	pain-like	behaviour.	This	thesis	specifically	focused	on	exploring	MIA-induced	central	sensitisation	and	the	associated	dysregulation	of	descending	controls	arising	in	the	brainstem,	which	was	assessed	through	measuring	the	DNIC	responses	in	early	and	late	phase	MIA	animals.	In	addition,	this	thesis	examined	the	innervation	of	the	knee	and	the	potential	for	an	MIA-induced	neuropathic	component	contributing	to	the	associated	chronic	pain.	Importantly,	the	findings	presented	in	this	thesis	demonstrate	subtypes	of	the	MIA	model,	which	may	correspond	to	patient	segments	who	may	respond	best	to	particular	therapeutic	interventions.			
7.2.1	Knee	histology	and	associated	pain-like	behaviour	
	While	it	is	difficult	to	exactly	mimic	the	aetiology	of	osteoarthritis	and	associated	chronic	pain,	an	MIA	injection	in	the	intrarticular	space	aims	to	cause	similar	joint	damage	to	that	observed	in	patients.	Therefore,	the	level	of	cartilage	damage	caused	by	the	MIA	injection	and	the	associated	chronic	pain	was	assessed	in	early	and	late	phase	MIA	animals.			Interestingly,	the	knees	taken	from	early	phase	MIA	animals	showed	no	significant	cartilage	damage,	despite	the	development	of	significant	pain	like	behaviour	in	these	animals.	Although	findings	in	this	thesis	demonstrate	no	increased	mRNA	expression	levels	of	the	pro-inflammatory	cytokines	IL-1β,	IL-6,	and	TNFα,	in	the	ipsilateral	lumbar	DRGs,	the	levels	of	these	pro-inflammatory	cytokines	were	not	investigated	in	the	joint,	which	is	where	an	inflammatory	infiltrate	has	been	reported	in	both	MIA	animals	and	OA	patients.	Therefore,	this	study	did	not	rule	out	the	possibility	of	an	inflammatory	infiltrate	within	the	joint,	which	could	be	driving	peripheral	sensitisation.	MIA	model	studies	have	demonstrated	a	significant	inflammatory	infiltrate	occurs	in	the	joint	
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rapidly	after	injection	(Guzman	et	al	2003,	Clements	et	al	2009,	Orita	et	al	2011).	There	is	significant	increase	in	the	levels	of	white	blood	cells	and	pro-inflammatory	cytokines	in	the	joint	in	the	first	week	following	MIA	injection,	with	levels	peaking	around	day	3-4	(Guzman	et	al	2003,	Clements	et	al	2009,	Orita	et	al	2011).	In	addition,	although	OA	is	not	traditionally	considered	an	inflammatory	condition,	an	inflamed	synovium	and	the	subsequent	release	of	pro-inflammatory	cytokines	are	linked	with	cartilage	degradation	in	OA	patients,	indicating	joint	inflammation	is	associated	with	an	accelerated	disease	pathogenesis	(Sellam	and	Berenbaum	2010).	Overall,	the	early	phase	MIA	model	may	present	a	useful	tool	for	exploring	the	inflammatory	component	associated	with	OA	but	may	not	accurately	represent	cartilage	joint	damage	observed	in	most	OA	patients.			On	the	other	hand,	in	knees	taken	from	late	phase	MIA	animals	there	was	significant	cartilage	damage.	This	is	in	agreement	with	other	MIA-induced	knee	pathology	studies,	which	identified	severe	cartilage	damage	and	proteoglycan	loss,	combined	with	initial	damage	to	the	subchondral	bone,	such	as	sclerosis,	lesions	and	fragmentation	(Guingamp	et	al	1997,	Guzman	et	al	2003).	Interestingly,	a	study	in	this	thesis	found	a	positive	correlation	between	the	extent	of	cartilage	damage	and	the	associated	pain-like	behaviour,	such	that	animals	with	more	extensive	cartilage	damage	avoided	placing	weight	on	the	injured	joint	and	showed	increased	levels	of	secondary	hyperalgesia	on	the	hind	paw.	This	indicates	that	the	pain	like	behaviour	that	develops	in	the	late	phase	MIA	model	is	an	accurate	representation	of	joint	damage	associated	chronic	pain,	and	provides	a	valid	translational	tool	to	OA	patients.			The	histological	findings	in	this	thesis	indicate	how	important	the	time	frame	is	for	the	extent	of	MIA-induced	joint	damage,	and	that	a	lengthier	model	may	more	accurately	represent	the	OA	joint	damage	observed	in	patients.	As	discussed,	early	phase	MIA	animals	could	provide	a	used	tool	for	further	exploration	of	the	inflammatory	component	to	OA.	Meanwhile,	late	phase	MIA	animals	demonstrated	extensive	cartilage	damage	and	translational	studies	may	help	to	further	our	understanding	of	cartilage	and	joint	damage	induced	development	of	chronic	pain.	However,	a	lengthier	MIA	model	may	allow	for	assessment	of	chronic	pain	associated	with	subchondral	bone	damage	and	remodeling,	which	can	be	observed	in	severe	cases	of	OA	in	patients	(Buckland-Wight	2004,	Brandt	et	al	2006).		
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7.2.2	The	expression	of	DNIC	and	associated	central	changes	in	the	MIA	
model		The	main	focus	of	this	thesis	involved	assessing	the	expression	of	DNIC	in	the	MIA	model,	which	proved	a	useful	tool	for	investigating	the	functional	state	of	descending	controls.			This	thesis	demonstrated	that	early	phase	MIA	animals	have	a	functional	DNIC	expression,	with	neuronal	inhibition	induced	by	a	noxious	conditioning	stimulus	at	levels	similar	to	those	observed	in	naïve	and	sham	control	animals.	As	it	has	been	indicated	in	a	cohort	of	patients	with	diabetic	neuropathy	that	those	with	a	functional	CPM	do	not	benefit	as	well	from	the	SNRI	duloxetine,	it	may	indicate	that	OA	patients	with	a	functional	CPM	may	also	not	necessarily	benefit	from	therapies	that	target	monoaminergic	signaling	and	aim	to	restore	this	system	(Yanritsky	et	al	2012).	In	addition,	previous	studies	have	demonstrated	that	rats	that	received	low	doses	of	MIA	(50mg/ml)	and	had	limited	joint	damage	were	sensitive	to	NSAIDs,	while	rats	that	received	high	doses	of	MIA	(80mg/ml)	develop	NSAID	resistant	ongoing	pain	(Havelin	et	al	2016).	Furthermore,	in	a	2mg	MIA	model	the	NSAID	Diclofenac	only	proved	effective	3	days	after	MIA	induction,	which	coincided	with	knee	swelling	(Fernihough	et	al	2004).	As	an	extensive	inflammatory	infiltrate	has	been	demonstrated	in	early	phase	MIA	animals,	it	would	indicate	that	tackling	the	inflammatory	component	to	the	associated	pain	with	NSAIDs	would	be	a	feasible	approach	(Guzman	et	al	2003,	Fernihough	et	al	2004,	Clements	et	al	2009,	Orita	et	al	2011).	These	findings	could	be	translated	and	explored	further	in	the	clinic,	such	that	OA	patients	who	present	with	joint	inflammation	and	an	efficient	CPM	system	may	benefit	most	from	NSAIDs	that	act	to	tackle	the	peripheral	inflammatory	source	of	pain	rather	than	therapeutic	interventions	that	aim	to	tackle	centrally	driven	chronic	pain.			On	the	other	hand,	late	phase	MIA	animals	had	abolished	DNIC	expression,	as	there	was	no	inhibition	of	mechanically	evoked	neuronal	firing	with	a	concurrent	noxious	ear	pinch.	The	DNIC	system	was	restored	with	the	NRI	and	MOR	agonist	Tapentadol,	and	by	activating	spinal	5-HT7	receptors,	indicating	that	the	system	was	not	completely	abolished	but	rather	masked	by	an	imbalance	in	descending	controls.	Previous	studies	have	indicated	that	as	the	MIA	model	progresses,	NSAID	resistant	ongoing	pain	develops	(Fernihough	et	al	2004,	Havlin	et	al	2006)	Furthermore,	patients	have	been	demonstrated	to	develop	referred	pain	and	hypersensitivity,	and	a	subset	of	patients	remain	with	chronic	pain	following	total	joint	replacement	surgery	(Gwilym	et	al	2009,	
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Wylde	et	al	2011).	These	findings	indicate	that	late	phase	MIA	animals	and	a	subset	of	OA	patients	develop	pain	that	can	no	longer	be	the	result	of	purely	peripheral	mechanisms.	Therefore,	therapeutic	interventions	that	aim	to	tackle	the	centrally	driven	contribution	to	OA	associated	chronic	pain	may	be	most	appropriate	in	this	subset	of	patients	(See	Section	7.1.2).	Specifically,	if	OA	patients	present	with	a	dysfunctional	CPM	system,	the	findings	presented	in	this	thesis	suggest	treatments	with	the	most	benefit	would	act	to	restore	CPM	expression	through	pharmacologically	modulating	the	balance	in	descending	inhibitory	and	facilitatory	controls.			Investigating	the	expression	of	DNIC	in	the	MIA	model	of	OA	has	provided	information	on	how	central	changes	and	an	imbalance	in	inhibitory	and	facilitatory	descending	controls	do	not	appear	to	develop	until	the	later	stages	of	disease	progression.	This	can	be	applied	to	the	OA	clinic,	as	through	assessing	both	the	level	of	joint	inflammation	and	the	efficiency	of	CPM,	valuable	insights	can	be	gained	on	the	most	effective	analgesic	approach	for	individual	patients.	
	
7.2.3	A	neuropathic	component	to	the	MIA	model		A	study	presented	in	this	thesis	indicated	that	while	Pregabalin	proved	ineffective	at	producing	an	inhibitory	effect	in	early	phase	MIA	animals,	Pregabalin	had	a	significant	inhibitory	effect	on	neuronal	firing	in	late	phase	MIA	animals.	As	gabapentinoid	drugs	have	proved	effective	treatments	in	neuropathic	conditions,	this	may	have	indicated	a	neuropathic	component	to	the	MIA-induced	pain	(Thakur	et	al	2014,	Patel	and	Dickenson	2016).	However,	ATF-3	staining	in	the	ipsilateral	lumbar	DRGs	suggested	there	was	no	MIA	induced	damage	to	peripheral	afferents	innervating	and	surrounding	the	knee.	In	addition,	there	was	no	upregulated	mRNA	expression	of	the	α2δ1	subunit	of	VGCCs	in	the	ipsilateral	lumbar	DRGs	or	dorsal	horn,	which	has	been	reported	in	animal	models	of	neuropathy	(Bauer	et	al	2009).	The	lack	of	ATF-3	staining	and	no	change	in	the	mRNA	expression	of	the	α2δ1	subunit	conflict	with	previous	MIA	studies	(Rahman	et	al	2009,	Thakur	et	al	2012).	As	the	same	dose	of	MIA	(2mg)	in	the	same	amount	of	saline	(25μL)	was	used	for	these	studies,	the	discrepancies	in	results	could	come	down	to	injection	technique	and	differing	levels	of	neuropathy	between	the	models.			The	results	presented	in	this	thesis	suggest	that	there	was	no	neuropathic	component	to	the	MIA	induced	pain	and	that	late	phase	MIA	animals	were	sensitive	to	Pregabalin	due	to	other	mechanisms,	such	as	upregulated	facilitatory	serotonergic	descending	controls	
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acting	at	5-HT3	receptors	(Suzuki	et	al	2005).	Nevertheless,	the	Fast	Blue	neuronal	tracer	study	did	demonstrate	that	the	knee	joint	is	innervated,	and	so	OA	induced	joint	damage	does	hold	the	potential	for	neuropathy.	Furthermore,	if	the	MIA	model	had	been	left	to	progress	for	longer	this	may	have	led	to	subchondral	bone	fibrillation	and	lesions,	and	as	the	subchondral	bone	contains	many	free	nerve	endings,	this	would	likely	result	in	peripheral	nerve	damage	and	may	reflect	the	more	advanced	cases	of	OA	observed	in	patients	(Guingamp	et	al	1997,	Guzman	et	al	2003,	Aso	et	al	2014).	Overall,	although	a	neuropathic	component	to	the	MIA	model	was	not	identified	in	this	thesis,	a	subset	of	patients	still	present	with	neuropathic	features	and	this	should	be	considered	when	deciding	on	the	appropriate	therapeutic	intervention	(Thakur	et	al	2014).			
7.2.4	Personalised	medicine	in	the	OA	clinic				Importantly,	the	findings	presented	indicate	that	accurate	diagnoses	and	personalised	medicine	approaches	could	be	explored	further	in	the	clinic	and	may	be	the	most	promising	approach	for	providing	effect	pain	relief	in	patients	with	OA.	As	discussed,	accurately	testing	the	levels	of	inflammation,	efficiency	of	CPM,	and	development	of	neuropathy,	would	provide	valuable	insights	into	which	therapeutic	intervention	would	likely	produce	the	most	effective	pain	relief.	In	addition,	a	combination	therapy	of	Pregabalin	and	Tapentadol	was	found	to	efficiently	inhibit	pre-conditioned	neuronal	firing,	and	also	reinstate	DNIC.	This	suggests	that	combination	therapies	may	be	a	useful	approach	for	targeting	different	mechanisms	of	OA	induced	chronic	pain.	For	instance,	if	an	OA	patient	presented	with	neuropathic	features	and	an	inefficient	CPM,	this	treatment	approach	could	tackle	both	components.	Not	only	will	accurate	diagnostics	and	a	personalised	medicine	approach	provide	a	better	quality	of	care	to	patients,	it	will	also	avoid	wasteful	expenditure	on	treatments	that	would	prove	ineffective	in	a	subset	of	patients.			Table	7.2	summarizes	the	key	findings	on	the	aeitiology	of	the	MIA	model	as	covered	by	the	studies	in	this	thesis	compared	to	previous	studies	investigating	the	MIA	model.							
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Table	7.2	The	aeitiology	of	the	MIA	model	
Feature	 Stages	of	MIA	model	
Early	phase	MIA	 Late	phase	MIA	 Other	studies	 References	
Joint	
Histopathology	
Little	articular	cartilage	degradation.	
Significant	articular	cartilage	degradation	and	exposure	of	subchondral	bone.	
14	days	post-injection:	Severe	cartilage	damage	and	proteoglycan	loss.		Initial	damage	to	subchondral	bone,	including	sclerosis,	fragmentation,	bone	lesions.	
Guingamp	et	al	1997	Guzman	et	al	2003			Mohan	et	al	2011	
Peripheral	
Inflammation	
No	increase	in	mRNA	expression	of	pro-inflammatory	cytokines	in	ipsilateral	lumbar	DRGs.	
No	increase	in	mRNA	expression	of	pro-inflammatory	cytokines	in	ipsilateral	lumbar	DRGs.	
Significant	inflammatory	infiltrate	in	joint	soft	tissue	structures	in	early	phase	MIA	animals,	which	declines	over	time.	
Guzman	et	al	2003	Clements	et	al	2009		Orita	et	al	2011	
Peripheral	
nerve	damage	
No	ATF-3	positive	staining	in	ipsilateral	lumbar	DRGs.	
No	ATF-3	positive	staining	in	ipsilateral	lumbar	DRGs.	
A	significant	increase	in	the	number	of	ATF-3	positive	cell	bodies	in	L4	and	L5	DRGs,	3,	7	and	14	days	post	MIA	injection.		A	significant	increase	in	ATF-3	positive	cell	bodies	in	L4	DRG	14	days	post	injection.		ATF-3	staining	observed	in	2.1%	of	L3,	L4	and	L5	DRG	cells	7	days	post	injection.	
Thakur	et	al	2012								Orita	et	al	2011						Ogbonna	et	al	2013	
Sensitivity	of	
dorsal	horn	
neurons	
No	increase	in	mechanically	evoked	WDR	
No	increase	in	mechanically	evoked	WDR	
Enhanced	WDR	neuronal	firing	rates	in	response	to	
Rahman	et	al	2009	Burnham	and	
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neuronal	firing	rates	compared	to	sham	controls.	
neuronal	firing	rates	compared	to	sham	controls.	
noxious	stimulations.	Enhanced	spontaneous	firing	rate	of	WDR	neurons.		
Dickenson	2013	McGaraughty	et	al	2010	Chu	et	al	2011	
Microgliosis	 No	significant	increase	in	the	mRNA	expression	of	Iba1	or	pro-inflammatory	cytokines	in	the	dorsal	horn.	
A	rise	in	the	mRNA	expression	of	Iba1	and	the	pro-inflammatory	cytokine	IL-1β,	but	this	did	not	reach	significance.	
Significant	shift	of	microglia	into	effector	morphometry	by	day	7.	Significant	proliferation	of	microglia	in	the	ipsilaterl	lumbar	spinal	cord.			
Thakur	et	al	2012			Sagar	et	al	2011	Ogbonna	et	al	2013	
Functionality	of	
descending	
controls	
Functional	DNIC	expression.	 Abolished	DNIC	expression.	 Endogenous	noradrenergic	inhibition	was	reduced	in	late	phase	MIA	animals.		Enhanced	serotonergic	excitatory	drive	modulates	evoked	neuronal	responses	in	late	phase	MIA	animals.	
Burnham	and	Dickenson	2013					Rahman	et	al	2009	
		
7.3	Methodological	considerations		While	the	preclinical	investigation	of	animal	models	of	chronic	pain	expands	our	understanding	of	the	neurobiology	of	pain	and	provides	useful	insights	into	the	molecular	mechanisms	of	effective	analgesics,	any	differentiations	between	animal	and	human	pathways	needs	to	be	considered.	An	awareness	of	the	limitations	of	each	experimental	technique	will	allow	for	the	most	accurate	conclusions	to	be	drawn,	and	for	appropriate	translation	from	preclinical	models	to	the	clinic.		
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7.3.1	Single-unit	in	vivo	recordings	
	
7.3.1.1	The	use	of	supra	threshold	stimulations	Single	unit	in	vivo	recordings	provide	a	useful	technique	for	unbiased	measurements	of	neuronal	responses	to	natural	and	electrical	stimulations,	and	in	turn	an	understanding	of	how	these	responses	can	be	modulated	by	pharmacological	manipulation	in	animal	models	of	chronic	pain.	Many	other	experimental	techniques	used	in	animals	models	of	preclinical	pain	research,	such	as	behaviour	and	electromyographic	recordings,	measure	nociceptive	responses	based	on	reflex	withdrawals,	yet	it	remains	questionable	how	reliably	reflex	withdrawals	reflect	the	human	pain	experience	(Mogil	2009).	In	addition,	behavioural	techniques	only	allowing	for	threshold	level	stimulations	due	to	ethical	reasons,	there	is	a	also	a	subjective	nature	to	the	tests,	which	may	introduce	bias.	In	contrast,	single-unit	in	vivo	recordings	allows	for	measurements	of	neuronal	responses	to	supra	threshold	stimuli,	which	are	likely	to	reflect	the	high	pain	levels	reported	by	patients	in	the	clinic	(Sikander	and	Dickenson	2013).			
7.3.1.2	The	search	strategy	for	neurones	There	are	limitations	to	single	unit	in	vivo	recordings	that	should	be	taken	into	consideration.	Firstly,	the	strategy	employed	for	finding	neurons	ensures	a	sample	of	neurons	are	selected	with	similar	characteristics,	and	whilst	this	allows	for	comparisons	between	studies	it	may	also	introduce	bias.	For	example,	neurones	with	a	high	level	of	baseline	spontaneous	activity	tend	to	be	excluded	from	studies	as	they	are	highly	excitable	and	are	likely	to	burst	following	a	few	noxious	stimulations	to	the	receptive	field.	In	addition,	a	high	level	of	tonic	spontaneous	activity	makes	it	difficult	to	distinguish	between	spontaneous	and	evoked	action	potentials,	and	therefore	makes	DNIC	induced	neuronal	inhibition	difficult	to	interpret.	However,	WDR	neurons	receiving	input	from	both	the	knee	and	hind	paw	in	MIA	animals	have	been	demonstrated	to	have	an	enhanced	spontaneous	firing	rate	compared	to	Shams	(McGaraughty	et	al	2010,	Chu	et	al	2011).	Therefore,	excluding	neurons	with	high	levels	of	spontaneous	firing	may	produce	an	underestimation	of	central	sensitisation	in	MIA	animals.	This	may	provide	one	explanation	for	why	mechanically	evoked	neuronal	responses	were	not	found	to	be	enhanced	compared	to	shams	in	this	thesis.			
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7.3.1.3	Descending	controls	and	anaesthesia	It	has	previously	been	considered	that	for	CPM,	the	conditioning	stimulus	may	attenuate	the	pain	response	partly	through	a	distraction	mechanism.	However,	human	studies	have	confirmed	that	the	CPM	system	acts	independently	from	distraction	(Moont	et	al	2010).	The	results	presented	in	this	thesis	with	anaesthetized	animals	provide	unequivocal	evidence	that	the	noxious	conditioning	stimulus	induces	neuronal	inhibition	through	a	mechanism	that	does	not	involve	distraction.	As	the	low	level	of	anaesthesia	used	is	constant	for	the	duration	of	the	experiment,	and	the	same	levels	are	used	between	animals,	any	anaesthesia-induced	reduction	in	spinal	neuronal	activity	should	also	remain	constant	and	allows	for	comparisons	between	studies.	However,	when	using	recordings	from	anaesthetized	animals,	the	effect	anesthesia	may	have	on	descending	modulation	needs	to	be	considered,	especially	when	taking	into	account	that	isoflurane	has	been	reported	to	mediate	antinociception	through	noradrenergic	descending	controls	acting	at	spinal	α2-adrenergic	receptors	(Kingery	et	al	2002).	If	isoflourane	were	modulating	descending	controls	through	this	mechanism,	outcomes	may	have	to	be	interpreted	more	carefully.	However,	the	alterations	observed	in	the	descending	noradrenergic	system	in	late	phase	MIA	and	SNL	animals	compared	to	shams,	when	all	animals	are	under	the	same	level	of	isoflurane	indicates	that	isoflurane	is	not	modulating	descending	noradrenergic	activity	enough	to	effect	DNIC	repsonses.	Furthermore,	the	potent	effects	produced	by	the	α2-adrenergic	receptor	antagonist	atipamezole	and	the	NRIs	Reboxetine	and	Tapentadol	suggests	there	is	little	competition	for	spinal	α2-adrenergic	receptors,	further	indicating	isoflurane	is	not	be	having	a	large	effect	on	these	receptors.			
7.3.1.4	The	DNIC	protocol	In	the	MIA	model,	DNIC	was	induced	with	both	a	concurrent	noxious	ear	pinch	and	knee	pinch.	The	concurrent	noxious	pinch	was	placed	on	the	MIA	injured	knee	to	assess	if	noxiously	stimulating	the	area	of	primary	hyperalgesia	could	induce	neuronal	inhibition.	However,	in	both	animal	DNIC	studies	and	human	CPM	paradigms	the	conditioning	stimulus	is	placed	distant	to	the	test	stimulus	(Bannister	and	Dickenson	2016a,	Yarnitsky	2015).	Therefore,	as	the	test	stimulus	is	placed	on	the	receptive	field	of	the	hind	paw,	and	the	concurrent	conditioning	stimulus	is	placed	on	the	ipsilateral	MIA	injured	knee,	these	two	sites	may	be	too	close	to	constitute	a	DNIC	response.	As	such,	the	inhibition	observed	in	neuronal	firing	upon	concurrent	noxious	MIA	injured	knee	pinch	in	late	phase	MIA	animals,	who	otherwise	demonstrate	an	abolished	DNIC	system,	may	be	due	to	other	mechanisms	rather	than	DNIC.	However,	DNIC	is	abolished	in	both	
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ipsilateral	and	contralateral	WDR	neurons	in	late	phase	MIA	animals.	Therefore,	the	DNIC	expression	was	also	assessed	in	contralateral	cells	with	a	concurrent	noxious	pinch	placed	on	the	MIA	injured	knee,	which	is	now	contralateral	to	the	hind	paw	receptive	field	and	would	count	as	a	distant	site.			
7.3.2	The	MIA	model	As	discussed	in	Section	5.1.1,	although	it	is	difficult	to	mimic	the	exact	aetiology	of	OA	in	an	animal	model,	the	2mg	MIA	model	produces	similar	joint	pathology,	associated	pain-behaviour	and	evidence	of	central	sensitisation.	Although	there	is	an	initial	inflammatory	infiltrate	into	the	joint	rapidly	following	MIA	injection,	the	inflammatory	response	begins	to	subside	by	day	7	and	continues	to	stay	low	at	the	later	stages	of	the	model	(Guzman	et	al	2003,	Orita	et	al	2011).	In	contrast,	although	a	higher	inflammatory	infiltrate	was	found	in	joint	tissue	from	patients	with	early	phase	OA,	patients	present	with	episodic	synovial	inflammation,	which	occurs	in	both	the	early	and	late	stages	of	the	disease	(Benito	et	al	2005,	Scanzello	and	Goldring	2012).	Therefore,	although	the	inflammatory	response	occurring	in	the	early	stages	of	the	MIA	model	represents	similarities	with	the	human	OA	condition,	the	fact	that	late	phase	MIA	models	develop	NSAID	insensitive	ongoing	pain	may	not	necessarily	be	reflective	of	patients	(Fernihough	et	al	2004,	Havelin	et	al	2016).	While	NSAIDs	may	prove	generally	ineffective	in	patients	with	advanced	OA,	they	may	prove	beneficial	in	OA	patients	undergoing	a	synovitis	flare,	which	can	be	detected	through	MRI	or	ultrasound	imaging	of	the	joint	(Scanzello	and	Goldring	2012).	Overall,	while	the	late	phase	MIA	model	shares	similar	structural	joint	changes	with	OA	patients,	it	may	not	characterize	inflammatory	flares	observed	in	OA	patients,	and	therefore	may	not	be	a	perfect	model	for	forward	translation	to	the	clinic	in	every	case.		
	
7.3.3	MIA	induced	histopathology	of	the	knee	While	cartilage	damage	has	long	been	considered	the	central	feature	for	initiating	OA,	and	MIA	was	shown	to	significantly	damage	articular	cartilage	in	late	phase	animals,	it	is	becoming	increasingly	clear	that	OA	should	be	considered	a	disease	of	the	whole	joint	(Loeser	2006,	Dieppe	2011).	Although	the	knee	histology	presented	in	this	thesis	showed	significant	degradation	of	the	articular	cartilage	and	exposure	of	subchondral	bone	in	late	phase	MIA	animals,	it	did	not	assess	any	damage	to	the	synovium,	subchondral	bone	or	surrounding	joint	structures,	such	as	the	muscles	and	ligaments.	Although	the	specific	OA	induced	joint	damage	varies	greatly	between	patients,	damage	can	occur	in	all	subchondral	joint	structures	and	contribute	to	the	development	of	
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disease	pathogenesis	(Wieland	et	al	2005)(See	Section	1.3.2).	As	this	thesis	explores	the	chronic	pain	associated	with	OA,	and	the	cartilage	itself	is	not	innervated	and	so	cannot	be	causing	pain	directly,	it	may	be	beneficial	to	use	a	method	that	allows	for	assessing	damage	to	the	whole	joint.	Furthermore,	one	feature	of	OA	induced	joint	damage	associated	with	flares	of	chronic	pain	in	patients	is	bone	marrow	lesions	(Felson	et	al	2001,	Zhang	et	al	2011).	Therefore,	a	technique	such	as	microCT,	which	is	capable	of	detecting	subchondral	joint	damage,	may	allow	for	a	clearer	understanding	of	what	may	be	driving	the	associated	chronic	pain	and	central	sensitisation	in	the	MIA	model	(Morenko	et	al	2004).	Overall,	assessing	the	damage	caused	by	MIA	to	the	joint	as	a	whole	may	provide	valuable	insights	on	how	translatable	the	MIA	induced	joint	damage	is	compared	to	OA	induced	joint	damage	in	patients.			
7.3.4	The	limitations	of	qPCR	In	this	thesis,	changes	in	the	mRNA	expression	of	monoaminergic	receptors,	glia	biomarkers,	pro-inflammatory	cytokines,	and	nerve	injury	markers	were	assessed	in	the	ipsilateral	lumbar	DRGs	and	dorsal	horn	using	qPCR.	While	little	changes	in	the	mRNA	expressions	were	reported	in	this	thesis,	it	should	be	considered	that	this	might	due	to	a	dilution	effect.	Firstly,	the	whole	of	the	lumbar	dorsal	horn	was	taken	and	used	for	RNA	extraction,	while	changes	in	mRNA	expression	may	occur	in	a	specific	areas	of	the	dorsal	horn.	Secondly,	the	cellular	heterogeneity	of	the	DRGs	and	dorsal	horn	should	be	taken	into	account.	When	investigating	monoaminergic	receptors	and	nerve	injury	markers,	the	interest	was	specifically	based	on	changes	to	mRNA	expression	in	the	neurons.	However,	in	the	dorsal	horn	the	glia	cells	alone	outnumber	neurons	ten	to	one	(McMahon	and	Koltzberg	2013).	Similarly,	it	has	been	demonstrated	that	from	a	dissociated	preparation	of	whole	ganglia,	10%	of	the	composition	constitutes	a	mixture	of	neuronal	cells,	while	the	remaining	90%	of	this	preparation	is	made	up	of	satellite	ganglia	and	other	non-neuronal	cell	types	(Thakur	et	al	2014b).	When	it	is	considered	that	only	certain	neurons	will	express	the	receptor	of	interest,	this	dilutes	the	chances	of	seeing	an	effect	further	still.	One	method	that	could	be	employed	to	remove	the	diluting	effect	would	be	to	separate	the	neurons	from	the	rest	of	the	tissue.	A	magnetic	purification	technique	has	been	demonstrated	to	achieve	this	in	DRG	tissues,	while	a	single	nucleus	RNA-sequencing	technique	can	provide	identification	of	neuronal	populations	in	the	spinal	cord	(Thakur	et	al	2014b,	Sathyamurthy	et	al	2018).	Overall,	it	should	be	considered	that	the	lack	of	significant	differences	observed	with	qPCR	in	this	thesis	does	not	necessarily	mean	there	were	no	changes	to	receptor	expression	in	the	
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neurons,	it	may	just	be	that	the	effect	was	too	small	to	be	detected	in	whole	tissue	preparations.			
7.4	Future	studies	This	thesis	demonstrated	that	testing	the	functionality	of	DNIC	using	in	vivo	single	unit	recordings	of	convergent	WDR	neurons	provides	a	robust	and	reliable	technique	for	assessing	the	function	of	descending	controls	in	animal	models	of	chronic	pain.	This	thesis	further	demonstrates	that	in	the	late	phase	MIA	model	of	OA,	where	there	is	substantial	cartilage	damage,	the	DNIC	system	is	abolished	due	to	an	imbalance	in	descending	inhibitory	and	facilitatory	controls.	In	addition	to	the	amendments	to	the	experimental	techniques	discussed	above,	further	studies	could	be	carried	out	to	better	understand	the	exact	molecular	mechanisms	underlying	the	joint	damage	induced	barrage	of	nociceptive	information	and	the	subsequent	imbalance	in	descending	controls	and	abolished	DNIC	expression.			
7.4.1	The	contribution	of	joint	damaged	induced	peripheral	nociceptive	
drive	and	the	dysfunctional	DNIC	system	This	thesis	demonstrated	that	significant	cartilage	damage	was	not	observed	until	the	late	phase	of	the	MIA	model,	and	that	a	longer	time	course	of	the	model	may	provide	a	tool	for	further	exploration	of	subchondral	bone	damage	induced	central	changes.	Interestingly,	DNIC	expression	is	abolished	as	the	model	progresses	to	14	days.	It	has	previously	been	demonstrated	that	the	DNIC	system	is	lost	in	a	SNL	rat	model	of	neuropathy	(Bannister	et	al	2015,	Bannister	et	al	2017).	However,	and	as	the	articular	cartilage	is	not	innervated	and	no	other	signs	of	neuropathy	were	detected	in	the	MIA	model	in	this	thesis,	it	suggests	that	the	modulation	of	descending	inhibitory	and	facilitatory	controls	and	the	subsequent	abolished	DNIC	expression	can	occur	in	other	pain	models,	even	without	neuropathy.				A	substantial	inflammatory	infiltrate	has	been	demonstrated	in	early	phase	MIA	animals	and	in	OA	patients,	and	it	should	be	considered	that	this	could	be	responsible	for	the	development	of	peripheral	sensitisation	(Guzman	et	al	2003,	Clements	et	al	2009,	Scanzello	and	Goldring	2012).	Furthermore,	the	barrage	of	nociceptive	signals	from	the	periphery	and	the	subsequent	continuous	stimulation	of	second	order	neurons	may	result	in	sensitisation	of	dorsal	horn	neurons	(Woolf	2011).	Therefore,	it	would	be	interesting	to	assess	how	inhibiting	this	peripheral	nociceptive	drive	early	in	the	MIA	
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model	impacts	the	development	of	central	sensitisation	and	the	subsequent	imbalance	in	descending	controls.			Firstly,	NSAIDs	are	effective	at	providing	pain	relief	in	early	phase	MIA	animals	(Fernihough	et	al	2004,	Havelin	et	al	2016).	Similarly,	NSAIDs	provide	effective	analgesia	in	the	early	stages	of	OA	in	patients,	through	preventing	the	synthesis	of	prostaglandins	and	preventing	peripheral	sensitisation	that	arises	due	to	the	inflammatory	component	of	OA	(Lin	et	al	2004,	Wieland	et	al	2005).	Secondly,	the	neurotrophin	NGF	is	part	of	the	‘inflammatory	soup’	produced	in	response	to	tissue	damage	and	is	thought	to	contribute	to	peripheral	sensitisation	as	it	sensitizes	TRPV1	channels	on	peptidergic	C	fibres,	especially	in	inflammatory	conditions	such	as	OA	(McMahon	1996).	In	addition,	the	NGF	neutralizing	antibody	Tanezumab	has	been	demonstrated	to	reduce	joint	pain	in	patients	with	moderate	to	severe	OA	of	the	knee	joint	(Lane	et	al	2010).	An	interesting	approach	for	assessing	the	impact	of	peripheral	sensitisation	could	be	to	induce	MIA	damage	and	then	apply	topical	NSAIDs	or	NGF	neutralizing	antibodies	to	the	knee	and	assess	if	the	DNIC	system	still	becomes	dysfunctional.	This	could	provide	valuable	insights	for	treatment	options	in	the	clinic	and	address	the	option	of	targeting	the	peripheral	component	early	on	disease	pathogenesis	with	the	aim	to	prevent	the	development	of	centrally	driven	chronic	pain.		
7.4.2	Further	assessing	DNIC	pharmacology	at	the	level	of	the	spinal	cord	As	discussed	in	Chapter	4,	the	descending	serotonergic	system	exerts	a	bi-directional	role	on	pain	processing	as	both	inhibitory	and	facilitatory	actions	have	been	demonstrated	upon	5-HT	release	in	the	dorsal	horn.	There	are	a	myriad	of	serotonergic	receptors	in	the	spinal	cord,	and	the	overall	pronociceptive	or	antinociceptive	action	of	descending	serotonergic	controls	depends	upon	the	receptors	subtypes	activated.	The	role	of	spinal	5-HT3	receptors	in	pain	transmission	have	been	extensively	studied,	and	play	a	facilitatory	role	in	pain	processing	in	MIA	animals	(Rahman	et	al	2009).	Furthemore,	blocking	the	actions	of	5-HT	at	spinal	5-HT3	receptors	restores	DNIC	in	a	model	of	neuropathy	(Bannister	et	al	2015).	This	thesis	investigated	the	tole	of	spinal	5-HT7	receptors	in	pain	transmission.	The	spinal	co-administration	of	the	5-HT7	receptor	antagonist	SB-267790	completely	blocked	the	inhibitory	actions	of	the	SSRIs	fluoxetine	and	citalopram,	which	indicates	a	principal	role	of	this	receptor	in	mediating	serotonergic	inhibition	(Bannister	et	al	2017).	These	findings	agree	with	previous	studies,	that	spinal	5-HT3	receptors	mediate	facilitation,	while	spinal	5-HT7	receptors	mediate	and	inhibition	of	the	pain	response	(Dogrul	and	and	Seyrek	2006,	Dogrul	et	al	
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2009).	However,	it	would	be	interesting	to	use	antagonists	and	agonists	for	the	remaining	spinal	serotonergic	receptors	in	early	and	late	phase	animals	to	better	understand	the	specific	roles	of	each	receptor	in	the	expression	of	DNIC.			
7.4.3	The	brain	areas	involved	in	the	development	of	a	dysfunctional	DNIC	
system	As	the	DNIC	system	is	lost	following	spinal	transection,	it	indicates	that	DNIC	requires	supraspinal	signals	and	the	activation	of	functional	descending	controls,	however	the	exact	brain	signaling	pathways	required	for	the	expression	of	DNIC	are	yet	to	be	conclusively	determined	(Le	Bars	et	al	1979b,	Dickenson	and	Le	Bars	1983).	Changes	in	the	level	of	activity	in	the	SRD	brainstem	nuclei	have	been	demonstrated	to	be	crucial	for	the	expression	of	DNIC	in	animals	and	CPM	in	humans	(Bouhassira	et	al	1992a,	Youssef	et	al	2015).	However,	complex	interactions	between	the	SRD,	higher	brain	structures	in	the	cortex,	and	midbrain	and	brainstem	structures	that	comprise	the	dorsolateral	funiculus	are	thought	to	be	required	for	the	activation	of	descending	monoaminergic	controls,	which	are	ultimately	responsible	for	mediating	DNIC	(See	Section	1.2.4)(Youssef	et	al	2016,	Bannister	and	Dickenson	2017).			As	the	MIA	model	is	a	robust	and	easily	inducible	animal	model	of	chronic	pain,	where	DNIC	is	functional	in	the	early	phase	but	abolished	in	the	late	phase,	this	model	offers	the	opportunity	for	assessing	changes	in	the	neuronal	activity	of	brain	structures	reported	to	be	involved	in	the	efficacy	of	DNIC.	In	human	CPM	studies,	fMRI	identified	a	reduction	of	activity	within	the	SRD	upon	a	concurrent	noxious	conditioning	stimulus,	which	was	responsible	for	mediating	the	CPM	response	(Youssef	et	al	2015).	Furthermore,	fMRI	highlighted	the	involvement	of	the	dlPFC,	CC,	amygdala	and	Pb	nucleus	in	modulating	the	CPM	response	(Youssef	et	al	2016).	Therefore,	this	technique	could	be	back	translated	to	the	MIA	model,	to	better	understand	changes	in	activity	occurring	in	the	brain	as	the	model	progresses	and	the	DNIC	system	becomes	abolished.	In	addition,	the	resolution	of	fMRI	allows	for	the	observation	of	neuronal	activity	across	the	entire	brain,	which	may	allow	for	a	better	understanding	of	how	brain	structures	interact	to	induce	a	DNIC	response,	and	highlight	any	alterations	in	these	connections	when	DNIC	is	lost	in	late	phase	animals	(Ferris	et	al	2006).			Despite	the	advantages	of	fMRI,	this	is	an	expensive	technique	that	requires	sophisticated	equipment.	Another	technique	that	could	be	employed	to	further	dissect	the	brain	structures	responsible	for	inducing	DNIC	is	brain	microinjections	and	blocking	
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or	activating	specific	brain	regions.	In	addition,	brain	microinjections	could	be	utilised	while	simultaneously	recording	DNIC	responses	in	WDR	neurons	using	in	vivo	single	unit	recordings,	which	would	be	difficult	to	combine	with	fMRI.	Therefore,	a	similar	approach	could	be	taken	as	that	presented	in	this	thesis,	where	the	DNIC	response	is	evaluated	in	convergent	WDR	neurons	while	pharmacologically	manipulating	the	monoaminergic	descending	controls.	However,	in	this	scenario	the	descending	controls	would	be	pharmacologically	manipulated	at	supraspinal	levels	rather	than	at	the	level	of	the	spinal	cord.	A	further	approach	could	be	to	take	electrophysiological	recordings	from	the	brain	structures	reported	to	be	involved	in	the	DNIC	system,	and	assess	any	changes	in	neuronal	activity	between	early	and	late	phase	MIA	animals.	Overall,	in	vivo	electrophysiological	techniques	provide	a	reliable	method	for	assessing	DNIC	in	animal	models	of	chronic	pain,	and	hold	potential	for	unraveling	the	roles	and	interactions	played	by	supraspinal	structures	in	activating	descending	controls	and	inducing	neuronal	inhibition	at	the	level	of	the	spinal	cord.			
7.5	Concluding	remarks		Firstly,	this	thesis	confirms	that	assessing	DNIC	responses	using	in	vivo	single	unit	recordings	of	convergent	WDR	neurons	in	the	dorsal	horn	provides	a	robust	and	reliable	technique	for	examining	the	functional	state	of	descending	controls	in	animal	models	of	chronic	pain.	Importantly,	as	DNIC	and	CPM	share	similar	pharmacology	and	altered	efficiencies	in	states	of	chronic	pain,	this	electrophysiological	technique	provides	a	useful	tool	for	forward	translation	to	the	clinic	(Yarnitsky	2010,	Yarnitsky	2015).	Overall,	the	work	presented	in	this	thesis	confirms	previous	findings	that	DNIC	represents	a	noradrenergic	endogenous	inhibitory	system	with	a	partly	descending	serotonergic	component	(Bannister	et	al	2017).			Secondly,	the	work	presented	in	this	thesis	investigated	an	MIA	induced	model	of	OA	in	the	rat.	It	was	demonstrated	that	although	both	early	and	late	phase	MIA	animals	develop	pain	in	both	the	knee	joint	and	ipsilateral	hind	paw,	only	late	phase	MIA	animals	display	significant	articular	cartilage	damage	in	the	knee	joint.	Due	to	the	joint	damage	induced	continuous	barrage	of	nociceptive	signaling	from	the	periphery	and	the	high	level	of	neuronal	plasticity	in	the	CNS,	it	is	likely	that	sensitivity	also	develops	in	second	order	neurons	in	the	dorsal	horn.	However,	the	results	presented	in	this	thesis	did	not	suggest	an	increase	in	evoked	activity	of	WDR	neurons,	which	contrasts	with	previous	findings	in	the	MIA	model	(Rahman	et	al	2009,	Burnham	and	Dickenson	2013)	
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However,	a	rise	in	the	mRNA	levels	of	the	pro-inflammatory	cytokine	IL-1β	and	the	microglia	biomarker	Iba1	were	detected	in	the	dorsal	horn	of	late	phase	animals	suggesting	the	development	of	microgliosis,	which	is	in	agreement	with	previous	findings	in	the	MIA	model	and	is	indicative	of	central	sensitisation	(Thakur	et	al	2012,	Ogbanna	et	al	2013).			Furthermore,	DNIC	is	abolished	in	late	phase	MIA	animals,	indicative	of	an	imbalance	in	descending	inhibitory	and	facilitatory	controls.	As	an	increased	serotonergic	facilitatory	drive	has	previously	been	demonstrated	in	MIA	animals,	and	blocking	spinal	5-HT3	receptors	has	been	demonstrated	to	restore	DNIC	in	a	model	of	neuropathy,	it	is	likely	there	is	an	increased	serotonergic	facilitatory	drive	acting	at	spinal	5-HT3	receptors	contributing	to	the	loss	of	DNIC	in	late	phase	MIA	animals	(Rahman	et	al	2009,	Bannister	et	al	2015).	A	study	in	this	thesis	demonstrated	that	DNIC	expression	could	be	restored	in	late	phase	animals	with	the	NRI	Tapentadol,	suggesting	a	decreased	noradrenergic	inhibitory	drive	also	contributes	to	the	loss	of	DNIC.	In	addition,	activating	spinal	5-HT7	receptors	restored	DNIC	expression	in	late	phase	MIA	animals.	As	the	5-HT7	receptors	are	colocalised	with	GABAergic	inhibitory	interneurons	and	disinhibition	is	reported	in	states	of	central	sensitisation,	it	is	likely	there	is	decreased	serotonergic	inhibitory	tone	acting	at	spinal	5-HT7	receptors	and	a	subsequent	decrease	in	the	activation	of	inhibitory	interneurons	in	the	dorsal	horn	(Todd	2012,	Brenchat	2010,	Viguier	et	al	2012).	A	general	schematic	of	the	peripheral	joint	damage	and	centrally	driven	chronic	pain	is	shown	in	Figure	7.2.	Overall,	the	studies	presented	in	this	thesis	indicate	that	restoring	the	balance	in	descending	inhibitory	and	facilitatory	controls	through	pharmacologically	manipulating	monoaminergic	signaling	is	an	effective	approach	for	providing	analgesia	in	the	MIA	model	of	OA.			I	hope	the	studies	presented	in	this	thesis	further	our	understanding	of	how	modulation	of	descending	controls	can	influence	the	chronic	pain	associated	with	OA.	I	hope	through	assessing	CPM	efficiency	in	the	OA	clinic,	patient	segmentation	and	a	personalised	medicine	approach	could	be	adopted	such	that	each	individual	patient	could	receive	the	most	appropriate	analgesic	therapy.			
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Figure	7.2.	The	overall	schematic	of	joint	damage	induced	peripheral	sensitisation,	central	
sensitisation	and	modulation	of	descending	controls.	The	MIA	induced	joint	damage	observed	in	late	phase	MIA	animals	results	in	a	continuous	barrage	of	nociceptive	signaling	from	the	periphery	to	the	dorsal	horn,	which	can	lead	to	an	increased	sensitivity	of	second	order	neurons	and	the	development	of	central	sensitisation.	Subsequently,	an	imbalance	in	descending	controls	develops,	such	that	there	is	a	decreased	noradrenergic	and	serotonergic	inhibitory	drive	acting	at	spinal	α2-adrenergic	and	5-HT7	receptors,	and	an	increased	serotonergic	facilitatory	
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drive	acting	at	spinal	5-HT3	receptors.	The	overall	consequence	is	a	loss	of	DNIC,	potentially	due	to	altered	signaling	in	the	brain	structures	reported	to	be	involved	in	the	efficacy	of	DNIC.	The	brain	structures	presented	in	red	have	been	shown	to	directly	impact	DNIC,	while	the	brain	structures	presented	in	blue	are	thought	to	play	an	indirect	role	on	the	expression	of	DNIC.					
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8.	Appendix	
	
8.1	Pharmacology	controls	
	Pharmacological	controls	were	carried	out	to	ensure	any	drug	effects	reported	on	neuronal	firing	were	due	to	drug	actions	rather	than	the	solution	they	were	delivered	in.	Pre-conditioned	neuronal	responses	and	DNIC	responses,	calculated	as	a	reduction	in	mechanically	evoked	neuronal	firing	induced	with	a	concurrent	noxious	ear	pinch,	were	tested.	A	DNIC	trial	was	carried	before	and	after	a	subcutaneous	injection	of	saline	(250μL)(Figure	8.1A),	the	spinal	application	of	saline	(50	μL)	(Figure	8.1B),	and	the	spinal	application	of	vehicle	(97%	normal	saline,	2%	cremaphor,	1%	DMSO)(50	μL)(Figure	8.1C).	The	saline	and	vehicle	solutions	had	no	effect	on	pre-conditioned	mechanically	evoked	neuronal	firing	or	on	the	level	of	neuronal	inhibition	induced	by	DNIC.		
	
Figure	8.1.	Pharmacology	controls.	A)	The	topical	application	of	vehicle	to	the	cord	had	no	effect	on	pre-conditioned	mechanically	evoked	neuronal	firing	or	the	neuronal	inhibition	induced	
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by	DNIC.	B)	A	subcutaneous	injection	of	saline	had	no	effect	on	pre-conditioned	mechanically	evoked	neuronal	firing	or	the	neuronal	inhibition	induced	by	DNIC.	C)	A	topical	application	of	saline	had	no	effect	on	pre-conditioned	mechanically	evoked	neuronal	firing	or	the	neuronal	inhibition	induced	by	DNIC.	Two-way	ANOVA	with	Bonferroni	correction.	*P<-0.05,	**P<0.01,	***P<0.001.		
8.2	MIA	injected	animals	and	saline	injected	sham	control	
weights	The	MIA	injection	produced	joint	damage	and	pain-like	behaviour,	but	other	than	that	we	want	the	animals	to	remain	in	relatively	good	health.	To	monitor	this	we	measure	the	weights	of	the	animals	over	the	course	of	the	model	and	check	the	animals	are	gaining	weight	in	course	with	saline	injected	sham	controls.	No	statistical	difference	was	found	between	the	weights	of	early	phase	MIA	injected	and	saline	injected	animals	over	the	course	of	the	model	(Figure	8.2A).	No	statistical	difference	was	found	between	the	weight	of	late	phase	MIA	injected	animals	and	saline	injected	sham	controls	over	the	course	of	the	model	(Figure	8.2B).			
	
Figure	8.2	The	weights	on	MIA	injected	and	saline	injected	sham	controls	over	the	course	
of	the	model.	A)	There	was	no	difference	between	the	weights	of	early	phase	MIA	injected	animals	and	saline	injected	sham	controls	over	the	course	of	the	model	(EP	MIA	n=10,	EP	Sham	n=13).	B)	There	was	no	difference	between	the	weights	of	late	phase	MIA	injected	animals	and	saline	injected	sham	controls	over	the	course	of	the	model	(LP	MIA	n=8,	LP	Sham	n	=10).	Two-way	ANOVA	with	Bonferoni	correction.			
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8.3	qPCR	primer	validation	
	When	new	primers	were	designed	using	pre-established	primer-blast	criteria,	a	serial	dilution	of	each	primer	was	created	to	produce	a	standard	curve.	The	resultant	PCR	product	was	then	ran	on	an	agarose	gel	using	electrophoresis	to	confirm	that	only	one	product	of	correct	length	was	being	amplified.	All	of	the	primers	used	for	this	thesis	that	were	designed	in	this	way,	only	one	band	was	produced,	and	these	were	all	of	appropriate	length	as	determined	by	comparing	the	band	to	a	DNA	ladder	(Figure	8.3).		
	
Figure	8.3	Primer	validations.	For	all	primers	designed	for	this	thesis,	when	the	PCR	products	were	ran	on	an	agarose	gel	only	one	band	was	produced	of	the	appropriate	size	indicating	the	primers	are	resulting	in	the	amplification	of	the	correct	product.			
8.4	Fast	Blue	neuronal	tracer		To	confirm	that	the	Fast	Blue	neuronal	tracer	was	only	being	taken	up	by	primary	afferents	innervating	the	knee	the	contralateral	lumbar	DRGs	were	also	taken	and	checked	for	unspecific	staining.	There	were	no	Fast	Blue	positive	cell	bodies	in	the	L3-L5	DRGs	contralateral	to	injection	(Figure	8.4).		
	
Figure	8.4	Fast	Blue	staining	in	the	lumbar	DRGs	contralateral	to	injection.	No	Fast	Blue	positive	cell	bodies	were	observed	in	the	L3,	L4	or	L5	DRGs	contralateral	to	Fast	Blue	injection.		
	 296	
References	
	Acton	J	McKenna	J	E	Melzack	R	(1992)	Amitriptyline	produces	analgesia	in	the	formalin	pain	test.	Experimental	neurology.	117:	94-96.	
	Alaaeddine	N	DiBattista	J	A	Pelletier	J	P	Cloutier	JM	Kiansa	K	Dupuis	M	Martel-Pelletier	J	(1997)	Osteoarthritic	synovial	fibroblasts	possess	an	increased	level	of	tumor	necrosis	factor-receptor	55	(TNF-R55)	that	mediates	biological	activation	by	TNF-alpha.	The	journal	of	rheumatology.	24:	1985-1994	Amin	A	K	Clayton	R	A	Patton	J	T	Gaston	M	Cook	R	E	Brenkel	I	J	(2006)	Total	knee	replacement	in	morbidly	obese	patients.	Results	of	a	prospective,	matched	study.	J	Bone	Joint	Surg	Br.	88:	1321-1326	Andrew	D	and	Greenspan	J	D	(1999)	Mechanical	and	heat	sensitization	of	cutaneous	nociceptors	after	peripheral	inflammation	in	the	rat.	The	American	physiological	society.	82:	2649-2656.		Animal	welfare	and	the	three	Rs:	replacement,	refinement	and	reduction.	(2011)	Understanding	animals	research.		Arden	N	Nevitt	M	C	(2006)	Osteoarthritis:	epidemiology.	Best	practise	and	research.	Clinical	rheumatology.	20:	3-25	Arendt-Nielsen	L	Nie	H	Laursen	M	B	Laursen	B	S	Madeleine	P	Simonsen	O	H	Graven-Nielsen	T	(2010)	Sensitization	in	patients	with	painful	knee	osteoarthritis.	Pain.	149:	573-581.	Arendt-Nielsen	L	Sluka	K	A	Nie	H	L	(2008)	Experimental	muscle	pain	impairs	descending	inhibition.	Pain.	140:	465-471	Ashina	S	Bendtsen	L	Jensen	R	(2004)	Analgesic	effect	of	amitriptyline	in	chronic	tension-type	headache	is	not	directly	related	to	serotonin	reuptake	inhibition.	Pain.	108:	108-114.	Aso	K	Ikeuchi	M	Izumi	M	Sugimura	N	Kato	T	Ushida	T	Tani	T	(2014)	Nociceptive	phenotype	of	dorsal	root	ganglia	neurons	innervating	the	subchondral	bone	in	rat	knee	joints.	European	journal	of	pain.	18:	174-181	Avila-Rojas	S	H	Velazquez-Lagunas	I	Salinas-Abarca	A	B	Barragan-Iglesias	P	Pineda-Farias	J	B	Granados-Soto	V	(2015)	Role	of	spinal	5-HT5A,	and	5-HT1A/1B/1D,	receptors	in	neuropathic	pain	induced	by	spinal	nerve	ligation	in	rats.	Brain	research.	1622:	377-385.	Avouac	J	Gossec	L	Dougados	M	(2007)	Efficacy	and	safety	of	opioids	for	osteoarthritis:	a	meta-analysis	of	randomized	controlled	trials.	Osteoarthritis	and	Cartilage.	15:957-965	Baba	H	Doubell	T	P	Woolf	C	J	(1999)	Peripheral	inflammation	facilitates	Abeta	fiber-mediated	synaptic	input	to	the	substantia	gelatinosa	of	the	adult	rat	spinal	cord.	Journal	of	neuroscience.	19:	859-867.	Backonja	M-M	(2003)	Defining	neuropathic	pain.	Anesth	Analg	97:	90	785	Bajaj	P	Bajaj	P	Graven-Nielsen	T	Ardent-Nielsen	L	(2001)	Osteoarthritis	and	its	association	with	muscle	hyperalgesia:	an	experimental	controlled	study.	Pain.	93:	107-114	Bannister	K	Bee	L	A	Dickenson	A	H	(2009)	Preclinical	and	early	clinical	investigations	related	to	monoaminergic	pain	modulation.	Neurotherapeutics.	6:	703-712.	
	 297	
Bannister	K	Dickenson	A	H	(2016a)	What	the	brain	tells	the	spinal	cord.	Pain.	157:	2148-2151.	Bannister	K	Dickenson	A	H	(2016b)	What	do	monoamines	do	in	pain	modulation?	Current	opinion	in	supportive	and	palliative	care.	10:143-148	Bannister	K	Dickenson	A	H	(2017)	The	plasticity	of	descending	controls	in	pain:	translational	probing.	Journal	of	Physiology.	593:	4159-4166.	Bannister	K	Lockwood	S	Goncalves	L	Patel	R	Dickenson	A	H	(2017)	An	investigation	into	the	inhibitory	function	of	serotonin	in	diffuse	noxious	inhibitory	controls	in	the	neuropathic	rat.	European	Journal	of	Pain.	21:	750-760	Bannister	K	Patel	R	Goncalves	L	Townson	L	Dickenson	A	H	(2015)	Diffuse	noxious	inhibitory	controls	and	nerve	injury:	restoring	an	imbalance	between	descending	monoamine	inhibitions	and	facilitations.	Pain.	156:	1803-1811.	Bannister	K	Sikander	S	Bauer	C	S	Dolphin	A	C	Porecca	F	Dickenson	A	H	(2011)	Pregabalin	suppresses	spinal	neuronal	hyperexcitability	and	visceral	hypersensitivity	in	the	absence	of	peripheral	pathophysiology.	Anesthesiology.	115:	144-152	
Bardin	L	Lavarenne	J	Eschalier	A	(2000)	Serotonin	receptor	subtypes	involved	in	the	spinal	antinociceptive	effect	of	5-HT	in	rats.	Pain.	86:	11-18.	Barnes	N	Sharp	T	(1999)	A	review	of	central	5-HT	receptors	and	their	function.	Neuropharmacology.	38:	1083-1152.	Basbaum	A	I	Bautista	D	M	Scherrer	G	Julius	D	(2009)	Cellular	and	molecular	mechanisms	of	pain.	Cell.	139:	267-284.	Basbaum	A	I	Fields	H	L	(1979)	The	origin	of	descending	pathways	in	the	dorsolateral	funiculus	of	the	spinal	cord	of	the	cat	and	rat:	further	studies	on	the	anatomy	of	pain	modulation.	The	journal	of	comparative	neurology.	187:	513-531.	Bauer	C	S	Nieto-Rostro	M	Rahman	W	Tran	Van	Minh	A	Ferron	L	Douglas	L	Kadurin	I	Ranjan	Y	S	Fernandez-Alacid	L	Millar	N	S	Dickenson	A	H	Lujan	R	Dolphin	A	C	(2009)	The	Increased	Trafficking	of	the	Calcium	Channel	Subunit		2	-1	to	Presynaptic	Terminals	in	Neuropathic	Pain	Is	Inhibited	by	the	α2δ	Ligand	Pregabalin.	Journal	of	neuroscience.	29:	4076-4088	Bee	L	A	and	Dickenson	A	H	(2007)	Rostral	Ventromedial	Medulla	Control	of	Spinal	Sensory	Processing	in	normal	and	pathophysiology	states.	Neuroscience	147:	786–793.	Bee	L	A	Bannister	K	Rahman	W	Dickenson	A	H	(2011)	Mu-opioid	and	noradrenergic	a2-adrenoceptor	contributions	to	the	effects	of	tapentadol	on	spinal	electrophysiological	measures	of	nociception	in	nerve-injured	rats.	Pain.	152:	131-139	Bee	L	A	Dickenson	A	H	(2008)	Descending	facilitation	from	the	brainstem	determines	behavioural	and	neuronal	hypersensitivity	following	nerve	injury	and	efficacy	of	pregabalin.	Pain.	140:	209-223	Bee	L	A	Dickenson	A	H	(2008)	Descending	facilitation	from	the	brainstem	determines	behavioural	and	neuronal	hypersensitivity	following	nerve	injury	and	efficacy	of	pregabalin.	Pain.	140:	209-223	Bellamy	N	Campbell	J	Robinson	V	Gee	T	Bourne	R	Wells	G	(2006)	Intraarticular	corticosteroid	for	treatment	of	osteoarthritis	of	the	knee.	Cochrane	database	syst	rev.	19:	CD005328	Bendele	A	M	(2001)	Animal	models	of	osteoarthritis.	J	Musculoskel	Neuron	Interact.	1:	363-376	
	 298	
Benito	M	J	Veale	D	J	FitzGerald	O	van	den	Berg	W	B	Bresnihan	B	(2005)	Synovial	tissue	inflammation	in	early	and	late	osteoarthritis.	Annals	of	the	rheumatic	diseases.	64:	1263-1267	Benzon	H	T	Rathmell	J	P	Wu	C	L	Turk	D	C	Argoff	C	E	Hurley	R	W	(2013)	Practical	management	of	pain:	fifth	edition.	Part	2,	Chapter	8.	Central	Ascending	pathways.	Elsevier	Health	Sciences.		Bernard	J	F	Bester	H	Besson	J	M	(1996)	Involvement	of	the	spino-parabrachio-amygdaloid	and	–hypothalamic	pathways	in	the	autonomic	and	affective	emotional	aspects	of	pain.	Progress	in	brain	research.	107:	243-255.	Bettica	P	Cline	G	Hart	D	J	Meyer	J	Spector	T	D	(2002)	Evidence	for	increased	bone	resporption	in	patients	with	progressive	knee	osteoarthritis.	Arthritis	and	Rhematism.	46:	3178-3184	Billups	D	Billups	B	Challiss	R	A	J	Nahorski	S	R	(2006)	Modulation	of	Gq	protein-coupled	IP3	and	Ca2+	signaling	by	the	membrane	potential.	J	Neurosci.	26:	9983-9995.	Bing	Z	Villanueva	L	Le	Bars	D	(1989)	Effects	of	systemic	morphine	upon	A	delta-	and	C-fibre	evoked	activities	of	subnuclues	reticularis	dorsalis	neurones	in	the	rat	medulla.	European	journal	of	pharmacology.	164:	85-92.	Bird	H	A	Tribe	C	R	Bacon	P	A	(1978)	Joint	hypermobility	leading	to	osteoarthritis	and	chondrocalcinosis.	Annals	of	the	rheumatic	diseases.	37:	203-211	Black	R	A	Castner	B	Slack	J	Tocker	J	Eisenman	J	Jacobson	E	Delaney	J	Winters	D	Hecht	R	Bendele	A	(2006)	Injected	TIMP-3	protects	cartilage	in	a	rat	meniscal	tear	model.	Osteoarthritis	Cartilage.	14:	S23-24	Blagojevic	M	Jinks	C	Jeffery	A	Jordan	K	P	(2010)	Risk	factors	for	onset	of	osteoarthritis	of	the	knee	in	older	adults:	a	systemic	review	and	meta-analysis.	Osteoarthritis	and	cartilage.	18:	24-33.	Blair	N	T	and	Bean	B	P	(2002)	Roles	of	Tetrodotoxin	(TTX)-Sensitive	Na+	Current,	TTX-Resistant	Na+	Current,	and	Ca2+	Current	in	the	Action	Potentials	of	Nociceptive	Sensory	Neurons.	The	Journal	of	Neuroscience.	22:	10277-10290.	Bleakman	D	Alt	A	Nisenbaum	E	S	(2006)	Glutamate	receptors	and	pain.	Seminars	in	Cell	and	Developmental	Biology.	17:	592-604.	Bliss	T	V	P	Collingridge	G	L	(1993)	A	synaptic	model	of	memory:	long-term	potentiation	in	the	hippocampus.	Nature.	361:	31-39	Bomholt	S	F	Mikkelsen	J	D	Blackburn-Munro	G	(2005)	Antinociceptive	effects	of	the	antidepressants	amitriptyline,	duloxetine,	mirtazapine	and	citalopram	in	animal	models	of	acute,	persistent	and	neuropathic	pain.	Neuropharmacology.	48:	252-263	Bondeson	J	Wainwright	S	D	Lauder	S	Amos	N	Hughes	C	E	(2006)	The	role	of	synovial	macrophages	and	macrophage-produced	cytokines	in	driving	aggrecanases,	matrix	metalloproteinases	,	and	other	destructive	and	inflammatory	responses	in	osteoarthritis.	Arthritis	research	and	therapy.	8:	R187	Bonnet	C	S	Walsh	D	A	(2005)	Osteoarthritis,	angiogenesis	and	inflammation.	Rheumatology.	44:7-16	
	 299	
Bonnington	J	K	and	McNaughton	P	A	(2003)	Signalling	pathways	involved	in	the	sensitisation	of	mouse	nociceptive	neurones	by	nerve	growth	factor.	Journal	of	Physiology.	551:	433-446.	Borden	P	Solymar	D	Sucharczuk	A	Lindman	B	Cannon	P	Heller	R	A	(1996)	Cytokine	control	of	interstitial	collagenase	and	collagenase-3	gene	expression	in	human	chondrocytes.	The	journal	of	biological	chemistry.	271:	23577-23581	Bouhassira	D	Bing	Z	Le	Bars	D	(1990)	Studies	of	the	brain	structures	involved	in	diffuse	noxious	inhibitory	controls:	the	mesencephalon.	Journal	of	neurophysiology.	64:	1712-1723.	Bouhassira	D	Bing	Z	Le	Bars	D	(1992b)	Effects	of	lesions	of	locus	coeruleus/subcoeruleus	on	diffuse	noxious	inhibitory	controls	in	the	rat.	Brain	Research.	571:	140-144.	Bouhassira	D	Chitour	D	Villanueva	L	Le	Bars	D	(1993)	Morphine	and	diffuse	noxious	inhibitory	controls	in	the	rat:	effects	of	lesions	of	the	rostral	ventromedial	medulla.	European	journal	of	pharmacology.	232:	207-215.	Bouhassira	D	Le	Bars	D	Villanueva	L	(1987)	Heterotopic	activation	of	Aδ	and	C	fibres	triggers	inhibition	of	trigeminal	and	spinal	convergent	neurons	in	the	rat.	Journal	of	physiology.	389:	301-317.	Bouhassira	D	Villanueva	L	Bing	Z	Le	Bars	D	(1992a)	Involvement	of	the	subnucleus	reticularis	dorsalis	in	diffuse	noxious	inhibitory	controls	in	the	rat.	Brain	research.	595:	353-357.	Bove	S	E	Calcaterra	S	L	Brooker	R	M	Huber	C	M	Guzman	R	E	Juneau	P	L	Schrier	D	J	Kilgore	K	S	(2003)	Weight	bearing	as	a	measure	of	disease	progression	and	efficacy	of	anti-inflammatory	compounds	in	a	model	of	monosodium	iodoacetate-induced	osteoarthritis.	Osteoarthritis	and	Cartilage.	11:	821-830.	Bove	S	E	Laemont	K	D	Brooker	R	M	Osborn	N	M	Sanchez	B	M	Guzman	R	E	Hook	K	E	Juneau	P	L	Connor	J	R	Kilgore	K	S	(2006)	surgically	induced	osteoarthritis	in	the	rat	results	in	the	development	of	both	osteoarthritis-like	joint	pain	and	secondary	hyperalgesia.	Osteoarthritis	and	Cartilage.	14:	1041-1048	Boyajian	C	L	Leslie	F	M	(1987)	Pharmacological	Evidence	for	Alpha-2	Adrenoceptor	Heterogeneity:	Differential	Binding	Properties	of	[3H]Rauwolscine	and	[3H]ldazoxan	in	Rat	Brain1.	J	Pharmacol	Exp	Ther.	241:	1092-1099	Bradesi	S	(2010)	Role	of	spinal	cord	glia	in	the	central	processing	of	peripheral	pain	perception.	Neurogastoenterology	and	motility.	22:	499-511.	Brandt	K	D	Braunstein	E	M	Visco	D	M	O’Connor	B	Heck	D	Albrecht	M	(1991)	Anterior	(cranial)	cruciate	ligament	transection	in	the	dog:	a	bona	fide	model	of	osteoarthritis,	not	merely	of	cartilage	injury	and	repair.	The	Journal	of	Rheumatology.	18:	436-446	Brandt	K	D	Radin	E	L	Dieppe	P	A	van	de	Putte	L	(2006)	Yet	more	evidence	that	osteoarthritis	is	not	a	cartilage	disease.	Annals	of	the	Rheumatic	diseases.	65:	1261-1265	Brandt	K	D	Smith	G	N	Simon	L	S	(2000)	Intraarticular	injection	of	hyaluronan	as	treatment	for	knee	osteoarthritis.	Arthritis	and	rheumatism.	43:	1192-1203	Brenchat	A	Nadal	X	Romero	L	Ovalle	S	Muro	A	Sanchez-Arroyos	R	Portillo-Salido	E	Pujol	M	Montero	A	Codony	X	Burgueno	J	Zamanillo	D	Hamon	M	Maldonado	R	Vela	J	M	(2010)	Pharmacological	activation	of	5-HT7	receptors	reduces	nerve	injury-induced	mechanical	and	thermal	hypersensitivity.	Pain.	149:	483-494	
	 300	
Brenchat	A	Zamanillo	D	Hamon	M	Romero	L	Vela	J	M	(2012)	Role	of	peripheral	versus	spinal	5-HT(7)	receptors	in	the	modulation	of	pain	under	sensitizing	conditions.	European	Journal	of	Pain.	16:	72-81	Bridgestock	P	and	Rae	C	P	(2013)	Anatomy,	physiology	and	pharmacology	of	pain.	Anaesthesia	and	intensive	care	medicine.	14:	480-483.		Brierly	S	M	Castro	J	Harrington	A	M	Hughes	P	A	Page	A	J	Rychkov	G	Y	Blackshaw	L	A	(2011)	TRPA1	contributes	to	specific	mechanically	activated	currents	and	sensory	neuron	mechanical	hypersensitivity.	Journal	of	Physiology.	14:	3575-3593.	Brink	T	S	Pacharinsak	C	Khasabov	S	G	Beitz	A	J	Simone	D	A	(2012)	Differential	modulation	of	neurones	in	the	rostral	ventromedial	medulla	by	neurokinin-1	receptors.	J	Neurophysiol	107:	1210	–1221.		Brown	D	G	Krupp	JJ	(2006)	N-methyl-D-aspartate	receptor	(NMDA)	antagonists	as	potential	pain	therapeutics.	Current	topics	in	medicinal	chemistry.	6:	749-770.	Buchanan	W	W	Kean	W	F	(2002)	Osteoarthritis	II:	Pathology	and	pathogenesis.	InflammoPharmacology.	10:	23-52	Buckland-Wright	C	(2004)	Subchondral	bone	changes	in	hand	and	knee	osteoarthritis	detected	by	radiography.	Osteoarthritis	and	Cartilage.	12:	S10-S19		Buckland-Wright	J	C	Lynch	J	A	Macfarlane	D	G	(1996)	Fractal	signature	analysis	measures	cancellous	bone	organisation	in	macroradiographs	of	pateints	with	knee	osteoarthritis.	Ann	Rheum	dis.	55:	749-755	Buhler	A	V	Choi	J	Proudfit	H	K	Gebhart	G	F	(2005)	Neurotensin	activation	of	the	NTR1	on	spinally-projecting	serotonergic	neurons	in	the	rostral	ventromedial	medulla	is	antinociceptive.	Pain.	114:	285-294.	Burnham	L	J	Dickenson	A	H	(2013)	The	antinociceptive	effect	of	Milnacipran	in	the	monosodium	iodoacetate	model	of	osteoarthritis	pain	and	its	relation	to	changes	in	descending	inhibition.	The	journal	of	pharmacology	and	experimental	therapeutics.	344:	696-707	Burnstock	G	(2000)	P2X	receptors	in	sensory	neurons.	British	Journal	of	Anaesthesia.	84:	476-488	Burr	D	B	(2004)	Anatomy	and	physiology	of	the	mineralized	tissues:	Role	in	the	pathogenesis	of	osteoarthritis.	Osteoarthritis	and	cartilage.	12:	S20-S30	Bymaster	F	P	Zhang	W	Carter	P	A	Shaw	J	Chernet	E	Phebus	L	Wong	D	T	Perry	K	W	(2002)	Fluoxetine,	but	not	other	selective	serotonin	uptake	inhibitors,	increases	norepinephrine	and	dopamine	extracellular	levels	in	prefrontal	cortex.	Psychopharmacology.	160:	353-361	Cadden	S	W	(1993)	The	ability	of	inhibitory	controls	to	‘switch	off’	activity	in	dorsal	horn	convergentneurone	s	in	the	rat.	Brain	research	628:	65-71.	Cai	Y	Wang	W	Hou	Y	Pan	Z	Z	(2014)	Optogenetic	activation	of	brainstem	serotonergic	neurons	induces	persisitent	pain	sensitization.	Molecular	Pain.	10:	70.	Calvino	B	Villanueva	L	Le	Bars	D	(1984)	The	heterotopic	effects	of	visceral	pain:	Behavioural	and	electrophysiological	approaches	in	the	rat.	Pain.	20:	261-271	
	 301	
Calvo	M	Bennet	D	L	(2012)	The	mechanisms	of	microgliosis	and	pain	following	peripheral	nerve	injury.	Experimental	neurology.	234:	271-282	Calvo	M	Bennett	D	L	H	(2012)	The	mechanisms	of	microgliosis	and	pain	following	peripheral	nerve	injury.	Experimental	neurology.	234:	271-282.	Carlson	C	S	Loeser	R	F	Purser	C	B	Gardin	J	F	Jerome	C	P	(1996)	Osteoarthritis	in	cynomolgus	macaques.	III:	Effects	of	age,	gender,	and	subchondral	bone	thickness	on	the	severity	of	disease.	Journal	of	bone	and	mineral	research.	11:	1209-1217.	Carniglia	L	Ramirez	D	Durand	D	Saba	J	Turati	J	Caruso	C	Scimonelli	T	N	Lasaga	M	(2017)	Neuropeptides	and	microglia	activation	in	inflammation,	pain	and	neurodegenerative	diseases.	Mediators	of	inflammation.	5048616	Caterina	M	J	Leffler	A	Malmberg	A	B	Martin	W	J	Trafton	J	Petersen-Zeitz	K	R	Koltzenburg	M	Basbaum	A	I	Julius	D	(2000)	Impaired	nociception	and	pain	sensation	in	mice	lacking	the	capsaicin	receptor.	Science.	288:	306-313.	Caterina	M	J	Rosen	T	A	Tominaga	M	Brake	A	J	Julius	D	(1999)	A	capsaicin-receptor	homologue	with	a	high	threshold	for	noxious	heat.	Nature.	398:	436-441	Caterina	M	J	Schumacher	M	A	Tominaga	M	Rosen	T	A	Levine	J	D	Julius	D	(1997)	The	capsaicin	receptor:	a	heat-activated	ion	channel	in	the	pain	pathway.	Nature.	389:	816-824.		Cerminara	N	L	Koutsikou	S	Lumb	B	M	Apps	R	(2009)	The	periaqueductal	grey	modulates	sensory	input	to	the	cerebellum:	a	role	in	coping	behaviour?	European	Journal	of	Neuroscience.	29:	2197-2206	Cesare	P	and	McNaughton	P	(1996)	A	novel	heat-activated	current	in	nociceptive	neurons	and	its	sensitisation	by	bradykinin.	Proc.	Natl.	Acad.	Sci.	93:	15435-15439.	Cesare	P	Moriondo	A	Vellani	V	McNaughton	P	A	(1999)	Ion	channels	gated	by	heat.	Proc.	Natl.	Acad.	Sci.	96:	7658-7663.	Chang	E	Chen	X	Kim	M	Gong	N	Bhatia	S	Luo	Z	D	(2015)	Differential	effects	of	voltage-gated	calcium	channel	blockers	on	calcium	channel	alpha-2-delta-1	subunit	protein-mediated	nociception.	European	journal	of	pain.	19:	639-648	Chang	E	Y	Chen	X	Sandhu	A	Li	C	Y	Luo	Z	D	(2013)	Spinal	5-HT3	receptors	facilitate	behavioural	hypersensitivity	induced	by	elevated	calcium	channel	alpha-2-delta-1	protein.	European	journal	of	pain.	17:	505-513	Chao	M	V	(2003)	Neurotrophins	and	their	receptors:	a	convergence	point	for	many	signalling	pathways.	Nature	Neuroscience.	4:	299-309.	Chaplan	S	R	Bach	F	W	Pogrel	J	W	Chung	J	M	Yaksh	T	L	(1994)	Quantitative	assessment	of	tactile	allodynia	in	the	rat	paw.	Journal	of	Neuroscience	methods.	53:	55-63.	Characterisation	of	the	MIA	Model	of	Experimental	Osteoarthritis,	University	College	London.	Chu	K	L	Chandran	P	Joshi	S	K	Jarvis	M	F	Kym	P	R	McGaraughty	S	(2011)	TRPV1-related	modulation	of	spinal	neuronal	activity	and	behaviour	in	a	rat	model	of	osteoarthritic	pain.	Brain	research.	19:	158-166	Chu	K	L	Faltynek	C	R	Jarvis	M	F	McGaraughty	S	(2004)	Increased	WDR	spontaneous	activity	and	receptive	field	size	in	rats	following	a	neuropathic	or	inflammatory	injury:	implications	for	mechanical	sensitivity.	Neuroscience	Letters.	372:	123-126	Chuang	H	Prescott	E	D	Kong	H	Shields	S	Jordt	S	Basbaum	A	I	Chao	M	V	Julius	D	(2001)	Bradykinin	and	nerve	growth	factor	release	the	capsaicin	receptor	from	PtdIns(4.5)P2-mediated	inhibition.	Nature.	411:	957-962.	Clapham	D	E	(2003)	TRP	channels	as	cellular	sensors.	Nature.	426:	517-524.	Clark	A	K	Malcangio	M	(2012)	Microglial	signalling	mechanisms:	Cathepsin	S	and	Fractalkine.	Experimental	Neurology.	234:	283-292.	
	 302	
Clements	K	M	Ball	A	D	Jones	H	B	Brinckmann	S	Read	S	J	Murray	F	(2009)	Cellular	and	histopathological	changes	in	the	infrapatellar	fat	pad	in	the	monoiodoacetate	model	of	osteoarthritis	pain.	Osteoarthritis	and	Cartilage.	17:	805-812	Collins	J	G	Kitahata	L	M	Matsumoto	M	Homma	E	Suzukawa	M	(1984)	Spinally	administered	epinephrine	suppresses	noxiously	evoked	activity	of	WDR	neurones	in	the	dorsal	horn	of	the	spinal	cord.	Anaesthesiology.	60:	269-275.	Conaghan	P	G	Felson	D	Gold	G	Lohmander	S	Totterman	S	Altman	R	(2006)	MRI	and	non-cartilaginous	structures	in	knee	osteoarthritis.	Osteoarthritis	and	cartilage.	14:	A87-A94	Conaghan	P	G	Porcheret	M	Kingsbury	S	R	Gammon	A	Soni	A	Hurley	M	Rayman	M	P	Barlow	J	Hull	R	G	Cumming	J	Llewelyn	K	Moscogiuri	F	Lyons	J	Birrell	F	(2015)	Impact	and	therapy	of	osteoarthritis:	the	arthritis	care	OA	nation	2012	survey.	Clinical	rheumatology.	34:	1581-1588	Connor	J	R	LePage	C	Swift	B	A	Yamashita	D	Bendele	A	M	Maul	D	Kumar	S	(2009)	Protective	effects	of	a	cathepsin	K	inhibitor,	SB-553484,	in	the	canine	partial	medial	meniscectomy	model	of	osteoarthritis.	Osteoarthritis	and	cartilage.	17:	1236-1243.	Cooper	G	M	(2000)	The	Cell:	A	Molecular	Approach.	2nd	edition.	Sunderland	(MA):	Sinauer	Associates.	Pathways	of	Intracellular	Signal	Transduction.	Cox	J	J	Reimann	F	Nicholas	A	K	Thornton	G	Roberts	E	Springell	K	Karbani	G	Jafri	H	Mannan	J	Rasshid	Y	Al-Gazali	L	Hamamy	H	Valente	E	M	Gorman	S	Williams	R	McHale	D	P	Wood	J	N	Gribble	F	M	Woods	C	G	(2006)	An	SCN9A	channelopathy	causes	congenital	inability	to	experience	pain.	Nature.	444:	894-898.	Craig	A	D	Heppelmann	B	Schaible	H	G	(1988)	The	projection	of	the	medial	and	posterior	articular	nerves	of	the	cats	knee	to	the	spinal	cord.	The	journal	of	comparative	neurology.	276:	279-288	Cross	M	Smith	E	Hoy	D	Nolte	S	Ackerman	I	Fransen	M	Bridgett	L	Williams	S	Guillemin	F	Hill	C	L	Laslett	L	L	Jones	G	Cicuttini	F	Osborne	R	Vos	T	Buchbinder	R	Woolf	A	March	L	(2014)	The	global	burden	of	hip	and	knee	osteoarthritis:	estimates	from	the	global	burden	of	disease	2010	study.	Annals	of	the	rheumatic	diseases.	0:	1-8	D’Mello	R	and	Dickenson	A	H	(2008)	Spinal	cord	mechanisms	of	pain.	British	journal	of	anesthesia.	101:	8-16.	Dakin	H	Gray	A	Fitzpatrick	R	MacLennan	G	Murray	D	(2012)	Rationing	of	total	knee	replacement:	a	cost-effectiveness	analysis	on	a	large	trial	data	set.	BMJ	open.	2:	e000332	Danziger	N	Weil-Fugazza	J	Le	Bars	D	Bouhassier	D	(1999)	The	journal	of	neuroscience.	19:	2394-2400.	Davies	A	Hendrich	J	Tran	van	Minh	A	Wratten	J	Douglas	L	Dolphin	A	C	(2007)	Functional	biology	of	the	α2δ	subunits	of	voltage-gated	calcium	channels.	Trends	in	pharmacological	sciences.	28:	220-228	Davies-Tuck	M	L	Wluka	A	E	Forbes	A	Wang	Y	English	D	R	Giles	G	G	O’Sullivan	R	Cicuttini	F	M	(2010)	Development	of	bone	marrow	lesions	is	associated	with	adverse	effects	on	knee	cartilage	while	resolution	is	associated	with	improvement	–	a	potential	target	for	prevention	of	knee	osteoarthritis:	a	longitudinal	study.	Arthritis	research	and	therapy.	12:	R10	De	Broucker	T	H	Cesaro	P	Willer	J	C	Le	Bars	D	(1990)	Diffuse	noxious	inhibitory	controls	in	man.	Involvement	of	the	spinoreticular	tract.	Brain.	113:	1223-1234.	
	 303	
De	Felice	M,	Sanoja	R,	Wang	R,	Vera-Portocarrero	L,	Oyarzo	J,	King	T,	Ossipiov	M	H,	Vanderah	T	W,	Lai	J,	Dussor	G	O,	Fields	H	L,	Price	T	J,	Porecca	F	(2011)	Engagement	of	descending	inhibition	from	the	rostral	ventromedial	medulla	protects	against	chronic	neuropathic	pain.	PAIN.	152:2701–2709.	De	Maeyer	J	H	Lefebvre	R	A	Schuurkes	J	A	J	(2008)	5-HT4	receptor	agonists:	similar	but	not	the	same.	Neurogastroenterol	Motil.	20:	99-112	De	Souza	J	B	Potvin	S	Goffaux	P	Charest	J	Marchand	S	(2009)	The	deficit	of	pain	inhibition	in	fibromyalgia	is	more	pronounced	in	patients	with	comorbid	depressive	symptoms.	The	clinical	journal	of	pain.	25:	123-127	Dejica	V	M	Mort	J	S	Laverty	S	Percival	M	D	Antoniou	J	Zukor	D	J	Poole	A	R	(2008)	Cleavage	of	type	II	collagen	by	Cathepsin	K	in	human	osteoarthritic	cartilage.	Musculoskeletal	pathology.	173:	161-169.	Dhaka	A	Viswanath	V	Patapoutian	A	(2006)	TRP	ion	channels	and	temperature	sensation.	Annu.	Rev.	Neurosci.	29:135–61		Dib-Hajj	S	D	Cummins	T	R	Black	J	A	Waxman	S	G	(2010)	Sodium	channels	in	normal	and	pathological	pain.	Annu.	Rev.	Neurosci.	33:	325-347.		Dib-Hajj	S	D	Yang	Y	Black	J	A	Waxman	S	G	(2013)	The	NaV	1.7	sodium	channel:	from	molecule	to	man.	Nature	Neuroscience.	14:	49-62.	Dickenson	A	H	(1995)	Spinal	cord	pharmacology	of	pain.	British	journal	of	anesthesia.	75:	193-200.	Dickenson	A	H	Chapman	V	Green	G	M	(1997)	The	pharmacology	of	excitatory	and	inhibitory	amino	acid-mediated	events	in	the	transmission	and	modulation	of	pain	in	the	spinal	cord.	Gen	Pharmac.	28:	633-638	Dickenson	A	H	Le	Bars	D	(1983)	Diffuse	Noxious	Inhibitory	Controls	(DNIC)	involve	trigeminothalamic	and	spinothalamic	neurones	in	the	rat.	Experimental	Brain	Research.	49:	174-180.	Dickenson	A	H	Le	Bars	D	(1987)	Supraspinal	morphine	and	descending	inhibitions	acting	on	the	dorsal	horn	of	the	rat.	Journal	of	physiology.	384:	81-107.	Dickenson	A	H	Le	Bars	D	Besson	J	M	(1980)	Diffuse	Noxious	Inhibitory	Controls	(DNIC).	Effects	on	trigeminal	nucleus	caudalis	neurons	in	the	rat.	Brain	research.	200:	293-305	Dickenson	A	H	Rivot	J	Chaouch	A	Besson	J	M	Le	Bars	D	(1981)	Diffuse	Noxious	Inhibitory	Controls	(DNIC)	in	the	rat	with	or	without	pCPA	pretreatment.	Brain	Research.	216:	313-321.	Dickenson	A	H	Sullivan	A	F	(1987)	Evidence	for	a	role	of	the	NMDA	receptor	in	the	frequency	dependent	potentiation	of	deep	rat	dorsal	horn	nociceptive	neurons	following	C	fibre	stimulation.	Neuropharmacology.	26:	1235-1238.	Dieppe	P	(2011)	Developments	in	osteoarthrtitis.	Rheumatology.	50:	245-247	Dieppe	P	A	Lohmander	L	S	(2005)	Pathogenesis	and	management	of	pain	in	osteoarthritis.	Lancet.	365:	965-973.	Dixon	W	(1965)	The	up-and-down	method	for	small	samples.	The	Journal	of	the	American	Statistical	Association.	60:	967-978.	Dogrul	A	Ossipov	M	H	Porecca	F	(2009)	Differential	mediation	of	descending	pain	facilitation	and	inhibition	by	spinal	5-HT3	and	5-HT7	receptors.	Brain	research.	1280:	52-59.	
	 304	
Dogrul	A	Seyrek	M	(2006)	Systemic	morphine	produce	antinociception	mediated	by	spinal	5-HT7,	but	not	5-HT1A	and	5-HT2	receptors	in	the	spinal	cord.	British	Journal	of	Pharmacology.	149:	498-505	Dolphin	A	C	(2013)	The	α2δ	subunits	of	voltage	gated	calcium	channels.	Biochimica	et	Biophysica	Acta.	1828:	1541-1549	Doly	S	Fischer	J	Brisorgueil	M	Verge	D	Conrath	M	(2005)	Pre-	and	postsynaptic	localization	of	the	5-HT7	receptor	in	rat	dorsal	spinal	cord:	immunocytochemical	evidence.	The	journal	of	comparative	neurology.	490:	256-269	Dougados	M	(1996)	Synovial	fluid	cell	analysis.	Baillieres	Clin.	Rheumatol.	10:	519–534		Ducy	P	Amling	M	Takeda	S	Priemel	M	Schilling	A	F	Beil	F	T	Shen	J	Vinson	C	Rueger	J	M	Karsenty	G	(2000)	Leptin	inhibits	bone	formation	through	a	hypothalamic	relay:	a	central	control	of	bone	mass.	Cell.	100:	197-207	Dugast	C	Almeida	A	Lima	D	(2003)	The	medullary	dorsal	reticular	nucleus	enhances	the	responsiveness	of	spinal	nociceptive	neurons	to	peripheral	stimulation	in	the	rat.	The	European	journal	of	neuroscience.	18:	580-588.	Dunham	J	Hoedt-Schmidt	S	Kalbhen	D	A	(1992)	Structural	and	metabolic	changes	in	articular	cartilage	induced	by	iodoacetate.	International	journal	of	experimental	pathology.	73:	455-464.	Edoff	K	Grenegard	M	Hildebrand	C	(2000)	Retrograde	tracing	and	neuropeptide	immunohistochemistry	of	sensory	neurones	projecting	to	the	cartilaginous	distal	femoral	epiphysis	of	young	rats.	Cell	and	tissue	research.	299:	193-200	Edwards	R	R	Ness	T	J	Weigent	D	A	Fillingim	R	B	(2003)	Individual	differences	in	diffuse	noxious	inhibitory	controls	(DNIC):	association	with	clinical	variables.	106:	427-437	Engelking	L	R	(2015)	Chapter	24	–	Introduction	to	Glycolysis	(The	Embden-Meyerhoff	Pathway	(EMP)).	Textbook	of	Veterinary	Physiological	Chemistry	(Third	Edition).	153-158.		Esser	M	J	Sawynok	J	(1999)	Acute	amitriptyline	in	a	rat	model	of	neuropathic	pain:	differential	symptom	and	route	effects.	Pain.	80:	643-653	Ethgen	O	Bruyere	O	Richy	F	Dardennes	C	Reginster	J	(2004)	Health	related	quality	of	life	in	total	hip	and	total	knee	atrhoplasty.	The	journal	of	bone	and	joint	surgery.	86:	963-974	Eyre	D	(2002)	Collagen	of	articular	cartilage.	Arthritis	research.	4:	30-35.	Falk	S	and	Dickenson	A	H	(2014)	Pain	and	Nociception:	Mechanisms	of	Cancer-Induced	Bone	Pain.	J	Clin	Oncol	32:1647-1654.	Fazzalari	N	L	Parkinson	I	H	(1997)	Fractal	properties	of	subchondral	cancellous	bone	in	severe	osteoarthritis	of	the	hip.	Journal	of	bone	and	mineral	research.	12:	632-640	Felson	D	T	Chaisson	C	E	Hill	C	L	Totterman	S	M	S	Gale	M	E	Skinner	K	M	Kazis	L	Gale	D	R	(2001)	The	association	of	bone	marrow	lesions	with	pain	in	knee	osteoarthritis.	Annals	of	internal	medicine.	134:	541-549	Felson	D	T	Neogi	T	(2004)	Osteoarthritis:	is	it	a	disease	of	cartilage	or	of	bone?	Arthritis	and	Rheumatism.	50:	341-344	Ferland	C	E	Laverty	S	Beaudry	F	Vachon	P	(2011)	Gait	analysis	and	pain	response	of	two	rodent	models	of	osteoarthritis.	Pharmacology	Biochemistry	and	Behavior.	97:	603-610.	Ferland	C	E	Laverty	S	Beaudry	F	Vachon	P	(2011)	Gait	analysis	and	pain	response	of	two	rodent	models	of	osteoarthritis.	Pharmacology	Biochemistry	and	Behavior.	97:	603-610	
	 305	
Fernihough	J	Gentry	C	Malcangio	M	Fox	A	Rediske	J	Pellas	T	Kidd	B	Bevan	S	Winter	J	(2004)	Pain	related	behaviour	in	two	models	of	osteoarthritis	in	the	rat	knee.	Pain.	112:	83-93	Ferreira-Gomes	J	Adaes	S	Castro-Lopes	J	M	(2008)	Assessment	of	movement-evoked	pain	in	osteoarthritis	by	the	knee-bend	and	catwalk	tests:	a	clinically	relevant	study.	The	journal	of	pain.	9:	945-954	Ferris	C	F	Febo	M	Luo	F	Schmidt	K	Brevard	M	Harder	J	A	Kulkarni	P	Messenger	T	King	J	A	(2006)	Functional	Magnetic	Resonance	Imaging	in	Conscious	Animals:	A	New	Tool	in	Behavioural	Neuroscience	Research.	Journal	of	neuroendocrinology.	18:	307-318	Field	M	J	Cox	P	J	Stott	E	Melrose	H	Offord	J	Su	T	Bramwell	S	Corradini	L	England	S	Winks	J	Kinloch	R	A	Hendrich	J	Dolphin	A	C	Webb	T	Williams	D	(2006)	Identification	of	the	α2δ1	subunit	of	voltage-dependent	calcium	channels	as	a	molecular	target	for	pain	mediating	the	analgesic	actions	of	pregabalin.	Proceedings	of	the	national	academy	of	sciences.	103:	17537-17542	Fields	(2004)	State-dependent	opioid	control	of	pain.	Nature	Neurosceince.	5:	565-575.	Fields	(2004)	State-dependent	opioid	control	of	pain.	Nature	Neurosceince.	5:	565-575.	Finan	P	H	Buenaver	L	F	Bounds	S	C	Hussain	S	Park	R	J	Haque	U	J	Campbell	C	M	Haythornthwaite	J	A	Edwards	R	R	Smith	M	T	(2013)	Discordance	between	pain	and	radiographic	severity	in	knee	osteoarthritis.	Arthritis	and	rheumatism.	65:	363-372.	Fleetwood-Walker	S	M	Mitchell	R	Hope	R	J	Molony	V	Iggo	A	(1985)	An	alpha	2	receptor	mediates	the	selective	inhibition	by	noradrenaline	of	nociceptive	responses	of	identified	dorsal	horn	neurones.	Brain	Res.	334:	243-254.	Flower	R	J	(2003)	The	development	of	Cox-2	inhibitors.	Nature	reviews	drug	discovery.	2:	179-191	Foley	S	M	(2003)	Opioids	and	chronic	neuropathic	pain.	New	England	Journal	of	Medicine.	348:	1279-1281	Freynhagen	R	Baron	R	Gockel	U	Tolle	T	R	(2006)	pain	DETECT	:	a	new	screening	questionnaire	to	identify	neuropathic	components	in	patients	with	back	pain.	Current	medical	research	and	opinion.	22:	1911-1920	Fujii	K	Motohashi	K	Umino	M	(2006)	Heterotopic	ischemic	pain	attenuates	somatosensory	evoked	potentials	induced	by	electrical	tooth	stimulation:	Diffuse	noxious	inhibitory	controls	in	the	trigeminal	nerve	territory.	European	journal	of	pain.	10:	495-504	Gale	D	R	Chaisson	C	E	Totterman	S	M	Schwartz	R	K	Gale	M	E	Felson	D	(1999)	Meniscal	sublaxation:	association	with	osteoarthritis	and	joint	space	narrowing.	Osteoarthritis	and	Cartilage.	7:	526-532	Gebhart	G	F	(2004)	Descending	modulation	of	pain.	Neurosceince	and	biobehavioural	reviews.	27:	729-737	Gee	N	S	Brown	J	P	Dissanayeke	V	U	K	Offord	J	Thurlow	R	Woodruff	G	N	(1996)	The	Novel	Anticonvulsant	Drug,	Gabapentin	(Neurontin),	Binds	to	the		α2δ	Subunit	of	a	Calcium	Channel.	The	journal	of	biological	chemistry.	271:	5768-5776	Giovannitti	J	A	Thoms	S	M	Crawford	J	J	(2015)	Alpha-2	adrenergic	receptor	agonists:	A	review	of	current	clinical	applications.	Anaesthesia	progress.	62:	31-39	Glasson	S	S	Askew	R	Shappard	B	Carito	B	A	Blanchet	T	Ma	H	Flannery	C	R	Kanki	K	Wang	E	Peluso	D	Yang	Z	Majumdar	M	K	Morris	E	A	(2004)	Characterisation	of	and	osteoarthritis	susceptibility	in	ADAMTS-4	knockout	mice.	Arthritis	and	Rheumatism.	50:	2547-2558.	
	 306	
Glasson	S	S	Askew	R	Sheppard	B	Carito	B	Blanchet	T	Ma	H	Flannery	C	R	Peluso	D	Kanki	K	Yang	Z	Majumdar	M	K	Morris	E	A	(2005)	Deletion	of	active	ADAMTS5	prevents	cartilage	degradation	in	a	murine	model	of	osteoarthritis.	Letters	to	Nature.	434:	644-648.	Glasson	S	S	Blanchet	T	J	Morris	E	A	(2007)	The	surgical	destabilization	of	the	medial	meniscus	(DMM)	model	of	osteoarthritis	in	the	129/SvEv	mouse.	Osteoarthritis	and	Cartilage.	15:	1061-1069	Glasson	S	S	Chambers	M	G	Van	Den	Berg	W	B	Little	C	B	(2010)	The	OARSI	histopathology	initiative	–	recommendations	for	histological	assessments	of	osteoarthritis	in	the	mouse.	Osteoarthritis	and	Cartilage.	18:	17-23.	Gold	M	S	and	Greenhart	G	F	(2010)	Nociceptor	sensitization	in	pain	pathogenesis.	Nature	Medicine.	16:	1248-1257	Goldring	M	B	(1998)	The	role	of	cytokines	as	inflammatory	mediators	in	osteoarthritis:	Lessons	from	animals	models.	40:	1-11	Goldring	M	B	(2000)	The	role	of	the	chondrocyte	in	osteoarthritis.	Arthritis	and	Rheumatism.	43:	1916-1926.	Goldring	M	B	Fukuo	K	Birkhead	J	R	Dudek	E	Sandell	L	J	(1994)	Transciprtional	suppression	by	interleukin-1	and	interferon-gamma	of	type	II	collagen	gene	expression	in	human	chondrocytes.	Journal	of	cellular	biochemistry.	54:	85-99	Goldring	S	R	(2009)	Role	of	bone	in	osteoarthritis	pathogenesis.	Medical	clinics	of	North	America.	93:	25-35	Graven-Nielsen	T	(2006)	Fundamentals	of	muscle	pain,	referred	pain,	and	deep	tissue	hyperalgesia.	35:	1-43	Green	G	M	Scarth	J	Dickenson	A	(2000)	An	excitatory	role	for	5-HT	in	spinal	inflammatory	nociceptive	transmission;	state-dependent	actions	via	dorsal	horn	5-HT3	receptors	in	the	anaesthetized	rat.	Pain.	89:	81-88	Grubb	B	D	(2004)	Activation	of	sensory	neurons	in	the	arthritic	joint.	Novartis	foundation	symposium.	260:	28-36	Guerne	P	A	Carson	D	A	Lotz	M	(1990)	IL-6	production	by	human	articular	chondrocytes.	Modulation	of	its	synthesis	by	cytokines,	growth	factors,	and	hormones	in	vitro.	Journal	of	immunology.	144:	499-505	Guingamp	C	Gegout-Pottie	P	Phillippe	L	Terlain	B	Netter	P	Gillet	P	(1997)	Mono-Iodoacetate-Induced	Experimental	arthritis.	Arthrtitis	and	Rheumatism.	40:	1670-1679	Gunja-Smith	Z	Nagase	H	Woessner	J	F	(1989)	Purification	of	the	neutral	proteoglycan-degrading	metalloproteinase	from	human	articular	cartilage	tissue	and	its	identification	as	stromelysin		matrix	metalloproteinase-3.	Biochemical	journal.	258:	115-119.	Guzman	R	E	Evans	M	G	Bove	S	Morenko	B	Kilgore	K	(2003)	Mono-Iodoacetate-Induced	Histologic	Changes	in	Subchondral	Bone	and	Articular	Cartilage	of	Rat	Femorotibial	Joints:	An	Animal	Model	of	Osteoarthritis.	Toxicologic	pathology.	31:	619-624	Gwilym	S	E	Keltner	J	R	Warnaby	C	E	Carr	A	J	Chizh	B	Chessell	I	Tracey	I	(2009)	Psychophysical	and	functional	imaging	evidence	supporting	the	presence	of	central	sensitization	in	a	cohort	of	osteoarthritis	patients.	Arthritis	and	Rheumatism.	61:	1226-1234	Hale	M	Upmalis	D	Okamoto	A	Lange	C	Rauschkolb	C	(2009)	Tolerability	of	tapentadol	immediate	release	in	patients	with	lower	back	pain	or	osteoarthritis	of	the	hip	or	knee	
	 307	
over	90	days:	a	randomized	double-blind	study.	Current	medical	research	and	opinion.	25:	1095-1104	Hannan	M	T	Felson	D	T	Pincus	T	(2000)	Analysis	of	discordance	between	radiographic	changes	and	knee	pain	in	osteoarthritis	of	the	knee.	The	journal	of	rheumatology.	27:	1513-1517	Harper	A	A	and	Lawson	S	N	(1985)	Conduction	velocity	is	related	to	morphological	cell	type	in	rat	dorsal	root	ganglion	neurons.	Journal	of	Physiology.	359:	31-46.	Hart	D	J	Cronin	C	Daniels	M	Worthy	T	Doyle	D	V	Spector	T	D	(2002)	The	relationship	of	bone	density	and	fracture	to	incident	and	progressive	radiographic	osteoarthritis	of	the	knee:	the	Chingford	study.	Arthritis	and	rheumatism.	46:	92-99	Hartmann	B	Ahmadi	S	Heppenstall	P	A	Lewin	G	R	Schott	C	Borchardt	T	Seeburg	P	H	Zielhofer	H	U	Sprengel	R	Kuner	R	(2004)	The	AMPA	receptor	subunits	GluR-A	and	GluR-B	reciprocally	modulate	spinal	synaptic	plasticity	and	inflammatory	pain.	Neuron.	44:	637-650.	Harvey	V	L	Dickenson	A	H	(2009)	Behavioural	and	electrophysiological	characterisation	of	experimentally	induced	osteoarthritis	and	neuropathy	in	C57B1/6	mice.	Molecular	Pain.	5:18.		Hatrick	C	Van	Hove	I	Stegmann	J	U	Oh	C	Upmalis	D	(2009)	Efficacy	and	tolerability	of	Tapentadol	immediate	relase	and	Oxycodone	HCl	immediate	release	in	patients	awaiting	primary	joint	replacement	surgery	for	end-stage	joint	disease:	a	10-day,	Phase	III,	randomized,	double-blind,	active-	and	placebo-	controlled	study.	Clinical	therapeutics.	31:	260-271	Havelin	J	Imbert	I	Cromier	J	Allen	J	Porecca	F	King	T	(2016)	Central	sensitisation	and	neuropathic	features	on	ongoing	pain	in	a	rat	model	of	advanced	Osteoarthritis.	The	journal	of	pain.	17:	374-382	
Hawker	G	A	Stewart	L	French	M	R	Cibere	J	Jordan	J	M	March	L	Suarez-Almazor	M	Gooberman-Hill	R	(2008)	Understanding	the	pain	experience	in	hip	and	knee	osteoarthritis	e	an	OARSI/OMERACT	initiative.	Osteoarthritis	and	Cartilage.	16:	415-422	Hayami	T	Pickarski	M	Zhuo	Y	Wesolowski	G	A	Rodan	G	A	Duong	L	T	(2006)	Characterization	of	articular	cartilage	and	subchondral	bone	changes	in	the	rat	anterior	cruciate	ligament	transection	and	meniscectomized	models	of	osteoarthritis.	Bone.	38:	234-243	Haywood	L	McWilliams	D	F	Pearson	C	I	Gill	S	E	Ganesan	A	Wilson	D	Walsh	D	A	(2003)	Inflammation	and	angiogenesis	in	osteoarthritis.	Arthritis	and	rheumatism.	48:	2173-2177	Hedborn	E	Hauselmann	H	J	(2002)	Molecular	aspects	of	pathogenesis	in	osteoarthritis:	the	role	of	inflammation.	59:	45-53	Hedlund	P	B	Sutcliffe	J	G	(2004)	Functional,	molecular	and	pharmacological	advances	in	5-HT7	receptor	research.	Trends	in	Pharmacological	sciences.	25:	481-486	Heinricher	M	M	Morgan	M	M	Fields	H	L	(1992)	Direct	and	indirect	actions	of	morphine	on	medullary	neurons	that	modulate	nociception.	Neuroscience.	48:	533-543	Heinricher	M	M	Tavares	I	Leith	J	L	Lumb	B	M	(2009)	Descending	control	of	nociception:	Specificity,	recruitment	and	plasticity.	Brain	research	reviews.	60:214-225	Helminen	H	J	Kiraly	K	Pelttari	A	Tammi	M	I	Vandenberg	P	Pereira	R	Dhulipala	R	Khillan	J	S	Ala-Kokko	L	Hume	E	L	(1993)	An	inbred	line	of	transgenic	mice	expressing	an	internally	
	 308	
deleted	gene	for	type	II	procollagen	(COL2A1).	Young	mice	have	a	variable	phenotype	of	a	chondrodysplasia	and	older	mice	have	osteoarthritic	changes	in	joints.	The	Journal	of	Clinical	Investigation.	92:	582-595	Hendrich	J	Minh	A	T	V	Heblich	F	Nieto-Rostro	M	Watschinger	K	Striessnig	J	Wratten	J	Davies	A	Dolphin	A	C	(2008)	Pharmacological	disruption	of	calcium	channel	trafficking	by	the	alpha2delta	ligand	gabapentin.	Proceedings	of	the	national	academy	of	sciences.	105:	3628-3633	Hepper	C	T	Halvorson	J	J	Duncan	S	T	Gregory	A	J	Dunn	W	R	Spindler	K	P	(2009)	The	efficacy	and	duration	of	intra-articular	corticosteroid	injection	for	knee	osteoarthritis:	a	systemic	review	of	level	I	studies.	J	Am	Acad	Orthop	Surg.	17:	638-646	Herrero	J	F	Laird	J	M	A	Lopes-Garcia	J	A	(2000)	Wind-up	of	spinal	cord	neurones	and	pain	sensation:	much	ado	about	something?	Progress	in	Neurobiology.	61:	169-203	Hill	C	L	Seo	G	S	Gale	D	Totterman	S	Gale	M	E	Felson	D	T	(2005)	Cruciate	ligament	integrity	in	osteoarthritis	of	the	knee.	Arthritis	and	rheumatism.	52:	794-799	Hochman	J	R	Davis	A	M	Elkayam	J	Gagliese	L	Hawker	G	A	(2013)	Neuropathic	pain	symptoms	on	the	modified	painDETECT	correlate	with	signs	of	central	sensitization	in	knee	osteoarthritis.	Osteoarthritis	and	Cartilage.	21:	1236-1242	Hochman	J	R	Davis	A	M	Elkayam	J	Gagliese	L	Hawker	G	A	(2013)	Neuropathic	pain	symptoms	on	the	modified	painDETECT	correlate	with	signs	of	central	sensitization	in	knee	osteoarthritis.	Osteoarthritis	and	Cartilage.	21:	1236-1242	Hochman	J	R	French	M	R	Bermingham	S	L	Hawker	G	A	(2010)	The	nerve	of	osteoarthritis	pain.	Arthritis	care	and	research.	62:	1019-1023	Hochman	J	R	Gagliese	L	Davis	A	M	Hawker	G	A	(2011)	Neuropathic	pain	symptoms	in	a	community	knee	OA	cohort.	Osteoarthritis	and	cartilage.	19:	647-654	Honorati	M	C	Neri	S	Cattini	L	Facchini	A	(2006)	Interleukin-17,	a	regulator	of	angiogenic	factor	release	by	synovial	fibroblasts.	Osteoarthritis	and	cartilage.	14:	345-352	Hoyer	D	Clarke	D	E	Fozard	J	R	Hartig	P	R	Martin	G	R	Mylecharane	E	J	Saxena	P	R	Humphrey	P	P	A	(1994)	International	union	of	pharmacology	classification	of	receptors	for	5-Hydroxytryptamine	(Serotonin).	Pharmacological	reviews.	46:	157-203	Hoyer	D	Engel	G	Kalkman	H	(1985)	Characterization	of	the	5HTIB	recognition	site	in	rat	brain:	binding	studies	with	(-)[1251]iodocyanopindolol.	European	Journal	of	Pharmacology	118:	1-12.	Hsieh	M	Donaldson	L	F	Lumb	B	M	(2015)	Differential	contributions	of	A-	and	C-	nociceptors	to	primary	and	seconday	inflammatory	hypersensitivity	in	the	rat.	Pain.	156:	1074-1083.	Hughes	S	Hickey	L	Donaldson	L	F	Lumb	B	M	Pickering	A	E	(2015)	Intrathecal	reboxetine	supresses	evoked	and	ongoing	neuropathic	pain	behavioursby	restoring	spinal	noradrenergic	inhibitory	tone.	Pain.	156:	328-334	Hunt	D	Raivich	G	Anderson	P	N		(2012)	Activating	transcription	factor	3	and	the	nervous	system.	Frontiers	in	molecular	neuroscience.	5:	1-17	Hunt	S	P	Pini	A	Evan	G	(1987)	Induction	of	c-fos	like	protein	in	spinal	cord	neurons	following	sensory	stimulation.	Nature.	328:	632-634.	Hunter	D	J	Gerstenfeld	L	Bishop	G	Davis	A	D	Mason	Z	D	Einhorn	T	A	Maciewicz	R	A	Newham	P	Foster	M	Jackson	S	Morgan	E	F	(2009)	Bone	marrow	lesions	from	osteoarthritis	knees	
	 309	
are	characterised	by	sclerotic	bone	that	is	less	well	mineralized.	Arthritis	research	and	therapy.	11:	R11.		Hunter	D	J	McDougall	J	J	Keefe	F	J	(2009b)	The	symptoms	of	OA	and	the	genesis	of	pain.	Rheumatic	disease	clinics	of	north	America.	34:	623-643	Hunter	D	J	Zhang	Y	Niu	J	Goggins	J	Amin	S	LaValley	M	P	Guermazi	A	Genant	H	Gale	D	Felson	D	T	(2006)	Increase	in	bone	marrow	lesions	associated	with	cartilage	loss:	A	longitudinal	magnetic	resonance	imagining	study	of	knee	osteoarthritis.	Arthritis	and	Rheumatism.	54:	1529-1535	Hunter	D	J	Zhang	Y	Niu	J	Tu	X	Amin	S	Goggins	J	Lavalley	M	Guermazi		Gale	D	Felson	D	T	(2005)	Structural	factors	associated	with	malalignment	in	knee	osteoarthritis:	The	Boston	osteoarthritis	knee	study.	The	journal	of	rheumatology.	32:	2192-2199	Ibuki	T	Hama	A	T	Wang	X	T	Pappas	G	D	Sagen	J	(1997)	Loss	of	GABA-immunoreactivity	in	the	spinal	dorsal	horn	of	rats	with	peripheral	nerve	injury	and	promotion	of	recovery	by	adrenal	medullary	grafts.	Neuroscience.	76:	845-858.	Itomi	Y	Tsukimi	Y	Kawamura	T	(2016)	Impaired	diffuse	noxious	inhibitory	controls	in	specific	alternation	of	rhythm	in	temperature-stressed	rats.	European	journal	of	pharmacology.	784:	61-68	Ivanavicius	S	P	Ball	A	D	Heapy	C	G	Westwood	F	R	Murray	F	Read	S	J	(2007)	Structural	pathology	in	a	rodent	model	of	osteoarthritis	is	associated	with	neuropathic	pain:	Increased	expression	of	ATF-3	and	pharmacological	characterisation.	Pain.	128:	272-282	Ivanavicius	S	P	Blake	D	R	Chessell	I	P	Mapp	P	I	(2004)	Isolectin	B4	binding	neurons	are	not	present	in	the	rat	knee	joint.	Neuroscience.	128:	555-560	Janusz	M	J	Bendele	A	M	Brown	K	K	Taiwo	Y	O	Hsieh	L	Heitmeyer	S	A	(2002)	Induction	of	osteoarthritis	in	the	rat	by	surgical	tear	of	the	meniscus:	Inhibition	of	joint	damage	by	a	matrix	metalloproteinase	inhibitor.	Osteoarthritis	and	Cartilage.	10:	785-791	Jensen	A	A	Mosbacher	J	Elg	S	Lingelhoehl	K	Lohmann	T	Johansen	T	N	Abrahamsen	B	Mattsson	J	P	Lehmann	A	Bettler	B	Brauner-Osborne	H	(2002)	The	anticonvulsant	gabapentin	(neurontin)	does	not	act	through	gamma-aminobutyric	acid-B	receptors.	Molecular	pharmacology.	61:	1377-1384	Jensen	T	S	and	Finnerup	N	B	(2014)	Allodynia	and	hyperalgesia	in	neuropathic	pain:	clinical	manifestations	and	mechanisms.	Lancet	neurology.	13:	924-935.	Jensen	T	S	Baron	R	(2003)	Translation	of	symptoms	and	signs	into	mechanisms	in	neuropathic	pain.	Pain.	102:	1-8	Jenson	T	S	and	Baron	R	(2003)	Translation	of	symptoms	and	signs	into	mechanisms	in	neuropathic	pain.	Pain	102:	1-8	Ji	R	Woold	C	J	(2001)	Neuronal	plasticity	and	signal	transduction	in	nociceptive	neurons:	implications	for	the	initiation	and	maintenance	of	pathological	pain.	Neurobiology	of	disease.	8:	1-10.		Jimenez	P	A	Glasson	S	S	Trubetskoy	O	V	Haimes	H	B	(1997)	Spontaneous	osteoarthritis	in	Dunkin	Hartley	guinea	pigs:	histological,	radiological,	and	biochemical	changes.	Laboratory	animal	science.	6:	598-601.	Johnson	A	R	Pavlovsky	A	G	Ortwine	D	F	Prior	F	Man	C	Bornemeier	D	A	Banotai	C	A	Mueller	W	T	McConnel	P	Yan	C	Baragi	V	Lesch	C	Roark	W	H	Wilson	M	Datta	K	Guzman	R	Han	H	Dyer	
	 310	
R	D	(2007)	Discovery	and	characterisation	of	a	novel	inhibitor	of	matrix	matelloproteinase-13	that	reduces	cartilage	damage	in	vivo	without	joint	fibroplasia	side	effects.	The	journal	of	biological	chemistry.	282:	27781-27791.	Julius	D	and	Basbaum	A	I	(2001)	Molecular	mechanisms	of	nociception.	Nature.	413:	203-210.	Kalbhen	D	A	(1987)	Chemical	model	of	osteoarthritis	–	a	pharmacological	evaluation.	The	Journal	of	Rheumatology.	14:	130-131.	Kalbhen	D	A	Blum	U	(1977)	Hypothesis	and	experimental	confirmation	of	a	new	pharmacological	model	of	osteoarthrosis.	Arzneimittelforschung.	27:	527-531	Kapoor	M	Martel-Pelletier	J	Lajeunesse	D	Pelletier	J	Fahmi	H	(2011)	Role	of	proinflammatory	cytokines	in	the	pathophysiology	of	osteoarthritis.	Nature	reviews:	Rheumatology.	7:	33-42	Karsdal	M	A	Madsen	S	H	Christiansen	C	Henriksen	K	Fosang	A	J	Sondergaard	B	C	(2008)	Cartilage	degradation	is	fully	reversible	in	the	presence	of	aggrecanase	but	not	matrix	matelloproteinase	activity.	Arthritis	research	and	therapy.	10:	R63.	Kashiwagi	M	Tortorella	M	Nagase	H	Brew	K	(2001)	TIMP-3	is	a	potent	inhibitor	of	aggrecanase	1	(ADAM-TS4)	and	aggrecanase	2	(ADAM-TS5).	J	Biol	Chem.	276:12501–12504.	Kataoka	K	Kanje	M	Dahlin	L	B	(2007)	Induction	of	activating	transcription	factor	3	after	different	sciatic	nerve	injuries	in	adult	rats.	41:	158-166	Kawasaki	Y	Zhang	L	Cheng	J	Ji	R	(2008)	Cytokine	mechanisms	of	central	sensitisation:	distinct	and	overlapping	role	of	Interleukin-1β,	Interleukin-6	and	Tumor	Necrosis	Factor-α	in	regulating	synaptic	and	neuronal	activity	in	the	superficial	spinal	cord.	The	Journal	of	Neuroscience.	28:	5189-5194.	Kean	W	F	Kean	R	Buchanan	W	W	(2004)	Osteoarthritis:	symptoms,	signs	and	source	of	pain.	Inflammopharmacology.	12:	3-31	Keinanen	K	Wisden	W	Sommer	B	Werner	P	Herb	A	Verdoorn	T	A	Sakmann	B	Seeburg	P	H	(1990)	A	family	of	AMPA-selecive	glutamate	receptors.	Science.	249:	556-560.	Kelly	S	Dobson	K	L	Harris	J	(2013)	Spinal	nociceptive	reflexes	are	sensitized	in	the	monosodium	iodoacetate	model	of	osteoarthritis	pain	in	the	rat.	Osteoarthritis	and	Cartilage.	21:	1327-1335	Kelly	S	Dunham	J	P	Murray	F	Read	S	Donaldson	L	F	Lawson	S	N	(2012)	Spontaneous	firing	in	C-fibres	and	increased	mechanical	sensitivity	in	A-fibres	of	knee	joint-associated	mechanoreceptive	primary	afferent	neurones	during	MIA-induced	osteoarthritis	in	the	rat.	20:	305-313	Kerstein	P	C	Camino	D	Moran	M	M	Stucky	C	L	(2009)	Pharmacological	blockade	of	TRPA1	inhibits	mechanical	firing	in	nociceptors.	Molecular	Pain.	21:	5-19.	Kevorkian	L	Young	D	A	Darrah	C	Donell	S	T	Shepstone	L	Porter	S	Brockbank	S	M	V	Edwards	D	R	Parker	A	E	Clark	I	M	(2004)	Expression	profiling	of	metalloproteinases	and	their	inhibitors	in	cartilage.	Arthritis	and	Rheumatism.	50:	131-141.	Kiani	C	Chen	L	Wu	Y	J	Yee	A	J	Yang	B	B	(2002)	Structure	and	function	of	aggrecan.	Cell	research.	12:	19-32.	Kim	S	H	and	Chung	J	M	(1992)	An	experimental	model	for	peripheral	neuropathy	produced	by	segmental	spinal	nerve	ligation	in	the	rat.	Pain.	50:	355-363.	
	 311	
Kim	Y	S	Chu	Y	Han	L	Li	M	Li	Z	LaVinka	P	C	Sun	S	Tang	Z	Park	K	Caterina	M	J	Ren	K	Dubner	R	Wei	F	Dong	X	(2015)	Central	terminal	sensitization	of	TRPV1	by	descending	serotonergic	facilitation	modulates	chronic	pain.	Neuron.	81:	873-887	Kingery	W	S	Agashe	G	S	Guo	T	Z	Sawamura	S	Davies	M	F	Clark	J	D	Kobilka	K	B	Maze	M	(2002)	Isoflurane	and	nociception:	spinal	alpha2A	adrenoceptors	mediate	antinociception	while	supraspinal	alpha1	adrenoceptors	mediate	pronociception.	Anaesthesiology.	96:	367-374	Kjorsvik	A	Tjolsen	A	Hole	K	(2001)	Activation	of	spinal	serotonin	(2A/2C)	receptors	augments	nociceptive	responses	in	the	rat.	Brain	research.	910:	179-181.		Kobayashi	K	Fukuoka	T	Obata	K	Yamanaka	H	Dai	Y	Tokunaga	A	Noguchi	K	(2005)	Distinct	expression	of	TRPM8,	TRPA1,	and	TRPV1	mRNAs	in	rat	primary	afferent	neurons	with	Aδ/C	fibres	and	colocalization	with	Trk	receptors.	The	journal	of	comparative	neurology.	493:	596-606.	Kobayashi	M	Squires	G	R	Mousa	A	Tanzer	M	Zukor	D	J	Antoniou	J	Feige	U	Poole	A	R	(2005b)	Role	of	interleukin-1	and	tumour	necrosis	factor	alpha	in	matrix	degradation	of	human	osteoarthritic	cartilage.	Arthritis	and	rheumatism.	52:	128-135	Konttinen	Y	T	Mandelin	J	Li	T	F	Salo	J	Lassus	J	Liljestrom	M	Hukkanen	M	Takagi	M	Virtanen	I	Santavirta	S	(2002)	Acidic	cysteine	endoproteinase	cathepsin	K	in	the	degeneration	of	the	superficial	articular	hyaline	cartilage	in	osteoarthritis.	(2002)	Arthritis	and	Rheumatism.	46:	953-960.	Kornaat	P	R	Bloem	J	L	Ceulemans	R	Y	Riyazi	N	Rosendaal	F	R	Nelissen	R	G	Carter	W	O	Hellio	Le	Graverand	Kloppenburg	M	(2006)	Osteoarthritis	of	the	knee:	association	between	clinical	features	and	MR	imaging	findings.	Radiology.	239:	811-817	Kosek	E	Orderberg	G	(2000)	Lack	of	pressure	pain	modulation	by	heterotopic	noxious	conditioning	stimulation	in	patients	with	painful	osteoarthritis	before,	but	not	following,	surgical	pain	relief.	Pain.	88:	69-78.	Krasnokutsky	S	Attur	M	Palmer	G	Samuels	J	Abramson	S	B	(2008)	Current	concepts	in	the	pathogenesis	of	osteoarthritis.	Osteoarthritis	and	cartilage.	16:	S1-S3.		Kraus	E	Le	Bars	D	Besson	J	M	(1981)	Behavioural	confirmation	of	“diffuse	noxious	inhibitory	controls”	(DNIC)	and	evidence	for	a	role	of	endogenous	opiates.	Brain	research.	206:	495-499	Kuner	R	(2010)	Central	mechanisms	of	pathological	pain.	Nature	Medicine.	16:	1258-1266.		Kwan	K	Y	Allchorne	A	J	Vollrath	M	A	Christensen	A	P	Zhang	D	Woolf	C	J	Corey	D	P	(2006)	TRPA1	contributes	to	cold,	mechanical,	and	chemical	nociception	but	is	not	essential	for	hair-cell	transduction.	Neuron.	50:	277-289.	Kwan	T	S	Padrines	M	Theoleyre	S	Heymann	D	Fortun	Y	(2004)	IL6,	RANKL,	TNF-aplha/IL-1:	interrelations	in	bone	resorption	pathophysiology.	Cytokine	and	growth	factor	reviews.	15:	49-60	Kwiat	G	C	Basbaum	A	I	(1992)	The	origin	of	brainstem	noradrenergic	and	serotonergic	projections	to	the	spinal	cord	dorsal	horn	in	the	rat.	Somatosensory	and	motor	research.	9:	157-173.	Lane	N	E	Schnitzer	T	J	Birbara	C	A	Mokhtarani	M	Shelton	D	L	Smith	M	D	Brown	M	T	(2010)	Tanezumab	for	the	treatment	of	pain	from	osteoarthritis	of	the	knee.	The	New	England	journal	of	medicine.	363:	1521-1531.	
	 312	
Lange	C	Steup	A	Black	P	Desjardins	P	(2006)	Rapid	pain	relief	after	bunionectomy	with	tapentadol,	a	novel	centrally	acting	analgesic.	European	journal	of	pain.	10:	S165-S165	Latremoliere	A	Woolf	C	J	(2009)	Central	sensitization:	a	generator	of	pain	hypersensitivity	by	central	neural	plasticity.	The	journal	of	pain.	10:	895-926.	Lautenbacher	S	Rollman	G	B	(1997)	Possible	deficiencies	of	pain	modulation	in	fibromyalgia.	The	clinical	journal	of	pain.	13:	189-196	Le	Bars	D	(2002)	The	whole	body	receptive	field	of	dorsal	horn	multireceptive	neurones.	Brain	research	reviews.	40:29-44.	Le	Bars	D	Chitour	D	Clot	A	M	(1981)	The	encoding	of	thermal	stimuli	by	diffuse	noxious	inhibitory	controls	(DNIC)	Brain	Research	230:	394-399	Le	Bars	D	Chitour	D	Kraus	E	Dickenson	A	H	Besson	J	M	(1981)	Effect	of	Naloxone	upon	Diffuse	Noxious	Inhibitory	Controls	(DNIC)	in	the	rat.	Brain	research.	204:	387-402.	Le	Bars	D	Dickenson	A	H	Besson	J	(1979b)	Diffuse	Noxious	Inhibitory	Controls	(DNIC).	II.	Lack	of	effect	on	non-convergent	neurons,	supraspinal	involvement	and	theoretical	implications.	Pain.	6:	305-327.	Le	Bars	D	Dickeonson	A	H	Besson	J	M	(1979a)	Diffuse	noxious	inhibitory	controls	(DNIC).	I.	Effects	on	dorsal	horn	convergent	neurones	in	the	rat.	Pain.	6:	283-304.	Le	Bars	D	Villanueva	L	(1988)	Electrophysiological	evidence	for	the	activation	of	descending	inhibitory	controls	by	nociceptive	afferent	pathways.	Progress	in	brain	research.	77:	275-299.	Le	Bars	D	Willer	J	C	(2008)	Diffuse	Noxious	Inhibitory	Controls	(DNIC).	The	senses:	a	comprehensive	reference.	5:	763-773	Lee	J	H	Fitzgerald	J	B	DiMicco	M	A	Cheng	D	M	Flannery	C	R	Sandy	J	D	Plaas	A	H	Grodzinsky	A	J	(2009)	Co-culture	of	mechanically	injured	cartilage	with	joint	capsule	tissue	alters	chondrocyte	expression	patterns	and	increases	ADAMTS5	production.	Archives	of	Biochemistry	and	Biophysics.	489:	118-126.	Lee	M	C	Zambreanu	L	Menon	D	K	Tracey	I	(2008)	Identifying	brain	activity	specifically	related	to	the	maintenance	and	perceptual	consequence	of	central	sensitization	in	humans.	The	journal	of	neuroscience.	28:	11642-11649	Leiphart	J	W	Dills	C	V	Levy	R	M	(2003)	Decreased	spinal	alpha2a-	and	alpha2c-	adrenergic	receptor	subtype	mRNA	in	a	rat	model	of	neuropathic	pain.	Neuroscience	letters.	349:	5-8.	Lemmon	M	A	and	Shlessinger	J	(2010)	Cell	signalling	by	receptor-tyrosine	kinases.		Cell.	141:	1117-1134.	Lewis	G	N	Heales	L	Rice	D	A	Rome	K	McNair	P	J	(2012)	Reliability	of	the	conditioned	pain	modulation	paradigm	to	assess	endogenous	inhibitory	pain	pathways.	Pain	research	and	management.	17:	98-102	Li	A	Aspden	R	(1997)	Mechanical	and	material	properties	of	the	subchondral	bone	plate	from	the	femoral	head	of	patients	with	osteoarthritis	or	osteoporosis.	Ann	Rheum	Dis	56:247–54	
	 313	
Li	A	Zhang	Y	Lao	L	Xin	J	Ren	K	Berman	B	M	Zhang	R	(2011)	Serotonin	receptor	2A/C	in	involved	in	electroacupuncture	inhibition	of	pain	in	an	osteoarthritis	rat	model.	Evidence-based	complimentary	and	alternative	medicine.	2011:	619650	Li	C	Y	Zhang	X	L	Matthews	E	A	Li	K	W	Kurwa	A	Boroujerdi	A	Gross	J	Gold	M	S	Dickesnon	A	H	Feng	G	Luo	Z	D	(2006)	Calcium	Channel	α2δ1	Subunit	Mediates	Spinal	Hyperexcitability	in	Pain	Modulation.	Pain.	125:	20-34		Li	P	Kerchner	G	A	Sala	C	Wei	F	Huettner	J	E	Sheng	M	Zhuo	M	(1999)	AMPA	receptor-PDZ	interactions	in	facilitation	of	spinal	sensory	synapses.	Nature	neuroscience.	2:	972-977.	Li	Z	Taylor	C	P	Weber	M	Piechan	J	Prior	F	Bian	F	Cui	M	Hoffman	D	Donevan	S	(2011)	Pregabalin	is	a	potent	and	selective	ligand	for	α2δ-1	and	α2δ-2	calcium	channel	subunits.	European	journal	of	pharmacology.	667:	80-90	Liane	L	White	W	B	Rostom	A	Hochberg	M	(2008)	Cox-2	selective	inhibitors	in	the	treatment	of	osteoarthritis.	Semin	Arthritis	Rheum.	38:	165-187	Light	A	R	and	Perl	E	R	(1979)	Spinal	termination	of	functionally	identified	primary	afferent	neurons	with	slowly	conducting	myelinated	fibres.	The	Journal	of	comparative	neurology.	186:	133-150	Lin	H	Heo	B	H	Kim	W	M	Kim	Y	C	Yoon	M	H	(2015)	Antiallodynic	effect	of	tianeptine	via	modulation	of	the	5-HT7	receptor	of	GABAergic	interneurons	in	the	spinal	cord	of	neuropathic	rats.	Neuroscience	letters.	598:	91-95	Lin	J	Zhang	W	Jones	A	Doherty	M	(2004)	Efficacy	of	topical	non-steroidal	anti-inflammatory	drugs	in	the	treatment	of	osteoarthritis:	meta-analysis	of	randomised	controlled	trials.	BMJ.	329:	324-330	Lindstedt	F	Berrebi	J	Greayer	E	Lonsdorf	T	B	Schalling	M	Ingvar	M	Kosek	E	(2011)	Conditioned	pain	modulation	is	associated	with	common	polymorphisms	in	the	serotonin	transporter	gene.	PLoS	One.	6:	e18252.	Little	C	B	Barai	A	Burkhardt	D	Smith	S	M	Fosang	A	J	Werb	Z	Shah	M	Thompson	E	W	(2009)	Matrix	metalloproteinase	13-deficient	mice	are	resistant	to	osteoarthritic	cartilage	erosion	but	not	chondrocyte	hypertrophy	or	osteophyte	development.	Arthritis	and	Rheumatism.	60:	3723-3733.	Little	C	B	Mittaz	L	Belluoccio	D	Rogerson	F	M	Campbell	I	K	Meeker	C	T	Bateman	J	F	Pritchard	M	A	Fosang	A	J	(2005)	ADAMTS-1-Knockout	mice	do	not	exhibit	abnormalities	in	aggrecan	turnover	in	vitro	or	in	vivo.	Arthritis	and	Rheumatism.	52:	1461-1472.	Little	C	B	Zaki	S	(2012)	What	constitutes	an	“animal	model	of	osteoarthritis”	–	the	need	for	consensus?	Osteoarhtritis	and	Cartilage.	20:	261-267	Litwick	A	Edwards	M	Dennison	E	Cooper	C	(2013)	Epidemiology	and	burden	of	osteoarthritis.	British	medical	bulletin.	105:	185-199	Liu	S	S	Buvanendran	A	Rathmell	J	P	Sawhney	M	Bae	J	J	Moric	M	Perros	S	Pope	A	J	Poultsides	L	Valle	C	J	D	Shin	N	S	McCartney	C	J	L	Ma	Y	Shah	M	Wood	M	J	Manion	S	C	Sculco	T	P	(2012)	Predictors	for	moderate	to	sever	acute	postoperative	pain	after	total	hip	and	knee	replacement.	International	Orthopaedics.	36:	2261-2267	
	 314	
Lo	G	H	LaValley	M	McAlindon	T	Felson	D	T	(2003)	Intra-articular	hyaluronic	acid	in	treatment	of	knee	osteoarthritis:	a	meta-analysis.	JAMA.	290:	3115-3121	Loeser	R	F	(2006)	Molecular	mechanisms	of	cartilage	destruction:	mechanics,	inflammatory	mediators,	and	aging	collide.	Arthritis	rheumatology.	54:	1357-1360	Loeser	R	F	Goldring	S	R	Scanzello	C	R	Goldring	M	B	(2012)	Osteoarthritis:	a	disease	of	the	joint	as	an	organ.	Arthritis	and	Rhematism.	64:	1697-1707	Lohmander	L	S	Englund	P	M	Dahl	L	L	Roos	E	M	(2007)	The	long-term	consequence	of	anterior	cruciate	ligament	and	meniscus	injuries:	osteoarthritis.	The	American	journal	of	sports	medicine.	35:	1756-1769	Lopes	D	M	Denk	F	McMahon	S	B	(2017)	The	molecular	fingerprint	of	dorsal	root	and	trigeminal	ganglion	neurons.	Frontiers	in	molecular	neuroscience.	10:	304.	Lopes-Castejon	G	Brough	D	(2011)	Understanding	the	mechanism	of	IL-1β	secretion.	Cytokine	growth	factor	reviews.	22:	189-195	Lorenz	J	Grassel	S	(2014)	Experimental	osteoarthritis	models	in	mice.	Methods	in	molecular	biology.	1194:	401-419	Lumb	B	M	(2014)	Descending	controls:	How	to	harness	for	the	relief	of	pain?	The	journal	of	physiology.	592:	4097	Lumley	M	A	Cohen	J	L	Borszcz	G	S	Cano	A	Radcliffe	A	M	Porter	L	S	Schubiner	H	Keefe	F	J	(2011)	Pain	and	emotion:	A	biopsychosocial	review	of	recent	research.	Journal	of	clinical	psychology.	67:	942-968	Luo	Z	D	Chaplan	S	R	Higuera	E	S	Sorkin	L	S	Stauderman	K	A	Williams	M	E	Yaksh	T	L	(2001)	Upregulation	of	dorsal	root	ganglion	(alpha)2(delta)	calcium	channel	subunit	and	its	correlation	with	allodynia	in	spinal	nerve-injured	rats.	The	journal	of	neuroscience.	21:	1868-1875	Lynch	J	A	Hawkes	J	D	Buckland-Wright	J	C	(1991)	Analysis	of	texture	in	macroradiographs	of	osteoarthritic	knees	using	the	fractal	signature.	Phys	Med	Biol	36:709–22	Malcangio	M	Ramer	M	S	Jones	M	G	McMahon	S	B	(2000)	Abnormal	substance	P	release	from	the	spinal	cord	following	injury	to	primary	sensory	neurons.	European	journal	of	neuroscience.	12:	397-399.	Malfait	A	Little	C	B	McDougall	J	J	(2013)	A	commentary	on	modelling	Osteoarthritis	pain	in	small	animals.	Osteoarthritis	and	cartilage.	21:	1316-1326	Malfait	M	Schnitzer	T	J	(2014)	Towards	a	mechanism-based	approach	to	pain	management	in	osteoarthritis.	Nature	reviews	rheumatology.	9:	654-664	Mantyh	P	W	Rogers	S	D	Honore	P	Allen	B	J	Ghilardi	J	R	Li	J	Daughters	R	S	Lappi	D	A	Wiley	R	G	Simone	D	A	(1997)	Inhibition	of	hyperalgesia	by	ablation	of	lamina	I	spinal	neurons	expressing	the	substance	P	receptor.	Science.	278:	275-279.	Mapp	P	I	(1995)	Innervation	of	the	synovium.	Annals	of	the	rheumatic	diseases.	54:	398-403	Mapp	P	I	Sagar	D	R	Ashraf	S	Burston	J	J	Suri	S	Chapman	V	Walsh	D	A	(2013)	Differences	in	structural	and	pain	phenotypes	in	the	sodium	monoiodoacetate	and	meniscal	transection	models	of	osteoarthritis.	Osteoarthritis	and	cartilage.	21:	1336-1345	Mary	E	Lynch	(2011)	The	need	for	a	Canadian	pain	strategy.	Pain	Res	Manag.	16(2):	77-80.		
	 315	
Masuhara	K	Nakai	T	Yamaguchi	K	Yamasaki	S	Sasaguri	Y	(2002)	Significant	increases	in	serum	and	plasma	concentrations	of	matrix	metalloproteinases	3	and	9	in	patients	with	rapidly	destructive	osteoarthritis	of	the	hip.	Arthritis	and	Rheumatism.	46:	2625-2631	McGaraughty	S	Chu	K	L	Perner	R	J	DiDomenico	S	Kort	M	E	Kym	P	R	(2010)	TRPA1	modulation	of	spontaneous	and	mechanically	evoked	firing	of	spinal	neurons	in	uninjured,	osteoarthritis	and	inflamed	joints.	Molecular	Pain.	6:14	McMahon	S	B	(1996)	NGF	as	a	mediator	of	inflammatory	pain.	Philos	Trans	R	Soc	Lond	B	Biol	Sci.	29:	431-440	McMahon	S	B	Malcangio	M	(2009)	Current	challenges	in	glia-pain	biology.	Neuron.	64:	46-54.	McMahon	S	B,	Koltzberg	M,	Tracey	I,	Turk	D	C	(2013)	Wall	and	Melzack’s	Textbook	of	Pain.	Sixth	edition.	Elsevier	Health	Sciences.		Merksey,	H	and	Bogduk	N	(1994)	Classification	of	chronic	pain,	IASP	Press	Seattle.		Milligan	E	D	Watkins	L	R	(2009)	Pathological	and	protective	roles	of	glia	in	chronic	pain.	Nature	reviews,	Neuroscience.	10:	23-26.	Milligan	M	J	(1995)	Serotonin	(5-HT)	and	pain:	A	reappraisal	of	its	role	in	the	light	of	receptor	multiplicity.	Seminars	in	neuroscience.	7:409-419.	Milligan	M	J	(1998)	The	induction	of	pain:	An	integrative	review.	Progress	in	Neurobiology.		57:	1-164.		Milligan	M	J	(2002)	Descending	control	of	pain.	Progress	in	Neurobiology	66:	355–474.	Mogil	J	(2009)	Animals	models	of	pain:	progress	and	challenges.	Nature	reviews	neuroscience.	10:	283-294	Mohan	G	Perilli	E	Kuliwaba	J	S	Humphries	J	M	Parkinson	I	H	Fazzalari	N	L	(2011)	Application	of	in	vivo	micro-computed	tomography	in	the	temporal	characterisation	of	subchondral	bone	architecture	in	a	rat	model	of	low-dose	monosodium	iodoacetate-induced	osteoarthritis.	Arthritis	research	and	therapy.	13:	R210.		Molinoff	P	B	(1984)	Alpha-	and	Beta-	adrenergic	receptor	subtypes	properties,	distribution	and	regulation.	Drugs.	28:	1-15	Momin	A	and	Wood	J	(2008)	Sensory	neuron	voltage-gated	sodium	channels	as	analgesic	drug	targets.	Current	opinion	in	neurobiology.	18:	383-388.	Monyer	H	Sprengel	R	Schoepfer	R	Herb	A	Higuchi	M	L	Burnashev	N	Sakmann	B	Seeburg	P	H	(1992)	Heteromeric	NMDA	receptors:	molecular	and	functional	distinction	of	subtypes.	Science.	256:	1217-1221.	Moont	R	Pud	D	Sprecher	E	Sharvit	G	Yarnitsky	D	(2010)	“Pain	inhibits	pain”	mechanisms:	Is	pain	modulation	simply	due	to	distraction?	Pain.	150:	113-120	Moore	K	A	Kohno	T	Karchewski	L	A	Scholz	J	Baba	H	Woolf	C	J	(2002)	Partial	peripheral	nerve	injury	promotes	a	selective	loss	of	GABAergic	inhibition	in	the	superficial	dorsal	horn	of	the	spinal	cord.	Journal	of	Neuroscience.	22:	6724-6731.	Moore	R	A	Straube	S	Wiffen	P	J	Derry	S	McQuay	H	J	(2014a)	Pregabalin	for	acute	and	chronic	pain	in	adults.	Cochrane	database	of	systematic	reviews.	CD007076	Moore	R	A	Wiffen	P	J	Derry	S	McQuay	H	J	(2014b)	Gabapentin	for	chronic	neuropathic	pain	and	fibromyalgia	in	adults.	Cochrane	database	of	systematic	reviews.	CD007938	Morenko	B	J	Bove	S	E	Chen	L	Guzman	R	E	Juneau	P	Bocan	T	M	A	Peter	G	K	Arora	R	Kilgore	K	S	(2004)	In	vivo	micro	computed	tomography	of	subchondral	bone	in	the	rat	after	intra-
	 316	
articular	administration	of	monosodium	iodoacetate.	Contemporary	topics	in	laboratory	animal	science	/	American	Association	for	Laboratory	Animal	Science.	43:	39-43	Morris	K	J	Cs-Szabo	G	Cole	A	A	(2010)	Characterization	of	TIMP-3	in	human	articular	talar	cartilage.	Connective	tissue	research.	51:	478-490.	Muir	H	(1995)	The	chondrocyte,	architect	of	cartilage.	Biomechanics,	structure,	function	and	molecular	biology	of	cartilage	matrix	macromolecules.	BioEssays.	17:	1039-1048.	Nelson	D	L	(2004)	5-HT5	receptors.	Current	drug	targets.	CNS	and	neurological	disorders.	3:	53-58.	Neogi	T	(2012)	Clinical	significance	of	bone	changes	in	osteoarthritis.	Therapeutic	advances	in	musculoskeletal	disease.	4:	259-267	Neugebauer	V	Lucke	T	Schiable	H	G	(1993)	N-Methyl-D-Aspartate	(NMDA)	and	non-NMDA	receptor	antagonists	blocks	the	hyperexcitability	of	dorsal	horn	neurons	during	development	of	acute	arthritis	in	rat’s	knee	joint.	Journal	of	neurophysiology.	70:	1365-1377	Neuhold	L	A	Killar	L	Zhao	W	Sung	M	A	Warner	L	Kulik	J	Tuner	J	Wu	W	Billinghurst	C	Meijers	T	Poole	A	R	Babij	P	DeGennaro	L	J	(2001)	Postnatal	expression	in	hyaline	cartilage	of	constitutively	active	human	collagenase-3	(MMP-13)	induces	osteoarthritis	in	mice.	Journal	of	clinical	investigation.	107:	35-44.	Neuhold	L	A	Killar	L	Zhao	W	Sung	M	A	Warner	L	Kulik	J	Turner	J	Wu	W	Billinghurst	C	Meijers	T	Poole	A	R	Babij	P	DeGennaro	L	J	(2001)	Postnatal	expression	in	hyaline	cartilage	of	constitutively	active	human	collengenase-3	(MMP-13)	induces	osteoarthritis	in	mice.	The	Journal	of	Clinical	Investigation.	107:	35-44	Newton	R	A	Bingham	S	Case	P	C	Sanger	G	J	Lawson	S	N	(2001)	Dorsal	root	ganglion	neurons	show	increased	expression	of	the	calcium	channel	alpha2delta-1	subunit	following	partial	sciatic	nerve	injury.	Molecular	brain	research.	95:	1-8	Nguyen	D	Deng	P	Matthews	E	A	Kim	D	Feng	G	Dickenson	A	H	Xu	Z	C	Luo	Z	D	(2009)	Enhanced	pre-synaptic	glutamate	release	in	deep-dorsal	horn	contributes	to	calcium	channel	alpha-2-delta-1	protein-mediated	spinal	sensitization	and	behavioral	hypersensitivity.	Molecular	pain.	5:6	Nichols	M	L	Allen	B	J	Rogers	S	D	Ghilardi	J	R	Honore	P	Luger	N	M	Finke	M	P	Li	J	Lappi	D	A	Simone	D	A	Mantyh	P	W	(1999)	Transmission	of	nociception	by	spinal	neurons	expressing	the	substance	P	receptor.	Science.	286:	1558-1561.	Niesters	M	Proto	P	L	Aarts	L	Sarton	E	Y	Drewes	A	M	Dahan	A	(2014)	Tapentadol	potentiates	descending	pain	inhibition	in	chronic	pain	patients	with	diabetic	polyneuropathy.	British	Journal	of	Anaesthesia.	113:	148-156.	Nir	R	and	Yarnitsky	D	(2015)	Conditioned	Pain	Modulation.	Current	opinion	in	supportive	and	palliative	care.	9:	131-137.	Nordling	C	Karlsson-Parra	A	Jansson	L	Holmdahl	R	Klareskog	L	(1992)	Characterization	of	a	spontaneously	occurring	arthritis	in	male	DBA/1	mice.	Arthritis	and	Rheumatism.	35:	717-722	O’Neill	J	Brock	C	Olesen	A	E	Andresen	T	Nilsson	M	Dickenson	A	H	(2014)	Unravelling	the	mystery	of	capsaicin:	A	tool	to	understand	and	treat	pain.	The	American	society	for	pharmacology	and	experimental	therapeutics.	64:	939-971.	
	 317	
Offenbaecher	M	Bondy	B	de	Jonge	S	Glatzeder	K	Kruger	M	Schoeps		P	Ackenheil	M	(1999)	Possible	association	of	fibromyalgia	with	a	polymorphism	in	the	serotonin	transporter	gene	regulatory	region.	42:	2482-2488.	Ogbonna	A	C	Clark	A	K	Gentry	C	Hobbs	C	Malcangio	M	(2013)	Pain-like	behaviour	and	spinal	changes	in	the	monosodium	iodoacetate	model	of	osteoarthritis	in	C57B1/6	mice.	European	Journal	of	Pain.	17:	514-526	Ogbonna	A	C	Clark	A	K	Malcangio	M	(2015)	Development	of	monosodium	acetate-induced	osteoarthritis	and	inflammatory	pain	in	ageing	mice.	Age.	37:	54	Ohtori	S	Inoue	G	Orita	S	Takaso	M	Eguchi	Y	Ochiai	N	Kishida	S	Kuniyoshi	K	Aoki	Y	Ishikawa	T	Miyagi	M	Kamoda	H	Suzkuki	M	Nakamura	J	Kubota	G	Sakuma	Y	Oikawa	Y	Toyone	T	Inage	K	Sainoh	T	Yamauchi	K	Takahashi	K	(2013)	Efficacy	of	Combination	of	Meloxicam	and	Pregabalin	for	Pain	in	Knee	Osteoarthritis.	Yonsei	University	College	of	Medicine.	54:	1253-1258	Okada-Ogawa	A	Porreca	F	Meng	I	D	(2009)	Sustained	morphine-induced	sensitization	and	loss	of	diffuse	noxious	inhibitory	controls	in	dura-sensitive	medullary	dorsal	horn	neurons.	The	journal	of	neuroscience.	29:	15828-15835.	Olave	M	J	Maxwell	D	J	(2004)	Axon	terminals	possessing	alpha2C-adrenergic	receptors	densely	innervate	neurons	in	the	rat	lateral	spinal	nucleus	which	respond	to	noxious	stimulation.	Neuroscience.	126:	391-403	Ong	C	K	S	Lirk	P	Tan	C	H	Seymour	R	A	(2007)	An	evidence-based	update	on	Nonsteroidal	anti-inflammatory	drugs.	Clin	Med	Res.	5:	19-34	Orderberg	G	(2004)	Characterization	of	joint	pain	in	human	OA.	Novartis	Foundation	Symposium.	260:	105-115.	Orita	S	Ishikawa	T	Miyagi	M	Ochiai	N	Inoue	G	Eguchi	Y	Kamoda	H	Arai	G	Toyone	T	Aoki	Y	Kubo	T	Takashi	K	Ohtori	S	(2011)	Pain-related	sensory	innervation	in	monoiodoacetate-induced	osteoarthritis	in	rat	knees	that	gradually	develops	neuronal	injury	in	addition	to	inflammatory	pain.	BMC	Musculoskeletal	disorders.	12:134	Ossipov	M	H	Dussor	G	O	Porreca	F	(2010)	Central	modulation	of	pain.	The	journal	of	clinical	investigation.	120:	3779-3787	Ossipov	M	H	Morimura	K	Porreca	F	(2014)	Descending	pain	modulation	and	chronification	of	pain.	Current	opinion	in	supportive	and	palliative	care.	8:	143-151	Oyama	T	Ueda	M	Kuraishi	Y	Akaike	A	Satoh	M	(1996).	Dual	effect	of	serotonin	on	formalin-induced	nociception	in	the	rat	spinal	cord.	Neuroscience	Research.	25:	129-135.	Ozaktay	A	C	Kallakuri	S	Takebayashi	T	Cavanaugh	J	M	Asik	I	DeLeo	J	A	Weinstein	J	N	(2006)	Effects	of	interleukin-1	beta,	interleukin-6	and	tumour	necrosis	factor	on	sensitivity	of	dorsal	root	ganglion	and	peripheral	receptive	fields	in	rats.	European	spine	journal.	15:	1529-1537	Parks	E	L	Geha	P	Y	Baliki	M	N	Katz	J	Schnitzer	T	J	Apkarian	A	V	(2012)	Brain	activity	for	chronic	knee	osteoarthritis:	dissociating	evoked	pain	from	spontaneous	pain.	European	journal	of	pain.	15:	843e1-843e14	Patel	R	Bauer	C	S	Nieto-Rostro	M	Margas	W	Ferron	L	Chaggar	K	Crews	K	Ramirez	J	D	Bennet	D	L	H	Schwartz	A	Dickenson	A	H	Dolphin	A	C	(2013)	α2δ1	Gene	Deletion	Affects	Somatosensory	Neuron	Function	and	Delays	Mechanical	Hypersensitivity	in	Response	to	Peripheral	Nerve	Damage.	Journal	of	Neuroscience.	33:	16412-16426	Patel	R	Dickenson	A	H	(2016)	Mechanisms	of	the	gabapentinoids	and	α2δ1	calcium	channel	subunits	in	neuropathic	pain.	Pharmacology	research	and	perspectives.	4:	1-13	
	 318	
Patel,	S.	(2012).	Neuronal	mechanisms	in	rodent	models	of	osteoarthritic	and	cancer	induced	bone	pain.	University	College	London.	Paulzen	L	Lammertz	S	E	Grunder	G	Veselinovic	T	Hiemke	C	Tauber	S	C	(2016)	Meausuring	citalopram	in	blood	and	cerebrospinal	fluid:	revealing	a	distribution	pattern	that	differs	from	other	antidepressants.	International	clinical	psychopharmacology.	31:	199-126	Peat	G	McCartney	R	Croft	P	(2001)	Knee	pain	and	osteoarthritis	in	older	adults:	a	review	of	community	burden	and	current	use	of	primary	health	care.	Ann	Rheum	Dis.	60:	91-97	Pereira	D	Peleteiro	B	Araujo	J	Branco	J	Santos	R	A	Ramos	E	(2011)	The	effect	of	osteoarthritis	definition	on	prevalence	and	incidence	estimates:	a	systemic	review.	Osteoarthritis	and	cartilage.	19:	1270-1285	Perrotta	A	Serrao	M	Ambrosini	A	Bolla	M	Coppola	G	Sandrini	G	Pierelli	F	(2013)	Facilitated	temporal	processing	of	pain	and	defective	supraspinal	control	of	pain	in	cluster	headache.	Pain.	154:	1325-1332	Petrovaara	A	(2006)	Noradrenergic	pain	modulation.	Progress	in	Neurobiology.	80:	53-83	Petrovaara	A	(2013)	The	noradrenergic	pain	regulation	system:	a	potential	target	for	pain	therapy.	European	journal	of	pharmacology.	716:	2-7.	Petrovaara	A	Kauppilla	T	Jyvasjarvi	E	Kalso	E	(1991)	Involvement	of	supraspinal	and	spinal	segmental	alpha-2-adrenergic	mechanisms	in	the	medetomidine-induced	antinociception.	44:	705-714	Phillips	C	J	(2009)	The	cost	and	burden	of	chronic	pain.	Reviews	in	pain.	3:	2-5.	Pineda-Farias	J	B	Barragan-Iglesias	P	Valdivieso-Sanchez	A	Rodriguez-Silverio	J	Flores-Murrieta	F	J	Granados-Soto	V	Rocha-Gonzalez	H	I	(2017)	Spinal	5-HT4	and	5-HT6	receptors	contribute	to	the	maintenance	of	neuropathic	pain	in	rats.	Pharmacological	Reports.	69:	916-923.	Pinto	M	Lima	D	Tavares	I	(2007)	Neuronal	activation	at	the	spinal	cord	and	medullary	pain	control	centres	after	joint	stimulation:	A	c-fos	study	in	acute	and	chronic	articular	inflammation.	Neuroscience.	147:	1076-1089	Pitcher	T	Sousa-Valente	J	Malcangio	M	(2016)	The	monoiodoacetate	model	of	osteoarthritis	pain	in	the	mouse.	Journal	of	visualized	experiments.	111:	e53746	Pomonis	J	D	Boulet	J	M	Gottshall	S	L	Phillips	S	Sellers	R	Bunton	T	Walker	K	(2005)	Development	and	pharmacological	characterization	of	a	rat	model	of	osteoarthritis	pain.	Pain.	119:	339-346	Pond	M	Nuki	G	(1973)	Experimentally-induced	osteoarthritis	in	the	dog.	Annals	of	the	Rheumatic	Diseases.	32:	387-388	Porreca	F	Ossipov	M	H	Gebhart	G	F	(2002)	Chronic	pain	and	medullary	descending	facilitation.	Trends	in	Neuroscience.	25:	319-325.	Porreca	F	Ossipov	M	H	Gebhart	G	F	(2002).	Chronic	pain	and	medullary	descending	facilitation.	Trends	in	Neuroscience.	25:	319-325.	Pozgan	U	Caglic	D	Rozman	B	Nagase	H	Turk	V	Turk	B	(2010)	Expression	and	activity	profiling	of	selected	cysteine	cathepsins	and	matrix	metalloproteinases	in	synovial	fluid	from	patients	with	rheumatoid	and	osteoarthritis.	Biological	chemistry.	391:	571-579	
	 319	
Pratta	M	A	Yao	W	Decicco	C	Tortorella	M	D	Liu	R	Copeland	R	A	Magolda	R	Newton	R	C	Trzaskos	J	M	Arner	E	C	(2003)	Aggrecan	preotects	cartilage	collagen	from	proteolytic	cleavage.	The	journal	of	biological	chemistry.	278:	45539-45545.		Prescott	E	D	and	Julius	D	(2003)	A	modular	PIP2	binding	site	as	a	determinant	of	capsaicin	receptor	sensitivity.	Science.	300:	1284-1288.	Pud	D	Granovsky	Y	Yarnitsky	D	(2009)	The	methodology	of	experimentally	induced	diffuse	noxious	inhibitory	control	(DNIC)-like	effect	in	humans.	Pain.	144:	16-19	Purves	D	Augustine	G	J	Fitzpatrick	D	Katz	L	C	LaMantia	A	McNamara	J	O	Williams	S	M	(2001)	Neuroscience,	2nd	edition.	Sinauer	Associates.		Rahman	W	Bannister	K	Bee	L	A	Dickenson	A	H	(2011)	A	pronociceptive	role	for	the	5-HT2	receptor	on	spinal	nociceptive	transmission:	An	in	vivo	electrophysiological	study	in	the	rat.	Brain	research.	1382:	29-36.	Rahman	W	Bauer	C	S	Bannister	K	Vonsy	J	Dolphin	A	C	Dickenson	A	H	(2009)	Descending	serotonergic	facilitation	and	the	antinociceptive	effects	of	pregabalin	in	a	rat	model	of	osteoarthritis	pain.	Molecular	pain.	5:	45	Rahman	W	Sizuki	R	Webber	M	Hunt	S	P	Dickenson	A	H	(2006)	Depletion	of	endogenous	spinal	5-HT	attenuates	the	behavioural	hypersensitivity	to	mechanical	cooing	stimuli	induced	by	spinal	nerve	ligation.	Pain.	123:	264-274.	Rahman	W,	D’Mello	R,	Dickenson	AH	(2008)	Peripheral	nerve	injury-	induced	changes	in	spinal	a2-adrenoceptor-mediated	modulation	of	mechanically	evoked	dorsal	horn	neuronal	responses.	Journal	of	pain.	9:350–359.	Rainville	P	(2002)	Brain	mechanisms	of	pain	affect	pain	modulation.	Current	opinion	in	neurobiology.	12:	195-204.		Rasanen	P	Paavolainen	P	Sintonen	H	Koivisto	A	M	Blom	M	Ryynanen	O	P	Roine	R	P	(2007)	Effectiveness	of	hip	or	knee	replacement	surgery	in	terms	of	quality-adjusted	life	years	and	costs.	Acta	Orthop.	78:108-115	Reginster	J	Bruyere	O	Lecart	M	(2003)	Naturocetic	(glucosamine	and	chondroitin	sulphate)	compounds	as	structure-modifying	drugs	in	the	treatment	of	osteoarthritis.	Current	opinions	of	rheumatology.	15:	651-655	Reichenbach	S	Sterchi	R	Scherer	M	Trelle	S	Burgi	E	Burgi	U	Dieppe	P	A	Juni	P	(2007)	Meta-analysis:	chondroitin	for	osteoarthritis	of	the	knee	or	hip.	Ann	Intern	Med.	146:	580-590	Revell	P	A	Mayston	V	Lalor	P	Mapp	P	(1988)	The	synovial	membrane	in	osteoarthritis:	a	histological	study	indicating	the	characterisation	of	cellular	infiltrate	present	in	inflammatory	osteoarthritis	using	monoclonal	antibodies.	Annals	of	the	rheumatic	disease.	47:	300-307	Richette	P	Bardin	T	(2004)	Structure-modifying	agents	for	osteoarthritis:	An	update.	Joint	Bone	Spine.	71:	18-23	Roby-Brami	A	Bussel	B	Willer	J	C	Le	Bars	D	(1987)	An	electrophysiological	investigation	into	the	pain-relieving	effects	of	heterotopic	nociceptive	stimuli.	Brain	110:	1497-1508.		Rodriguez-Raecke	R	Niemeier	A	Ihle	K	Ruether	W	May	A	(2009)	Brain	grey	matter	decrease	in	chronic	pain	is	the	consequence	and	not	the	cause	of	pain.	The	journal	of	neuroscience.	29:	13746-13750	
	 320	
Roughley	P	J	Mort	J	S	(2014)	The	role	of	aggrecan	in	normal	and	osteoarthritic	cartilage.	Journal	of	experimental	orthopaedics.	1:8.	Russell	R	I	(2001)	Non-steroidal	anti-inflammatory	drugs	and	gastrointestinal	damage	–	problems	and	solutions.	Postgrad	Med.	77:	82-88	Saamanen	A	M	K	Salminen	H	J	Dean	P	B	De	Crombrugghe	B	Vuorio	E	I	Metsaranta	M	P	H	(2000)	Osteoarthritis-like	lesions	in	transgenic	mice	harboring	a	small	deletion	mutation	in	type	II	collagen	gene.	Osteoarthritis	and	Cartilage.	8:	248-257	Sadeghi	M	Tzschentke	T	M	Christie	M	J	(2015)	μ-opioid	receptor	activation	and	noradrenaline	transport	inhibition	by	tapentadol	in	rat	single	locus	coeruleus	neurons.	British	journal	of	pharmacology.	172:	460-468	Sadouk	M	B	Pelletier	J	P	Tardif	G	Kiansa	K	Cloutier	J	M	Martel-Pelletier	J	(1995)	Human	synovial	fibroblasts	coexpress	IL-1	receptor	type	I	and	type	II	mRNA.	The	increased	level	of	the	IL-1	receptor	in	osteoarthritis	cells	is	related	to	an	increased	level	of	the	type	I	receptor.	Laboratory	investigation:	a	journal	of	technical	methods	and	pathology.	73:	347-355	Sagar	D	R	Burston	J	J	Hathway	G	J	Woodhams	S	G	Pearson	R	G	Bennett	A	J	Kendall	D	A	Scammell	B	E	Chapman	V	(2011)	The	contribution	of	spinal	glia	cells	to	chronic	pain	behaviour	in	the	monosodium	iodoacetate	model	of	osteoarthritis	pain.	Molecular	pain.	7:	88.		Sagar	D	R	Nwosu	L	Walsh	D	A	Chapman	V	(2015)	Dissecting	the	contribution	of	knee	joint	NGF	to	spinal	nociceptive	sensitization	in	a	model	of	OA	pain	in	the	rat.	Osteoarthritis	and	Cartilage.	23:	906-913	Sagar	D	R	Staniaszek	L	E	Okine	B	N	Woodhams	S	Norris	L	M	Pearson	R	G	Garle	M	J	Alexander	S	P	H	Bennett	A	J	Barrett	D	A	Kendall	D	A	Scammell	B	E	Chapman	V	(2010)	Tonic	modulation	of	spinal	hyperexcitability	by	the	endocannabinoid	receptor	system	in	a	rat	model	of	osteoarthritis	pain.	Arthritis	and	Rheumatism.	62:	3666-3676	Sahebjam	S	Khokha	R	Mort	J	S	(2007)	Increased	collagen	and	aggrecan	degradation	with	age	in	the	joints	of	Timp3−/−	mice.	Arthritis	Rheum.	56:905–909.	Saito	T	Koshino	T	(2000)	Distribution	of	neuropeptides	in	synovium	of	the	knee	with	osteoarthritis.	Clinical	orthopaedics	and	related	research.	376:	172-182	Saklatvala,	J	(1986)	Tumour	necrosis	factor	α	stimulates	resorption	and	inhibits	synthesis	of	proteoglycan	in	cartilage.	Nature	322:	547–549		Samuels	J	Krasnokutsky	S	Abramson	S	B	(2008)	Osteoarthritis:	A	tale	of	three	tissues.	Bulletin	of	the	NYU	Hospital	for	Joint	Diseases.	66:	244-250	Sandy	J	D	Flannery	C	R	Neame	P	J	Lohmander	L	S	(1992)	The	structure	of	aggrecan	fragments	in	human	synovial	fluid.	Journal	of	clinical	investigation.	89:	1512-	1516.	Sandy	J	D	Verscharen	C	(2001)	Analysis	of	aggrecan	in	human	knee	cartilage	and	synovial	fluid	indicates	that	aggrecanse	(ADAMTS)	activity	is	responsible	for	the	catabolic	turnover	and	loss	of	whole	aggrecan	whereas	other	protease	activity	is	required	for	C-terminal	processing	in-vivo.	Biochemical	journal.	358:	615-626.	Sathyamurthy	A	Johnson	K	R	Matson	K	J	E	Dobrott	C	I	Li	L	Ryba	A	R	Bergman	T	B	Kelly	M	C	Kelley	M	W	Levine	A	J	(2018)	Massively	parallel	single	nucleus	transcriptional	profiling	defines	spinal	cord	neurons	and	their	activity	during	behaviour.	Cell	reports.	22:	2216-2225	
	 321	
Sawynok	J	Esser	M	J	Reid	A	R	(1999)	Peripheral	antinociceptive	actions	of	desipramine	and	fluoxetine	in	an	inflammatory	and	neuropathic	pain	test	in	the	rat.	Pain.	82:	149-158	Scanzello	C	R	Goldring	S	R	(2012)	The	role	of	synovitis	in	osteoarthritis	pathogenesis.	Bone.	51:	249-257	Schaible	H	G	(2004)	Spinal	mechanisms	contributing	to	joint	pain.	Novarits	foundation	symposium.	260:	4-22	Schaible	H	G	Ritcher	F	Ebersberger	A	Boettger	M	K	Vanegas	H	Natura	G	Vazquez	E	von	Banchet	G	S	(2009)	Joint	pain.	Experimental	brain	research.	196:	153-162	Scheinin	M	Lomasney	J	W	Hayden-Hixson	D	M	Schambra	U	B	Caron	M	G	Lefkowitz	R	J	Fremeau	Jr	R	T	(1994)	Distribution	of	a2-adrenergic	receptor	subtype	gene	expression	in	rat	brain.	Brain	research:	Molecular	brain	research.	21:	133-149	Schiene	K	Dr	Vry	J	Tzschentke	T	M	(2011)	Antinociceptive	and	Antihyperalgesic	Effects	of	Tapentadol	in	Animal	Models	of	Inflammatory	Pain.	Journal	of	pharmacology	and	experimental	therapeutics.	339:	537-544	Schmidt	R	Schmelz	M	Forster	C	Ringkamp	M	Torebjork	E	Handwerker	H	(1995)	Novel	classes	of	responsive	and	unresponsive	C	nociceptors	in	human	skin.	The	journal	of	Neuroscience.	15:	333-341	Schroder	W	Dr	Vry	J	Tzschentke	T	M	Jahnel	U	Christoph	T	(2010)	Differential	contribution	of	opioid	and	noradrenergic	mechanisms	of	tapentadol	in	rat	models	of	nociceptive	and	neuropathic	pain.	European	journal	of	pain.	14:	814-821	Schroder	W	Tzschentke	T	M	Terlinden	R	De	Vry	J	Jahnel	U	Christoph	T	Tallarida	J	R	(2011)	Synergistic	interaction	between	the	two	mechanisms	of	action	of	Tapentadol	in	analgesia.	The	journal	of	pharmacology	and	experimental	therapeutics.	337:	312-321	Schuelert	N	McDougall	J	J	(2006)	Electrophysiological	evidence	that	the	vasoactive	intestinal	peptide	receptor	antagonist	VIP6-28	reduces	nociception	in	an	animal	model	of	osteoarthritis.	Osteoarthritis	and	Cartilage.	14:	1155-1162	Schuelert	N	McDougall	J	J	(2009)	Grading	of	monosodium	iodoacetate-induced	osteoarthritis		reveals	a	concentration-dependent	sensitization	of	nociceptors	in	the	knee	joint	of	the	rat.	Neuroscience	Letters.	465:	184-188	Schuelert	N	McDougall	J	J	(2012)	Involvement	of	Nav1.8	sodium	ion	channels	in	the	transduction	of	mechanical	pain	in	a	rodent	model	of	osteoarthritis.	Arthritis	research	and	therapy.	14:	R5.	Sellam	J	Berenbaum	F	(2010)	The	role	of	synovitis	in	pathophysiology	and	clinical	symptoms	of	osteoarthritis.	Nature	reviews:	Rheumatology.	6:	625-635	Shaible	H	G	(2012)	Mechanisms	of	chronic	pain	in	osteoarthritis.	Current	rheumatology	reports.	14:	549-556	Sharma	L	Song	J	Felson	D	T	Cahue	S	Shamiyeh	E	Dunlop	D	D	(2001)	The	role	of	knee	alignment	in	disease	progression	and	functional	decline	in	knee	osteoarthritis.	JAMA.	286:	188-195	Sherrington	C	S	(1906)	The	Integrative	Action	of	the	Nervous	System	(Scribner,	New	York).	Shibakawa	A	Aoki	H	Masuko-Hongo	K	Kato	T	Tanaka	M	Nishioka	K	Nakamura	H	(2003)	Presence	of	pannus-like	tissue	on	osteoarthritic	cartilage	and	its	histological	character.	Osteoarhritis	and	Cartilage.	11:	133-140.	
	 322	
Shomberg	D	Olsen	J	K	(2012)	Immune	responses	of	microglia	in	the	spinal	cord:	contribution	to	pain	states.	Experimental	neurology.	234:	262-270.	Sikander	S	Dickenson	A	H	(2013)	Editorial	II:	No	need	for	translation	when	the	same	language	is	spoken.	British	journal	of	anaesthesia.	111:	3-6	Simms	B	A	Zamponi	G	W	(2014)	Neuronal	voltage-gated	calcium	channels:	structure,	function	and	dysfunction.	Neuron.	82:	24-45	Sindrup	S	H	Otto	M	Finnerup	N	B	Jensen	T	S	(2005)	Antidepressants	in	the	treatment	of	neuropathic	pain.	Basic	and	clinical	pharmacology	and	toxicology.	96:	399-409	Singh	J	A	Gabriel	S	Lewallen	D	(2008)	The	impact	of	gender,	age,	and	preoperative	pain	severity	on	pain	after	TKA.	Clin	Orthop	Relat	Res.	466:	2717-2723	Singh	V	P	Jain	N	K	Kulkarni	S	K	(2001)	On	the	antinociceptive	effect	of	fluoxetine,	a	selective	serotonin	reuptake	inhibitor.	Brain	Research.	915:	218-226	Smith	M	S	Schambra	U	B	Wilson	K	H	Page	S	O	Hulette	C	Light	A	R	Schwinn	D	A	(1995)	a2-Adrenergic	receptors	in	human	spinal	cord:	specific	localized	expression	of	mRNA	encoding	aE-adrenergic	receptor	subtypes	at	four	distinct	levels.	Molecular	Brain	Research.	34:	109-117	Smith	S	(2012)	OANation	2012.	Arthritis	care.		Snider	W	D	and	McMahon	S	B	(1998)	Tackling	pain	at	the	source:	new	ideas	about	nociceptors.	Neuron.	20:	629-632.	Snutch	T	P	(2005)	Targeting	chronic	and	neuropathic	pain:	The	N-type	calcium	channel	comes	of	age.	The	journal	of	the	American	society	for	experimental	NeuroTherapeutics.	2:	662-670.	Soderling	T	R	Derkach	V	A	(2000)	Postsynaptic	protein	phosphorylation	and	LTP.	Trends	in	neuroscience.	23:	75-80.	Sofroniew	M	V	Vinters	H	V	(2010)	Astrocytes:	biology	and	pathology.	Acta	Neuropathol.	119:	7-35	Song	R	Tortorella	M	D	Malfait	A	Alston	J	T	Yang	Z	Arner	E	C	Griggs	D	W	(2007)	Aggrecan	degradation	in	human	articular	cartilage	explants	is	mediated	by	both	ADAMTS-4	and	ADAMTS-5.	Arthritis	and	Rheumatism.	56:	575-585.	Sonohanata	M	Furue	H	Katafuchi	T	yasaka	T	Doi	A	Kumamoto	E	Yoshimura	M	(2004)	Actions	of	noradrenaline	on	substantia	gelatinosa	neurones	in	the	rat	spinal	cord	revealed	by	in	vivo	patch	clamping	recording.	J.	Physiol.	(Lond)	555:	515-526.	Srikanth	V	K	Fryer	J	L	Zhai	G	Winzenberg	T	M	Hosmer	D	Jones	G	(2005)	A	meta-analysis	of	sex	differences	prevalence,	incidence	and	severity	of	osteoarthritis.	Osteoarthritis	and	cartilage.	13:	769-781	Stanton	H	Rogerson	F	M	East	C	J	Golub	S	B	Lawlor	K	E	Meeker	C	T	Little	C	B	Last	K	Farmer	P	J	Campbell	I	K	Fourie	A	M	Fosang	A	J	(2005)	ADAMTS5	is	the	major	aggrecanase	in	mouse	cartilage	in	vivo	and	in	vitro.	Letters	to	Nature.	434:	648-652.	Stegmann	J	U	Engles	C	Steup	A	Schwarz	H	J	Desjardins	P	Grond	S	(2006)	Tapentadol,	a	novel	centrally	acting	analgesic	with	a	dual	mode	of	action:	efficacy	and	safety	in	clinical	acute	pain	models.	European	journal	of	pain.	10:	S167b-S167	
	 323	
Stone	L	S	Broberger	C	Vulchanova	L	Wilcox	G	L	Hökfelt	T	Reidl	M	S	Elde	R	(1998)	Differential	distribution	of	alpha2A	and	alpha2C	adrenergic	receptor	immunoreactivity	in	the	rat	spinal	cord.	Journal	of	Neuroscience	18:	5928-5937.	Summers	R	McMartin	L	(1993)	Adrenoceptors	and	their	second	messenger	systems.	Journal	of	neurochemistry.	60:	10-23	Sutton	K	G	Martin	D	J	Pinnock	R	D	Lee	K	Scott	R	H	(2002)	Gabapentin	inhibits	high-threshold	calcium	channel	currents	in	cultured	rat	dorsal	root	ganglion	neurones.	British	journal	of	pharmacology.	135:	257-265	Suzuki	R	Dickenson	A	H	(2000)	Neuropathic	pain:	nerves	bursting	with	excitement…	Neuroreport.	11:	R17-21	Suzuki	R	Morcuende	S	Webber	M	Hunt	S	P	Dickenson	A	H	(2002)	Superficial	NK-1	expressing	neurons	control	spinal	excitability	through	activation	of	descending	pathways.	Nature	neuroscience.	5:	1319-1326.	Suzuki	R	Rahman	W	Rygh	L	J	Webber	M	Hunt	S	P	Dickenson	A	H	(2005)	Spinal-supraspinal	serotonergic	circuits	regulating	neuropathic	pain	and	its	treatment	with	gabapentin.	Pain.	117:	292-303	Suzuki	R	Rygh	L	J	Dickenson	A	H	(2004)	Bad	news	from	the	brain:	descending	5-HT	pathways	that	control	spinal	pain	processing.	Trends	in	pharmacological	sciences.	25:	613-617.	Sweeney	S	E	Firestein	G	S	(2004)	Rheumatoid	arthritis:	regulation	of	synovial	inflammation.	The	international	journal	of	biochemistry	and	cell	biology.	36:	372-378.	Talbot	J	D	marrett	S	Evans	A	C	Meyer	E	Bushell	M	C	Duncan	G	H	(1991)	Multiple	representations	of	pain	in	human	cerebral	cortex.	Science.	251:1355-1358.	Taylor	C	P	Garrido	R	(2008)	Immunostaining	of	rat	brain,	spinal	cord,	sensory	neurons	and	skeletal	muscle	for	calcium	channel	alpha2-delta	(α2-δ)	type	1	protein.	Neuroscience.	155:	510-521	Tchetverikov	I	Lohmader	L	S	Verzijl	N	Huizinga	T	W	J	TeKoppele	J	M	Hanemaaijer	R	DeGroot	J	(2005)	MMP	protein	and	activity	levels	in	synovial	fluid	from	patients	with	joint	injury,	inflammatory	arthritis,	and	osteoarthritis.	Annals	of	the	Rheumatic	Disease.	64:	694-698	Thakur	M	(2012)	Pharmacological,	Neurochemical	and	Functional	characterization	of	the	MIA	model	of	experimental	osteoarthritis.	University	College	London.		Thakur	M	Crow	M	Richards	N	Davey	G	I	J	Levine	E	Kelleher	J	H	Agley	C	C	Denk	F	Harridge	S	D	R	McMahon	S	B	(2014b)	Defining	the	nociceptor	transcriptome.	Frontiers	in	molecular	neuroscience.	7:	1-11	Thakur	M	Dickenson	A	H	Baron	R	(2014)	Osteoarthritis	pain:	nociceptive	or	neuropathic?	Nature	Reviews	Rheumatology.	10:	374-380	Thakur	M	Rahman	W	Hobbs	C	Dickenson	A	H	Bennet	D	L	H	(2012)	Characterisation	of	a	peripheral	neuropathic	component	of	the	rat	monoiodoacetate	model	of	osteoarthritis.	PLoS	ONE.	7:	e33730.	Thompson	A	J	Lummis	S	C	R	(2006)	5-HT3	Receptors.	Current	pharmaceutical	design.	12:	3615-3630	Todd	A	J	(2010)	Neuronal	circuitry	for	pain	processing	in	the	dorsal	horn.	Nature	Neuroscience.	11:	823-836.	Todd	A	J	and	Spike	R	C	(1993)	The	localization	of	classical	transmitters	and	neuropeptides	within	neurons	in	lamina	I-III	of	the	mammalian	spinal	dorsal	horn.	Progress	in	Neurobiology.	41:	609-645.	
	 324	
Todd	A	J	and	Sullivan	A	C	(1990)	Light	microscope	study	of	the	coexsistence	of	GABA-like	and	Glycine-like	immunoreactivities	in	the	spinal	cord	of	the	rat.	The	journal	of	comparative	neurology.	296:	496-505.	Todd	A	J	Puskar	Z	Spike	R	C	Hughes	C	Watt	C	Forrest	L	(2002)	Projection	neurons	in	lamina	I	of	rat	spinal	cord	with	the	Neurokinin-1	receptor	are	selectively	innervated	by	substance-P	containing	afferents	and	respond	to	noxious	stimulation.	The	jounal	of	neuroscience.	22:	4103-4113.	Tominaga	M	and	Caterina	M	J	(2004)	Thermosensation	and	Pain.	Journal	of	Neurobiology.	61:	3-12.	Townson	L	D	(2017)	Descending	controls	and	peripheral	contribution	to	pain	in	the	monosodium	iodoacetate	model	of	osteoarthritis.	University	College	London.		Tracey	I	and	Mantyh	P	W	(2007)	The	Cerebral	Signature	for	Pain	Perception	and	Its	Modulation.	Neurone.	55:	377-391	Tracey	I	and	Mantyh	P	W	(2007)	The	Cerebral	Signature	for	Pain	Perception	and	Its	Modulation.	Neurone.	55:	377-391.	Treede	R	D	Jensen	T	S	Campbell	J	Cruccu	N	G	Dostrovsky	J	O	Griffin	J	W	P.	Hansson	P		Hughes	R		Nurmikko	T	Serra	J	(2008)	Neuropathic	pain	Redefinition	and	a	grading	system	for	clinical	and	research	purposes.	Neurology.	70:	1630-1635.	Treede	R	D	Jensen	T	S	Campbell	J	N	Cruccu	G	Dostrovsky	J	O	Griffin	J	W	Hansson	P	Hughes	R	Nurmikko	T	Serra	J	(2008)	Neuropathic	pain.	Neurology.	70:	1630-1635	Troeberg	L	Nagase	H	(2012)	Proteases	involved	in	cartilage	matrix	degradation	in	osteoarthritis.	Biochim	Biophys	Acta.	1824:	133-145.	Tsuda	M	Shigemoto-Mogami	Y	Koizumi	S	Mizokoshi	A	Kohsaka	S	Salter	M	W	Inoue	K	(2003)	P2X4	receptors	induced	in	spinal	microglia	gate	tactile	allodynia	after	nerve	injury.	Nature.	424:	778-783.	Tsujino	H	Kondo	E	Fukuoka	T	Dai	Y	Tokunaga	A	Miki	K	Yonenobu	K	Ochi	T	Noguchi	K	(2000)	Activating	transcription	factor	3	(Atf3)	Induction	by	axotomy	in	sensory	and	motorneurons:	a	novel	neuronal	maker	of	nerve	injury.	Molecular	and	cellular	neurosciences.	15:	170-182	Tzschentke	T	M	Christoph	T	Kogel	B	Schiene	K	Hennies	H	Engleberger	W	Haurand	M	Jahnel	U	Cremers	T	I	F	H	Friderichs	E	De	Vry	J	(2007)	(-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-	phenol	Hydrochloride	(Tapentadol	HCl):	a	Novel	μ-Opioid	Receptor	Agonist/Norepinephrine	Reuptake	Inhibitor	with	Broad-Spectrum	Analgesic	Properties.	The	journal	of	pharmacology	and	experimental	therapeutics.	323:	265-276	Tzschentke	T	M	Christoph	T	Kogel	B	Y	(2014)	The	Mu-Opiod	receptor	agonist/Noradrenaline	reuptake	inhibition	(MOR-NRI)	concept	in	analgesia:	The	case	of	Tapentadol.	CNS	Drugs.	28:	319-329	Tzschentke	T	M	Folgering	J	H	A	Flik	G	De	Vry	J	(2012)	Tapentadol	increases	levels	of	noradrenaline	in	the	rat	spinal	cord	as	measured	by	in	vivo	microdialysis.	Neuroscience	letters.	507:	151-155	Tzschentke	T	M	Jahnel	U	Kogel	B	Christoph	T	Englberger	W	De	Vry	J	Schiene	K	Okamoto	A	Upmalis	D	Weber	H	Lange	C	Stegmann	J	U	Kleinert	R	(2009)	Tapentadol	hydrochloride:	a	next-generation,	centrally	acting	analgesic	with	two	mechanisms	of	action	in	a	single	molecule.	Drugs	of	today.	45:	483-496	
	 325	
Udo	M	Muneta	T	Tsuji	K	Ozeki	N	Nakagawa	Y	Ohara	T	Saito	R	Yanagisawa	K	Koga	H	Sekiya	I	(2016)	Monoiodoacetic	acid	induces	arthritis	and	synovitis	in	rats	in	a	dose-	and	time-	dependent	manner:	proposed	model	specific	scoring	systems.	Osteoarthritis	and	Cartilage.	24:	4-11	Unnerstall	J	R	Kopajtic	T	A	Kuhar	M	J	(1984)	Distribution	of	a2	Agonist	Binding	Sites	in	the	Rat	and	Human	Central	Nervous	System:	Analysis	of	some	Functional,	Anatomic	Correlates	of	the	Pharmacologic	Effects	of	Clonidine	and	Related	Adrenergic	Agents.	Brain	Research.	319:	69-101	Urch	C.	E	and	Dickenson	A	H	(2003)	I	n	vivo	single	unit	extracellular	recordings	from	spinal	cord	neurones	of	rats.	Brain	Research	Protocols.	12:	26-34.		Vaccarino	A	L	Clemmons	H	R	Mader	Jr	G	J	Magnusson	J	E	(1997)	A	role	of	periaqueductal	grey	NMDA	receptors	in	mediating	formalin-induced	pain	behaviour	in	the	rat.	Neuroscience	Letters.	236:	117-119.	van	der	Kraan	P	M	Vitters	E	L	van	Beuningen	H	M	van	de	Putte	L	B	A	van	den	Berg	W	B	(1990)	Degenerative	knee	joint	lesions	in	mice	after	a	single	intra-articular	collagenase	injection.	A	new	model	of	osteoarthritis.	Journal	of	experimental	pathology.	71:	19-31	Van	Wijk	G	Veldhuijzen	D	S	(2010)	Perspective	on	diffuse	noxious	inhibitory	controls	as	a	model	of	endogenous	pain	modulation	in	clinical	pain	syndromes.	The	journal	of	pain.	11:	408-419	Vane	J	R	Bakhle	Y	S	Botting	R	M	(1998)	Cyclooxygenases	1	and	2.	Annu	Rev	Pharmacol	Toxicol	38:	97-120	Vanegas	H	Schaible	H	G	(2004)	Descending	control	of	persistent	pain:	inhibitory	or	facilitatory?	Brain	research.	Brain	research	reviews.	46:	295-309	Viguier	F	Michot	B	Kayser	V	Bernard	J	Vela	J	Hamon	M	Bourgoin	S	(2012)	GABA,	but	not	opioids,	mediates	the	anti-hyperalgesic	effects	of	5-HT7	receptor	activation	in	rats	suffering	from	neuropathic	pain.	Neuropharmacology.	63:	1093-1106	Vilceanu	D	and	Stucky	C	L	(2010)	TRPA1	mediates	mechanical	currents	in	the	plasma	membrane	of	mouse	sensory	neurons.	PLoS	One.	5:	e12177	Villanueva	L	Bouhassira	D	Bing	Z	Le	Bars	D	(1988)	Convergence	of	heterotopic	nociceptive	information	onto	subnucleus	reticularis	dorsalis	neurons	in	the	rat	medulla.	Journal	of	neurophysiology.	60:	980-1009.	Villanueva	L	Cadden	S	W	Le	Bars	D	(1984a)	Evidence	that	Diffuse	Noxious	Inhibitory	Controls	(DNIC)	are	mediated	by	a	final	post-synaptic	mechanism.	Brain	Research.	298:	67-74.	Villanueva	L	Cadden	S	W	Le	Bars	D	(1984b)	Diffuse	Noxious	Inhibitory	Controls	(DNIC):	evidence	for	post-synaptic	inhibition	of	trigeminal	nucleus	caudalis	convergent	neurons.	Brain	Research.	321:	165-168.	Villanueva	L	Chitour	D	Le	Bars	D	(1986)	Involvement	of	the	dorsolateral	funiculus	in	the	descending	spinal	projections	responsible	for	diffuse	noxious	inhibitory	controls	in	the	rat.	Journal	of	Neurophysiology.	56:	1185-1195	Vincent	K	Tracey	I	(2008)	Hormones	and	their	interaction	with	the	pain	experience.	Reviews	in	Pain.	2:	20-24.	
	 326	
Vonsy	J	L	Ghandehari	J	Dickenson	A	H	(2009)	Differential	analgesic	effects	of	morphine	and	gabapentin	on	behavioural	measures	of	pain	and	disability	in	a	model	of	osteoarthritis	pain	in	rats.	European	journal	of	pain.	13:	786-793	Wade	W	E	Spruill	W	J	(2009)	Tapentadol	Hydochloride:	A	centrally	acting	oral	analgesic.	Clinical	Therapeutics.	31:	2804-2818	Warren	J	B	(2012)	Antidepressants	and	the	developing	nervous	system.	British	Journal	of	Clinical	Pharmacology.	73:	1-3.	Waxman	S	G	Kocsis	J	D	Black	J	A	(1994)	Type	III	Sodium	channel	mRNA	is	expressed	in	embryonic	but	not	adult	spinal	sensory	neurons,	and	is	reexpressed	following	axotomy.	Journal	of	neurophysiology.	72:	466-470.	Wei	F	Dubner	R	Zou	S	Ren	K	Bai	G	Wei	D	Guo	W	(2010)	Molecular	depletion	of	descending	serotonin	unmasks	its	novel	facilitatory	role	in	the	development	of	persistent	pain.	The	Journal	of	Neuroscience.	30:	8624-8636.		Wenham	C	Y	J	Conaghan	P	G	(2010)	The	role	of	synovitis	in	osteoarthritis.	Therapeutic	advances	in	musculoskeletal	disease.	2:	349-359.	Westacott	C	I	Sharif	M	(1996)	Cytokines	in	osteoarthritis:	mediators	or	markers	of	joint	destruction?	Seminars	in	arthritis	and	rheumatism.	25:	254-272	Westlund	K	N	Carlton	S	M	Zhang	D	Willis	W	D	(1990)	Direct	catecholaminergic	innervation	of	primate	spinothalamic	tract	neurones.	J.	Comp.	Neurol.	229:	178-186.	Whiteside	G	T	Muglani	R	(2001)	Cell	death	in	the	superficial	dorsal	horn	in	a	model	of	neuropathic	pain.	Journal	of	neuroscience	research.	15:	168-173.	Wiberg	M	Westman	J	Blomqvist	A	(1987)	Somatosensory	projection	to	the	mesencephalon:	An	anatomical	study	in	the	monkey.	Journal	of	comparative	neurology.	264:	92-117.		Wieland	H	A	Michaelis	M	Kirschbaum	B	J	Rudolphi	K	A	(2005)	Osteoarthritis	–	an	untreatable	disease.	Nature	reviews:	drug	discovery.	4:	331-345.	Wiffen	P	J	McQuay	H	J	Edwards	J	Moore	R	A	(2005)	Gabapentin	for	acute	and	chronic	pain.	Cochrane	database	of	systematic	reviews.	3:	CD005452.	Wilder-Smith	C	H	Schindler	D	Lovblad	K	Redmond	S	M	Nirkko	A	(2004)	Brain	functional	magnetic	resonance	imaging	of	rectal	pain	and	activation	of	endogenous	inhibitory	mechanisms	in	irritable	bowel	syndrome	patient	subgroups	and	healthy	controls.	Gut.	53:	1595-1601	Willer	J	C	De	Broucker	T	Le	Bars	D	(1989)	Encoding	of	nociceptive	thermal	stimuli	by	diffuse	noxious	inhibitory	controls	in	humans.	Journal	of	Neurophysiology.	62:	1028-1038	Witting	N	Svensson	P	Ardent-Nielsen	L	Jensen	T	S	(1998)	Differential	effect	of	painful	heterotopic	stimulation	on	capsaicin-induced	pain	and	allodynia.	Brain	research.	801:	206-210	Woold	C	J	and	Ma	Q	(2007)	Nociceptors	–	noxious	stimulus	detectors.	Neuron.	55:	353-364.	Woolf	A	D	Pfleger	B	(2003)	Burden	of	major	musculoskeletal	conditions.	Bulletin	of	the	world	health	organization.	81:	646-656	Woolf	C	J	(2010)	What	is	this	thing	called	pain?	The	Journal	of	Clinical	Investigation.	120:	3742-3744.		Woolf	C	J	(2011)	Central	sensitization:	implications	for	the	diagnosis	and	treatment	of	pain.	Pain.	152:	S2-S15.	
	 327	
Woolf	C	J	and	Doubell	T	P	(1994)	The	pathophysiology	of	chronic	pain	–	increased	sensitivity	to	low	threshold	Aβ	fibre	input.	Current	opinion	in	neurobiology.	4:525-534.	Woolf	C	J	Salter	M	W	(2000)	Neuronal	plasticity:	increasing	the	gain	in	pain.	Science.	288:	1765-1768.	Wylde	V	Hewlett	S	Learmonth	I	D	Dieppe	P	(2011)	Persistent	pain	after	joint	replacement:	Prevelance,	sensory	qualities,	and	postoperative	determinants.	Pain.	152:	566-572	Wylde	V	Palmer	S	Learmonth	I	D	Dieppe	P	(2012)	Somatosensory	abnormalities	in	knee	OA.	Rhuematology.	51:	535-543	Xin	W	Weng	H	Dougherty	P	M	(2009)	Plasticity	in	the	expression	of	the	glutamate	transporters	GLT-1	and	GLAST	in	spinal	dorsal	horn	glial	cells	following	partial	sciatic	nerve	ligation.	Molecular	pain.	5:	1744-1769.	Yarnitsky	D	(2010)	Conditioned	pain	modulation	(the	diffuse	noxious	inhibitory	control-like	effect):	its	relevance	for	acute	and	chronic	pain	states.	Current	opinion	in	anaesthesiology.	23:	611-615.	Yarnitsky	D	(2015)	Role	of	endogenous	pain	modulation	in	chronic	pain	mechanisms	and	treatment.	Pain.	156:	S24-S31	Yarnitsky	D	Crispel	Y	Eisenberg	E	Granovsky	Y	Ben-Nun	A	Sprecher	E	Best	L	Granot	M	(2008)	Prediction	of	chronic	post-operative	pain:	pre-operative	DNIC	testing	identifies	patients	at	risk.	Pain.	138:	22-28.	Yarnkitsky	D	Granot	M	Nahman-Averbuch	H	Khamaisi	M	Granovsky	Y	(2012)	Conditioned	pain	modulation	predicts	duloxetine	efficacy	in	painful	diabetic	neuropathy.	Pain.	153:	1193-1198.	Youssef	A	M	Macefield	V	G	Henderson	L	A	(2015)	Pain	inhibits	pain:	human	brainstem	mechanisms.	NeuroImage.	124:	54-62.	Youssef	A	M	Macefield	V	G	Henderson	L	A	(2016)	Cortical	influences	on	brainstem	circuitry	responsible	for	conditioned	pain	modulation	in	humans.	Human	brain	mapping.	37:	2630-2644.	Yu	X	M	Askalan	R	Keil	G	J	2nd	Salter	M	W	(1997)	NMDA	channel	regulation	by	channel-associated	protein	tyrosine	kinase	Src.	Science.	275:	674-678.	Zeni	J	A	Higginson	J	S	(2011)	Knee	osteoarthritis	affects	the	distribution	of	joint	moments	during	gait.	The	Knee.	18:	156-159	Zhang	J	An	J	(2007)	Cytokines,	inflammation	and	pain.	International	Anaesthesiology	clinics.	45:	27-37	Zhang	J	An	J	(2007)	Cytokines,	inflammation	and	pain.	International	anaesthesiology	clinics.	45:	27-37	Zhang	W	Jones	A	Doherty	M	(2004)	Does	paracetamol	(acetaminophen)	reduce	the	pain	of	osteoarthritis?:	a	meta-analysis	of	randomised	controlled	trials.	Annals	of	the	rheumatic	diseases.	63:	901-907	Zhang	Y	Chen	K	Sloan	S	A	Bennett	M	L	Scholze	A	R	O’Keefe	S	Phatnani	H	P	Guanierni	P	Caneda	C	Ruderisch	N	Deng	S	Liddelow	S	A	Zhang	C	Daneman	R	Maniatis	T	Barres	B	A	Wu	J	Q	
	 328	
(2014)	An	RNA-Sequencing	Transcriptome	and	Splicing	Database	of	Glia,	Neurons,	and	Vascular	Cells	of	the	Cerebral	Cortex.	Journal	of	Neuroscience.	34:	11929-11947	
Zhang	Y	Jordan	J	M	(2010)	Epidemiology	of	osteoarthritis.	Clinics	in	geriatric	medicine.	26:	355-369	Zhang	Y	Nevitt	M	Niu	J	Lewis	C	Torner	J	Guermazi	A	Roemer	F	McCulloch	C	Felson	D	T	(2011)	Fluctuation	of	knee	pain	and	changes	in	bone	marrow	lesions,	effusions	and	synovitis	on	magnetic	resonance	imaging.	Arthritis	and	Rheumatism.	63:	691-699	Zhou	C,	Luo	ZD	(2014).	Electrophysiological	characterization	of	spinal	neuron	sensitization	by	elevated	calcium	channel	alpha-2-delta-1	subunit	protein.	European	journal	of	pain.	18:	649–658.								
